<SEC-DOCUMENT>0001104659-23-040275.txt : 20230331
<SEC-HEADER>0001104659-23-040275.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331165853
ACCESSION NUMBER:		0001104659-23-040275
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annovis Bio, Inc.
		CENTRAL INDEX KEY:			0001477845
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262540421
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39202
		FILM NUMBER:		23788880

	BUSINESS ADDRESS:	
		STREET 1:		1055 WESTLAKES DRIVE, SUITE 300
		CITY:			BERWYN
		STATE:			PA
		ZIP:			19312
		BUSINESS PHONE:		610-727-3913

	MAIL ADDRESS:	
		STREET 1:		1055 WESTLAKES DRIVE, SUITE 300
		CITY:			BERWYN
		STATE:			PA
		ZIP:			19312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QR Pharma, Inc.
		DATE OF NAME CHANGE:	20091202
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>anvs-20221231x10k.htm
<DESCRIPTION>FORM-10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/31/2023 8:46:15 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: 904f1345-9f28-4320-b2d1-fcea8f85811e -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:anvs="http://annovisbio.com/20221231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" xs:nil="true" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Xf7htH0lWUyGsLBri-KMXw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" xs:nil="true" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_vtx97sYDjUWOZpnKxkT_Zg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" xs:nil="true" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" name="us-gaap:PreferredStockValue" id="Hidden_b5CxiFHgF0qmCxB9v3qZrQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" xs:nil="true" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" name="us-gaap:PreferredStockValue" id="Hidden_CKmZMxNY9EKNzVKvLMFfig"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:IncomeTaxExpenseBenefit" id="Hidden_t3JpmuFC0kuECNoYyOooVw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" name="us-gaap:IncomeTaxExpenseBenefit" id="Hidden__67SmLkLaUCM7ruMNqJSrg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Ckrb12oy306ddpZ53Niy3w">3.10</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Z-k-vGB7x0igdz-3Y49S8A">1.90</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_6_KSFjJM1EG1R1--0NDhUw">8162326</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_J9co3IqiOkWlnUxwzu281Q">7626278</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_UFtYtOJrnUSr5vcQImd2vA">8162326</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_sqdL1CGCLUGcVu3lQoOFAw">7626278</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Nrt4V6gKP0yrinHj-NMeNg">3.10</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_cE1AXSw2LUaR4c9ANXGfMw">1.90</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityCentralIndexKey" id="Tc_r0ohK5OqsE2oeUsZThKMMA_2_1">0001477845</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:DocumentFiscalYearFocus" id="Tc_mrtisNQvx0C1zNtDbaS5ew_3_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:DocumentFiscalPeriodFocus" id="Tc_R70AsucFIkCeoefQ8EGKcg_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:AmendmentFlag" id="Tc_vxm8Evbkn0qNOrHpP4PJzw_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_jrIh6zL5GUqxKHMNRWtSUA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_J9mXrKEvB0-Y0wdQqsv3gA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_VaKD4RT3_UaqR1WyWSHEKw">8100570</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_yN13rWRPTE6hgWOZKM6n6A">8163923</ix:nonFraction><ix:nonNumeric contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_KVKI4UZ8Bk-1Y1WhTV4ecA">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_-usZI0ypmUm4aeI3-2x4jw">P10Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" id="Hidden_CbSvzWDZTEOpLcmifvaG0g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" id="Hidden_r0R8eMcNNUyTWF9TpK0MRg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_gNBJeOes40Sa4G7lAiK58Q">1.07</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_yz2vRgL14Ee_24qI4nZ8pg">0.73</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_lfDs6h-8fEqFxxCy5m72Yg">8163923</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_TrJXSBRKJUCKwzud_WAemA">8163923</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_lMJqv36yQEq7BdUNqY6Ieg">2.72</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_boWkpKJFu0uuOAEChJvoRg">2.16</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_DQvTMB6qb0iEL1KK36wy4g">8161787</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Hidden_T1ooRgaQ1UGTXvhVXaOfsw">8161787</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_7ty8NaL6r0CeyGD1HaVNKQ">8161787</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_R0KpXRjzSkGPJsqmSAn4QQ">0.93</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_9ngmT9i0wEWaZaFs0Tn7og">0.79</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_xAceUuxj_k6APHwI_SdT0w">8163923</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_4QktL8LOGkiNKn26kRJbBQ">8163923</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_pn_EzwJF0kmaifLIJ3rdcw">1.79</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_eHH7Nb15lUyp1mobGSzCaw">1.37</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_7bkd4o4uLU2Z4AnzXUusqA">8160702</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_Mp7_dZUxd0uqceObnl9uHA">8160702</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Hidden_i3zSlr-JE0itqi6e7cvv4A">8160702</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_KBQaGnyoDUm3mQc2xmzb9g">0.72</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_AKXvNQ6KhkS17REUIUfQMQ">0.64</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_8zaKdW06ikS0JQjXfKGprw">8157445</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_DZ4J0sJ2wk27Iq8VEWpVhA">8157445</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_dnHdAMHdnkqQ9vuiISGRLg" decimals="0" name="us-gaap:OperatingExpenses" id="Hidden_Fw2LNw0ysUal1BJuAIrjEg">660150</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_OH-39ladgkuRg5xVxhjYLQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_GpbuznL6YEmHJGSBM-Kb3Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_kuozT-fkoU2VpC3sMRmgDg">8100570</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_IBAq19urw02_lqWC_B7pSQ">8163923</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_qZ-A84FzdESZGsmj4aQNUg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_H9ncv06sKU6bMQBrdA79rg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_1KpyqUlIYEikh7iSvFo8QQ">8100570</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_QRqrEN-rqUqjxJGEYuDI_g">8163923</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_qn4O9gSl_kCk8I6TK9rTRA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_8PJAW-kx3EmoTBTdRqBIqQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_9SEDlZkijEKqtC-ySnJpRg">8100570</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_tZ3jki-L5k2vnk0YROVQzg">8163923</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="anvs-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_PvoPPon-90icfGwFkudlGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TM4iBB8MpUGj7gk1hZK8HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HMHHIWqltEadtnNp5K9vRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dTPFMCnlUizoPLVgqDo4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M7i_UvTYrEaVMR0_3od1qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g1bPv-XlnEmFJB2EbHQo5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NnkAeElpr0ibdtyQmsK5Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qSbmtBj3ukCilwIfxwYMSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUHeKFPJvkygSacsBdj1pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0e58ugnkhkOqtDHQqnqd4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaZWK6ekPEC6t6LMwn5FUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_8tsiqJi9lEmJN9HBgLWOwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_FZnw0o15xUmaQw2wDnDl_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember_ChYbVG2dh0qNdtn6AHEW_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_R4senxF1EkumiKnOchMvOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_02HyU60TGUyED-4dfwaJfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_OUuVKvuXtkq-u1fVxFEu_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_VkaIA_opVUSZSU228t78pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_3phu_26-8EC8DSLEqSiFAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_RvTsofmI_0GsR8XGxxfQXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_1at2mAbtLEy8kiywIeDbHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_PerformanceBasedVestingConditionsMember_I8m5rTHYtEm0RpeBerchIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:PerformanceBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_nvrj-dGqOU6aKJERC6DdWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_qE-sUUUt40qGRKaPxGSmLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_mSBoJpEAKkmTzpJqFergRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_lxMQ0mAjHESuECDwuJ190w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_43OsGov8_0CKtp0gYKTwQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_T8bl_sZlz0iFUq0CaXz_5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_2llG4i7HYUGYKyNFCvAp9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JqPg780lPE6Z6dP0xYgvjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_TPQKDu5CTUOwF4Ecbc0PEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YB8rDynTHE2DxJUQucQRvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_zrhC9mvgWEyE7HMFE93j7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_vPBTijcqYUq2cqEFk9j3ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ32022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_ZSIgU1AfXUyGc1qV1Zr89Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ22022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_5aHRq5IyM0K4Mq8xtwIIPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-26</xbrli:startDate><xbrli:endDate>2021-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_fb4PhuZvEUyAYxprN1iN7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">anvs:GeneratedIn2017AndPriorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ra5Wzdd2lUi3_iM1PWytxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Vi7H0gbpBkCBZr8biy-aFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_Yo6y8AqHFEmOOGOfLBgYxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_dnHdAMHdnkqQ9vuiISGRLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ12022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_AWaPPOKacE-NwSyODgUlNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uW5FryWwhEWgQoKhnkkxmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_WXJELeDryUOIsQTMpZhzWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_f6rfiOKViEG45RyBdeRPZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_zpReF9mePUKpfeIdK6dAxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ12022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l0Xel958IUW2OO3_3ATtqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_j-zkwi6Aj0y2twXZeHsjQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_rxJ3y47tSUmoX-kh_xFoXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_RbtDYEkBt0OdMp6ezICorA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_LvDPCB7paUK0MB8bwYZ-Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D51ABbLLJ0ar_OgKMrKt6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2-H7GqSKf02_tqC2kOqgJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NsdytOcdbEOeqNX5Qs-pDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OuG0ig-8I06-e5XU6-7N0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_6jD9f0YxekO4JmQcbKrXIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RelzNNUAf0uWCtCDxtOuNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nspaGMfz_EWneA97LJAfPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_fqcjJ89wu0-oiY1nhms5jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_MPv8wqMPt0GCQzly0NPo-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_758s6N7iQkGfVS2-JwP_gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_30_2023_SP8NqcwiSE6CQzfBJ-nCsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_18_2023_To_1_18_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CNEPyGXQ7U2LW4h39gTpIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-18</xbrli:startDate><xbrli:endDate>2023-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_26-oGseMPEeNfRhaZLLSPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ32022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_LXOH7EPaEECDbJNsMwmZFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ22022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_j4BX7lHcikG53t8xkKi-0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_3z17PfnHWEakqKGVOPTu-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_-fLIo0BDvUSb0fXlQjkFBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_9kGGHtw_vEKel92_hHoiuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_96WRLFOAHkurv9DzLPZC-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_DAlmQA-0OE6r9GQ5s8nIWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_JTrJWz3ebEirZiY64Y8mVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_X5uz9eIYMECujKqaMEdMmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_14_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_6KFn8E6JGkafxkOpuyUeRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_0xEMeWQcf0WgCqU3s1_d0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_w1NQBqyLWUGiwqQ90rxdHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ12022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Milestone_di9IgBJq0ESfRR3NInDDpg"><xbrli:measure>anvs:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_S5Vg8LIuQ0WQwX_rru60RA"><xbrli:measure>anvs:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_lawsuit_1hwym7Rltkul7iLlrQNJ9Q"><xbrli:measure>anvs:lawsuit</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><a id="_c2f51d93_bdb7_4e30_813e_2ba30f9bdfa0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:2pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Form&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:DocumentType" id="Narr_pOPz8kdKpU6TpGUxiNx63w"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_560de5c3_833a_4b71_ad6c_b1899e914aec"></a><a id="Tc_8vqxfLN8HEyGct1ccvYJGg_0_1"></a><a id="Tc_FGxWFbl_xEafW3Q5JcM74w_2_0"></a><a id="Tc_Ef78kdtQxU6nmXEqQr5AhA_4_1"></a><a id="Tc_3_sbLXoOq0u7gOoNgaEKdw_6_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:DocumentAnnualReport" id="Tc_P4ucR5fCjEySk7X-usoWUQ_0_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p></td></tr><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:DocumentPeriodEndDate" id="Narr_92Y3KbIJg0CcSyGeEXYuaQ"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:CurrentFiscalYearEndDate" id="Narr_ATP2Dlm39k668VIJri0UKA"><b style="font-size:8pt;font-weight:bold;">December&#160;31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2022</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:DocumentTransitionReport" id="Tc_BXkWENABUk20fXePHQHoHw_4_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p></td></tr><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityFileNumber" id="Narr_DSEz1xGJSkyMyQkokeNeOA"><b style="font-size:8pt;font-weight:bold;">001-39202</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityRegistrantName" id="Narr_Mlk16xvnHkajby_fZ7KntQ"><b style="font-weight:bold;">Annovis Bio,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityIncorporationStateCountryCode" id="Narr_dwI3f9Wq1ESgysB_hf3k8g"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">(State or other jurisdiction of</span><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">incorporation or organization)</span></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityTaxIdentificationNumber" id="Narr_gNzL-pMzTEiGCZ_moR0U-Q"><b style="font-size:8pt;font-weight:bold;">26-2540421</b></ix:nonNumeric><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">(I.R.S. Employer</span><span style="font-size:8pt;"><br /></span><span style="font-size:8pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityAddressAddressLine1" id="Narr_PIMa9t_ZfUKc4TGUL6zwEg"><b style="font-size:8pt;font-weight:bold;">1055 Westlakes Drive, Suite&#160;300</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityAddressCityOrTown" id="Narr_GdXpn2u-PUig6EPi7urklw"><b style="font-size:8pt;font-weight:bold;">Berwyn</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityAddressStateOrProvince" id="Narr_gGBaazbZXEKT9QUF4xzvUQ"><b style="font-size:8pt;font-weight:bold;">PA</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityAddressPostalZipCode" id="Narr_xu-IRZTw7U2YvcG7UbAK8A"><b style="font-size:8pt;font-weight:bold;">19312</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices including zip code)</p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:CityAreaCode" id="Narr_XVvqr5qKM0itJNJYlsOaUA"><b style="font-size:8pt;font-weight:bold;">610</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:LocalPhoneNumber" id="Narr_KCBkBUlylEakXpyvSU2Mvg"><b style="font-size:8pt;font-weight:bold;">727-3913</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1b4e4fcb_93fd_4b50_845d_0ea62902d24d"></a><a id="Tc_1a0iApm3eU2dQloQqp70WA_1_0"></a><a id="Tc_BfsDZLymxkWydIwKPEm-8g_1_2"></a><a id="Tc_zHQxUYXlVEe5YuuZ6JuR0Q_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:27.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:2.05%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:27.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:2.05%;border-bottom:1.0pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:Security12bTitle" id="Tc_HQ5dOSAqwEqU_iTBYWSoUA_2_0"><span style="font-size:8pt;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:27.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:TradingSymbol" id="Tc_axjOKcqmBECO6yJtKCAd2A_2_2"><span style="font-size:8pt;">ANVS</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.05%;border-bottom:1.0pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.96%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:SecurityExchangeName" id="Tc_XUy8DgR2tUq2IXd4N-QxAg_2_4"><span style="font-size:8pt;">New York Stock Exchange</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_DG_C8NdKiUuN9uVNEHLZCA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act. Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityVoluntaryFilers" id="Narr_1-88DwKJBUiHhNnno7tllA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityCurrentReportingStatus" id="Narr_S2vB_GCOY0SxFGeL70X1Sw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> &#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityInteractiveDataCurrent" id="Narr_0AvjcITMn0yM4BeXSjGexw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> &#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &quot;emerging growth company&quot; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Large&#160;accelerated&#160;filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityFilerCategory" id="Narr_GFMDeCf9CU-R9-N1QnWG1Q"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntitySmallBusiness" id="Narr_LLVwzxWFMUSB51AuBnVo5w"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:26%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityEmergingGrowthCompany" id="Narr_OJRliLtt0kedgHP-Ehx4Og"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:22%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityExTransitionPeriod" id="Narr_YGbP4D8dkkiIYCFTRZ23fg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:IcfrAuditorAttestationFlag" id="Narr_PZMGt3eztEGNL2TJMxR1QA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;<span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#39;s executive officers during the relevant recovery period pursuant to Section 240.10D-1(b).&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> No&#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:EntityShellCompany" id="Narr_MfxWmm0LuEGATtGyvBiAxw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">As of June&#160;30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" name="dei:EntityPublicFloat" id="Narr_YW-BX1P-00uwb5JwtY3wtg">63,483,880</ix:nonFraction> based on the closing sale price as reported on the NYSE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">The number of shares of the issuer&#8217;s common stock outstanding as of March 30, 2023, was <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_30_2023_SP8NqcwiSE6CQzfBJ-nCsg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_JgsYDSQfhkOBCufYfiodHg">8,216,678</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">Certain portions, as expressly described in this report, of the registrant&#8217;s proxy statement for the 2023 Annual Meeting of the Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fb41dfda_e5da_4cba_b13c_094a064fe226"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CautionaryNoteRegardingForwardLookingSta"><span style="font-style:normal;font-weight:normal;">Cautionary Note Regarding Forward-Looking Statements.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SummaryofRiskFactors_151760"><span style="font-style:normal;font-weight:normal;">Summary of Risk Factors.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_289954"><b style="font-style:normal;font-weight:bold;">Part I.</b></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_749608"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_749608"><span style="font-style:normal;font-weight:normal;">Business.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_448269"><span style="font-style:normal;font-weight:normal;">Item1A.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_448269"><span style="font-style:normal;font-weight:normal;">Risk Factors.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_556571"><span style="font-style:normal;font-weight:normal;">Item1B.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_556571"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_424245"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_424245"><span style="font-style:normal;font-weight:normal;">Properties.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_59244"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_59244"><span style="font-style:normal;font-weight:normal;">Legal Proceedings.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_448345"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_448345"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_847922"><b style="font-style:normal;font-weight:bold;">Part II.</b></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_371514"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_371514"><span style="font-style:normal;font-weight:normal;">Controls and Procedures.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_404053"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_404053"><span style="font-style:normal;font-weight:normal;">Other Information.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_953652"><b style="font-style:normal;font-weight:bold;">Part III.</b></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsandExecutiveOfficersandCo"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsandExecutiveOfficersandCo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_144002"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_144002"><span style="font-style:normal;font-weight:normal;">Executive Compensation.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions and Director Independence.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Principal Accountants Fees and Services.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_494222"><b style="font-style:normal;font-weight:bold;">Part IV.</b></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_558755"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_558755"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">95</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#IndextoFinancialStatements"><span style="font-style:normal;font-weight:normal;">Index to Financial Statements.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_225846"><span style="font-style:normal;font-weight:normal;">Signatures.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_45204933_4cdc_4f20_812c_14ba13e5f878"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Explanatory Note</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restatement of Previously Issued Quarterly Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the preparation of our 2022 audited combined financial statements and notes thereto, we concluded that there were material research and development expenses and related balance sheet errors in our previously issued unaudited condensed financial statements as of and for each of the quarterly and year to date periods ended March 31, 2022, June 30, 2022 and September 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses. As a result of such errors, we concluded that each of the issued 2022 unaudited condensed financial statements were materially misstated, and have restated herein our previously issued unaudited condensed financial statements for each of the quarterly and year to date periods ended March 31, 2022, June 30, 2022, and September 30, 2022. The restatement corrections impact certain components within operating cash flows of the unaudited condensed statements of cash flows. Total operating cash flows, investing activities, financing activities, and cash and cash equivalents are unchanged as a result of the restatements and as a result are not restated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In this Annual Report on Form 10-K for the year ended December 31, 2022, we are restating (the &#8220;Restatement&#8221;) our previously issued (i) unaudited condensed balance sheets as of March 31, 2022, June 30, 2022 and September 30, 2022, (ii) unaudited condensed statements of operations and comprehensive loss for the three months ended March 31, 2022, three and six months ended June 30, 2022, and three and nine months ended September 30, 2022, (iii) unaudited condensed statements of cash flows for the three months ended March 31, 2022, six months ended June 30, 2022 and nine months ended September 30, 2022, in each of the Quarterly Reports on Form 10- Q for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022 (the &#8220;Prior Quarterly Financial Statements&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The financial information that was previously filed or otherwise reported for the Prior Quarterly Financial Statements is superseded by the information in this Annual Report on Form 10-K, Note 12 - Restatement of Previously Issued Unaudited Condensed Financial Statements. We have not filed and do not intend to file amendments to our Quarterly Reports on Form 10-Q for any of the quarterly periods in fiscal year 2022. Accordingly, investors should rely only on the restated Financial Statements and related disclosures included in this 2022 Form 10-K for the applicable periods or in future filings with the SEC (as applicable), and not on any previously issued or filed reports, earnings releases or similar communications including the Financial Statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Internal Control Considerations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Restatement described above, management has determined that there was a material weakness in the Company&#39;s operation of effective internal control over financial reporting related to its application of ASC 606 for collaboration and license agreements as of December 31, 2022. For a discussion of management&#8217;s considerations of the Company&#8217;s disclosures controls and procedures, internal controls over financial reporting, and the material weakness identified, refer to &#8220;Controls and Procedures&#8221; in Part II, Item 9A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f23fea42_39ba_4f0b_8f9e_33c2c62a4597"></a><a id="CautionaryNoteRegardingForwardLookingSta"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cautionary Note&#160;Regarding Forward-Looking Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form&#160;10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The forward-looking statements in this Annual Report on Form&#160;10-K include, among other things, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash and cash equivalents balance, runway and needs as well as financing plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of regulatory submissions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our business strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to market acceptance of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks associated with our reliance on third-party organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitive position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position and our ability to maintain and protect our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our results of operations, financial condition, liquidity, prospects, and growth strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the industry in which we operate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trends that may affect the industry or us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should refer to Part&#160;I,&#160;Item&#160;1A &#8220;Risk Factors&#8221; of this Annual Report on Form&#160;10-K for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of the risks, uncertainties and assumptions described under &#8220;Risk Factors&#8221; and elsewhere, we cannot assure you that the forward-looking statements in this Annual Report on Form&#160;10-K will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.</p><a id="SummaryofRiskFactors_151760"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary of Risk Factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the principal risks described below in Part I, Item 1A &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. We believe that the risks described in the &#8220;Risk Factors&#8221; section are material to investors, but other factors not presently known to us or that we currently believe are immaterial may also adversely affect us. The following summary should not be considered an exhaustive summary of the material risks facing us, and it should be read in conjunction with the &#8220;Risk Factors&#8221; section and the other information contained in this Annual Report on Form 10-K .</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because our auditor has issued a going concern opinion regarding our company, there is an increased risk associated with an investment in our company.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require substantial additional capital to fund our operations, and if we fail to obtain necessary funding, we may not be able to complete the development and commercialization of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited operating history and no history of commercializing pharmaceutical products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are heavily dependent on the success of Buntanetap, our most advanced product candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have concentrated our research and development efforts on the treatment of Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;), diseases that have seen limited success in drug development. Further, Buntanetap is based on a new approach to treating AD and PD, which makes it difficult to predict the time and cost of development and subsequent obtaining of regulatory approval. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are not successful in discovering, developing, and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials, including the enrollment and retention of patients, are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for Buntanetap or any other product candidates, our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials. Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are further subject to audit and verification procedures that could result in material changes in the final data. Furthermore, undue reliance on interim analyses may be detrimental to our long-term clinical development plans, which could harm our business, operating results, prospects or financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market opportunities for Buntanetap or any other product candidates, if approved, may be smaller than we anticipate, which could adversely affect our business, financial condition and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we obtain regulatory approval for Buntanetap or any product candidates, we will still face extensive and ongoing regulatory requirements and obligations. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The successful commercialization of Buntanetap and any other product candidates we develop will depend in part on market acceptance; the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies; and our sales, marketing and distribution capabilities. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A variety of risks associated with operating internationally could materially adversely affect our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently rely on third parties for the production of clinical supply of Buntanetap and for the conduct, supervision and monitoring of our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner or do not comply with regulatory standards and requirements, it may harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Changes in methods of product candidate manufacturing or formulation may result in additional cost or delay. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enacted and future healthcare and other legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, increase the liabilities to which we may become subject, and affect the prices we may set or the manner in which we conduct and plan to conduct our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain, maintain and enforce patent or other intellectual property protection for Buntanetap or any future product candidates or technology or if the scope of the patent protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, our ability to successfully commercialize Buntanetap or any future product candidates may be adversely affected and we may not be able to compete effectively in our markets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be subject to claims challenging the inventorship of our patents and other intellectual property. We may additionally become subject to third parties&#8217; claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The cash and cash equivalents that we use to meet our working capital and operating expense needs are held in deposit accounts at two financial institutions. If one or both financial institutions fail, our deposit accounts could be adversely affected due to the loss of or delay in obtaining access to all or a portion of our uninsured funds.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of our common stock has been volatile and fluctuated substantially in the past, and may continue to experience volatility and substantial fluctuations in the future, which could result in substantial losses for purchasers of our common stock. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have been subject to securities class action litigation in the past, and could be subject to such litigation in the future. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We identified a material weakness in our internal control over financial reporting, which resulted in the restatement of our financial statements for several prior quarterly and year-to-date periods. If remediation of this material weakness is not effective, or if we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately or timely report our financial condition or operating results, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The restatement of our prior quarterly financial statements may affect investor confidence and raise reputational issues and may subject us to additional risks and uncertainties, including increased professional costs and the increased possibility of legal proceedings and regulatory inquiries.</span></td></tr></table><div style="margin-top:10pt;"><a id="_949ebe75_6e9e_429f_aeee_9573dce0409b"></a><a id="PARTI_289954"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART I</b></p><a id="Item1Business_749608"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 1. Business.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Company</b></p><a id="_Hlk64273646"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio, Inc. is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;). We are developing our lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, Buntanetap was observed to inhibit the synthesis of neurotoxic proteins&#8212;APP/A&#946; (&#8220;APP&#8221;), tau/phospho-tau (&#8220;tau&#8221;) and &#945;-Synuclein (&#8220;&#945;SYN&#8221;)&#8212;that are one of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that Buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.</p><a id="_Hlk64273716"></a><a id="_Hlk64273808"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2021, we completed two Phase 1/2 clinical studies: one in 14 early AD patients, and one in 54 early PD patients (together, the &#8220;AD/PD Trials&#8221;). In the AD/PD Trials, early AD patients were defined as those with a Mini Mental State Examination (MMSE) score between 19 and 28 and early PD patients as those patients at Hoehn &amp; Yahr stages 1, 2 or 3. MMSE is a brief screening instrument used to assess cognitive function, with total scores ranging from 0 to 30 and a lower score indicating greater disease severity, while the Hoehn &amp; Yahr scale is a medical assessment used to measure staging of the functional disability associated with PD where a higher stage indicates greater disease severity. In collaboration with the Alzheimer&#8217;s Disease Cooperative Study (&#8220;ADCS&#8221;), we also conducted a trial in 16 early AD patients (the &#8220;ADCS Trial&#8221;). In the ADCS Trial, early AD patients were defined as those patients with a MMSE score between 19 and 28. All three clinical trials were double-blind, placebo-controlled studies. We designed the studies by applying our understanding of the underlying neurodegenerative disease states, and measured both target and pathway validation in the spinal fluid of patients to determine whether patients improved following treatment. In addition to meeting their primary endpoints of safety and tolerability and secondary endpoint of pharmacokinetics of Buntanetap, our AD/PD Trials met exploratory endpoints of measures of biomarkers and improvements in cognition in AD patients, and in function in PD patients. We believe that the AD/PD Trials represent the first double-blind placebo-controlled studies that showed improvements in AD patients, as measured by ADAS-Cog, and in PD patients, as measured by UPDRS. Following completion of the AD/PD Trials, we submitted our data to the&#160;U.S. Food and Drug Administration (&#8220;FDA&#8221;) and requested direction to further pursue the development of Buntanetap in early PD patients. With the FDA&#8217;s guidance, we initiated a Phase 3 study in early PD patients in August 2022 (our &#8220;Phase 3 PD Study&#8221;). In the Phase 3 PD Study, early PD patients were defined as those at Hoehn &amp; Yahr stages 1, 2 or 3 and OFF times of less than two hours per day. OFF time refers to when PD motor and/or non-motor symptoms occur between medication doses. We also submitted a proposed protocol for the treatment of moderate AD to the FDA, and after receiving permission to proceed, we initiated a Phase 2/3 study in mild to moderate AD patients in February 2023 (our &#8220;Phase 2/3 AD Study&#8221;). In the Phase 2/3 AD Study, mild to moderate AD patients were defined as those with a MMSE score between 14 and 24. At the completion of the ADCS Trial, the data showed that Buntanetap is a translational inhibitor in humans just like in animals, and we further observed that there was statistical improvement in cognition in early AD patients, just like in the AD/PD Trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our Phase 3 PD Study and Phase 2/3 AD Study each have built in interim analyses. Our Phase 3 PD Study incorporated an interim analysis at two months, the results of which were disclosed on March 31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132 patients from all cohorts collectively for which baseline and two-month data was available. As the interim analysis was conducted at two months of the six-month endpoint and only on 132 patients, it may not be indicative of the results at six months for the full patient population because as the trial progresses, clinical outcomes may materially change as patient enrollment continues and more patient data become available, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Based on the results of the interim analysis, we intend to proceed with the Phase 3 PD Study as planned in accordance with the previously established protocol. We remain blinded to the Phase 3 PD Study and we do not have safety or efficacy data from the trial. A separate safety interim analysis is in process and we expect that interim analysis to be released in the second quarter of 2023. We intend to disclose the results of an interim analysis for our Phase </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2/3 AD Study in Fall 2023. We plan to consult with the FDA following completion of these interim analyses, to obtain feedback on our ongoing and planned AD and PD studies, including conducting an open label extension study following the completion of the initial trials. Using the data from the Phase 3 PD Study interim analysis, we intend to design an 18-month long disease-modifying Phase 3 study in the same early PD patients. In addition, we intend to conduct a short 6-month study in advanced PD patients during the second half of the 18-month disease modifying Phase 3 study, at which time we will define the advanced PD patient population for the purposes of such study. Similarly, using the data from the Phase 2/3 AD Study interim analysis, we intend to design an 18-month disease modifying Phase 3 study in the same early AD patient population. In addition, we intend to conduct a short 6-month study in advanced AD patients during the second half of the 18-month disease modifying Phase 3 study, at which time we will define the advanced AD patient population for the purposes of such study. We expect both the ongoing Phase 3 PD Study and the Phase 2/3 AD Study to be completed by the end of 2023, and we intend to announce the data from the final analyses in the first quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By the end of 2026, our goal is to have conducted the required pivotal studies for Buntanetap to be able to file two new drug applications (&#8220;NDAs&#8221;) with the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein, and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD as well as body and brain function associated with PD. Based on pre-clinical and clinical data collected to date, we believe that Buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling Buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or &#945;SYN, indicating that doing so does not change the course of neurodegeneration. Our goal is to develop a disease modifying drug (&#8220;DMD&#8221;) for patients with neurodegeneration by leveraging our clinical and pre-clinical data to inhibit the three most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and accordingly these diseases present two unmet needs of the aging population and two potentially large U.S. markets if a DMD is developed and approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> Our leadership team has substantial experience and extensive industry knowledge, and has been successful with respect to meeting clinical timelines, enrollment progression and data readouts. Maria L. Maccecchini, our Founder, President and CEO, founded Annovis in May 2008 to develop better therapeutics for neurodegeneration. She was previously the Founder and CEO of Symphony Pharmaceuticals/Annovis, a biotech company that sold to Transgenomic in 2001. She was also the General Manager of Bachem Bioscience, the U.S. subsidiary of Bachem AG, Switzerland. Dr. Maccecchini did one postdoc at Caltech and one at the Roche Institute of Immunology. Her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University. Henry Hagopian, our Chief Financial Officer, has over 30 years of experience in corporate finance, accounting, treasury and capital raising in both public and private companies. Prior to joining Annovis, Mr. Hagopian was Senior Vice President, Finance and Treasurer at Organogenesis, where he assisted in raising several rounds of capital in excess of $310 million. He spent 15 years in positions at AT&amp;T, Lucent Technologies and CIRCOR International, Inc. Mr. Hagopian holds an M.B.A. and M.S. from the Carroll Graduate School of Management at Boston College. Cheng Fang, Senior Vice President, Research and Development, has broad scientific knowledge and over a decade of experience working in the field of neurodegenerative diseases. She previously worked at Clarivate Analytics and the Cornell Institute for Medical Research. As a Research Assistant Professor at Boston University, she designed projects on prion disease and AD. She has a PhD in biology and neuroscience from Pennsylvania State University. She also holds a B.S. in biopharmaceutics from Nanjing University. Eve Damiano, Senior Vice President, Regulatory, has spent over 35 years in the biotechnology sector, focusing on the definition and execution of regulatory strategies. Ms. Damiano has held various senior management positions throughout her career, with experience garnered at companies including Centocor, MedImmune, OraSure Technologies and Vicuron Pharmaceuticals. Ms. Damiano holds a track record in the definition and execution of regulatory strategies. She holds an M.S. from the Drexel University College of Medicine. Melissa Gaines, Vice President, Clinical Operations, is an accomplished clinical research professional with over 20 years&#8217; experience garnered from positions held in academia, contract research organizations and pharmaceutical companies. She was previously Senior Director, Clinical Operations, for Worldwide Clinical Trials, and has over a decade of experience at INC Research. She has demonstrated proven success in leading cross-functional teams as well as driving operational success. She holds a B.A. in Psychology from Millersville University of Pennsylvania.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Mechanism of Action</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our lead product candidate, Buntanetap, is designed as an oral translational inhibitor of neurotoxic aggregating proteins (&#8220;TINAP&#8221;) such as APP, tau and &#945;SYN. To understand how Buntanetap can potentially inhibit translation, we undertook two </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:251.21pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">complementary approaches: a macro approach to examine all proteins in the cell whose translation is affected by Buntanetap, and a micro approach to study the mechanism of action using molecular biology, to understand and validate the binding and function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">First, the non-biased proteomics approach was applied to explore what proteins in the total protein universe were specifically downregulated by Buntanetap. We have observed that, in addition to the proteins already known to be reduced by Buntanetap, other neurotoxic aggregating proteins - huntingtin protein (&#8220;HTT&#8221;) and TDP43 - were downregulated as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A detailed analysis of the reduction of these protein levels was conducted in five different laboratories using multiple methodologies. The results observed in the analysis revealed that the mRNAs of these proteins have a special region, an atypical stem loop, that is preserved and responsible for their translation. When this region is bound to an RNA binding protein, the mRNA is not translated. When this region is free, the mRNA is translated. In neurodegenerative conditions, the mRNA coding for these neurotoxic proteins is over-translated, produces high levels of these proteins and causes them to become toxic. Buntanetap was observed to specifically increase the affinity between this special region and the RNA binding protein, thereby showing the potential to prevent the mRNA from being released and translated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This leads to lower translation, lower levels of neurotoxic proteins, and less toxicity in the brain. By preventing the overexpression of these neurotoxic proteins, Buntanetap is designed to reverse the downstream toxic cascade that leads to neurodegeneration and reinstates homeostasis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This rigorous approach to understanding the mode of action shows that while Buntanetap does lower the levels of more than one neurotoxic protein, it is exquisitely specific for the atypical stem loops in the mRNAs of these proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following illustration shows the mechanism of action of Buntanetap:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k003.jpg" alt="Graphic" style="display:inline-block;height:251.21pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:446.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 12pt 0pt;">MOA; Chen XQ et al. Pharmaceutics 09-2021 Iron and Neurodegeneration; Wong f. et al. Frontiers Aging Neuroscience; 03-2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The special region in the mRNA is a 5&#8217;UTR iron responsive element (&#8220;IRE&#8221;) present in all mRNAs of neurotoxic aggregating proteins. The RNA binding protein is the Iron Regulatory Protein -1 (&#8220;IRP1&#8221;) that specifically binds the IREs of neurotoxic aggregating proteins.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:273.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">The Toxic Cascade Leading to Nerve Cell Death and Loss of Function</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. Buntanetap and ANVS405, our product candidates designed to treat acute neurodegeneration, including traumatic brain injury (&#8220;TBI&#8221;), have a mechanism of action we believe to be unique. The mechanism of action is designed to inhibit the over-translation of and reduce the levels of APP, tau and &#945;SYN, which play a central role in the pathogenesis of both AD and PD. This leads us to believe that Buntanetap has the potential to be a promising drug for the treatment of both AD and PD. Our approach is innovative in that we do not have a single therapeutic target for a single disease; instead, we are developing a technology platform that has the potential to target the mRNAs of multiple neurotoxic proteins, which are potentially impactful for multiple diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="anvs-20221231x10k004.jpg" alt="Graphic" style="display:inline-block;height:272.96pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:485.18pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In our AD/PD Trials, we observed that Buntanetap reduced levels of neurotoxic proteins, improved axonal transport and synaptic function, reduced inflammation, improved the health of nerve cells and improved cognition and function in mild to moderate AD and PD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have observed that Buntanetap reduced the levels of multiple neurotoxic proteins in animals and reversed the toxic cascade. In addition, Buntanetap was observed to reverse the entire toxic cascade in animals and recover function, be it in the brain, the body, or the eyes.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:229.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pipeline</b></p><a id="_Hlk64273925"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our pipeline consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.</p><a id="_Hlk64273969"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k005.jpg" alt="Graphic" style="display:inline-block;height:229.47pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:437.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Buntanetap</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our lead product candidate, Buntanetap, is an orally administered drug being developed for chronic indications such as AD and PD, and it has been observed to improve axonal transport in these diseases in preclinical studies by inhibiting the overproduction of neurotoxic proteins that kill nerve cells. Buntanetap further demonstrated improvements of cognition, including memory and learning, in AD mice and movement, including colonic motility and grip strength, in PD mice. Buntanetap was tested in three Phase 1 clinical studies that showed it to be well tolerated. This safety data is applicable to the clinical development of Buntanetap for AD, PD, and potentially other chronic neurodegenerative diseases. We have completed three Phase 1/2 clinical trials for Buntanetap.  We are presently treating PD patients in our Phase 3 PD Study and AD patients in our Phase 2/3 AD Study.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that Buntanetap has the potential to be the only drug to improve both cognition in AD patients, and motor function in PD patients. Additionally, Buntanetap was observed to protect nerve cells from dying in the brain of traumatic brain injury mice and to protect nerve cells from dying in the eye of glaucoma rats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ANVS405</span></p><a id="_Hlk64274024"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ANVS405 is an intravenous drug being developed for acute indications, and focused on protecting the brain after TBI and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS405 was given to rats intravenously after TBI to determine whether ANVS405 would reach the brain in less than 15 minutes, as opposed to 1.5 hours if given orally. TBI rats that were treated with ANVS405 after the insult exhibited enhanced memory and learning and lower microglia activation, a measure of inflammation. The program has been funded by a grant from the U.S. Army which has been completed, and we plan to seek additional grant funding to further the development of ANVS405 for acute indications of brain and nerve trauma. If and when we receive such sufficient funding, we plan to conduct a follow-on study to evaluate the effect of ANVS405 administered to TBI rats at various intervals post-injury to determine how long after a TBI we can effectively treat a patient. Our plan is to seek further funding to conduct the toxicology and pharmacokinetics (&#8220;PK&#8221;) studies in animals, file the initial new drug application (&#8220;IND&#8221;), conduct the safety and PK studies in humans and continue with Phase 2 and Phase 3 efficacy studies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ANVS301</span></p><a id="_Hlk64274065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 was observed to improve memory and learning in very old rats by lowering the number of errors from six to three and shortening run times from approximately 75 to approximately 28 seconds. ANVS301 is in a Phase 1 clinical trial that was conducted and financed by the National Institutes of Health (&#8220;NIH&#8221;). The single ascending dose study has been completed, and we expect to evaluate the continued development of ANVS301 based upon funding availability. When both the single and multiple ascending dose safety studies are complete, we will review the data and decide whether to pursue the indication of advanced AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical Trials of Buntanetap</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Development Plan for Alzheimer&#8217;s Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The development of Buntanetap for AD is expected to include a short study for moderate AD showing symptomatic efficacy, a long 18-month study in early AD showing disease-modifying efficacy, and a second short 6-month study in advanced AD. We expect to discuss the development plan with the FDA following receipt of the results from the interim analysis of the first study in Fall 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In February 2023, we initiated the first of the three studies: a Phase 2/3 clinical trial of Buntanetap in 320 mild to moderate AD patients, which were separated into four cohorts of 80 patients (the &#8220;Phase 2/3 AD Trial&#8221;). The Phase 2/3 AD Trial is expected to be conducted at approximately 80 sites in the U.S. The Phase 2/3 AD Trial is a double-blind placebo-controlled efficacy study which treats mild to moderate AD. The inclusion criteria for mild to moderate AD is a MMSE score of 14 to 24. Patients participating in the trial are age 55-85, have a study partner, are of non-child-bearing age or agree to effective contraception, and have no evidence of suicidal ideation. Patients participating in the trial can remain on any drugs they regularly take, whether for AD or for other conditions, as long as they are stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients with cancer within the last year and patients suffering from alcohol or substance abuse are excluded from participating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Patients will be randomly assigned to receive either 7.5, 15 or 30 mg of Buntanetap or placebo once per day. Patients will visit the clinic for the first-time dosing in clinic, followed by an at home dosing period of 12 weeks. The study plan incorporates an interim analysis at six-weeks, the results of which are expected in Fall 2023. The Phase 2/3 AD Trial is designed to assess the efficacy, safety, tolerability, and PK of Buntanetap. The co-primary endpoints of the Phase 2/3 AD Trial are evaluated using the following measures: Alzheimer&#39;s Disease Assessment Scale-Cognitive Subscale 11 (ADAScog 11), which measures cognitive functions and non-cognitive functions such as mood and behavior; and ADCS-Clinical Global Impression of Change (ADCS-CGIC), which focuses on clinicians&#39; observations of change in the patient&#39;s cognitive, functional, and behavioral performance since the beginning of a trial. The FDA requested to include two co-primary endpoints to have an objective primary endpoint (ADAScog, cognition) and a subjective primary endpoint (ADCS-CGIC, activities of daily living). Together, these co-primary endpoints are intended to provide in a more complete picture of the study and treatment results. The secondary endpoints are evaluated using the following measures: the ADCS-Instrumental Activities of Daily Living Scale (ADCS-ADL), which measures 6 basic activities of daily living items, including basic self-care tasks such as feeding, mobility and bathing, and 17 instrumental activities of daily living items, which include a broad range of activities based on cultural norms and gender roles; MMSE; and the digital symbol substitution test (DSST), which asks individuals to record associations between different symbols and numbers within time limits to assess cognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The second trial we intend to conduct is an 18-month disease-modifying Phase 3 study in early AD patients, in which patients will be randomly assigned to receive either placebo or a dose of Buntanetap once per day, to be determined based upon the results of the Phase 2/3 AD Trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The third trial we intend to conduct is a six-month study in advanced AD patients, which is expected to take place during the second half of the 18-month disease modifying Phase 3 study. In this six-month study, patients will be randomly assigned to receive either placebo or a dose of Buntanetap once per day, to be determined based upon the results of the Phase 2/3 AD Trial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:277.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="anvs-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:277.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:403.44pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Development for Parkinson&#8217;s Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development plan of Buntanetap for PD is expected to include a short study for early PD patients showing symptomatic efficacy, a long 18-month study in the same patient population showing disease-modifying efficacy, and a second short 6-month study in advanced PD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In August 2022, we initiated a Phase 3 clinical trial of Buntanetap in 450 early PD patients, which were separated into three cohorts of 150 patients (the &#8220;Phase 3 PD Trial&#8221;). The Phase 3 PD Trial is expected to be conducted at approximately 53 sites in the U.S. and 49 sites in the EU. The Phase 3 PD Trial is a double-blind placebo-controlled efficacy study which treats early PD. The inclusion criteria for early PD are Hoehn &amp; Yahr 1, 2 and 3 with less than 2 hours of OFF time, as well as a MMSE score of 22 to 30. Patients participating in the trial are age 40-85, are of non-child-bearing age or agree to effective contraception, and have no evidence of suicidal ideation. Patients participating in the trial can remain on any drugs they regularly take, whether for PD or for other conditions, as long as they are stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients with cancer within the last year and patients suffering from alcohol or substance abuse are excluded from the trial. Patients are randomly assigned to receive either 10 or 20 mg of Buntanetap or placebo once per day. Patients visit the clinic for the first-time dosing in clinic, followed by an at home dosing period of 6 months. The study plan incorporated an interim analysis at two months, the results of which were disclosed by the Company on March 31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132 patients from all cohorts collectively for which baseline and two-month data was available. As the interim analysis was conducted at two months of the six-month endpoint and only on 132 patients, it may not be indicative of the results at six months for the full patient population because as the trial progresses, clinical outcomes may materially change as patient enrollment continues and more patient data become available, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Based on the results of the interim analysis, we intend to proceed with the Phase 3 PD Study as planned in accordance with the previously established protocol. We remain blinded to the Phase 3 PD Study and we do not have safety or efficacy data from the trial. A separate safety interim analysis is in process and we expect that interim analysis to be released in the second quarter of 2023. The study is designed to assess the efficacy, safety, tolerability, and PK of Buntanetap. The Phase 3 PD Trial&#8217;s primary endpoints are evaluated using the following measures: the MDS-Unified Parkinson&#39;s Disease Rating Scale (MDS-UPDRS) Part II and III, which is a 42-item rating scale designed to assess Parkinson&#39;s disease-related disability and impairment, and evaluates activities of daily living and motor function; and safety and tolerability, which is assessed using physical examinations, vital signs, clinical laboratory test results, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:252.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">electrocardiogram findings, adverse events (AEs) leading to study discontinuation, drug related AEs, severity of AEs and AEs. Specifically, The FDA requested two co-primary endpoints to have an objective primary endpoint (MDS-UPDRS Part III, motor function) and a subjective primary endpoint (MDS-UPDRS Part II, activities of daily living). Together, these co-primary endpoints are intended to provide in a more complete picture of the study and treatment results. The secondary endpoints are evaluated using the following measures: the MDS-UPDRS total score, which includes the Part II and III measures we well as mentation, behavior, and mood symptoms, and complications of dopaminergic therapy; the participant global impression of change (PGIC), a participant-reported outcome which asks how their condition has changed compared to their condition at the beginning of treatment; and the Change on Clinical Global Impression of Severity (CGIS), which measures the severity of movement impairment as assessed by the site rater.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The second trial we intend to conduct is an 18-month disease-modifying Phase 3 study in early PD patients, in which patients will be randomly assigned to receive either placebo or a dose of Buntanetap once per day, to be determined based upon the results of the Phase 3 PD Trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The third study we intend to conduct is a six-month study in advanced PD patients, which is expected to take place during the second half of the 18-month disease modifying Phase 3 study. In this six-month study, patients will be randomly assigned to receive either placebo or a dose of Buntanetap once per day, to be determined based upon the results of the Phase 3 PD Trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:251.96pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:485.18pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 1/2 AD/PD Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;white-space:pre-wrap;">In 2021, we completed a Phase 1/2 clinical trial of Buntanetap in 14 early AD and 54 early PD patients (the &#8220;AD/PD Trials&#8221;) which were conducted at 12 sites in the U.S.  The AD/PD Trials were double-blind placebo-controlled studies which treated mild to moderate AD and early PD patients for 25 +/- 2 days. The inclusion criteria for the AD portion of the AD/PD Trials were MMSE 18-28 and age 45 and older and for the PD portion of the AD/PD Trials were MMSE 18-30, age 45 and older and Hoehn &amp; Yahr 1, 2 or 3. Patients participating in the trial were of non-child-bearing age or agreed to effective contraception, and had no evidence of suicidal ideation. Patients participating in the trial could remain on any drugs they regularly take, whether for PD, for AD or for other conditions, as long as they were stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients who had cancer within the prior year and patients who suffered from alcohol or substance abuse were excluded from the trial.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:147.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The AD/PD Trials were designed to assess the safety, tolerability, and PK of Buntanetap. The studies met their primary endpoints of safety and tolerability, as measured by the percentage of patients with treatment-emergent adverse events in the Buntanetap treatment arms as compared to the placebo groups, and secondary endpoint of pharmacokinetics of Buntanetap, as measured by the concentration of Buntanetap in plasma. The studies also met exploratory endpoints of measures of biomarkers related to neurotoxic protein cascade, and improvements in cognition in AD patients and function in PD patients. We believe the AD/PD Trials were the first double-blind, placebo-controlled studies that showed improvements in AD patients as measured by ADAS-Cog, and in PD patients as measured in UPDRS.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;white-space:pre-wrap;">The studies were conducted in two parts.  The first part of the AD/PD Trials was in 14 early AD patients and 14 early PD patients.  Patients were randomly assigned to receive either 80 mg of Buntanetap or placebo once per day.  The second part of the AD/PD Trials was a dose response analysis in 40 early PD patients in which patients were randomly assigned to receive 5 mg, 10 mg, 20 mg, or 40 mg of Buntanetap once per day.  In both parts of the AD/PD Trials, patients visited the clinic for the first-time dosing in clinic, followed by an at home dosing period of 25 +/- 2 days.  We measured levels of neurotoxic proteins, neurotransmitters, neurotrophic factors, inflammation, and nerve cell death in all patients, as well as cognitive and functional improvements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Safety and PK</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Safety results show that Buntanetap was well-tolerated in all dose groups. No serious adverse events were reported. The adverse events seen included problems related to CNS sampling: headaches, back and leg pain. PK parameters for Buntanetap in plasma of AD and PD patients were similar to those seen in Phase 1 in our single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) studies in healthy volunteers, and in a proof-of-concept study in mild-cognitive impaired (&#8220;MCI&#8221;) patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction of Neurotoxic Proteins</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We observed that Buntanetap administration for 25 days lowered secreted APP &#945; and &#946; as well as total-tau and phosphorylated-tau levels in AD patients, and alpha-synuclein levels in PD patients. APP and its downstream products and tau are the neurotoxic proteins involved in AD, while &#945;SYN is the primary neurotoxic culprit of PD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in Biomarkers After 25 Days Treatment with Buntanetap</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:146.98pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:450.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">* All values are in comparison to placebo based on all data points.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cerebrospinal fluid (&#8220;CSF&#8221;) was extracted before starting the study at baseline and at time 0 to 6 hours at the end of the study in both placebo and Buntanetap treated patients. The values from time 0 to 6 hours were pooled to lower variability and the placebo values were deducted from the treated values. In all but one case, Ab42, we saw that the levels in Buntanetap treated patients were lower than in placebo patients. With respect to Ab42, we observed that levels were slightly higher, which is consistent with our hypothesis that Ab42 levels are lower in advanced AD and higher in early AD. We believe that higher Ab42 levels we observed suggest that the course of AD was reversed and the patients improved.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:164.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inflammation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We observed that Buntanetap reduced inflammation in both AD and PD patients, shown by Complement C3, YKL-40, GFAP and sTREM2.</p><a id="_Hlk94000917"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in Inflammatory Markers after 25 Days Treatment with Buntanetap</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k009.jpg" alt="Graphic" style="display:inline-block;height:153.73pt;width:437.19pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">*All values are in comparison to placebo based on all data points.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Again, CSF was extracted at baseline and for 6 hours after the study and the values of the placebo patients were subtracted from the Buntanetap treated patients. We observed that inflammatory markers were generally reduced in both patient populations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Axonal and Synaptic Function</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We observed that Buntanetap reduced neurofilament light (&#8220;NFL&#8221;) levels in both AD and PD patients, suggesting a potential improvement in axonal integrity. We also observed that Buntanetap reduced neurogranin (&#8220;NG&#8221;) levels in both AD and PD, potentially suggesting more intact synaptic functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Changes in Synaptic Markers after 25 Days Treatment with Buntanetap</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k010.jpg" alt="Graphic" style="display:inline-block;height:164.22pt;width:438.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">*All values are in comparison to placebo based on all data points.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:195.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The same CSF as above was used to measure neurofilament light and neurogranin before and after treatment and to compare Buntanetap patients to placebo. In both patient populations neurofilament light and neurogranin are lower in treated than in placebo patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe these results suggest that Buntanetap has the potential to reduce neurotoxic proteins, rescue axonal transport, reduce inflammation, and protect synaptic functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cognition in AD Patients</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We performed ADAS-Cogs and WAIS coding tests to evaluate Buntanetap&#8217;s effects on AD patients&#8217; cognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k011.jpg" alt="Graphic" style="display:inline-block;height:194.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:142.48pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">* P&lt;0.05</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ADAS-Cog11 was performed at the beginning of the study at baseline and at the end at 25 days in the Buntanetap-treated and the placebo groups. Although the study was not powered for efficacy, ADAS-Cog11 improved by 4.4 points, a statistically significant improvement of 28.57%. A result is considered to be statistically significant when the probability of the result occurring by random chance, rather than from the efficacy of the treatment, is sufficiently low. The conventional method for determining the statistical significance of a result is known as the &#8220;p-value,&#8221; which represents the probability that random chance caused the result (e.g., a p=0.01 means that there is a 1% probability that the difference between the control group and the treatment group is purely due to random chance). Generally, a p-value less than 0.05 is considered statistically significant. An improvement in ADAS-Cog11, which is reflected by a lower ADAS-Cog11 result, indicates increased cognitive performance. At 25 days, the treated group&#8217;s improvement from baseline was 3.3 points, or 20.71%, better than the placebo group&#8217;s improvement from baseline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:169.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k012.jpg" alt="Graphic" style="display:inline-block;height:169.47pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:193.47pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">* P&lt;0.05</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The WAIS coding test measures speed in movement and thinking. Treated AD patients showed a 6.6 point, or 16.17%, statistically significant improvement from baseline. Furthermore, the treated group&#8217;s improvement from baseline was 3.1 points, or 8.8%, better than the placebo group&#8217;s improvement from baseline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Motor Function in PD Patients</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In Parkinson&#8217;s disease, we pooled the original 14 PD patients with the additional 40 PD patients, and looked at the MDS-UPDRS and WAIS coding tests to evaluate Buntanetap&#8217;s effects on PD patients&#8217; mobility and functionality. We the 54 PD patients received doses of either 5mg, 10mg, 20mg, 40mg or 80mg Buntanetap treatment or placebo once per day. We observed a statistically significant improvement in Part II, III and IV individually. Specifically, Part III of the MDS-UPDRS measures the motor functions and has long been used as a standard to assess drugs&#8217; effects on patients&#8217; mobility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k013.jpg" alt="Graphic" style="display:inline-block;height:161.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:191.97pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">**p&lt;0.01</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We combined the two best doses, 10 and 20 mgs, and all doses, and saw an improvement of 3.6 (16.4%) for 10 and 20 mg, and of 2.4 (13.3%) for all doses combined compared to baseline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:219.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20221231x10k014.jpg" alt="Graphic" style="display:inline-block;height:218.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:204.72pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Century Gothic';">* p&lt;0.05 ** P&lt;0.01 *** P&lt;0.001</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 18pt;">In the WAIS coding test, PD patients show a statistically significant improvement both from baseline (17.1% for 10+20mg; 13.3% for all doses combined) and from placebo (27.1% for 10+20mg; 23.3% for all doses combined).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 1/2 ADCS Trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We also completed a double-blind, placebo-controlled Phase 1/2 study in early AD patients in conjunction with the ADCS. We treated patients for four weeks with Buntanetap and measured target and pathway engagement in the spinal fluid. This means that we measured levels of neurotoxic proteins, neurotransmitters, neurotrophic factors, inflammation and nerve cell death as well as cognitive improvement. Since Buntanetap is designed as a translation inhibitor, we also measured the rate of synthesis and degradation of A&#946; (SILK &#8211; stable isotope labeling kinetic study) to determine if our drug changes the speed of translation.  Under an agreement with the University of California San Diego, where ADCS is located, we contracted to provide study supplies and PK analysis at our cost but the remaining costs of the ADCS Trial are paid for by the NIH.  The study ended after 16 patients were enrolled and treated. Patients participating in the study were of non-child-bearing age or agreed to effective contraception and had no evidence of suicidal ideation. Patients participating in the study could remain on any drugs they regularly take, either for AD or for other conditions, as long as they were stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients who had cancer within the prior year and patients who suffered from alcohol or substance abuse were excluded from the study. The study was conducted at six sites in the U.S., including the University of California San Diego, Johns Hopkins, Indiana University, Washington University, Cleveland Clinic, and Columbia University. While only 16 patients were treated in total, based on the SILK data, we observed that Buntanetap has the potential to slow the translation of APP/Abeta, leading to overall lower levels and lower overall synthesis of the neurotoxic protein. The Alzheimer&#8217;s Disease Assessment Scale &#8211;Cognitive Subscale (ADAScog) of the treated patients demonstrated what we observed in our small AD/PD study &#8211; statistical improvement in cognition at one month of treatment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 1 Studies </span></p><a id="_Hlk64274141"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Three phase 1 clinical studies have been completed with Buntanetap. Clinical studies with single and repeated daily oral administration of Buntanetap, showed Buntanetap to be well tolerated up to doses of 80 mg once a day or 60 mg four times a day. A single dose of 160 mg was associated with an increased incidence of nausea and vomiting; therefore, higher doses were not tested. Buntanetap is not an AChE inhibitor, but its N1 dimethyl metabolite has some AChE inhibitor activity and may be responsible for these observations. The only consistent AEs seen were dizziness/fainting and headaches. These effects were seen to varying degrees at all doses of Buntanetap and in the placebo group. There were no serious AEs in any of the clinical studies. In the repeat dose studies, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">treatment with 60 mg four times a day was not associated with any side effects not also seen in placebo. The adverse events seen included nausea, vomiting and dizziness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Proof-of-Concept Study in Humans</span></p><a id="_Hlk64274250"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the human proof-of-concept (&#8220;POC&#8221;) study, four patients with MCI were treated for 10 days with Buntanetap with a dose of 60 mg four times a day (240 mg/day), which we observed in a previous safety study to be a well-tolerated level. CSF and plasma were drawn over 12 hours on Day 0 before any administration of Buntanetap and on Day 11 after the last administration of Buntanetap. During each 12-hour period, a total of nine CSF samples were taken and levels of Buntanetap and metabolites were measured in plasma and CSF at all time points. The human POC study was discontinued prior to completion as a cost saving measure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pharmacokinetics</span></p><a id="_Hlk64274281"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap&#8217;s PK in plasma corresponded to what we had seen in the previous clinical safety studies: a half-life of five hours. In CSF, however, Buntanetap showed a much longer half-life of over 12 hours. We conducted an identical experiment in rats, where it is possible to measure the PK of Buntanetap in plasma, CSF and brain. By taking the human plasma/CSF and rat plasma/CSF/brain levels, we were able to extrapolate to the human brain levels and calculate them to be eight times higher than plasma levels. This is generally consistent with the data we have in mice, where in several studies, Buntanetap levels were found to be approximately six to eight times higher in brain than in plasma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap&#8217;s extended presence in the brain is matched by an extended effect, reducing levels of APP, tau and &#945;SYN for the whole 12-hour period tested. The extended effect of Buntanetap in the four human patients was generally consistent with the preclinical data in rodent brains.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe the persistence of Buntanetap in the CSF and brain and the extended pharmacodynamic effect observed has the potential to make Buntanetap a good candidate for once-a-day dosing. Extrapolated brain levels of Buntanetap at 60 mg four times a day were far in excess of levels we believe are required to down-regulate APP and &#945;SYN. The doses of Buntanetap needed to lower the levels of neurotoxic proteins are similar for the toxic proteins, suggesting similar dosing in AD and PD. We further compared Buntanetap brain levels of mice that showed improved memory, learning and colonic motility and estimated that the optimum brain levels measured were between 150 and 500 nM. Using three different extrapolation/comparison calculations we estimated that a daily dose of 5 mg to 25 mg may be able to achieve potentially desired brain levels in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pharmacodynamics</span></p><a id="_Hlk64274343"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap pharmacodynamics was performed on the same 18 CSF samples taken from each person as above. Since we had data for four patients with 18 time points each, it was possible to conduct statistical analysis of the data using a repeated measure mixed model analysis of variance. The p-value represents the probability that the difference between compared groups is due to chance rather than drug effect, and when that probability is less than 5%, or p&lt;0.05, the result is considered statistically significant. FDA evidentiary standards for drug approval require that the trial design must permit a valid comparison with a control group to permit a quantitative assessment of the effect of the drug, which may include demonstration of statistical significance.</p><a id="_Hlk64274462"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Comparison with Healthy Volunteers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also compared the levels found in four healthy volunteers with the levels seen in the four MCI patients before and after 10 days of Buntanetap administration. The heathy volunteers did not go through the entire study as did the MCI patients. They gave one CSF sample taken by lumbar puncture in the morning and that sample was only used to measure sAPP&#945;, sAPP&#946; and tau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We used a single measurement from the same time point in each of the mornings of Day 0 and Day 11 for each MCI patient because this was similar to the timing for the healthy volunteers. In this very limited comparison, we were able to show that all four patients experienced a decrease in sAPP&#945;, sAPP&#946; and tau. These reductions brought the average levels of sAPP&#945;, sAPP&#946; and tau in the treated MCI patients close to the average levels we measured in healthy volunteers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We used the same 18 samples collected from the CSF of the mildly cognitive impaired patients and measured four inflammatory factors and one control factor. In accordance with our hypothesis the levels of inflammatory markers were significantly </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:255.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reduced. We also measured Factor FH, a complement regulatory protein, as our control factor. As we had expected, Factor FH was not downregulated by Buntanetap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Axonal Transport in Human Nerve Cells</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When the information highway of a nerve cell slows down, the nerve cell is unable to properly communicate with other nerve cells, internal organs and the periphery and it gets sick and dies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transfer of information in a nerve cell is called axonal transport and when transport and synaptic transmission are impaired, the cell releases lower levels of neurotransmitters, leading to impaired nerve cell health. The diseased cell is then attacked by the immune system, which is activated when it detects a diseased cell, and it eventually kills the cell. Impairment in axonal transport, therefore, leads to inflammation and eventually to nerve cell death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="anvs-20221231x10k015.jpg" alt="Graphic" style="display:inline-block;height:254.96pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:467.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Preclinical Animal Studies </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By inhibiting the overexpression of neurotoxic proteins, Buntanetap improved or prevented the symptoms associated with chronic as well as acute neurodegeneration in several animal models. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">APP/PS1 Transgenic Mouse Model of AD</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">APP/PS1 AD transgenic (&#8220;tg&#8221;) mice were treated for one month with Buntanetap, before behavioral evaluation. Buntanetap was observed improving spatial-working memory in a 2-day radial arm water maze test in this mouse AD model at a 25 mg/kg oral dose and showing a dose response at 10 mg/kg oral dose. In the same study, Buntanetap was observed improving synaptic function and long-term potentiation in hippocampal slices at both doses in a dose-dependent fashion. Buntanetap treatment did not affect wild-type mice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trisomic Mouse Model of AD-DS</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">DS trisomic mice display several abnormal behaviors reminiscent of AD, including memory loss. They have elevated levels of APP that has been shown in mice to contribute to deficient memory and learning, cognitive impairment as well as dementia. DS trisomic mice are used as a model for AD, because they exhibit similar deficits as seen in AD. Thus, we considered whether </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Buntanetap could re-establish healthy behavior in these mice like that seen in wild-type mice. We measured the rate of spontaneous alternations in a Y-maze and found that the alternation rate is significantly lower in DS trisomic mice versus wild-type mice reflecting impaired working memory. While Buntanetap treatment increased alternation rate in DS trisomic mice it had no obvious effects in wild-type mice. We also found an effect on the exploratory activity reflected by the number of arm entries, again reflecting impaired working memory. All DS trisomic mice treated with Buntanetap displayed improved working memory to a variable extent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">SNCAA53T and SNCAA30P Mouse Models of PD</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We used these PD tg mice as models of early gastrointestinal dysfunction, which is common in PD patients and precedes the onset of motor symptoms by many years to decades. Untreated PD tg mice resemble pre-Parkinson&#8217;s patients, showing symptoms of constipation by three months of age. Here we assessed the colonic motility by measuring the time required to expel a glass bead inserted into the colon at four and seven months of age. Buntanetap statistically significantly (p=0.034 at four months and p=0.0001 at seven months) decreased the bead expulsion time between Buntanetap treated and placebo treated mice; thus, it improved the colonic motility of PD tg mice. Furthermore, even after we stopped treatment for nine weeks, the constipation was still reduced. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">TBI in Rats</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">TBI causes severe cognitive and neurological impairment, which can incapacitate the patient, reduce quality of life, and increase the risk of morbidity and mortality. TBI is known to increase the risk for neurodegenerative disorders such as AD and PD. Several studies have analyzed changes in the brain after TBI and identified up-regulation of neurotoxic proteins, such as APP, tau, and &#945;SYN.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In our study (manuscript in preparation), rats were subjected to either fluid percussion injury (&#8220;FPI&#8221;) or sham operation to one side of the brain. Three different ANVS405 doses or saline were given intraperitoneally to rats subjected to FPI for four weeks, with the first dose administered one hour post-injury. At the termination of the treatment, all the rats were first tested for their performance in the water maze, and then they were sacrificed for brain staining of living cells and determination of microglia activation. 10 mg/kg ANVS405 improved memory and learning as measured by water maze performance. Furthermore, sections of the brain were stained with tyrosine hydroxylase (&#8220;TH&#8221;), wherein TH stains only live cells. The amounts of TH immunoreactivity in the whole striatum of the brain slices were measured. The rats treated with all three doses of ANVS405 showed higher TH staining in the ipsilateral area of the brain than the vehicle treated animals. Thus, ANVS405 protects the striatum following FPI in rats. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because FPI can induce microglial activation, we next checked whether ANVS405 would reverse this pathology. In our study, we found that ANVS405 increased the number of resting microglia and reduced the number of activated microglia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stroke Mice</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap was tested in a stroke model, in which mice were challenged with MCAo-induced stroke (middle carotid artery occlusion induced stoke) and after four weeks, the number of surviving neurons was quantified. After four weeks the locomotor function, behavior, and cognition of these mice were also evaluated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap in combination with pifithrin-&#945; (PFT-&#945;) given to mice after the induced stroke improved mice locomotor activity and cognitive function. While both treatments yielded improvements in locomotor and cognitive function, the combined Buntanetap/PFT-&#945; treatment proved able to enhance stroke-induced endogenous neurogenesis and improve the functional recovery in stroke animals. The combined treatment also significantly improved cognitive function more than the single treatment with PFT-&#945; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Markets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">With there being a very large potential market for neurodegenerative diseases, most pharma companies have a program studying some aspect of nerve and brain degeneration. Some newer approaches target tau, whose expression is more closely associated with cognitive decline. Similarly, for PD, several companies are trying to inhibit &#945;SYN. So far, we believe that neither drugs attacking tau nor &#945;SYN have shown positive results. Hence there is a substantial need for a different disease-modifying strategy. There is more than one neurotoxic protein in the brain of AD and of PD patients, and the same neurotoxic proteins are involved in the pathogenesis of AD and PD. A significant portion of AD patients&#8217; brains display mixed PD pathology and vice versa. Therefore, just attacking one </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of these proteins may result in no or lower efficacy than attacking them all. To prove that this approach is possible, we are studying the effects of Buntanetap on the levels of several neurotoxic proteins and other surrogate markers, in parallel, in AD and PD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alzheimer&#8217;s Disease Market</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">AD is a neurodegenerative disorder with cognitive, functional, and behavioral alterations. AD is age related, and its incidence is increasing with the aging of the population. It is estimated that currently 44 million victims of AD dementia exist in the world and by 2050, more than 100 million people worldwide will be living with AD. In the United States, it is estimated that there are six million patients with AD. Nearly eightfold as many people have preclinical AD as have symptomatic AD and are at risk for progressing to manifest disease. Disease modifying treatments (&#8220;DMTs&#8220;) that will prevent or delay the onset or slow the progression of AD are urgently needed. Similarly, medications to effectively improve cognition or ameliorate neuropsychiatric symptoms of patients in the symptomatic phases of AD are needed to improve memory and behavior.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The incidence rate of AD increases significantly with age. Individuals between ages 64 to 75 have an incidence rate of 0.4%, which increases to 3.2% for people between ages 75 and 84 and finally to 7.6% for people aged 85 and above. These incidence rates are cumulative as an individual ages, which means that an individual reaching 90 years of age will have a 38% chance of suffering from AD while an individual reaching the age of 95 will have a 76% chance of suffering from AD. AD is becoming increasingly common as the global population ages and as the health systems in developing countries improve. There is a significant need to identify drugs that prevent, delay the onset, slow the progression, or improve the symptoms of AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parkinson&#8217;s Disease Market</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PD is also a progressive neurodegenerative disorder with movement and non-movement symptoms, functional, behavioral and cognitive alterations. PD, like AD, is age related and is becoming markedly more common with the aging of the world&#8217;s population. PD affects about 1% of the population over the age of 60, while in individuals over the age of 85, this prevalence reaches 5%, highlighting the impact that advancing age has on the risk of developing this condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PD affects about 10 million people worldwide, of which nearly one million are in the U.S. While a 2014 study estimated that the incidence in the U.S. will rise to 1.2 million by 2030, a later 2022 study found that there are nearly 90,000 new cases of PD diagnosed each year in the U.S., potentially supporting an even greater future incidence rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The National Parkinson&#8217;s Foundation estimates that the economic burden of PD is at least $25 billion a year in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, there are no available treatments capable of curing PD, with current therapies seeking only to ameliorate dopamine-related motor symptoms of the disease. There is a clear and unmet medical need for new DMTs that can slow or prevent PD progression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.37;margin:0pt 0pt 10pt 0pt;">Mixed Pathologies Market</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the unmet need of AD and PD patients, approximately 50% of patients exhibit mixed pathologies, with some pathologies resembling AD and some resembling PD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Dementia is increasingly being recognized in cases of PD; such cases are termed PD dementia (&#8220;PDD&#8221;). The spread of fibrillar &#945;SYN pathology from the brainstem to limbic and neocortical structures seems to be the strongest neuropathological correlate of emerging dementia in PD. Up to 50% of patients with PDD develop sufficient numbers of A&#946; plaques and tau-containing neurofibrillary tangles for a secondary diagnosis of Alzheimer&#8217;s disease, and these pathologies may act synergistically with &#945;SYN pathology to confer a worse prognosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Another study looking at the incidence of mixed pathologies diagnosed community-dwelling older persons. Those with dementia most often have multiple brain pathologies, which greatly increases the odds of dementia. Specifically, in people with </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">dementia, over 50% had multiple diagnoses (AD, PD/Lewy body dementia, PDD or infarcts). After accounting for age, persons with multiple diagnoses were almost three times more likely to exhibit dementia compared to those with one pathologic diagnosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that a therapy that only addresses A&#946;, tau or &#945;SYN is less likely to help people with mixed pathologies. Since Buntanetap is designed to inhibit more than one neurotoxic protein, we believe that it may have the potential to slow or eventually stop AD, PD and mixed pathology diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Approaches and Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alzheimer&#8217;s Disease Approaches</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drug development for AD has proven to be very difficult. Drugs which have been approved for the treatment of AD include cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-D-aspartate receptor antagonist (memantine). Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Most clinical trials conducted have addressed amyloid targets. Since A&#946; accumulates for years before the symptoms of AD are visible, some pharmaceutical companies are testing their drugs earlier, including cognitively normal people or those who have genetic profiles that place them at high risk for developing AD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An increasing number of agents are directed at tau-related targets. Neurofibrillary tangles are one of two major pathological hallmarks of AD. Correlation studies conducted by Braak and Braak demonstrate that neurofibrillary tangle burden more closely correlates with cognitive decline than amyloid plaque load. Several phase 3 studies conducted with tau approaches have failed. There are still several anti-tau approaches in the clinic. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In summary, at present we believe there are no disease-modifying agents on the market. The first large effort to develop a DMD for AD has targeted A&#946;42, but all A&#946;42 approaches to date have failed. The first companies testing tau have shown negative results. Many companies have pulled out of AD research and are waiting to see what approach might have a better outcome. Since the AD brain contains several neurotoxic proteins&#8212;amyloid precursor protein and its toxic fragments A&#946;42 and IC99, a well as tau and &#945;SYN. We believe that a DMD drug needs to target more than just one toxic protein to be efficacious and we are developing Buntanetap with this approach in mind.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A concerning observation derived from a review of the AD pipeline is the lack of agents targeting the moderate to advanced stages of AD. With over 15 million people affected by AD dementia worldwide, there is an urgent need to develop more effective symptomatic treatments for moderate to advanced stage disease. The paucity of agents directed at this population represents a significant weakness of the AD drug development pipeline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parkinson&#8217;s Disease Approaches</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Levodopa (&#8220;L-DOPA&#8221;) was introduced for use in treating PD more than 40 years ago and remains the mainstay of therapy for improving the symptoms of the disease. Unlike dopamine, which cannot cross the blood&#8212;brain barrier, L-DOPA is effectively absorbed into the brain, where it metabolizes into dopamine. It is typically administered five times a day and works well in controlling symptoms for one to five years. Unfortunately, the effects of L-DOPA in any patient diminish with time.  There are several other drugs available to treat PD, which also seek to modulate dopamine levels. Combination drug therapy is common in PD. For instance, the use of other drug classes such as the catechol-O-methyltransferase (COMT)  inhibitors and the monoamine oxidase (MAO) inhibitors allow patients to reduce L-DOPA dosing levels. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The market for PD drugs is estimated at $2 to $3 billion worldwide, despite high-volume generics. The most important current therapy for PD, L-DOPA, is prescribed as a generic. While volume growth in the category is expected to remain healthy, dollar growth will likely remain relatively flat as some of the category&#8217;s larger brands contend with generic inroads. The size of the current market reflects the absence of innovative branded therapies more than it does the medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">So far, we believe that only Buntanetap and Exenatide are in the later stages of clinical development for disease-modification and no products have yet shown efficacy in PD patients long term. Although several drugs have shown potential neuroprotective </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ability in preclinical studies, demonstrating these effects in clinical studies remains a challenge. Beyond drug therapies, a few cell and gene therapy approaches are also being explored. Progress across these newer technology platforms has been slow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis has filed seven families of patents and patent applications to prolong the patent life of Buntanetap. The pending patent applications were invented and filed by Annovis and include claims directed to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">method</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of treating neurodegenerative diseases such as AD and PD;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of treating and/or preventing acute brain and nerve injuries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of prevention and treatment of disease states due to metal dis-homeostasis such as AD or PD as well as other acute or chronic neurodegenerative diseases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of treating viral and bacterial infections of the brain, including COVID-19;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of inhibiting cancer metastasis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a combination with some drugs; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of treating neuropsychiatric indications.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 14, 2023, our patent portfolio comprised 44 total issued patents plus 13 pending patent applications in various jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The issued patents have expiration dates, assuming all required fees and other charges are paid, between 2031 and 2038. Assuming each of our current patent applications are approved, our patent coverage will extend until 2043. The first patent application family we filed, which would be expected to expire, assuming all required fees and other charges are paid, in 2031, covers the use of Buntanetap at much lower doses and expands its use to the treatment of AD, PD and other neurodegenerative disorders such as Huntington&#8217;s disease, prion diseases, amyotrophic lateral sclerosis, tauopathies and frontotemporal dementia, based on our preclinical research. In August 2019, the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) granted the first of our Annovis patents from this family covering PD and Lewy body diseases. Subsequently the USPTO also granted patents covering tau and tauopathies, chronic traumatic encephalopathy, prion diseases, amyotrophic lateral sclerosis, Alzheimer&#8217;s and Huntington&#8217;s disease. The second patent application family covers ANVS405&#8217;s use in acute brain and nerve trauma and would be expected to expire, assuming all required fees and other charges are paid, in 2036, before any patent term adjustments or extensions. In December 2020, the European Patent Office (&#8220;EPO&#8221;) approved the whole patent, and it has since been approved in number of other countries. However, the USPTO entered a species restriction as to the condition being treated and we are therefore currently pursuing claims directed to traumatic brain injury. We intend to file additional divisional applications when we have successfully reached a conclusion to the pending application, assuming we are not able to cover the remaining acute conditions (stroke, nerve injury and spinal cord injury) for which patent coverage is being sought in the pending application. The third patent application family relates to the use of the mechanism of action of Buntanetap and ANVS405 to prevent and treat neurodegenerative diseases and would be expected to expire, assuming all required fees and other charges are paid, in 2038, before any patent term adjustments or extensions. The first divisional of this application was approved in December 2022; it covers the prevention of neurodegenerative diseases and we are awaiting the official publishing of the patent. In May 2020, we filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of Buntanetap or related compounds which would be expected to expire, assuming all required fees and other charges are paid, in 2041, before any </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">patent term adjustments or extensions; we have not received any office actions, yet. Recently we also filed three provisional patents - Buntanetap in cancer, Buntanetap and combinations, Buntanetap in neuropsychiatric indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Sales and Marketing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If Buntanetap is approved for AD or PD, we plan to enter into sales and marketing agreements with one or several pharmaceutical companies to sell to neurologists, geriatric specialists and to primary care physicians. We also may explore the use of a variety of types of collaboration, co-promotion, distribution and other marketing arrangements with one or more third parties to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Buntanetap is a small molecule that is manufactured using a patented process. We do not own, operate, and currently have no plans to establish, any manufacturing facilities. We therefore rely, and expect to continue to rely, solely on third-party contractors for manufacturing clinical supplies for our current and future potential product candidates, and plan to do so for commercial supplies also if any of our product candidates received marketing approval. We also rely on these third parties for encapsulating, packaging and stabilizing clinical trial materials. Presently we are working with a U.S. supplier for the manufacture of good manufacturing practice (&#8220;cGMP&#8221;) active pharmaceutical ingredient (API) to meet our Buntanetap clinical study supply demands.  We have also engaged a backup API manufacturing contractor, with primary operations in China.  We have an agreement with a local U.S. supplier for the encapsulating, packaging, and stability of the clinical trial material.  These arrangements will allow us to enter large and long-term advanced clinical studies. We have only limited supply agreements in place with respect to Buntanetap and our product candidates, and these arrangements do not extend to commercial supply. We do not have long term committed arrangements with respect to Buntanetap, any of our other product candidates, or other materials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Government Regulation of Drug Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice regulations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Approval by an independent institutional review board (&#8220;IRB&#8221;), at each clinical site before each trial may be initiated.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;), requirements to establish the safety and efficacy of the proposed drug product for each indication.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an NDA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA advisory committee review, if applicable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of user fees and securing FDA approval of the NDA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) and the potential requirement to conduct post-approval studies.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it initiates at that institution. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on www.clinicaltrials.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Special FDA Expedited Review and Approval Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To be eligible for a fast-track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast-track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement, these six- and ten-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast-track designation are also likely to be considered appropriate to receive a priority review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, products tested for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;) that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on IMM or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act passed in July 2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. At the completion of our two Phase 2 trials, one in PD and one in AD, Annovis will petition the FDA to classify Buntanetap as a breakthrough therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation and Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a product with orphan status receives the first FDA approval for a disease or condition, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease if the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Marketing Approval and Post-Approval Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA, for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. While the FDA is not bound by the recommendations of an advisory committee, it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing for the FDA to reconsider the application. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fines, warning letters or holds on post-approval clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product seizure or detention, or refusal to permit the import or export of products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Coverage and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of our lead product candidate, Buntanetap, or any other for which we may seek regulatory approval. Sales in the U.S. will depend in part on the availability of adequate financial coverage and reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. Medicare Part D, Medicare&#8217;s outpatient prescription drug benefit, contains protections to ensure coverage and reimbursement for oral oncology products, and all Part D prescription drug plans are required to cover substantially all oral anti-cancer agents. However, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Sales of Buntanetap or any other product candidates will therefore depend substantially on the extent to which the costs of our products will be paid by third-party payors. Achieving favorable coverage and reimbursement from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) and/or the Medicare Administrative Contractors is typically a significant gating issue for successful introduction of a new product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our operations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, which prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provisions of the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program or making false statements in connection with the delivery of or payment for healthcare benefits, items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payment Sunshine Act requirements, under the Patient Protection and Affordable Care Act, which require manufacturers of certain drugs and biologics to track and report to CMS payments and other transfers of value they make to U.S. physicians and teaching hospitals as well as physician ownership and investment interests in the manufacturer.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation Outside the United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To market our future products in the European Economic Area (&#8220;EEA&#8221;), which is comprised of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein, and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are two types of MAs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#8220;EMA&#8221;) and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA assess the risk-benefit balance of the product based on scientific criteria concerning its quality, safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data and Marketing Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment in development. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EEA, an application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, the EMA or the member state competent authorities, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar medicinal product for the same indication. The period of market exclusivity is extended by two years for medicines that have also complied with an agreed PIP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &#8220;clinical superiority&#8221; by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs are eligible for incentives made available by the EU and its Member States to support research into, and the development and availability of, orphan drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Human Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 2023, we had five full-time employees. We also utilize the services of twelve consultants. We also contract with additional consultants and third parties for the conduct of certain clinical development, accounting and administrative activities. We are in the process of hiring additional employees as we advance in our clinical trial program. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, training, incentivizing, and integrating our existing and new employees, advisors and consultants. We offer competitive compensation packages. We incentivize high performers through an annual bonus program based on our performance for which all employees are eligible. We also offer equity incentive plans, the purpose of which are to attract, retain and reward personnel through the granting of stock-based compensation awards in order to increase stockholder value and the success of our company by motivating team members to perform to the best of their abilities and achieve our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Delaware in 2008. Our principal executive offices are located at 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312 and our telephone number is (610)727 3913. Our website address is www.annovisbio.com. The inclusion of our website address is, in each case, intended to be an inactive textual reference only and not an active hyperlink to our website. The information contained in, or that can be accessed through, our website is not part of this Annual Report on Form 10-K.</p><a id="_1962fd95_263b_4978_88c2_38abc9150022"></a><a id="Item1ARiskFactors_448269"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because our auditor has issued a going concern opinion regarding our company, there is an increased risk associated with an investment in our company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 we had cash and cash equivalents of $28,377,693, and we have continually operated at a loss with an accumulated deficit of $54,054,744 as of December 31, 2022. We have not attained profitable operations and are dependent upon obtaining financing to continue operations for the next twelve months from the date of these financial statements. Our future is dependent upon our ability to obtain financing or upon future profitable operations. We reserve the right to seek additional funds through public/private placements of our common stock and/or through debt financing. Our ability to raise additional financing is unknown. For these reasons, our auditors stated in their report that they have substantial doubt we will be able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical stage biopharmaceutical company with a limited operating history and have incurred losses since our formation. We incurred net losses of $25,328,567 and $14,487,132 for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $54,054,744. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to research and development, including our preclinical and clinical work, and to intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur significant additional operating losses for the next several&#160;years, at least, as we advance Buntanetap and any other product candidates through clinical development, complete clinical trials, seek regulatory approval and commercialize the drug or any other product candidates, if approved. The costs of advancing product candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any of our product candidates to marketing approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses will also increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commence our Phase&#160;3 trials in AD and PD, or conduct clinical trials for any other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scale-up cGMP drug supply manufacturing and complete necessary work to support an NDA for Buntanetap in AD or in PD;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are required by the FDA to complete additional toxicological/pharmacological studies to support an NDA for Buntanetap in AD or in PD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are required by the FDA to complete multiple Phase&#160;3 trials to support an NDA for Buntanetap in AD or in PD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing and distribution infrastructure to commercialize our drug, if approved, and for any other product candidates for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, scientific and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts, as well as to support our requirements as a public reporting company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license or invent other product candidates or technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under &#8220;&#8212;Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval&#8221; and &#8220;&#8212;Risks Related to Commercialization.&#8221; This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of Buntanetap and any other product candidates, acquiring additional product candidates, obtaining regulatory approval for Buntanetap and any other product candidates, and manufacturing, marketing, and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our company will be materially and adversely affected. Furthermore, this could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates, achieve our strategic objectives or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We will require  substantial additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of Buntanetap.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development of biopharmaceutical product candidates is capital-intensive. Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of Buntanetap. If we obtain receive regulatory approval for Buntanetap or any other product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution. We will require additional capital for the further development and potential commercialization of Buntanetap and may also need to raise additional funds sooner to pursue a more accelerated development of Buntanetap. Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reliably estimate the actual amount of financing necessary to successfully complete the development and commercialization of Buntanetap or any other product candidates. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Based on our current operating plan, we believe that our current cash and cash equivalents and funding from existing grants will enable us to fund our operating expenses and capital expenditure requirements until the fourth quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could deploy our available capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. Our current cash and cash equivalents and funding </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">from existing grants may not be sufficient to complete development of Buntanetap or any other product candidates, and we will require substantial capital in order to advance Buntanetap or any other product candidates through clinical trials, regulatory approval and commercialization. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from factors that include but are not limited to, inflation, the conflict between Russia and Ukraine and other factors, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts, or even cease operations. We expect to finance our cash needs through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop Buntanetap or any other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for Buntanetap or any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical development plans we establish for Buntanetap and any other future product candidates, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we discover or in-license and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing and cost of regulatory meetings and reviews by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirements of regulatory authorities in any additional jurisdictions in which we may seek approval for Buntanetap and any future product candidates and our anticipated timing for seeking approval in such jurisdictions&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development, regulatory, CMC quality and commercial personnel&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of the implementation of commercial-scale manufacturing activities, if any product candidate is approved, including as a result of inflation, any supply chain issues or component shortages; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products&#894; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements&#894; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any products or technologies that we may in-license or acquire; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delays and cost increases that may result from the COVID-19 or any future pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Conducting clinical trials and preclinical studies and potentially identifying future product candidates is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize Buntanetap or any future product candidates. If approved, Buntanetap and any future product candidates may not achieve commercial success. Our commercial revenue, if any, will initially be derived from sales of Buntanetap, which we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we would be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts, or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, or on less favorable terms than we would otherwise choose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have  limited operating history and no history of commercializing pharmaceutical products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were established and began operations in 2008. Our operations to date have been primarily focused on conducting preclinical and clinical studies. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, reliance should not be placed upon the results of any particular quarterly or annual period as indications of future operating performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In general, under Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to use its pre-change net operating loss carryforwards (&#8220;NOLs&#8221;) to offset future taxable income. Due to previous ownership changes, our ability to use our NOLs could be limited by Section&#160;382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section&#160;382 of the Code. Furthermore, our ability to use NOLs of companies that we may acquire in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">future may be subject to limitations. For these reasons, we may not be able to use a material portion of the NOLs, even if we attain profitability in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inflation could adversely affect our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While inflation in the United States has been relatively low in recent years, during 2021 and 2022, the economy in the United States encountered a material level of inflation. The impact of COVID-19, geopolitical developments such as the Russia-Ukraine conflict and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and long-term economic activity, including whether inflation will continue and how long, and at what rate. Increases in inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, along with the uncertainties surrounding COVID-19, geopolitical developments and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks could have a material adverse impact on our financial condition, results of operations or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves, or on less favorable terms than we would otherwise choose. In addition, if one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our clinical development goals on schedule and on budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We are heavily dependent on the success of Buntanetap, our most advanced product candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business will be materially  harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We do not have any products that have gained regulatory approval. Currently, our lead clinical stage product candidate is Buntanetap. As a result, our business is entirely dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize Buntanetap in a timely manner. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development and may be able to better sustain the delay or failure of a lead product candidate. We cannot commercialize Buntanetap in the United States without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize Buntanetap outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Buntanetap for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that Buntanetap is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. If the FDA is not satisfied with the quantity and nature of the data we collect, we may be forced to undertake additional preclinical studies or clinical trials to obtain regulatory approval, which will lead to delays in our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">clinical development plans and cause us to incur additional costs, both of which may have a material adverse effect on our business. Even if Buntanetap were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for Buntanetap in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other product candidate that we may in-license, develop or acquire in the future. Furthermore, even if we obtain regulatory approval for Buntanetap, we will still need to develop a commercial organization, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize Buntanetap, we may not be able to earn sufficient revenue to continue our business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternatives that render any product candidates we develop obsolete&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may not be accepted as safe and effective by physicians, patients, the medical community or third-party payors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited financial and personnel resources and, as a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause it to fail to capitalize on viable commercial drugs or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product, we may relinquish valuable rights to that product through collaboration, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such product. If we are unsuccessful in identifying and developing additional product candidates or are unable to do so, our business, results of operations, cash flows, financial condition and/or prospects may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business disruptions, including but not limited to those associated with widespread health emergencies, could harm our ability to complete or could materially delay our clinical trials, as well as cause disruptions to the FDA and other governmental authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations and the operations of our suppliers, contract research organizations (&#8220;CROs&#8221;), hospitals, clinical trial sites, regulators, consultants and other third parties with whom we conduct business could be subject to earthquakes, power shortages, telecommunications or infrastructure failures, cybersecurity incidents, physical security breaches, water shortages, floods, hurricanes, typhoons, blizzards and other extreme weather conditions, fires, and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers or suppliers to produce Buntanetap and its components and on CROs and clinical sites to conduct our clinical trials, and do not have a redundant source of supply for all components of our product candidate. Our ability to obtain clinical or, if approved, commercial, supplies of Buntanetap or any future product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption, and our ability to commence, conduct or complete our clinical trials in a timely manner could be similarly adversely affected by any of the foregoing. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Furthermore, the emergence of widespread health emergencies or pandemics, such as COVID-19, could lead to quarantines, business shutdowns, labor shortages, disruptions to the healthcare system, and overall economic instability. If the suppliers, CROs, hospitals, clinical trial sites, regulators, consultants and other third parties with whom we conduct business were to experience shutdowns or other business disruptions, our ability to enroll patients and conduct our clinical trials in the manner and on the timelines presently planned could be materially and negatively impacted. As an example, in March 2020, the clinical trial sites participating in our Phase 1/2 trial in AD patients in collaboration with the ADCS temporarily suspended enrollment of new patients because of the ongoing COVID-19 pandemic and patient recruitment and treatment were completed later than anticipated. In addition, due to restrictions related to COVID-19 during 2020, we experienced delays in opening clinical trial sites for our AD/PD Trials.  The extent to which other future emerging widespread health emergencies or pandemics could have a material impact on our clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently unpredictable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic and any future epidemic or pandemic disease outbreak could also potentially further affect the business of the FDA, EMA or other regulatory authorities, which could result in delays in meetings related to our planned clinical trials. The COVID-19 pandemic and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the COVID-19 pandemic impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus, including the identification of new variants, the rate of vaccine administration, and the actions to contain its impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, Buntanetap and our other product candidates may not have favorable results in later preclinical and clinical studies or receive regulatory approval. The historical failure rate for product candidates in our industry is high, particularly in the earlier stages of development. Furthermore, product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory approval to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching an agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining Institutional Review Board (&#8220;IRB&#8221;) approval at each site, or Independent Ethics Committee (&#8220;IEC&#8221;) approval at sites outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients failing to complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing patient safety concerns that arise during the course of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding a sufficient number of clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of product candidate for use in clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board (&#8220;DSMB&#8221;), for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in &#8220;&#8212;Risks Related to Our Dependence on Third Parties.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for Buntanetap or any other product candidates, our business will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for Buntanetap or any other product candidate. We are not permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA. Approval from the FDA and comparable foreign authorities may be delayed or denied for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing the active ingredient in our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. For diseases like AD and PD, the FDA has stated that one single Phase&#160;3 trial is adequate for approval if it demonstrates robust and unquestionable efficacy. However, the circumstances under which a single adequate and controlled study can be used as the sole basis of demonstrating efficacy of a drug are exceptional.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Of the large number of drugs in development, only a small&#160;percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market Buntanetap or another product candidate, which would significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or applicable foreign regulatory agency may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have concentrated our research and development efforts on the treatment of AD and PD, diseases that have seen limited success in drug development. Further, Buntanetap is based on a new approach to treating AD and PD, which makes it difficult to predict the time and cost of development and subsequent obtaining of regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Efforts by biopharmaceutical and pharmaceutical companies in treating AD and PD have seen limited success in drug development, and there are no FDA-approved disease modifying therapeutic options available for patients with AD and PD. As a result, the design and conduct of clinical trials of Buntanetap or any future product candidate may take longer, be more costly or be less effective as a result of the novelty of development in these diseases. We cannot be certain that our approach will lead to the development of approvable or marketable products. In some cases, we may use endpoints or methodologies that regulatory authorities may not consider to be clinically meaningful and that we may not continue to use in clinical trials or that we may determine after the initiation of the trial to no longer be an appropriate endpoint or methodology. Any such regulatory authority may require evaluation of additional or different clinical endpoints in our clinical trials or ultimately determine that these clinical endpoints do not support marketing approval. In addition, if we are required to use additional or different clinical endpoints by regulatory authorities, Buntanetap may not achieve or meet such clinical endpoints in our clinical trials. Even if a regulatory authority finds our clinical trial success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we may conduct for our product candidate. Further, even if we do achieve the prespecified criteria, our trials may produce results that are unpredictable or inconsistent with the results of other efficacy endpoints in the trial. Regulatory authorities also could give overriding weight to other efficacy endpoints over a primary endpoint even if we achieve statistically significant results on that primary endpoint if we do not do so on our secondary efficacy endpoints. Regulatory authorities also weigh the benefits of a product against its risks and may view the efficacy results in the context of safety as not being supportive of approval. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The only drugs approved by the FDA to treat AD and PD to date address the diseases&#8217; symptoms. No new treatments have been approved for AD since 2003. From 2004 to 2022, phase 2 and 3 clinical trials for unique compounds with various mechanisms of action intended to combat AD had a development success rate of just 2%. AD drug candidates have the highest failure rate of nearly 100%, compared to 50% to 80% for all other drug candidates. As a result, the FDA has a limited set of products to rely on in evaluating Buntanetap. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of Buntanetap for the treatment of AD and PD. We cannot be sure that Buntanetap, or any other product candidate we develop, will ultimately prove to be safe and effective, scalable or profitable. Moreover, public perception of drug safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to prescribe novel treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As product candidates progress through clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize safety, efficacy, yield and manufacturing batch size, minimize costs and achieve consistent quality and results. For example, the manufacturing process being used to produce clinical material for our planned clinical trials is different than that used in prior trials of Buntanetap. There can be no assurance that such changes will achieve these intended objectives. These changes and any future changes we may make to Buntanetap or any future product candidates may also cause such candidates to perform differently and affect the results of future clinical trials conducted with the altered materials. Such changes or related unfavorable clinical trial results could delay initiation or completion of additional clinical trials, require the conduct of bridging studies or clinical trials or the repetition of one or more studies or clinical trials, increase development costs, delay or prevent potential marketing approval and jeopardize our ability to commercialize Buntanetap or any future product candidates, if approved, and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may develop Buntanetap and future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may develop Buntanetap and future product candidates for use in combination with one or more other approved therapies for AD or PD. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, we will not be able to market and sell any product candidate we develop in combination with an unapproved AD or PD therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved AD and PD therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. For example, during the COVID-19 pandemic, we had difficulties enrolling a sufficient number of patients for our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patient enrollment and retention in clinical trials depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility and exclusion criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature and design of the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the existing body of safety and efficacy data with respect to the product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials being conducted by other companies or institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting, which could adversely impact the outcomes of our trials and could have safety concerns for the potential patients. Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which may make it more difficult to fully enroll our clinical trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and recruiting patients may prove costly. The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. If patients are unwilling or unable to participate in our trials for any reason, including the existence of concurrent clinical trials for similar target populations, the availability of approved or authorized therapies, the effects of the COVID-19 pandemic, or the fact that enrolling in our trials may prevent patients from taking a different product, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting trials and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a specified number of patients for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Furthermore, results of early clinical trials may differ from results of later clinical trials due to changes in patient population size. The clinical trials that we have completed to date included a limited patient population, and we may observe differences in the safety and efficacy of Buntanetap and our other product candidates as the patient population increases in size. Accordingly, the data that we have observed to date may not be reflective of ongoing and future clinical trial data. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in prospective clinical trials. Even if our clinical trials for Buntanetap are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Further, others, including regulatory agencies may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular development program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed meaningful by others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are further subject to audit and verification procedures that could result in material changes in the final data. Furthermore, undue reliance on interim analyses may be detrimental to our long-term clinical development plans, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to evaluate all data fully and carefully. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Moreover, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim &#8220;topline&#8221; or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, Buntanetap and any future product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. We intend to rely on interim data from our Phase 3 PD Study and Phase 2/3 AD Study to obtain feedback on our ongoing and planned AD and PD studies, and ultimately design future studies. Specifically, we plan to use the data from the Phase 3 PD Study interim analysis to design an 18-month long disease-modifying Phase 3 study in the same early PD patients, and intend to conduct a short 6-month study in advanced PD patients during the second half of the 18-month disease modifying Phase 3 study. Similarly, using the data from the Phase 2/3 AD Study interim analysis, we intend to design an 18-month disease modifying Phase 3 study in the same early AD patient population, and intend to conduct a short 6-month study in advanced AD patients during the second half of the 18-month disease modifying Phase 3 study. Such reliance on the Phase 3 PD Study and Phase 2/3 AD Study interim analyses could be detrimental to our long-term clinical development plans, as data available at the time of the built-in interim analyses could be materially different from the data that would be available if we completed a longer study, or a study with increased patient enrollment. Accordingly, if the interim data upon which we rely is later shown to be materially different from the final, complete study results, the basis upon which we set forth our development plans may be called into question and our ability to obtain approval for, and commercialize, Buntanetap may be harmed, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As is the case with biopharmaceuticals generally, it is likely that there may be adverse side effects associated with Buntanetap or any future product candidates&#8217; use. Serious adverse events or undesirable side effects caused by Buntanetap or any other product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Patients treated with Buntanetap to date, at high doses have experienced adverse events that include nausea, vomiting and dizziness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If unacceptable side effects arise in the development of our product candidates, we, the FDA or the IRBs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, if Buntanetap or any future product candidates are associated with undesirable side effects in clinical trials or demonstrate characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved. We may also be required to modify our development and clinical trial plans based on findings in our ongoing clinical trials. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is possible that as we test Buntanetap or any future product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of these product candidates becomes more widespread following any regulatory approval, more illnesses, injuries, discomforts and other adverse events than were observed in earlier trials, as well as new conditions that did not occur or went undetected in previous trials, may be discovered. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for Buntanetap or any other product candidates, if approved, may be smaller than we anticipate, which could adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to initially seek approval for Buntanetap for AD and PD in the U.S. The precise incidence and prevalence for the conditions we aim to address with Buntanetap or any future product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on a number of internal and third-party estimates. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations and market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these indications. While we believe our assumptions and the data underlying our estimates are reasonable, we have not independently verified the accuracy of the third-party data on which we have based our assumptions and estimates, and these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, including as a result of factors outside our control, thereby reducing the predictive accuracy of these underlying factors. The total addressable market across all of the potential indications for Buntanetap and any future product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each such product candidate which receives marketing approval for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of such product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our business, financial condition and results of operations. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates. Further, even if marketing approval is obtained, we have no experience as a company in commercializing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Furthermore, we have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If Buntanetap or any future product candidates ultimately receives marketing approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company with the marketing, sale or distribution of biopharmaceutical products and there are significant risks involved in the building and managing of a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenue and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain FDA approval for Buntanetap or any other product candidates in the United States, we may never obtain approval for or commercialize Buntanetap or any other product candidates in any other jurisdiction, which would limit our ability to realize their full market potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future growth may depend, in part, on our ability to develop and commercialize Buntanetap and any future product candidates in foreign markets. We are not permitted to market or promote any product candidate before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for Buntanetap or any future product candidates. In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we obtain regulatory approval of product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">different regulatory requirements for approval of drugs in foreign countries&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced protection for intellectual property rights&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the existence of additional third-party patent rights of potential relevance to our business&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers and regulatory requirements&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with export control and import laws and regulations&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign reimbursement, pricing and insurance regimes&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is common&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing regulatory requirements with respect to manufacturing of products&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions resulting from the impact of public health pandemics or epidemics (including, for example, the COVID-19 pandemic).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for Buntanetap or any product candidates, we will still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development and regulatory difficulties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS.&#160;If any of our product candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on manufacturing such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as Buntanetap or any future product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for Buntanetap or any future product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of Buntanetap or any future product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We may seek a Breakthrough Therapy designation for Buntanetap from the FDA  in PD and AD at the end of the first Phase&#160;3 study in PD, and at the end of the Phase 2/3 study in AD, respectively. However, we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may seek a Breakthrough Therapy designation for Buntanetap or one or more of our other product candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit, delay or cease commercialization of any products that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The use of Buntanetap or any other product candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. This risk will be even greater if we commercialize our product candidates, especially if our products are prescribed for off-label uses (even if we do not promote such uses). For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. Claims could also be asserted under state consumer protection acts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs or be required to limit, delay or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of our business reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of participants from our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#8217;s attention and our resources from our primary business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to commercialize Buntanetap or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased market demand for any product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant negative financial impact; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decline in our stock price.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The product liability insurance coverage we carry or acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. In connection with all our clinical studies, we carry insurance for product liability claims in the United States and in Europe. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of Buntanetap or any future product candidates. Although we maintain such insurance, a successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting the commercialization of any product candidates we develop. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment benefits liability, workers&#8217; compensation, products liability, and directors&#8217; and officers&#8217; insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. No assurance can be given that an insurance carrier will not seek to cancel or deny coverage after a claim has occurred. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If Buntanetap is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies in the United States and other jurisdictions. These organizations may have significantly greater resources than we do and may conduct similar research; seek patent protection; and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors may, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical, and human resources than we do, and future mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain quicker regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implement more effective approaches to sales and marketing; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">form more advantageous strategic alliances.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel; establishing clinical trial sites and patient registration; and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, or are more convenient or are less expensive than Buntanetap. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for Buntanetap, which could result in our competitors establishing or strengthening their market position before we are able to enter the market. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competing products may render Buntanetap or any future product candidates we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The successful commercialization of Buntanetap and any other product candidates we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as Buntanetap, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our drug and any other product candidates we develop. Accordingly, we will need to successfully implement a coverage and reimbursement strategy for any approved product candidate. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available, or at an acceptable level, for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and offer to reimburse patients only for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&#160;and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules&#160;and regulations are likely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if Buntanetap or any product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, which would adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap and any future product candidates may not be commercially successful. If Buntanetap or any other product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number of factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the indications for which our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of sales and marketing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to offer our products for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of our product together with other medications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product liability claims; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of our products as well as availability, safety and efficacy of competitive drugs; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable publicity relating to the product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing Buntanetap, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have any infrastructure for the sales, marketing or distribution of Buntanetap, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market and successfully commercialize our drug or any product candidate we develop, if approved, we must build our sales, distribution, marketing, managerial and other non-technical capabilities or collaborate with third parties to perform these services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets overseas. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in a product and such collaborator&#8217;s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of Buntanetap, if approved, for certain markets overseas; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of Buntanetap, we may be forced to delay the potential commercialization of the drug or reduce the scope of our sales or marketing activities. If we need to increase our expenditures to fund commercialization activities for Buntanetap we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We may also have to enter into collaborative arrangements for Buntanetap at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to it or otherwise agree to terms unfavorable to us. Any of these occurrences may have an adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to establish adequate sales, marketing and distribution capabilities, we will not be successful in commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A variety of risks associated with operating internationally could materially adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have no international operations, but our business strategy includes potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the burden of complying with multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to obtain and maintain regulatory approvals for the use of our products in various jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional potentially relevant third-party patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limits in our ability to penetrate international markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Dependence on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, consultants, vendors and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse and other healthcare laws and regulations; or laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently rely on a third-party contract manufacturing organization (&#8220;CMO&#8221;), for the production of clinical supply of Buntanetap and intend to rely on CMOs for the production of commercial supply of Buntanetap, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of Buntanetap and any product candidates we develop, if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to have manufactured a sufficient clinical supply of Buntanetap drug substance to enable us to complete our clinical trials, and we have also engaged two CMOs to provide clinical and commercial supply of the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We do not and will not have control over the process or timing of the acquisition of these raw materials by our CMOs. Supplies of raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of the manufacture of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently rely and in the future intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials. Our reliance on CROs for clinical development activities limits our control over these activities, yet we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our CROs will be required to comply with the Good Laboratory Practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed, and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form&#160;10-K also apply to the activities of any collaborators and there can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of our business and our stock price could be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs, and our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively the &#8220;ACA&#8221;) was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there may be additional challenges and amendments to the ACA in the future. It is uncertain the extent to which any such changes may impact our business or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal&#160;year. These reductions went into effect in April&#160;2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless additional action is taken by Congress. In January&#160;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. Additionally, the orphan drug tax credit was reduced as part of a broader tax reform. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act (&#8220;FCA&#8221;) which, among other things, impose criminal and civil penalties, including through civil whistleblower or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">qui tam</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,&#160;public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;), which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Any clinical trial programs we conduct or research collaborations we enter into in the EEA may subject us to the General Data Protection Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we conduct clinical trial programs or enter into research collaborations in the EEA, we may be subject to the General Data Protection regulation (&#8220;GDPR&#8221;). The GDPR applies extraterritorially and implements stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">transfers of data from the European Union (&#8220;EU&#8221;) to other jurisdictions, short timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health data, other special categories of personal data and coded data and additional obligations if we contract third-party processors in connection with the processing of personal data. The GDPR provides that EU member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to &#8364;20&#160;million or up to 4% of the total worldwide annual turnover of the preceding financial&#160;year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad if and when we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities, and any training or compliance programs or other initiatives we undertake to prevent such activities may not be effective. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed as a result of military conflicts in other countries may impact our ability to continue activities at future clinical trial sites within regions covered by such sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. These export and import controls and economic sanctions could also adversely affect our supply chain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and any contract manufacturers and suppliers we engage are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. While the materials we use require operations involving the use of hazardous and flammable materials, including chemicals and biological materials, we do not produce any materials ourselves and contract with third parties for the manufacture and the disposal of these materials and wastes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years.  In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on us due to our tax losses generated during all prior years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">U.S. tax legislation enacted in 2017 has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, and revising the rules&#160;governing NOLs. The legislation could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury and Internal Revenue Service, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain, maintain and enforce patent or other intellectual property protection for Buntanetap or any future product candidates or technology or if the scope of the patent protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, our ability to successfully commercialize Buntanetap or any future product candidates may be adversely affected and we may not be able to compete effectively in our markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our drug development programs and product candidates. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and proprietary information. Our success depends in large part on our ability to obtain, maintain and defend patent protection in the United States and other countries with respect to Buntanetap and any future product candidates. Because we have not conducted a formal freedom to operate analysis for patents related to Buntanetap since 2008, we may not be aware of patents issued since then that a third-party might assert are infringed by Buntanetap or any future product candidates, which could materially impair our ability to commercialize Buntanetap or any future product candidates. We generally seek to protect our proprietary position, in part, by filing patent applications in the United States and abroad relating to Buntanetap and any future product candidates, manufacturing processes, and methods of use.  If we are unable to obtain, maintain or enforce patent protection, our business, financial condition, results of operations and prospects could be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Changes in either the patent laws or their interpretation in the United States and other jurisdictions may diminish our ability to protect our intellectual property, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our protection. We cannot predict whether the patent applications we currently or may in the future pursue will issue as patents in any particular jurisdiction, will provide sufficient protection against competitors or other third parties, or if these patents are challenged by our competitors, will be found to be invalid, unenforceable, or not infringed.  Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and product candidates. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection before public disclosures are made.  Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, third-party collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we may not be able to prevent any third party from using any of our technology that is in the public domain to compete with Buntanetap and any future product candidates or technologies. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">in light of the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to invent the inventions claimed in any of our licensed patents or pending patent applications, or that we or our licensors were the first to make the inventions claimed in those owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. If a third party can establish that we or our licensors were not the first to make or the first to file for patent protection of such inventions, our owned or licensed patents and patent applications may not issue as patents and even if issued, may be challenged and invalidated or rendered unenforceable.  Furthermore, even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain additional patent protection to prolong the patent life of our product candidates, we may not be able to continue development of our product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek to protect and prolong our proprietary position by filing patent applications in the United States and abroad related to our development programs and product candidates. If the patent applications we own with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for Buntanetap or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future product candidates. Any such outcome could have a materially adverse effect on our business and our company could cease to exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis has filed seven families of patent applications to prolong the patent life of Buntanetap. Unless these applications are approved by the U.S. and international patent offices, the patent life of using Buntanetap is limited. The first patent application family we filed, which would be expected to expire in 2031, covers the use of Buntanetap at much lower doses and expands its use to the treatment of AD, PD and other neurodegenerative disorders such as Huntington&#8217;s disease, prion diseases, amyotrophic lateral sclerosis, tauopathies and frontotemporal dementia, based on our preclinical research. In August 2019, the USPTO granted the first of our Annovis patents from this family covering PD and Lewy body diseases. Subsequently the USPTO also granted patents covering tau and tauopathies, chronic traumatic encephalopathy, prion diseases, amyotrophic lateral sclerosis, Alzheimer&#8217;s and Huntington&#8217;s disease. The second patent application family covers ANVS405&#8217;s use in acute brain and nerve trauma and would be expected to expire in 2036, before any patent term adjustments or extensions. In December 2020, the EPO approved the whole patent, and it has since been approved in number of other countries. However, the USPTO entered a species restriction as to the condition being treated and we are therefore currently pursuing claims directed to traumatic brain injury. We intend to file additional divisional applications when we have successfully reached a conclusion to the pending application, assuming we are not able to cover the remaining acute conditions (stroke, nerve injury and spinal cord injury) for which patent coverage is being sought in the pending application. The third patent application family relates to the use of the mechanism of action of Buntanetap and ANVS405 to prevent and treat neurodegenerative diseases and would be expected to expire in 2038, before any patent term adjustments or extensions. The first divisional of this application was approved in December 2022; it covers the prevention of neurodegenerative diseases and we are awaiting the official publishing of the patent. In May 2020, we filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of Buntanetap or related compounds which would be expected to expire in 2041, before any patent term adjustments or extensions; we have not received any office actions, yet. Recently we also filed three provisional patents - Buntanetap in cancer, Buntanetap and combinations, Buntanetap in neuropsychiatric indications. While the issuance of our new patents gives us some comfort that the patent life relating to methods of using Buntanetap may be prolonged to 2031, 2036 and 2038, the fact that only a portion of the family claims has so far been allowed could result in very limited patent coverage. It is possible that we will fail to identify further patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that provide further coverage of Buntanetap or any other product candidate in the United States or in other foreign countries.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our patents may be challenged in courts, in patent offices or before other administrative bodies which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio, along with the unpredictable nature of patent prosecution, may not provide us with sufficient rights to similarly challenge other parties or exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Even if patents do successfully issue and even if such patents further cover Buntanetap or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Our patent rights may be subject to such priority, validity, inventorship, scope and enforceability disputes. Legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming and likely to divert significant resources from our core business, including distracting our management and scientific personnel from their normal responsibilities and generally harm our business. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. If we encounter delays in regulatory approvals, the period during which we could market a product candidate under patent protection could be reduced. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. However, in certain instances, the laws of the United States are more restrictive than those of foreign countries. For example, a recent series of U.S. Supreme Court cases has narrowed the types of subject matter considered eligible for patenting. Accordingly, certain diagnostic methods are considered ineligible for patenting because they are directed to a &#8220;law of nature.&#8221; Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated, held unenforceable, in whole or in part, or reduced in term. Such a result could limit our ability to stop others from using or commercializing similar or identical technology and products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We or our licensors may be subject to claims that former employees, consultants, collaborators or other third parties have an interest in our patent rights, any potential trade secrets, or other intellectual property as an inventor, co-inventor or owner of any potential trade secrets. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging inventorship or our patent rights, any potential trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become subject to third parties&#8217; claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. Some claimants may have </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be subject to third-party claims including infringement, interference or derivation proceedings, post-grant review and <i style="font-style:italic;">inter partes</i> review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if we believe third party infringement claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Proceedings challenging our patents or those that we license may also result in our patent claims being invalidated or narrowed in scope. Similarly, if our patents or patent applications are challenged during interference or derivation proceedings, a court may hold that a third-party is entitled to certain patent ownership rights instead of us. Further, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, methods of manufacture, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages, if we are found to be infringing a third party&#8217;s patent rights. If we are found to have infringed such rights willfully, the damages may be enhanced and may include attorneys&#8217; fees. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. Modifying our product candidates to design around third-party intellectual property rights may result in significant cost or delay to us and could prove to be technically infeasible. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of eligibility, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because someone connected with prosecution of the patent withheld relevant information, or made a misleading statement, during prosecution. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Furthermore, our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing on our patents or other intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Finally, even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our future product candidates, or their manufacture or use may currently be unpublished. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time we may identify patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are irrelevant to our business based on various factors including our interpretation of the scope of the patent claims and our interpretation of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates so that we no longer infringe on the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical and pharmaceutical industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (&#8220;AIA&#8221;) which was passed in September&#160;2011, resulted in significant changes to the U.S. patent system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files&#160;a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file&#160;a patent infringement suit and provide opportunities for third parties to challenge any issued patent with the USPTO. This applies to all of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent&#160;years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent&#160;years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. In addition, the USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the EU. These products may compete with our product candidates, and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. Furthermore, the requirements for patentability differ in certain jurisdictions and countries. For example, unlike other countries, China has a heightened requirement for patentability, and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent.  Prosecution of patent applications in other jurisdictions is often a longer process and patents may grant at a later date, and with a shorter term, than in the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. We may not be able to prevent third parties from practicing our or our licensors&#8217; inventions in all countries outside the United States, or from selling or importing products made using our intellectual property in and into the United States or other jurisdictions. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. If we do not have sufficient patent life to protect our products, our business, financial condition, results of operations, and prospects will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, we may be able to extend the term of a patent covering each product candidate under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five&#160;years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The total patent term including the extension cannot exceed 14&#160;years following regulatory approval. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, under certain circumstances, patent terms covering our products or product candidates may be extended for time spent during the pendency of the patent application in the USPTO, referred to as Patent Term Adjustment (&#8220;PTA&#8221;). The laws and regulations underlying how the USPTO calculates the PTA is subject to change and any such PTA granted by the USPTO could be challenged by a third-party. If we do not prevail under such a challenge, the PTA may be reduced or eliminated, resulting in a shorter patent term, which may negatively impact our ability to exclude competitors. Because PTA added to the term of patents covering pharmaceutical products has particular value, our business may be adversely affected if the PTA is successfully challenged by a third party and our ability to exclude competitors is reduced or eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not address all potential threats to our competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to Buntanetap or our future product candidates but that are not covered by the claims of the patents that we own or license from others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our collaborators might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ownership of our patents or patent applications may be challenged by third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to seeking patent protection for our product candidates and proprietary technologies, we may also rely on trade secret protection and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. Because we expect to rely on third parties to manufacture Buntanetap and any future product candidates, and we expect to collaborate with third parties on the development of Buntanetap and any future </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. However, trade secrets or confidential know-how can be difficult to maintain as confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Furthermore, we cannot guarantee that we have entered into applicable agreements with each party that may have or have had access to any potential trade secrets or proprietary technology and processes. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. If any of our potential trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have not yet registered our trademarks in the United States or other jurisdictions. Failure to secure such registrations could adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not yet registered our trademarks in the United States or other jurisdictions. If we do not successfully register our trademarks, we may encounter difficulty in enforcing, or be unable to enforce, our trademark rights against third parties, which could adversely affect our business and our ability to effectively compete in the marketplace. We have also not yet registered trademarks for any of our product candidates in any jurisdiction. When we file registration applications for trademarks relating to our product candidates, those applications may be rejected, and registered trademarks may not be obtained, maintained or enforced. During trademark registration proceedings in the United States and foreign jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties may oppose pending trademark registration applications or seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademark registrations may not survive such proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In addition, any proprietary name we may propose to use with Buntanetap or any future product candidate in the United States must be approved by the FDA, regardless of whether we have registered, or applied to register, the proposed proprietary name as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe, misappropriate or otherwise violate the existing rights of third parties and be acceptable to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on, misappropriating or violating other marks. We may not be able to protect our rights to these trademarks and trade </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">names, which we need to build name recognition among potential collaborators or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an opportunity to respond to such rejections, we may be unable to overcome them. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. There could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain names or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In response to an inability to enforce our patent rights, or in the event of successful litigation against us by third parties, or in the normal course of future business operations, we may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require us to pay license fees or royalties or both. Furthermore, if we or our licensors are unsuccessful in any proceedings sought to enforce our patent rights, such patents and patent applications may be narrowed, invalidated or held unenforceable, we may be required to obtain licenses from third parties. Although at this time, we are unaware of any intellectual property that interferes with ours or is complementary and needed to commercialize Buntanetap, a third party may also hold intellectual property, including patent rights that are important or necessary to the future development or commercialization of Buntanetap or our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize Buntanetap or our product candidates, in which case we would be required to obtain a license from these third parties. If any of these situations were to occur, such a license may not be available on commercially reasonable terms, or at all, which could materially harm our business. Even if a license can be obtained on acceptable terms, the rights may be nonexclusive, which could give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, contractors, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us and not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against any of the foregoing claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership or right to use. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our proprietary information may be lost, or we may suffer security breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Certain federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular categories of personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, disruption of our operations, delays in our regulatory approval efforts, damage to our reputation, costs to recover or reproduce the data and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If any security breach or other incident, whether actual or perceived, were to occur, it could impact our reputation and/or operations, cause us to incur significant costs and liabilities, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture Buntanetap, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any actual or perceived disruption or security breach affects our systems (or those of our third-party collaborators, service providers, contractors or consultants) or were to result in a loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development and commercialization of Buntanetap or any future product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities. In addition, a security failure could result in violations of applicable privacy and other laws.  If this information is inappropriately accessed and used by a third party or a team member for illegal purposes, such as identity theft, we may be responsible to the affected individuals for any losses they may have incurred as a result of misappropriation.  In such an instance, we may also be subject to regulatory action, investigation or liable to a governmental authority for fines or penalties associated with a lapse in the integrity and security of our team members&#8217; or patients&#8217; information.  We may be required to expend significant capital and other resources to protect against and remedy any potential or existing security breaches and their consequences.  In addition, our remediation efforts may not be successful and we may not have adequate insurance to cover these losses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Security breaches could also significantly damage our brand and our reputation with existing and prospective clients and third parties with whom we do business.  Any publicized security problems affecting our businesses and/or those of such third parties may negatively impact the market perception of our products and discourage third parties from doing business with us.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Employees, Managing Our Growth and Our Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the development, regulatory, commercialization and business development expertise of Maria L. Maccecchini,&#160;PhD, as well as the other principal members of our management, scientific and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop product candidates, gain regulatory approval, and commercialize new products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to experience significant growth in the number of our employees and the scope of our operations. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results. Furthermore, we may experience losses related to investments in other companies, including as a result of failure to realize expected benefits or the materialization of unexpected liabilities or risks, which could have a material negative effect on our results of operations and financial condition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek to enter into collaborations, license agreements and other similar arrangements in the future, and may not be successful in doing so.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may seek to enter into collaborations, joint ventures, licensing arrangements or other similar arrangements with third parties for the development or commercialization of Buntanetap and any future product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints. These relationships or those like them may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish or maintain a strategic partnership or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">potential to demonstrate safety and efficacy. Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us. For example, we may need to relinquish valuable rights to our future revenue streams, research programs, intellectual property or product candidates, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements may restrict us from entering into additional agreements with other potential collaborators. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. In addition, if we enter into such collaborations, we will have limited control over the amount and timing of resources that our collaborators will dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on any future collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Furthermore, we may not be able to maintain such collaborations if, for example, the development or approval of a product candidate is delayed, the safety of a product candidate is questioned or the sales of an approved product candidate are unsatisfactory. Any delays in entering into new strategic partnership agreements related to our drug candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Collaborations involving Buntanetap or any future product candidates would pose significant risks to us, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected or at all&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to any product candidate that achieves regulatory approval may not commit sufficient resources to the marketing and distribution of such products&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws, resulting in civil or criminal proceedings&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays in or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive&#894;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly enforce, maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not provide us with timely and accurate information regarding development, regulatory or commercialization status or results, which could adversely impact our ability to manage our own development efforts, accurately forecast financial results or provide timely information to our stockholders regarding our out-licensed product candidates&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to invest resources and attention into such collaboration, which could distract from other business objectives&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the collaborators and us regarding ownership of or other rights in the intellectual property generated in the course of the collaborations&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated, including for the convenience of the collaborator, prior to or upon the expiration of the agreed upon terms and, if terminated, we may find it more difficult to enter into future collaborations or be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to Buntanetap or any future product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business and operations would suffer in the event of failures involving our information technology systems, or those of any of our service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), team member misconduct, human error, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of Buntanetap or any other product candidate could be delayed. It is not possible to prevent all threats or to our information technology systems and information and those of our third-party service providers, over which we exert less control, and any controls we implement to do so may prove to be ineffective.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The cash and cash equivalents that we use to meet our working capital and operating expense needs are held in deposit accounts at two financial institutions. If one or both financial institutions fail, our deposit accounts could be adversely affected due to the loss of or delay in obtaining access to all or a portion of our uninsured funds.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cash and cash equivalents that we use to meet our working capital and operating expense needs are held in deposit accounts at two financial institutions. The balance held in these accounts regularly exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;), standard deposit insurance limit or similar government guarantee schemes. If one or both of the financial institutions in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of such uninsured funds or be subject to a delay in accessing all or a portion of such uninsured funds. Any such loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our operating expense obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For example, on March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) and Signature Bank, were closed by state regulators and the FDIC was appointed as the receiver for each bank. The FDIC created successor bridge banks and all deposits of SVB and Signature Bank were transferred to the bridge banks under a systemic risk exception approved by the U.S. Department of the Treasury, the Federal Reserve and the FDIC. If one or both of the financial institutions in which we hold our funds for working capital and operating expense needs were to fail, we cannot provide any assurances that such governmental agencies would take action to protect our uninsured deposits in a similar manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market price of our common stock has been volatile and fluctuated substantially in the past, and may continue to experience volatility and substantial fluctuations in the future, which could result in substantial losses for purchasers of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The market price of our common stock is highly volatile. For example, from August 1, 2022 to March 30, 2023, the sale price of our common stock on the New York Stock Exchange ranged from as low as $9.84 to as high as $23.91 and daily trading volume ranged from 5,000 shares to 768,700 shares. The market price of our common stock may be subject to wide fluctuations in response to a variety of factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of our clinical trials, and the results of trials of our competitors or those of other companies in our market sector&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enroll subjects in our future clinical trials&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or unanticipated developments in the completion of our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in submitting an NDA and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory approval of Buntanetap or any future product candidates or additional indications thereof, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to successfully develop and commercialize Buntanetap or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and rate of physician and market adoption of any of our current and future product candidates&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain additional funding or obtaining funding on unattractive terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries applicable to Buntanetap or any other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, supply or distribution delays or shortages, including our inability to obtain adequate product supply for Buntanetap or any other product candidates, or the inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success or failure of our efforts to identify, develop, acquire or license additional product candidates&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products, services or technologies by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial projections we provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the estimates and projections of the investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of companies similar to ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts&#8217; reports or recommendations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our stockholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting standards, policies, guidelines, interpretations or principles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated fluctuations in our financial condition and results of operations&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of news releases by other companies in our industry, and especially direct competitors, including about adverse developments related to safety, effectiveness, accuracy and usability of their products, reputational concerns, reimbursement coverage, regulatory compliance, and product recalls&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, including but not limited to the impact of the COVID-19 pandemic; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement or progression of geopolitical events (including in relation to the conflict between Russia and Ukraine)&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political, regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and market conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance. The market price of our common stock may decline, and our stockholders may lose some or all of their investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our failure to meet the New York Stock Exchange&#8217;s continued listing requirements could result in a delisting of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">If we fail to satisfy the continued listing requirements of the New York Stock Exchange, such as the corporate governance requirements or the minimum closing bid price requirement, the New York Stock Exchange may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair our stockholders&#8217; ability to sell or purchase our common stock when they wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, or prevent future non-compliance with the listing requirements of the New York Stock Exchange.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have been subject to securities class action litigation in the past, and could be subject to such litigation in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent years. During the year ended December 31, 2021, two securities class action complaints were filed against us and our executive officers following disclosure of interim results from the AD/PD Trials.  Both complaints were voluntarily dismissed without prejudice by the plaintiffs. If we again face such litigation in the future, it could result in substantial costs, a diversion of management&#8217;s attention and resources, and damage to our reputation, which could have a material adverse effect on our business, financial condition and results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our directors, executive officers and certain stockholders own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant control over matters subject to stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our directors, executive officers, and stockholders affiliated with our directors and executive officers own approximately 30.9% of the current voting power of our outstanding common stock. Therefore, acting together, they have the ability to substantially influence all matters submitted to our board of directors or stockholders for approval. For example, these holders may be able to control the appointment of our management, elections and removal of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. The interests of these holders may not always coincide with our corporate interests or the interests of other stockholders, and they may act in a manner with which our stockholders may not agree or that may not be in the best interests of our other stockholders. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. So long as they continue to own a significant amount of our equity, these holders will be able to strongly influence or effectively control our decisions. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts may publish about us, our business, our market or our competitors. We do not have any control over these analysts. If our financial performance fails to meet analyst estimates or one or more of the analysts who cover us downgrade our common stock or change their opinion of our common stock, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be sole source of gain for our stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">for the foreseeable future. In addition, any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock would be our stockholders&#8217; sole source of gain on an investment in our common stock for the foreseeable future. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares. See &#8220;Dividend Policy&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We identified a material weakness in our internal control over financial reporting, which resulted in the restatement of our financial statements for several prior quarterly and year-to-date periods. If remediation of this material weakness is not effective, or if we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately or timely report our financial condition or operating results, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We identified a material weakness in our internal control over financial reporting as of February 23, 2023. As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a &#8220;material weakness&#8221; is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our company&#39;s annual or interim financial statements will not be prevented, or detected on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The material weakness identified related to the proper classification of research and development expenses, which impacted our previously issued condensed financial statements as of and for the three months ended March 31, 2022, three and six months ended June 30, 2022 and three and nine months ended September 30, 2022. As further described in note 12 to our financial statements included elsewhere in this Annual Report on Form 10-K, there were material amounts inappropriately classified as research and development expense which should have been classified as prepaid assets and other assets. We are taking steps to remediate the material weakness and are in the process of supplementing our existing internal controls related to the proper classification of research and development expenses. In response to the material weakness, we are enhancing our review procedures over significant contracts with contract manufacturing organizations and contract research organizations, augmenting existing staff and strengthening our review process. The incremental internal controls created to respond to this material weakness are being integrated into our internal controls testing plan and they will be tested during 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we plan to complete the above remediation process and associated evaluation and testing as quickly as possible, we may not be able to do so and our initiatives may prove not to be successful. If our remedial measures are insufficient to address the material weakness, or if additional material weaknesses or significant deficiencies in our internal control over financial reporting are discovered during the evaluation and testing process, we will be unable to assert that our internal control over financial reporting is effective and our independent registered public accounting firm will be unable to express an opinion on the effectiveness of our internal control. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The restatement of our prior quarterly financial statements may affect investor confidence and raise reputational issues and may subject us to additional risks and uncertainties, including increased professional costs and the increased possibility of legal proceedings and regulatory inquiries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As discussed in note 12 to our financial statements included elsewhere in this Annual Report on Form 10-K, we determined to restate our condensed financial statements as of and for the three months ended March 31, 2022, three and six months ended June 30, 2022 and three and nine months ended September 30, 2022 after we identified material amounts inappropriately classified as research and development expense which should have been classified as prepaid assets and other assets. As a result of this error and the resulting restatement of our condensed financial statements for the impacted periods, we have incurred, and may continue to incur, unanticipated costs for accounting and legal fees in connection with or related to the restatement, and have become subject to a number of additional risks and uncertainties, including the increased possibility of litigation and regulatory inquiries. Any of the foregoing may affect investor confidence in the accuracy of our financial disclosures and may raise reputational risks for our business, both of which could harm our business and financial results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after we no longer qualify as an emerging growth company, we incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the New York Stock Exchange, and other applicable securities rules and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Pursuant to Section 404 of SOX, we are required to furnish a report by our senior management on our internal control over financial reporting. While we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To comply with Section 404, we are required to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and maintain a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. We have had a material weakness in our internal control over financial reporting in the past, and cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the NYSE, SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering (&#8220;IPO&#8221;) on January 31, 2020, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Provisions in our restated certificate of incorporation and our amended and restated bylaws that became effective upon the closing of our IPO may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing advance notice bylaw provisions for proposals from stockholders for presentation at annual meetings and forum selection bylaw provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our restated certificate of incorporation that became effective upon the closing of our IPO specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders with respect to our company and our directors. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that the stockholder believes is favorable for disputes with us or our directors, which may discourage meritorious claims from being asserted against us and our directors. Alternatively, if a court were to find this provision of our charter inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations. We adopted this provision because we believe it makes it less likely that we will be forced to incur the expense of defending duplicative actions in multiple forums and less likely that plaintiffs&#8217; attorneys will be able to employ such litigation to coerce us into otherwise unjustified </p><a id="_47637838_3692_4642_bc3a_37d33028d3a9"></a><a id="Item1BUnresolvedStaffComments_556571"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b7c8bafe_ff72_4241_851a_525d3df9ba77"></a><a id="Item2Properties_424245"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our offices are in Berwyn, Pennsylvania, where we have leased and have access to 1,500&#160;square feet of office space pursuant to a short-term lease agreement. We believe that our facilities are adequate to meet our current needs.</p><a id="_f5c59858_751a_4354_8587_f4deb3d82255"></a><a id="Item3LegalProceedings_59244"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.</p><a id="_8abb4c89_5f44_4e73_ac66_ad1d45d7026c"></a><a id="Item4MineSafetyDisclosures_448345"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_80e5ff44_bfec_4718_afb4_9b2dd7ca7dad"></a><a id="PARTII_847922"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our common stock is listed on the New York Stock Exchange under the symbol &#8220;ANVS&#8221;.  Our common stock began trading on the New York Stock Exchange on November 18, 2021.  From January 29, 2020, the date of our initial public offering, to November 17, 2021, our common stock traded on the NYSE American.  Prior to January 29, 2020, there was no public market for our stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Holders of Record</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 30, 2022, there were approximately 19 holders of record of shares of our common stock. This number does not reflect the beneficial holders of our common stock who hold shares in street name through brokerage accounts or other nominees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information called for by this item regarding equity compensation plans is incorporated by reference to Part&#160;III,&#160;Item&#160;12 of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We did not issue any equity securities during the year ended December 31, 2022 that were not registered under the Securities Act and that have not otherwise been described in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7c6f4444_90a9_4708_9792_949a6ee599f0"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing at the end of this Annual Report on Form&#160;10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form&#160;10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements&#8221; and Item&#160;1A. Risk Factors of this Annual Report on Form&#160;10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Company Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">We are a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;). We are developing our lead product candidate, Buntanetap, which is designed to address AD, PD and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound.  In several studies, Buntanetap was observed to inhibit the synthesis of neurotoxic proteins&#8212;APP/A&#946; (&#8220;APP&#8221;), tau/phospho-tau (&#8220;tau&#8221;) and &#945;-Synuclein (&#8220;&#945;SYN&#8221;)&#8212;that are one of the main causes of neurodegeneration. High levels of </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that Buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.</span></p><a id="_cp_text_1_66"></a><a id="_cp_text_1_67"></a><a id="_cp_text_1_73"></a><a id="_cp_text_1_74"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2021, we completed two Phase 1/2 clinical studies: one in 14 early AD patients, and one in 54 early PD patients (together, the &#8220;AD/PD Trials&#8221;). In the AD/PD Trials, early AD patients were defined as those with a Mini Mental State Examination (MMSE) score between 19 and 28 and early PD patients as those patients at Hoehn &amp; Yahr stages 1, 2 or 3. MMSE is a brief screening instrument used to assess cognitive function, with total scores ranging from 0 to 30 and a lower score indicating greater disease severity, while the Hoehn &amp; Yahr scale is a medical assessment used to measure staging of the functional disability associated with PD where a higher stage indicates greater disease severity. In collaboration with the Alzheimer&#8217;s Disease Cooperative Study (&#8220;ADCS&#8221;), we also conducted a trial in 16 early AD patients (the &#8220;ADCS Trial&#8221;). In the ADCS Trial, early AD patients were defined as those patients with a MMSE score between 19 and 28. All three clinical trials were double-blind, placebo-controlled studies. We designed the studies by applying our understanding of the underlying neurodegenerative disease states, and measured both target and pathway validation in the spinal fluid of patients to determine whether patients improved following treatment. In addition to meeting their primary endpoints of safety and tolerability and secondary endpoint of pharmacokinetics of Buntanetap, our AD/PD Trials met exploratory endpoints of measures of biomarkers and improvements in cognition in AD patients, and in function in PD patients. We believe that the AD/PD Trials represent the first double-blind placebo-controlled studies that showed improvements in AD patients, as measured by ADAS-Cog, and in PD patients, as measured by UPDRS. Following completion of the AD/PD Trials, we submitted our data to the&#160;U.S. Food and Drug Administration (&#8220;FDA&#8221;) and requested direction to further pursue the development of Buntanetap in early PD patients. With the FDA&#8217;s guidance, we initiated a Phase 3 study in early PD patients in August 2022 (our &#8220;Phase 3 PD Study&#8221;). In the Phase 3 PD Study, early PD patients were defined as those at Hoehn &amp; Yahr stages 1, 2 or 3, and OFF times of less than two hours per day. OFF time refers to when PD motor and/or non-motor symptoms occur between medication doses. We also submitted a proposed protocol for the treatment of moderate AD to the FDA, and after receiving permission to proceed, we initiated a Phase 2/3 study in mild to moderate AD patients in February 2023 (our &#8220;Phase 2/3 AD Study&#8221;). In the Phase 2/3 AD Study, mild to moderate AD patients were defined as those with a MMSE score between 14 and 24. At the completion of the ADCS Trial, the data showed that Buntanetap is a translational inhibitor in humans just like in animals, and we further observed that there was statistical improvement in cognition in early AD patients, just like in the AD/PD Trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Phase 3 PD Study and Phase 2/3 AD Study each have built in interim analyses. Our Phase 3 PD Study incorporated an interim analysis at two months, the results of which were disclosed on March 31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132 patients from all cohorts collectively for which baseline and two-month data was available. As the interim analysis was conducted at two months of the six-month endpoint and only on 132 patients, it may not be indicative of the results at six months for the full patient population because as the trial progresses, clinical outcomes may materially change as patient enrollment continues and more patient data become available, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Based on the results of the interim analysis, we intend to proceed with the Phase 3 PD Study as planned in accordance with the previously established protocol. We remain blinded to the Phase 3 PD Study and we do not have safety or efficacy data from the trial. A separate safety interim analysis is in process and we expect that interim analysis to be released in the second quarter of 2023. We intend to disclose the results of an interim analysis for our Phase 2/3 AD Study in Fall 2023. We plan to consult with the FDA following completion of these interim analyses, to obtain feedback on our ongoing and planned AD and PD studies, including conducting an open label extension study following the completion of the initial trials. Using the data from the Phase 3 PD Study interim analysis, we intend to design an 18-month long disease-modifying Phase 3 study in the same early PD patients. In addition, we intend to conduct a short 6-month study in advanced PD patients during the second half of the 18-month disease modifying Phase 3 study, at which time we will define the advanced PD patient population for the purposes of such study. Similarly, using the data from the Phase 2/3 AD Study interim analysis, we intend to design an 18-month disease modifying Phase 3 study in the same early AD patient population. In addition, we intend to conduct a short 6-month study in advanced AD patients during the second half of the 18-month disease modifying Phase 3 study, at which time we will define the advanced AD patient population for the purposes of such study. We expect both the ongoing Phase 3 PD Study and the Phase 2/3 AD Study to be completed by the end of 2023, and we intend to announce the data from the final analyses in the first quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By the end of 2026, our goal is to have conducted the required pivotal studies for Buntanetap to be able to file two new drug applications (&#8220;NDAs&#8221;) with the FDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein, and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD as well as body and brain function associated with PD. Based on pre-clinical and clinical data collected to date, we believe that Buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling Buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or &#945;SYN, indicating that doing so does not change the course of neurodegeneration. Our goal is to develop a disease modifying drug (&#8220;DMD&#8221;) for patients with neurodegeneration by leveraging our clinical and pre-clinical data to inhibit the three most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and accordingly these diseases present two unmet needs of the aging population and two potentially large U.S. markets if a DMD is developed and approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We have never been profitable and have incurred net losses since inception. Our accumulated deficit at December 31, 2022 was $54,054,774. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when we will be able to achieve or maintain profitability, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses consist of expenses incurred in development and clinical studies relating to our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses associated with clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, such as salaries, benefits, travel and other related expenses, including stock-based compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments to third-party contract research organizations (&#8220;CROs&#8221;), contractor laboratories and independent contractors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed. Clinical development expenses for our product candidates are a significant component of our current research and development expenses. Product candidates in later stage clinical development generally have higher research and development expenses than those in earlier stages of development, primarily due to increased size and duration of the clinical trials. We track and record information regarding external research and development expenses for each study or trial that we conduct. From time to time, we use third-party CROs, contractor laboratories and independent contractors in clinical studies. We recognize the expenses associated with third parties performing these services for us in our clinical studies based on the&#160;percentage of each study completed at the end of each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our research and development expenses in 2022 were primarily related to our Phase 3 study in early PD patients.Our research and development expenses in 2021 were primarily related to the AD/PD Trials which began treating patients in August 2020.  We expect that our research and development expenses in 2023 and for the next several&#160;years will be significantly higher than in 2022 as a result of costs associated with our planned Phase 3 trials. These expenditures are subject to numerous uncertainties regarding timing and cost to completion. Completion of our clinical development and clinical trials may take several&#160;years or more and the length of time generally varies according to the type, complexity, novelty and intended use of our product candidates. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of sites included in the clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll suitable patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of patient populations participating in the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient follow-ups;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development stage of the product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety profile of the product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the stage of our research and development, we are unable to accurately determine the duration or completion costs of our development of Buntanetap. As a result of the difficulties of forecasting research and development costs of Buntanetap as well as the other uncertainties discussed above, we are unable to determine when and to what extent we will generate revenues from the commercialization and sale of approved product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our executive, finance, accounting, and administrative functions. Our general and administrative expenses also include professional fees for legal services, including patent-related expenses, consulting, tax and accounting services, insurance, rent and general corporate expenses. We expect that our general and administrative expenses will increase with the continued development and potential commercialization of our product candidates. We expect that our general and administrative expenses in 2023 and for the next several&#160;years will be significantly higher than in 2022 as we increase our employee count.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $27,536,031 which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2,764,240 will expire beginning 2032. The remaining federal NOL carryforwards generated beginning in 2018, do not expire. NOL carryforwards generated beginning in 2021 are permitted to offset 80% of taxable income in future&#160;years. As of December 31, 2022, the Company also had U. S. state NOL carryforwards of $30,082,914 which may be available to offset future income tax liabilities and will expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (the &#8220;IRS&#8221;) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections&#160;382 and 383 in the Internal Revenue Code. This could substantially limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have based our management&#8217;s discussion and analysis of financial condition and results of operations on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates that affect the reported amounts of assets and liabilities and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to clinical development expenses and stock-based compensation.  The clinical development cost to advance any of our product candidates to marketing approval is substantial and involves numerous risks and uncertainties associated with pharmaceutical product development.  As a result, we are unable to accurately predict the timing or amount of increased expenses and, as a result, clinical development expense could be materially different as the costs are incurred.  We measure and record compensation expense using the applicable accounting guidance for share-based payments using the Black-Scholes option pricing model to value option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. These assumptions used in calculating the fair value of stock-based awards represent our best estimates and involve inherent uncertainties and the application of judgment.  As a result, if factors change and we used different assumptions, stock-based compensation expense could be materially different for stock-based awards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are more fully discussed in Note&#160;2 to our audited financial statements appearing at the end of this Annual Report on Form&#160;10-K, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on third parties to conduct our clinical studies and to provide services, including data management, statistical analysis and electronic compilation. At the end of each reporting period, we compare the payments made to each service provider to the estimated progress towards completion of the related project. Factors that we consider in preparing these estimates include the number of patients enrolled in studies, milestones achieved and other criteria related to the efforts of our vendors. These estimates are subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, we record net prepaid or accrued expenses related to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We account for grants of stock options to employees and non-employees based on their grant date fair value and recognize compensation expense over the vesting periods. We estimate the fair value of stock options as of the date of grant using the Black-Scholes option pricing model. The Black-Scholes model requires us to make assumptions and judgments about the variables used in the calculations, including the expected term, the expected volatility of our common stock, the risk-free interest rate and the expected dividend rate. Given the lack of a public market for our common stock prior to the IPO, the expected stock price volatility is based on a weighted approach that incorporates the historic daily volatility of our common stock since the IPO and the historic daily volatility of similar companies that have been publicly traded for a period commensurate with the expected term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Years ended December 31, 2022 and 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Operating expenses and other income were comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,515.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,479.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,995.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,058.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 182.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by $8,036.5 thousand for the&#160;year ended December 31, 2022 compared to the&#160;year ended December 31, 2021. The increase was primarily the result of an increase of $6,629.5 thousand in expenses related to our clinical trials, including production of material, an increase in stock-based compensation expense of $1,357.7 thousand, and an increase of $202.4 thousand in other personnel expenses, partially offset by a decrease of $100.5 thousand in expenses related to our long-term toxicology studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by $2,937.5 thousand for the&#160;year ended December 31, 2022 compared to the&#160;year ended December 31, 2021. The increase was primarily the result of increases of $3,097.2 thousand in stock-based compensation expense, partially offset by a decrease of $230.4 thousand in conference and meeting expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest income, net increased $159.8 thousand for the&#160;year ended December 31, 2022 compared to the&#160;<span style="white-space:pre-wrap;">year ended December 31, 2021. The increase was primarily the result of higher interest rates compared to the prior year.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant income decreased $36.8 thousand for the&#160;year ended December 31, 2022 compared to the&#160;year ended December 31, 2021. The decrease was the result of income recognized related to a grant from the NIH to reimburse the costs of our long-term toxicology studies in rats and dogs, which studies began in November&#160;2019 and were substantially completed as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock, convertible preferred stock and convertible promissory notes. To date, we have not generated any revenues from the sale of products, and we do not anticipate generating any revenues from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of December 31, 2022, our principal source of liquidity was our cash and cash equivalents, which totaled $28,377.7 thousand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Financings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We closed an equity offering on May 26, 2021, raising gross proceeds of $50,000.0 thousand and net proceeds of $46,648.4 thousand, after deducting underwriting discounts and issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have sufficient capital on hand to fund our operations for the next 12 months and will need to raise additional capital to meet our obligations as they become due. We believe that our current cash and cash equivalents and funding from existing grants will be sufficient to fund our operating expenses and capital expenditure requirements until the fourth quarter of 2023, including our ongoing Phase 2/3 AD Trial and our ongoing Phase 3 PD Trial. We will need to raise substantial additional capital to complete the development and commercialization of our product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. However, there can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. We have no committed external sources of funds. If we are unable to raise sufficient additional capital or defer sufficient operating expenses, we may be compelled to reduce the scope of our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur significant operating losses for the foreseeable future, and for these losses to further increase, as we ramp up our clinical development programs and begin activities for commercial launch readiness. We may also encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for Buntanetap or any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical development plans we establish for Buntanetap and any other future product candidates, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we discover or in-license and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing and cost of regulatory meetings and reviews by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirements of regulatory authorities in any additional jurisdictions in which we may seek approval for Buntanetap and any future product candidates and our anticipated timing for seeking approval in such jurisdictions&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development, regulatory, CMC quality and commercial personnel&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of the implementation of commercial-scale manufacturing activities, if any product candidate is approved, including as a result of inflation, any supply chain issues or component shortages; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products&#894; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements&#894; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any products or technologies that we may in-license or acquire; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delays and cost increases that may result from the COVID-19 or any future pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds as required, we may need to delay, reduce, or terminate some or all development programs and clinical trials. We may also be required to sell or license our rights to product candidates in certain territories or indications that we would otherwise prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to address our liquidity needs, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially and adversely affect our business and financial prospects. See the section of this Annual Report on Form 10-K titled &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes our cash flows from operating, investing and financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Statement of Cash Flows Data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,312.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (9,132.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 46,743.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,308.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 37,611.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December 31, 2022, cash used in operations was $17,312.9 thousand compared to $9,132.1 thousand for the&#160;year ended December 31, 2021. The increase in cash used in operations was primarily the result of the costs associated with our AD/PD Trials and higher personnel expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect cash used in operating activities to increase in 2023 as compared to 2022 due to an expected increase in our operating losses associated with ongoing development of our product candidates and planned increases in our personnel count. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities was $4.6 thousand during the&#160;year ended December 31, 2022, attributable to proceeds from the exercise of stock options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities was $46,743.5 thousand during the year ended December 31, 2021, attributable to net proceeds from our equity offering of approximately $46,648.4 thousand, and proceeds from the exercise of stock options of $95.1 thousand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restatement of Previously Issued Quarterly Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During its preparation of its 2022 audited combined financial statements and notes thereto, the Company concluded that there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed financial statements as of and for each of the quarterly and year to date periods ended March 31, 2022, June 30, 2022 and September 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company noted the following items were improperly expensed during the three months ended March 31, 2022:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Payments, in the amount of $800,840, were improperly recorded in research and development expenses during the three months ended March 31, 2022. These amounts should have been recorded as prepaid expenses and other current assets as of March 31, 2022.  </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Research and development expense amounts totaling $140,690 were not recorded during the three months ended March 31, 2022. This amount should have been recorded in accrued expenses and other current liabilities as of March 31, 2022.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These errors in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets of $800,840, accrued expenses and other current liabilities of $140,690 and an overstatement of operating expenses and net loss of $660,150 as of and for the three months ended March 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company noted the following items were improperly expensed during the three and six months ended June 30, 2022:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments, in the amount of $2,883,977 were improperly recorded in research and development expenses during the three months ended June 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of June 30, 2022. Additionally, $102,232 was expensed during the three months ended June 30, 2022 related to the prior quarter restatements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These errors, including the errors from the three months ended March 31, 2022, in the accounting for research and development expenses resulted in a cumulative understatement of prepaid assets and other current assets of $3,441,895, as of June 30, 2022, and an overstatement operating expenses and net loss of $2,781,745 and $3,441,895 for the three and six months ended June 30, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company noted the following items were improperly expensed during the three and nine months ended September 30, 2022:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments, in the amount of $1,320,321, were improperly recorded in research and development expenses during the three months ended September 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of September 30, 2022. Additionally, $130,826 was expensed during the three months ended September 30, 2022 related to the prior quarter restatements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These errors, including the errors from the six months ended June 30, 2022, in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets of $4,631,390 as of September 30, 2022, and an overstatement of operating expenses and net loss of $1,189,495 and $4,631,390 for the three and nine months ended September 30, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Detailed restatements of the Company&#39;s condensed quarterly financial statements are provided in this Annual Report on Form 10-K, Note 12 - <i style="font-style:italic;">Restatement of Previously Issued Unaudited Condensed Financial Statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively.  We adopted this standard prospectively. As such, the adoption did not have an impact on our financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">JOBS Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Section&#160;107 of the JOBS Act also provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)&#160;of the Securities Act for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><a id="_66af9d0b_d6c0_4069_b57e_1bebf438e1a9"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This item is not required for smaller reporting companies.</p><a id="_a6c6b6df_bd6a_4a89_be69_fc8f0c2b93af"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial statements, accompanying notes and Report of Independent Registered Public Accounting Firm are included in this Annual Report on Form&#160;10-K beginning on page&#160;F-1, which are incorporated in this Item&#160;8 by reference.</p><a id="_1f7d6066_1bb5_4817_bb0e_2840de0325c7"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_a961ccde_f131_420b_861d_12b6a6fe3d7a"></a><a id="Item9AControlsandProcedures_371514"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of the end of the period covered by this Annual Report on Form&#160;10-K. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, as a result of the material weaknesses in our internal control, our disclosure controls and procedures were not effective to ensure that the information required to be disclosed by us in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules&#160;and forms, and that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as our principal financial and accounting officer, to allow timely decisions regarding required disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Identified Material Weakness</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the audit of our financial statements as of December 31, 2022 and 2021 and for the years ended December 31, 2022 and 2021, we identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness related to the proper classification of research and development expenses, which impacted our previously issued condensed financial statements as of and for the three months ended March 31, 2022, three and six months ended June 30, 2022 and three and nine months ended September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Remediation Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management, with the oversight of the Audit Committee of the Board of Directors, has updated our internal processes and controls to strengthen their effectiveness and developed a remediation plan which includes the following actions: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enhance our review procedures over significant contracts with contract manufacturing organizations and contract research organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Augment existing staff; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Strengthen the review process.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will not be able to conclude whether the actions we are taking will fully remediate the material weakness in our internal control over financial reporting until the updated controls have operated for a sufficient period of time and management has concluded, through testing, that such controls are operating effectively. We may also conclude that additional measures may be required to remediate the material weakness in our internal control over financial reporting, which may necessitate further action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management utilized the criteria established in the Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) to assess the effectiveness of our internal control over financial reporting as of December 31, 2022. Based on the assessment, management has concluded that, as of December 31, 2022, our internal control over financial reporting was not effective, due to the remaining material weakness in our internal control over financial reporting described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As an emerging growth company, management&#8217;s assessment of internal control over financial reporting was not subject to attestation by our independent registered public accounting firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, as the material weakness relating to our internal control over financial reporting described above was identified subsequent to December 31, 2022. We are now taking actions to remediate the material weakness, which may result in changes in our internal control over financial reporting in periods subsequent to December 31, 2022.</p><a id="_79151b12_6a51_4af0_a345_511ca20059d5"></a><a id="Item9BOtherInformation_404053"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ef5d63f8_06d4_4113_87ca_4bfea26bcdbe"></a><a id="PARTIII_953652"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;III</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Item10DirectorsandExecutiveOfficersandCo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors and Executive Officers and Corporate Governance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;10 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following is a list of our executive officers as of the date of this Annual Report.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;background:#ffffff;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:14.05pt;"><td style="vertical-align:bottom;width:48.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:bottom;width:48.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:bottom;width:48.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Henry Hagopian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_70d3d162_d4ba_43a0_baee_027886479cf4"></a><a id="Item11ExecutiveCompensation_144002"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;11 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC.</p><a id="_485d6d3b_8d7a_43d9_a24f_09926ebc4d37"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;12 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Equity Compensation Plan Information</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;securities&#160;to&#160;be&#160;issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;securities&#160;remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;upon&#160;exercise&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;available&#160;for&#160;future&#160;issuance&#160;under&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding&#160;options,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise&#160;price&#160;of&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">equity&#160;compensation&#160;plans&#160;(excluding&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;warrants&#160;and&#160;rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;options,&#160;warrants&#160;and&#160;rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">securities&#160;reflected&#160;in&#160;column&#160;(a))</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(b)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(c)</p></td></tr><tr><td style="vertical-align:bottom;width:31.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity compensation plans approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,657,342</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13.95</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 392,874</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity compensation plans not approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,400</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7.50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,659,742</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13.95</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 392,874</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7b1424a3_03f6_43b4_ac76_3b071437a285"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions and Director Independence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;13 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC.</p><a id="_f5e7abe0_808b_4c00_97e4_1ec8cc03021f"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accountants Fees and Services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;14 by reference to the definitive proxy statement for our 2023 annual meeting of shareholders, to be filed with the SEC.</p><a id="_efcecc54_4504_4f0d_b609_ffb9b2353598"></a><a id="PARTIV_494222"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits and Financial Statement Schedules.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Documents filed as part of this report:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements. The financial statements as set forth under Item&#160;8 of this Annual Report on Form&#160;10-K are incorporated herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules. All financial statement schedules have been omitted because they are not applicable, not required, or the information is shown in the financial statements or related notes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits. See (b)&#160;below.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Exhibit</b></p></th></tr><tr><td style="vertical-align:bottom;width:12.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">3.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920011925/tm206971d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit&#160;3.1 to Form&#160;8-K filed February&#160;6, 2020.)</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Exhibit</b></p></th></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">3.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920011925/tm206971d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit&#160;3.2 to Form&#160;8-K filed February&#160;6, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919005362/a2239691zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Certificate evidencing shares of the Registrant&#8217;s common stock. (Incorporated by reference to Exhibit&#160;4.1 to Amendment No.&#160;3 to Form&#160;S-1 filed September&#160;20, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920038326/tm2013055d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Warrant to purchase common stock issued to ThinkEquity, a division of Fordham Financial Management,&#160;Inc. in connection with the closing of the IPO. (Incorporated by reference to Exhibit&#160;4.2 to Form 10-K filed March 25, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.3</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920038326/tm2013055d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities. (Incorporated by reference to Exhibit&#160;4.3 to Form 10-K filed March 25, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.1+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920038326/tm2013055d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Employment Agreement dated as of March&#160;24, 2020 between the Registrant and Maria Maccecchini. (Incorporated by reference to Exhibit&#160;10.1 to Form 10-K filed March 25, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.2+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919003982/a2239177zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Annovis Bio,&#160;Inc. 2018 Equity Incentive Plan. (Incorporated by reference to Exhibit&#160;10.2 to Form&#160;S-1 filed July&#160;3, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.3</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919004651/a2239387zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement dated as of December&#160;19, 2014 among the Registrant and the signatories thereto. (Incorporated by reference to Exhibit&#160;10.5 to Amendment No.&#160;1 to Form&#160;S-1 filed August&#160;8, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.4</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919003982/a2239177zex-10_7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investigator-Initiated Clinical Trial Agreement dated June&#160;27, 2016 between The Regents of the University of California and the Registrant. (Incorporated by reference to Exhibit&#160;10.7 to Form&#160;S-1 filed July&#160;3, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.5+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919004651/a2239387zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Annovis Bio,&#160;Inc. 2019 Equity Incentive Plan. (Incorporated by reference to Appendix A to the Proxy Statement on Schedule 14A filed on April 19, 2021.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.6+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20221231xex10d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Award Agreement for the Annovis Bio, Inc. 2019 Equity Incentive Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.7+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465922095769/tm2224778d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter, dated August 29, 2022, by and between the Registrant and Henry Hagopian III. (Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed August 29, 2022.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.8+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465922099298/tm2225662d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Separation Agreement, dated September 9, 2022, by and between the Registrant and Jeffrey B. McGroarty. (Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed September 12, 2022.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">23.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of WithumSmith+Brown, PC.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">24.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Power_of_Attorney"><span style="font-style:normal;font-weight:normal;">Power of Attorney. (Included on signature page to this Annual Report on Form&#160;10-K.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">31.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">31.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">32.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">32.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20221231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Labels Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File &#8211; the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_19129572_5eed_41f2_81d6_2dec275629a7"></a><a id="Item16Form10KSummary_558755"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2c60985c_0a4f_47f5_a731_c494a43da1d9"></a><a id="IndextoFinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">ANNOVIS BIO,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Table of Contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page(s)</b></p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BalanceSheets_148726"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December 31, 2022 and 202</span></a>1</p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations_7171"><span style="font-style:normal;font-weight:normal;">Statements of Operations for the&#160;Years ended December 31, 2022 and 202</span></a>1</p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StockholdersEquityDeficit_933195"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">Statements of Changes in Stockholders&#8217; Equity  for the&#160;Years ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows_169542"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the&#160;Years ended December 31, 2022 and 202</span></a>1</p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoFinancialStatements_177435"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Financial Statements</span></a></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_93e0844b_af90_4ef4_971c_96e8b3ec5b23"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">To the Stockholders and the Board of Directors of Annovis Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We have audited the accompanying balance sheets of Annovis Bio,&#160;Inc. (the &#8220;Company&#8221;), as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders&#8217; equity and cash flows for each of the two&#160;years in the period ended December&#160;31, 2022 and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two&#160;years in the period ended December&#160;31, 2022, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Substantial Doubt Regarding Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The accompanying financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 1 to the financial statements, the entity has a history of recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management&#39;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restatement of Previously Issued Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As discussed in Note 12 to the financial statements, the Company has restated its 2022 quarterly financial information for an error in the accounting for research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:AuditorName" id="Narr_N-Faw33akESwAH8DVq6y8g">WithumSmith+Brown, PC</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:AuditorLocation" id="Narr_H0n8gRTx10KGf3rB9CcW0Q">East Brunswick, New Jersey</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">March 31, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">PCAOB ID Number <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="dei:AuditorFirmId" id="Narr_zP4aI-KjdE2ttrf9Zj1dOQ">100</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b9d6902f_913e_4650_a516_349c86cb6ffb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="BalanceSheets_148726"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6c5307e4_e7b3_4da2_9c91_7be2f777aa9f"></a><a id="Tc_tUdSXudSqEmp_lUcFepevQ_1_2"></a><a id="Tc_eeVFYopblUSzLHspQc3NKg_2_2"></a><a id="Tc_bS40jryEG0uetdESNVgezQ_2_5"></a><a id="Tc_Av_q2MdjR0a_VndkYuuAIw_4_0"></a><a id="Tc_oFy-r8M3SEKW9sG97dgxWw_5_0"></a><a id="Tc_6yMmDZ45Lkm9hNvgcthHuQ_6_0"></a><a id="Tc_VtqICq27dEeaHMCbnHOR1Q_6_2"></a><a id="Tc_b2-IktcWrEC6kxdvtOwkfg_6_5"></a><a id="Tc_bm7wIwlkvEqqBgmsMF-vSA_7_0"></a><a id="Tc_WMgdN42jCEestPCeQzy14g_8_0"></a><a id="Tc__iaVzDvFUEi3Mn6amnRzUQ_9_0"></a><a id="Tc_XWSGaQO1N0q68ZH6X6TIZQ_9_2"></a><a id="Tc_gsq7m9zmLkCkqStqPCr32Q_9_5"></a><a id="Tc_WgjoVBl9DE2_dZJMbt_21A_10_0"></a><a id="Tc_qHbBti5QYk2clVkzU4WocA_11_0"></a><a id="Tc_AkgJ89nEtUSYip3ltC4OdA_12_0"></a><a id="Tc_Gnhrhc_9AUevLLoLf70ucg_12_2"></a><a id="Tc_rB-AYCXiNEKshljqqFfChw_12_5"></a><a id="Tc_O3w9VxOHiE-seZmtObXvgg_13_0"></a><a id="Tc_wv7c3UPkHUGOg7k3PGypCQ_14_0"></a><a id="Tc_m70JwbsCzkm4QgUvCAzKww_15_0"></a><a id="Tc_EneoReEXWkKNcsiYyV6sDA_16_0"></a><a id="Tc_cjN-re-ldEWRSjEwZW8bvA_17_0"></a><a id="Tc_sHkv92Q8KU2C7dmvXA1NmQ_18_0"></a><a id="_6d558747_ea69_4a32_bf17_e8e414c7e7b5"></a><a id="_6d558747_ea69_4a32_bf17_e8e414c7e7b5_2"></a><a id="_6d558747_ea69_4a32_bf17_e8e414c7e7b5_3"></a><a id="Tc_nm1KbC68Hkq3wpYboDJBUg_19_0"></a><a id="Tc_0-Sx9IoruEap2rw0N-a-GA_20_0"></a><a id="Tc_ecNxkhLeUEKyDGwQNh17gA_21_0"></a><a id="Tc_j4QM1qN4QUeSGMHwrt3quA_22_0"></a><a id="Tc_PJ9mtVZxsUaJo01KzL0Cnw_23_0"></a><a id="Tc_Hxls-XGcNUW3y7mJ1WxXsA_23_2"></a><a id="Tc_F7IbQakUn0SO9TW-O1NO9A_23_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_rbPA7t9Q-EKsvOcIKp8r1Q_6_3">28,377,693</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_CZT18GFPXUKyfTT1Vr-P3w_6_6">45,686,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_les5kNXLhkSBy8-NGoD-PA_7_3">7,644,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_8WUxRsEXg0Gn4SS5JdRxUA_7_6">315,464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_CC1KjgoAdUSbkR3yOqVIQg_8_3">36,022,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_7viYsc1Fw0KotpoqhVeLWQ_8_6">46,001,478</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_q9na98xDYEmT7k23AX2s0w_9_3">36,022,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_mWkEMOqIlE6hrwfrQeWGZA_9_6">46,001,478</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_kGzJsh55r0W9j3q1GnyE5A_12_3">3,961,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_iWTu1qGdU0mtrlp4JaIzjg_12_6">688,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_V29fGD16bkyrTolkuxb2DA_13_3">3,737,285</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc__NivYae4DECQhcrJ6R8LuQ_13_6">818,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_li4rTvvcxkyayZaVkkQwlQ_14_3">7,698,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_pXWXynWN2k-rvPqrb-L2vQ_14_6">1,506,514</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_XZEqqm6DCkuAgp-1DATTug_15_3">7,698,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_dDTtrSi9nEWu22erCPnIoQ_15_6">1,506,514</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_I5m8uWjUNUuVw_GRX3RnjA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_dpTfywwYJEWR_Imbr2PBGA">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr__2qH8Bzmd0Cq0wpgEt29aA"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_ybhwGJaYYU2YEJyKS8Cmbg">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_zIvcn8sdKU6zS1-WerLYJQ"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_Wlh5DK0F90qF10tPvyBVpQ">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_b5CxiFHgF0qmCxB9v3qZrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_CKmZMxNY9EKNzVKvLMFfig;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_MJKqjJhFsUSZrlu3vWb00w"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_OqIeg8r1QEWQ86f2KVkywA">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_4MIu96yVwUewojBeKQN5Rw"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_QZDKLf1L1U-_8kvioL3ebA">35,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_20uICi3EP02RM78Pionb5g">8,163,923</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_ojgEHk46KEa_okqxBZ44LA">8,100,570</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_VaKD4RT3_UaqR1WyWSHEKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_yN13rWRPTE6hgWOZKM6n6A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31,&#160;2022 and December&#160;31,&#160;2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_xQwW6Gi_aUyZq9g-nSlllA_19_3">816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_kyd7SF9rKkmkWnbLve9lEw_19_6">810</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_lLpikxCcYkm32LqNog8TLg_20_3">82,377,488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_eTwjqBQbrEy6HyTSMFINdg_20_6">73,220,361</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_FRYZEMf8_kKNovhFLEYZRw_21_3">54,054,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_w0TmMIZxq0mFm843rArC4Q_21_6">28,726,207</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_UfXHzcC5GkOygx5RW2GBSw_22_3">28,323,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_cHafilgpBEW-IXIvn0YboQ_22_6">44,494,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_z1vcPbVKfU-dlB7u_XrTGw_23_3">36,022,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_kTREx4nwakWT0uiB73dVCw_23_6">46,001,478</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9e58b4c0_c028_4d2d_a43a_62d4f81a1de5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="StatementsofOperations_7171"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d4963940_5a91_40ff_8386_48669054e401"></a><a id="Tc_s6VqFhAKNESWCuEzGppk1A_1_3"></a><a id="Tc_MjNdjO_ymk6eYFUQJyZRcA_3_3"></a><a id="Tc_hvZnIBXy4EehKzIOFhIgxg_3_6"></a><a id="Tc_i5pCt9Yxh0mT4wHEH5pK8w_4_0"></a><a id="Tc_kYYHLIJ2kky64Cf1PoNecg_5_0"></a><a id="Tc_vzbfvvFr-0ylvTTmkWq46A_5_3"></a><a id="Tc_FAcs-lM4FU2Pot-7MN0nFw_5_6"></a><a id="Tc_v0RxjXSZmUeALg6D-RqY5g_6_0"></a><a id="Tc_iuvwqkrhZE6WuuA76q-mVg_7_0"></a><a id="Tc_DGLbQLVbGUGBmX8qG_NZSQ_8_0"></a><a id="Tc_VaE1IALmwUWWlgUWjxX2QA_9_0"></a><a id="Tc_xtwLTXtBDkemFY00tb16gQ_10_0"></a><a id="Tc_oC8DRDWDLkOmsRubWdneoA_11_0"></a><a id="Tc_-l-pAQSS9UCIhaugq-xjjw_11_4"></a><a id="Tc_470HYNT9UEe5uvNJPRguPQ_12_0"></a><a id="Tc_v2M8MX60H0ib_wq276AsTA_13_0"></a><a id="Tc_KshQzbkgy0qRviUbC-XrPQ_14_0"></a><a id="Tc_0c0Rj-SZhUikhk_TD2ptJw_15_0"></a><a id="Tc_YAc5swx0PEmeBh2d4Ds5gA_15_3"></a><a id="Tc_EoR6ey9aaU-8EcTmmqNK0A_15_6"></a><a id="Tc_K1zP7rCCgkm01eco0Dvjxg_16_0"></a><a id="Tc_TjRp_HmrcE-TXExDEVNKdg_17_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_XnNoxGMrcUqS5vG-wHmfzA_5_4">16,515,543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_1WbSJwezc02cJvMb-K_p8g_5_7">8,479,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_RaF43VHWFEaVvyUUPPwbNg_6_4">8,995,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_zKBgjxB--U2N1UkqQQNRBQ_6_7">6,058,190</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_B8mYt3BOzU-uBlfBFc2qaA_7_4">25,511,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_D3sWkABtpEGY0hpPmYPMHw_7_7">14,537,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_UxNA8JXLZUeCfKNklmztUg_8_4">25,511,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_A2sOGFe6LE2v_NCsZYVIZg_8_7">14,537,221</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_BLgyX717W0Gh5eVXzjMLVA_10_4">182,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_I5jT2iib8EKoceR2vIHp8g_10_7">13,335</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="anvs:IncomeFromGrants" scale="0" id="Tc_IHy02bUBRkCnvgTpJzLOHw_11_7">36,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_wzALTo9Y2UGL99QVpYsrQg_12_4">182,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_KorbpRA6jkqT70iiGcLenw_12_7">50,089</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_aIv3MOozTEKDY09tbPO9CQ_13_4">25,328,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_sKNFjU-YuE24rTR8IWlx-A_13_7">14,487,132</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_t3JpmuFC0kuECNoYyOooVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__67SmLkLaUCM7ruMNqJSrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_2ex5VNwWHU6kAFx4ClYbSQ_15_4">25,328,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_zfTFTWihCEmRDpU-AyD-bA_15_7">14,487,132</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Ckrb12oy306ddpZ53Niy3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_NoNx4yDJZEe--Y9e-scikA_16_4">3.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Z-k-vGB7x0igdz-3Y49S8A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Mbz9bEGV20KEuN81tFlb1w_16_7">1.90</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_4xFR2QCsIkK7WtpWb1Rn-g_17_4">8,162,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ob_4qLVO_U6MrVsBAm1PDA_17_7">7,626,278</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b3a50197_2d7d_4790_b8af_91d639f57ad8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="StockholdersEquityDeficit_933195"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Changes in Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the Years Ended December 31, 2022 and 2021 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_eed35834_721c_46ca_810a_d8274a4740b2"></a><a id="Tc_6BxqgjnhvE6_6zFTU7zgbw_1_2"></a><a id="Tc_fH2ER7xrBkyu-tTSEbLY9A_2_7"></a><a id="Tc_QrzI4tRiZ0Wm5jWVySJH5w_2_11"></a><a id="Tc_bohfNW7M9E6VD3u4C7j4AA_2_13"></a><a id="Tc_KV-vK-XeWkW5aiPRApB4Rg_3_2"></a><a id="Tc_R91P3R3R_EqnKjIrUU0uqQ_3_7"></a><a id="Tc_F3gLDYaBm0uYCKNWEPFgPw_3_10"></a><a id="Tc_q0CrqEmbfU-ivhNo1hmvyw_3_13"></a><a id="Tc_x9ElFEk2S0KUBVUUx_hUPw_4_2"></a><a id="Tc_ikocwwoF20G6VQPcz2BMIg_4_4"></a><a id="Tc_wllUvLxsuUCbteX23aldUw_4_7"></a><a id="Tc_E0u_38AKUU6SAmWfexREVQ_4_10"></a><a id="Tc_1oYbkR8crUmjOVBDB2gbMQ_4_13"></a><a id="Tc_XVV34fZpQ0Wnti6hIB0amg_5_0"></a><a id="Tc_5lA0lkyYF0eRR0ZKFhngaQ_5_4"></a><a id="Tc_zcPEda7LJ0GXu6gqUPooyg_5_7"></a><a id="Tc_Nf2VueYLvk6Kx0H49ytRWQ_5_10"></a><a id="Tc_FKRpc57HN0-6p3-W4RhQ9Q_5_13"></a><a id="Tc_AJR7j2alsUqEr4TqNzzXqg_6_0"></a><a id="Tc_WCRC0c25s06RudSvSJ0z-w_6_11"></a><a id="Tc_nNCRtc2_9k-5I6uKOweLTA_7_0"></a><a id="Tc_R7RFT3_r5kiQ217I53O0WA_7_11"></a><a id="Tc_URmjZ53VzEy8SOsh_LODbw_8_0"></a><a id="Tc_khcwOxImDkiJr4uH_8oEKg_8_11"></a><a id="Tc_KqCSBm-VzUa8eINjOdqWNg_8_14"></a><a id="Tc_LR1VuN3yGEaW3zrUzvnt6w_9_0"></a><a id="Tc_cUVqW01oaU-HXpctqLDXQg_9_2"></a><a id="Tc_lmC4TH2mwkKRfcaFi7XqAA_9_5"></a><a id="Tc_rO43U_UEjEGP4Gt0kMO7PQ_9_11"></a><a id="Tc_pV2pK8-DoEKKUtQnC3yRmg_10_0"></a><a id="Tc_LTqVf5KvBEeCy5Q1zZgZig_10_2"></a><a id="Tc_WRBSmhuokUSTp851SV6k4Q_10_5"></a><a id="Tc_e1bxVu_YE0ipJV_J2Sh5Bw_10_8"></a><a id="Tc__fNUK6YYuEe50N55EAq2Kg_11_0"></a><a id="Tc_anZ8iU84hEyDgiJjs1qaQw_12_0"></a><a id="Tc_Vo6myb19O0GMVoeoJBRPVA_12_11"></a><a id="Tc_xiQRWBberkOXNUYdksH8iA_13_0"></a><a id="Tc_LNE5A1NujEqTdMXenWGkrw_13_2"></a><a id="Tc_8FeqNETdhEK7gRFunw7xwg_13_5"></a><a id="Tc_9xTBMZhG40qtdiamqbOJrw_13_11"></a><a id="Tc_z9gIkUkGvEqHQr20nijuYg_14_0"></a><a id="Tc_OTEPA2TKQE-cwUA87et7CA_14_2"></a><a id="Tc_1KSVJkweekisMds--JY61A_14_5"></a><a id="Tc_BWiGyh0NrUukHEa3coFQQg_14_8"></a><a id="Tc_oBnP8aU8yUWOKQE1kfE5zg_15_0"></a><a id="Tc_iAijTVCP7EyLcfNvOdbUyA_15_4"></a><a id="Tc_EzNaqxNOVEWG_IUKeBhbLA_15_7"></a><a id="Tc_YC9SsGATXUKuwawa3mYkxg_15_10"></a><a id="Tc_0XZk1LxUzk25hpneuEuQdg_15_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:60.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b> </p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; </b></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaZWK6ekPEC6t6LMwn5FUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_6pJqXEPbw0KgUUar7eeLgQ_5_2">6,891,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaZWK6ekPEC6t6LMwn5FUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_pwK9zpVjtUmQtDQrpJSqhA_5_5">689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qSbmtBj3ukCilwIfxwYMSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_sWktbgxisE6BG4xQE_FxvA_5_8">21,779,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NnkAeElpr0ibdtyQmsK5Lg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_wHZT5SP4LUqF1961aIgjrA_5_11">14,239,075</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Ap1nBkQeWUeLay4RUZSeYw_5_14">7,540,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_cQ_1NF31fEibN8TeLMWIBw_6_2">1,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_f3xb-wovcE6rT3RJjV6ImA_6_5">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_NmreNIgz0Eq18NhSMYnPRw_6_8">46,648,313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_y6p8Zfrwtk6uUoYKYEv4hA_6_14">46,648,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Je2ZPO0ZnkKtHC0VLp_Fzg_7_2">155,038</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_ycQpHKOYu0SBz4DP-Gy1YA_7_5">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_8f5pTr7w_0-ZNlN3dZafqQ_7_8">95,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_Fkco0yq2zkCpMOH3SD-ajA_7_14">95,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cashless exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA" decimals="INF" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_QyQIhUBtbkSz-BUa6DPKPw_8_2">53,924</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_IWl9H_KuX02ZeTPBVLwvqg_8_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ" decimals="0" format="ixt:numdotdecimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" sign="-" scale="0" id="Tc_X1kbYMgPaUO0wZsB4wNKog_8_8">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc__Zq2yrZEw0-D2NOVXsaakw_9_8">4,697,627</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_xJkRNUBLVkOSRcp4pgRgtQ_9_14">4,697,627</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l0Xel958IUW2OO3_3ATtqQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_D7IOjhe5cU-6SgflIegqTw_10_11">14,487,132</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_iY7HKoFCgUici0gkI7FB8Q_10_14">14,487,132</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Balance, December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0e58ugnkhkOqtDHQqnqd4w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_SB0yWJoIfEGxveOI7--iLg_11_2">8,100,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0e58ugnkhkOqtDHQqnqd4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_BjizUWTEeESQOwh3vNevbQ_11_5">810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g1bPv-XlnEmFJB2EbHQo5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ma4s4fFOTUO7nJRLMAktvQ_11_8">73,220,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M7i_UvTYrEaVMR0_3od1qQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_WAEPwl6zmEak93H2eHaa4Q_11_11">28,726,207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_F3XsYM7LDk6aw7BSgH9azA_11_14">44,494,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TM4iBB8MpUGj7gk1hZK8HA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_VVXeNmEyyEWH3xYJamIrEg_12_2">63,353</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TM4iBB8MpUGj7gk1hZK8HA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_5OMERvRYjE-fpbXACY_B8Q_12_5">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_758s6N7iQkGfVS2-JwP_gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_X6kWIZrwc0u6cfwNZ-hM2w_12_8">4,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_FBQnbM48gkqSj1MK-rG6CA_12_14">4,613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_758s6N7iQkGfVS2-JwP_gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_XhY5IX2kSUm03aZFhR6h3w_13_8">9,152,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_gDn8uv8RNkKmsYboq3YHFQ_13_14">9,152,520</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uW5FryWwhEWgQoKhnkkxmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_pxnwsyrOIUej5H8x4GyUeA_14_11">25,328,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_X4pYUGNlfUC8tWStorkXNA_14_14">25,328,567</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUHeKFPJvkygSacsBdj1pQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_30uIWfkPAkmmvwbh8Fjzgw_15_2">8,163,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUHeKFPJvkygSacsBdj1pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_eFvPYcRpBE23oOBBd882Hg_15_5">816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dTPFMCnlUizoPLVgqDo4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_K80B-NPpTk2erT_-ZprjzQ_15_8">82,377,488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HMHHIWqltEadtnNp5K9vRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_YZ5xzxfT9ki3WagwqBU3AA_15_11">54,054,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_fCMJHllwxEqcDnTmOHBl7A_15_14">28,323,530</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aa558d46_4b83_4c8e_998a_3e071ba937ee"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="StatementsofCashFlows_169542"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2988c841_52ab_4bd5_a283_472ccbafd74a"></a><a id="Tc_-nB60NkrXUywbxChXK2xzg_1_2"></a><a id="Tc_PES_8o9vYUSzOEOvdZ_fPg_2_2"></a><a id="Tc_x0N5_RI8nEytUPuR5Rii9w_2_5"></a><a id="Tc_3-0GUftyK0mcyYSKp1cKgQ_3_0"></a><a id="Tc_tK07i6w7x0KmaIWvb_Ry6A_4_0"></a><a id="Tc_DWLE0jQ5D0iVLQ4GSR2b1g_4_2"></a><a id="Tc_FXfZ9OhwpkKLvPoEczagzg_4_5"></a><a id="Tc_sI55NkxKNUqep09UgUB8jg_5_0"></a><a id="Tc_CvUdcnIO5EOtFxMcDaDVTw_6_0"></a><a id="Tc_fIJ7N3DuHEqeGQ-8Y8V2zw_7_0"></a><a id="Tc_zrWgbLeiXEi7k6Gs04crHg_8_0"></a><a id="Tc_94LRS5XGakC2pOqGhW8GNQ_9_0"></a><a id="Tc_eEsknI1ITUOV2jmN-a3C8g_10_0"></a><a id="Tc_bKwln8EO1Eys38kghMjuLw_11_0"></a><a id="Tc_DL8ziC8C3km7E9bmeVgqlg_12_0"></a><a id="Tc_luLgg0-Xd0eWhaNhMf3ldw_13_0"></a><a id="Tc_jONRDC9UxUaR_eClX8_k6w_13_3"></a><a id="Tc_p3wDFYe4A0Or384kc1CT9A_14_0"></a><a id="Tc_rWGAL684i0m7OBVzIemsMQ_15_0"></a><a id="Tc_eCwnMOWRREK2lK73InC3Ng_16_0"></a><a id="Tc_N6Vudp2T8E2DxMNXX4QO_w_17_0"></a><a id="Tc_VyT_ISdIMEqMTxyqO2JSfA_18_0"></a><a id="Tc_MuzEMJ3MSkOV8-L_XA-ghg_18_2"></a><a id="Tc_o_USTwOMekiLh45GcsrgHQ_18_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_yYmpA7aXokKZJedsNJQLOg_4_3">25,328,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_hxtcUPqT6kqnlAGNY4ocpQ_4_6">14,487,132</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_SbE16mYUPU-xh6bouMSIZg_6_3">9,152,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_2JvPyg6Yiku-ILqFe_pFTw_6_6">4,697,627</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_qzGZZWOZ0kSR5lOpHHY3LA_8_3">7,328,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_Cwh9OLUfw0isb-Ugl1B4VQ_8_6">270,788</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_xTBaGSbUi0yxP1l292728w_9_3">3,273,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_7ByMc3keQ0q5ytbT6S2_XA_9_6">346,218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_a6Lv3JInNE21elJExq-waw_10_3">2,918,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_3B-qi6HwIkCb6S1VYFq_Sg_10_6">581,916</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_Ya-u0rH2rEamKsLSvw3iEw_11_3">17,312,934</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_ngMElJQ_eEeeAPf-KrotBQ_11_6">9,132,159</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="Tc_A1qUyWciVEWbHpghxpS8Vg_13_6">46,648,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_JkKqg5-cukiE_tRqUm_xDg_14_3">4,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_H-YaydA5GUK29O8C2ZUuEQ_14_6">95,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_Zvi4lsMV40KpxModkjdp_w_15_3">4,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_rPscFT8yeEeUkON5v9PR8Q_15_6">46,743,515</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_bCHJjucdl024s1Y4zh9n-g_16_3">17,308,321</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_qNQw09B2M0-tOd_C8D3Skw_16_6">37,611,356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_Y0F0wj0FZEy-Z6sN0YShaw_17_3">45,686,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_q-FW_1403UOONCOq0607nw_17_6">8,074,658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_GmED4OfqqEW_-5NbGGxpOg_18_3">28,377,693</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_en-MR1E44EecHogbkLsIAQ_18_6">45,686,014</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_674f57c1_3a6d_40ba_8129_1efdd01183e2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annovis Bio,&#160;Inc.</b></p><a id="NotestoFinancialStatements_177435"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">December&#160;31, 2022 and 2021</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_lwEiwIt8i0KgGtPOX-Fe6w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1)&#160;Nature of Business, Going Concern and Management&#8217;s Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Annovis&#8221;) was incorporated on April&#160;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company&#8217;s lead product candidate, Buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_pMAWKVFHn0WslcrRAGIbJQ">no</ix:nonFraction>t generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#8217;s future operations are dependent on the success of the Company&#8217;s efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#8217;s primary source of capital has been the issuance of equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 26, 2021, the Company closed an underwritten public offering of <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_5aHRq5IyM0K4Mq8xtwIIPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_VGjaksxqHUmn1FtjIyVIdA">1,000,000</ix:nonFraction> shares of its common stock at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_8tsiqJi9lEmJN9HBgLWOwQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_jx64HxjRjEa2xN_FJ38LgA">50.00</ix:nonFraction> per share, for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_5aHRq5IyM0K4Mq8xtwIIPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_c0EISKZ45UO4GjKVMtAB7Q">50.0</ix:nonFraction><span style="white-space:pre-wrap;"> million.  The net proceeds of the offering were approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_5aHRq5IyM0K4Mq8xtwIIPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_Fb7cAj25FUe4P75oZkgZCw">46.6</ix:nonFraction><span style="white-space:pre-wrap;"> million, after deducting underwriting discounts and issuance costs paid by the Company.  The Company&#8217;s common stock trades on the New York Stock Exchange under the ticker symbol &#8220;ANVS&#8221;.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the Company&#39;s inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_g6HpD6zG00O3xn-p9ipb8g">54.1</ix:nonFraction> million. The Company&#39;s net loss was $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_ZLAMm_npEkeiNlnKBx5ciA">25.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_cJ6P0aiJX0GfChpI5AGhUg">14.5</ix:nonFraction> million for the years ended December 31, 2022 and 2021, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires management to assess the Company&#39;s ability to continue as a going concern for one year after the date the financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of December 31, 2022 is sufficient to fund operations through the third quarter of 2023, but not for more than one year after the date of this filing and therefore management has concluded that substantial doubt exists about the Company&#39;s ability to continue as a going concern. Management&#39;s plans to mitigate this risk include raising additional capital through equity. Management&#39;s plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_tN-VkBfhp0KLn3sAmT_T9A" continuedAt="Tb_tN-VkBfhp0KLn3sAmT_T9A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2)&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:BasisOfAccounting" id="Tb_YEzRwFmNmUashG5LiQxYXQ" continuedAt="Tb_YEzRwFmNmUashG5LiQxYXQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_tN-VkBfhp0KLn3sAmT_T9A_cont1" continuedAt="Tb_tN-VkBfhp0KLn3sAmT_T9A_cont2"><ix:continuation id="Tb_YEzRwFmNmUashG5LiQxYXQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:UseOfEstimates" id="Tb_Alu8fOQ6pkGR_HODxixTvA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_fvmw005TvUaLjnMWwIb5oA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Basic and Diluted Net Income per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options  and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_ociDvZRgjUa-6bHUJZLICA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_MUIEZW5uYEq9OcoFJvNwaQ">250,000</ix:nonFraction>. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#8217;s financial condition, results of operations, and cash flows.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="anvs:IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" id="Tb_tXg-z1uKa0SooBRsY3iBEA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company&#8217;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_FTN2nUDwnkaZhuoxnhsiiw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="Tb_5NMSQVouVESavzsNXJQu9g" continuedAt="Tb_5NMSQVouVESavzsNXJQu9g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g)&#160;Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors, and are realized in the ordinary course of business.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_tN-VkBfhp0KLn3sAmT_T9A_cont2"><ix:continuation id="Tb_5NMSQVouVESavzsNXJQu9g_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="anvs:GrantIncomePolicyTextBlock" id="Tb_HAW7kLnuw0KjPqriLgBqFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h)&#160;Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_efXOChXmNESUIxRWNdnLVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i)&#160;Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur. For stock awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met. Stock option modification expense is calculated as the incremental fair value of the modified award over the fair value of the original award measured immediately before the award&#39;s terms were modified. For vested awards, the incremental fair value is recognized immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_Nw87KG8Qv0Ot-CL8EwgcSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j)&#160;Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2022 or 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_BAdRWtRJNE6kBZXCQQA1zg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k)&#160;Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. We adopted this standard prospectively. As such, the adoption did not have an impact on our financial statements.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_LLt4dh2HEU2dCLgsB256Vw" continuedAt="Tb_LLt4dh2HEU2dCLgsB256Vw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3)&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7751c273_da10_4c97_843e_a4dca186eb03"></a><a id="Tc_XX0ij18k70-9GwKLXisG3A_1_5"></a><a id="Tc_x6xIksHPsUqPWFN0g_TTrQ_2_5"></a><a id="Tc_cvdQEYf7cEKE5ml2mDOktQ_3_2"></a><a id="Tc_Xxvsgo8OQUSh8QSyHzlcrg_3_5"></a><a id="Tc_H1ejlUzU0E2g4WFz1An7Ag_3_8"></a><a id="Tc_nCDgLKKAlkSuZgI0vGwB3g_3_11"></a><a id="Tc_ERI-L4l67kqhHQ1rb1gbLw_4_0"></a><a id="Tc_anpSAf70FE6UZBBY4GzjFQ_4_2"></a><a id="Tc_NgU7OK9ow0e1mBvAqZwp-w_4_5"></a><a id="Tc_boL4Qv1h_UmlQRvKh6gjrQ_4_8"></a><a id="Tc_IYn7kLh9JE-Tw2cQOnQqXg_4_9"></a><a id="Tc_Pk-AAQH8WUqludA0OLFLuA_4_11"></a><a id="Tc_7SkWrfZAs0qY8rgL1x6LrA_4_12"></a><a id="_b3030a14_ed0e_4b05_8ce0_2007a6c6ff0a"></a><a id="Tc_J3CLRUVMNUCyZTMiTmErSQ_1_5"></a><a id="Tc_0YNHIzmkxEWL1oXew1Zy0g_2_5"></a><a id="Tc_mhvEJK78mkm80FchDxkRyA_3_2"></a><a id="Tc_9pe6hhhGqE6f5GkNZJH2Dg_3_5"></a><a id="Tc_jMAFQJRnjkm4N-RrHj4Siw_3_8"></a><a id="Tc_Th8ba5DNFEKOIMoTdtFXhg_3_11"></a><a id="Tc_Z58W1NdOk06Yw5yWmABCDQ_4_0"></a><a id="Tc_iBoU_e2a2U6tC6zKR2qupA_4_2"></a><a id="Tc_PmUs-7P6U0K_KQB9ST8fhA_4_5"></a><a id="Tc_XDqHS8S5oEiJkl8fIg8YPg_4_8"></a><a id="Tc_4FGMMevnLUCy9vQqMyNYpQ_4_9"></a><a id="Tc_kkUjfvdIpkOQvYbZ5hHPvA_4_11"></a><a id="Tc_xSTdxw0bS0et_t-zEnAbvg_4_12"></a><ix:continuation id="Tb_LLt4dh2HEU2dCLgsB256Vw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;3&#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2022 and 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_XRka0RneXEmjoQnpk5-zbw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NsdytOcdbEOeqNX5Qs-pDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_TlHiVcd1oUmpUoHKr_xb7A_4_3">26,001,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D51ABbLLJ0ar_OgKMrKt6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_UMJQWGVA_kOryHoF1OENiw_4_6">26,001,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at  </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OuG0ig-8I06-e5XU6-7N0w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_b5zQwaakgkWXDRnegWil1g_4_3">60,031</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2-H7GqSKf02_tqC2kOqgJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_zjp0c3y6-0qd1ZrJ-ODprw_4_6">60,031</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="anvs:OtherNonoperatingIncomeGrantIncomeTextBlock" id="Tb_BEm30JPFnEa2YTfesh7C3Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, as modified in September 2020, the Company received a Notice of Award for a $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_JTrJWz3ebEirZiY64Y8mVw" decimals="-5" format="ixt:numdotdecimal" name="anvs:GrantsReceivableNoticeOfAwardAmount" scale="6" id="Narr_WY7BhcORdU2R5q2X4ODSPw">1.9</ix:nonFraction>&#160;million grant from the National Institute on Aging of the National Institutes of Health&#160;(the &#8220;NIH&#8221;) to cover costs of long-term chronic toxicology studies of Buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November&#160;<span style="white-space:pre-wrap;">2019.   The Company recognized grant income of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_96WRLFOAHkurv9DzLPZC-Q" decimals="0" format="ixt:numdotdecimal" name="anvs:IncomeFromGrants" scale="0" id="Narr_xE_98ID8QkO5ZfM6j4YrEw">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_DAlmQA-0OE6r9GQ5s8nIWA" decimals="0" format="ixt:numdotdecimal" name="anvs:IncomeFromGrants" scale="0" id="Narr_JLVUW4aHEE-ZFI1Tg61Hhw">36,754</ix:nonFraction> for the&#160;years ended December 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_DAlmQA-0OE6r9GQ5s8nIWA" decimals="0" format="ixt:numdotdecimal" name="anvs:ProceedsFromGrants" scale="0" id="Narr_0lrkbvb94EavyA_PyaQZ0A">36,754</ix:nonFraction> during the&#160;year ended December 31, 2021 and recorded a grant receivable of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_j-zkwi6Aj0y2twXZeHsjQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Narr_HoV5TomEIEmrxAWdRWOGng">0</ix:nonFraction> as of December 31, 2021, and had <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_DAlmQA-0OE6r9GQ5s8nIWA" decimals="0" format="ixt-sec:numwordsen" name="anvs:UnreimbursedEligibleCostsIncurredDuringPeriod" scale="0" id="Narr_FANmLHcLzk2QKVM0iQCFNA">no</ix:nonFraction> unreimbursed, eligible costs incurred under the grant. As of December 31, 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_X5uz9eIYMECujKqaMEdMmA" decimals="0" format="ixt-sec:numwordsen" name="anvs:GrantAwardRemainingAmountAvailable" scale="0" id="Narr_h-N4-2rN3EidIdsupYxrJw">no</ix:nonFraction> remaining funds available under the grant.</p></ix:nonNumeric><a id="Tc_DsEWugat1kWl-gECNbBkOQ_1_2"></a><a id="Tc_0ks0Ubh8V0CzkvlSNgGUug_2_2"></a><a id="Tc_jssyy90YxkuFMWDygUXE2w_2_5"></a><a id="Tc_7XaXFnWRwk-JygPR_pjCBw_3_0"></a><a id="Tc_rM0yf65nnkmeqwbRfzLMsw_3_2"></a><a id="Tc_ZBy-UUI7uk-MQvb3N73pEg_3_5"></a><a id="Tc_u3PsRlB0UESaW2Y2QpZcPQ_4_0"></a><a id="Tc_H0N2Q3CVEkW2i8nwSu3wBQ_5_0"></a><a id="Tc_OKhNVmlQvUexeKQF_5Fs6Q_6_0"></a><a id="Tc_5fX-OESJ0keuM7Qfe4lwww_7_2"></a><a id="Tc_8NNJGPJra0uqnBw7IPju8Q_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" id="Tb_QyPPIqcDiUiBbTT7gLOrJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_4PSpDhUuK0KEWP4h_qgnYQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_rs5K79yrskqTWqnD9gQs6A_3_3">67,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_fqMvH-BzTECJbvQWpRn4nA_3_6">43,736</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidResearchAndDevelopmentExpenseCurrent" scale="0" id="Tc_s4-TX09ZfUCzD6defCpxPQ_4_3">7,528,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidResearchAndDevelopmentExpenseCurrent" scale="0" id="Tc_VmOujrgvj0qbTwfD2r5vMg_4_6">232,752</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_Zlse23832EqTeZq2Gxvk6A_5_3">37,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_6ksTRVoTWE29mZRWzYwteg_5_6">29,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_NMtC2MRQbkO_s2qg5jcu6g_6_3">11,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_ylFWSUIVPkye41VOvyEL1g_6_6">9,865</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_E2ony6b4c0qQgRJPKIDprQ_7_3">7,644,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_EORnfzhD-0ydq-JbWyJjHw_7_6">315,464</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_jq6DwuiueEuiw29RS5gRGg_1_2"></a><a id="Tc_utgY1kKCf0qd_K8vJOLJRw_2_2"></a><a id="Tc_3U13-t8vl0yCIPDx8GkrOg_2_5"></a><a id="Tc_6XkT_VSwlkGNa3Zs-_B72g_3_0"></a><a id="Tc_UTzBCPjW0kmrODGqo_b2YQ_3_2"></a><a id="Tc_W6L5V69g1k-HlSEqm0-8EQ_3_5"></a><a id="Tc_0Ro0STWuEUq_ndnyzZoIew_4_0"></a><a id="Tc_93hEAPcvDkWgId73bvyFpw_5_2"></a><a id="Tc_vsP8C9SGRkednUZimZwMqg_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_7XviygOOB0Wtg82g2ZboNQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_yb8_L51LTUe7FC3_3sN_CQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_kR8rpUN4Z0mp82tDpc-9Ag_3_3">556,827</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_kDOIfCOUT0KKyb9l0W4xZw_3_6">712,768</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_a1_WySV2BEqjsBIxch5TcA_4_3">3,180,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_XsK6b1Ezs0-xW3_295vTNA_4_6">105,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_p22xoJYCqUe9rbgatoZ6TQ_5_3">3,737,285</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_ZJIiCfrh5E6fMzAVcHMcng_5_6">818,440</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;">See Note&#160;7 for further detail on the accrued license payments.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_BZRQpHPgIE-l79JwhlrU_w" continuedAt="Tb_BZRQpHPgIE-l79JwhlrU_w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7)&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company has entered contracts with contract research organizations (CROs) and contract manufacturers (CMOs) related the Company&#39;s clinical trials.  The contracts require upfront payments, milestone payments, and pass through cost reimbursement, to be made.  While the contracts are cancellable with (written) notice, the Company is obligated for payments for services rendered through the termination date of the project with the CRO/CMO.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its office facilities under a&#160;month-to-month operating lease. Total rental expense was $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_-i5wvsSW6Ui6i0xjIfJCYw">66,802</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_B3qUJx14bUujs2P_vgMZ-Q">51,760</ix:nonFraction> for the&#160;years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the &#8220;Licensor&#8221;). Under the license agreement, the Company paid a minimum annual fee of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_9kGGHtw_vEKel92_hHoiuw" decimals="0" format="ixt:numdotdecimal" name="anvs:LicenseAgreementMinimumAnnualCommitment" scale="0" id="Narr_GEEdLwmLdUSyY6t1O44hpw">46,000</ix:nonFraction> and was required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Licensor also granted the Company a buy-out option which was exercisable at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company had the right to terminate the agreement at any time by giving <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_9kGGHtw_vEKel92_hHoiuw" format="ixt-sec:durwordsen" name="anvs:LicenseAgreementPeriodOfAdvanceNoticeOfTermination" id="Narr_3bmZSDNTjkOXkA6eS35K7g">90&#160;days</ix:nonNumeric> advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement were recognized in general and administrative expense in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> In July 2021, the Company gave notice to the Licensor of its termination of the license agreement and the license agreement was terminated effective October 14, 2021. The Company has paid to the Licensor the prorated annual fees through the termination date.  </span><ix:nonFraction unitRef="Unit_Standard_Milestone_di9IgBJq0ESfRR3NInDDpg" contextRef="As_Of_10_14_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_6KFn8E6JGkafxkOpuyUeRw" decimals="INF" format="ixt-sec:numwordsen" name="anvs:CumulativeNumberOfMilestonesAchieved" scale="0" id="Narr_6e-iC0dmtUeShg6LMcFEzw">No</ix:nonFraction> milestones had been achieved as of the termination date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreements were approximately&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_-fLIo0BDvUSb0fXlQjkFBw" decimals="0" format="ixt:numdotdecimal" name="anvs:MaximumAggregateSeverancePayments" scale="0" id="Narr_hg9kP97yyEy8jRwe4q6zyw">1,291,900</ix:nonFraction>&#160;at December&#160;31,&#160;2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#8217;s liquidity, financial condition and cash flows. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BZRQpHPgIE-l79JwhlrU_w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_lawsuit_1hwym7Rltkul7iLlrQNJ9Q" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="Narr_utMgC_3zyUSenGimxGe5aQ">two</ix:nonFraction> securities class action complaints were filed against the Company and its executive officers following disclosure of interim results from the AD/PD Trials. Both complaints were voluntarily dismissed without prejudice by the plaintiffs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December&#160;31, 2022, the Company did not have any pending legal actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The extent to which the COVID-19 pandemic could have a material impact on the Company&#8217;s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_239c0343_fdce_4ec9_a4bd_789da5ce4d31"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_u0YRdOGK7kKfRgNtA9WL-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160; Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board of Directors (&#8220;Board&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Voting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_S5Vg8LIuQ0WQwX_rru60RA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt-sec:numwordsen" name="anvs:NumberOfVotesForEachShareOfCommonStock" scale="0" id="Narr_1zYx-q2PJ0u-xgDUeg-CZg">one</ix:nonFraction> vote for each share of common stock held. There is no cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preferred stock may be issued from time to time by the Board in one or more series.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In conjunction with the IPO, the Company granted the underwriters <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_v4RPxY4sD0CTVBymcl0LPw">100,000</ix:nonFraction> warrants to purchase shares of Company common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_BuARBqTqaECYcrVPAU53og">7.50</ix:nonFraction> per share, which is <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg" decimals="2" format="ixt:numdotdecimal" name="anvs:PercentageOfExercisePriceToShareOfferingPrice" scale="-2" id="Narr_mMqEi2uIeUm5VYEmjCn0Lw">125</ix:nonFraction>% of the initial public offering price. The warrants have a <span style="-sec-ix-hidden:Hidden_KVKI4UZ8Bk-1Y1WhTV4ecA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span>-year term and were exercisable as of January&#160;29, 2021. During the year ended December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_0xEMeWQcf0WgCqU3s1_d0A" decimals="INF" format="ixt:numdotdecimal" name="anvs:ConversionOfWarrantsNumberOfWarrantsConverted" scale="0" id="Narr_iPj4-V_-wE-_sXudyqUYjA">97,600</ix:nonFraction><span style="white-space:pre-wrap;"> of the warrants were tendered to the Company by the holders pursuant to cashless exercises.  Warrants outstanding as of December 31, 2022 and 2021, were </span><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_rxJ3y47tSUmoX-kh_xFoXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_m2HX2Ls4TkCJlHd-bPZUIw">2,400</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_RbtDYEkBt0OdMp6ezICorA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_XWCalEQYIUa9kmoSdizCWA">2,400</ix:nonFraction><span style="white-space:pre-wrap;">, respectively.  The Company accounts for the warrants as a component of stockholders&#8217; equity.</span><span style="white-space:pre-wrap;">  </span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_NUw0TNx1y0aMqF4_FpQEwQ" continuedAt="Tb_NUw0TNx1y0aMqF4_FpQEwQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective upon the closing of the Company&#8217;s IPO on January&#160;31, 2020, the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) became effective, succeeding the Company&#8217;s previous equity incentive plan. <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_1_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_qE-sUUUt40qGRKaPxGSmLA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_hZnpdn26r0C3urctVzvF5A">No</ix:nonFraction> new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_5_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_lxMQ0mAjHESuECDwuJ190w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Zfq6OPfHJUm1qrAmWPJXcg">1,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_mSBoJpEAKkmTzpJqFergRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_4WqteoiUxUy3mDFKYUD-eg">2,000,000</ix:nonFraction>. As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_nvrj-dGqOU6aKJERC6DdWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_OuKrF4YuBkGEl5lZhAzbhQ">392,874</ix:nonFraction> shares were available for future grants.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_pB9TiEQW7kaiZTIk9cuynw_1_2"></a><a id="Tc_I0dF1P1kCEWYyIkq8-rp8w_2_2"></a><a id="Tc_lvrxx54hOUyvjYhn90k2MA_3_2"></a><a id="Tc_YAzUQ3BShU-rc6-J0DybiA_3_5"></a><a id="Tc_1En09D9BxE6jIVPHMxbZiw_4_0"></a><a id="Tc_5yZhcvM6J0mg5vY5NumZ8Q_4_2"></a><a id="Tc_Tr4XruEs40eOhOe0yOttaQ_4_5"></a><a id="Tc_HAJqMMn0t0OtNP_ulpZ-fQ_5_0"></a><a id="Tc_AJrjtvgz2Eu-ljeCP-U7cQ_6_2"></a><a id="Tc_A3z2TNg3J0iLc_b2gTj8gQ_6_5"></a><a id="Tc_yo9cwMuQKkWoV-wQOu7xHA_1_7"></a><a id="Tc_YJrzBpStWEibh92u3mtwiA_2_7"></a><a id="Tc_BOYT7WAKk0mbqz_YapS2Ew_3_7"></a><a id="Tc_9SNaFRv0jkGuFMwQb7sudw_4_4"></a><a id="Tc_qrTG48YWeU6CX4wvRzGrWA_4_7"></a><a id="Tc_S7F2ymNyOUSSfvf3fKbyBg_4_9"></a><a id="Tc_Wq0ekvsmyECdZcDPyuXExw_5_2"></a><a id="Tc_EAjRU3t0x0-qgqn-P6CWLA_5_4"></a><a id="Tc_b_npy5AeLECDw5VexQEeNA_5_7"></a><a id="Tc_oV65Ul7LAUileST05LQbbw_5_9"></a><a id="Tc_LEYMh-pGyESfQucGhCWFZA_6_2"></a><a id="Tc_dzK2l3tY6ECqcDjYoVhJBg_6_4"></a><a id="Tc_62SobsxpTUu9aViJHk8q5Q_6_7"></a><a id="Tc_CFChUQNBukOP1ExNjqULGw_6_9"></a><a id="Tc_jstSXkGGHE6VX7gbyfjGLA_7_0"></a><a id="Tc_dmsXSuCBokyIh5jiBSdfvw_8_0"></a><a id="Tc_GqDE1Aye_Eit6eYLD3j6qg_9_0"></a><a id="Tc_pe0hwSRDM06DZf4REZe3Hw_10_0"></a><a id="Tc_VfV7z_Kl0Ue-LMlocuLV1g_10_2"></a><a id="Tc_PVA0OpqBgE-ePQvAVyLKgQ_10_5"></a><a id="Tc_Rs08kbxJyESfxHPYCRatbQ_11_0"></a><a id="Tc_aEK_PhkCeUOQwb21rf9cXw_12_0"></a><a id="Tc_aAISWL0Rf0CCMdrYWaYRrQ_13_0"></a><a id="Tc_Ank_6L1BwEmUyo6tVR6eTg_14_0"></a><a id="Tc_ecx-54Zh80a8p7cwJPoozw_15_0"></a><a id="Tc_OuPQzGirH0ez9mhq_9J6Hg_16_0"></a><ix:continuation id="Tb_NUw0TNx1y0aMqF4_FpQEwQ_cont1" continuedAt="Tb_NUw0TNx1y0aMqF4_FpQEwQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board. Stock options have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_43OsGov8_0CKtp0gYKTwQQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_Y_XgzbnKyEe2swHkf7xfIg">10 years</ix:nonNumeric> after date of grant and are exercisable in cash or as otherwise determined by the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2022 and 2021 was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_yjYjzdUCqUm0gtCla-Ow_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_TPQKDu5CTUOwF4Ecbc0PEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_CPZzaXeq1EOPfQl3DvSXVQ_4_3">5,778,117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_zrhC9mvgWEyE7HMFE93j7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_g-L15D7P_kKI2KdGVGOBnA_4_6">2,680,882</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JqPg780lPE6Z6dP0xYgvjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_J52MLKbm8U6fpDwG1Kp1qw_5_3">3,374,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YB8rDynTHE2DxJUQucQRvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_PJ-ui7fLu0Ok2lcM6ixbug_5_6">2,016,745</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_GioKQK1PD0meIRWw7db45g_6_3">9,152,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_T3EVJESBsEG_8X7RIpGMBA_6_6">4,697,627</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock option activity for the years ended December 31, 2022, and 2021, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_igMs_OI1AE-rquLF9_ENWw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_eHH_OihEfkyS4QcMi0xUEg_7_2">1,111,466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc__P9W2giTUUCH3ksm5TDR7w_7_5">2.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_VOBDI1bSMk6aLjZ8ppv5mQ_8_2">538,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_jjOna_SrE0OJOkG9HoQMOA_8_5">33.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_mldFL0bcVkus6OhsYDTFKA_9_2">159,813</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__m7VIpvGLUGSz4vFAd-4eA_9_5">2.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_AMb6-QxPdESjeVpmw3blHg_11_2">1,489,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_XuPv2B-qsUS2Isfjps9WYA_11_5">13.82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_UmE7EE6lsUKnU9-PtsY2eA_12_2">348,294</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_uK9iiTBzm0KNmOMdVCOP5A_12_5">15.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_ZE9kSK23P0y_T6NfyGO23g_13_2">70,101</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_unUeImpgVESEb6j-6ECihg_13_5">1.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_KXMUU6e-tkKiowLAW5rEwQ_14_2">110,599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_B5_qOjd1h0aks9t09HPw1Q_14_5">25.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_yTeN7UR9xE-Rh-wonBo9pw_15_2">1,657,342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_MO6NbVs_YEqIn2wrjDPSwA_15_5">13.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_JY7Z-r73MECDnN6G3VVrPw_15_7"> 6.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_rNQVCmILjkONcY3bgfaIag_15_9">9,907,660</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_4uSNCNICBU-39I_goobw3A_16_2">1,310,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_hk-Pl0Pb-0ylPecu3OMruw_16_5">11.64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_FcYnCvWCWEW0FM5wK9J9bA_16_7"> 5.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_Ee0qZ_sUX0m4mGObjUqAIA_16_9">9,591,460</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_P1Xv8bnWXkuQL8eG3ziciQ">803,357</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_WzozBTDYIkeCYw-JOVvvGA">11,163,998</ix:nonFraction>, respectively. As of December 31, 2022, there was $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_nQKSpMqio0K03R-68ZI3CQ">4,089,400</ix:nonFraction> unrecognized compensation expense related to unvested options. That cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_myNHGNZsHkK2fS_mnbnTnA">1.39</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the years ended December 31, 2022 and 2021, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_uATh9xu7QkS9Fj1l7pDr-w">348,294</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_1RrkCxeVy0-v5JUwIsje-A">538,095</ix:nonFraction> options, respectively. Under the grant agreements for the 2022 stock option grants, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_02HyU60TGUyED-4dfwaJfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_i3bZtdHsxUaL2L-V13A7zg">10,000</ix:nonFraction> of the options vested immediately, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_R4senxF1EkumiKnOchMvOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_UT11gOEOkkmUb4YmmVgDww">9,947</ix:nonFraction> of the options vested on March 29, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_FZnw0o15xUmaQw2wDnDl_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_sdrUiHsSakW2RLsOPD8mJQ">9,947</ix:nonFraction> of the options vest on March 31, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember_ChYbVG2dh0qNdtn6AHEW_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_XAfgpkf-mEyf869E5pIGZQ">43,333</ix:nonFraction> of the options vest on August 29, 2023, and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_OUuVKvuXtkq-u1fVxFEu_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_fukEOMXNLkCxTo-7ieGIuA">255,067</ix:nonFraction> of the options vest in substantially equal quarterly installments over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_T8bl_sZlz0iFUq0CaXz_5g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Mj15FLR8XUC_1QkkLlJLmQ">two years</ix:nonNumeric><span style="white-space:pre-wrap;"> from the date of grant.  </span><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_PerformanceBasedVestingConditionsMember_I8m5rTHYtEm0RpeBerchIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_5jxSYRjrmESOqLRh_WlxIw">20,000</ix:nonFraction> of the options have performance-based vesting conditions. As of December 31, 2022, it was not considered probable that the performance conditions would be achieved, and <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_MPv8wqMPt0GCQzly0NPo-A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_iScyHlKmU06kPHwD2dZeLg">no</ix:nonFraction> compensation expense was recognized during the period related to these options. Under the grant agreements for the 2021 stock option grants, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_RvTsofmI_0GsR8XGxxfQXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_ASlUn0kDTU-C2TT3YNiZDg">143,391</ix:nonFraction> of the options vested immediately, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_3phu_26-8EC8DSLEqSiFAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_vcJqj7YdEkyYUHvpLH7Eqg">155,253</ix:nonFraction> of the options vested on March 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_VkaIA_opVUSZSU228t78pQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_QP-8-stVOkqpPxLY3XKLOg">155,251</ix:nonFraction> of the options vest on March 31, 2023 and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_1at2mAbtLEy8kiywIeDbHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Narr_BCkAx016sUWr3FZfMGcq5A">84,200</ix:nonFraction> of the options vest in substantially equal quarterly installments over <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_2llG4i7HYUGYKyNFCvAp9A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_GTvRXCJVjk-svI8YxwITkg">two years</ix:nonNumeric><span style="white-space:pre-wrap;"> from the date of grant.  All of the options have a </span><span style="-sec-ix-hidden:Hidden_-usZI0ypmUm4aeI3-2x4jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span><span style="white-space:pre-wrap;">-year term.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average grant date fair value of options issued during the&#160;years ended December 31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_KsG_kYSO3kioyJP4lHfxfA">13.24</ix:nonFraction> per share and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_a3J1-fxLaE6zdmIQmk_NvA">27.13</ix:nonFraction><span style="white-space:pre-wrap;"> per share, respectively.  The fair value was estimated using the Black Sholes option pricing model.  The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment. The risk-free rate was based on the interest rate payable on U.S. Treasury securities at the time of grant for a period that is commensurate with the expected term of the option.  Given the lack of </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_AFdV4GZy4EmmG2PWOesQPA_1_2"></a><a id="Tc_He9jitxKkkKtoGi63v7JXg_1_5"></a><a id="Tc_ea_RGgw1S0GgTxrPA8F-Gg_2_2"></a><a id="Tc_rBLN7vxjR0KTiMQKGdnZRQ_2_5"></a><a id="Tc_5REnNRcLqUewmHFwvv9RVg_3_0"></a><a id="Tc_EX2LcQH4JUSCEEjOPnEtDg_3_3"></a><a id="Tc_E4Y61XRSeEa3hMghU6qsIQ_3_6"></a><a id="Tc_Ft2IBY8RCEGrRVITajUcKQ_4_0"></a><a id="Tc_Z7rr4kXaiUKHJ0uYzZ2C4g_5_0"></a><a id="Tc_gOp6u3qVy0uYGv2bLB6-UQ_5_3"></a><a id="Tc_wKNFh8qI1UShSOcUluFD7Q_5_6"></a><a id="Tc_tBB4GPPCA0abweb2GwPjTA_6_0"></a><ix:continuation id="Tb_NUw0TNx1y0aMqF4_FpQEwQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">a public market for the Company&#8217;s common stock prior to the IPO, the expected stock price volatility was based on a weighted approach that incorporates the historic daily volatility of the Company&#8217;s common stock since the IPO and the historic daily volatility of similar companies that have been publicly traded for a period commensurate with the expected term of the option.  The expected dividend yield is </span><ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_9HNDUZj2TUC2iY2ZjHk8Nw"><ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_TLE3BZAt00qew1H5UTXVhg">0</ix:nonFraction></ix:nonFraction>% because the Company has not historically paid and does not expect for the foreseeable future to pay a dividend on its common stock. The weighted average assumptions used in the valuation of options granted were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_JMxAhKxQlk6SBgHfy0WWiQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_mwOZ5rtJNEOTE_p_c343tw_3_2">2.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_E8TSze9mO02DGTQpp_2pBQ_3_5">1.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_MafLX0QSkEyzKUJ5Bqrhzg_4_2"> 5.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_nIVhpLNQK0mDUUVgRO6a2Q_4_5"> 5.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_NJ5lDUyTjk2pWfJSfqLEkw_5_2">112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_vgSuRCY_FkqfHDo8YhnlYQ_5_5">113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_ODMkR_wTi0CJx46Xry3eyw_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_UTPlf7v5MU-DamQrI72uLg_6_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, previously issued stock options were modified for an employee who is no longer employed with the Company. As a result of this modification, $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="0" id="Narr_jpHcfoz7S0ClDFWkTcrScQ">1,219,572</ix:nonFraction> was recognized as stock option modification expense and included in general and administrative expenses on the accompanying statement of operations.</p></ix:continuation><a id="Tc_JWJYuSzEAUy3JHMvuTRBCw_1_2"></a><a id="Tc_v6rDRf4ZuEycoceaHu0Pew_2_2"></a><a id="Tc_qCa_Y_TNLEmjj6lSIx0c-Q_3_2"></a><a id="Tc__TsqPvdcqEeOPiJD8HjuvQ_3_5"></a><a id="Tc_N2oV9TcAVky-ljxmoVEfmA_4_0"></a><a id="Tc_RtayJh4deEun3TasDtCOIw_5_0"></a><a id="Tc_jaIutu7RHk2i8DciaVmD4w_5_2"></a><a id="Tc_Q0yLyecqFEudIBJNO91k6g_5_5"></a><a id="Tc_73d1W1VmJE-RogcvsAcnwg_6_0"></a><a id="Tc_YSQ8dzkvykC1THCz8UzfGg_7_0"></a><a id="Tc_zDKzPgsgwUOTuRbxgvuwRg_8_0"></a><a id="Tc_VjHNr2n0vU23gD2u1EBGUw_1_2"></a><a id="Tc_zer1fhXBpkCw1KunkYUFUg_2_2"></a><a id="Tc_-lw6OzLmxkalvB4Qop6sFQ_2_4"></a><a id="Tc_Z_EtK6ZxCUSYC7YtBVspZw_3_0"></a><a id="Tc_q2QbR-XJ0ES9PWvb4G9D2g_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:EarningsPerShareTextBlock" id="Tb_pCCq_Ds4uk-xrrwO6l1B_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10) Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reported a net loss for the&#160;years ended December 31, 2022 and 2021, and the basic and diluted net loss per share attributable to common stockholders are the same for both&#160;years because all warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per share:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb__BcQgJJijUOiprh-7-3wZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ym1bLTjPm0uvRxgYWEqBQQ_5_3">25,328,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_CISIZv0npUud81xfgyj4sQ_5_6">14,487,132</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_L1vTe5La_U-XgqzpJRWaew_7_3">8,162,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_bJE23B6_b0yBzHQjTCPcAA_7_6">7,626,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Nrt4V6gKP0yrinHj-NMeNg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_kOaLchG5HEC-y7o5nvJ06Q_8_3">3.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_cE1AXSw2LUaR4c9ANXGfMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_SZN2WXtmHE-FfD0D26sN8g_8_6">1.90</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Potential common shares that are excluded from the computation of diluted weighted-average shares outstanding are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb__Yp-dRXMcEWRydVFbitcFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RelzNNUAf0uWCtCDxtOuNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Efo6wKDrnkO-7_OXVX4OgQ_3_2">1,657,342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_fqcjJ89wu0-oiY1nhms5jg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ABqMfrH5806eR7r0nQOePA_3_4">1,489,748</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_6jD9f0YxekO4JmQcbKrXIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_tMIEnSOIbkiCOzg_LJNQUw_4_2">2,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nspaGMfz_EWneA97LJAfPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_KFwrEIdFKEeSQ91-1NBxkw_4_4">2,400</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dc22ecab_c6bc_46a5_9a4d_1b51576b8d6d"></a><a id="_dc22ecab_c6bc_46a5_9a4d_1b51576b8d6d_2"></a><a id="_dc22ecab_c6bc_46a5_9a4d_1b51576b8d6d_3"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_27fcWaHFQUebh74UpUBD5Q" continuedAt="Tb_27fcWaHFQUebh74UpUBD5Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(11) Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal and state provision (benefit) for income taxes was&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="Narr_h_811DTrKE-80Al_FVl_Yw"><ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="Narr_F-JjEJ3P5kyatXudElbK8w">0</ix:nonFraction></ix:nonFraction>&#160;for the&#160;years ended December 31, 2022 and 2021.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_vlWD3_ClAkyZnv8K8weAIQ_1_2"></a><a id="Tc_0xg3Io5tpU-EEX5_kKZu-w_2_2"></a><a id="Tc_ZvR3UYX500CJwfTl2kv_xQ_3_2"></a><a id="Tc_zXawSowEf0SS1c97p6g5ew_3_4"></a><a id="Tc_7UOaPq3KNU2U4shpaTvCcA_4_0"></a><a id="Tc_4be6s8DeX0-WdbtvkO1gHQ_4_3"></a><a id="Tc_2_9rqWB82ECV-W7zTJcVLA_4_5"></a><a id="Tc_4J2cED_pDUmLIDckaOf2Vg_5_0"></a><a id="Tc_aZGad1ViDUOATigfQcUcbg_5_3"></a><a id="Tc_evuafSfPV0GNjZpwbNU8dg_5_5"></a><a id="Tc_Y0RNDW32S0ykYC-DwuWvWg_6_0"></a><a id="Tc_6vQb-_7lV0qWEySgvLPrWg_6_3"></a><a id="Tc_F0Iof_f_L0ynqCgTBjmfQw_6_5"></a><a id="Tc_ue1JBJGQF0WYTtZTPri-aA_7_0"></a><a id="Tc_gVmyLCDH4US6aQJk0cntkw_7_3"></a><a id="Tc_khgoXhcoKUGzcDJvyR_wDA_7_5"></a><a id="Tc_KsS5GXsL3Uq4v3QbP0cmCA_8_0"></a><a id="Tc_dbktYAyKck6Zg5Ruj4jhkA_8_3"></a><a id="Tc_I7UiKSLsi029t1rEhg4fgA_8_5"></a><a id="Tc_N05KKI-ylE-VMxO9jAw0hA_9_0"></a><a id="Tc_ClnwtG6sOU23f7JyKD04ag_9_3"></a><a id="Tc_SZvKtQWVqE2VlSXMMSRYdg_9_5"></a><a id="Tc__7I3c5_L00OGuhrY8sJ6NA_10_0"></a><a id="Tc_WdHVJ8bBikauuul5fu2cHA_10_3"></a><a id="Tc_ElJMA15TZEqp7g2FqxZe3w_10_5"></a><a id="Tc_dVjcifAk4ECK2xm1bZnyog_1_2"></a><a id="Tc_wgOzKXXvu028-1enjRdh-w_2_2"></a><a id="Tc_Up_gObVF6Eqjqjz3GtIDDg_2_5"></a><a id="Tc_ZCgMtVQwUku25jAH4sk5kQ_3_0"></a><a id="Tc_KFh7LNVfKEmoFNMGDZUcDQ_3_2"></a><a id="Tc_KildGmoxF0CSN6ThPakcZQ_3_5"></a><a id="Tc_NRlcWn-iQE-dV8lmQhr5kg_4_0"></a><a id="Tc_Aaic6LKt70SgIn3fi-NyzQ_5_0"></a><a id="Tc_BLjBMkV-zEKT9efxKeQz2A_6_0"></a><a id="Tc_6VL1vHuyYkuGtPsAqn0nvQ_7_0"></a><a id="Tc_GT6rb1Zb4UWavcr2DRXmYg_8_0"></a><a id="Tc_nrwsT99ovkGirNsZktyNIA_9_0"></a><a id="Tc_u2mUF_hNaUaacglsQXixng_10_0"></a><a id="Tc_mS0mbQ5l2UWQOIwIa3Q40w_10_2"></a><a id="Tc_wgAm41413E-9CBz3fhU0vQ_10_5"></a><ix:continuation id="Tb_27fcWaHFQUebh74UpUBD5Q_cont1" continuedAt="Tb_27fcWaHFQUebh74UpUBD5Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2022 and 2021 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_I2_9YPm-sUulcf_i7ZCTyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_g_2m8o6o6k6PEpi8xL9geg_4_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_ZrIUAMgHxUCVUU3nIIW7iw_4_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_ryNdSOGmUUCIk2TRtDdDzQ_5_2">5.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_tRGk1KNz4EyQG6MYOLtfAA_5_4">13.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_S7iU6IgExkOUVvSfI3lLjg_6_2">1.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="Tc_NDlfdFEzZkKa499xOQU_AQ_6_4">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_JtwcaH5NBkyTLVM8NQKmhA_7_2">3.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_dvBSNFnKak6KlEDPqzgDHg_7_4">2.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_-fR3FEb7oU2kSvOkyY5y_A_8_2">0.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_YV4vQzs00Umqw9Po0ydrsw_8_4">15.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_xoTu4WtkqU2X32ew2aD8Rw_9_2">29.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_ZU8FbIIDukOuU22RHNHYcQ_9_4">52.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_bMCbSZ-4iUup2voE4MZENQ_10_2">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_Xhj4JeqTDk6kP8O7j0jqjw_10_4">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets are comprised of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_eqKAcmtylkWBQZggDMsPkA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_AxfpDq6r_Ei3MaDYP8fLJg_3_3">7,919,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_RmPn1-Mup0m3aeD9rSJ9Eg_3_6">6,512,249</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_rxbZWRQUREaVqMwvR6nnGg_4_3">3,767,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_6nbSMJoe70KcX47y11Y8mQ_4_6">1,759,129</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" scale="0" id="Tc_iGCkslC98kKu-P24wzN6-g_5_3">1,725,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" scale="0" id="Tc_ZeYsYyddsk63xe6egVhU6w_5_6">2,002,431</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="anvs:DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" scale="0" id="Tc_EzIDo_EhBkiuQCGPl2dvwQ_6_3">3,445,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_aS4j6nJ-O0qtCl18HQT2RA_7_3">1,618,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_s-bksqraYUeBdPyfqGtwMQ_7_6">648,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_rPW8xEzOKUWbyJqGKUL2TQ_8_3">18,476,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_4KkuvO8XpEywIPcE9ApZxw_8_6">10,921,886</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_Fniel6PNQ0265WGw5wU3Qw_9_3">18,476,267</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_JCJ6LiFIX0mEcqC1gFz9xA_9_6">10,921,886</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_5Ynoq_ziQEm3sD4IoeX7uQ_10_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_Gu3HHaUhykmD8X4v9WWCrQ_10_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Vi7H0gbpBkCBZr8biy-aFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_0Th3As4rDEyg4zIX--QtbA">27,536,031</ix:nonFraction> which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_fb4PhuZvEUyAYxprN1iN7Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_akLmlD8umkW22zGg049Qjw">2,764,240</ix:nonFraction> will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2022, the Company also had U.S. state NOL carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ra5Wzdd2lUi3_iM1PWytxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_lR96rOIGHUua3U4FwauDhQ">30,082,914</ix:nonFraction> which may be available to offset future income tax liabilities and will expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2022 and 2021 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company experienced a net change in valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_Q7y7QOPTL06Qmz-r61Rynw">7,554,381</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_XmQ-XjXpv0iaN9raLN1XZg">7,672,071</ix:nonFraction> in the&#160;years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_PvoPPon-90icfGwFkudlGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="Narr_pKGHOUHwhUKxrW9CvUcemw">1,618,294</ix:nonFraction> available to reduce future tax liabilities which expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#8217;s tax&#160;years from </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_27fcWaHFQUebh74UpUBD5Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2019 to the present remain open for review. All open&#160;years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="0" id="Narr_lEvDb1NQvku2xY_mBV6HJA">no</ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" id="Narr_aOZdcvKejkGfvytE2OhgrQ">no</ix:nonFraction> amounts have been recognized in the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="Tb_qKJqleUqRkGjODxKE5RuIw" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(12) Restatement of Previously Issued Unaudited Condensed Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During its preparation of its 2022 audited combined financial statements and notes thereto, the Company concluded that there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed financial statements as of and for each of the quarterly and year to date periods ended March 31, 2022, June 30, 2022 and September 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company noted the following items were improperly expensed during the three months ended March 31, 2022:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments, in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_w1NQBqyLWUGiwqQ90rxdHg" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidResearchAndDevelopmentCurrent" sign="-" scale="0" id="Narr_ftAm0Q2JK0W-a9DCdSVfWA">800,840</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, were improperly recorded in research and development expenses during the three months ended March 31, 2022. These amounts should have been recorded as prepaid expenses and other current assets as of March 31, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Research and development expense amounts totaling </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_zpReF9mePUKpfeIdK6dAxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_XFVwFmtSD0-gjNkRIFNjjA">140,690</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> were not recorded during the three months ended March 31, 2022. This amount should have been recorded in accrued expenses and other current liabilities as of March 31, 2022.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">These errors in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_w1NQBqyLWUGiwqQ90rxdHg" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Narr_aOdp0PDZkkStVOsEcYossA">800,840</ix:nonFraction></span><span style="font-weight:normal;">, accrued expenses and other current liabilities of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_w1NQBqyLWUGiwqQ90rxdHg" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" sign="-" scale="0" id="Narr_DhPx7rxtWUG0S0Nv-DrZtg">140,690</ix:nonFraction></span><span style="font-weight:normal;"> and an overstatement of </span><span style="-sec-ix-hidden:Hidden_Fw2LNw0ysUal1BJuAIrjEg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating expenses</span></span><span style="font-weight:normal;"> and net loss of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_zpReF9mePUKpfeIdK6dAxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Narr_1bGE7np1YEivhFuZRFsfEg">660,150</ix:nonFraction></span><span style="font-weight:normal;"> as of and for the three months ended March 31, 2022. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company noted the following items were improperly expensed during the three and six months ended June 30, 2022:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments, in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_LXOH7EPaEECDbJNsMwmZFA" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidResearchAndDevelopmentCurrent" scale="0" id="Narr_xcP-hz_9A0a4iXj57jX-2A">2,883,977</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> were improperly recorded in research and development expenses during the three months ended June 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of June 30, 2022. Additionally, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_ZSIgU1AfXUyGc1qV1Zr89Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_g5lxvamPik-wOXnY88AgTQ">102,232</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> was expensed during the three months ended June 30, 2022 related to the prior quarter restatements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">These errors, including the errors from the three months ended March 31, 2022, in the accounting for research and development expenses resulted in a cumulative understatement of prepaid assets and other current assets of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_3z17PfnHWEakqKGVOPTu-g" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Narr_97sIu_fXHkGUyaAgrVO9wg">3,441,895</ix:nonFraction></span><span style="font-weight:normal;">, as of June 30, 2022, and an overstatement operating expenses and net loss of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_AWaPPOKacE-NwSyODgUlNA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Narr_8Nn2N9vSU02nPqRYwR4OFw">2,781,745</ix:nonFraction></span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_f6rfiOKViEG45RyBdeRPZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Narr_8WBY_viyh0Ch-UzCmeCJaA">3,441,895</ix:nonFraction></span><span style="font-weight:normal;"> for the three and six months ended June 30, 2022, respectively.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont1" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company noted the following items were improperly expensed during the three and nine months ended September 30, 2022:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments, in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_26-oGseMPEeNfRhaZLLSPQ" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidResearchAndDevelopmentCurrent" scale="0" id="Narr_V2WGUdPBlESTv8rW_dhxHg">1,320,321</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, were improperly recorded in research and development expenses during the three months ended September 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of September 30, 2022. Additionally, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_vPBTijcqYUq2cqEFk9j3ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_2-mxADRjY0a2dkTLLVv76Q">130,826</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> was expensed during the three months ended September 30, 2022 related to the prior quarter restatements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">These errors, including the errors from the six months ended June 30, 2022, in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_j4BX7lHcikG53t8xkKi-0w" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Narr_U4RA-ruN_kWOKXytEGRoMg">4,631,390</ix:nonFraction></span><span style="font-weight:normal;"> as of September 30, 2022, and an overstatement of operating expenses and net loss of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_Yo6y8AqHFEmOOGOfLBgYxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Narr_jaeQlC-OOUmnf5YOiLpcxw">1,189,495</ix:nonFraction></span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_WXJELeDryUOIsQTMpZhzWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Narr_hMrX0ZYpVEqPQ-YowSuI7w">4,631,390</ix:nonFraction></span><span style="font-weight:normal;"> for the three and nine months ended September 30, 2022, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of such errors, the Company concluded that the previously issued 2022 unaudited condensed financial statements were materially misstated and has restated herein our previously issued unaudited condensed financial statements for each interim period within the fiscal year ended December 31, 2022. The restatement corrections impact certain components within operating cash flows of the unaudited condensed statements of cash flows. Total operating cash flows, investing activities, financing activities, and cash and cash equivalents are unchanged as a result of the restatements and as a result are not restated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The following tables present the amounts previously reported, the restatement impact and the amount as restated. The 2022 quarterly restatements will be effective with the filing of our future 2023 unaudited interim condensed financial statement filings in Quarterly Reports on Form 10-Q.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The values as previously reported for the fiscal quarters ended September 30, 2022, June 30, 2022, and March 31, 2022 were derived from our Quarterly Reports on Form 10-Q filed on November 8, 2022, August 8, 2022 and May 4, 2022, respectively. </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_52b5cf05_af1d_48fe_a497_d73f5c8d5ceb"></a><a id="Tc_a7_B5iLr8kmdr8KABr9Y0g_1_2"></a><a id="Tc_ak7xVxjJfEap9Nfh9ZrEQg_2_2"></a><a id="Tc_09LB0Pr59UeiJhlLQS1PWg_3_2"></a><a id="Tc_1CeX3ePryUmtO3YRmwu1EQ_3_5"></a><a id="Tc_O-5DlgJReEaHJRJo0BZnIw_3_8"></a><a id="Tc_wPNCmaGtkEiMxGC9VhYhNA_4_2"></a><a id="Tc_3R7vW5kyXkOFPTyGo63GEg_4_5"></a><a id="Tc_qv3q7zmrCUmQ2YIjebOhUw_4_8"></a><a id="Tc_5td9ODi22EaZjPdOlET9Cw_5_0"></a><a id="Tc_lipgtZ0nJkiaX3gi-XA6dQ_6_0"></a><a id="Tc_V_Gxb2X560KV5u41ibkM4A_7_0"></a><a id="Tc_FENA6fMnN0q8Y9lMlKdUBQ_7_2"></a><a id="Tc_aHJ6BXWgFUmir3ecXl7K_g_7_5"></a><a id="Tc_YhtAmIo47EOgmzJLFCmSDA_7_6"></a><a id="Tc_ixhs8k1YckOVUn17IfuQ7g_7_8"></a><a id="Tc_4PP1SYkn5EKIDo4Cbk_j0g_8_0"></a><a id="Tc_bAH2_SEcUUmhqXPj4v7imA_9_0"></a><a id="Tc_AkUjxqGReUOfElCX5210KA_9_3"></a><a id="Tc_PCoMpQFmk0qL1349tKgzew_9_6"></a><a id="Tc_0G4FMn6aX0S7IskbERaqQw_9_9"></a><a id="Tc_KYMROckaAE6P7wkFXeLjkw_10_0"></a><a id="Tc_8ct5fXyN4E-Dj4ITZVkjow_11_0"></a><a id="Tc_DssU5zttGEqParG4kV_QTg_11_2"></a><a id="Tc_CJ_8GlWKT0WNCCQnQ6T7PQ_11_5"></a><a id="Tc__lvO0NjAXEOsoEnfl8uoRA_11_8"></a><a id="Tc_0yKUxJILZU-K_-HLjn_d2w_12_0"></a><a id="Tc_8h5XDhCdjEWv6YPteZ_35A_13_0"></a><a id="Tc_IxDeBIX4JUW7uddMds_fvA_14_0"></a><a id="Tc_xQld8o_E8EmCEp4Ebx12ZQ_14_2"></a><a id="Tc_3ht0fhoePUSysiIbuLTDHg_14_5"></a><a id="Tc_UdLk9ZriNki3rclXSmTzhw_14_6"></a><a id="Tc_oMSmblBaPEGDcyu_b4hesg_14_8"></a><a id="Tc_lgZAs2fNykCvz8G-odLjEQ_15_0"></a><a id="Tc_HrrWLh2Vp0auJ2C-UyPEHg_16_0"></a><a id="Tc_1J2DQIvNy0Kp9HbhbaIsXw_17_0"></a><a id="Tc_NKT04WMaC0WuyL6EZJpTsQ_17_2"></a><a id="Tc_T67xKGUBpkWPv7Glt4mjFQ_17_5"></a><a id="Tc_fNRT7s1MO0m45VRPLeTOIg_17_8"></a><a id="Tc_Xhl9DK1xUU6RMQfkSyngrQ_18_0"></a><a id="Tc_m2cOixvJmUadBNTXP9Jpeg_19_0"></a><a id="Tc_G1S3hyFJvUivcJOEuKZIwQ_20_0"></a><a id="_66b1bd82_a960_48c6_9cec_5104d181d0bf"></a><a id="_66b1bd82_a960_48c6_9cec_5104d181d0bf_2"></a><a id="_66b1bd82_a960_48c6_9cec_5104d181d0bf_3"></a><a id="Tc_4sNB5i7GdE6kZPLqLZW1aA_20_3"></a><a id="Tc_g0dtJHL1sUW-f1-fZGlu0A_20_6"></a><a id="Tc_XAg_kAjBgE6rqlohqVhh4A_20_9"></a><a id="Tc_CmXRHbqlqUiPF2pCkkybVA_21_0"></a><a id="Tc_ADNUSJXepkqsn78KnM1H_w_21_6"></a><a id="Tc_A_GImuStYkGLIzjneNYFvw_22_0"></a><a id="Tc_g6DQnInhxU-EP3lKOydFeA_22_6"></a><a id="Tc_7wCb4UhXNEGxYltIFRYpdg_23_0"></a><a id="Tc_63tycjNMJUOJZ33m_eWJGw_24_0"></a><a id="Tc_N6vM7qP8Zk6mF_ubZVWOBA_25_0"></a><a id="Tc_jHOG9k4gr0aVqc571wrq-A_25_2"></a><a id="Tc_6GF2GQb_y0mQ3cWtac6fTQ_25_5"></a><a id="Tc_dOhnapX7j0SRihqhAubCng_25_8"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont2" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont3"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="Tb_2qLIkySzv0StxjVBrGRekw" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Annovis Bio, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Balance Sheets</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;March&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_wixdQIKbZka2p4guTMXwHg_7_3">42,668,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_Niwz1b7HK0aWQISTGcvaZg_7_9">42,668,838</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_Jwhz9qeFBkKAufnE7W94fA_8_3">627,902</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_NpWU6braFUS7lBIWTi1Snw_8_6">800,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_lvXM0k8OVU2DKWxJKjV_hA_8_9">1,428,742</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred clinical materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_AQhjnDrBRUeYTJWFq8j7og_10_3">43,296,740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_GtOkbpwBOEajYEaWgHecJg_10_6">800,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_4Z0bG-VNt0e-uRj6q1x9CQ_10_9">44,097,580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_pHK9_fSE3UiC929dGw-5qQ_11_3">43,296,740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_SZDcsuT7xUeFRydAMnpuAQ_11_6">800,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_DdQH2hjTH0297VeNTyYa0g_11_9">44,097,580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_O2s_9dnfI0aAx08GIfzprQ_14_3">928,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_Zx3efvuktEm6hRoeRpFufQ_14_9">928,997</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_2Qub7qZ6cEGCmsiKWUVnVg_15_3">327,435</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_oDsitqs87EadiQLDiTrvdQ_15_6">140,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_DHESKU93CUKF9hu-GAxlyA_15_9">468,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_wuNW_80iX0GZ682UkMa6Ww_16_3">1,256,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_zAqim6vWtkqpOyNs0g6hjg_16_6">140,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_E6ZuJ2rQMke6sWoMlPPGwQ_16_9">1,397,122</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc__YBCzy-mAUexNaFYuh9zmA_17_3">1,256,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_alFRJyvw3EeP8H63NtyMmA_17_6">140,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_1e6fXRCE70iZpR1YErlwpQ_17_9">1,397,122</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_I5tGCvO66UmWrLOaAluzvw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Ry2ZHHGzLUy_aSDssmVOng">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_SGx8wr9nrkiRFeBwViY7zw"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_m6UYssGd-kKXcuHJc_41uw">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_mPBnIAgf_EevaeFtZfaBMw"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ryXRZHegDUaceoDct1gibQ">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_EdrO6uNXE0SQxFpchdA0BA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_bZEXKiaaWk6eW1b8LdVZRg">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_0RL3F7BOq0eXlIJX-tsq1A"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_QsXUrHmmzUWi7iGh-3b29g">35,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_k6VCP_Dkh0SZRyDqVO6-mg">8,163,923</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_L03kiGPbsUmWoa9nI9ioiw">8,100,570</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_9SEDlZkijEKqtC-ySnJpRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_tZ3jki-L5k2vnk0YROVQzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at March 31, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_VvCaFqDFaUeqGVXzPAjHuw_21_3">816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_wXEO1ZpbDUW4Od4wiOhZQA_21_9">816</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_3MwrrKVaS020VurZMd9xuQ_22_3">76,659,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_39PMv2nqFkGc70g9uWDQJw_22_9">76,659,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_7TPoUQmS5Eu8kbwNQVhxzg_23_3">34,620,420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="Tc_EoCQnqkvSkOPnlHvwdQnhA_23_6">660,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_VzGG6tSx302ajH_iYaKwqQ_23_9">33,960,270</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_-1x8_hIHNEGNNlAfZ8dLLA_24_3">42,040,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_jPPu8ZbcFE-1XcrO1vIqWg_24_6">660,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_y7Ch2EYGBESD8m10npHCeA_24_9">42,700,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_0Bt37UTw4kqqExzXm85Hfw_25_3">43,296,740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_eSv2H4TPoEKnM70wl2muRA_25_6">800,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_74jGUH32xUKi9cHimMe7Iw_25_9">44,097,580</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4c98ea54_3270_4a99_893f_4d7ad8719404"></a><a id="Tc_gEHynbtuhkG0uT95uFHLiw_1_2"></a><a id="Tc_e4MtgBuiK0ucSsA3_NQz5w_2_2"></a><a id="Tc_gekltVYhlEmk7z420RnAfg_2_5"></a><a id="Tc_z_Av7Set8kSuC7SrR-JdSA_2_8"></a><a id="Tc_rod4eECQa0Kc9-TiS7Ud2A_3_2"></a><a id="Tc_iCvWyYJ7ikuz4UbxhRuqzA_3_5"></a><a id="Tc_RA4fljzWbUm-c4KHni3CNg_3_8"></a><a id="Tc_XssOZg5UTUmdrBL7KopXCw_4_0"></a><a id="Tc_qV3ONesdM0G15WuSpeBF2w_5_0"></a><a id="Tc_WYjTfYFcw0-zAQ_efgmeew_5_2"></a><a id="Tc_NlFX01xZnkCpS9Rp-uhenw_5_5"></a><a id="Tc_RDsufVKo40ufMYiycdlglw_5_8"></a><a id="Tc__6YuwU69kEO3RVNvdWmAag_6_0"></a><a id="Tc_-E2OYcaSLUOETTomIB1zZw_6_6"></a><a id="Tc_s88KeDO0gEGlbgovZARvZA_7_0"></a><a id="Tc_g8ILwOp9nEqxIwOIzoGtCQ_9_0"></a><a id="Tc_cHyAQvuZZ0CUErEsInZ1FQ_10_0"></a><a id="Tc_PpQ8ogfiHUyqGwGA5IZZRg_11_0"></a><a id="Tc_wLcYA-dI4kWydalHHAlkcQ_11_6"></a><a id="Tc_DixUk29DMkWaNrKqJBqFhg_12_0"></a><a id="Tc_MXfItqDRJk2YQnFOCTRVsw_12_3"></a><a id="Tc_izhFWnD-Bkapgi4XibO6oQ_12_6"></a><a id="Tc_Mx-TBHnQu0q0tnZPSVR-KQ_12_9"></a><a id="Tc_jAuqlxfW6EuesAtfGinMUw_13_0"></a><a id="Tc_5A2o8aUR7E-PIE3yhZu9jw_13_6"></a><a id="Tc_yV8j_sO6S06Ezr1Zj11xpA_15_0"></a><a id="Tc_eF4VZjZu_EqgLGmaDK5Trg_16_0"></a><a id="Tc_IQjY9SD_FEG8kbJRfgecDg_16_3"></a><a id="Tc_iMLZZjUFXkqjjlOoWaYakQ_16_6"></a><a id="Tc_bvYf03ukt028OsqV61nTrA_16_9"></a><a id="Tc_ZG-BdA6RdUyBjQCMB5BQXw_17_0"></a><a id="Tc_-xvyIEsJ6UmyDmLaV3dotg_17_2"></a><a id="Tc_T1eMEt80zkij-Wh_B7RPOA_17_5"></a><a id="Tc_VlXvkdAKtU6U3mIFDv4TbQ_17_8"></a><a id="Tc_4De9O8-ffUuXf7xs-0SoNQ_18_0"></a><a id="Tc_zxIqVvpdsUOoMAHA-uG0IQ_18_6"></a><a id="Tc_w_ovY-jQ00W1aoNtUFxjSA_19_0"></a><a id="Tc_DyOjs3Uq4UydfWIgzLnvdw_19_6"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont3" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont4"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont1" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_HqW9D565E0mmJmg2hvgXLg_5_3">2,809,791</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="0" id="Tc_vy3tKays80uZpSC4gqPuYA_5_6">660,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_Hs9qOteogUeAn9DdvAAF0A_5_9">2,149,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_-unX50w-5EiYL_RGDmcnlQ_6_3">3,104,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_wZ-VwS2GSEan2B4I_WCIzA_6_9">3,104,071</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_yt3K7Df9OEKfw19Sz35Kgg_7_3">5,913,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" sign="-" scale="0" id="Tc_TfEIuPkG7EGs7FYVdbe4MA_7_6">660,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_YKovfsIFPkyftM9AZawKnw_7_9">5,253,712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_wSIk8t1mMU-u6R--fT9psQ_9_3">5,913,862</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="Tc_VwyBrnY3MUSynjXIFZVfew_9_6">660,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_NREftvFeBkidbTwp6TlzHQ_9_9">5,253,712</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_ccu0clcPMEmPZh3P850T4A_11_3">19,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_X-9sepZcEkyNwDba6HfCrA_11_9">19,649</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_7a5jxtQjmkGq8TU3izXLaA_13_3">19,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_0wYNc8lNFkmTOtH6JqN3fw_13_9">19,649</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_Gujuq_Zx6kG9Ysdj9EkP6g_15_3">5,894,213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="Tc_nEs7veYL0kGO4VRJhmDGeg_15_6">660,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_F-H0ymWCPEOtSMAS0jt5iw_15_9">5,234,063</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_NoVbWWQNnkyLHkYRY_TwQA_17_3">5,894,213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_HZ_JyW4pVUaX5LMICWuDiw_17_6">660,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_hUCkyeoUYUid8hZEjk_13w_17_9">5,234,063</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KBQaGnyoDUm3mQc2xmzb9g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Y3VFxN0ln0qkAGUqLRD8Fg_18_3">0.72</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_AKXvNQ6KhkS17REUIUfQMQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_XMgDHZNvdECOOz3xrHueTQ_18_9">0.64</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_BKlbS2zsk0GJMUFPSlWY7A_19_3">8,157,445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_4dpEzKdZd0KCkQxREXIrkg_19_9">8,157,445</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f52b460f_ae7d_4614_8ec0_1b7e03e964d1"></a><a id="Tc_fMi0xrkQfkS654LTM0uCfA_1_2"></a><a id="Tc_6gEO1dXxCkOVmiLjVkIlTg_2_2"></a><a id="Tc_72bSRsZMWUKMjoZqW8dICQ_2_7"></a><a id="Tc_SAQaQnNzXk2Eob-fy7_2Jw_3_2"></a><a id="Tc_K3ucddpnDEaK70pZaCTr5w_3_5"></a><a id="Tc_6Q0n_umbUkyv-u9_gAO3PA_3_7"></a><a id="Tc_AURybghMKUms3VZ2ASsK1A_4_0"></a><a id="Tc_wzRX94w__kq5S_39yzfRPQ_5_0"></a><a id="Tc_PESSBJXyVEimqq2W-kjfaA_5_2"></a><a id="Tc_GGdQETZwr0eyh0_Ab0peJQ_5_7"></a><a id="Tc_lcfr0lhRD0aNsINnGLxWsQ_6_0"></a><a id="Tc_o0QUYTjoN0ulh9uiH2lwXw_7_0"></a><a id="Tc_aU_A63OSkkO5aXsZUxOBoQ_7_5"></a><a id="Tc_NYBYPVR-L0WuMkXrpM3m5A_8_0"></a><a id="Tc_kVJkAgyRCEyqg7wl2bU1Ug_9_0"></a><a id="Tc_vBY14z_EQkKdVrz9xRGVgQ_10_0"></a><a id="Tc_vBndsR9PdkmCvAYg91UBBg_10_5"></a><a id="Tc_gyHshshpDEeuCDGkemYv2g_11_0"></a><a id="Tc_JPZqOOmokESBpUpVhVFXEA_12_0"></a><a id="Tc_p7avYUV-_0C35YAcTuj8Pg_12_5"></a><a id="Tc_M08tOsodTEyTXVouBkB3Cw_13_0"></a><a id="Tc_QwDsqeF4eECpYWgHqIfNmA_14_0"></a><a id="Tc_HHVgqXETcUSlw_cWMvFezw_14_5"></a><a id="Tc_l91LKRVcOEqD3qPnxZs51A_15_0"></a><a id="Tc_RWI6yUtCZUq36YC5BAhQRA_15_5"></a><a id="Tc_2FKb-2Lc8U6NVDxj35HBSQ_16_0"></a><a id="Tc_qn0cSorkdUilApnPL-JdYQ_16_5"></a><a id="Tc_hTFopZ5lKkyIy7Q6QgDjXw_17_0"></a><a id="Tc_2I9mSJs_OUyrotP63hwcug_17_5"></a><a id="Tc_zj17zXsxp065qdzPQE3cGQ_18_0"></a><a id="Tc_9jto--u_gUGYXEOaE1DJhA_18_2"></a><a id="Tc_dMxMXkIfz0GeKwxCGA_duw_18_5"></a><a id="Tc_OBU2xlPTz0O74BkG98Wn9Q_18_7"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont4" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont5"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont2" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;March&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement&#160;Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_1BxBK8Fbj0yPwRiP-1uSxg_5_3">5,894,213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="Tc_BquCXkGJh0K4tjo6NvySLQ_5_5">660,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_uaMGU2asSUOFHGuefCuXcA_5_8">5,234,063</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_sVqD_wWwaU2hbRJVhv7GiA_7_3">3,434,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_8umeeX29w0e6_XcD-lXWcQ_7_8">3,434,944</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_oPVHrPQjbkenL1dzQWz2gw_9_3">312,438</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_0zwyzFgZDEiR3vz49mMbsw_9_5">800,840</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_tIYxhj8ncUCZSZ3znx6y2A_9_8">1,113,278</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_BUW_BdbOxkSkBPJBTOwQAQ_10_3">240,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_PkvMxr6bIUuTpmpbLyQ2Kg_10_8">240,923</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_eEgYgcClc0GaWzM8PQV81A_11_3">491,005</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_FolrhFAKrE-LhRuL2PCePg_11_5">140,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_fKYlWcciq06EiaLcPGfF1w_11_8">350,315</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_C9kyAo4Es0eHlu-C3i9UPA_12_3">3,021,789</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_KzdGM0aD-EigbBeOQAPFFQ_12_8">3,021,789</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_EBy4dVaSV0mydvKwhCNbLQ_14_3">4,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_VG9N9JclxUWPWxf6uv4Fyw_14_8">4,613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_0c58XmoAs0qxlHdMD7SV-Q_15_3">4,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_xKjRz1e63UyEELZEN5MrTg_15_8">4,613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_7o8gn_8pOEy0XQQz0x4IAQ_16_3">3,017,176</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_uX9ftuwtWk6jYJq0e_3RFw_16_8">3,017,176</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_LvDPCB7paUK0MB8bwYZ-Gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_HKuWf0oxFEmqHfCsLmKCFg_17_3">45,686,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_MXCKPVKLHE6UZDi_jwTgGg_17_8">45,686,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_h8M-SZ64O0qJtNRtP-K5yg_18_3">42,668,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_i2Xg5p92UUeh1CjAfob_2Q_18_8">42,668,838</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c2b572d0_46d2_43ef_8db2_f65ecd2d61dc"></a><a id="Tc_x8C8Yc5W3UGqZdCE9La3Mw_1_2"></a><a id="Tc_iJRwPTKMXEiQLtcXyi06pQ_2_2"></a><a id="Tc_eB2T5N7_4kKKMmADNtQ4cQ_3_2"></a><a id="Tc_2kESIsY8M0m2vhoWKENoCg_3_5"></a><a id="Tc_yhnSoC7OhU-stw46Ag0u1A_3_8"></a><a id="Tc_c2mgM94bJE6lU1XDAdkt3Q_4_2"></a><a id="Tc_5eqCtU4bO0SXPBRqAetbXQ_4_5"></a><a id="Tc_6dlcEJCkbEeuPzfOi8X2pw_4_8"></a><a id="Tc_N1IyMPXKDkGYi6PiAjguGA_5_0"></a><a id="Tc_RW52xW_nsEO3soJnzCI6ow_6_0"></a><a id="Tc_wbOYpFdzmk2RvTtoc5DgRg_7_0"></a><a id="Tc_eHduZo5UokCvkczawLSqJg_7_2"></a><a id="Tc_Zn66JHONPUOEJftb4R3bGg_7_5"></a><a id="Tc_j45PqK_ywE-JkU6xGxRWuw_7_6"></a><a id="Tc_1-3moBJJ2EuZ9J57tpVl1w_7_8"></a><a id="Tc_6Cjpv0sY1ka52udszdGO3w_8_0"></a><a id="Tc_C1mDD1f6EkayE46etTUH6Q_9_0"></a><a id="Tc_pgkm7tk5DkqW-j18DWa3Eg_9_3"></a><a id="Tc_4rNcPKvTMU6mfcchF9ybWw_9_6"></a><a id="Tc_kQloJCjwM0CPc8sQTXXerQ_9_9"></a><a id="Tc_mUWzBfa1P0-wpCOlujZyXw_10_0"></a><a id="Tc_nMmZfXpdzUSZTlhjYXTr7Q_11_0"></a><a id="Tc_P1Z5MX2MOUOp0KrVbUcqoQ_11_2"></a><a id="Tc_cFRyVtjyj0ir7pTcnslHJw_11_5"></a><a id="Tc_1PvcFzJKkEqeNxHdDYi3Dw_11_8"></a><a id="Tc_TAk33ticTEibsEWKlM63vQ_12_0"></a><a id="Tc_mzHUxjbPREGGXht82agLFA_13_0"></a><a id="Tc_WzOn_xlvAkiisl6HKnr_Zw_14_0"></a><a id="Tc_rBG2yQRKB0e6ASg5s_GJYA_14_2"></a><a id="Tc_Tbfk5XZCo0O03Vmzz9MNEQ_14_5"></a><a id="Tc_p03uxfXWMkOIP0R_0sIpfA_14_6"></a><a id="Tc_A7lizk9nfEG-92GqHhfBxg_14_8"></a><a id="Tc_qYFhUxZ-akO--bCfAkfyCQ_15_0"></a><a id="Tc_8mv9Hgx5u0eWZtQcJIETPA_15_6"></a><a id="Tc_s6lLaxYoWkK4K_hAGNmpmA_16_0"></a><a id="Tc_uQa3QNeqw0OoxeELnZfKVA_16_6"></a><a id="Tc_PkVAXWRj00CNaXxZkSQJdg_17_0"></a><a id="Tc_SpZQScupTEm4_y8sRWwQPw_17_2"></a><a id="Tc_PG60sKcjgEGeu1-sabiFjg_17_5"></a><a id="Tc_aoJFDCJufk-hqd2BiQ89DA_17_6"></a><a id="Tc_sUB57MnB4UK0o_D1O3iHPg_17_8"></a><a id="Tc_qn3bJzzFLkuDS_g4IetZMA_18_0"></a><a id="Tc_ND5Di1XE6EOWSpfbj9Tihg_19_0"></a><a id="Tc_GKLXL3W8YkalcnQHP_IlKA_20_0"></a><a id="_b5c57481_98ad_49a2_8a2d_9ba6ffa38faa"></a><a id="_b5c57481_98ad_49a2_8a2d_9ba6ffa38faa_2"></a><a id="_b5c57481_98ad_49a2_8a2d_9ba6ffa38faa_3"></a><a id="Tc_xDb-8u1OCUCX4qnF8jTeig_20_3"></a><a id="Tc_Zs4lMmc1C02hwje4sZhPgg_20_6"></a><a id="Tc_Xgn889XM7UWYS6ZJ3x4KfA_20_9"></a><a id="Tc_oEJVG_jn80qzwqQBCCFx0g_21_0"></a><a id="Tc_yV0sUDKgJEyVd63BmTLiQg_21_6"></a><a id="Tc_v_vzm0J_CkqdFat3ooZTVA_22_0"></a><a id="Tc_ppMFV6KrcEGtTONeyL58JQ_22_6"></a><a id="Tc_OGcror4x6kSiqkVzH_6Chg_23_0"></a><a id="Tc_pynjqZth1E-cMHxNKcRiOg_24_0"></a><a id="Tc_UkAo87lmEUi3WtgrYhg7kQ_25_0"></a><a id="Tc_aOWgc2iu2USSBLrPxKf68Q_25_2"></a><a id="Tc_chDZbX2XJkeTYyqyNYePAA_25_5"></a><a id="Tc_1dYAqNWCFkOdEal7wgEA2w_25_8"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont5" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont6"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont3" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_9G8zaOFadEiH566Nudts-g_7_3">35,974,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_SWKbKlz-i0S-WB8DmgfskQ_7_9">35,974,251</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc__dy3Fs7GckO5qu-XW0xc4g_8_3">551,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_6H0d4FjWUUKvXpeTGxhi4g_8_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_N3zYrBj_f0eBLPksfg7IOw_8_9">3,992,967</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deferred clinical materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_6heW0Fa8gkyIN5iRp0XFeg_10_3">36,525,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_x1Bndns7AkWbVp2wrYdaCA_10_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_lSZbTw41m0GMftrDhwCDEA_10_9">39,967,218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_Brl02dCTfUeNHjRPqkK49g_11_3">36,525,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_S9fhPDj0sUCWukdRmnu9rA_11_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_kVt12jzr8kOuKlbcxZJ_jA_11_9">39,967,218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_9DYautdyx061FS--Bgvc1w_14_3">901,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_3y6kdXDn7kiJXpwqWIvMtQ_14_9">901,841</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_1ZFgyO2q302dfaozfqLiHQ_15_3">397,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_nc2z7vf5VEi054O3Atf6xA_15_9">397,544</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_8vln-8YwUEWZ3SZ7HYR21A_16_3">1,299,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_U9zkh6iTWEy5Xjs44l0J2A_16_9">1,299,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_ahTAbOtiUkKHAHbqtp0TEg_17_3">1,299,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_Dl_vjptKGEW60Etn91VfiQ_17_9">1,299,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Preferred stock &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_k6Npi8Ts-EOzFpW626gTGQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_uEOvHaAIx0GJRfds0rWgSw">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_2h9mLw5zCE2gtAmY-HZBBw"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_SSdMg2hMM0ezta7qoDI-AA">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_IcifYrB16kGmraMptJfH7w"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_2L4mun-LqE2DUxOarPakog">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Common stock &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr__S9uIk8jdkGcfltP3N_68A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ZJhfTMiHkk6uwZO5xKbJkQ">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_YYeZpTRSkEydkhsAQBh_Jw">35,000,000</ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_CEiY9jqmske6r0sz2pO_Qg">8,163,923</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_9X6XMkZM6UW_fQOcYqTASw">8,100,570</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_1KpyqUlIYEikh7iSvFo8QQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_QRqrEN-rqUqjxJGEYuDI_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at June 30, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_J5Quxl_LjkKtGS8swl1llA_21_3">816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_L4E7M4Fe_0C7zXJkM_LWnA_21_9">816</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_2IhcomDOqEeLhNjD2nuDQA_22_3">78,563,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_jjxXiTzWjEGchAE-J1Zu8Q_22_9">78,563,673</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_8wGPbkr9bkWJXbbM1hU5Ng_23_3">43,338,551</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="Tc_aOR1zZZ-rEma5qcYQPlO4A_23_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_l9mq97u5W0OkfcUubgTdlg_23_9">39,896,656</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_tOjIIuSnsEqxNnKbl8pCKQ_24_3">35,225,938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_IDIqUcdoKEmSbaRsuSTsVw_24_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Q6YH68Fgckaw8h0T9L8XNA_24_9">38,667,833</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_myUYiNaKfkqlpIkFIavbWQ_25_3">36,525,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_hHo20TRw1k6eEzm-F-i5vA_25_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_YPRzZ96LNkGNeFMxFkjCIQ_25_9">39,967,218</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bb3f9a0a_5418_4491_ba6e_8063f39514ec"></a><a id="Tc_6fcYpDrOmE2C5HetBIFVHQ_1_2"></a><a id="Tc_1ZiJQolTz0Sq2EwSNaD3gA_2_2"></a><a id="Tc_Pf4ZEPpMdU6ggVDg13dw8A_2_5"></a><a id="Tc_TRqqVPX7MUuHiGRqHojcxQ_2_8"></a><a id="Tc_GVKdOeN7xk-yMcWgbe2EGw_3_2"></a><a id="Tc_d-FA1XL_LE26TpruutCOrw_3_5"></a><a id="Tc_EJu2bSM6a02t3a5EJMlNfA_3_8"></a><a id="Tc_q70lC-R2X0i8jBeOjXHqPw_4_0"></a><a id="Tc_-DhPG43Jlk6UnuhsRkCLCA_5_0"></a><a id="Tc_-vAjJ5Pu1U-JHXa-PONzfw_5_2"></a><a id="Tc_UHoBB-80EUO-xv4quFKhig_5_5"></a><a id="Tc_CO4wmq7kmUWfGztwBomVYQ_5_8"></a><a id="Tc_BZ0k2syhcUGKEyL4PIrIWw_6_0"></a><a id="Tc_TnBHlXMglUi9TK77uBWJbg_6_6"></a><a id="Tc_R4NZW6ODB0qBNxr6MPiHUQ_7_0"></a><a id="Tc_fRMpyLJA8k-FroJQ_TBs_g_9_0"></a><a id="Tc_kZRSxcR5oUmMp5shEcLEOA_10_0"></a><a id="Tc_VVBy0DdBZ02nnnYdNU2cMQ_11_0"></a><a id="Tc_6fl1OvFOWU2EVXHAvvYSnw_11_6"></a><a id="Tc_4Lc0vDHfZ0iiWk2JlYli_w_12_0"></a><a id="Tc_uGyf0u1ae0GUDya6dkLbzA_12_3"></a><a id="Tc_9B02ZN0cAU-bDvWNilWuww_12_6"></a><a id="Tc__yibNgAC7k-oRMFG_AK-2Q_12_9"></a><a id="Tc_vBMUzoi_mkOm9TIvBExCVQ_13_0"></a><a id="Tc_Zca72i3BtUaTJTwa1UIobQ_13_6"></a><a id="Tc_9jQkre2lXUmUOrs6aS6fJA_15_0"></a><a id="Tc_SF0isbBrM0GzoKKr_sXeDQ_16_0"></a><a id="Tc_wFZkykqU3E6GI9Bze4ZfyQ_16_3"></a><a id="Tc_NE5gDEZKYUW3GFEzGidr3g_16_6"></a><a id="Tc_OKlGb-N9O0GfDVi-QDrq5w_16_9"></a><a id="Tc_MlLGSApGV0u0i0aKR3Q9ag_17_0"></a><a id="Tc_Gdc564uXv0iZhc-WLCZV-Q_17_2"></a><a id="Tc_3tvs7Tb1BkOs9Y1TsLE9Jg_17_5"></a><a id="Tc_ShsVQAR6YEak7mxjIJIO0Q_17_8"></a><a id="Tc_SvKzFa_ktEO1ZCH4HuNLSg_18_0"></a><a id="Tc_rciYRA36FE2aA-2WTD5doA_18_6"></a><a id="Tc_cCCsL8jxxkuJ3PCgWaxzYQ_19_0"></a><a id="Tc_yKvaQDJhEE-SQcOoe2am7g_19_6"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont6" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont7"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont4" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_o5mJ3iBToU2wTRazx64xpQ_5_3">6,815,708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="0" id="Tc_7ocb7TZM60iocagMevlmng_5_6">2,781,745</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc__ngrXPv-UEaOr4VDbrOMqA_5_9">4,033,963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_wi2B6tc3YEiO5H7wOhqUQA_6_3">1,938,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8211;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_uJDsGiru7kKYDauhVDruPw_6_9">1,938,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_IyJN1SBH0Em7MXZVMf28NQ_7_3">8,754,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" sign="-" scale="0" id="Tc_1NJhnax4iEe_Ccc32wuU8Q_7_6">2,781,745</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_U1JkjfhEQkinTaB_4Sk6yg_7_9">5,972,410</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_ynDMKdr82UG7v3sqzixQgw_9_3">8,754,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="Tc_sOidMctHyEGjjL8YpbrXMw_9_6">2,781,745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_OzcMZ4wh1UOsIXi7xlbjmg_9_9">5,972,410</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_NN3K6eY8L0Glzd74naHxEg_11_3">36,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_hjW1eXxPLESFtc91Xj8ohw_11_9">36,024</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_y5K9MoPCuk2aQGIsnkBIOA_13_3">36,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_RfocnmTIIku41vJrf8Wkzw_13_9">36,024</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_2TmKkieHrEa8kzEP_N74pA_15_3">8,718,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="Tc_cf4-4ZvnM06RNJRdZzUGdw_15_6">2,781,745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_X-lR0lCLeU-bs6b-ko5hcw_15_9">5,936,386</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Cy-NshiUkUmpRbHdBwQu7A_17_3">8,718,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_rg-FUR1IskqImHNKYDaQIg_17_6">2,781,745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_VbBJRyXC2EqJr_Ud5KcJQA_17_9">5,936,386</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_gNBJeOes40Sa4G7lAiK58Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_quaI-tJmb0WO0x2AQDGgrg_18_3">1.07</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_yz2vRgL14Ee_24qI4nZ8pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_WNof0lP6gkaR1dP_KKZYhw_18_9">0.73</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_wz7SNLH85kiPvHLCmaLgDQ_19_3">8,163,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_OAGrz3-jc0CBihJpHJ3BOQ_19_9">8,163,923</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_71e18291_b973_4269_bce1_9c0e256e476d"></a><a id="Tc_0BuI_wxu50a9HC-LgPDBdA_1_2"></a><a id="Tc_ub0aW_cGGkyewXYiJ6jbOw_2_2"></a><a id="Tc_s2_-LZS69UaWFFaaDd1Orw_2_5"></a><a id="Tc_39pLzH6N8kSZzn6sYMV3Hg_2_8"></a><a id="Tc_3_TNXuLsaU6D64DNo6ceDQ_3_2"></a><a id="Tc_hHDFh1o5XUadYPdevMCkWQ_3_5"></a><a id="Tc_ysowpWxwUEWVJIlV6XMDmQ_3_8"></a><a id="Tc_zFlLF1QT90i_AtYDdQdJfQ_4_0"></a><a id="Tc_XN0wys8W0kyz5flWNtX-gg_5_0"></a><a id="Tc_gUBaT_olCkCulo8WSorydg_5_2"></a><a id="Tc_XRgH7XZe8EKI3INezJF-UQ_5_5"></a><a id="Tc_Q5QyZXZLmU-rn5qq2sFBjw_5_8"></a><a id="Tc_o_goNp5EmEqlN80oZk7zWw_6_0"></a><a id="Tc_pPGm-Hn4gkWk-Q7npVe1XA_6_6"></a><a id="Tc_TttRROLpFkWXanK6QH-66A_7_0"></a><a id="Tc_YpHOZudLDU2WJ2GIBTP8ew_9_0"></a><a id="Tc_I_MY7Gj2JkCHm0a63ch9jQ_10_0"></a><a id="Tc_gKOLcxtb8EyFBafpkmJWXg_11_0"></a><a id="Tc_ZppvuUaTgkWoMh1zmn0OUw_11_6"></a><a id="Tc_OB7C5Qce_U6dtJTxF07STQ_12_0"></a><a id="Tc_tAfOiFaIl060f25SSYJRMg_12_3"></a><a id="Tc_bA7JKoKFME2iepqztlQetg_12_6"></a><a id="Tc_xKHmTNO1Lk-3mvcbWPkZmQ_12_9"></a><a id="Tc_XsCGQzBZXEWel7FwTdpUZg_13_0"></a><a id="Tc_xVkoiyFTRUS_u_X7KpDnnA_13_6"></a><a id="Tc_8LmYqr6PNEy7oh-ybqyhfQ_15_0"></a><a id="Tc_Awg65QMOuE-NkABhZMOMWQ_16_0"></a><a id="Tc__8eSd7WMx0G7ivFTQ2NNsw_16_3"></a><a id="Tc_EwUj4-JDp02V1YSuwQXkfQ_16_6"></a><a id="Tc_cNlORs2e-US754lYzwuoRA_16_9"></a><a id="Tc_-BIYjBC2aU6wegSG-2GZPw_17_0"></a><a id="Tc_690qmqaymESU81TxPGWWIA_17_2"></a><a id="Tc_jVpSiWjg70KFER_wGl-yPg_17_5"></a><a id="Tc_o0-UuzroREq5-GzHxRSGPQ_17_8"></a><a id="Tc_TJszuy2zw0-XzCWOvBgDwA_18_0"></a><a id="Tc_28OuDFcHMkadh2UOlQznjQ_18_6"></a><a id="Tc_hlsMrMuIHEqOvXZxDcHazw_19_0"></a><a id="Tc_4uwTwErQ5kK4vOTiPPKUOw_19_6"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont7" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont8"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont5" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_8An-BmCzK0uJDe-StNScZg_5_3">9,625,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="0" id="Tc_T4d_QMpqnUSEpuhaSwTruA_5_6">3,441,895</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_0quCY_N2vEKh_FjF0E7LMQ_5_9">6,183,604</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_9U_dIXOfdUS0YfSb5dmiQw_6_3">5,042,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_uxPMfCTHkUW-vz-SuZkFiA_6_9">5,042,518</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_zFQfH8AIZkCiKET__meFYQ_7_3">14,668,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" sign="-" scale="0" id="Tc_ndVVcOPCMEu3ic3ZcSuiWA_7_6">3,441,895</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_-cJ6UYoXkkWjpWsmQO-8Cg_7_9">11,226,122</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_eatTnLa_ckahm_ZdXx9N_w_9_3">14,668,017</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="Tc_n5nt_jMIoECuoHRIAM8koA_9_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_PYzRbQZskUm4yznqaEo_uw_9_9">11,226,122</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_iIyfyxJEVUWrYQxP1XbwyA_11_3">55,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_MLi5Ch52lUSAgudHdfeiXQ_11_9">55,673</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_TJEBeszT1UyL5DTUngEREQ_13_3">55,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_VYeRPpi7NUS7-tSkWe_ryA_13_9">55,673</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_wFahqPM6XECcnu0vwfsjtA_15_3">14,612,344</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="Tc_gdgJR1MhAE-fMl7xkSYBWA_15_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_vvDe_Zd7OUuZHRCgbJuCUQ_15_9">11,170,449</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_bLgjFgYgCUay7rfdp9rI9g_17_3">14,612,344</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_xuBx1XYkm0GSSqjKYVXJnQ_17_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_s2zy4OHDxEqu1s2DOHN_fw_17_9">11,170,449</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pn_EzwJF0kmaifLIJ3rdcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_LRc8CrGv5kKm4YJ15jD90Q_18_3">1.79</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_eHH7Nb15lUyp1mobGSzCaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_PPqcimxuAUCKkbh0JB7knA_18_9">1.37</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ETwv68YNoUe_xZgYh0JkJw_19_3">8,160,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_i3zSlr-JE0itqi6e7cvv4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 8,160,702</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_725f1426_a581_4a8d_ad51_00c4f113240b"></a><a id="Tc_FACCbLsIhU-5Bk90y5lClw_1_2"></a><a id="Tc_rfcQqoSAukiOTT3L-sodKA_2_2"></a><a id="Tc_ENqxjD9CmkGr_vC0HYNKXA_2_8"></a><a id="Tc_SA6VkCUgj0SlmRVt5cW4Kg_3_2"></a><a id="Tc_0hzbgEJT80KXTZrM4B5u6Q_3_5"></a><a id="Tc_AdGfS5hU-U6UBwB3XrLZ5g_3_8"></a><a id="Tc_AM7C1-AFNUqJ3jDoYQnA9g_4_0"></a><a id="Tc_24dZqQYrNEeWfPLsqYI_uA_5_0"></a><a id="Tc_9mwgFc-66EeRH9qj-PsIFg_5_2"></a><a id="Tc_e4en3lHU70KRtqFc_dFfgw_5_8"></a><a id="Tc_N2jdjz5BBk2J5bcLh43YXg_6_0"></a><a id="Tc_OjB1cOUr9EGOC_hA4uK1AQ_7_0"></a><a id="Tc_86ol_yJF8EKtY6ayp8DG1Q_7_6"></a><a id="Tc_vJVurDCHSUOv0zOzv077Ug_8_0"></a><a id="Tc_U304yHdpOUCUke1nSxOxpg_9_0"></a><a id="Tc_OuV-CFbpPUOhV5ojrK-cVg_10_0"></a><a id="Tc_Z69wef_UwUO1zMRQm-ydMw_10_5"></a><a id="Tc_MlBta8Z9hEOkiC6FGfcRMQ_11_0"></a><a id="Tc_ML7rPGAcU0SDLKGr1-nZFg_11_5"></a><a id="Tc_EGTizL-qZkiZYCWuwwX1hw_12_0"></a><a id="Tc_jK15dWkxvEO9t2ca2zq0Ww_12_6"></a><a id="Tc_9Sxe7f-d70qkOL8hWLnuWw_13_0"></a><a id="Tc_19iLtdhVQUyPsGLGwp5HYw_14_0"></a><a id="Tc_52sBCDmCOkywZm34ZzJRnQ_14_3"></a><a id="Tc_qMStxtdjz0y5cHTBNloGOg_14_6"></a><a id="Tc_DT-ZbALnUkynqYETra3bsw_14_9"></a><a id="Tc_hhPTBtt0UEK8GRhuIjXDXw_15_0"></a><a id="Tc_44gPFYB7K0O2IQK6LzBimg_15_6"></a><a id="Tc_DTJwLyEjjUmH7I2l6wFRqQ_16_0"></a><a id="Tc_S508zovxjk62r282qKS1Qw_16_6"></a><a id="Tc_pZADzJMxjUCrbU05Kuga2Q_17_0"></a><a id="Tc_gX4lTB2_xEuS5JTeVheXPA_17_6"></a><a id="Tc_o0ERo-9x7ECb9otpuTAKgg_18_0"></a><a id="Tc_eFPRMHBhdU6Ra4wAto1Mvw_18_6"></a><a id="Tc_I-bkgPfat06N0a9d6pyfjw_19_0"></a><a id="Tc_SnXHxInefEmkxMKqQyMuOA_19_2"></a><a id="Tc_W_UyiVeOvkiloPhNR_SWnQ_19_6"></a><a id="Tc_Okk3hU1-WUi61zYgRpFUJw_19_8"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont8" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont9"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont6" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement&#160;Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_pdYrGzQ2k0mkYd4g_1F5Tg_5_3">14,612,344</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="Tc_1z5qBwousUakXrCnI6Jijw_5_6">3,441,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_4LQsozcEEUaOh3ISBzgiyA_5_9">11,170,449</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_ODXB0vTHi02JviLC7jP1oA_7_3">5,338,705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_syhIE0qb7EmFJ7w54G5ZzA_7_9">5,338,705</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_9c6ha9Yme0C0J-J6BtBhYw_9_3">235,608</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_GNDbT1CWhU2ks5TvDMzDAw_9_6">3,441,895</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_67QE-lMRoUaVtv4-XLrTLw_9_9">3,677,503</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_1gfX96iMK06vVkEX9NNb-w_10_3">213,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_54-INwseN0uiKAEfHXq-bA_10_6">213,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_EFfl5sfbsUmF9JBQWN8-xg_11_3">420,896</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_hMm9R8xBk0CgQtPoUgG7gA_11_6">420,896</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_UMWoRzWxmEWfmZnucZMijA_12_3">9,716,376</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_y51qmdwOckGy2lpniC5Zvg_12_9">9,716,376</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_pIEOnAuU7Ey-dNeUilYugA_15_3">4,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_T-DuJ-0x_E2xF3RPSTFYcA_15_9">4,613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_MyJlG7FIy0idi2wbfGz89w_16_3">4,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_7c2B4vLLqEmoNmcAEhrBTg_16_9">4,613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_H1R1wQhOPEOtH3czlcXN0A_17_3">9,711,763</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_dDYFstDysUu-KJgcx75Lgg_17_9">9,711,763</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_LvDPCB7paUK0MB8bwYZ-Gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_KJejLRaMvkyXRD-i7wJXpA_18_3">45,686,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_jJMJh2L7CU62CXV9VskpNg_18_9">45,686,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_w2fRTWsGR0uf1U1ld8fhiA_19_3">35,974,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_Q_DuPNP9UkaUIPYfQINFFw_19_9">35,974,251</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e29fe309_d57d_4582_919a_d3947312c7d5"></a><a id="Tc_uTX_792LG0SlHjb-TueO2Q_1_2"></a><a id="Tc_ARgIALMRUEWfi4WVXN0-mw_2_2"></a><a id="Tc_cvunM-1brEu43OuqA4P_vg_4_2"></a><a id="Tc_7tGrJDQ7XkulI72kz_9TuA_4_5"></a><a id="Tc_Z5eaPxabokKwcojej3mnug_4_8"></a><a id="Tc_rp9MsPwM1E-3DqgS6pWB1g_5_2"></a><a id="Tc_Hd6KjrSdG0y09f7tmIbiZA_5_5"></a><a id="Tc_udmmdkdKM0Gbagn7OxzgpQ_5_8"></a><a id="Tc_VoB8YxzviUmTpx2DE3WBxg_6_0"></a><a id="Tc_ESiSnPrGSUm6OAli4SZCBg_7_0"></a><a id="Tc_YzBiW7HMvkOvr16XQLJ_xA_8_0"></a><a id="Tc_e-kW-f9q7EO6KVL4yNO_Gg_8_2"></a><a id="Tc_Dpgr_HCuDEyHaApae_VDug_8_5"></a><a id="Tc_lAoiKQUA90Kmw2piFyNkXA_8_6"></a><a id="Tc_Sb8j5hBiiEGj-W88Q87Tgg_8_8"></a><a id="Tc_QJZRvs_pKUSGYQcjVZNNXQ_9_0"></a><a id="Tc_T6_XfrjX50S0L-Z7rqUOzw_10_0"></a><a id="Tc_evpcvjI1Jk--mEpxDIcqlQ_11_0"></a><a id="Tc_RdhaBmTwr0u1sdGRmkpVjQ_11_2"></a><a id="Tc_vtbfYbRolEuUHtsvne0RsA_11_5"></a><a id="Tc_w7RPddx0Fkax7Z7QMXIfuA_11_8"></a><a id="Tc_twDLwk76BUa9fe_0OtQslQ_12_0"></a><a id="Tc___qs32v_w0iNzzVByoA8-w_13_0"></a><a id="Tc_fr6eM7uZpEW6pb6H-sGVgw_14_0"></a><a id="Tc_PIqXKJrhBkCbSWXwD2PDtA_14_2"></a><a id="Tc_yvoCvAsotEmVAX7JWGtBmQ_14_5"></a><a id="Tc_z0ZokAnD3USp5ejBgyKLug_14_6"></a><a id="Tc_69PrHolmqEqqvckTC0Z4AQ_14_8"></a><a id="Tc_bpCd_P2bREeu5qAT5J3ZIA_15_0"></a><a id="Tc_iNaszw47I0y484-5D5etgA_15_6"></a><a id="Tc_Op_PySku0kyRdCLYrbzjag_16_0"></a><a id="Tc_0KZibWt8t0WADG0MejmozA_16_6"></a><a id="Tc__IdklUvsoU2UthmZPBKGWA_17_0"></a><a id="Tc_z-Uy_K6ECUSF_G5LmbGrAA_17_2"></a><a id="Tc_kMRLVom11UWaYuD93dY-Ag_17_5"></a><a id="Tc_Xv9ffoWEf06yVmlI39gLfQ_17_6"></a><a id="Tc_hhvggHMEq06K-NiYOYG79A_17_8"></a><a id="Tc_0dXOri9NCkC2Fxn3885VbQ_18_0"></a><a id="Tc_m0ZRmmAQjk2CWDddXRgzaQ_19_0"></a><a id="Tc_fSs5xG_OmkutJRsHok9bBA_20_0"></a><a id="_4cdef8bb_b1d1_4aed_882a_f90964343538"></a><a id="_4cdef8bb_b1d1_4aed_882a_f90964343538_2"></a><a id="_4cdef8bb_b1d1_4aed_882a_f90964343538_3"></a><a id="Tc_6NsFF7MwG0C5Ttaod6LkoQ_20_3"></a><a id="Tc_LAMMbpi_2U6BOnj5tFZNaQ_20_6"></a><a id="Tc_CJDWSlfsxkmlmoGLwjVq8A_20_9"></a><a id="Tc_4IUOU_sEekSUMbcjq_tQpg_21_0"></a><a id="Tc_ylOMztEgP02DfY5u3p6cZg_21_6"></a><a id="Tc_IXkrUM-1FEiS19a4LudzXw_22_0"></a><a id="Tc_Tdu3ivV7f06ICFhQJML60w_22_6"></a><a id="Tc_8IMLMO3M-0OnJqWIddf8jg_23_0"></a><a id="Tc__Ac1WjDEQU2aeQvcXXCXog_24_0"></a><a id="Tc_mjpPZx-v0kiZ5ID4Qfbq_A_25_0"></a><a id="Tc_uTHWrGQMJkKwQBBErQg8Gg_25_2"></a><a id="Tc_34_rHhjVnkyj9rscA5NC3g_25_5"></a><a id="Tc_AjHFaxJylE6_EEK9DjnDEg_25_8"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont9" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont10"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont7" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont8"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_UX87sJaHh0-YwrNmAkivsQ_8_3">31,987,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_AZei8dMRmkKpXAFwVAI0LQ_8_9">31,987,091</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_tQ1VzicMaEeCkgLeVfd_mg_9_3">499,947</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_8hpDVfnIDUyLKdn7DIySlA_9_6">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_WkgtWVH5jEKerXty3RU7KA_9_9">5,131,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_Kqpmb4uub02B5OQxqvGvxA_10_3">32,487,038</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_uaApY1MKI0WnpgWtQE0s4A_10_6">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_IZ8gHkLBuEGdGxt3IP7guQ_10_9">37,118,428</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_qSZATTqUK0aV_hRhWm-DGQ_11_3">32,487,038</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_Zy1xJT6KWkKxH-DVJiUJMA_11_6">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_C18Hsp0erkeOzJb9wLlCow_11_9">37,118,428</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_6yCK5mkDWEe4VMPGjxkR4Q_14_3">1,845,705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_TvzbbFel0k6puAYQ2u9voQ_14_9">1,845,705</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_9jtgHhGgDkKJQnMzFkCG9w_15_3">680,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_8_IZveOKbkKv_EC5slciGA_15_9">680,830</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_Ujchfe4mlUOt18-WvAt1bA_16_3">2,526,535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_7LDE9sIGMUmGnRyGciQ1cg_16_9">2,526,535</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_PP9gfoII2UuhR9SnN_YrRw_17_3">2,526,535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_N_9QqsIew0emI0nF-rHAtA_17_9">2,526,535</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Cz0S_s49M06WsD9eMfe2yg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_xLX0Jj-8L0mOyNtYKDIzkw">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_CpM6Nd-e7ku5f5f52BgQzQ"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_aDMey5SG1EyXuGX1_dO8YA">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_H0xIjTOa30SO6213TW7N0w"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_xE6Dlup-00iZ7oq44jTPUw">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock &#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_6bc6-tCLIUWmfOGwa71GzQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_mCjdq055H0-mveYfuhXCRw">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_R2xgaCJt8UKpRMyjMDqMfg"><ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_6V7WOAhEAk2PeqzA2lZ3Lw">35,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_r3yoT0deLkGq-xe2gXrXvQ">8,163,923</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_WWuLLOUFDUmYhWzae64IrQ">8,100,570</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_kuozT-fkoU2VpC3sMRmgDg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_IBAq19urw02_lqWC_B7pSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at September 30, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_XN7NTxiuk0quKpyGtT3GWg_21_3">816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_4vh-dHIlbkKp5s0bL6ZdDg_21_9">816</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_VU0DbYuxvk2cOGZD2MvINA_22_3">80,919,684</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_dp6nBQjdPE-iTbWXXABU6g_22_9">80,919,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_-G8-jrJj0kuJVugvyW6CKA_23_3">50,959,997</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="Tc_iKZYxd7TXEK_EzOSo3Z-pg_23_6">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_xmUlAtBFhEuPZxDFuHKNWg_23_9">46,328,607</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_HfebGYLoPkavpB5Jn21_kQ_24_3">29,960,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_pFe7ApA3yUSQPHlvR4-B3w_24_6">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_iM-7r9cYg0ibE4qpQOZiew_24_9">34,591,893</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_SdkEhP0Sf0agjn-qVl2BbQ_25_3">32,487,038</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_CZ0UI5ObUUaskzAyABkkew_25_6">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_u9QQvLWg00K5PEpqPquKWA_25_9">37,118,428</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9fd1f039_ae1c_4d2b_9aab_de134c83526b"></a><a id="Tc_trgDJIdXZU6oz-Z8uQx7dA_1_2"></a><a id="Tc_Q_k5TMIR3k2YEBwnxTReOw_2_2"></a><a id="Tc_z-RTLaZVvUa-ZWZmbTpPBA_2_5"></a><a id="Tc_44xekrOemEeqrVsSh2dY4g_2_8"></a><a id="Tc_VPmDh_HMq02QpC78VjPLSA_3_2"></a><a id="Tc_dKrdlQHf7US9Rv0sdeS34g_3_5"></a><a id="Tc_m_HR3B2ZikeVAxubCcJJDw_3_8"></a><a id="Tc_yNl-ruLTRUmw6TQKxRrNig_4_0"></a><a id="Tc_9QZF8sbXyUylOO-Hn9Iq7g_5_0"></a><a id="Tc_YKXUhyrBRUeLKDu27cDpxQ_5_2"></a><a id="Tc_iSIBjP6jD0iEwN1rDThMoA_5_5"></a><a id="Tc_aeXUsULD40K9FufTtZw63g_5_8"></a><a id="Tc_px0QooiGiE-08kP3_R0o2g_6_0"></a><a id="Tc_p1vQ75kzm0iggNBYBMzhaA_6_6"></a><a id="Tc_Iex5-UwQh0G3wWPq_Ui6wA_7_0"></a><a id="Tc_Jr1b34kUj0StYRdmtakrYg_9_0"></a><a id="Tc_0Lfwmkqv00SZSju_Ovdeuw_10_0"></a><a id="Tc_n-ot7iD4UkGNfJ2g7HlgBQ_11_0"></a><a id="Tc_5BNdhPhtSUiRIP45oK5JcA_11_6"></a><a id="Tc_M7jxaA_DKEey3qQmtFbI3A_12_0"></a><a id="Tc_8GTCjdxFdUCwinLhyzY2cw_12_3"></a><a id="Tc_vawzDZlQ6ke_g3JneSV-IQ_12_6"></a><a id="Tc_V07dmr2dSECqxr4VsOhkCA_12_9"></a><a id="Tc_3NCQSV3k-Ua_t-WTT_yWWg_13_0"></a><a id="Tc_X9Wrs-dZwEGpRvkRYyD5pQ_13_6"></a><a id="Tc_Oxsj5wKy2EqW0axmPPOT5g_15_0"></a><a id="Tc_vrN_MXzeoU6TMoDbPKRXMg_16_0"></a><a id="Tc_DvFTtXQFBkW9Ey9KiVfnmA_16_3"></a><a id="Tc_IAGxdYcRh0WUiBikRc2epw_16_6"></a><a id="Tc_GyXqvGVsTU2CWvyo8EY5sw_16_9"></a><a id="Tc_fKhsVNzoMU-5h8OaBP74qw_17_0"></a><a id="Tc_F3aaEANQqE-kvGBKeAKVYA_17_2"></a><a id="Tc_s3-wyc94pkGOjj4HHDusVQ_17_5"></a><a id="Tc_r1f2a3lD6kiNjbUAMgUMCQ_17_8"></a><a id="Tc_2cYdA_33o0a3FoNeW2tbYw_18_0"></a><a id="Tc_luAlY2zmr0iCUrfUU3K1cg_18_6"></a><a id="Tc_2b5wovkHNEm2OB4YY1diqg_19_0"></a><a id="Tc_0dPUlDfKv0O89SRWUrgI5A_19_6"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont10" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont11"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont8" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont9"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_Z9sDJozay0qHnvt8pXgInQ_5_3">5,313,033</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="0" id="Tc_GgptHgxVHESZZ1uHU8P7kw_5_6">1,189,495</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_GOZ0PYl4AkWqErt9Lm9RpA_5_9">4,123,538</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_4TAByEZk2kWo2F9IIuuysw_6_3">2,361,299</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_3bg8skT3QEKtnm7fQgGR8w_6_9">2,361,299</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_cP5c2Mn0wUqbIBcrn5p2tA_7_3">7,674,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" sign="-" scale="0" id="Tc_QQR6FXUs_kOnbViSvpdbbA_7_6">1,189,495</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_UL2sZxBh50ucE-eKHEGKqw_7_9">6,484,837</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_P7yCQxTfxkS64x4OzGtcnQ_9_3">7,674,332</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="Tc_qfZ6fUg4BE2BgO8uVQhPtg_9_6">1,189,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_Fw5d2pNjt0uSLH3czem9sw_9_9">6,484,837</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_HCfwBnp8402NjqBFyc73eg_11_3">52,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_vTAbYYAU9EK7rp7u3iz50Q_11_9">52,886</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_zeGJEQZHh0qFVA_u6287GA_13_3">52,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_TdxqbIlyXUeBdzcm-epBqw_13_9">52,886</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_4qX-2KbE8U2uPW-Tv84qeA_15_3">7,621,446</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="Tc_TqqQdkvHe0umfJiyL0vVuw_15_6">1,189,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_pBW-wSw5W0K8K6Lny_VgQg_15_9">6,431,951</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_WIQzVzuDyUCRTQRBCXz29Q_17_3">7,621,446</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_1WGX4U_fpkaBUChUvA5b3w_17_6">1,189,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_chVu4ms6MUCdBr_Nlr_Idw_17_9">6,431,951</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_R0KpXRjzSkGPJsqmSAn4QQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_9X8Pl4azs0CVHun4BKDC_g_18_3">0.93</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9ngmT9i0wEWaZaFs0Tn7og;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_EskCT7db4UOBOQS5PFOY0A_18_9">0.79</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_GhHqjyE_DEy6WZTRzENcpQ_19_3">8,163,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_a7xkdo8tbkKfBjHmUyP2xA_19_9">8,163,923</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bc5c1fc2_1199_4597_b485_d994a3fecebe"></a><a id="Tc_Z7GhaANwM02f8gXAKKvcxw_1_2"></a><a id="Tc_AeSLCvWIJk6VtcypqPIykw_2_2"></a><a id="Tc_rm_1Omv0_E2Fh0UivJLK9w_2_5"></a><a id="Tc_YJjxeY_Ex0eKNVACCxKEfw_2_8"></a><a id="Tc_WhR3KVMWG0CKxr1Uf8kwJw_3_2"></a><a id="Tc_SZxLQ12wRkWp_Cb7ROmAGg_3_5"></a><a id="Tc_YSH5D9yjs0uo_uL7O7xUMg_3_8"></a><a id="Tc_-IspJYvAeU-zOip-XUdQlg_4_0"></a><a id="Tc_oJsw1YT-tkur2suce_oQ_Q_5_0"></a><a id="Tc_LJjjmBf48EKhUtnhyLr00g_5_2"></a><a id="Tc_lUhiNvEevk2Yv7ND45bd-Q_5_5"></a><a id="Tc_zXLL-mVsQEi2tsTJdCSNAw_5_8"></a><a id="Tc_2cMGQj-tqkC2WT1pPHBUiw_6_0"></a><a id="Tc_FCWqPEGPF0u8S71VSh5x-w_6_6"></a><a id="Tc__EGPbe5f9kSIsakJ2ccaHQ_7_0"></a><a id="Tc_0JgJNanggUm8KG5Ft1qbrA_9_0"></a><a id="Tc_SCu8mN2RbUasQnjtAqG8ew_10_0"></a><a id="Tc_7fhjvvYiSEeZ2vWwg4BFbw_11_0"></a><a id="Tc_vlXNEg4gOEatNlzGqqRMKg_11_6"></a><a id="Tc_DFURV_jzkECjATiXdeLphQ_12_0"></a><a id="Tc_2L_kNICpgUWOWSQqCALvvQ_12_3"></a><a id="Tc_GOP-Tr4JiEajYcY28BC_Gw_12_6"></a><a id="Tc_cMFveG6PUUeN7Vy3b8Qz1g_12_9"></a><a id="Tc_it_dZvt6iUC_DVaNcZUIAQ_13_0"></a><a id="Tc_ohXubjL40kmJX-qxjOyx5w_13_6"></a><a id="Tc_kSM5TVFzk0aaOMIuVf0l2A_15_0"></a><a id="Tc_D0x1PSO2r0GPLZvYv14hkg_16_0"></a><a id="Tc_lUu8IaIMFEq6gShH9WcNpg_16_3"></a><a id="Tc_jfukCC13HEGjN4wHQc1qTg_16_6"></a><a id="Tc_WgZSOXqUPUaRudyC58_U4A_16_9"></a><a id="Tc_rqwvGb26q0aDIRIhl1dZbA_17_0"></a><a id="Tc_hm-FwxwJBUC_R4OFSzJLmg_17_2"></a><a id="Tc_8UOMPl26Hk6qhvHIqdMrHg_17_5"></a><a id="Tc_WwhYX6Q7JEaRvptnzCEVWg_17_8"></a><a id="Tc_HY8zL__06ESJeRBHr4wgIA_18_0"></a><a id="Tc_B29FdhzSSU2hBd2LG8WEeQ_18_6"></a><a id="Tc_7PbnX8KRqE6HsP-1Xx_DYQ_19_0"></a><a id="Tc_bjQM6s9jF0WGvuoVZMkIiQ_19_6"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont11" continuedAt="Tb_qKJqleUqRkGjODxKE5RuIw_cont12"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont9" continuedAt="Tb_2qLIkySzv0StxjVBrGRekw_cont10"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_pW6Ej8hda0etgc-OsmvC7A_5_3">14,938,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" sign="-" scale="0" id="Tc_oS3yOZ5ZwUy8q5g6g32TmQ_5_6">4,631,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_v6j87_BvwkmHz0xNOv0hyA_5_9">10,307,142</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_HGt7zFWTqEGVt8ALqvKw8A_6_3">7,403,817</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8211;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_kM42Eve7dkWFIkSd1TeV9A_6_9">7,403,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_Goiq01EpBUSjNYetHUk0lA_7_3">22,342,349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" sign="-" scale="0" id="Tc_1FLLYbf0OEeHgSAa9gy2Lw_7_6">4,631,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_JRZDTEYhsUuszXlbWqlC_w_7_9">17,710,959</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_usVD0Mm2wEKSJ3wMZDhyrA_9_3">22,342,349</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="Tc_SqeYRW02qUa4TxFz6UTqAA_9_6">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_G1jQHuvDckuP5f1BN5-tbw_9_9">17,710,959</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_ufzevBFickGBxh37oyqpMg_11_3">108,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_oEnMXxZ-kUCN9Mb3U1nM3g_11_9">108,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8211;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_6NatII2hQ0epfvqsbRW6Yg_13_3">108,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_frS8L9PPaUOe8duLZVznBg_13_9">108,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_iOxvppWWg0yylnmrOY04wQ_15_3">22,233,790</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="Tc_3EXdcfi6102aorF027f98w_15_6">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_p1PLZ6vcb0eX1FwkNog64A_15_9">17,602,400</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_3P-GwDV97keri41xDbPBsw_17_3">22,233,790</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_B6MMys1m7EG6Ujou9XHYZA_17_6">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_5-apegCtOEi2A1SwL5IM3w_17_9">17,602,400</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_lMJqv36yQEq7BdUNqY6Ieg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_wrEXMObYK0yZS9TjXghB9w_18_3">2.72</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_boWkpKJFu0uuOAEChJvoRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_y3bUZBSx_ES86AQSn5iHCA_18_9">2.16</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_T1ooRgaQ1UGTXvhVXaOfsw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 8,161,787</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_cOrcpa8qxUKfCqM5BQF3ew_19_9">8,161,787</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_715746d9_d809_43b2_bc68_90e4daaf2a53"></a><a id="Tc_trUMSVmyMk-VXCEvavBmLA_1_2"></a><a id="Tc_YVa8iFsAoU6MM1WA-K15Cg_2_2"></a><a id="Tc_lKHN43Ku_Uewxd0e3OHEdg_2_7"></a><a id="Tc_Db4nJ62Xk0ufVZF0FaZZRw_3_2"></a><a id="Tc_9FDrVmMBtU2EOR8s3YhuNQ_3_5"></a><a id="Tc_1Joh1gO1o0-10g1GQ8QouA_3_7"></a><a id="Tc_WD1B1mwrfE2wI6jdUgsglw_4_0"></a><a id="Tc_-q4vx2Atl0GBOVLAz_Ag_Q_5_0"></a><a id="Tc_EirogYStrkuPnpwUy0tXKw_5_2"></a><a id="Tc_SM147vXmi06QCWfIClZZbQ_5_7"></a><a id="Tc_ZwNUmlSqaUqNkrahFTchwQ_6_0"></a><a id="Tc_kJSmNW8luUW_Lw9TkOMxFQ_7_0"></a><a id="Tc_xYWr6-JyxUaWsjjIZ_8Nxg_7_5"></a><a id="Tc_3cobCfFrz0GheSV98jnH_w_8_0"></a><a id="Tc_wdqmEV3glkuMsHiYlMOcvQ_9_0"></a><a id="Tc_J27pin5QA0-alAMhkNLn2w_10_0"></a><a id="Tc__hiX6rrErEeotDsjOAxpxg_10_5"></a><a id="Tc_MLp0OaIk6EmiyIUCTOPFyg_11_0"></a><a id="Tc_C1sPtcTCek679AhPzAVSjQ_11_5"></a><a id="Tc_iFLVSCZFbkeH-6RbKFJs8A_12_0"></a><a id="Tc_WdcIrQAV8Ue5oklDqwkCOQ_12_5"></a><a id="Tc_2Xsx4yGmTk21pHHDNYQcFQ_13_0"></a><a id="Tc_-naaB91LI06b9zQXOlHoUQ_14_0"></a><a id="Tc_93_JtIIwcEyrP8DEphY-qQ_14_3"></a><a id="Tc_8levQSaobk-SYSQUqTGkCA_14_5"></a><a id="Tc_wH64gpN5t0qPz0h838EJ-Q_14_8"></a><a id="Tc_mMpAjsNkMEe1kpZ8Vair7g_15_0"></a><a id="Tc_9axMBbhKbEaI1lJ0Ve5Y9A_15_5"></a><a id="Tc_D8s-xwjSREC8k-phm6ai8w_16_0"></a><a id="Tc_GOWFe4Q29km8KJEhPK0CXw_16_5"></a><a id="Tc_9pim69h58UeYZ6IULcimdg_17_0"></a><a id="Tc_vtoGNklT6kuAdFvcVpSwjQ_17_5"></a><a id="Tc_Unync36yaU6brm_n83zyvg_18_0"></a><a id="Tc_n8ki5bEHzECwGn3Lu1ZwCw_18_5"></a><a id="Tc_FR7n9KVqzUCTngpLq1mBZg_19_0"></a><a id="Tc_htYWydKBak-kshh_Rt4HEw_19_2"></a><a id="Tc_LqPJrI2MB0aWSQttqgTIMA_19_5"></a><a id="Tc_cTpk9cKCw0ynxRxsBmaUGA_19_7"></a><ix:continuation id="Tb_qKJqleUqRkGjODxKE5RuIw_cont12"><ix:continuation id="Tb_2qLIkySzv0StxjVBrGRekw_cont10"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement&#160;Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc__p87WMhZqESBIuWtxOAukg_5_3">22,233,790</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="Tc_raiHnq-L2Eu82yp7kvU4zA_5_5">4,631,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_qzljjub1EEmcyClGBmxCsA_5_8">17,602,400</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_ODHm6DM7a0CvIlsRx4s88g_7_3">7,694,716</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_DhbjTxcw2USaDGjBsc09VA_7_8">7,694,716</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_YdAei--rr0Ct2vJ2xKvesQ_9_3">184,483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_CZMyvMkq4kKLu_DXGbcWJg_9_5">4,631,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_MEMz5PlWe0ONH3QBQgQiUg_9_8">4,815,873</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_OCZshHGohEGu2yJXRXmGFA_10_3">1,157,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_IgzsOCnJtkSXnqHf7q_8Vw_10_8">1,157,631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_BIpyznnu8k23RC_nl-MmmA_11_3">137,610</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_xe2gPu_DWESlwB70Gb-KBg_11_8">137,610</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_x9MYshzDb0WjI0E8Mi4rug_12_3">13,703,536</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_Gy1KacYnfk2kiVjjAIa-eg_12_8">13,703,536</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_7kITeSIDp0OvG_cwR6BdRQ_15_3">4,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc__YK0gQUgKkK8YWQbWLwSow_15_8">4,613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_SvRkJIEW70mX_d7SUePl2g_16_3">4,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_8fogJMM4fkui2uFtNa6Idg_16_8">4,613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_btwncQ63YEi_t5uh2-wERw_17_3">13,698,923</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_diTt85NvKk-4gJA9WTY8zQ_17_8">13,698,923</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_LvDPCB7paUK0MB8bwYZ-Gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_yV41rP5AtEiN3SCtDItlOg_18_3">45,686,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_9Gq_jBy510OzZdjvk8ef1Q_18_8">45,686,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_6gm-3rmslEa60-JrEKEiLw_19_3">31,987,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA" contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_51i01hA_kkSvuCKNnPr_PQ_19_8">31,987,091</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g" name="us-gaap:SubsequentEventsTextBlock" id="Tb_S7X4h7ueHUePlQqiShKhGA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(13) Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 18, 2023, the Company granted options to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA" contextRef="Duration_1_18_2023_To_1_18_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CNEPyGXQ7U2LW4h39gTpIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_5Ldbsn53-06JFIolqkL8Qg">81,705</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ" contextRef="Duration_1_18_2023_To_1_18_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CNEPyGXQ7U2LW4h39gTpIw" decimals="2" format="ixt:numdotdecimal" name="anvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" scale="0" id="Narr_pMHMxsRR9kaht2Kehne1yA">13.17</ix:nonFraction> per share to employees, members of the board of directors and consultants to the Company.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1669cf13_6cb8_4d95_97b9_1e224e3c79bb"></a><a id="SIGNATURES_225846"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with the requirements Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANNOVIS BIO,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:49.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:47.2%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ MARIA MACCECCHINI</p></td></tr><tr><td style="vertical-align:top;width:49.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td></tr><tr><td style="vertical-align:top;width:49.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Power_of_Attorney"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Each of the undersigned hereby constitute and appoint Maria Maccecchini and Henry Hagopian, and each of them, his or her true and lawful attorneys-in-fact and agents, with full and several power of substitution and resubstitution, for him or her and in his or her name, place and stead in any and all capacities, to sign one or more amendments to this Annual Report on Form&#160;10-K, each in such form as they or any one of them may approve, and to file the same with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done so that this Annual Report and any amendments shall comply with the Securities Exchange Act of 1934, as amended, and the applicable rules and regulations adopted or issued pursuant thereto, as fully and to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their substitute or resubstitute, may lawfully do or cause to be done by virtue hereof.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Signature</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:18.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MARIA MACCECCHINI</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 31, 2023</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Maria Maccecchini</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal executive officer)</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ HENRY HAGOPIAN</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (principal </p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 31, 2023</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Henry Hagopian</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">financial and accounting officer)</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MICHAEL HOFFMAN</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board and Director</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 31, 2023</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Michael Hoffman</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ CLAUDINE BRUCK</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 31, 2023</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Claudine Bruck</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ REID MCCARTHY</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 31, 2023</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Reid McCarthy</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MARK WHITE</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 31, 2023</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Mark White</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>anvs-20221231xex10d6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/31/2023 08:46:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 10.6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NONQUALIFIED STOCK OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">THIS AGREEMENT</font><font style="font-size:12pt;">, effective as of _____________, 20__, is made by and between Annovis Bio, Inc. (the &#8220;Company&#8221;), a Delaware corporation, and [________________] (the &#8220;Employee&#8221;), an employee of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recitals</b><b style="font-size:12pt;font-weight:bold;">:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, </font><font style="font-size:12pt;">the Company has established the Annovis Bio, Inc. 2019 Equity Incentive Plan, as amended (the &#8220;Plan&#8221;), the terms of which are hereby incorporated by reference and made a part of this Agreement; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS</font><font style="font-size:12pt;">, the Company&#8217;s Board of Directors has determined that it would be to the advantage and best interest of the Company and its stockholders to grant the stock option provided for herein under the Plan to the Employee as an incentive for increased efforts during the Employee&#8217;s employment by the Company, subject to the execution and delivery of this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">NOW, THEREFORE</font><font style="font-size:12pt;">, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 1.1 - Definitions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Whenever the following terms are used in this Agreement, they shall have the meanings specified below unless the context clearly indicates to the contrary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;Act&#8221; shall mean the Federal Securities Act of 1933, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;Cause&#8221; shall have the meaning set forth in Section 5(f)(v)(D) of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;Change of Control&#8221; shall have the meaning set forth in Section 12(a) of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;Code&#8221; shall mean the Internal Revenue Code of 1986, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;Committee&#8221; shall mean the Committee established in accordance with Section 2(a) of the Plan, if one has been appointed, or the Board of Directors of the Company, if no Committee has been appointed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;Common Stock&#8221; shall mean the $.0001 par value Common Stock of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;Option&#8221; shall mean the nonqualified stock option to purchase Common Stock granted under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;Plan&#8221; shall have the meaning set forth in the Recitals section of this Agreement.</font></p><p style="display:none;line-height:0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;Subsidiary&#8221; shall mean any corporation in an unbroken chain of corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain then owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">&#8220;Termination of Employment&#8221; shall mean the time when the employee-employer relationship between the Employee and the Company or a Subsidiary is terminated for any reason, including, but not limited to, a termination by resignation, discharge, death or retirement, but excluding any termination where there is a simultaneous reemployment by the Company or a Subsidiary.  The Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to Termination of Employment, including, but not limited to, the question of whether a Termination of Employment resulted from a discharge for Cause, and all questions of whether a particular leave of absence constitutes a Termination of Employment; provided, however, that a leave of absence shall constitute a Termination of Employment if, and to the extent that, such leave of absence interrupts employment for purposes of Section 422(a)(2) of the Code and the then applicable Regulations and Revenue Rulings under said Section.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GRANT OF OPTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 2.1 - Grant of Option</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Effective as of the date hereof, the Company grants to the Employee the Option to purchase any part or all of an aggregate of [____]&#160;</font><font style="font-size:12pt;white-space:pre-wrap;">shares of Common Stock upon the terms and conditions set forth in this Agreement.  The Option shall be subject in all respects to the provisions of this Agreement and of the Plan.  The Option is not intended to be an incentive stock option under Section 422 of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 2.2 - Purchase Price</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The purchase price of the shares of Common Stock covered by the Option shall be $[____] per share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 2.3 - Adjustments in Option</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The number of shares subject to issuance upon exercise of the Option and the purchase price thereof are subject to adjustment in accordance with Section 3(b) of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXERCISABILITY OF OPTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 3.1 - Exercisability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Subject to the provisions of this Article 3, the Option shall vest and become exercisable in eight consecutive quarterly installments of [____]&#160;shares on the [__] day of [_________], [_________], [_________] and [_________]of each year, commencing [_________] and continuing through [_________], provided that a Termination of Employment has not occurred prior to the applicable vesting date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">No portion of the Option that is not exercisable at the time of the Employee&#8217;s Termination of Employment shall thereafter become exercisable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 3.2 - Duration of Exercisability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Option shall remain exercisable until it becomes unexercisable under Section 3.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 3.3 - Termination of Option</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Option may not be exercised to any extent after the first to occur of the following events:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The expiration of ten years from the date the Option was granted;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The expiration of three months after the Employee&#8217;s Termination of Employment, unless such Termination of Employment results from the Employee&#8217;s death;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">The expiration of one year after the date of the Employee&#8217;s death; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">the date of the Employee&#8217;s Termination of Employment if the Termination of Employment is for Cause.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 3.4 - Acceleration of Exercisability.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If a Change of Control shall occur prior to the termination of the Option pursuant to Section 3.3, the Option shall vest in full and become immediately exercisable upon such Change of Control, irrespective of whether the Option, or any portion thereof, had yet become exercisable pursuant to Section 3.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXERCISE OF OPTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 4.1 - Person Eligible to Exercise</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">During the lifetime of the Employee, only the Employee may exercise the Option or any portion thereof.  After the death of the Employee, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section 3.3, be exercised by the Employee&#8217;s personal representative or by any person empowered to do so under the Employee&#8217;s will or under the then applicable laws of descent and distribution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 4.2 - Partial Exercise</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised in whole or in part at any time prior to the time when the Option or portion thereof becomes unexercisable under Section 3.3; provided, however, that each partial exercise shall be for whole shares only.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 4.3 - Manner of Exercise</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of the Company of all of the following prior to the time when the Option or such portion becomes unexercisable under Section 3.3:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Notice in writing signed by the Employee or the other person then entitled to exercise the Option or any portion, stating that the Option or portion is thereby exercised, such notice complying with all applicable rules established by the Committee;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">(i)</font><font style="display:inline-block;width:24.67pt;"></font><font style="font-size:12pt;">Full payment (in cash or by check) for the shares with respect to which the Option or portion is exercised; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:12pt;">If the Committee in its sole discretion shall so permit, shares of Common Stock owned by the Employee duly endorsed for transfer to the Company with a fair market value on the date of delivery equal to the aggregate purchase price of the shares with respect to which the Option or portion is exercised;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(iii) </font></font><font style="font-size:12pt;">If the Committee in its sole discretion shall so permit, through a cashless exercise; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(iv)</font></font><font style="font-size:12pt;">If the Committee in its sole discretion shall so permit, a combination of the consideration provided in the foregoing subsections 4.3(b)(i), 4.3(b)(ii) and 4.3(b)(iii);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;white-space:pre-wrap;">A bona fide written representation and agreement in a form satisfactory to the Committee, signed by the Employee or other person then entitled to exercise the Option or portion, stating that the shares of stock are being acquired for the Employee&#8217;s own account, for investment and without any present intention of distributing or reselling said shares or any of them except as may be permitted under the Act, and then applicable rules and regulations thereunder, and that the Employee or other person then entitled to exercise the Option or portion will indemnify the Company against and hold it free and harmless from any loss, damage, expense or liability resulting to the Company if any sale or distribution of the shares by such person is contrary to the representation and agreement referred to above.  The Committee may, in its absolute discretion, take whatever additional action it deems appropriate to ensure the observance and performance of such representation and agreement and to effect compliance with the Act and any other federal or state securities laws or regulations.  Without limiting the generality of the foregoing, the Committee may require an opinion of counsel acceptable to it to the effect that any subsequent transfer of shares acquired on an Option exercise does not violate the Act, and may issue stop-transfer orders covering such shares.  Share certificates evidencing stock issued on exercise of the Option shall bear an appropriate legend referring to the provisions of this subsection 4.3(c) and the agreements herein.  The written representation and agreement referred to in the first sentence of this subsection 4.3(c) shall, however, not be required if the shares to be issued pursuant to such exercise have been registered under the Act, and such registration is then effective in respect of such shares; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">In the event the Option or portion shall be exercised pursuant to Section 4.1 by any person or persons other than the Employee, appropriate proof of the right of such person or persons to exercise the Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 4.4 - Conditions to Issuance of Stock Certificates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">The shares of Common Stock deliverable upon the exercise of the Option, or any portion thereof, may be either previously authorized but unissued shares or issued shares that have then been reacquired by the Company.  Such shares shall be fully paid and nonassessable.  The Company shall not be required to issue or deliver any certificate or certificates for shares of Common Stock purchased upon the exercise of the Option or portion thereof prior to fulfillment of all of the following conditions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The admission of such shares to listing on all stock exchanges or stock markets on which such class of stock is then listed;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The completion of any registration or other qualification of such shares under any state or federal law or under rulings or regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Committee shall, in its absolute discretion, deem necessary or advisable;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">The obtaining of any approval or other clearance from any state or federal government agency which the Committee shall, in its absolute discretion, determine to be necessary or advisable; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">The lapse of such reasonable period of time following the exercise of the Option as the Committee may from time to time establish for reasons of administrative convenience.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 4.5 - Rights as Stockholder</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The holder of the Option shall not be, nor have any of the rights or privileges of, a stockholder of the Company in respect of any shares purchasable upon the exercise of any part of the Option unless and until such part of the Option is exercised in accordance with its terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRANSFER OF OPTIONS AND SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 5.1 - Options Not Transferable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Neither the Option nor any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of the Employee or the Employee&#8217;s successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy) and any attempted disposition thereof shall be null and void and of no effect; provided, however, that this Section 5.1 shall not prevent transfers by will or by the applicable laws of descent and distribution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.1 - Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules.  All actions taken and all interpretations and determinations made by the Committee in good faith shall be final and binding upon the Employee, the Company and all other interested persons.  No member of the Committee shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or the Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.2 - Withholding</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">All amounts which, under federal, state or local law, are required to be withheld from the amount payable with respect to any Option shall be withheld by the Company.  Whenever the Company proposes or is required to issue or transfer shares of Common Stock, the Company shall have the right to require the recipient to remit to the Company an amount sufficient to satisfy any federal, state or local withholding tax requirements prior to the delivery of any certificate or certificates for such shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.3 - No Right of Continued Employment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Nothing contained in this Agreement or in the Plan shall confer upon the Employee any right to continue in the employ or other service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and any Subsidiary, which are hereby expressly reserved, to discharge the Employee at any time for any reason whatsoever, with or without Cause.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.4 - Shares To Be Reserved</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Company shall at all times during the term of the Option reserve and keep available such number of shares of Common Stock as will be sufficient to satisfy the requirements of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.5 - Notices</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of its Secretary, and any notice to be given to the Employee shall be addressed to the Employee at the address given beneath the Employee&#8217;s signature hereto.  By a notice given pursuant to this Section 6.5, either party may hereafter designate a different address for notices to be given to such party.  Any notice that is required to be given to the Employee shall, if the Employee is then deceased, be given to the Employee&#8217;s personal representative if such representative has previously informed the Company of the Employee&#8217;s status and address by written notice under this Section 6.5.  Any notice shall have been deemed duly given when sent by U.S. mail, postage prepaid; by an overnight delivery service, charges prepaid; or by confirmed facsimile.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.6 - Survival</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Each provision of this Agreement that, by its terms, is intended to survive beyond the exercise of the Option shall continue in effect thereafter until such time as such term shall no longer apply.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.7 - Entire Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Agreement and the Plan set forth the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings between the parties regarding the Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.8 - Successors and Assigns</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Agreement shall inure to the successors and assigns of the parties; provided, however, that neither this Agreement nor any rights hereunder may be assigned by the Employee, except to the extent expressly permitted herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.9 - Titles</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Section 6.10 - Counterparts; Facsimile or Electronic Transmission</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">This Agreement may be executed by the parties on separate counterparts, both of which shall be an original and both of which together shall constitute one and the same agreement.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.docusign.com</u><font style="font-size:12pt;">) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(Signature page follows.)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">IN WITNESS WHEREOF</font><font style="font-size:12pt;">, this Agreement has been executed and delivered by the parties hereto.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANNOVIS BIO, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Henry Hagopian III</p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[Employee Name]</p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee&#8217;s Address:</p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email Address:</p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>anvs-20221231xex23d1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/31/2023 08:46:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Registration No. 333-252625) and Form S-8 (Registration No. 333-236457) of Annovis Bio, Inc. (the &#8220;Company&#8221;) of our report dated March 31, 2023, which includes an explanatory paragraph relating to the Annovis Bio, Inc.&#8217;s ability to continue as a going concern, relating to the financial statements of the Company as of and for the years ended December 31, 2022 and 2021, which appear in this Form 10-K.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ WithumSmith+Brown, PC</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">East Brunswick, New Jersey</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>anvs-20221231xex31d1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/31/2023 08:46:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">I, Maria Maccecchini, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">I have reviewed this Annual Report on Form 10-K of Annovis Bio, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Maria Maccecchini</p></td></tr><tr><td style="vertical-align:bottom;width:50.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td></tr><tr><td style="vertical-align:bottom;width:50.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>anvs-20221231xex31d2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/31/2023 08:46:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Henry Hagopian, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I have reviewed this Annual Report on Form 10-K of Annovis Bio, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:57.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Henry Hagopian</p></td></tr><tr><td style="vertical-align:bottom;width:57.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Henry Hagopian</p></td></tr><tr><td style="vertical-align:bottom;width:57.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>anvs-20221231xex32d1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/31/2023 08:46:28 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Annovis Bio, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2022 as field with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Maria Maccecchini</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>anvs-20221231xex32d2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/31/2023 08:46:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Annovis Bio, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2022 as field with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Henry Hagopian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Henry Hagopian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>anvs-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2023 8:46:27 PM-->
<!--Modified on: 3/31/2023 8:46:27 PM-->
<xsd:schema targetNamespace="http://annovisbio.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:anvs="http://annovisbio.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2022" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40601 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails">
        <link:definition>41101 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" id="DisclosureIncomeTaxesDeferredTaxesDetails">
        <link:definition>41102 - Disclosure - Income Taxes - Deferred taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" id="StatementStatementsOfChangesInStockholdersEquity">
        <link:definition>00300 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlans" id="DisclosureNatureOfBusinessGoingConcernAndManagementSPlans">
        <link:definition>10101 - Disclosure - Nature of Business, Going Concern and Management's Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10501 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10601 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10701 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10901 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11001 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11101 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11301 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30603 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30903 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31003 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31103 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails" id="DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails">
        <link:definition>40101 - Disclosure - Nature of Business, Going Concern and Management's Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40301 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureGrantIncomeDetails" id="DisclosureGrantIncomeDetails">
        <link:definition>40401 - Disclosure - Grant Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" id="DisclosureCommitmentsAndContingenciesLeasesDetails">
        <link:definition>40701 - Disclosure - Commitments and Contingencies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" id="DisclosureCommitmentsAndContingenciesLicenseAgreementDetails">
        <link:definition>40702 - Disclosure - Commitments and Contingencies - License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" id="DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails">
        <link:definition>40703 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersEquityCommonStockDetails" id="DisclosureStockholdersEquityCommonStockDetails">
        <link:definition>40801 - Disclosure - Stockholders' Equity- Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" id="DisclosureStockholdersEquityWarrantsDetails">
        <link:definition>40802 - Disclosure - Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" id="DisclosureStockBasedCompensationSummaryOfPlansDetails">
        <link:definition>40901 - Disclosure - Stock-Based Compensation - Summary of plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>40902 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>40903 - Disclosure - Stock-Based Compensation - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" id="DisclosureStockBasedCompensationAdditionalDisclosuresDetails">
        <link:definition>40904 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>41001 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" id="DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails">
        <link:definition>41002 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" id="DisclosureIncomeTaxesAdditionalDisclosuresDetails">
        <link:definition>41103 - Disclosure - Income Taxes - Additional disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails" id="DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails">
        <link:definition>41201 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails" id="DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails">
        <link:definition>41202 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails" id="DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails">
        <link:definition>41203 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" id="DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails">
        <link:definition>41204 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails" id="DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails">
        <link:definition>41205 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41301 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureGrantIncome" id="DisclosureGrantIncome">
        <link:definition>10401 - Disclosure - Grant Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10801 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements" id="DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements">
        <link:definition>11201 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables" id="DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables">
        <link:definition>31203 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element id="anvs_IncomeFromGrants" name="IncomeFromGrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="anvs_NumberOfVotesForEachShareOfCommonStock" name="NumberOfVotesForEachShareOfCommonStock" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_UnderwritersWarrantsMember" name="UnderwritersWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_PercentageOfExercisePriceToShareOfferingPrice" name="PercentageOfExercisePriceToShareOfferingPrice" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" name="DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" name="AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="anvs_PrepaidResearchAndDevelopmentExpenseCurrent" name="PrepaidResearchAndDevelopmentExpenseCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" name="PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" name="EarningsPerShareBasicAndDilutedNumeratorAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" name="EarningsPerShareBasicAndDilutedDenominatorAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_ProceedsFromGrants" name="ProceedsFromGrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" name="NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_GrantsReceivableNoticeOfAwardAmount" name="GrantsReceivableNoticeOfAwardAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_NatureOfBusinessAndLiquidityAbstract" name="NatureOfBusinessAndLiquidityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_LicenseAgreementMinimumAnnualCommitment" name="LicenseAgreementMinimumAnnualCommitment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="anvs_LicenseAgreementTermsAmendedMay2012Member" name="LicenseAgreementTermsAmendedMay2012Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_CumulativeNumberOfMilestonesAchieved" name="CumulativeNumberOfMilestonesAchieved" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_MaximumAggregateSeverancePayments" name="MaximumAggregateSeverancePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" name="LicenseAgreementPeriodOfAdvanceNoticeOfTermination" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_EquityIncentivePlan2019Member" name="EquityIncentivePlan2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_StockPurchaseAgreementAxis" name="StockPurchaseAgreementAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_StockPurchaseAgreementDomain" name="StockPurchaseAgreementDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_EquityIncentivePlan2018Member" name="EquityIncentivePlan2018Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_GeneratedIn2017AndPriorMember" name="GeneratedIn2017AndPriorMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" name="ShareBasedPaymentArrangementVestingPeriodOneYearMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_GrantAwardRemainingAmountAvailable" name="GrantAwardRemainingAmountAvailable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" name="ConversionOfWarrantsNumberOfWarrantsConverted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_SecondaryPublicOfferingMember" name="SecondaryPublicOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" name="IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="UnreimbursedEligibleCostsIncurredDuringPeriod" id="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AwardsGrantedIn2021Member" id="anvs_AwardsGrantedIn2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" id="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" id="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementVestingPeriodThreeYearsMember" id="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" id="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonOperatingIncomeGrantIncomeAbstract" id="anvs_NonOperatingIncomeGrantIncomeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherNonoperatingIncomeGrantIncomeTextBlock" id="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" id="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PerformanceBasedVestingConditionsMember" id="anvs_PerformanceBasedVestingConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AwardsGrantedIn2022Member" id="anvs_AwardsGrantedIn2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" id="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" id="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TimingOfAccrualsForResearchAndDevelopmentExpensesMember" id="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaidResearchAndDevelopmentCurrent" id="anvs_PrepaidResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ErrorCorrectionsDueToExpensesRecordedInQ12022Member" id="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ErrorCorrectionsDueToExpensesRecordedInQ22022Member" id="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ErrorCorrectionsDueToExpensesRecordedInQ32022Member" id="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>anvs-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2023 8:46:27 PM-->
<!--Modified on: 3/31/2023 8:46:27 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#StatementBalanceSheets" roleURI="http://annovisbio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#StatementStatementsOfOperations" roleURI="http://annovisbio.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://annovisbio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" />
  <calculationLink xlink:role="http://annovisbio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638158923866693155" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638158923866693155" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158923866693155" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638158923866693155" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158923866693155" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923866693155" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638158923866693155" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923866693155" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638158923866693155" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638158923866693155" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638158923866823149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638158923866693155" xlink:to="us-gaap_LiabilitiesCurrent_638158923866823149" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638158923866823149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158923866823149" xlink:to="us-gaap_AccountsPayableCurrent_638158923866823149" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923866823149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158923866823149" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923866823149" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638158923866823149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638158923866823149" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158923866823149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638158923866823149" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638158923866823149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158923866823149" xlink:to="us-gaap_PreferredStockValue_638158923866823149" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638158923866833151" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158923866823149" xlink:to="us-gaap_CommonStockValue_638158923866833151" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638158923866833151" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158923866823149" xlink:to="us-gaap_AdditionalPaidInCapital_638158923866833151" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638158923866833151" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158923866823149" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638158923866833151" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158923866833151" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158923866833151" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638158923866833151" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158923866833151" xlink:to="us-gaap_OperatingIncomeLoss_638158923866833151" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638158923866833151" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638158923866833151" xlink:to="us-gaap_OperatingExpenses_638158923866833151" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638158923866833151" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638158923866833151" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638158923866833151" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638158923866833151" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638158923866833151" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638158923866833151" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638158923866843149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158923866833151" xlink:to="us-gaap_NonoperatingIncomeExpense_638158923866843149" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638158923866843149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638158923866843149" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638158923866843149" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants_638158923866843149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638158923866843149" xlink:to="anvs_IncomeFromGrants_638158923866843149" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638158923866843149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638158923866843149" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923866843149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923866843149" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638158923866843149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923866843149" xlink:to="us-gaap_ProfitLoss_638158923866843149" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638158923866843149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923866843149" xlink:to="us-gaap_ShareBasedCompensation_638158923866843149" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638158923866843149" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923866843149" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638158923866843149" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638158923866853147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923866843149" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638158923866853147" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158923866853147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923866843149" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158923866853147" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158923866853147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158923866853147" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638158923866853147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158923866853147" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638158923866853147" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638158923866853147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158923866853147" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638158923866853147" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_638158923866853147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_638158923866853147" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638158923866853147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_638158923866853147" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638158923866853147" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638158923866853147" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638158923866863158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="us-gaap_SecurityDeposit_638158923866863158" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638158923866863158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638158923866863158" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638158923866863158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638158923866863158" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158923866863158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158923866863158" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158923866863158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158923866863158" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638158923866863158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638158923866863158" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638158923866863158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638158923866863158" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638158923866863158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638158923866863158" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158923866873146" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158923866873146" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Income Taxes - Deferred taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638158923866873146" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638158923866873146" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638158923866873146" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638158923866873146" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158923866873146" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158923866873146" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158923866873146" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_638158923866873146" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158923866873146" xlink:to="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_638158923866873146" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_638158923866873146" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158923866873146" xlink:to="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_638158923866873146" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158923866873146" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158923866873146" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158923866873146" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158923866873146" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158923866873146" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158923866873146" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>anvs-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2023 8:46:27 PM-->
<!--Modified on: 3/31/2023 8:46:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#StatementStatementsOfChangesInStockholdersEquity" roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails" roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureGrantIncomeDetails" roleURI="http://annovisbio.com/role/DisclosureGrantIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockBasedCompensationSummaryOfPlansDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockBasedCompensationAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureIncomeTaxesAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://annovisbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="anvs-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://annovisbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_StockPurchaseAgreementAxis" xlink:label="anvs_StockPurchaseAgreementAxis_1" xlink:title="anvs_StockPurchaseAgreementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_StockPurchaseAgreementDomain" xlink:label="anvs_StockPurchaseAgreementDomain_1" xlink:title="anvs_StockPurchaseAgreementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="anvs_StockPurchaseAgreementAxis_1" xlink:to="anvs_StockPurchaseAgreementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:anvs_StockPurchaseAgreementAxis_1 To anvs_StockPurchaseAgreementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1" xlink:title="us-gaap_AwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardDateAxis_1" xlink:to="us-gaap_AwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardDateAxis_1 To us-gaap_AwardDateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:title="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_1" xlink:title="us-gaap_AdjustmentsForErrorCorrectionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1 To us-gaap_AdjustmentsForErrorCorrectionDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Business, Going Concern and Management's Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_SecondaryPublicOfferingMember" xlink:label="anvs_SecondaryPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_SecondaryPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="anvs_UnderwritersWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NatureOfBusinessAndLiquidityAbstract" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_NatureOfBusinessAndLiquidityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Grant Income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GrantsReceivableNoticeOfAwardAmount" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_GrantsReceivableNoticeOfAwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_IncomeFromGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ProceedsFromGrants" xlink:label="anvs_ProceedsFromGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_ProceedsFromGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GrantsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GrantAwardRemainingAmountAvailable" xlink:label="anvs_GrantAwardRemainingAmountAvailable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="anvs_GrantAwardRemainingAmountAvailable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_LicenseAgreementTermsAmendedMay2012Member" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="anvs_LicenseAgreementTermsAmendedMay2012Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_LicenseAgreementMinimumAnnualCommitment" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="anvs_LicenseAgreementMinimumAnnualCommitment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_CumulativeNumberOfMilestonesAchieved" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="anvs_CumulativeNumberOfMilestonesAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_MaximumAggregateSeverancePayments" xlink:label="anvs_MaximumAggregateSeverancePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredCompensationArrangementsAbstract" xlink:to="anvs_MaximumAggregateSeverancePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stockholders' Equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="anvs_UnderwritersWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-Based Compensation - Summary of plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EquityIncentivePlan2019Member" xlink:label="anvs_EquityIncentivePlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="anvs_EquityIncentivePlan2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EquityIncentivePlan2018Member" xlink:label="anvs_EquityIncentivePlan2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="anvs_EquityIncentivePlan2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AwardsGrantedIn2022Member" xlink:label="anvs_AwardsGrantedIn2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="anvs_AwardsGrantedIn2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AwardsGrantedIn2021Member" xlink:label="anvs_AwardsGrantedIn2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AwardDateDomain" xlink:to="anvs_AwardsGrantedIn2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PerformanceBasedVestingConditionsMember" xlink:label="anvs_PerformanceBasedVestingConditionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_PerformanceBasedVestingConditionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Income Taxes - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GeneratedIn2017AndPriorMember" xlink:label="anvs_GeneratedIn2017AndPriorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="anvs_GeneratedIn2017AndPriorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" xlink:label="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" xlink:to="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" xlink:to="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" xlink:to="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidResearchAndDevelopmentCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="anvs_PrepaidResearchAndDevelopmentCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="anvs_IncomeFromGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>anvs-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2023 8:46:27 PM-->
<!--Modified on: 3/31/2023 8:46:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well Known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents, Carrying Value</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Security Deposits, and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid assets and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Interest, and Employee-Related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_IncomeFromGrants" xlink:to="anvs_IncomeFromGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_IncomeFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_IncomeFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_IncomeFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic loss per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted loss per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Changes in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options, shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cashless exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cashless exercise of warrants, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business, Going Concern and Management's Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business, Going Concern and Management's Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:to="anvs_NonOperatingIncomeGrantIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" xlink:to="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for the grant income classified as other non-operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income, Grant Income [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:to="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_QuarterlyFinancialDataAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialDataAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restatement of Previously Issued Unaudited Condensed Financial Statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restatement of Previously Issued Unaudited Condensed Financial Statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Income per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xlink:to="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for issuance costs associated with equity issuances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Costs Associated with Equity Issuances [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Costs Associated with Equity Issuances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GrantIncomePolicyTextBlock" xlink:label="anvs_GrantIncomePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GrantIncomePolicyTextBlock" xlink:to="anvs_GrantIncomePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average assumptions used to determine fair value of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of shares excluded from the computation of diluted weighted-average shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of income tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant components of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Restatement of Previously Issued Unaudited Condensed Financial Statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_SecondaryPublicOfferingMember" xlink:label="anvs_SecondaryPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_SecondaryPublicOfferingMember" xlink:to="anvs_SecondaryPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_SecondaryPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secondary sale of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_SecondaryPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secondary Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_UnderwritersWarrantsMember" xlink:to="anvs_UnderwritersWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_UnderwritersWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Underwriters warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_UnderwritersWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NatureOfBusinessAndLiquidityAbstract" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Liquidity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of exercise price to the share offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Exercise Price to the Share Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of exercise price to the share offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC Insured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, Federally insured limit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xlink:to="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the National Institute on Aging of the National Institutes of Health.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NIH</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GrantsReceivableNoticeOfAwardAmount" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GrantsReceivableNoticeOfAwardAmount" xlink:to="anvs_GrantsReceivableNoticeOfAwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of grant awarded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Notice of Award Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice of Award, grant amount</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ProceedsFromGrants" xlink:label="anvs_ProceedsFromGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ProceedsFromGrants" xlink:to="anvs_ProceedsFromGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ProceedsFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ProceedsFromGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xlink:to="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of unreimbursed eligible costs incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unreimbursed Eligible Costs Incurred During the Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unreimbursed, eligible costs incurred under the grant</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GrantAwardRemainingAmountAvailable" xlink:label="anvs_GrantAwardRemainingAmountAvailable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GrantAwardRemainingAmountAvailable" xlink:to="anvs_GrantAwardRemainingAmountAvailable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GrantAwardRemainingAmountAvailable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The remining balance of funds available under a grant award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GrantAwardRemainingAmountAvailable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Award, Remaining Amount Available</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_GrantAwardRemainingAmountAvailable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining funds available</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:to="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research and Development Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid clinical trial expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll and related benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional and clinical fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rental expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_LicenseAgreementTermsAmendedMay2012Member" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_LicenseAgreementTermsAmendedMay2012Member" xlink:to="anvs_LicenseAgreementTermsAmendedMay2012Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terms of the license agreements, as amended May 2012, under research and development arrangements accounted for as a contract to perform research and development for others.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_LicenseAgreementMinimumAnnualCommitment" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_LicenseAgreementMinimumAnnualCommitment" xlink:to="anvs_LicenseAgreementMinimumAnnualCommitment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum amount of annual commitment under the terms of a license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Minimum Annual Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum annual fee</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_CumulativeNumberOfMilestonesAchieved" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CumulativeNumberOfMilestonesAchieved" xlink:to="anvs_CumulativeNumberOfMilestonesAchieved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cumulative number of milestones achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Number of Milestones Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestones achieved</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xlink:to="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of advance notice required to terminate the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Period of Advance Notice of Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for advance notice of termination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Officers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementsAbstract" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreements</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_MaximumAggregateSeverancePayments" xlink:label="anvs_MaximumAggregateSeverancePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_MaximumAggregateSeverancePayments" xlink:to="anvs_MaximumAggregateSeverancePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_MaximumAggregateSeverancePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_MaximumAggregateSeverancePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Aggregate Severance Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_MaximumAggregateSeverancePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate severance payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Information about Litigation Matters [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, New Claims Filed, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new claims filed</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NumberOfVotesForEachShareOfCommonStock" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfVotesForEachShareOfCommonStock" xlink:to="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote for each share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes for Each Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote for each share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant term</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants converted in a noncash (or part noncash) transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Warrants, Number of Warrants Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants converted in a non-cash transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EquityIncentivePlan2019Member" xlink:label="anvs_EquityIncentivePlan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EquityIncentivePlan2019Member" xlink:to="anvs_EquityIncentivePlan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EquityIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Company's 2019 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EquityIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EquityIncentivePlan2018Member" xlink:label="anvs_EquityIncentivePlan2018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EquityIncentivePlan2018Member" xlink:to="anvs_EquityIncentivePlan2018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EquityIncentivePlan2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to the 2018 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EquityIncentivePlan2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of the year (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of the year (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of year (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted-Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of the year (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of year (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AwardsGrantedIn2022Member" xlink:label="anvs_AwardsGrantedIn2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AwardsGrantedIn2022Member" xlink:to="anvs_AwardsGrantedIn2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AwardsGrantedIn2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to awards granted in 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AwardsGrantedIn2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards granted in 2022</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AwardsGrantedIn2021Member" xlink:label="anvs_AwardsGrantedIn2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AwardsGrantedIn2021Member" xlink:to="anvs_AwardsGrantedIn2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AwardsGrantedIn2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to awards granted in 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AwardsGrantedIn2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards granted in 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate vesting of awards under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate Vesting</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One year vesting period of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vests one year from grant date</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two year vesting period of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vests two years from grant date</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Three year vesting period of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vests three years from grant date</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period of equal quarterly installments over two years for award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vests in equal Quarterly installments over two years</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PerformanceBasedVestingConditionsMember" xlink:label="anvs_PerformanceBasedVestingConditionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PerformanceBasedVestingConditionsMember" xlink:to="anvs_PerformanceBasedVestingConditionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PerformanceBasedVestingConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to performance-based vesting conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PerformanceBasedVestingConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance-based vesting conditions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average recognition period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option modification expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" xlink:to="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Numerator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" xlink:to="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Denominator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal and state provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal income tax benefits at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:to="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Capitalized Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xlink:to="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to amortization of research and experimental expenditures (Section 174).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Amortization of Research &amp; Experimental Expenditures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Section 174</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GeneratedIn2017AndPriorMember" xlink:label="anvs_GeneratedIn2017AndPriorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GeneratedIn2017AndPriorMember" xlink:to="anvs_GeneratedIn2017AndPriorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GeneratedIn2017AndPriorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to tax years 2017 and prior.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GeneratedIn2017AndPriorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Generated in 2017 and prior</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized income tax interest and penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period, Error Correction, Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error correction adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Correction, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Correction, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" xlink:label="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" xlink:to="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to timing of accruals for research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Timing Of Accruals For Research And Development Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Timing of accruals for research and development expenses</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member" xlink:to="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to error corrections due to expenses recorded in Q1 of 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Corrections Due to Expenses Recorded in Q1 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Corrections Due to Expenses Recorded in Q1 2022</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member" xlink:to="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to error corrections due to expenses recorded in Q2 of 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Corrections Due to Expenses Recorded in Q2 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Corrections Due to Expenses Recorded in Q2 2022</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member" xlink:to="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to error corrections due to expenses recorded in Q3 of 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Corrections Due to Expenses Recorded in Q3 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Corrections Due to Expenses Recorded in Q3 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Corrections and Prior Period Adjustments Restatement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Data</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidResearchAndDevelopmentCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PrepaidResearchAndDevelopmentCurrent" xlink:to="anvs_PrepaidResearchAndDevelopmentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PrepaidResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PrepaidResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research and Development, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PrepaidResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously Reported [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">As Reported</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period, Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restatement Impacts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The exercise price of options granted during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of shares granted</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>anvs-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2023 8:46:27 PM-->
<!--Modified on: 3/31/2023 8:46:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://annovisbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#StatementBalanceSheets" roleURI="http://annovisbio.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://annovisbio.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#StatementStatementsOfOperations" roleURI="http://annovisbio.com/role/StatementStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#StatementStatementsOfChangesInStockholdersEquity" roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://annovisbio.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureNatureOfBusinessGoingConcernAndManagementSPlans" roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureFairValueMeasurements" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureGrantIncome" roleURI="http://annovisbio.com/role/DisclosureGrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureAccruedExpenses" roleURI="http://annovisbio.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://annovisbio.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockBasedCompensation" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureNetLossPerShare" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureSubsequentEvents" roleURI="http://annovisbio.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureAccruedExpensesTables" roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureNetLossPerShareTables" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails" roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureGrantIncomeDetails" roleURI="http://annovisbio.com/role/DisclosureGrantIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockholdersEquityCommonStockDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersEquityCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockBasedCompensationSummaryOfPlansDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureStockBasedCompensationAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureIncomeTaxesAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails" roleURI="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://annovisbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638158923867243147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638158923867243147" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638158923867243147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638158923867243147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638158923867243147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638158923867243147" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638158923867243147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638158923867243147" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638158923867323149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638158923867323149" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638158923867323149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638158923867323149" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638158923867323149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638158923867323149" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638158923867323149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638158923867323149" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638158923867323149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638158923867323149" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638158923867323149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638158923867323149" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638158923867323149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638158923867323149" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638158923867323149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638158923867323149" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638158923867323149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638158923867323149" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638158923867333151" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638158923867333151" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638158923867333151" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638158923867333151" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638158923867333151" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638158923867333151" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638158923867333151" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638158923867333151" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638158923867333151" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638158923867333151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638158923867333151" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638158923867343147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638158923867343147" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638158923867343147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638158923867343147" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638158923867343147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638158923867343147" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638158923867343147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638158923867343147" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638158923867343147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638158923867343147" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638158923867343147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638158923867343147" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638158923867343147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638158923867343147" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638158923867343147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638158923867343147" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638158923867343147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638158923867343147" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638158923867353149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638158923867353149" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638158923867353149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638158923867353149" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638158923867353149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638158923867353149" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638158923867353149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638158923867353149" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638158923867353149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638158923867353149" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638158923867363152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638158923867363152" xlink:to="us-gaap_AssetsCurrentAbstract_638158923867363152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638158923867363152" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158923867363152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638158923867363152" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923867363152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638158923867363152" xlink:to="us-gaap_AssetsCurrent_638158923867363152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638158923867363152" xlink:to="us-gaap_Assets_638158923867363152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867363152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867363152" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638158923867363152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158923867363152" xlink:to="us-gaap_AccountsPayableCurrent_638158923867363152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158923867363152" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923867363152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158923867363152" xlink:to="us-gaap_LiabilitiesCurrent_638158923867363152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867363152" xlink:to="us-gaap_Liabilities_638158923867363152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638158923867363152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867363152" xlink:to="us-gaap_CommitmentsAndContingencies_638158923867363152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867363152" xlink:to="us-gaap_StockholdersEquityAbstract_638158923867373152" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867373152" xlink:to="us-gaap_PreferredStockValue_638158923867373152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867373152" xlink:to="us-gaap_CommonStockValue_638158923867373152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867373152" xlink:to="us-gaap_AdditionalPaidInCapital_638158923867373152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867373152" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638158923867373152" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867373152" xlink:to="us-gaap_StockholdersEquity_638158923867373152" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867373152" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638158923867373152" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638158923867373152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638158923867373152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638158923867373152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638158923867373152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638158923867383150" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638158923867383150" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638158923867383150" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638158923867383150" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638158923867383150" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638158923867383150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158923867383150" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638158923867383150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158923867383150" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638158923867383150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158923867383150" xlink:to="us-gaap_OperatingExpenses_638158923867383150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638158923867383150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867383150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638158923867383150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867383150" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638158923867383150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants_638158923867393150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867383150" xlink:to="anvs_IncomeFromGrants_638158923867393150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638158923867393150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867383150" xlink:to="us-gaap_NonoperatingIncomeExpense_638158923867393150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158923867393150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158923867393150" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638158923867393150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638158923867393150" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158923867393150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638158923867393150" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638158923867393150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638158923867393150" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638158923867393150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638158923867393150" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638158923867393150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638158923867393150" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638158923867393150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638158923867393150" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638158923867403151" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158923867403151" xlink:to="us-gaap_StatementEquityComponentsAxis_638158923867403151" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158923867403151" xlink:to="us-gaap_CommonStockMember_638158923867403151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158923867403151" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638158923867403151" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158923867403151" xlink:to="us-gaap_RetainedEarningsMember_638158923867403151" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158923867403151" xlink:to="us-gaap_EquityComponentDomain_638158923867403151" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158923867403151" xlink:to="us-gaap_StatementLineItems_638158923867403151" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158923867403151" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" xlink:to="us-gaap_StockholdersEquity_638158923867403151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" xlink:to="us-gaap_SharesIssued_638158923867403151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638158923867403151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638158923867403151" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158923867403151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638158923867403151" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638158923867403151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638158923867403151" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638158923867403151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_638158923867413149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" xlink:to="anvs_StockIssuedDuringPeriodValueWarrantsExercised_638158923867413149" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_638158923867413149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_StockIssuedDuringPeriodValueWarrantsExercised_638158923867413149" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_638158923867413149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638158923867413149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638158923867413149" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158923867413149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" xlink:to="us-gaap_NetIncomeLoss_638158923867413149" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158923867413149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" xlink:to="us-gaap_StockholdersEquity_638158923867413149" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638158923867413149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158923867403151" xlink:to="us-gaap_SharesIssued_638158923867413149" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867413149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867413149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638158923867413149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867413149" xlink:to="us-gaap_ProfitLoss_638158923867413149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158923867413149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867413149" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158923867413149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158923867413149" xlink:to="us-gaap_ShareBasedCompensation_638158923867423149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867413149" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867423149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867423149" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638158923867423149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867423149" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638158923867423149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867423149" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158923867423149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867413149" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923867423149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867423149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867423149" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638158923867423149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867423149" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638158923867423149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867423149" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158923867423149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638158923867423149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158923867423149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158923867423149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158923867433150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158923867433150" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlans" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Business, Going Concern and Management's Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638158923867433150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638158923867433150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638158923867433150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638158923867433150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638158923867433150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638158923867433150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureGrantIncome" xlink:type="extended" xlink:title="10401 - Disclosure - Grant Income" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_OtherNonoperatingIncomeGrantIncomeTextBlock" xlink:label="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_638158923867433150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:to="anvs_OtherNonoperatingIncomeGrantIncomeTextBlock_638158923867433150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10501 - Disclosure - Prepaid Expenses and Other Current Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_638158923867443151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_638158923867443151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638158923867443151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638158923867443151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10701 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638158923867443151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638158923867443151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10801 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638158923867443151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638158923867443151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10901 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638158923867443151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638158923867443151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11001 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638158923867443151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638158923867443151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11101 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638158923867453151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638158923867453151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements" xlink:type="extended" xlink:title="11201 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_638158923867453151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_638158923867453151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11301 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638158923867453151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638158923867453151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_638158923867453151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccounting_638158923867453151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638158923867453151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638158923867453151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638158923867453151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638158923867453151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638158923867463157" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_638158923867463157" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638158923867463157" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_638158923867463157" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GrantIncomePolicyTextBlock" xlink:label="anvs_GrantIncomePolicyTextBlock_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="anvs_GrantIncomePolicyTextBlock_638158923867463157" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638158923867463157" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638158923867463157" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638158923867463157" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638158923867463157" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638158923867463157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638158923867463157" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638158923867473153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638158923867473153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638158923867473153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638158923867473153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638158923867473153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638158923867473153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638158923867473153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638158923867473153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31003 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638158923867473153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638158923867473153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638158923867473153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638158923867473153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31103 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637250510374017182" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638158923867473153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637250510374017182" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638158923867473153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637250510374017182" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638158923867483151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables" xlink:type="extended" xlink:title="31203 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_6" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_638158923867483151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Business, Going Concern and Management's Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTable_638158923867483151" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638158923867483151" xlink:to="us-gaap_StatementEquityComponentsAxis_638158923867483151" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158923867483151" xlink:to="us-gaap_EquityComponentDomain_638158923867483151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638158923867483151" xlink:to="us-gaap_CommonStockMember_638158923867483151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638158923867483151" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638158923867483151" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638158923867483151" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638158923867483151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_SecondaryPublicOfferingMember" xlink:label="anvs_SecondaryPublicOfferingMember_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638158923867483151" xlink:to="anvs_SecondaryPublicOfferingMember_638158923867483151" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638158923867483151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638158923867483151" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638158923867483151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638158923867483151" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638158923867493148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158923867493148" xlink:to="anvs_UnderwritersWarrantsMember_638158923867493148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638158923867483151" xlink:to="us-gaap_ClassOfStockLineItems_638158923867493148" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NatureOfBusinessAndLiquidityAbstract" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638158923867493148" xlink:to="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638158923867493148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158923867493148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="us-gaap_SharePrice_638158923867493148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638158923867493148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638158923867493148" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638158923867493148" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638158923867493148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638158923867493148" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158923867503150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="us-gaap_NetIncomeLoss_638158923867503150" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158923867503150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158923867503150" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_638158923867503150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638158923867493148" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice_638158923867503150" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_638158923867503150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashFDICInsuredAmount_638158923867503150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637538572007802700" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638158923867503150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637538572007802700" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638158923867503150" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638158923867503150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638158923867503150" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638158923867503150" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638158923867503150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638158923867503150" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638158923867503150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638158923867503150" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638158923867513151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638158923867503150" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638158923867513151" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638158923867513151" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638158923867513151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638158923867513151" xlink:to="us-gaap_FairValueInputsLevel1Member_638158923867513151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638158923867503150" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638158923867513151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638158923867513151" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158923867513151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638158923867513151" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638158923867513151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Grant Income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NonOperatingIncomeGrantIncomeAbstract" xlink:label="anvs_NonOperatingIncomeGrantIncomeAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NonOperatingIncomeGrantIncomeAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158923867513151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158923867513151" xlink:to="us-gaap_TypeOfArrangementAxis_638158923867513151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638158923867513151" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158923867513151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember" xlink:label="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_638158923867513151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158923867513151" xlink:to="anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_638158923867513151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158923867513151" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158923867523148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GrantsReceivableNoticeOfAwardAmount" xlink:label="anvs_GrantsReceivableNoticeOfAwardAmount_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158923867523148" xlink:to="anvs_GrantsReceivableNoticeOfAwardAmount_638158923867523148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158923867523148" xlink:to="anvs_IncomeFromGrants_638158923867523148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ProceedsFromGrants" xlink:label="anvs_ProceedsFromGrants_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158923867523148" xlink:to="anvs_ProceedsFromGrants_638158923867523148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158923867523148" xlink:to="us-gaap_GrantsReceivableCurrent_638158923867523148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_UnreimbursedEligibleCostsIncurredDuringPeriod" xlink:label="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158923867523148" xlink:to="anvs_UnreimbursedEligibleCostsIncurredDuringPeriod_638158923867523148" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GrantAwardRemainingAmountAvailable" xlink:label="anvs_GrantAwardRemainingAmountAvailable_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158923867523148" xlink:to="anvs_GrantAwardRemainingAmountAvailable_638158923867523148" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638158923867523148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_638158923867523148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance_638158923867523148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_SecurityDeposit_638158923867523148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923867523148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923867523148" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638158923867533150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638158923867533150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638158923867533150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638158923867533150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923867533150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923867533150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638158923867533150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract_638158923867533150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638158923867533150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638158923867533150" xlink:to="us-gaap_OperatingLeaseExpense_638158923867533150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638158923867533150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_OtherCommitmentsTable_638158923867533150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638158923867533150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638158923867533150" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638158923867533150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638158923867533150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638158923867533150" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638158923867533150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_LicenseAgreementTermsAmendedMay2012Member" xlink:label="anvs_LicenseAgreementTermsAmendedMay2012Member_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638158923867533150" xlink:to="anvs_LicenseAgreementTermsAmendedMay2012Member_638158923867543151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638158923867533150" xlink:to="us-gaap_OtherCommitmentsLineItems_638158923867543151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_LicenseAgreementMinimumAnnualCommitment" xlink:label="anvs_LicenseAgreementMinimumAnnualCommitment_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638158923867543151" xlink:to="anvs_LicenseAgreementMinimumAnnualCommitment_638158923867543151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_CumulativeNumberOfMilestonesAchieved" xlink:label="anvs_CumulativeNumberOfMilestonesAchieved_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638158923867543151" xlink:to="anvs_CumulativeNumberOfMilestonesAchieved_638158923867543151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination" xlink:label="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638158923867543151" xlink:to="anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination_638158923867543151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638158923867543151" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638158923867543151" xlink:to="srt_TitleOfIndividualAxis_638158923867543151" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638158923867543151" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638158923867543151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638158923867543151" xlink:to="srt_ExecutiveOfficerMember_638158923867543151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638158923867543151" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638158923867543151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638158923867543151" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract_638158923867543151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_MaximumAggregateSeverancePayments" xlink:label="anvs_MaximumAggregateSeverancePayments_638158923867543151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementsAbstract_638158923867543151" xlink:to="anvs_MaximumAggregateSeverancePayments_638158923867543151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638158923867543151" xlink:to="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_638158923867553150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_638158923867553150" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_638158923867553150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersEquityCommonStockDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders' Equity- Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_NumberOfVotesForEachShareOfCommonStock" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1" xlink:to="anvs_NumberOfVotesForEachShareOfCommonStock_638158923867553150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stockholders' Equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_4" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638158923867553150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638158923867553150" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638158923867553150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638158923867553150" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638158923867553150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_UnderwritersWarrantsMember" xlink:label="anvs_UnderwritersWarrantsMember_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158923867553150" xlink:to="anvs_UnderwritersWarrantsMember_638158923867553150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638158923867553150" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638158923867553150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638158923867553150" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638158923867553150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158923867553150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638158923867553150" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158923867553150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638158923867553150" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice_638158923867563152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638158923867553150" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638158923867563152" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638158923867553150" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_638158923867563152" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638158923867553150" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638158923867563152" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-Based Compensation - Summary of plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867563152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867563152" xlink:to="us-gaap_PlanNameAxis_638158923867563152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638158923867563152" xlink:to="us-gaap_PlanNameDomain_638158923867563152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EquityIncentivePlan2019Member" xlink:label="anvs_EquityIncentivePlan2019Member_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638158923867563152" xlink:to="anvs_EquityIncentivePlan2019Member_638158923867563152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EquityIncentivePlan2018Member" xlink:label="anvs_EquityIncentivePlan2018Member_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638158923867563152" xlink:to="anvs_EquityIncentivePlan2018Member_638158923867563152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867563152" xlink:to="us-gaap_AwardTypeAxis_638158923867563152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158923867563152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638158923867563152" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158923867563152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158923867563152" xlink:to="us-gaap_EmployeeStockOptionMember_638158923867573151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867563152" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867573151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867573151" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638158923867573151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867573151" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638158923867573151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867573151" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638158923867573151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867573151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867573151" xlink:to="us-gaap_IncomeStatementLocationAxis_638158923867573151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638158923867573151" xlink:to="us-gaap_IncomeStatementLocationDomain_638158923867573151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638158923867573151" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638158923867573151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638158923867573151" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638158923867573151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867573151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867573151" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867573151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638158923867583153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867573151" xlink:to="us-gaap_ShareBasedCompensation_638158923867583153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stock-Based Compensation - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158923867583153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158923867583153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638158923867583153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638158923867583153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158923867583153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158923867583153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638158923867583153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158923867583153" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638158923867583153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638158923867583153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638158923867583153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381589238675831531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381589238675831531" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638158923867583153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638158923867583153" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638158923867583153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638158923867583153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638158923867583153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638158923867583153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638158923867593152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638158923867593152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638158923867593152" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638158923867593152" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638158923867583153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638158923867593152" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_638158923867593152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_638158923867593152" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638158923867593152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_638158923867593152" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638158923867593152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638158923867593152" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638158923867593152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638158923867593152" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867603149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867603149" xlink:to="us-gaap_AwardTypeAxis_638158923867603149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638158923867603149" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158923867603149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158923867603149" xlink:to="us-gaap_EmployeeStockOptionMember_638158923867603149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867603149" xlink:to="us-gaap_AwardDateAxis_638158923867603149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_638158923867603149" xlink:to="us-gaap_AwardDateDomain_638158923867603149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AwardsGrantedIn2022Member" xlink:label="anvs_AwardsGrantedIn2022Member_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638158923867603149" xlink:to="anvs_AwardsGrantedIn2022Member_638158923867603149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AwardsGrantedIn2021Member" xlink:label="anvs_AwardsGrantedIn2021Member_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638158923867603149" xlink:to="anvs_AwardsGrantedIn2021Member_638158923867603149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867603149" xlink:to="us-gaap_VestingAxis_638158923867603149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638158923867603149" xlink:to="us-gaap_VestingDomain_638158923867603149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638158923867603149" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_638158923867603149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_638158923867603149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638158923867603149" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_638158923867603149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638158923867603149" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_638158923867613149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638158923867603149" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember_638158923867613149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638158923867603149" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_638158923867613149" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PerformanceBasedVestingConditionsMember" xlink:label="anvs_PerformanceBasedVestingConditionsMember_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638158923867603149" xlink:to="anvs_PerformanceBasedVestingConditionsMember_638158923867613149" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158923867603149" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638158923867613149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638158923867613149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638158923867613149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158923867613149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638158923867613149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638158923867613149" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638158923867623151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638158923867623151" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638158923867623151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638158923867623151" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638158923867623151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638158923867623151" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638158923867623151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638158923867623151" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_638158923867623151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_638158923867623151" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638158923867623151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158923867613149" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638158923867623151" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638158923867623151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638158923867623151" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638158923867623151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638158923867623151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638158923867623151" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638158923867623151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638158923867633148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638158923867623151" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638158923867633148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638158923867633148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638158923867623151" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638158923867633148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract" xlink:label="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_638158923867633148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_638158923867633148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158923867633148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract_638158923867633148" xlink:to="us-gaap_NetIncomeLoss_638158923867633148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract" xlink:label="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_638158923867633148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_638158923867633148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638158923867633148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_638158923867633148" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638158923867633148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638158923867633148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_638158923867633148" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638158923867633148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638158923867633148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_638158923867633148" xlink:to="us-gaap_EarningsPerShareBasic_638158923867633148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638158923867633148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract_638158923867633148" xlink:to="us-gaap_EarningsPerShareDiluted_638158923867633148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638158923867643150" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638158923867643150" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638158923867643150" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638158923867643150" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638158923867643150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638158923867643150" xlink:to="us-gaap_EmployeeStockOptionMember_638158923867643150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638158923867643150" xlink:to="us-gaap_WarrantMember_638158923867643150" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638158923867643150" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638158923867643150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638158923867643150" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638158923867643150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_638158923867643150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_638158923867643150" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638158923867643150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638158923867643150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_638158923867643150" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638158923867643150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158923867653149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158923867653149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158923867653149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158923867653149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158923867653149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158923867653149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638158923867653149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158923867653149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638158923867653149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158923867653149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638158923867653149" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158923867653149" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158923867653149" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158923867653149" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638158923867653149" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Income Taxes - Deferred taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637251288811670906" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251288811670906" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158923867653149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158923867653149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158923867653149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" xlink:to="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_638158923867663149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" xlink:to="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_638158923867663149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158923867663149" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" xlink:to="us-gaap_DeferredTaxAssetsGross_638158923867663149" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638158923867663149" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638158923867653149" xlink:to="us-gaap_DeferredTaxAssetsNet_638158923867663149" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Income Taxes - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637251306845174076" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251306845174076" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638158923867663149" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638158923867663149" xlink:to="us-gaap_StatementEquityComponentsAxis_638158923867663149" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158923867663149" xlink:to="us-gaap_EquityComponentDomain_638158923867663149" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638158923867663149" xlink:to="us-gaap_CommonStockMember_638158923867663149" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638158923867663149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638158923867663149" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638158923867663149" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638158923867663149" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638158923867673152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638158923867673152" xlink:to="us-gaap_DomesticCountryMember_638158923867673152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638158923867673152" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638158923867673152" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638158923867663149" xlink:to="us-gaap_TaxPeriodAxis_638158923867673152" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis_638158923867673152" xlink:to="us-gaap_TaxPeriodDomain_638158923867673152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_GeneratedIn2017AndPriorMember" xlink:label="anvs_GeneratedIn2017AndPriorMember_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_638158923867673152" xlink:to="anvs_GeneratedIn2017AndPriorMember_638158923867673152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638158923867663149" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638158923867673152" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638158923867673152" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638158923867673152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638158923867673152" xlink:to="us-gaap_ResearchMember_638158923867673152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638158923867663149" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638158923867673152" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638158923867673152" xlink:to="us-gaap_OperatingLossCarryforwards_638158923867673152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638158923867673152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638158923867673152" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638158923867673152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638158923867683153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638158923867673152" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638158923867683153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158923867683153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638158923867673152" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158923867683153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638158923867683153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638158923867673152" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638158923867683153" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638158923867683153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638158923867673152" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638158923867683153" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867683153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_1" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867683153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638158923867683153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867683153" xlink:to="srt_RestatementAxis_638158923867683153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638158923867683153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638158923867683153" xlink:to="srt_RestatementDomain_638158923867683153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638158923867683153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638158923867683153" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638158923867683153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_638158923867683153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867683153" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_638158923867683153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_638158923867683153" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_638158923867693150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember" xlink:label="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain_638158923867693150" xlink:to="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_638158923867693150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_638158923867693150" xlink:to="anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_638158923867693150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_638158923867693150" xlink:to="anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_638158923867693150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member" xlink:label="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_638158923867693150" xlink:to="anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_638158923867693150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867683153" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867693150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidResearchAndDevelopmentCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentCurrent_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867693150" xlink:to="anvs_PrepaidResearchAndDevelopmentCurrent_638158923867693150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867693150" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638158923867693150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867693150" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923867693150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867693150" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923867693150" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867693150" xlink:to="us-gaap_OperatingExpenses_638158923867693150" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158923867693150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867693150" xlink:to="us-gaap_NetIncomeLoss_638158923867693150" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_2" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867703152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867703152" xlink:to="srt_RestatementAxis_638158923867703152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638158923867703152" xlink:to="srt_RestatementDomain_638158923867703152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638158923867703152" xlink:to="srt_ScenarioPreviouslyReportedMember_638158923867703152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638158923867703152" xlink:to="srt_RestatementAdjustmentMember_638158923867703152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867703152" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867703152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867703152" xlink:to="us-gaap_AssetsAbstract_638158923867703152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638158923867703152" xlink:to="us-gaap_AssetsCurrentAbstract_638158923867703152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638158923867703152" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158923867703152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923867703152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638158923867703152" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638158923867703152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638158923867703152" xlink:to="us-gaap_AssetsCurrent_638158923867713152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638158923867703152" xlink:to="us-gaap_Assets_638158923867713152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867703152" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867713152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638158923867713152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158923867713152" xlink:to="us-gaap_AccountsPayableCurrent_638158923867713152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158923867713152" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638158923867713152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158923867713152" xlink:to="us-gaap_LiabilitiesCurrent_638158923867713152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_Liabilities_638158923867713152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_CommitmentsAndContingencies_638158923867713152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_StockholdersEquityAbstract_638158923867713152" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638158923867713152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_PreferredStockValue_638158923867713152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638158923867723151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_CommonStockValue_638158923867723151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638158923867723151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_AdditionalPaidInCapital_638158923867723151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638158923867723151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638158923867723151" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158923867723151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_StockholdersEquity_638158923867723151" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638158923867723151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158923867713152" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638158923867723151" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638158923867723151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_4" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638158923867723151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638158923867723151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_4" xlink:to="us-gaap_PreferredStockSharesAuthorized_638158923867723151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_4" xlink:to="us-gaap_PreferredStockSharesIssued_638158923867733151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_4" xlink:to="us-gaap_PreferredStockSharesOutstanding_638158923867733151" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_4" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638158923867733151" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_4" xlink:to="us-gaap_CommonStockSharesAuthorized_638158923867733151" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_4" xlink:to="us-gaap_CommonStockSharesIssued_638158923867733151" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_4" xlink:to="us-gaap_CommonStockSharesOutstanding_638158923867733151" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_3" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867733151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867733151" xlink:to="srt_RestatementAxis_638158923867733151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638158923867733151" xlink:to="srt_RestatementDomain_638158923867733151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638158923867733151" xlink:to="srt_ScenarioPreviouslyReportedMember_638158923867733151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_638158923867733151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638158923867733151" xlink:to="srt_RestatementAdjustmentMember_638158923867733151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867733151" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_OperatingExpensesAbstract_638158923867743150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158923867743150" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638158923867743150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158923867743150" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638158923867743150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158923867743150" xlink:to="us-gaap_OperatingExpenses_638158923867743150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_OperatingIncomeLoss_638158923867743150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867743150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867743150" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638158923867743150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_IncomeFromGrants" xlink:label="anvs_IncomeFromGrants_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867743150" xlink:to="anvs_IncomeFromGrants_638158923867743150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638158923867743150" xlink:to="us-gaap_NonoperatingIncomeExpense_638158923867743150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158923867743150" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638158923867743150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638158923867743150" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158923867753152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_NetIncomeLoss_638158923867753152" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638158923867753152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_EarningsPerShareBasic_638158923867753152" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638158923867753152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_EarningsPerShareDiluted_638158923867753152" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638158923867753152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638158923867753152" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638158923867753152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867743150" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638158923867753152" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867803150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract_5" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867803150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638158923867803150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867803150" xlink:to="srt_RestatementAxis_638158923867803150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638158923867803150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638158923867803150" xlink:to="srt_RestatementDomain_638158923867803150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638158923867803150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638158923867803150" xlink:to="srt_ScenarioPreviouslyReportedMember_638158923867803150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_638158923867803150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638158923867803150" xlink:to="srt_RestatementAdjustmentMember_638158923867803150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867803150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638158923867803150" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867803150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867803150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867803150" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867803150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867803150" xlink:to="us-gaap_ProfitLoss_638158923867813156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867803150" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158923867813156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158923867813156" xlink:to="us-gaap_ShareBasedCompensation_638158923867813156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867803150" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867813156" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867813156" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638158923867813156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867813156" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638158923867813156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158923867813156" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158923867813156" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638158923867803150" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158923867813156" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867803150" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867813156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867813156" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638158923867813156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867813156" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638158923867813156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158923867813156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638158923867813156" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158923867813156" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638158923867823153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867803150" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638158923867823153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158923867823153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867803150" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158923867823153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381589238678231531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638158923867803150" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381589238678231531" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638158923867823153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638158923867823153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638158923867823153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638158923867823153" xlink:to="us-gaap_SubsequentEventTypeAxis_638158923867823153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638158923867823153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638158923867823153" xlink:to="us-gaap_SubsequentEventTypeDomain_638158923867823153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638158923867823153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638158923867823153" xlink:to="us-gaap_SubsequentEventMember_638158923867823153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638158923867823153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638158923867823153" xlink:to="us-gaap_SubsequentEventLineItems_638158923867823153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158923867833152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158923867823153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158923867833152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20221231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_638158923867833152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158923867823153" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_638158923867833152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>anvs-20221231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %/ E0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSTVP:+S)01#89^Q*K;LJ8MQVLI#<\DU1C_9)^$46K7FIIX'L4O;N42S2+)*
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M#&\4: YRI"2N-PY.<GI5._\ @CX4O[-;?R+VT*W5W=BXLK^:"<-=?\?*>8C
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M3)S*]EU-'[;I8W/!OC6U\:1ZJ(;&^TR\TJ\-A>V.HQJDT,OEI(N=K,I#)(C
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M*W[@MLB!/1!P/SZ_C75_%KQ-_P (EX O)D;;<WKK9PXZY;.XC_@(/YU'\-_
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M;Q@IDG,NW=D#=-J_Q/\ %^I^%?A9>#56AO=6TRPO[Q]+MVB6[N&U+389XRC
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MLX\WSER=\8Z@< ,<[EYS]R7&@:7=3V\TVFV<LUO(LT,C0*6C=59593C@A7<
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MQ7H&<=/4I8Y0=YH\.CD-3'T)2PLU*<?L:\SCW727FEKY'RAX;TW6_B#X@M]
M\+:7=ZYK%P<1VMG'O?']X]E4=V8A1W-?J'^R+^S!#^SWX5N+O59(;[QIJZ+_
M &A<PG=';1@Y6WB8]0"<LW&YO8*!ZO\ #SP%X.\!:%%!X*T/2='TJX19%?2H
M459U(RK%QR^0>I)KJ ,D"L<1BY5URK1'F4,*J7O/<YGQ=K\MH5T^R<K=2KN>
M1>L2'IC_ &CS]!SZ5Y[JUI)8K#<,[;(Y09 S$@JWRDGW&0<^QKK]$7^UM:N[
MV3YM\K,N>P!PH_("IO$^CI/!.C+F.12"/8C!HIVA9"FW+4F\-PP2VHW1J77K
MD5OQV\(Z1)^5>3MXHU+1/#<+V2>=J37<-DR"(2L6,FQBJ%D!;C(RP'-1Z-\:
M;U]7A2\M89[:2VMR8;5MLIED\K)B4Y:7'F?<X("GTYJ5.4M40II:,]?>R@F7
M#1K^ KGM<\.J%WID<Y5EX(/J#V/O7+?\+SM8[>.9](E,;EANAN5E!/E+(J#
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M1?YU<\1_\A+_ (#_ %-5;$?Z;;\?\M%_G5SQ"/\ B8?\!_J:Z8_P7ZHY9/\
M?Q]&95%.Q[48]JYCJN-HIV/:C'M0%QM%.Q[48]J N-KR+X\_ >P^)^CSW]@B
M6'B>WS/#=QQY\Y]JJ3*JC=,PC5E1"P7+<^WK^/:C'X5<).#YHG1A\34PM15J
M+M)'AO[,GQ:O/&6E7OAGQ &C\2Z'^[E260/(44@%7()RZ$J#R3AESR&KU'Q
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M7K'D!1110 4444 %%%% !5>Y^\M6*KW/5:"X;D-%&*,4'0%%&*,4 %%&*,4
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M_HY!8$,,C:Y'T8>#7@7CC]H'X8Z5!:76G:3I?C6SNWN+ZYN-.^R$1FV$4AD
ME*^=,1=*T:IEGW$KG/.OIW[5'A;4)-01['4;1]/O-5M;M;A45HEL4>1IL;LF
M.58VV$=PRG!4@ TSV6BN:^&WCNU^)G@71_$UG:76G1:A"7>QOE"W%K*K%)(9
M0"0'1U9& /5372T%7"BBB@!5&6'UK"\1?\?P_P!W^M;J_>'UK#\0#-\/]W^M
M>?C?X1U8;^*95%.Q1BO T/9&T4[%&*- &T4[%&*- /,]9F_M+XBW"OREI''
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M^U)XJ\0#3+26X"M>64$\XC@87%MY:3L<9R'1\J,$\\\@U\^\4\9*2?;J?I^
M^KXYU<%@L*HIP?+%6<G.Z=W-I2T5W9-1LK6M<^W3-&LZ0F1%F<$I$6 =@.I
MZFGXKX0O/AQ\2OB=X6N_C%=SVWG&$W]J5E=+W[/'_%;JHQ&F S*N[) SU;)^
MA_V4/BYJ7Q:^'UR^L-)=:KI5S]FFOV50MRK#<A^4 ;@.&P/0_P 5>=5P_)'F
M3O;<\K$Y=["A[>%6,TFHR2O[LG>RU5I+1^]&ZNO1OVC%&*?@T8-<5SQ[C,48
MI^#1@T7"X^T'^EP_[X_G5O71_IW_  '_ !JO: _:H?\ ?'\ZM:V,WW_ ?ZFN
MF/\ !?JCFD_WJ]#,Q1BGX-&#7-<Z;C,48I^#1@T7"XS%&*?@T8-%PN,Q7/\
MC_PPGC#P;J^D/D&YMV5'2WBG=6QD%$E!3?V!;@$YXKH\&C!^E-2:=T.,W"2E
M'='SQ^R#XKD;0];\&7Y\O4M#N7/DM/',Z#(616:,E"P;:QVG&9?:OH3%?+7Q
M7LKKX ?&.S^(MG:2-X7NV6"_YMK>"-Y"5$$,:!68D!G9V!^;82< X^D?"OBW
M1_&^DQZEHE]%?VK $E#\\9/\+KU4^Q_#-=5=7M4CL_S/<S6G[22Q]->Y5U=M
ME/[2?9WUL^C-3%&*?BC!KEN>%<9BC%/P:,&E<+C,48I^#1@T7"XS%&*?@T8-
M%PN,Q1BGX-&#1<+DED/],A_WQ79)]Q?I7'V8_P!+A_WA78)]Q?I7M8#X9'D8
MWXD.HHHKU3S0HHHH **** "BBB@ J*89(J6HINHH*CN1X]J,>U&/848]A0:!
MCVHQ[48]A1CV% !CVHQ[48]A1CV% !CVHQ[48]A1CV% $5U9P7UM+;W,,=Q;
MRJ4DAE4.CJ>H8'@CV-?.OQ9_8]L/$VL7OB?PEJESH'B>1KF]9EF8+<W1B1;=
M"W(BB0IT5=V&/(KZ/Q["D+ $ D GH,]:#OP>/Q. J>TP\[/9]FGNFNJ9\CN/
MVF/AG<O;V]U:>,M-BFDCCGO8-S/%';"9I21EU5FW1(I;<S <#/'8?"'XQ_&/
MQKXSMM+U_P"'%AIFD1)!)J6HBX:!K=9H#+'M1V.]ONAE'W22"0:^B:.3_P#K
MH/1K9M3Q%.4:F%I\[5N9)Q:?>T6HW^5K].@8]J,>U&/848]A0?/ACVHQ[48]
MA1CV% !CVHQ[48]A1CV% !CVHQ[48]A1CV%  !R*P]=_X_1]/ZUN@<CZUBZX
M,W8X_A_K7!C?X1TX;^(9=%/V^U&WVKP+'K7&44_;[4;?:BP7&44_;[4;?:BP
M7&44_;[4;?:BP7&5YS\6_@7X>^+.F,EY$+/4X4N'M+R$%5CN9(Q&)Y%4J964
M*,9/;%>D[?:C;[549.#O$VHUZF'J*K1DXR6S1\J'X2?&?X322)X)\4MJ^B1R
M3&&SO=LA$,=N'5F4C&^20-&J(O&5)-26_P ;/CUI5W;6-_\ #O3]1NYI[>U0
M@/$IEFA,P4L&"@*H(=ONJPP3FOJ<889&#]*7!]3^=='MK_%%,]G^UU4_WG#P
MF^]G%^K<7%M][F9X?N=1O-!TZ?6+*+3=6EMT>[LX9O-2"4J"Z*_\0!R,]ZS/
M$GPY\*>,;^VOM>\-:5K5Y;(8X9[^T29T0G)4%@>,]JZ7;[4;?:N=-IW6AX/-
MK=:$,,,=M#'##&D4,:A$CC4*JJ!@  <  <8J.RL+73+?R+.U@LX,EO*MXEC3
M)ZG"@#)JUM]J-OM2)T&44_;[4;?:E8=QE%/V^U&WVHL%Q]I_Q]0_[X_G5G6O
M^/W_ (#_ %J"U7_2H>/XQ_.K.L#-Y_P&NF/\%^I@W^]7H9U%/V^U&WVKFL;W
M&44_;[4;?:BP7&44_;[4;?:BP7&44_;[4;?:BP7*6I:7::O;&"[@CG3!VET!
M,9*E=RDCY6P3@CD9KYOU;]D?4?"FL0:A\-/%%SX<17@A6V:5R(8$B;S7+9W2
MRO($.,HHR>*^G=OM1M]JUA4E3^$[\+C\1@N;V,M);IJZ?JG=/^N[/E2S\9_M
M(^$TM8=0\/V&OEQ:*2\08K).[+Y9=-H)CV@NV2%# Y->J? [XA>//B%:W5[X
MK\(6OAO3-I%G<13GS)Y%D9'#1,2R@;<ACC/&,YKU?[I'.">![TI!)R>3ZFJE
M44E;E1OB<?2Q%-Q^KPC)_:BFK>B3Y=?3_-1T4_;[4;?:L+'DW&44_;[4;?:B
MP7&44_;[4;?:BP7&44_;[4;?:BP7'V?_ !]P_P"\*ZY/N+]*Y2T7%U#Q_$*Z
MM/N+]*]G ?#(\K&?$AU%%%>J>>%%%% !1110 4444 %12]14M12]10-;C***
M*#0**** "BBB@ HHHH *\Z\?:[=:;\5?A9I\+8M]1O-1CG'J$L9'7]0*]%KR
MKXF_\EJ^#/\ U_ZK_P"FZ6@3/5:***!A1110 4444 %%%% !1110 =Q]:QM;
MYNQ]*V1UK(UH9NQ]/ZUP8W^$=.'_ (AFX^E&/I3\"C KP3U+C,?2C'TI^!1@
M4!<9CZ48^E/P*,"@+C,?2C'TI^!1@4!<9CZ4Z)=TJ#U(%+@4^ #SH_\ >'\Z
M!-Z'GWP0UVZ\2_#6PU&\(:XDO-1C)]H[ZXC7_P =05W>/I7FO[-PS\'],_["
M&J_^G.ZKTW K2I;G9%-^ZAF/I1CZ4_ HP*S-+C,?2C'TI^!1@4!<9CZ48^E/
MP*,"@+C,?2C'TI^!1@4!<=:C_28O]\?SJQK _P!,_"H;8?Z1%_O#^=6-6'^E
MCZ5T1_@OU1@W^]7H4,?2C'TI^!1@5SF]QF/I1CZ4_ HP* N,Q]*,?2GX%&!0
M%QF/I1CZ4_ HP* N,Q]*,?2GX%&!0%SA/'&MW.F?$'X9V$) @U/4;Z&<>JII
M\\B_^/(*[C'TKSGXDC'Q5^#O_87U'_TU7->DX%:2VCZ?J90>LAF/I1CZ4_ H
MP*S-;C,?2C'TI^!1@4!<9CZ48^E/P*,"@+C,?2C'TI^!1@4!<=:#_2HO]X5U
M2?<7Z5S%J/\ 28O]X5TZ?<7Z5[& VD>9B]T.HHHKU3@"BBB@ HHHH **** "
MHY1DBI*9)U% UN1[:-M+107<3;1MI:* N)MHVUCWGC7P[IUS?6]WK^EVMQ8"
M$W<,U[&CVXE8+#Y@+93>Q 7.-Q( S6U0*XW;1MIV#1B@+C=M>(?&7X:?$;Q9
M\;_A%X@\*>(K33/"VA7ES)KEM/:QR2A&A9=T189)D4M$1_#N#CH:]OC=94#Q
ML)$89#*<@CZU6TK5K'7;&.]TV]M]0LI"P2YM)5EC8JQ5L,I(.&!!]""* W+)
M&3Z4;:/,4R&/<OF ;BF><>N*=@^E 7&[:-M.P:I:7K.GZY%-+IM_;:A%!,]M
M*]I,LJQRH=KQL5)PRD8*GD'K0%RWMHVU4FUO3K>^M+*6_M8[R[9UM[=YU$DQ
M09<(N<L5')QT'6KN#Z4!<;MHVTM% [B;:-M+10%Q O-9&LC-T/I_6MD=:R-7
M7_21]*X,9_".C#OWS.Q1BG[:-OO7A'IW&8HQ69I7BW0==^Q_V9KFF:E]MCDF
MM?L=Y'-]HCC8)(\>UCN56(5B,@$@'!K7V4]A*2>Q'BC%2;:;N7S-F]=^-VS/
M./7'I2"XW%&*DV$G SGI573M2LM8MOM.GWEO?VV]X_.M95E3<K%77<I(RK @
MCL00:87)L5#>P3SV=Q%;71L;EXV6*Z$8D,+D':^T\-M.#@\'&*M;:-AI7!NZ
ML>/?LL^ ?'7PX^$L&C_$/5K/5?$ U"]N!]@A1(88I+AY%4%0-Q8LTAST\S;_
M  UZ[BG(5DW;75]IVG:<X/H?>J]GJ-GJ,UW%:WEO=2VDOD7,<$JNT$F VQP#
M\K893@X."#WJY2YFY,F-HI(FQ1BG%E5E4NH9ONJ3@GUP.].V5!5R/%&*DVU4
MMM4L;V_O;&VO;:XO;(H+JVBE5I;<NNY!(H.4W+R,XR.10',3XHQ4%_JMAI2*
MU[?VMDK21PJ;B98P9'.V-!DCYF/"CJ3P,U;V&F',1XHQ3]M&VD.XZV'^D1?[
MP_G5C5AF[S[5#;K_ *1'_O#^=6-4&;K\*Z%_!?JC!O\ >+T*&*,4_;1MKG-[
MC,48I^VC;0%QF*,5E1^,?#\KR*FO:6[1WPTQPM[&2MX>EL?FXE/_ #S^][5L
M[*>PE)/8CQ1BI-AI&PBEF8*H&2S< "D%QF*,4D]Q#;6LES--'%;1H9'F=@J(
M@&2Q8\  <YZ8I+.Z@U"T@NK6>*ZM9T66*>%P\<B,,JRL.""#D$<&@.9'CWQ;
M^'OQ!\4?&;X3:YX9\06FF^%-#O+F?6[:>VCDFPT#QAHBPR3(KO$1_#D..17L
MF*52K,RJZLRXW*#DKGID=J=L-6Y7278F*2;:ZD>*,5)LJII6J6.O:?#?Z9?6
MVI6,V?+NK.998GP2IVNI(."".#U!%05<GQ1BJZ:K82:BNGI?6KW[0FX6U693
M*T0;:9 F<E0WR[L8SQUJYL- <R9'BC%/VT;:!W&8HQ3]M&V@+CK48N8O]X5T
MZ_='TKF[88N8O]X5TB_='TKV,#M(\[%;H6BBBO4.$**** "BBB@ HHHH *8X
MR13Z8PR:!H;@T8-+@48%!0F#1@TN!1@4 ? '[27[,?Q'\:?'/Q_XP\.:+/<V
M.HZAX8LI(?.C":EIL3Q37+*"XP\$]M WS8)4OC->J_ KPK\;-.^.#7GBV?7!
MI"_VP->N-2U..XTK4"]V&TO^S+=7+0".#(?*IZ-N/-?56*,4$V/S'^'B_M$?
M$OX,2:[X-U7QU<W%UI-_;W.I7^N1.E[=+K*+:MIZM)NB:*".X$C,$#+\IW9&
M?9?$?PB^-LWQ0N="L]7\6WGA\WL=M;ZW<^(%_LU_#_\ 9K130SQ[Q(U^UR=W
MG;-V2&#A5Q7VC'#'"@6-%1!T51@"GXH"Q\!?"CX6?M >$Y?@)HUG'K_AGPIH
M6FV=MK-K/?I=;+N*[?[<)T6XVO;S0;!#]\1K]U$:LKPA\)/VBM \/++:R>*]
M)O-(CT^;3=*M=6B2TFF;Q#=M=B6$/LD'V"1&(. 1MZLH _1+%&*!V/BO]HGX
M2?%&/XN?%KQ5\/['Q&=2U[P9IUGHFJ:5JZQ107D%X?.B,;2KM8Q,&0[2O^MY
M!<YYOXL>"?VCM-^(GB*P\#+XP?PW;Z#J&E6>H3Z^+G^T&_LS-I=;GG'EW!NQ
MC*1(0>2[!L#[WP*,"@+'P?XK\!?M#:):ZGI^B7?C;7K:T\1V%[IEO=:PH_M&
M%].A^UPW%XL\4T$*W1E*[=R@K@HRXKF]<^&_[1'A*R>U\%^&M;TJ9_&6MZ^+
MO3-614E6;5HY$CFA\](WC>V\Q@[K(>J[%)W#]%<48H"Q^=MO^S]\;O"E_<VO
M@O3-5TS5[;7?&MY:ZOJ.IQ7%J?MD .G31%Y&*;MQ4Y4'S,LX(YKJ],^&7QRU
MZ\TNQ:^^('A_P3<Z],XAO/$B/K5K:#1W5S/<I*^8WOPIC7<Q4$G" C'W-BC%
M 6. ^ 2>+4^"?@=/'@F'C--(MTU?[2R-*;D(!(7*DJ6R.2.IKOL&EP*,"@8F
M#1@TN!1@4 )C!K)U89N1]/ZUKXK*U3_CX'T_K7#C/X1O0^,H8-(RDHP]5(_2
MI,48KPCT;GYI_#C]F+X^?##0M,7PKITVFWL?@6^^R^==1+)IFK75U:_:[5&W
M$*TD5L9(V'RAY6Y'6N_U#PM^TCI7@6(V<?BS6KJ]T/Q%IUO:1ZBEO=:5<3-"
M^GR3-+<LTOE[9U27>T@#*#BONW%&*Z77;=VD8*DELSXQ_P"%=_&^/PSKNHWM
M]XVO6N/&J"[T73]<2&[D\/)#G_0&+@1.T[Y;YU9DC*@@=>2?X+?M!:=J(\12
MC7+WQOJ'@.PTRXU;3]:B0QS0ZB[W-LY+A?M#V3*J2!2GG;VRI.ZOOO%&*2K/
ML@]DNY\*W'@O]H%+SP_)9P^/%T"+7+F>\L9_$$1OSX=:[M3#9O)YC;KX;;B3
M>'W" F,R$L!71_";P)\6_#&N^ X/$VF>)F\(PW>L2SV6@ZC%;O!?2ZO)+;7%
M\HD4RVIM67Y5+8).Y"37V/BJM]JMCI9MQ>WMM9&X?RH?M,RQ^:_]U=Q&X^PY
MINLY:<J#V:6K9\:65U\4_%W[3OCJ#PUJ'B>72]"\9?9[J675%&C0:6=)5I+4
M6Y?<9VFDB9&5<+R=RX;.'_PK']I+2_"7@-+36/&5_KLN@V\LDL^O1;--UXW<
M9N&U ,P\VT%JNU8U\P9\SC<X:ON]8E3+JBKO^8LHQN]\]Z=1[:VT4+V=UN?G
MUK_P7^/7A&/Q5IO@N#Q)I]A>^--;U.XO;'5_,>YAN%4Z=<P+]H1BL;>9YL;%
M=S>7O#JO&MXI^$OQ]NM=\3_V?=>)-.2]U+6]0:_T&_CL?MDHT*U6Q8@/D*]]
M$ZA3TY!(4Y/T3\5?VJO"7PG\3MH-U9ZGK5]##YMV=*2-TM&/*12,SKAV'S;1
MD@8)ZBNI^$GQL\+_ !JTJ[O?#EQ,'LY!'<V5X@CN(LC*L5#$%6YPP)&01U!%
M:N511YG'0[)9?B(4%B94Y*G+:5GROT>QXA\6OAG\0O%.O_ ?Q<FG:S>:WHNA
MZC:ZV-,U%;:2TO[C3T6.5T$BJR^>K!]I/&!@BN%M_!/[0^@7'P52R'BZ^GM(
M-)O?$^I7NN"Y62:2X U*UGB:94"1Q'Y2$E)'W64J2?N;%&*Q59I6L<OL_,^$
M/#WP^_:*TWP3XAMK[5_'1O=5\*[]_P!NAO)[;54UB4)% &F0QJ]B(]Y1P=K$
MAMX JKK?PS^.<,WC.^TWPCK6DZIXHDT$W%[I&NEKBU>WT5HI")!<Q/<!;G:C
M&23 /SD2 <_?.*,4_;OLA>R\S\_['X(?&2;Q2GB#6-#UZ]\0ZW!X'N]0OO[1
MB:WCFLYD&II-#Y@ D4?.I52,>9M(+D&Y?> OVFY=)UJ.*[\6PZO)$L>JW7]M
MPM#>W9UB%XYM*0/_ */$EB)@P(0$$*59@2?O3%&*/;OL@]EYGEO[.^B^,/#O
M@O6=*\97&I7EQ9^(M4ATNZU>Y%Q=3:6+AOL;O*"2Y,9'+?-Z@5Z?@T_%&*YV
M^9W-HKE5A;<'SX_]X5/J8_TH_2HK?B>/_>%3ZES<GZ5NOX+]49M_O$4L&C!I
M^*,5SFUQF#2@'(IV*,4"N?G_ #_LO?$[3/BTGBG1M)E73]8^*D^LZO9W$L;)
M';P7;RZ=J:KN^[LEF1U'S$%/ER*])^!^@_&;PQ9^+[[QO<^(K:SA\&RK?/KV
MJQWGVG7U:5GN]/$;-Y-OY6T!<(,[<*"I)^M\4A7(((R#U!%=+KMJS1A[)+9G
MY]?"C0_CI\1OA'X>U*SU?QU;Z-KO_"*2S7UUKL;W[@L_]JWEJ^\F*W:!X\(W
M)9<[,@YZ/Q3\&_CMXN?XD>';FY\07&GZAH_B*R>XO];1M-U%'5!HD=G&'W12
M*%(F9E7=EPY?=7W"D:QJ%10B@8"J, #V%.Q1[=WND@]EW9\%:;\.?VA'U9[2
M.+Q+I?A=?#3V=AIUY?+=J8O[)>(V=P/M!19S=_,LI5V^X X3(&UX"^''QXT+
MQ/X3OY;CQ/:V&FZGX3LI-)_M*/\ L_\ LT:4L>KEX VT[)U )'(;)0'))^V\
M48I>V?9![+S/BKQK\$/B<GQX\=W7AT>+-*T;Q7XP\/WDVO:+K0B1=(6U,5\H
M4R91T<<?(<)MV],5S'BKPG^TW>^)O&IT6T\6Z-IE]%)#;P1:VLZQR1ZM:F&:
MWFDN&(+V?GD[4B7&Y"K$9/WYBC%-5WIH@]EYGQYX>\(_''0/B'X5MI)/%>N^
M&]*\;:G%MU+5%$,VAN\1M[JYN%F$DKQCS=D3HX<$J0I -<!\-OAC\??!@^#/
MA^Q\/Z]X?T+29HHM:>TU5?L\EK/J%X;M9H1.$1DBEB<,L<CG((9"F#^@6*,4
MO;/LOZ_X</9>9^=7P]^ WQV\!^$+#3=!TC7=&U+3?"=UI=S.^JPL\\QUR&:1
M+.9I&\MI+,2F,G:%8L3M8YKHM?\ AQ^T9J&CWS:9J'C?3+2WL=?N_#UD^NQM
MJ$3^=:MI=M?2>8PF?BY.&9L(0K/U!^\\48JOK$F[V0>R2ZE73S</I]HUTNVZ
M,*&8<#$FT;AQ[YJ?!I^*,5RFXS!HP:?BC% [BVP_TB/_ 'A71K]T?2N?MQ^_
MC_WJZ!?NCZ5Z^!^%GGXEZH6BBBO4.,**** "BBB@ HHHH *:W6G4UJ $HHHH
M*N%%%% 7"BBB@+A1110%PHHHH"X4444!<**** N%%%% 7"BBB@+A1110%PK*
MU,?Z0/I6L*R]1_UX^E<.,_A&]%^^4L48I]%>$=XS%&*?10 S%&*?10 U%#,%
MZ9.*_-+XJ>+[3XA>._$^J^(@NHW<.I3VMI;SNSQ64$;F-%A4XV@[-S' RQ.:
M_2^OE/\ :/\ V.-0^(WBT^)/!-]I^F7-\P.J6%\7CBDDR<W*.H;#$8W)@!B-
MV<YSVX:<8-WT/LN%,?@,OS%5<Q7N--7M?E>FME=ZVMIW[7/)?V,?B3>>'OC&
MGAJW>YN]$UU3 UJ6,BV[I&[QRJ,X4#:RL1U5AG[HK[\O8Y9+*Y2 E9VB=8R#
MM(8J=O/;G'-?.'PJ^!OA+]D[0KGQOXVUZVN=:BB:'[9'&5AA#<>7;QXWR2N
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@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>anvs-20221231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %L H<# 2(  A$! Q$!_\0
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MK'[/WC*;7A#J?B;PUXI06EOIQG>8V6L -]GCBW$^7#<<(0/E5T!XW&M#Q_\
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M^[VJ0&49!Y]Q7/3KPG.48.[6A5U?1FKX>\3ZO?VL<6HM)J<-LHMX\7/E11,
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MFOB58+;Q7XT\2^+M'CE6=M(U V=O:SNO*^<+6VA:5 >?+=BA(&Y3@8ZCQOX
MT3XA:4+'6K3SU0EH9D8I+ Q&-R,.AZ'!R#@9!KHJ*QK4:>(INE6BI1>Z>J9<
M)RIR4H.S1YQ8? O1HM5M;_5M6UWQ/+:$M;1ZWJ!G2!\@[U "\_*.N1[9 QT'
M@SX?:?X(NM9NK6XN[R[U:Y^U74]XZLY;G &U5PHR<#WKIZ*XJ.68/#S52E22
MDM;];M6WZZ::]-#:>(JS3C*6AQL/PIT./6?$M\WVB:'Q#&([_3Y''V=R!C>
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M-<3,3D,7 '*G!''!&>N<PVGP:TNVN?"T\FJ:K=R>'-PLC<2QG*G&$?$8R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX/_;VUNPM/BKI-GJOAJUU
MK3FT.*22:5%WK^_N/E#<-CC. >YK[PK\Z/\ @HSXFN=*^.'A^T@,:1_\(['/
M-++@!%^T7 R">_![5Q8Q7I6-J23E9GSGK_PZ\":ZD+6=CJ&AN[J46UD6>(#J
M?E8AAZ'DU-#\(Y/#UX-6T/P[8:Q8>5Y(A2Y:=58D_O&4[6#=.@QUKS?XB?M
MQ.WV'1[;3M2E#A8YD7/3H3@8X]NM06GQ6^('AV&S\0RV9M]%@95\L#:6XY;/
M7/-?.U<*ZJY9[>IM*E3EL)XA\/P6SZMJ;?8(KFWD(6WTY69+=Y#\JJV"%8XQ
MDFL@>'+J[>"YF+VYN1\RK&K8;N05Z] #GGDUZ'X>TRT^,IN]5T_6K.S:]N ;
MS3=SQN4!ZD#Y6)ZG/3%>K:G\)[*Y\"+HFA6EK/=M"K17,^H@RH=X.,$J 20>
M<4H4:\$H--_Y'FN*4K'S%IEP^FZR\\MO:W>TJ2MU")&?;P  2,G)Z#TY&*VI
M=9O+E1J&EM-<RVZEI9+B&-UB) #1JH&U1Z'H.PS7?P_LO>+[[4+6T35M(B!D
M5FCFO$<@@YW'!)Y [5MZK^RG<:$;BY_X3[1I?,V^8D\,F%<YW*K8.5P>_4_2
MM_JTI:SCH9R2O=G@]@E_XEU<R0[Y;L3!YKU@,Q*H&%4# "\<UZ5JDUQX9TUY
M[H0NERF6C2((&<8+ \CDX )'7'2O0] ^"$7AW1;V2RUBQO)8(O,82,Z;N0&?
M>1A<#/2N;T;X!>)/BCJKOI^HZ==V=B0LKS3B3RG9B$&%SGIZ?RKBJ82K6:@X
M6CZ=.PE%3>IR^K^,]5L4$%TTFE1/&T8M(G ,LNTCYCU'L#T_&HO"_A*TT>U@
M\2ZU>F\N[E$>VL[I06B&XA6;.1N/7'^SZUUGQ ^!#_#[Q'OUW5XKV\(^UO!"
M[?OI@%"E4Z!!DGWQ7#-IFN:]JFC21SMY=[=I##YZYE.<EB0>@.2<C/7M4XK"
M.G2LGRI[]WY&_*H^\M#V:/2H_$=XEW>7J6,-M:B^.Z78B-C]U'CU(QP?6N6O
M;.&:\=F^S!?+20(C+L4LN>0!S]TG\16[X]-K_P (%=Q6T5T^AVL26<%S#+M>
M\O"_[UVX.Z-<;0O3*UQ5XEQIRPV=\TAA,4>Q(X@"I;8%) /S;<<9ZYKBI1A!
MIP1M3FI:G9GP[-=:?NA@D,J#8TD#8,RAR-Y^IQZ]!16"/$EAI5Q:Z9HD%QJE
MR8)0L<Z=,R(Y8JN<$@?J:*[%&I4]Z.QU*<NC/&KGQ!X3GL!;_;_*O, B>&%H
MXV8\%23U'OQBIM&L+G3-?^SZ?*T,[!9D(8J&7'#*<_-S7E6K:;*$B>:-UF3"
M2PL<,C?2O0_">IVLNF6VG7;2?:[1?-ANX1\T9S]WW%>C*G%1;.RE-N=^J/M#
MX"_'$^++<:%XAD,>JHRQV[NIS/QT8@8SP<$]:]TAL( !MBY)R&[U^>5AXH:\
MEL)+2^,6I12 3N!M; Y5U(Z8->SV/[4'B3P(MJ-5MK;Q-H9./[33<DJC/(9N
M02/IS583$V7)5^3-,30O[U,]E^(?P@TKQ!OO0D\-V,EF@; 8$<Y7O^'-7OAU
MX9M-"T6"*S\P11J03)GYB?8]*T?AY\2]'^*?A\ZMH<ADMUD\J2.7&Y&QT.#7
M6! L&U$4>PKTE2I.7M((\]RG;ED?#_QYGN;3Q9K,Z ^:MR0991A$0CC&.H/K
M7COB2=]8DTKSGL1&FT,T"A7 &<#/7UKZU^.OPTNM>E$MHA$TC[=HZ2'LIXKR
M6Y_9=U?PS<QZG>W-O>"V$EPZ%RBJ-HPI'/3!Z#GUKR.1P;9W*2DDCRZWUVVM
M]39;@I&DA_<^6,@*./F_SS6=>:J[NUO(S6U[(/,4IW7/;N,BNQO/AM>:@5U6
MVTRZ-M)EDN+>,LKGH2" >.#7-0:?HW]HQW$]^CRQ,8UC+@$?[/;-<7[I>]RO
M[CJO-Z<R*#^.DT9EM;=/.8CYYG0N!GM@U8TOXV:GI5I<0#389M.>3?MEC(YZ
M'YASV_"NFU7P_9?N&$:CS$W%,9V^YK#FTJ#3WBC,1N%4%U@6/>2N,=!65.M1
MO91U+J4JK7Q:&/;>*=&O;V2[M]-%S,YR+>ZG;;"Y_C !Y_&OIW]@K7[:X_:K
M\"P16$,$DWVX-(K$MQ83G\OK7A,%AHMN8I+JSA,CQ_*#&(U1>^>GZU]'_L-Z
M=H47[3W@>6RL8DNL7CK<PR94@V%P",>O-53K4I8FFG%[JWWBG"<:,M5L_P C
M]8J**P9/&5E%(R&*XRI(.%7_ !K[IM+<^9-ZBN?_ .$VL?\ GE<?]\K_ /%4
M?\)M8_\ /*X_[Y7_ .*I<R'9G045S_\ PFUC_P \KC_OE?\ XJC_ (3:Q_YY
M7'_?*_\ Q5',@LSH**Y__A-K'_GE<?\ ?*__ !5'_";6/_/*X_[Y7_XJCF06
M9T%%<_\ \)M8_P#/*X_[Y7_XJC_A-K'_ )Y7'_?*_P#Q5',@LSH**Y__ (3:
MQ_YY7'_?*_\ Q5'_  FUC_SRN/\ OE?_ (JCF069T%%<_P#\)M8_\\KC_OE?
M_BJ/^$VL?^>5Q_WRO_Q5',@LSH**Y_\ X3:Q_P">5Q_WRO\ \51_PFUC_P \
MKC_OE?\ XJCF069T%%<__P )M8_\\KC_ +Y7_P"*H_X3:Q_YY7'_ 'RO_P 5
M1S(+,Z"BN?\ ^$VL?^>5Q_WRO_Q5'_";6/\ SRN/^^5_^*HYD%F=!17/_P#"
M;6/_ #RN/^^5_P#BJ/\ A-K'_GE<?]\K_P#%4<R"S.@HKG_^$VL?^>5Q_P!\
MK_\ %4?\)M8_\\KC_OE?_BJ.9!9G045S_P#PFUC_ ,\KC_OE?_BJ/^$VL?\
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MY&(]F &2.*^NX8EBC4!MP]<YS7YFZ!XD?5[RYCEO#=1Q\J\K'> !C R?RK]
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M_P!ARU\K]ISP48K:.TB O2Z0KM#'[%.,D5XW;06XLA.(Q(DS;B"W#''0]_\
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M9JUUO?R.8T/7H/ ?Q!^,^JZCJ>KW6E>&(;.:TL[S6+J>)!+:>:Z*DDC*2[X
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MT7T,)"[3N8COG(Z8KR\30E*\EN=-*:C9'R?KT.E&*2-3BTP?,B'6/'!=6&>
M>,'!Y%<W8Z-I"ZHT5FT\D4R[;EI!GW#(<\_I5S3YX9;AO*<'*E92%/.>2OY\
M5?T-/*NTGO$6.8R^6"JG:% ZXZ\#M7AM-)M;_F>JK7)+^Z;3%_LRZ8V<B-&X
M+I\WED?>&"<XZ\9QFO<_V*=1AN?VL? RV#I-:A+R.65<MEA87!Z].:^>?'6D
M:UXPL;>\72=1@AM6$27LD6SCG:1WQCO7I?\ P3TL-9\.?MA>![&X<_99C?\
MFHYSR-/N2"/?@5TX>A#VD)=;K3YF56K+DDNEC]GJ^:OBSI3ZWXOT*QCM;6[D
MFBU!%2\8K&I*)ALA6.1U''4=1UKZ5KRF_L[>;4_M$D$;SPNXBE9 6CW?>VGJ
M,X&<=<5[>:8-8_#_ %=NR;BWZ*2;^](\G#5?8U.?R?XIH\)UVP;3/%#Z?.4E
MF5-+M#K<AQ):.#GS%XS\VPC.X=1DFNVTW3M-\0:WXI/B..&YN+6=DCCNS\MO
M:; 5=,_<S\Q+CG(Z\5VESHNG7AN#<6%M.;@*LWF0JWFA3E0V1R!VSTIE_P"'
M]+U5HFO=-M+QHAMC-Q KE!Z#(XKYFCD4J$Y234HN3?*]K>_9/>]N:]W=WNMK
M6]&>-4XI6:=K77R_RV_X-_*I(/[<T3P-<:K E[++JGD+/=1AY)[?+[-Y(R01
M@\]>O>KVC:8#;^-+L:5I[".\U!!?LV+F/Y#\JCR^G./OCJ>/7U"YL;:\:%I[
M>*=H7$D1D0,8V'1EST/N*ICPQHXNY+H:38BZDW;Y_LR;VW ALMC)R"<^N30L
MBG":FI)O2[:U=HJ-]GU5^_GU#ZZFFK6_X>_E_70\:T>ZO](U/2=8L0TR:?H-
MK)=6J]9H"S!\>Z\,/]VF?93_ ,(1X<U4?9]3M[&WF>ZTF63:_DM,V9H^<JP(
M W#D8'7D5[?;Z186C!H+*WA81" &.)5/ECHG ^Z/3I4#^&-'DCMHVTFQ:.VS
MY"FV0B+)R=HQ\O//%<*X:JQ@X>U3NGIT4G*#OUT]U7BU9V\V;?VA%M/EZ_A9
MZ?CON7;29;BUAE0,$D164/UP1D9]ZEHHK[Y*RLSQ&%%%%,04444 %%%% !11
M10 4444 %%%% !1110 4444 ='X>_P"07<?]=E_D:\(_:4\*:AXP^)7PSLM'
MO6T_6X8-6O-/N5/"W$26\D8;_98KM/LQKW?P]_R"[C_KLO\ (U=KW<NQ,L)-
M5HJ[2?XIK]=NIXV8X:.,INC)V3:?W-/]-^FY\0Z5XFO+O0](US49+3PKJ+_$
M^XGNFU1"8+&;[*N\2 NAVJV1RZ].HKT;XA^)+2P\7OKVJZ]I=Y8:GX U+3[;
M6+(>597ESYZL(HLR2#<5'"[V)(./2OIBBO<GFL9S4O9V2OI?H_.USPH91*$'
M'VMV[:VZKRYK:_UV/B7X@V/B+PGI'A.RL[-3>P?#22WU.UNK=FEBMW:-+D*F
MY<21JS'YN/D.17K'A+4_#?@GXGOK&LZG"GAN[\/:=:^%-?U*55MQ!'&WGQ><
MV%21SL<@X+ 'TQ7T%14U<U]M3]G*'=.SMN[]O+[FUUTNEE/L:GM(S[-)J]K*
MW?S^])]-?D3Q59S0_ 3QK=VUN]EX7O\ Q9!=Z%;O$8A]E>XA/F1H0"L;MN91
M@<'(&"*])T[6-'\ _%GXB7OC^[LM-_M5(6TN_P!2 2&YL$B >WB=N&*L?GB'
MS$L&P<@U[E16<\R52+A*&COL]=>7K;?W=7UOT-(98Z<E.,]5;=::<W2^WO:+
MI9;GR;>VL\/P(T_PZ+"[MM>UGQ'+-X(L)6,5S9()_,@F.>8UB0LQ)'"L!QD8
MQ-/FCDT_X4:#I,;Z;XLTO6-2L]3AN90\ZZD8&W3.V,L'8APQSQ@9.VOLVBMX
MYO9-.GNV]^K37;:S];W=];&$LFNTU4V48[=$T^^]UZ)65M+GSW\+/%'PZTGX
M4Z%X4\2PV)UR*5(=0\/7MB;F^?4,Y>0VP5I')/S"0*1@@Y]-[]HF.\EUGX7)
M83P6UZ?$\0BFN83-&C>3+@L@="P]@P^M>S45Q/&I5_;J+O[SLW=7:Z:?YW.Y
M8%_5_J\I*WNI-*SM%]=?RM8^+OBEX+U+X5W0\.Z%*FJ6]IX#NTU6:XMMTCVL
MVH*;J2%%8!&4R,ZAB0JH1R0#7J?A/5/#W@;XIWFK:[J4%OH-]H.G0>%M=U.5
M4@:U2+][$LS8579BDA7@L.<8%>_45TU,U=:G[.I&]T[N]F[M.^W=?<VCEIY2
MJ-7VE.5DFFDU=*R:MOV?WI,^1?%%G/;_  $URXAMI++PY>^-8[O0;:2(Q!;%
M[F,JR1G!CC=_,=5*CALXPPKO/#/B'^ROVDOB/9?\)/H.C_:[W2E_L[4HMUU>
M_P"AQC; ?/3!YQ]Q^2..Q]^HJ99GSPG!P^*_7NX/JG=^[KWO?0J.5\DX3C/X
M;=.RFNC5E[VBZ)6U/A+PMX8U;Q19?"F/P_=?8_$-E8:W?Z;(2 AGBU!V5'SQ
MM<90YXPW-7[6_@\0_#.Y\33:Y'X*\5IXLUC4].AU)2+61V56GM)F9=H+(Q0*
MWWOF7!R<?;U%=LL\<G=T^K>_=R;6JU3O;;OWTXHY"H*RJ=$MNRBD]&K-<M]^
MW;7F?AEJ4NK_  [\-7D^DIH4LVGP,VFQ1>4EM\@^14_A4=E[# KIJ**^:G)3
MFY)6N?3TXN$%%N]D%%%%9F@4444 %6]+_P"/Q?H:J5;TO_C\7Z&IELRH[HVZ
M_''_ (+'6UQ-^T]X89(7>W7P?;;G5>%/VV]ZFOV.K\?_ /@L(;RZ_:4\,6=E
M \CMX2MF8HQQ@WMX!N'ID5Q2O;0ZF?"&BV,\ESY4$3@* SRL,+'GN?:O28O#
MUA9&QFU6 F!U5C(^XA\,<@ =<@9SZ5%X*L8=!TN:*^=&FN3B:5@67 (&W'?B
MK$VMW!OS:W$CM81&3RQ*1M("LV<$<=1^=<LU*,DQ7+6O>$]!CM'NX+FYBE=U
M"6\8V[F);! [\!3CZU=?0)K4^#+9&:2#S))\*P/&]<;@.^>>:K6S0ZC:0SWT
MIE:W4%#&VU 203\W<X'UKN_A_P"#Y?''B;PAX=\/HMSJEQ=RFUAE^1)1C)^]
MU. >O>NBG!VOT'*6J1W/Q+:)/BQ,Y0;TLXMQ #,PV@ #\<<].M>O>!K]1XIU
MM> 7TJ$D \'&VO)_V@O!?B'PE\5I$U33+O1P(HP)9HRB3C@81^0S$C& :[+P
M5=2KXFO2Y(W:,H^?@\$=:[(VN['+)Z'=^,G(T^_'&/,5@0?7%>8Z?"T7Q"U:
MY*X*Z?*X8'@ *:[+Q!<-<6NH M@%D)YY[5RT=PQUCQ$Z-A8]'G8@#J=A[UKT
M,$?&?AX6<OAFZ>=0;B2ZD=Y,D%?KQU_'THL==AM-(TN.*)7_ 'JEFWD9 ((&
M/KGGVJ+P]'(_A7Q ES*KR@G;@D!2XZX QVQFGZ=HH6PL_,_U<2L S YQD]/7
MI^M>?*GS+4[^9;'8ZEK5OK\EI+#< R!.?F&\8^5OT4?TKRO4[2V35PCRA^C&
MW+$^7QDY'OS72>9 );N:/AW*JR0@X?KT':N0N+9+[Q,9%;[/!!A)/-.3GD?C
M7-"GRRLC1.S.L\":9IVO^([R&\>/RTCW^602TA!P%51UP"2?845BZ2LD7C:R
MEMKR.U!B;-SD*F=ISR?7-%<.(A/G]V6AG).YV_B'2(;^TL+F)5E9HBYP/N[C
MW)]!6[X&U":%)K*_O)9-.?\ U<CC<(]HY&>V>U6=*\$M?:;=Q6TLT4,D@2,1
MGDL3D@=\<UUWACP3:: RI-;M/."?.CN#N#CTQ[?_ %Z\ZK5@H.+U/H*4)N?-
M'0P)_$,NG0V3Z?&=A#2,D@W>6,_?'X<UQ_Q.UFTN[EVTR8W!G1$G+9!D8?Q8
M_P :Z#QNEQ:7,T-I(TEH9,",1?O0O7:6[@?2LB+PQ9W>G?:PP<'#*V=I5O1O
M\:*3@K20ZBJ.\6CEO#M_+IUY;7<ZRVL=K()"ZC/0Y_6OTL_9-U#6H[2XO?!@
M>XO)XVN)49<R%#C. W;I@"OA?0M!2XL=1AGB25E\IXRXQNY/ /0BOKO]FOQ;
MJO@F)[^PN&MYU;REVH,>6!R,=",C]*:KPC75R'1G[%L^H[?XT>,4N#!>SO:7
M"\-%+;A6!^A%7U^+_BKHUZN?:)?\*-(^.FF>*K:.#Q5H=O>*?E%U;KAU]\'D
M?@:V?^$ T#Q4AF\+ZS&92,_8[HX8>P[_ *5[]*:J1]V5SRIQ<7JCB?$_CS5O
M$L4":A*MR(6)0!0O7KT^E>>>)K?4I$>ZT.Z^S7B L;:?YX)_]DC^$^XKM_&/
M@O6_#4F;RSDBC_YZ 94_\"%<]I[NWR,H)SR6%83G+GY#NPM:6&:JP2?DU=/R
M:>_]6/)_!6N^'Y;J]T^/1+?0M::8RW5JZ[O,D[E2>WM78VNF1ZJT:PV5LZPM
MO4+;J I^H%<I\?O VRQB\5:8@@O+-E6<P\%ESPWU!X^A]JZ;X7_$.3Q;X>MY
M!;@/#B&=81C:P'W@/0]:PGA_?3D]#[3-<LP]7+:>>97&U.3Y9P;O[.?9/K%[
MJ^JND]R+6/#MW<H&>S6X9')V!@ P],&K7[.WPZNK7]HWP=J\FEV]M%:&\=9H
MF&5W6DZ;<?\  NV:T=7U34;2Z9(TCE3JK&09/MBNP_9\UF^U#XI:-%,D(53/
MO*D-@>1)C!^N*PIT:7MEO=,^)<Y\CVLT?8%>7W?_ !]S?[[?SKU"O+[O_C[F
M_P!]OYU[=0\^)#1116)84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '1^'O^07<?]=E_D:NU2\/?\@NX_P"NR_R-7:]*C\!Q
M5?B"BBBMC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "K>E_\?B_0U4JWI?_ !^+]#4RV94=T;=?EK_P5:UZ+0?C'I4I@B=V\-6H
M,K$!E'VN[Q[XR3^=?J57XP_\%I=2N8?VFO"MLDK"#_A#[9]@Z%C>WH)_05R:
M]#J9\UV?C"'2K=9YYE *EUC0#=R.O/?H/I7*:?/<:]JOFKE84RQ5VXY_I_A7
M"_VM-+(K2L'(  W#L.U;5EXFEMT<Q1JCA0,AC@]N143C*0K,]8M]7M]*@ATZ
M&U*$G(N(B#YAP<856R3D]<=J]"\+WVJZ5KW@K4]-E?3]3M;D["A*O&V]5P./
MO$=Q_C7A/AOQI):7\=ZEI!+>(0PW1ELX].>/_K5[#X&-]XU\4>#-)TS0Y+[7
M+Z\#0I&,2/SN.&R,#J?PIPBUN)GVGK7[<VI^']?F\-^/?#NE^-/#S!5,=RJB
MX"\9;)R">>XKTOP[X!^#OQFOA>^"M8D\+>(+NP\M=(O1\FT]-H/H>/E/X5YK
MJG[$-G%KL_BKXI^,-/\ !FD2D$6*S"6XE4=,$]#VP U>R^"_%_P_\!"*S^&7
MA(ZG>1VVU-:U$$L<= "?F]^U=*_NF7^(\K^)_P  /&O@6TOY+G3OM6G!%_TZ
MT^>, 8Y;NOXUX]%:RI+XME5?.VZ)*$1LX+;<=.G_ .NOIOQ^WQ"^(%K+_:VH
M3_9G /V2 [(AZC:.OXUX_JGA*]T.V\3W(M6DD.FLB*R<,> !BM%MN<\E9Z'P
M/<Z =%T:]-C<7+O=KAEN(MA4;@?ND]<BM*=$.E12_:9$:2'H5/!&2./J/Y5Z
MI<_"[5KJ1WFCS<.?-P/F SR5]NV!5>[^&4\=GY)A)*K@C'&?I4.#Z%\Z1XA;
M1.EO;(!LEPH65OE!<C))..F0*Y@V]Y:ZQ=-*-SR!PY;DD\_-]>?UKW/4?#;6
MJ".2!P8QO"GHS'@'Z"N-'A8QS7;[<CD]/6E[.QNIHXR?3$:WCDFQ'$T(4$ D
M#D?_ !-%=,-%_>6T94B!5)(ZC//]317.Z2;-'J>L>#]2$42(9K:*6:3=%(9!
MER#C '?J.E=S+.!;(D^[[5*YS.0-SX[C X'M7SAJ2?N[*&R>*.*/#.Y<90]3
M[CFO0/#?CJ.'1X8+EY=1N(78"X"%DP3G;TZ^]?)5\/=:/5GT5*L[JZV+NL74
MDVKRQ/:^=& 2BKG/NQ->?O'+I.J75OD26\I/R-G<B'J1C_\ 57K_ (=LYO&O
MB.T\K3'M5EPQG92(NN<9/!)_*OJ67P;H>FP0W4^F67VL1".,) I8+W' Z5&'
MIR2=]+#Q%6-T][GA_P */@I+XP\/Z>]X\MCHI_>QL'V22#Z$94$\U]$?#WX)
MLFL+8^&VN;D&/(MI&#8YY.XXXKE]>\?67AC3I,A3*B8CM4QN<XX'L/?H*\\M
MOC]XXTFX:[\/ZA!H%])"T3LB^<R(<$A">,\=<5V1I4M).-UW/3PN2YMF%-UZ
M%)^S7VG:,?\ P*5E^)]M:;\#],\)6\=]XP\06VE*!N-M#(&=CZ9/] :U+/XI
M^$= 8P^$=(6ZN8^/MUYU^H!Y_E7Q/X&_9K^-/QQUAO%\6I7H@N #'JFMS&($
MC(.P$AB/H,5[*GP(^+/P\TDW>JV%MXA6W!+7&C7&\D>I0@,/?&17?"4X).$+
M1/#Q.$EAY<M6<6_*49?^DMGIWB7QQKGBS?'>W;- 3S"G"#\._P"-<VMG*K'R
MG'OFN9T/Q6UXA5B6=3B6&0_.A]_\:Z*PU2.Z7RQ$T?\ NG(K:-2%1[G"XRBB
M/Q)81ZAX=U&QE0F.>W>,\9Y*FOGO]G;77TWQ)J.FO(T<5Q#OP/[Z'_!C^5?1
M&NSV]EI=W=32E%AA=R=QQPI-?+_P)$EQ\4+1U.T>7.SGT&QOZD5M+<_7N$J7
MUGAK.*53X%%27^)*4OT1]">(!>W%N#'!%<19^]@;C_C76_L^:5J5O\5M%GDL
MK2VMOW^2CGS,>1)C(QCK[UFOJ5JH,;M$4 X'4_E77_ W4DN_B/I*0MYD0$WS
M8(Q^Y>N=0C*HI<Q^0\S46K'U-7D'BN5X=,UB2-VCD2&9E=3@J0IP0:]?KR^[
M_P"/N;_?;^==L^ASQ/STL_V@/'7@[P_\,/&<5]J_B31_#7@/3[KQ)8-++.^H
M7&IB>*VD?Y_WDJSVT/+ G;,^&'-36T?Q:\3Z%X+^&_\ PFE_-X\L-5\2Z3?:
MN_B"[L TZ10W%O<2-;AFE\I;E&2%QL8 *2JFOO\ HJ+E6/C7X@_&#QQHWQV7
MQ;9RZS>?"_P+=6?ASQ#>6\L$>F3R3 B_N9X3,LFZ!I[,JR1NJ^7/EE -><_%
M;XC^-8/A[;7%EK/B*]G7Q7XRAD:TU^\LY(+>"6413%H27DCM%_>B'!4K$5 Y
MQ7Z(44KA8^#?B5\1]1M?%?QR$/CN*[O].\,"XT:X@\;W5C/DZ$LIN++2HLP3
M*SDRF3<"A)9<E0:]E^ /CBQB\1^-Y=&\777BCX8Z;H]A?2:Q?:M+JL5GJ6R9
MKR&.[D>1W584MI'C+L(VDX"[\5]&T47"Q\1?"[XN>(X-9\1WOQ;O_$7A/P+\
M1M*O-:T;4;[4T@735A9W2&SD@G:2$M8R02[66-S)#+M5N:S?!_Q'\;7/A'4G
M\;^)?$^CZVU_I<>KK*39SV'A)XSLU)(8Y'$4LK _:+A0'@+2#]UY2D?=]%%P
ML?#?Q*\4:Y>0ZQHOPB^(>JW7A"[U;PU9V/B=M7GU2*RU2YOS%/!%>/(SW$7E
M&W>2(R.JEBOR[RHCTGXW^._''PK\=:/##X@L?B)XE\?/X=MM)LKU1>:4D-C9
M2:B+.265418U2Z:-BZ+NE1N"Q%?=%%%PL?'_ ,/OCMJ,6L?!;3_'7B%O#>L:
M;-K/AOQ+;ZIJ"6ZW-_;PPK 9L2&-Y)5:.5<,P)F^0D$$]GXPM+BP_:&\;RV^
MM^((HK;P#_:\-DNNWOV.*[:2ZA,JV_F^4#LC3 "X#+O #?-7T;11<9^?7PR^
M+7C6;]GO7-"M]5UR?XA>)[W3-&TG1FUJ6_U2W6?3HII]1BN;IU,8F@2XN(UW
MK%$Z8#ABV-V?XG?%"_\ #_PKT33;W4[?XB^%-<U+3]9T6^N09M96SL'N(8;G
MRY&1WN;<1$/N=1))N!.W-?=%%.XK'P%X:^,>K:IX?^"'B67QEK=RVHZA<^;X
M;.JS6VIW44VMM'%-&I+1WWEJ@AEMI/,\N%F9/+.)!K^#W^+%I\+_ !IX]M_$
M^K/HUY?W&G.(-2NM6OXH(]>GBNKV&WF1DMG@LPR)'!Y@<('(W*%K[FHHN%CX
MC^*7C?\ LS0O'<7PF\<ZMXD\(1^&A/>ZG#XFNM2CT_4_MMND"0:BTDDB/)"T
M^^))#M"(VU2_[RQ\)Y]2\4>)?@]/JGB+Q-;W5UK7B"VU'P__ ,)3J+G3OLK2
MRPV%T?-7[0\+$ R2J3(A4$O&$K[4HI7'8****D HHHH **** .C\/?\ (+N/
M^NR_R-7:I>'O^07<?]=E_D:NUZ5'X#BJ_$?!/Q$^%OQ%\4P>)=%\.Z1JNEW[
M_%75/%UEJ$MDZPL;+2UEL269<&*6\6! P/.UMI)!KG-1^'OQ,\:Z#\1+[6_"
MFJM<?$N^\->)1I6J:/->PZ9Y>M&$VEQ$ F\16,=FTL;%6*J^=JCC]&:*OE(Y
MC\^/BU^S=XD\"^+/A3I.G:9=^+-!\-Z:&U+Q!9:%+-=::C:Y;W#-I:HS&":(
M';&BF1DMT< /MYZKQ#X OI=&\56,_@G7+O\ :&N?$-W/HGC:/2)Y(XHFNBUG
M/'JH7RK>TCM=B/;&52=DJ>4QDP_V[13Y0YCX[N_A/XFE^.%_X#_L"\'PPTC4
M[OXAV.H+ PM9+N:#9'IZ$##,MY-=76S^'$?'W:\G^%_PTT[2_A[\"8?%WPU.
MHZ-I>HLWB;2[7X5:E#*DG]BW$2->PM'*;]Q.T8^TI&%W8.!U'Z.44<H<Q\D7
M_A_XCQ?L7Z3X"T_2=6/BKQ5<3Z':)?R2M)H^E7%S,T9O9PLK0^58;8B[!BLA
M1<,W7A+SP)\18?@[HWPQL/"FI:;\6?"/B*2T\%^*;+SY-.TK3S'YRS/J3VX1
MX%MI#9O&R;I611Y>067[RHHY0YCXD\(^"?#5C)X;E\=?"CQ#??#N'PK%9:=H
M%_X:N=:.FZRMQ*=1:XM8X79YYB8F6^\LJX23$B^9A_.?&/PC^,ME9IXBL=)U
MZ[UK2?A[J5B-)NM]R][IUSJ%T(]-EF42>9=0VKVT@569B\ !WYW'](:*.4.8
M^#/B9X+^+GBS4/!.N^%/"]TB_"/PYIMW:6^HS7%C+?ZB\<$MW';P_9W%V?LL
M)M=K/&%DN' )92M>X_!"Y2_^*_QHL=5\.ZW;6GB34K75+7^UM NXK.ZM#I5C
M$ZM-)$(=V\.C0EM^5<%?E./H*BCE"Y^>_BGX ZW9?LU:)I'A'X7:7-K[?$O5
M+]]&U30#]DN+=)=4%JUU&H7]QY9@1'8A K18.W%6/&W@#XI>.-!^'7_"":+K
M<MO\*?#%CJME-XN:YTJ]U#5_W;F-8FMW%PZP6TD#1L44->8W_+S^@%%'*',?
MGA\8? _Q'\0_$#XB>./#'AKQ#/H/B[4/"MK?Z'=:=-%)]G2.PN$O(XS'O,EO
M)'-#*O\ ")6W!3&:D^(7PS\0ZEKGQXL]!\%:WJ=CXEC2[:^UC0+E+J*Y&K6X
M-HQ7]UJ5JT:R7$+J6>"'="QC!Q7Z%T4<H<Q\?3_ :T^$^I>"M*\<Z1=?$GX7
MVL&K3'3=+\.S7VG:=JMS=":(_P!DP^>X@6%IHH3B40G=DH9 3XS\8?@WX]U[
M0? 'V#P5J<_AFS;Q'-IUC>:7+>:EX?T2:XTT6PMUR3;WL<*S2V\3'>@C$00,
MFQ?TGHHY04CY_P#V??A9I?@[XT_&K6[/PA#H<6HZG8?V?J)TH6CW,#:9:/-L
M<HI93<>8S@?\M=Y;YLU] 44525B6[A1110 5;TO_ (_%^AJI5O2_^/Q?H:F6
MS*CNC;K\7/\ @M- TW[4OA3:"1_PAMJ.!G_E]OJ_:.ORC_X*N6]Q<?M&>&EA
MX!\+6XSM!_Y>[NN38Z6[(_,:#3'D(X/Y5OZ=X::>,@*=QP,?C7U)\*O@/JOC
M4QR7(BM[0_,9IH00![#'->GR_ _P9X7O_LU\_P!KN@-QCMU"X'N>WTK9)]3%
MU;'R3X*^&EU>ZC;%8G.7 X%?9/[.WP \6#QYX2U/1'.G:E9',-S(.$.P@]1Z
M$BO4?A]\/-!M]/@O])T2,IP=\V68?A7K\'B%-!LHV@D$$RJ"OE#;MX]JU;26
MA%^9W98N_P!CG5/%/B-M;\5:B=9O6(.ZXG,F/IGI7J.A?!67P]"L=K;0( ,9
M##./RKQZP^(6LZCJ$<?]HW3[C@*LC8.>E?1?AQ7\%^&SJ6M7$DEY,HVPNY)'
MHOU]:PG?J;14>ASNM^'9M%1?M7E;GZ*K9./6N+UW2=.NK:6*:)"'7##'45NZ
MKK\NK7<EU.^78].P'8"N'\2:H8]Q4DCT%913+E:QRVJ>&O#EIC$2PD\%MN:X
M3Q=X>TC3Y<.J\G.<<'WK5\2W!N(V5BR-)\HP><>M>3Z]KMY9W'V*??>B%=P(
M/S;.H)_SVKLCINSDDD]C \36>EL7*Q*&5=H)'Z?K7EVJZ=:0^9Y) #C:0XX(
MKL=?:^FC9U4[ -_S<$?45QLOVB2*0M!\IXSC/-;W(C>YR.L6<%FJQA?X>#C@
M?-FBMB^TB[N"IEM)"I&5)7J.V**Q:5S?F:.=^'WPIU+5;F2#5K%HY+@,UI'*
M=JL0,GGTYKZ'\#?"_0?#>GQW@4:E?0#=L. B'N".@Y]:RXM5BN/$MOJLEP7F
MM;<A+2!,)"6Z*I[G Y-7])NI5OYK?9]F^WL)95W9)P,?7Z_B:^(G6@I/2[Z'
MTJIRY5K;N>BGQ!<ZG#LACA@MXP-S! HS[>IKD?%OQ N-)S!;?Z]EZN<[1ZXI
MGB'6$TVWE2.1$2%1N<#A!7C_ (U\3#1])U'5YSO,2%E5C]YCPH_/%:8>$JD[
MS>B/T?@K(\+F&(JXW'+]Q07-)='NU?RLFVO*W4?XAUC4(H)-1A@75FAE5[N
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MJ::=+=)=7NI60O)[2)+&5K=;B=MYRLY4JS.?WG()8YKPKP+HGCKX4?$SXO\
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M\(OB]X%^-'Q \;Z?X<E\207#:]/X4L%OK&%+"_N/LH2YE+.K/'.D07:S,8S
MV4'F!E+L+(^KV^(_A)?#^I:\WBC11H>F326]]J9U"'[-:2HVV1)9=VU&5B 0
MQ!!X--UOXE^$/#-KJ=UK'BK1-*MM+$)OYK[4884M!-Q"92S 1[_X=V-W;-?&
M=M^R!\1?AQ\*OB/\-;$6?C;0?%NBV5P+FP4:<$U2&2**X\U)KIV:2XA5)&F4
MJK-"V50D;IXOV:/B)X?L?B5I%]HVJ^);5-3T=?"6NZ)JMK!JD-M:03_9[A1<
M2A))8"\4$B3-&)4\Q@3QN+OL%EW/M"/QKX>EO)K1->TQ[J&Q74Y8%O(RZ6C9
MVW#+G(B.UL.?E.T\\54_X67X0^QR7?\ PE6B?98]+37'G_M&'8NGONV7A;=@
M0-M;$OW#M.#P:^)[O]E_XRZ[J,6KSZ9INC7VJ:=I?@36;/2[J*WM$\/-8V_V
MV6WB1ML9BN!.B(H!P6VKMVYVO"7[-OC32=(UK2M=\$W>LZ/#X$MO"EM;V>LV
MMM<SBWUJ]>)H)3(0DJ6KV\Z&3:I<*C,IW;2[[!9=SZXB^*_@B=]!2/QCH$CZ
M^C2:0J:I 3J2*,LUO\W[T =2F<5'K'Q?\!^'?#.G>(]5\;>'=,\/:D0+'5KS
M5H(K2Z)!8>5*SA'R 3\I/ )KY(TWX'_%@7'PXO9?!X3Q%IUR8]0U66;3?LEY
MI[:E-<,-2M%? O$5DN([BU,I-Q+-N('[QNL^"WPJ\>?!.P^&6O:CX(N_%5UI
MO@B#PQ=Z-IE[8_;=(N4F>626-IYXX724%$<I+NS#%A7&2I=A9'T^WC?PZMW9
M6IU_2Q<WUH^H6L)O(]]Q;* 6GC7=EHP&4EQD#<.>:V_"VJV6NV]CJ6FWEOJ&
MG7D"W%M>6LJRPSQ.H9'1U)#*P(((."""*^"M8_9#^)3-H&K:1;6NCZ[H>B^(
M-3T>VM;Q6L=.O;O4HIX='(W(7A:T>ZMRP 1=Q((PE?8?[-OAC4_!/P4^&_AW
M6K;[%K&D^&M/L+VV\Q9/*GBM8TD3<I*MAE(RI(.."14MMIE))-6/5Z^ /^"D
M,>GZ-XW\-:TUK%-J$]A%9O+(@D*0+/*WRJ?=VR:^_P"OSW_X*-VL.J_$C3+>
M;4%LQ:>'X[D)N^>0-<3@[5_X"/SK*&YM+8^8;OQ1K.C^(KBST^]N[$0$Q$(S
M>42#P<'L01Q72^'M,U'4+>WU#49?MDTLFR( 8PO7)_'-5M&T=_'NLB2<K &E
MQO"C<R(B+N;GC..E?0&E_#_0;/1S'!JK"2- <L@ R*Z8Z')*ST-'PWX@BT/0
MUMT8"4 <>O'-<7XN\5S7&KB.TC9EDD6!D)VC/4G/:L_4]5L;,Q06]XTCLW!7
MC-6/AZMUKFOZ>ECIJZW>?;"Z6DW_ "V90, ]..,_A5<J6I*;>A]0?LZ?"^72
MM(/C'Q(LGEA3+:6TD?S ?\]"OJ>P_&M/Q-XBU;Q=J37+V-U%:J2L$)B;Y5]3
MQU-:5AXU^+!$<4O@Z&%  .@V@8] W:MJ'Q7\0B/WGAF,''91_P#%5RN][LZU
M:UD>>W*W=M%OE@EA3IET('ZUY[XPU&6'+Q-L(Z>A^M>L?$WQ+XIO=$2TU73E
MTB.23=%,H!8L >V3QS7RUXS\<:EH-T]GKULK02';#J5K]P_[R]C0K+5['IX+
M+:^9-T\):4U]F_O-?W4_B]%KY%A[*]UZ:6)Y5624,S$G"(.N0?8>]>,>(O&W
MV.X @S="&1VAN(%)) VJX8Y..F.>"&'K70^+?%E]IFB73V\\[V\L;?/#( HS
MQD'N", BO+]9EU'0;"SNE+I;3P*EU;(^)'4*>I_ G [=:J;T/+5.4&X25FNY
MZK'8V^HZ==33SR1V[$) =P=HW*@[2<?WMV!Z?C7&WOA1KN',BP6\P8#N5<GU
M':L;4/B+J3PV>F1WH5)(XPS3QA44$*5R.%7!_B]"0:?HOQ!DABN["_ \](]H
MEDX209+&121G &,#OQ0JD5HV*4'NB!+0J@9YMBIF-HB6^7!QTY_3WHKHM:O;
M#P7>Z?KH<RVVJ6RLJ;-P$FWYP3TZ ?EFBJ<H]R4FT<MH>HW%M(\2HHD)RSGD
M9[FNVLIX["UN+R;Y[F484GDGV%>:1:[%:@,3M4_,Q[D5UEM?--817;[@7(V(
M>F#7YJN;FN?:5$DK' Z-\3T\9W=S:F<6\QN/+-H&.XJ,DL1CG.,9S@"L/XV0
M377@LQQ;L&=6; X( .!^=>4:1>MH_P 4%F.Z-4OSOYQ\I;!_0U]':A)BSDA:
M-IH9P8WC1@I8$=B?\FOK8VIPT/TGAR?-PAFL:?QW5_\ "[+\E(^9?A_XMN/!
M?B2WNQ'$\?,4\4ZDJ\9ZJWM7H\E_?V$$6KZ1-'9S6TXN+.)"6FA0ON5HI!U"
MD#D<CN*Y#Q[X(N+"4S"#RRB;MP!!8=LC'IBO8?V,_B_=? 'Q6_B35?#=MX@T
M22!K0^>N\VCR$8; !.TXY 'O]5)*5I)GXPM+IH^N/AU^W+X'^,GAG3O#_P 7
MO!C>(-2M8E":@+;;([=&VGY3GG)VD ]<5UEK^U#\,_AE',OPP^&[6OB+RC;Q
M7VK9^13T <LS,N2/E5@#7$>(?^"F\&@:G<6X^$.AS1Q/@2FXVAQ_>_U)QV_.
MOK?X'?%%O'GPIN_B#XX\$Z/X(T'ROM-JSLLKRP!<F1@8UP">%Z[NO<5O&T]I
M:^A=*<*,^:K3YEV;:_)H_-WXE7>N?$74K_4_&C3ZC<7CEKAKB-E5&[!#_ %'
M0#H*\^\0>.;#PA);V4T-Y+&J@>=M:147L2Q/S?@:^D?C5\<[WXS?$TV]E:0:
M=X>@0&PT\0*ID3/S-(1QO;Y3CL.*\UUC3'O8I+!M-$\!WI&&4,K*3\R'N".Q
MKS76]FVXJZ/T/"<4U,NIN.686G1FU\5G*7R<F[?=8X"\O2+B34['4(=1@M$6
MX\N!B3M./NKW([]Z]Y^%'Q9FU6SAM[FX#%H]\,C-@D#J/7\Z\0E\#6^F:=)H
M\<L\;3C,%MYNR42#E5W <'WP58?W:A\'726U]#.@:WUFRW>98WDBEF8<$;#@
MDG/8#/:LG!M\\&?&XC%5<74E4Q<G*;W;U;^9]GQ>-;:[M$MY96,JGYLCI[9K
MU;X 2V4OQ%TAH%42'SLG')_<O7RAX#\=6>NW<EMK&CKISHH*30S$!CT(())_
M"OIG]F^6RA^)VCP0733.PF95EQN \B3OWKNH3DYKFL>5522T/L>O+[O_ (^Y
MO]]OYUZA7E]W_P ?<W^^W\Z]*H<L2&BBBL2PHHK@/$'Q[\!^%/[9.K>($L5T
M?5+71K]Y;:;9;W=PB/"A8)C#+*AW@E5S\Q&#A@=_17GFN?'_ ,#^'W>.XU*]
MN+A-8DT#[+IVD7M[.U\D'GO"L4,+NV(CO+*"N,\\&MF#XH^&+C2/%6J#5!'8
M>%I98=9FFADC%F\5NEQ(&#*"=L4J,2N1SCJ" 6 ZJBN$7XY^!6\(>%/%(\01
M?V#XJO+;3]'O/)EQ=7$Y(BCV[=R$E6!WA=I!W8J+6_C]X \.Z;XRU#4/$<,%
MGX.N(K7791!*_P!BEE"&-2%0E\^8@RFX D@X((!8#T"BN=LOB'X=U+QO?>#[
M75(I_$=C8Q:E<6**Q,=O*S*C[L;3DJ> <C() # GD?\ AIKX</\ #R;QS;:]
M-J/A6"_?39M0T[2[R[$,Z$A@Z11,ZKD >85"'<F&.]<E@/4**X4_&_P5%;Z]
M-=:R=,30;"TU+4QJ=I/9O:07(<P%UE12';RW'EXWA@%*@D Y=Y^TI\/-+\.:
M]K>IZS=Z-9Z$D,NHPZOI%[97=O'*XCBE-M-"LQC9VVB14*Y##/RM@L!Z=16)
MH7C;1/$VL:SI>EWZWE[H[PI>HB-MC,T2S18<C:X:-U;*DCGGGBMND 4444 %
M%%% !1110 4444 %%%% '1^'O^07<?\ 79?Y&KM4O#W_ ""[C_KLO\C5VO2H
M_ <57X@HHHK8R"BBN5\1?%/PMX3\9^'O">KZO'8^(/$$5S-I=G)&Y-TMNH>;
M:P4J"JL#M)!(S@'!P =517F%Q^TK\/8=&T'4X-7O=4AUS31K%C!H^BWU_=/9
M''^DO;P0O+%%E@-\B*,\9SQ717?Q8\(VFB>&M9.N6\^E>);RWL-(O;0-<17<
MTX)B56C# !MI^8X48Y(HN@LSK:*\\T3]H+X?^([R*TTWQ%'=W,OB&X\*B)+:
M8,-3@CDEEMV!3Y2$B=MQPA &&.1FOX7_ &C? 7C'3]$OM,U+4#8ZYJ*:5I=S
M>:)?VD=[<-%+*JQ-- @==D$I\P90;<%LD ET%F>ET5R=I\5O"=_\3;[X>6^M
M0R^,K'3DU6XTH(^^.U9P@DW;=I^9ER <C<I( 8$XEM^T5\.;O1]'U2/Q/;FQ
MU?7SX7L96AE4SZF)'C^SA2F0=R,-Q 4\'.""2X6/1Z*\YUO]HKX=>&](\8ZI
MJ?B>WLK#P?>Q:=KDTL,H%G<2>7L0C9E\^:G*;AR>>#C:UWXK^$_#7C_PWX(U
M/6H;3Q3XBCGFTO3F1RURL*[I#N"E5P,D!B-V#C.#@N%CK**\KM_VG?AY.NNL
MVI:I:)H>H6^E:@]]X>U&V6"[GDCCAAW26ZAF9IHCA<X617.%.ZKVO_M#> ?#
M'B&ZT?4=;EBFLIHK:^O8].NI=/L)I"H2.ZO4B-O;N=Z?++(I^=,CYER7069Z
M-17GR_'_ , OJNJZ8OB&-K_2];M?#EY;BVFWPW]Q@01$;.CEAB0?)P<L,''H
M- !1110 4444 %%%% !5O2_^/Q?H:J5;TO\ X_%^AJ9;,J.Z-NOS6_X*/6CW
M?[17AU0[",^&805!X_X^;OFOTIKX=_;5\$KXA^.&C7C2>4$T&&+('/\ Q\7/
M?_@5<\%=G1/8^=_AKI$=O()4&ZW9VBWJ,!E7C/XG^5=MJEW+#',EL3(V.1TQ
MWYK;\*_#ZTTS3I+62[$4<A# 1G+*?6NCM/#&DP,S?VC"NY@S*X / QBNGG2.
M=4[[GS7J*7?VR6-(GDE+80*#^E>H?#==3\"-8ZE%)]DOT!E\U.2K')/7OS].
MM>EE_"6FW05HH&N#_P M"N<X^E-FUSP]>'RA KJ@S]TX&:.=-ZHM0Y=F:%I^
MT/XR8[&UBY.<L&91C!QCM7T7X$U[5] \%S^*?&>IS+$\8:&TE ! [<?WF[#M
M7G7PB^%&B:MM\8:Q;K!H]F#) MP<(^WG>1_='ZUQOQE^,A\>ZMY%GE=)M\BV
M3'WST+D?R]!464G:([\NK8>+OB+>>-]:FU"X<K&6VP0 _+&G8?XUYQXWBBU7
M3IX+B,/"_P![/85M6$,;OL$B2,#\VSZ=*I>(-1A@MY(EBW#DG(XQZ5JET"G5
MG1G&K3E:2=TUNGW/F?4XYM"N[JP,ADA.?+8C@^A -<S<O:SK/Y[JDCQ%5>5C
M*)&88*@X^4KN'/3->G_%*UC*6EP(HXY267,9R"![^W'YUYQ/I=N]G*4LFFDF
M)\V1ON[."1G^'G'.._>N&S4G _7^(Z-/.LDPW$\(I56_9U;=9+:7J[:^J.4E
MU-+M_*6X61+=A&BEB<G[OS-GD 8.!QTJSXD\96LNF#3[&S7^T7C\J6XDW9MU
M&1P0W3[PZ=/SK??30^G320PVMO91F0K;VS9:)\YSD]<XVCIC&/>N(U#3]3M[
M"ZFU(/:VC,?-EG0-)<.H^ZH4<=.I-)1L?E*>AWU^EYXU^&VCBWW326%R8BL/
M/&SJ<45N^!;G2O\ A6EW<0V\H6.YC\Q"=I#$=?E(X]LT5V*FI*YS.3B['G4F
M@N+D&0DH< +Z8ZT[Q_XQD\->'!L#&5R((W7HA(^]^ S6UJ4EQ;:KB\@:V.P,
MJ.,<=C7B?Q%\47'B6YN=.B6/[%:S;AL!WN1P>3QWZ5\'1IN=17V1]/5FHPN<
MOXA2#[9LMT,9@X,G\4G<MG)YSZ5[GX)\0+XR\*PM%=&&^A"I*Z_>1UZ''H1_
M,U\YO=?9V:)R[H.-K###_"N\^#OB%M*U>_@M[594N8<^9,6!C9>1R >#R.1W
M[5[J5M]CZ+A7/:63XJ=/%+FH5H\E1>3ZKS5W\F^IM_$;Q,^O^(+F&Y%PUQ:,
M MO.N(XUQU"KGKQR?6K&B0:9I/B/2KB^C>XA,I%P(I,M V<J& Q2>.O#MOX\
M1]7T&4)KENOEW%DYVO(H'W2/7^=4O@=/H?B#Q]HND^.]8D\-Z3:2;KBZBLGG
ME>)>7CV("2Y P&(P._2I=/2Z/,SG*YY96]V2G1EK":U4E^DE]J.Z9]U_LM_L
MNVGQSU2R\:>)7+^%-.8RRR,GEI?.I(,1!'10!N;@C&,\\9'[8?[8=OX\\06O
MAGPO%;WGPVTJ46\ZQ@!+F52 &QQA4(^0 X.,GM7T9)^UA^SAK7PULO!MAXHU
M#2/#D\8MX1IMA<P,54\J6$9QD@[LCG)SUKQK7/!W[&5G<7VLW>I>((PY$=R8
M8KIHF)]56(@_4=">U:<JC'DBUKOJ?-W<G>29X@TME>W<=U:SK!&Z(3+;2 R0
M/_ ^.W!YZUHV&HW$6K"PO&6XN0GGP749_=SIT; [,.XSCG-1_%K7/V<+"WTV
M;X3:OJ$UW*7AO%U 3Q+D;/*7$J*.[=.,"N0N+N33;VV#WL4=J/WJ>6PDEMWQ
M]3Q[9P0:\V2="34M4SO@U55UN=[J>GV^L)<I,Y@W$?OR=I''&UJ\B\<>#=0L
M$6ZTY9M:O+>42_,["94[A)!G@^C;O:NXTOQ5:ZOK,FD7L$ETTP_<."5@FC !
M+;>JD=QS]:Z6[MM(TS291'-::7''QP I7/4'')!__56L;/5&+36AY/X+UR/Q
M/J$5@1<B;4Y?(C8QB,1,HR5;GA@1U P>M?>_[*5A'8>//#JOO>Z'GQF24Y9@
M().:^5M"\');Z>?$5K$OFJ&)D+ EVZ*P'T/UKZ&_9.\8C5_BYX0M"I5MMR #
M[6LIS6M/DA4BWU,9\THM+H??U>7W?_'W-_OM_.O4*\ON_P#C[F_WV_G7JU#C
MB0T445B6%?-WC;]E_4O'&J^-DU(Z/?:'XC\::/KTEE<R2'S+&VM[>*XBD'EX
MWMY3[0"001EE[?2-%-.P'R9X(_8[\3:/9:%I?B#Q/_:]GIOC>\UY]1M=3NK+
M4)K!M--G;@S6ZQNMQD1[]K $;OF;)!V?$_[/?CSQ%;_$+PBEUHUAX*\:^)XM
M6OM7AU.9]3CL/L]K%+;K ]JT9D?[+C>\C+MD;*G'/TU13NPL?(VL_L8>(M7L
M9?"=QXEMK[P;::OJ>OZ5>71":A;WMU:.J,8H8$A417<TTZF/ &Y0%&!5;2_V
M+?$<EO-8ZYJ.B:G8>)Y](U/QHOF2_P"GWT%]=W=T8U\K#))Y\$:[BIVQ8( "
MBOL*BCF86/CKPQ^R-\2_!%I>ZII?BG1KOQOJFB:CX>O]:O)9E_T=OL4&GRKM
MB):2&WM'8@X'F2'!(9F.TG['FM^#O"?COPAX3\11ZCX9\1Z5IT< UYHXI[2]
MM&2,$"VMD1HWMHXU+%=^Z%2=V\L/JNBB["QX#X[_ &=]<\6^-_B#K]MJFGV3
MZJ?#E[HOFJ\H6[TN>:?;<Q@+F)V>-?E8G&XX! !R?B?^S_XT^-QUC4_$L/AK
M2;^73[71[/1[2]GOK1[8:C:WES)<3O;Q%F86P18Q#@<Y8[SM^E**+A8\3_9P
M^ VJ? W4_'D-SJL6J:)J5_;G0QO9I[6QAMUAAMY<J!^[55C4@ME44D@G%>V4
M44MP"BBBD 4444 %%%% !1110 4444 ='X>_Y!=Q_P!=E_D:NU2\/?\ (+N/
M^NR_R-7:]*C\!Q5?B"BBBMC(*^?OVD/V:M0^.7C/PYK5GJ5II,V@Z-J4>FZ@
MQ)N;'59);.6SN(UV%2BM;.) 2"R.5P0QQ] T4-7!.Q\Q?"?X"?$7X#Z9H%WX
M<'A?Q'J[>$=,\.:Q8ZKJ-S9P1SV7FF*XMKA+:5F0_:)0T31(3A&##!4[I_9O
MU;3?AK\+_#-GJUE>W7AGQ?#XFU*[G5X(Y\W%Q<7"P( Y7Y[@A$8X"@ MQS]
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M7 R!V(YY]*PI_$=,E=:'E5MXKS>NT3;G-MN,3M\RG)!SZ<Y_*J&J>)?MUO\
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M5+12U\\# -+L_=+GLHR0>O7WQTK2SV/Q0[CX42?VCI7B.U$1$#"%_):3@%6
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M8C>$S@G..W/IT["O7H/"-CX9T]X(5)D,7F27#?>?VXZ#VK!T:UO'N+JRC+I
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M(#;$@A,95BZZG@W]HZZ\5_%K3/!,WA:+2GN]%MM8,TVLPR2E983)O@1%,=S
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M?*^Q[6<2S*H/F %07^4_)4-K^US;0>#H/$.L>&SIL%]X&3QGIL4=_P"<UXV
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M7UA=<B:&;R(M+L[;[3#=)'YN]3,ESIZ@LS+NEDQG;\I=!8^H:*\2^!'QNO\
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M[P(!K;\%_L\^)-$\=^$?%NI:AI<NH)KFL>(-=M[1I!#%->VB0)#:[ERZIY:
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MH Z/P]_R"[C_ *[+_(U=JEX>_P"07<?]=E_D:NUZ5'X#BJ_$%%%%;&04444
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M7P1;>%M*N=2\/W.L>(=9&G)KCZ3/!I]DIB9T5X/M3M)([(8T'G("SKZ8;LO
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MXF>,-+\9ZSIFI^$[6UT36=4TZVTV[T:Y9YTM)G1-]R+P!"X09<1$+DG:<8H
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MO6"")+G([9%0_P#"P]4MBP?R[A1V85JL3#9F'U>H]4<3XCTNXLX(XE#(5W*
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MXGKX9U"&WTGQ5X8N='T_2;IF6#3+B4S,5CVJ=EN9)F?8H^0LVT8(  -_P_\
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M4=.TF(FXO3'+!$_EHA4[F,><*5Y/&!75?$GP6L_P!MF^'_P^\2^'_"&GZ_\
M;_$'A#6A/:W6I0HD9+\R/(8OE4?*W!7<%RF1Z)\0?V;?$5I!\)$^'5SHL3>!
M!.P'B"295N)'\D[R(E8G<R.S#*X+#''3HM:\+_'+6]"TC4$\2^%]'\4Z9J33
MG3K!+@Z3?VQC"A9V=3-N&Z7@?*<H>&567'Z_14:/U>:48RD[.325YR:O%>35
MI=-'T-O[.KN5?ZQ!N4HQ7,HQ;=H04K2?FG>.TM5U+/[+%WX&OOART_@&]U)M
M'>X=FTK4KMIGTQR2Q@56)V+\V1@G=U)))->)_&[X)^"[O]K+P#ITNC;[/Q1]
MKN]7C^U3#[3+AVW9#Y3D X0J/:O<?V>/@OJ?PJB\4ZGKMYI\VN^)=0:_NK71
MHF2QM?F<K'#NPQ&')R0,<#G&YCQ_\']9\5?'OX?^-[2YL8])\/Q3QW4,TCB=
MRZL!Y8"%3]X9RPKS*6,AA\QK5*59\KC+6[U?*[:Z7M+9_,]6K@IXG+J%.M17
M,I0TLM%S*^FMKQW7R/#_  KXZA^$O[57Q22V\)^)?$EN;:SMHK;PW8&]D@5(
MHL%P6! P, DG)KA?#-U]N_9 ^.5SY,MOYWB))/)G7;(F9[8[6'9AG!'K7U7X
M ^$&L^%?CW\0/&]W<V,FD^((8([6&&1S.A15!W@H%'W3C#&O/+']EWQ5:_!#
MXF^#GU#1SJ?B;6/[0LY1-+Y,<?FQ/B0^5N#8C;HK#D<UZM/,,)S1;DD_W%W?
M?EM?_P !ZGDU,NQG+*T6U^_LK+3FOR_^!=!_[)6B>"+#4+6YT'X9>+?"NNR:
M&HNM>UFVGCLKP$PEUB9YF4EV"NN%'RJ<8'%<]^W-\,O#4E[X/\1MIN=9U77+
M;3;RY\^7][;[&^3;NVKT'*@'WKVOX-Z-\5?#HM-*\:-X.?P_8Z<EK:MH)NS=
MF1-BH7,H";=@?. #G;CC-5?VCOA!K/Q?TWPG;Z-<V-L^DZU#J4YOI'0-&@8$
M+M1LMST.![UYM/'>SS95Y5/=ZOF;TL]+OY:=#TZN ]ID[H1I>]I9<JCK=:V6
MG?7J>8^+O#-OXH^,/A[X#:7-=^'/ASI.DOJE_96%S();\%CMA:5MS&,,X)7/
M.6[A"M?XL> ;']DZ_P##'C;X=/=Z/I-QJD&G:SX>-Y+-;7\;[R'Q(7(D #*#
MSC(( ^;=ZM\9/@EJ/BWQ+HWCCP7J\7AWQ[HZF**XN8R]K>P'.8)P 2!R<, 2
M S#!.TISH^"?C[XI>,M#U;XLZQX?;1] F2[LM \,Q3&WN;@$GS)VG&[CY1M^
M8$9'RY;=I1QM-QISE5_=J+YX.]Y2UN[?:<KJTF]/*QE6P-12J0C1_>.2Y)JU
MHQTLK_94;.\4M?.YYU^TA?:E^RY\0Y/'_@R:V@@\8PS6NI:5*RA&O%0F.Z5,
M<X9]S''4L"1YO'/_ !L^%%M\+OV.HBURFIZ]K6J6FIZMJJR"4W,\BLW$@)WH
MN2%.<'+-P7->U7G[.U_\3/BIKGBCXF/INH:2MD^F:'HUA(\B6L+A@\KEXU_>
M_,2" <%N#\B8X_7/V8_B'JWP%O/AE)K6AWMO8ZI'/HFH7$\R/]C!<^7.HB.U
MAD8VEA\Q7("C/;A\=0@L/&55<T'!S?\ ,ELK]>39]_D<6)P&(F\1*-)\LU-0
M7\K=KNW3GU:[?]O&CXXM+SX\_M):C\-]6U.\L? WA[3(;Z]TRRF:+^U9',;A
M)67!\OYUXSQLXP3N7N?!_P"S'X>^&OCBRUWP5J>K>%].6,I?Z%;W;S6E^PSL
M>02ER"-S#KZ;=IW%H/B?\#]<OOB#:?$;X>ZY;Z#XS@MUM+FWU&-GL=3@#+^[
MFV_,HP.J@D[4QM(W"?PCX1^,&I^-K'7/&OBW0],TVP0QIH7A:WE:WO=V=S3-
M/\P(^4#&>G&WYMWCSQ'-AXQH5U""A9PUUE;72S3;>JET[JQ[-/#<N)D\10<Y
MN=XS5M(WTUNFE%:./7L[E']K;XAZYX(\!:5IWARZ.FZQXDU2'1TU%0=UJD@;
M>ZD=&X !Z@$D8(!K*G_8D\$1Z.LFFW^M:9XS3,R^+HM0F-XUR<DRLN[:<L<D
M*%)'\0)S7I7QH^$FF_&KP+<>'=0N);&42+=65_!R]I<H#LD R-P^9@1D95C@
MJ<,/-)/!'[1&I:(OANZ\:>$K#3R#;R>)+*WN&U9H>1O"$",2$8Y4J1U#9&:6
M$Q'+A80P]94I)OFO=76EGHGS):KE_#4K&8?FQ4YXB@ZL6ERVL^5ZW6K7*WH^
M;\587]K/6]0TKX8:#\/M*O)[[Q#XONX-$BN;C;YLL8*B:5RH5<ME V !B1N!
MVS_V4=3U?1_"?C7X4W5ZD/B;P?=3VUG<2)PT,I9H9@I!)7?N;G.%9!W K4\8
M?LT77Q6^+-AJOCZZM->\'Z5HZ6-K:QS2P75U<\&2>81A%3+%SA&Q\J<#FJMC
M^RS+\./BK9:]\,;FV\*Z'<:7-IVIP/<RSSJ[$E)XA,LJN5;RSM<A3Y>.-Q-=
M,:V#^H?4W-<[]^]O=YKZ*][_  Z6Y=W\CDE1QO\ :'UU4WR+W+7][EMJ[6M\
M6M^;9?,\M_9?T[P]X9^*O]@^,X-:\,_%VUFN3/>OJ<IA\0+(_F9DRQ#D8R /
ME<#=EF^[U/PP\"6G[66M^+/%_P 0I[S5-"L=6FTO1_#:7DL-M:*@4F1@A4ER
M&0;@1GYL@_*%V]!_9Z^(^O>.? FH>/\ Q%H.H6'@MWDL]1T^.9M3U'#(8UN7
MD & %R2"3G.=Q8N->3X'>//ACXWUS7?A/KFAQZ9K\[75_P"'_$L,OV:&8G/F
M0O"-PY+#;\H P#NPNWLQ.,HU*DYTJR5645:5W:-I.ZC*UX\RLUV^&YQX;!5J
M=.$*M!NE&3O&RO*\59RC>TN5W3[_ !6.W^%GP9LO@M<ZS_9?B+5&\+3#?:Z%
M?3B2UTP;F=S&S98 EB>HZDMN.&'R-I?CG7(/BW:_M"74I'A"^\1R>'WC93F*
MQ\L(DAQCY0,G_?CY^\,_0][\+_C%JW@3QFFI>-=)N_$GB2W^R1Z;$DD.EZ9&
M6*N89-C2LQB)'*K\S9)8J&K$N/V$?A\WPW?38=*">+_[-\I=9-]<[/MGE_ZT
MIOV["_)&SIT&:QPF*PU"52>,J\\JEHMI7]VWO7OR];>]JW:^IMC,)BL1&E#!
MTN2-.\TI.WO7]VUN;I?W=$KVTL97[0/@K1?B)^UI\+?#WB&S_M#1[S2[SS[;
MS7BW[(YW7YD96&&53P>U4[&PD^ _QC\0?#72+ZZG\$Z]X8N]4L=,N9VE&G3
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MBZ=:%GI=&\_?IROT3/U.HHHKZP^?"BBB@ HHHH **** "BBB@ HHHH ****
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(:*OF9GRG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>anvs-20221231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $R D@# 2(  A$! Q$!_\0
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M+\VCL:*X[_A/]0_Z$?Q)_P!\VG_R11_PG^H?]"/XD_[YM/\ Y(J/:Q\_N?\
MD;_V?7_N_P#@4?\ ,[&O OVE;#Q3_:]G?>&]3\26WE^&]<D-MH\\BP/=16P:
MUW*H.7+NVWN2HQG%>F?\)_J'_0C^)/\ OFT_^2*/^$_U#_H1_$G_ 'S:?_)%
M'M8^?W/_ "#^SZ_]W_P*/^9X5XE^+GQG\)+!I4>D6>J307[VYUIM)N5ANO\
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M]5"68!_\F*<OCR^7./ OB,9.3A;/_P"2*/:Q\_N8?V?7_N_^!1_S.RJE<_\
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MJ-OVB-'7_F%7_P#Y#_\ BJ\/DZU5EZ&K6 H=OQ#G9[LW[2&C+_S"=0_\A_\
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M;_P*'_Q%:*MB/^?7XH+1[GADD$O_ #RD_P"^#5=X9<?ZJ3_O@U[LW[242_\
M,NM_X%C_ .(J-OVEXE_YEQ__  +'_P 16BK8C_GU^*)M'N>!R0RY/[J3_O@U
M5E@ER?W4G_?!KZ!;]IZ)?^9:?_P,'_Q%1-^U)$O_ #++_P#@8/\ XBM%7Q/_
M #Y_\F06CW/G/4()?LS_ +F3JO\  ?[PJ.6"7)_<R_\ ?!_PKZ#U+]J>)[1U
M_P"$88?,I_X_!_>'^Q4C_M80K_S*SG_M]'_Q%:+$8K_GS_Y,A<L>Y\WRVTW_
M #QE_P"^#566WF_YXR_]\'_"OI4_M;0C_F5'_P# T?\ QNHV_:\A'_,IN?\
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M_P",U&W_  5%M!_S3.7_ ,'"_P#QFK6/S+_H#_\ )XBY*?\ -^!^>DEA=_\
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M7]C'X-ZQ\!?V<?"?@WQ"T)URU6:>\2W<.D<DLSR% PX;:' )'&0<<5[%JO\
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M>FDM_P!_H_\ XJH6^$GBTG_D$-_W^C_^*JX_QJ\6#I=V_P#X#+4#_&_Q<O\
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M!_Y"VG_^"Z.H)/VU_BPO35]._P#!;'6BCFG:'_DPKT_,L/\ LM?%$]/"K_\
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M_P!=$_\ 0%HH O4444 %?+GC"S\<:[(-2MY/$(\4:3>:[.!#98BM2MO,+&.
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M,#>++IVO)%[%H8N(B?[K$D5@2?M!?$KX274)^+?@:W3PZ[!'\2^&9&F@M\G
M:6,DL!GOQ[ ]*CE_O/\ KY'T]/)\367+1A0E4_D4TY^B7/9OR3;\KGL?VCX@
M_P#/AX:_\#KC_P",T?:/B#_SX>&O_ ZX_P#C-=1I>IVFM:;:ZA87$=W9742S
M03PMN21&&58'N"#5JK]F_P"9_P!?(^6EBE%N,J$4UY2_S.-^T?$'_GP\-?\
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MX>&O_ ZX_P#C-=E11[-_S/\ KY#^N1_Y\P^Y_P#R1QOVCX@_\^'AK_P.N/\
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M*X+Q-^SQX:T'1[R\U#Q+JEK9HB16S+%'(UO<.EE!&Z@(2[&2RMR%((R6&,'
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M6T:-+^1?<B7.7<MW_B[6C;,#JER>5_B_VA3F\8:X"?\ B:W/_?58U]_Q[/\
M5?\ T(4Y^]:JA2_D7W(CGGW9IMXRUWG_ (FUU_WU_P#6J-_&FO#_ )B]U_WU
M_P#6K+;O4+ULJ%'^1?<B>>?=FL_C;7P/^0O=?]]__6J)O&_B#G_B<7?_ 'V/
M\*R7Z5$W>M5AZ/\ (ON1'M)]V:Y\<^(<_P#(9N_^^_\ ZU1/X[\1#_F-7?\
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MC12HC0J>#AY.O<CTKAI/^"=_A[P#^T7\-/B1\)$TWP-8>'I)1K&F?OY3?QR
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M25.58 BO<Z*H^7/(?@#\(?$/P^OO&_B?QGK&GZOXS\9:E%?ZC_8UN\%C;+%
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M@T8=\L6W\G.,"N[TK]H.VU&]*G0+U+&YU.ST_3KQIH42=;BRCN@[EW C(63
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M[U,WP?G.?^)I'_WY/^-:+,L)_/\ @_\ (CZO5_E/.&[U"]>EGX-SG_F*1_\
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M_P#X/+C_ .*H_P"%6V?_ $'_ !/_ .#RX_\ BJ.:I_+^/_ #V.#_ .?S_P#
M?_MBK)\#_"KV?V-8;V+3V:T:6RCOYA!-]FC2.(.F[##9'$#GKY:YZ5WU<7_P
MJVS_ .@_XG_\'EQ_\51_PJVS_P"@_P")_P#P>7'_ ,51S5/Y?Q_X >QP?_/Y
M_P#@/_VQVE5-5_Y!EW_UR;^5<M_PJVS_ .@_XG_\'EQ_\55?4?AA:1Z?<L->
M\39$;'_D.7'I_O4<U3^7\?\ @!['!_\ /Y_^ _\ VQWE%<7_ ,*ML_\ H/\
MB?\ \'EQ_P#%4?\ "K;/_H/^)_\ P>7'_P 51S5/Y?Q_X >QP?\ S^?_ (#_
M /;':45Q?_"K;/\ Z#_B?_P>7'_Q5'_"K;/_ *#_ (G_ /!Y<?\ Q5'-4_E_
M'_@!['!_\_G_ . __;':45Q?_"K;/_H/^)__  >7'_Q5'_"K;/\ Z#_B?_P>
M7'_Q5'-4_E_'_@!['!_\_G_X#_\ ;':45Q?_  JVS_Z#_B?_ ,'EQ_\ %4?\
M*ML_^@_XG_\ !Y<?_%4<U3^7\?\ @!['!_\ /Y_^ _\ VQVE%<7_ ,*ML_\
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M:I_+^/\ P ]C@_\ G\__  '_ .V.THKB_P#A5MG_ -!_Q/\ ^#RX_P#BJ/\
MA5MG_P!!_P 3_P#@\N/_ (JCFJ?R_C_P ]C@_P#G\_\ P'_[8Z>S_P"/^_\
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ME(XU_P 3Y&/^8Y<>H_VJL_\ "K;/_H/^)_\ P>7'_P 51S5/Y?Q_X >QP?\
MS^?_ (#_ /;':45Q?_"K;/\ Z#_B?_P>7'_Q5'_"K;/_ *#_ (G_ /!Y<?\
MQ5'-4_E_'_@!['!_\_G_ . __;':45Q?_"K;/_H/^)__  >7'_Q5'_"K;/\
MZ#_B?_P>7'_Q5'-4_E_'_@!['!_\_G_X#_\ ;':45Q?_  JVS_Z#_B?_ ,'E
MQ_\ %4?\*ML_^@_XG_\ !Y<?_%4<U3^7\?\ @!['!_\ /Y_^ _\ VQVE4KG_
M )"=E_NR?R%<Q_PJVS_Z#_B?_P 'EQ_\55:?X8VBW]JG]O\ B?#*_P#S'+CM
MC_:HYJG\OX_\ /8X/_G\_P#P'_[8[VBN+_X5;9_]!_Q/_P"#RX_^*H_X5;9_
M]!_Q/_X/+C_XJCFJ?R_C_P  /8X/_G\__ ?_ +8[2BN+_P"%6V?_ $'_ !/_
M .#RX_\ BJ/^%6V?_0?\3_\ @\N/_BJ.:I_+^/\ P ]C@_\ G\__  '_ .V.
MTHKB_P#A5MG_ -!_Q/\ ^#RX_P#BJ/\ A5MG_P!!_P 3_P#@\N/_ (JCFJ?R
M_C_P ]C@_P#G\_\ P'_[8[2BN+_X5;9_]!_Q/_X/+C_XJC_A5MG_ -!_Q/\
M^#RX_P#BJ.:I_+^/_ #V.#_Y_/\ \!_^V.FLO^/_ %'_ *Z)_P"@+15#PMHR
M:"+^TCNKR[59@WFWUR\\G*+QN8DX]J*U5[:G!-14FHNZ^XW:***9 445\9?#
MW]L[5_%G_!1+QG\&9)[1O!]CI[P:>JP@3?VA#'%)-E^I'_'P,?[ H ^S::[K
M$C.[!$499F. !ZFO _VL/VK[/]E;_A7]UJ>CC4=)\2:XNE7EU]I\HV$1&6G
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M%+J>KR6_D1A8]Q547<2<ER2>!PH  '/.Q?L>^*M,TRU\%W/Q(L!\%].\0_\
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M KY"TK]KKQ!K'P\F^SRZ?<^(I;UIOMT>+>*SL6>S>,>7(I\V0+>K'@8W>6[
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MGR,NY[D_IT'%=95+6/\ D&S?A_,5=KQ)2<VY2=VSQY2<FY2>H4445)(4444
M%%%% !5*Y_Y"=E_NR?R%7:I7/_(3LO\ =D_D* +M%%% !1110 4444 %%%%
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MO!=YJ>O7MU;PZ?:OJ%O#!>-82K/=*+6"83SJ8PR(AG4"1P% *'(W"MGP_P#
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M5=H **** "BBB@ HHHH **** *5G_P ?]_\ [Z?^@"KM4K/_ (_[_P#WT_\
M0!5V@ HHHH **** "BBB@ HHHH I:Q_R#9OP_F*NU2UC_D&S?A_,5=H ****
M "BBB@ HHHH *I7/_(3LO]V3^0J[5*Y_Y"=E_NR?R% %VBBB@ HHHH ****
M"BBB@"C9?\?^H_\ 71/_ $!:*++_ (_]1_ZZ)_Z M% %ZBBB@ HHHH ****
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M* (8K989II 26E(9L]L #^E%344 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>anvs-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %R AH# 2(  A$! Q$!_\0
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MNIH **** "BF[O:@-GL: '44TMCL:7=[4@%HI-U-,H!Q@TP'T4U7W#I1O]J
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M(O/AMX8U"P@LKG1+.:UA4K'&T8PH/459D\$Z'-H46C2:=#)I<0 2U9<HH'3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML/B(UXW6YLT445S'4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\5^*;/PII,UY=.#M7]W"
MI^>5NRJ.Y-,\;>,].\#:#<:GJ<RQ0QK\H9L%V[*/<U\ZS_&?P_J>J)K^NWD$
MFHQJ5L].C;=';+ZL>[5I3@ZDK(YJ];V4=%=G:2375W=1>(_$4*#52I%G8 Y6
MU4]S_M>IK'NKJ2\G>:5B[L<DUQ]Y\9-#OIVEFU!&=CW/2H?^%L>'?^?Z/\Z^
MNPL*.&C9-7/E:BJU9.31V-%<=_PMCP[_ ,_L?YT?\+8\._\ /]%^==?MJ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9^KZ!I^OQ+%J-G!>Q*=P2= P!]<&LK_ (5MX6/70-.)_P"O=?\ "NEH
MI6 YK_A6WA;_ *%_3O\ P&7_  H/PU\+?]"_IW_@,O\ A72UR'BKXL^$_!.I
M06&M:S#8WDP#+$P8D*?XFP#M'N:-161:_P"%;>%O^A?T[_P'7_"C_A6WA;_H
M7]._\!U_PK>M[R&ZMXYX9%EAD4.DB'(8'H0:E#@T:A8YO_A6WA;_ *%_3O\
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M)V\DFL[X?_#OP?\ '[QI\<]=^*?BV]L?$&D7TT%C:MJ!MOLD*J2KHN1G)&*
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M.M7_ (I?LK_#3XQSVMQXG\-PW-U;*$CN8&,,NP?PEEP2/8UZA_:=K_S\1?\
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M/F-13I8>K%2A!-/R7^1<IUH2<92=UYL[?_A.K;^Y??\ @6_^-!\=6W]R^_\
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M%'0 5^8Y[F<,5+V--74>I^AY)E\\/'VU1ZOH7QT%+2"EKY,^L"BBB@ HHHH
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M ._2_P"%'^LF*[(/]7</_,S\AEFO_P#H#:E_X#-_A2F6_/\ S!=2_P# 9O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]I#:!FCC!<,SL3R2<4 ,TCX]>(;C6=+T_5O![Z.->M9)M&>2X!,KJF[RY!_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>anvs-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %0 H<# 2(  A$! Q$!_\0
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M#H14M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKBTTV"?QC:Z-X>:XU&.T\9310V@UA8?*\G:9(9(E^_+G:H\WR<I@$T >RQ?
MK14G,RWU_D^)X_%0!=3_ *0D*Q"/)7)3:H)S\V<\ULZ%\,=/T"/PFD%U=2#P
MY#-!;>85/FB10I+X'4 <8Q7C\_Q5UJ;4H8_$GC6'X>SQ:=87-C"FG++'K4LH
MS*PCF3S7 ;Y/*CV.N=Q/(K!/BCQ+X-_MF*7Q?)H^CZEXLUEIM;U%K>W2Q$94
MPVZ/)!(N)-SM\RDD1;5()H ]RL/@]I-EX(/A4W5W<:9)J<FIS";86F+W9NFB
M;Y<;"YVXQG:,9[U)XP^$VE^+_$=MK,EW=6%ZNF7FD2BU*!;FVN%&Y'!4YV,
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M=V%UX%U%]1M+>W5"ERS!05D)Y ^0=/6BZ"Y\(?$SXOZA_P %#_CM\'-"\!>
M]>TC2/".KQZUK6M:Y:B%K,!T+QY!(  CX&<LQ  XS7JWPR\'WOBS]NS]J[2S
M]IL(-9\.VUA#?F-@@9X(TW*Q&#MW=O2OO!50;N%&3DXXS2MY;<$@X]Z871^4
M?PS_ &Q=2_9F_9\U/X!>(?A%K]SX_P!)2[T>SAM+0M9:CYS/B5S]XYWG[JL&
M&,$9.)_&'P1\0?"_]EK]DGPIX@TV[?5H_'MO?:A8F(R-:K-+))L<+G:%#J#G
MH<U^JO[LD'Y<CH?2E!0=Q^=*Z"Y^?G[6VCW-_P#\%*_V;KN.PGGM8(%\V=86
M:-")YB,L!@8//-;UYX3NO$G_  4K^)5DD<]K;ZK\,_L*WXB(19',:<-C&X @
MX]J^Y<IC&1CTS2Y4C&1CZT707/RC^ O[7FM?LV? W4O@)K?P=\1:A\0M(:\L
M+&VLK,FUU#S6=O,F)^; W')4,&4 \5S.M:'JC?\ !('PW8C3+S[=_P )9N:T
M6V?S /M4Q^YC./P]*_8$[,Y)&<8SGFC*]<CZYHNAGYL^.?!M_P"+O^"EOA:Q
M$=W:VNH?#A]/.HI"Q6!Y+*Z3.[&,@L.#7*?LT_M2R?\ !/SP%KWP=^)/PY\3
MR^)=+U.YN[&XTBV62WU%),;&#EA@$KPPW?+CN"*_5+"L".HZ$4GDH=N4!V\K
MD9Q]*8'!?!7XC:G\5?A=HGBG6/">H>"=0U"'S'T;5"#-$,X!XYVL.1D X(R!
M7R9^W!^T18^&O%VH?#3XN_![4?$7PBU;3?.LM>T;,]S)>CE63[JQ,GS#KN'!
MY4D5]XE >HS2-$CKM90R]<$9H _*<^%O&>G?\$@_$^GZW9:BD5QJ4<N@:==(
M7NXM.:^A:)74#/7>PX'!!X%=/^U[I7B#X6_$7]F3XZQ>'=0U_P ->&-*M+35
MHK&,O+!\@8$CME9'P3@;EP2,U^F>T9SCFD\M>>.O7WH _/;]F>]O_P!K+]H+
MX\_%73]"U/PQX8U?PQ'X4TR35(O*EFD:/!?N 1M!."<;EYKRSX#?M?ZU^SE\
M"+_X"Z[\&?$=[\0]*6[L+*SM+/=;7_FL[%YC]X ;CDJ&#* 01SC]6Q$BJ%50
MJKT & *7RUW;L#=C&[OCZT ?G'\ _@E+\8?^"3MYX-O8WTW42FH7MM]LC,/E
M3P73S1YW8PI*;<^C9J;_ ()>> ];^+E_J'[0?CN<7^MBRB\*Z&V,!;:WB2.2
M;W9MNW/KYGK7VQ\=/A2/C;\+/$/@>36KWP_;:U +::_T\*TRQ[E+*-W'S %3
M[$U;^#/PJT?X(_#+P_X'T!7&E:+;"VB>7&^4Y)>1L?Q,Q9C[F@#M!P*6BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y+XF?#K3?B7X5NM'U&2
M6W#_ #P7<#;9+>4?==3_ #!X(R#7RO86>G?#GQ*OA'X@>&[2\O@-]MJMMO1+
MN,GAQSCV(Z@]:^U",BN.^)OPRT?XHZ"VFZK" \69+2\3B6UEQPZ'^8Z$<&O.
MQF$^L0T=I+8ZL-65&?O*ZZGD<7AGX?3('3PRK(>A\P_XU)_PBOP_Q_R*R_7S
M#_C7G&F:AKGPT\0MX7\8*L5QDFTNQ_JKN(' =#_,'D&O1(Y5E0,C!E/0CFO@
MJ[KT)\DVS[NAA,+B*:J0;L_,?_PBW@#_ *%=?^_A_P :/^$6\ ?]"NO_ '\/
M^-)16'UBIW?WG1_9M#S^\/\ A%? &?\ D5Q_W\;_ .*I?^$5\ ?]"N/^_C?_
M !5)4EM;3WDOEP0O,_\ =C4DTU6JR=DW]Y,LNP\5=WMZC/\ A%? '_0KC_OX
MW^-'_"*^ !_S*Z_]_&_QJQ<Z7>V4?F7%I- G3=)&5%5LYHE5JQ=I-K[Q1R_#
M35XNZ]13X7\ _P#0L ?]M#_C1_PBW@$_\RR/^_A_QI*ECM)Y+62X2%S!&0'D
M X4^AHC6JRT3?XA++\/'5W^\9_PB?@''_(L?^1&_QI/^$4\ ?]"P/^_C?_%4
MT#!-+25>HNK^\O\ LVAY_>.'A?P"IR/# !'I(W^--'A7P!_T*X_"1O\ &K,.
ME7MS#YL5G-+$>CI&2/SJ*"UGN9V@C@D>9<YC526'X5ISUVEOKZF7U'"Z^]MO
MJ,_X13P!_P!"P/\ OL_XT#PKX S_ ,BN/^_A_P :GNM.O+)=T]M- O3,B$"J
MQ.*B56K'25U]XXX##35XN_S'_P#"*^ ?^A8'_?P_XTW_ (17P#_T*X_[^'_&
MK::1?R0"9+*=HB-P<1D@BJ9/)'<=11*I5A\7Y#A@<-)VB[_,?_PBO@ @ ^%Q
MQ_TT/^--/A3X?CIX77_OX?\ &F],CJ:L"PN1;Q3^0_E2G:C[>&/H*I5:KV;!
MY?AX[O\ $B_X17P O(\+K_W\/^-'_"+^ 2/^17&?^NA_QI]S:3V,YAN(GAD
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MU&D90 9  Z #@#TJ2OT0_. HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLC$]@_MO"]W]QTY]Z0D9Z5S/_"@_C.>OB/0/S?\ ^-TO_"@_C-_T,6@_F_\
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M9_\ H8M _-__ (W1_9&)VY0_MK">?W'2<8/8T \\US7_  H+XS?]#%H/YO\
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MP/X>OVU! EO&L<:+'&BA51!@*!T '84EK;Q6EO'!!&L,,:A$CC7:J*!@  =
M!VJ:OM:%&&'AR0/B*U:>(FZDW=A111708!1110 4444 %%%% !1110 4444
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M9\0Z5I/E%5E^VWT<)C+ E00Q&,@$CU ->.?LX^,-8E\>_$?P3<>,9/B)X?\
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M_$4FE^';66Q\6^'+=(OM>GB1HX8[E5) DXWY5BKY9@ <U]'4 %%%% !1110
M4444 %%%% !117F?[0'Q^\,?LU> '\9>,!?G1ENHK0_V? )I?,DSM^4LO'RG
MG- 'IE%?+GP;_P""D/P0^.'BZS\+Z+KU]I>NWS^5:6NLV36_VAST1'!9-Q[
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M&>W%?=EQ^RPGC+]FJ\^$_P 1?&.L^/)]0B)N_$5^0+D3[PZ/$#D*J,!M4D\
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M%3C/7I7T]^TS^S##\?OA[X4\)Z?J\?A2S\/ZS9ZI#LL_/3R[=65857<NT8(
M.>,=#5O0/V=I-$_:M\3_ !F.N+,FM:%!HW]C?9-IA\MD/F>;N^;.SIM'7K0!
M\)? K]JOXD_ W]GK]I"SU_7KGQCK'PZU.#3-%O\ 4F:X=)9II8-S,QW,@9 X
M#$XY'2LKXA_!#XV_#S]DN[^.Z?M!>)+O7-8TZVU/5-)-W(EL+>Y9&VPOO^61
M2Z8VJHX8# KZ@M_V/K'X,^%_V@-8UNQO_BYI7Q"NA?W'A72+-8+J-!+(^V)F
MEQ(Z^:&!&T_N^ 3Q7P#X[GMO&'PJE^&W@_XF_$_QI=M)%;Z+\)]0\/R0RZ:R
MR#Y;F8,RR+$,X"@#.. !0!^MO[(NMZAXC_9=^%^JZI?3ZEJ5WX?M)KB\NY#)
M+,YC!+,QY))[FOD7]H?X>_$+]DGXY^+_ (T^%= M/'?P?\5-%<>,_#=S&DTD
M7:24(PZ#EPPR 6(88YK[,_9L\%:C\.?V?/AYX6UB'RM5TK0[2UNXNNR58U#+
MD<'!R/PKYW^+?[#?Q.\4^-O%<G@OX\:SX:\#>+Y"^M:!?Q/>LH==DJ0NS<(R
M<!>,#C) % 'S=_P40@MOC5XP_9H\8>"_%5WI_AKQ<8['1XHHFB&G/YT7^D*@
M(VR#S%4@8(\H<U] _ KQ=XI/_!2+XI^#-2\2ZIJ>@Z5X9M#!8W-R[6XE$=H&
ME6,G:K,6<DCNQYKM?B9^P5I7BW3_ (&Z5X=\0MX<T;X778N+>VFM#=/>@/$Y
M#/O7:Q,1).#RYXIG[0O[&7B;QM\6E^*?PE^(DWPQ\=75F--U6X%MY\-[ ,;2
M1V<!5'0@[1T(S0!\_>'OVEO&_P ,_A'^V#XK&NWVJ:GX?\8R:;H9U&5KB.P$
MEPT2A%8D!5# A>GRCBN!^,_[+/QE\+?L=ZY\3=9^.6L>(KG6-+AOO$'AR^E>
M:QEMIG1E6)F8@.NZ,Y"J." 0.OVU\.OV&_"?AG]GKQ-\,O$E]=^*;CQ=-)?^
M(]=D/ESWEZY#>>G79M905!STYSDUXE?_ /!-CXG^(O -_P##S6OVC-8N_A_!
M"L.DZ4--SM"L#&MQ^\!=$ X0-C(!XQB@##\3_%#Q)^SAKW[*'Q!FU34/^%9:
MUX:L?#NNV(N&-I%,T"E)S%G:& ?=N[B(UZ+^RS\4_$'[4'[5_P 2_B#9:IJ2
M_"?PU /#^AV2W#+:7EUD%[CR@<,VT,<GH)$J+]O+P[I/@C]A_1/A?>:=+XN\
M1W$>GZ)H*6UNX=KR((@N0!G8%4'.3CY]N3FOHW]F;X'Z9^SK\%_#7@C3(5#6
M5LKWTZCFYNW ,TI^K=/0 #M0!ZFOW12TW=['\J-WL?RH =13=WL?RHW>QH =
M13=WL:-WL: '44W=[&C=[&@!U%-W>QHW>QH =13=WL:-WL: '44W=[&C=[&@
M!U%,\SDY4C\*<"&'% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!@^-O"%CXZ\+ZEH.I>>ME?1^7(]K*8I5Y!!5QR"" <U^?/Q3\#:A\#
M_'9T;Q =0U31;K$FGZNEW/%YB$_<?#;=X[CCUK])*YSQYX(TCXB>&K_0=;M4
MN]/NTVLK#E&QPZGLP/((KQ,VRQ9E0<%)QDMFFT>MEF/6 KJI."G%[II.Z^>Q
M^?\ ##X?G0,#JQ'MJ4W_ ,53_L>@>NK'_N)3?_%5G_$CX=ZS^SWXJAT;5Y_[
M1T>\!?3M47@3*#RC#LZY&1^-,CG690R'*FOYSS!YIEM=T*]25UUYG_F?T;EN
M"R;,\.J^&IQ:?]U:>3T-06?A\]]6_P#!E-_\52?8] /?5Q_W$IO_ (JL^BO,
M_M'&?\_9?>_\SU?[!R[_ )\Q^Y?Y&C]B\/\ ][5O_!E-_P#%4&R\/^NK?^#*
M;_XJLZ@=#1_:.,_Y^R^]_P"8?V#EW_/J/W+_ "-#[)H [ZO_ .#*;_XJC[+H
M'KJ__@QF_P#BJSZ!UH_M+&?\_9?>_P#,/[!R[_GS'[E_D:'V/0#WU;_P93?_
M !5'V70/75__  8S?_%5G]J*/[1QG_/V7WO_ ##^P<N_Y\Q^Y?Y%_P"R: 3U
MUC_P93?_ !5+]DT =]8_\&4W_P 56>.M!I_VEC/^?LOO?^8?V#EO_/F/W+_(
MT/LF@>NL?^#*;_XJC[)H'KK'_@RF_P#BJSB<#)X% ((R#D4O[1QG_/V7WO\
MS#^P,N_Y\Q^Y?Y&C]ET#UUC_ ,&,W_Q5'V/0#WU?_P &4W_Q59]%/^TL9_S]
ME][_ ,P_L'+O^?,?N7^1H?9- '?5_P#P8S?_ !5'V/0#G)U?K_T$9O\ XJL^
ME/3\:7]HXS_G[+[W_F']@Y=_SYC]R_R+_P!CT =]7_\ !E-_\51]ET#UU?\
M\&,W_P 56?11_:.,_P"?LOO?^8?V#EW_ #YC]R_R- 6N@'OJ_P#X,9O_ (JE
M^QZ!ZZQ_X,9O_BJS>_'&:=@@ G//3@TUF.-:O[65O5_YD/(\L32=&.ODO\B\
M;30,\'6/_!E-_P#%4OV30/76/_!E-_\ %50[@TE+^TL9_P _9?>_\RED.7?\
M^8_<O\C0^R:!ZZQ_X,IO_BJ/LN@>NL?^#&;_ .*K/HH_M'&?\_9?>_\ ,?\
M8.6_\^8_<O\ (T/L>@'OJ_\ X,IO_BJ/L?A_UU;_ ,&4W_Q54-K."54D 9)
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MZ1;1W0L/)_UT8C&2I!XY![=Z\WTWX?"[^'6H>+[O4%LK:*X%M:VPCW-<R8Z
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M?V4>91OI=WU:M_D<Q\1?A@/!%CI&KV&KQ:UH>J FVNE0HQP,D%3T_P#K5G>
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M[6OOIJ['T/\ %/XG1^"/B;'H<GAS2+[0WBA,R/:KYF')#$-_3%>3_';P#:>
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M&'?''_0_Z=_X+V_^*H_U(S7LOO0GQWE#W;^YGC^W!%)MXZ\>E>P_\,.>./\
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MO[F>.$$C'2@+@YX/I7L?_##OC?\ Z*!I_P#X -_\52?\,.^./^B@:=_X /\
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M_<SQ_:-M-V$D$,1C\J]B_P"&'?''_10-._\  !O_ (JE7]AWQN.OQ T__P
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M]X?Z]Y1_,_\ P%GC^VC;7K__  PYXW_Z*!IW_@ W_P 52C]AWQN/^:@:?_X
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M11D>M?/%S\1?B):?%;Q=I?AOP:OB+53IFD74UK?:R+73M-9TGWH)O+8N[,N
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MO&"<CTK+TKX.:_8^%?[/=[(W'_"=MXEPLS;?LIO_ +1MSM^_L[=,]^]>W44
M<9X>\)7^E_$KQ?KTYA-EJT&GQ6X1R9 8%E#[AC YD&,$]^E>%7?P0\::'\/?
M%'AZ?P-X3^).F^(/%>K:M=:1JFHO;;;>X</;R1R&(A9%.=V "."C9%?5%% '
M*_"[PWJ7A'X>^&]%UB[^WZG8:?!;7-P'9P\BH <,WS,!T#-R0 3R:ZJBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_ R/_XJC_A./#W_ $'=,_\  R/_ .*K\A_MNB_] *"C[;HW_0"@I\T_(/\
MB$F(_P"@K_R7_P"V/UX_X3CP]_T'=,_\#(__ (JC_A-_#W_0<TS_ ,#(_P#X
MJOR'^VZ-_P! *#\Z7[=HW_0"@I<T_(7_ !"3$?\ 05_Y+_\ ;'Z[_P#"<>'O
M^@[IG_@9'_\ %4?\)QX>_P"@[IG_ (&1_P#Q5?D1]MT7_H!0?G1]MT7_ * 4
M'YT^:?D-^$F(6^*_\E_^V/UW_P"$X\/?]!W3/_ R/_XJC_A./#W_ $'-,_\
M V+_ .*K\B/MNB_] *#\Z/MNB_\ 0"MZ.:?D'_$),1_T%?\ DO\ ]L?KO_PG
M'A[_ *#FF?\ @;%_\51_PG'A[_H.Z9_X&Q?_ !5?D/\ ;-%_Z -O1]MT4?\
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M]**/9H]+_6S._P#H*E]Y\%_\.T=:_P"BD+_X ?\ V5'_  [1UK_HI _\ /\
M[*OO2BCV:'_K9GG_ $%2^\^"_P#AVEK7_12!_P" '_V5'_#M+6O^BD+_ . '
M_P!E7WI11[-"_P!;,[_Z"I?>?!?_  [3UO\ Z*0O_@!_]E1_P[3UO_HI"_\
M@!_]E7WI12]E$?\ K;GG_05+[SX+_P"':>N?]%(7_P  /_LJ/^':>M_]%(7_
M , /_LJ^]**/9H7^MF>?]!4OO/@O_AVGK?\ T4A?_ #_ .RH_P"':6M_]%(7
M_P  /_LJ^]**/9H?^MN>?]!4OO/@O_AVEK?_ $4A?_ #_P"RH_X=I:W_ -%(
M7_P _P#LJ^HO'OQ<FT?XG^#?A]H$2:AXBUF1KV^W*633],B&99Y,="[;8XP>
MK,3R%(KT+7-=L?#6@WVL:I<I9:=86[W5S<R [8HD4L[''.  31[-"_ULSO\
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M,,MQ=(9$\Q#Y4:,Y4I\Q(! '4BCV41?ZV9Y_T%2^\^6/^':>MGK\2%_\ /\
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MWI11[*(O];,\_P"@J7WGP7_P[3UO_HI"_P#@!_\ 94?\.T];_P"BD+_X ?\
MV5?>E%'LHC_UMSS_ *"I?>? ]S_P3,UNYMY(C\254.I7/]GYQ[_>KZO^!?P'
M\-_L_P#@6'PUX;@8J6$UY?7#;I[V<@!I9#^'"C@#@5Z315**6IY6/SG,,SBH
M8RLYI=&QJK@^U.HHJSQ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M\[OB)X4\'Z;KGQDEU[2?%2_M ZGJT\OA:^TZ*Z$]POR_V;]AE3]UY287S Q^
M7$F\8Q7UQ\5+;7;K]E?Q7;ZM']J\32>$+F.[CLT+^9=FS8.(U7KE\X ]J]8P
M/2C  QVH ^1_BIX$BF_9@^!>@P:'*]M9ZWX5,ME%:L3"J-'YC,@&5 YW$CCG
M-=Y\=_!>L>.O&%_I&A.]AJ.J> ];TRWU/:RI%-+);",-(.G?'?J1TKWS STH
M"@#&!CTH ^+O''Q,T+XF_LYK\&M \-ZG/\1KK38- 'AF739H3HURBJANI9F0
M1K% R^8)58[MJ[,DUZ=\#_"4ND?M"_&74+ZTDEOG@\/V0U>6 K]J6.QPY1R/
MF&_.0">3SS7T&0#U%&T<<#CI0!\1MX?U.W^#7C*SATJ^C ^,R7,%NEK(";?^
MUK9S(J[?]7]YMP^7J<U[]X"TCR/VB/BQJCV3Q-<6NBPQW;Q$"55BF)57(Y )
MY /!//:O7L48'I0!\)V$FF>#?A0MYK?B77_AGKUAXY\23Z#K=GI$MW%'NO)3
MY,T&Q@\,R-PIQNV@JP(%?6?P3U_7/%GPL\+:UXETI=#UZ^L4FN[!8FB$3G_8
M;E,C#;3RN[!Z5W.*,4 +1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>anvs-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #$ ED# 2(  A$! Q$!_\0
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M'!_K=D/_ $%Q_'_(][HK-L=4GU"RM[J.S(CGC650T@SAAD9_.I_M-U_SY_\
MD45X+33LSZY-25T6Z*J?:+K_ )\__(HKYCU/_@HC\/M)U&ZLI]'U_P ^VE:%
M]L$1&Y3@X/F>U=6'PE?%75&#E;>QO3HU*M^17/J>BOD__AY#\./^@/XA_P#
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M_OV_^%:>RJ?RO[B/:P_F7WFU16+_ ,)CH_\ S^#_ +]O_A1_PF.C_P#/X/\
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MYS@9ZX..AQCW_P 5]"TR_O[:?[6JVGF)]H%N3%-*@4O#&1RT@WJ,8Y.0"<'
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M?F:^)_\ @F-_QZ?$/_?L/_;BON.OR7/?^1C5^7_I*/D<=_O$OE^2*G]E6O\
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M!X6?M*%&,9=U%)_@CGKYAC,3#V=>M*2[.3:_%E>+3[>%PR1A6'?)JQ117><
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M[ZJQ11<"O]D_Z;3?]]4C6ORG]]-T_OU9IK_<;Z47$>%/]ZDITGWORIM?4GS
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MT0;;G_GI%_WP?\:-MS_STB_[X/\ C4]%("#;<_\ /2+_ +X/^-&VY_YZ1?\
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M5;HH J?:+O\ Y]%_[^C_  H^T7?_ #Z+_P!_1_A5NB@"I]HN_P#GT7_OZ/\
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M]3$HHHK[\^@/NK_@F;)*EG\0O+A$OSV&<OMQQ<5]O?:+O_GT7_OZ/\*^)_\
M@F-_QZ?$/_?L/_;BON.OR7/?^1C5^7_I*/D<=_O$OE^2*GVB[_Y]%_[^C_"O
M/?BC)*\]GYD0B^7L^[N:]-KS?XL?\?%G_N_U-?$9O_N<OE^9TY3_ +W'Y_D>
M?T445^>GZ 7=%)&K6I W'S!@9Q7N'VB[_P"?1?\ OZ/\*\0T/_D+VG_705[U
M7V.0_!4]4?'Y[\=/T94^T7?_ #Z+_P!_1_A1]HN_^?1?^_H_PJW17U1\N5/M
M%W_SZ+_W]'^%'VB[_P"?1?\ OZ/\*MT4 5/M%W_SZ+_W]'^%'VB[_P"?1?\
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MYA3*?;_Z^/\ WA0![5!<-Y$?^CR_=']WT^M2?:'_ .?>7_QW_&GV_P#J(_\
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M +=%5/[*M/\ G@M']E6G_/!: +=%5/[*M/\ G@M']E6G_/!: +=%5/[*M/\
MG@M']E6G_/!: +=%5/[*M/\ G@M']E6G_/!: +=%5/[*M/\ G@M']E6G_/!:
M +=%5/[*M/\ G@M']E6G_/!: +=%5/[*M/\ G@M']E6G_/!: +=%5/[*M/\
MG@M']E6G_/!: +=%5/[*M/\ G@M']E6G_/!: +=%5/[*M/\ G@M']E6G_/!:
M +=%5/[*M/\ G@M']E6G_/!: +=%5/[*M/\ G@M']E6G_/!: +=%5/[*M/\
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M?LS^-/VAO%<L-OXAL/#GAFP\+W.FV+26BW<MQ>W3CS7*L!Y.Q8( DJDN"SX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>anvs-20221231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #- D<# 2(  A$! Q$!_\0
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M_P!J+6-*;QQ:^'-?M_&O]EZ3X0U34I8;>\T@.!&?L*6,GFB:'<_VKSUVL?X
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M,I<'_:'0_&G]EOQ'XOUWXT^+;?PWXA?Q6_C'0W\-7]A>3PR1V.RTCO);8(X
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M0 4444 %%%% !1110 4444 %>&Z)^QO\-HOAM8>"O$VC1>-M*L-4OM6MFUI
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M9F))8\DG)K1^Q6__ #PB_P"^!1]BM_\ GA%_WP* %^UP?\]H_P#OL4?:X/\
MGM'_ -]BD^Q6_P#SPB_[X%'V*W_YX1?]\"@!?M<'_/:/_OL4?:X/^>T?_?8I
M/L5O_P \(O\ O@4?8K?_ )X1?]\"@!?M<'_/:/\ [[%'VN#_ )[1_P#?8I/L
M5O\ \\(O^^!1]BM_^>$7_? H 7[7!_SVC_[[%'VN#_GM'_WV*3[%;_\ /"+_
M +X%'V*W_P">$7_? H 7[7!_SVC_ .^Q1]K@_P">T?\ WV*3[%;_ //"+_O@
M4?8K?_GA%_WP* %^UP?\]H_^^Q1]K@_Y[1_]]BD^Q6__ #PB_P"^!1]BM_\
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M7_B97/##!'[UJ_IKAK^)/T7YG?G_ /!I^OZ'+T445]\?$!7W]\(/^28^&_\
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M5[;7Y/F?^^5?4_4<M_W.GZ#/)C_N+^5'DQ_W%_*GT5YAZ0SR8_[B_E1Y,?\
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M_P#?)KV['C7/K?\ 9.6X/PWO?*DB5?[2DX>,D_ZJ+W%>T[+W_GM!_P!^F_\
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M+W_GM!_WZ;_XJC9>_P#/:#_OTW_Q56J*LH9&'"_O&5F]5&!_,T^BB@ HHHH
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M6+:HSZX%3?VI9_\ /S%_WV*M45+=]RDK;%7^U+/_ )^8O^^Q1_:EG_S\Q?\
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M 'Y_^RH\B\_Y^H_^_/\ ]E0!;HJIY%Y_S]1_]^?_ +*CR+S_ )^H_P#OS_\
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M*[6YRU9%G\(M0O+!H-7ALI!I^EIIFGK;7,J>>49R)9&4*R JP4H"W#2#)!%
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MGO[>0/#>1L94@:!D419V_*YX<Y&6QC!8#MFNSFF\E<['D]D&30!)153^T/\
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M7POUK5M3O/#FA^+6T?Q'X>\3,NE7C1S>)9[>.[6[FWW+X$^ZZ,K>9M4R*H3
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M&L&V\=:)>>.+_P (0WN_Q%86,.I7%GY3C9;S/(D;[R-IRT4@P#D;>0.*^)/
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M1EDRS':>.3QS3]$T'3/#.EP:9H^G6FE:;;C;#9V,"PPQC.<*B@ <DG@5>HH
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M'#,&8<G<<DYK6HH YJV^&7@^RM=2MK?PIH<%OJ;B6^ABTZ%4NW!W!I0%PYR
M<MGGFKY\):&=1^WG1M/-]]I^V?:OLL?F^?Y?E>;NQG?Y?R;NNWC..*UJ* ,?
MQ-X.T#QK9)9^(=#TW7K-'$BV^IVD=S&K=F"N" ?>DOO!?A[5)M*EO-!TR[ET
ME@^GO/9QNUF0  821^[. /NXZ"MFB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH A%I
M+MKH0QBY9!&9M@WE 20N[KC))Q[U-110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>anvs-20221231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #; DD# 2(  A$! Q$!_\0
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MLG2/[6@O?M3B39MAFB)27DKTP1N (!R!X_\ #G5?CA^TEH-Y\2O"_P 4-/\
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MXRSO([DC&"W&,#'SQX8^//B_QC\:-?M[GXI^"_A]IFA>,#X8A\ :S8H^H:E
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MSLRS15;S;O\ Y]XO^_Q_^)H\V[_Y]XO^_P ?_B:H19HJMYMW_P ^\7_?X_\
MQ-'FW?\ S[Q?]_C_ /$T 6:*AB>X9L211HOJLA/]!4U !1110 4444 %%%07
MTDL-E<201^;.D;-''_>8#@?B: )Z*\=\(^.-3D\-:_<0ZR=<NTT:"]A,JH3'
MJ+PS/);*J@?=\M#Y?++D@]:Y^[\>:C!#>10>,9Y-)MX9KBSUG]RS7=VMM#(M
ML6V;6&YW.P#<?N_PXH ^@J*\,U/Q_P"*/!6L33Z[*]S8//%</;V[Q@PJRRLL
M(+*-FY5 V$LS-$<']Z*]R4[@#Z^M "T55,]T#Q:@C_KJ/\*3[1=?\^@_[^C_
M  H MU7O]/M=5L9[*]MH;RSN$,4UO<1AXY$(P593P01U!IGVBZ_Y]!_W]'^%
M'VBZ_P"?0?\ ?T?X4 8FD_#'P=H-FMIIGA/0].M5>*406FFPQ('B):)MJJ!E
M"25/\))QBK.J> O#.MZ=J.GZCX=TF_L-2F^T7MK=6,4D5U+@#?*K*0[85>6!
M/RCTK2^T77_/H/\ OZ/\*/M%U_SZ#_OZ/\* (-$\-Z1X9LGL]'TJRTJT=S(U
MO8VZ0QLQ !8JH R0 ,^PKC?$_P !_".N?#;Q/X(TK3XO!FD>(XWBU%_#%O#9
M2RK)Q+RJ8W.NY"Q!.&/?FNMUG7)=#T>^U&>R9H+."2XD6.0%BJ*6('O@5X*W
M[=/@I6(.E:QD<?ZM/_BJQG6ITM)NQZ&%R_%8U-X>FY);V/>K#PEHFF6^C0VV
ME6<2:+"+?3<0J39Q[!'MB)&4&P!>.H&*I:A\-/"&K:;8:=?>%=$O-/T^4SV=
MI<:=#)%;2$DEXT*X1LDG( .2:\2_X;J\%?\ 0*UC_OVG_P 51_PW5X*_Z!6L
M?]^T_P#BJR^M4/YCM_L+,O\ GRSOK_\ 9H^'^K?$6+Q=?Z!97[PZ)%H,.CW5
MI!)IT,,=PUPCI"8R%D#NWS ].W>N[U+P?H.L-*U_HFG7S2VZVDAN;2.0O"K[
MUC.0<H&^8+T!YZUX-_PW5X*_Z!6L?]^T_P#BJ/\ ANKP5_T"M8_[]I_\51]:
MH?S!_869?\^6>Y7GP_\ "^H^)[?Q)=>&](N?$5NH6'5YK")[N(=@LQ7>!]#6
MI<:18WE_9WT]E;SWMGO^S7,D2M)!O&'V,1E=P !QU YKYY_X;J\%?] K6/\
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M<D@<=>E &G17+ZC\1]&T_0],U56N;VWU)/-M8[2W:261 AD9MG4!5!)S].I
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M+K_T4U?E1-_K7_WC7A9E\4?F?J7!O\&MZK\F,HHHKQS]#"BBB@ K])_V7O\
MD@_A3_KG-_Z425^;%?I/^R]_R0?PI_USF_\ 2B2O4R[^*_3]4?#<7_[C#_&O
MRD=C\1_^2>>*/^P5=?\ HEJ_*^7_ %K_ %-?JA\1_P#DGGBC_L%77_HEJ_*^
M7_6O]37Z/E'P3]4?F&'V8RBBBO?.L**** "OTF_9E_Y(9X4_ZXR_^CY*_-FO
MTF_9E_Y(9X4_ZXR_^CY*\7-OX,?7]&<V(^%'J%%%%?*' %%%% !1110 4444
M %<CXT\%W_B*UN4TW7)],>[>-;E93)+$\*@[HT570QEN,LI!QG&"<CKJ* .)
MU?P'J%_9Z2+34;+2[O3(F@MVM[ F%8WB\N11&9.!]TKSQM .X9JAI/P<M=-N
M8+:6\2]\/VWFO#IEQ;AB9)(1"_F/G#K@.0NT<N>3@5Z+10!Y_P"$_A-'X3\5
M)K$&I,8_LIA>UCA\M7<XR>&VA.,A O!_BQQ7>RQ+,A5QE3[XI]% %3^R[;^X
MW_?;?XT?V7;?W&_[[;_&K=% %3^R[;^XW_?;?XT?V7;?W&_[[;_&K=% %3^R
M[;^XW_?;?XT?V7;?W&_[[;_&K=% 'R!^TS D'Q(8("!]FCZDGM[UY-7KO[3_
M /R4IO\ KVC_ )5Y%7\_YQ_R,*_^)_F?T9DO_(MP_P#A7Y!1117CGLA1110!
M]5_LMV4-Q\/KUG4DC47&0Q'_ "RC]Z]A;2[8*?W9Z?WV_P :\D_94_Y)Y??]
MA%__ $5%7LS?=/TK][R3_D64?\)_/.??\C2O_B/E.;_6-]:93YO]:WUIE?P
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MS*<MDX4*<9.:]9?1;"2>29K.%I9)!*[E!EV">6"?7Y#MY[5ECX>>&!IT-@-
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M[]K_ (4?9KC_ )_&_P"_:_X5]"?D9;HJI]FN/^?QO^_:_P"%'V:X_P"?QO\
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M  B^K_\ 0,NO^_34?\(OJ_\ T#+K_OTU>/9GZ%SQ[F716I_PB^K_ /0,NO\
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M#X!&6S&%P,DACTKU:0.5/ELJMZL,C^8I]% %7R[S_GO!_P!^C_\ %4>7>?\
M/>#_ +]'_P"*JU10!5\N\_Y[P?\ ?H__ !5'EWG_ #W@_P"_1_\ BJM44 5?
M+O/^>\'_ 'Z/_P 51Y=Y_P ]X/\ OT?_ (JK5% %7R[S_GO!_P!^C_\ %4>7
M>?\ />#_ +]'_P"*JU10!5\N\_Y[P?\ ?H__ !5'EWG_ #W@_P"_1_\ BJM4
M4 5?+O/^>\'_ 'Z/_P 51Y=Y_P ]X/\ OT?_ (JK5% %7R[S_GO!_P!^C_\
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MEE*I\I;."0GR@(,0%APU>Z*20"1@^GI2T4 52U[GB.#'N[?X4FZ^_P">=O\
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M )]T_*@"W153^RK3_GW3\J/[*M/^?=/RH MT54_LJT_Y]T_*C^RK3_GW3\J
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MW.P#<?N_PXH ^@J*\,U/Q_XH\$ZS-/KLKW-A)/%</;V[Q@Q*RRLL(+*-FY5
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M:_O=3T\0.X6VN+M66Y=%W8&]78;<;0#\H%2>%/@;X(\#^/\ Q!XVT/1/[/\
M$NOECJ5XEW.RW!9E9F,3.8U8E%Y50>,9KNZ*9F87B+P)X<\7313:WH6G:O+$
MNV-[VV24H,YP"P.*@N?ASX:N]6\,:E)I%N+SPR)AH[QY1;,2Q&&0(JD+@QG;
M@@X'3%=)15.3:LWH.YY9?_LN_"O4OA]!X'N/!6GMX7M[V34K:P0R)]EN9'9W
MEA=6#Q-N=^49< D# XKKOA[\-O#/PI\-1:!X2T:WT328Y'E\BW!)>1CEI'=B
K6=V/5V)8X&372T5(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>anvs-20221231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $$ +X# 2(  A$! Q$!_\0
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M_P#/M_X^?_B:A\?_ /+G]'_FM<?7'4JRC)I'T>$P-&M1C.:U?^9VW_">0_\
M/M_X^?\ XFC_ (3R'_GV_P#'S_\ $UQ-%9>WF=?]FX?L_O.V_P"$\A_Y]O\
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MK\M/VV?^3E/%?^[:?^DL5=U#XC]F\'/^1_6_Z\R_]+@>&4445VG]CA5[0_\
MD-:?C'_'Q'U_WA5&KVA_\AK3_P#KXC_]"%,SJ_PY>C/VFQ>YZV^/HU6J**\D
M_P Q@KS#X^';H?AT_P#483_TGGKT^O+?V@CCP_X?/_483_TGGKMP7^\P]3"M
M_#9\R?M!Z59:U\*=9&I:[K.@6%L$N)I]#57N)=KKMBV$'?N8J ,CYMIS@&LK
MX7Z+?CQG<:MK.E?$&*^CL9+:"\\:7]E-%'&\B,\<:6[DAV**267HF,CH=_XP
M7NFVWPN\3OK%G+J.EFR:.XM(;@V[3*[! OF_\LP2PR_\(R>U<%\%[NQT[Q%:
M6'DZC%J]S8ZA]HAE\376JV\'V2]6W^59CT<X*R8!X85]A*"]LCRT_=/;=6DS
M8$9_Y;0?^CHZ^LZ^0M2DS9@?]-[?_P!'1U]>UXF<*SA\_P!#KPCOS?(****^
M=/0"BBB@ HHHH **** "BBB@ K\M/VV?^3E/%?\ NVG_ *2Q5^I=?EI^VS_R
M<IXK_P!VT_\ 26*NBA\1^[>#G_(_K?\ 7F7_ *7 \,HHHKM/['"KVA_\AK3_
M /KXC_\ 0A5&KVA_\AK3_P#KXC_]"%,SJ_PY>C/VPHHHKR3_ #&"O*OVASM\
M-Z ?^HPG_I//7JM>4?M&''AC03_U&$_]$3UWX#_>J?J85_X4CYM^*WB&?PS\
M-?$VJVUO97<MI822^3J(S;LN,/YBDC<H4L2F1NQM[UYE^SPGAG3=9U2#PWXG
M\)ZM'<6XGEM/#OADZ7)]X8=W+L64;B-AZ%LUWWQ>M].U#X9>)+;5KV33M/DM
M")+J"#SY8CN4HT<?\;[PNU>[8KG/A=XNU;5M0MDUCQ9J6K2WEK=/%IVIZ%;V
M$L3VUPL,Q=HF;YU8@;.F&SVQ7V\X_OHW[?UU7Y,\9/W&>JWTF;=!_P!-[?\
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MC]I3Q7G^[:?^DL5=%#XC]V\'/^1_6_Z\R_\ 2X'AE%%%=I_8X5>T/_D-:?\
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M(ZLZ9^PK\5[34K6=].T[9'*KG_B8)T!!HYX]S.IQAP\X22Q]+;^>/^9^D?\
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M4T") S;$E0R(OFHS?*K1[@S$ $D@5ROC/]M_P!HFD>$-?TC5K?4_#6I>(_[
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M[L=&^(\PNI;6$*!I4X4X>V]-LI\U5/"D #@4WQ?^QSI_B/X+>%OAE8>-M?\
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B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>anvs-20221231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #B 0(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z\!^)WQ
M5?Q?<3Z#X?NGBT.-C'?:G;N5:\8'#0PL.1&#P\@Z\JIZFK_QL\4>)]7O9_"^
MCZ%KD>CA0+[4;2RD8W8(SY,3*/E3!^=^I^Z.YKRS19H;FR@DMXS#!MVI&T9C
M*!3MV[3]W&",>U?39;@8->WJ-/LOU?Z'FXBN[\D3U/X7?%";09;70/$5T\]A
M*PAT[5IVRR,>%MYV/?LDA^]PK?-@O[?7RE=26T5@ZW=N]W;SLELUND)F,QD8
M(J;!RV68#'O7J/PA\4Z_;7R>&]5TG7)M.6,O9:M?V4D9B5?^6$[N/F('W).2
MP&&^8 OCF.#C%NK3T[K]470JOX)'KE%%%?/G>%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\?:$,VG
M_;:?_P!'/7V#7R#H(_T,?]=I_P#T<]?29-O4^7ZGG8O[/S_0V4&+K1O^PQIO
M_I9#7U+7RZJXN=&_[#&F_P#I9#7U%6.;?'$O"[,****\$[@HHHH *^:_C9^V
MC:?!&Z^(-KJ/A.ZOKOPO-I!M8(+L!M4MKU)&>=!L)00BWNMP^;/D]1NX^E*\
MH\?_ +-'@WXE?%'2_'FMK>RZK8:3<Z-]ECG"VMQ!,DL9,J;269%N)PAR,>:W
M6@#SSXC?MKV_@K1O$VHZ9X.N?$ZZ5K\NC6D-E?*LE_#;V"WM_=J"AVI A=<<
M[F4#(+"M'XI?MB:?\/;CQ#]A\/-K]CINAZ/KD.HQ7GEV\D.H74L"22L(V,4$
M8B\QY<-A6^[QRFB_L&?"JQT+PKHNKV>H>+=)\-V=[;6=IKMR)E>2ZF66>YE*
MJI>8[%C#9P$&,=ZUO#W[)6B>#].AA\/^,?%VC7UOH=AX>@U2WO+=KF.SLYIY
M8$R\#*W%PR'<I!5$& 1D@%SQ'^T9_P (W\(_"/BH:':ZWKOBO4+;2-'TC1-8
MBNK6[NYV<1A;T*$\K9&\ADV\*I^7/%5M9_:LT/X=+:V'Q'TN\\,>(EM_MNIV
M>EQRZO:Z7:-,T,=W<7,,86.%V4X9U4\-E1M)J\?V5/!,?P>T?X=VSZK8Z?H^
MH#6-/U6VNPNH6NH"=Y_M:2;=HD,DDAQLV8<KMV\5B^(?V./#WBUS+K7C+QGJ
M4][8IIFN2R:C"AUZS2=YDM[L)"HV*TLBCR1&=CLI)!H YOXE?ML:9HGCN#PY
MX4MQJ$, UV/4M9U&PNEL(IM.T^6Y=(9E7;,4DC5)%3+ $XR176>&OVO_  -J
M&NZ+X;U&[NX]>NOL5K<W<&EW(TR*\N;%+R*+[0R;5,D;DHK'=\I!P:H:A^Q)
MX)U#7M0OVUOQ/%8W4NKSQ:+'?Q_8;.74[>6"]>%#$6!<3.XW,P5C\H )4Z,G
M[(_A>TLI1INI:K#?)JNGZY;2SS*Z)=V.GK8V^Y0H)C\N-6=002V2&7@  O>!
MOVH_"?Q4TSQ?/X6CU56\/Z7'JC7.L:3<6EO-!-$\EO-&64&2.18RX*C)7D=:
MPO!7[9G@G5V\)Z3JMU=?\)!JUMH_VBYT_2;LZ9#<:C;I-:J9W3$8EW;4$A#9
MX(!KE_V0OV2_$_P)\#>+?"OBK6M)O='UJTBM5AT:,&;?Y3Q33M.T,;?.I3;$
MP<1[3AVW&NUT3]COP3H-E;VMM?:VT<-QX=N5,ES&26T:-([3/[OHPC7S/[QS
MC;0!U'BSXQW/A7XW>!O 4GAN:6Q\4Q7K1:Z;R-4BDMX3,T8A +M\H&6.T#<,
M;N<8WP>_:0@^,/Q-\8^&K'P]<6.C:/:VU]INNS7 9-8MY9KB S1QA<I'YMK*
M$8L=Z@,, BM'X@?L_6?Q$^*/A7QO=^+?$>GW/AO>++2["6V%DPD!6<.KP,[>
M:AV-\X^4?+M/-5OAK^RI\./@]X[U;Q9X,T0>'M1U'2XM):&T;$$,2.[[HT(.
M&8LN<DC$:8 YR <G;?MBV4_B/XJ:<WA:ZAL_"&DZAJ^E:@]TOE^(([!GBOA$
M-O[ORKA1%DEL[@W XK;^"O[1>I?$;Q3:^&?$_@T^#]:U'P]#XHTS[/J:ZA;7
ME@[(C'S!'&4D1I(PR%?XP0QKG]+_ &!?A5H5I8+ID&JZ?J$6G7^EWVJPW@^U
M:M#>6[PW'VIBI#L2_F@J%Q(JGH,'M_A#^SCH7PBU@ZS'K>O>*M<72X=$M]1\
M0W,<LEI81'<EM"L4<:(FX!B=NYBHR3@4 >4>"_V^M-UOQ#J=GK?A*73["&'5
M+BVFT74!JUULL;X6<GVFUCC5[8N[!D+%E*Y.X8K0US]NWPO=)*GA;3=3O[>X
M\&:CXMM/$%UIT_\ 9T M&>-X[D(OF*%DC97*CAMJC)=<]7<?L;_#Z7X7:IX(
MBBN[2VU+5FUJXU6%8/MTMS]L:\3S&,129$D; 25'78 I!K*M/V&_ VG^&K#0
M[36?$MK:6^@:OX:F:.[A#7ECJ,KS3I+^YQE99"Z% N"H!W#B@#5M/VQOAQ%X
MEC\+:AK+?\)%'8^?<BVLYC;>>MG]KDMT<C_6"'+A#SCC[WRU@ZS^WCX#M?"J
M:WH^C^*=>#7VD6WV*'1+B&X>#47*VMW&DBJ9(GVN%*_?=0@Y85KVW[&/@>Q\
M7ZKK]I>ZK;/JML\%Y:*+5HY9'L_LC3"1H#,C&, [5D";QNV=<RZC^QWX.O\
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MFG_?(H C_M"U_P"?F'_OX*/[0M?^?F'_ +^"I/L\7_/-/^^11]GB_P">:?\
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MBBORL_%#T;]GIG3XM:,8T\QML^%W8S^Y?O7V-]IN_P#GS'_?T?X5\>?LZ_\
M)7=%_P!V?_T2]?9]?T;X<_\ (IJ?]?'_ .DP/ZT\)_\ D1U?^OLO_28%/[3=
M_P#/F/\ OZ/\*/M-W_SYC_OZ/\*N45^IG[24_M%W_P ^8_[^C_"K2$E06&UN
MXSG%.HH **** "OS?^)1>/XH> FMO^$,M[QM*U=1<^/&W6+I]KC)C@08(G!P
MQ8$90$<]OT@KX'U#X>^-?&!\QA\-]1TR.>X%C%XA\-S7L\,9G<[6<RXSZ[0
M?2O7P*;C-+R_4Y*^DH_/]#T+P 9SX4T0W,OA>:7^W;'+^#@1I^/ML'W<D_/_
M 'N?2OK:OD_P1X;O?"GA?1=.U"#0+:Y77;!S'X9TXV-E@WL&,1%CAO4YYKZP
MI8_[%PH=0HKF-4TS7;CQOH][!<(-$MUD6>W$S(6+(WS,H&'P1'C)X^8]ZZ.9
M967]U(L9]67=_45Y)UDE%5/)O/\ GZB_[\__ &5'DWG_ #]1?]^?_LJ +=%5
M/)O/^?J+_OS_ /94>3>?\_47_?G_ .RH MT54\F\_P"?J+_OS_\ 94>3>?\
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M %TF_P#1SU]-U\S^$A_Q)+?_ *Z3_P#HYZ]O+=I_+]3BQ&\?G^AJ:B/DTO\
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M -^F_P * +E%4_[5MO[S_P#?IO\ "C^U;;^\_P#WZ;_"@"Y15/\ M6V_O/\
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M* "OG+P:/^)!:_[\W_HZ2OHVOG3P:,^'[7_?F_\ 1TE>QE^T_E^IQU]X_/\
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>anvs-20221231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #8 0 # 2(  A$! Q$!_\0
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MOTKO*\V\=-M^(6E_]@BY_P#1]O75ADI5$GY_D9U-(D']H>)_^AH7_P %<?\
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MB@ KS'X@MM^(.E?]@BZ_]'V]>G5Y9\26V^/])_[!-U_Z/MZ[<'K67S_(QJ_
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M#+C*LV>O^S^M==:K"A3=6H[);G4VDKL[2BO /^&FKK_H#P_]]FC_ (::NO\
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M<:,T1V[78C(!7Y_E&-W'.>H!V=%1RM*N/+17]=S[?Z&H_,NO^>$7_?T__$T
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MVG_[Y'^- %JBJOVX_P#/M/\ ]\C_ !H^W'_GVG_[Y'^- %JBJOVX_P#/M/\
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M?,\=_ CZ(_9K_P!1XL_Z_H?_ $FCKVBO&?V;QMB\6#_I]@_])HZ]FKX3,?\
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M#_O$/\/ZL****^!/E3:\&?\ (RV/^_7LU>+^$)%B\163.P50_)->O?VG:_\
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M_P!]BC[=;?\ /Q%_WV* ,SQG_P BS??[J_\ H0KQFO8/&%W _AN]59HV8J,
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M"!GV_"M[X$_ _P /_L]^ (?"/AJ2\ETV.XDN=]]-YLI=\;LMZ<"N+_5[*_\
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M/;.X^&UI:VGA:ZFGDC^RV[P>9*LC1REU<!]X>-E.X9^7'0"@#LO[-M_[C?\
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1B@*2<D<#!10!ZM1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>anvs-20221231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $D 1$# 2(  A$! Q$!_\0
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M0P1*7DED8*J*!DDD\  =Z+:YBO+>*>"5)X)5#QRQL&5U(R""."".] $E%%%
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M#/\ H;="_P#!E#_\51_PM#P9_P!#;H7_ (,H?_BJ/^%7^#/^A2T+_P %L/\
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M,_Z%+0O_  6P_P#Q-'_"K_!G_0I:%_X+8?\ XF@ _P"%H>#/^AMT+_P90_\
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MQO\ ^"CO_)V7BG_KWL?_ $EBK]D*_&__ (*._P#)V7BG_KWL?_26*ONN#O\
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MR+_=< BG 8&!P* *IOG!(^QW!QW 7_XJD^WO_P ^=S^2_P#Q57** *?V]_\
MGSN?R7_XJC[>_P#SYW/Y+_\ %5<HH I_;W_Y\[G\E_\ BJ/M[_\ /G<_DO\
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M._Z^(_\ T(5_1_7D8_>/S/2P>TBM#=M*X4VTT8/\3A<#\C5FBBO)/1"BBB@
MKP;]I(9\2^$/^O34?_0[2O>:\*_:-7=XG\(?]>>H_P#H=I7JY7_OD/G^3.7%
M?P7\OS/G7XKZ[<^%O!%[?V>JR:-=B2&&&Y@T_P"WSL\DBHL4,&X!Y7+!5R<
MG)X%<'\%="T&P\<:O=W>G^*;/X@W=BKW<_BN.**:ZM/, W1+;GR-H?:"!\RD
MC/6NP^/M[I.D?#>6]UN>YL;"'4+)O[3LYEBETV3[0FR[4L"#Y388K@[@",<U
MD_"D^'M;\7WFJQ_%*V^)7B**Q-K']G:UC2RM#(K/MA@XRSA-SMG[J@8%?9SE
M>NEV_P"#TOOVLO4\B*]QGU3^S:,>(_%__7II_P#Z%=5[Q7A7[.:[?$OBX?\
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M9Z6#VD%%%%>2>B%%%% !7AW[0R[O%/A$?].6H_\ H=I7N->)?']=WBSPB/\
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M*/PNQ+C&6Z/G_P#X8&_9_P#^B9Z7_P!_I_\ XY1_PP-^S_\ ]$STO_O]/_\
M'*^@**KVM3^9_>3[.'9'@4/[!?P"@E26/X:Z8DB,&5A-/P1R#_K*]R_LV/\
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M)6@8,"G<>3C!_O>U=.&DHU4Y.V_Y,RJ)N.GE^9B>71Y=/_X1;QO_ ,\_#?\
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M'&NIW#QV%BUBPM[33[>^#2VT\A>)I([CY/F964*^5#8&MXE_;<MX]/UV/1/
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M&QI$"X8K@8)Z=L5Z!10!GZ#H&F>%=&L](T;3[72=*LXQ%;65E"L4,*#HJHH
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M7KNLZ/9>(='OM*U*V2\TZ^@DM;FVE&4EB=2KH?8J2/QKYM_8L^#'C;X;7OQ
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M8*%MHM[O(R*5+ N[$;]H.U10!Z?:6D%A:PVMK#';6T*+'%#$H5(T P%4#@
M  "IJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>anvs-20221231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20221231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %4 G # 2(  A$! Q$!_\0
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MJ/-L>^9S2TR/[OTXSZT^J("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8EX/:O ];^$'Q+\;7_B>Z,6LZ$+V2YBMU&L$*#<7:1B4*LORI!;Q>:%X)9\
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M6$$TEO)<+.I5)(^9%)'=1R?0<U(SI:*C@GCN88YH766*10Z.AR&4C((/I4E
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M_H<_"'_@M>NGV"_Y^1_'_(\3VC_E?X?YGOU%> _\(W^T7_T.?A#_ ,%KT?\
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M^O-\'Q^[?FZ6-2R_: U+7O''B7POHG@F]U&ZT.XEMYKP72I;C$1>,LQ7Y2[
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M/_\ 0=TS_P #(_\ XJE_X3+0/^@YIG_@7'_C7.:FS16-_P )GX?/37=,_P#
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M?V@O LYVR3/87D"L5RV=JM^6 >:]DTS:D898LNX)))X''('N:?MY^7_@,?\
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MV-1?\)Q\5SO*?$?<BDC)T2 $XJ\\!6*3<^2WW'Z 'T(_"JPRT<<,\A=A'UZ
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MI\"-(N;VZEO+AKN^!EF<LQ NI !D^@ %9'[#&?\ ACSX;YZ_V2__ *-DJ_\
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MI,_((C\FT'Y@!V_6I)HS*8Y$5XQTSCJ>XH IE'!C"RLRABH+'[U,NH_]&#D
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MUUVO?&70]%\.:5KD%KJNMZ;J4'VF"72+%[@>5@$LV.%&#W]Z7UF%K^SC^/\
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M)75O\CO'_9"U+Q3X5\;7?B+6+JW\7:Y>7-W%;V&IR#3R<YM_-3: Y7 R2#C
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ME99%#,QY)PHY]JN?LC:UJ'B'X':5?:I>SZA>R7=ZK3W+EW(%S( ,GL  /PH
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M6=(C:,%0I*J<%\<"J%GHEKHL<L5NKQ++(92!_>/-6]+:YM3<-<3^<&8NJ@8
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M]KDV%;=P\!*YP2A'!].*O7?P+\+SW$4\>GM%<17TNI07%O=R1R)/(-LA5@>
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M') 8EQNZC"YQ7+P:5+<:9JI2:"0W&22J=<9ZT"/:_P!A]M_[(OP];UTZ4_\
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MR.W0(I))/'3'%<A;>+/B5J^O:3H%MK.DV5U+8W6J7VH"T%S#!")U2!  0"Y
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MX%+L!T!;&3S0@;>I\M>)OVB?'GAGQ->74LMI>^%+/5;R-8H;,">[L[.T#7#
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M!F4H-V >!GV))_&H3X>L)"GF6-L^R3SD#1 A7.<L..O/6GN'0\F^*/CWQ/\
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M/"]_:WTVO7&M7FDZ5:V<:77-]>-*\UW%"S,-C! 8RW'&>YKT3X;ZM?P?L_\
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MU&T@N9K:6TDF@21H9_OQDC)1L<9&<'%:5%%,3U"BBBF(**** "BBB@ HHHH
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M:D1W97P-I'4THP10,C,1,(/H:><L!GTI?+=3GJ#V]*0\ DY]*!#7W#EON\U
MRAR%7@=:GF&XISBHIOD(P<$CK0,:$$9&3R:KWLRQ(2A&X<\U9;DY!W8%,:(.
M"I Y&,X]:!%(W#7,2MN*LW'/2GI:R"(QR'=$1U%9^FV$D'FJS%F67@GM6PRE
MR5W;3CCFF!%%;K;J%B&!2,K2'!X%.MTDC^61MQ'.10['<5 H Q_$,]S;Z7=-
M;HK2K&2@?H37SU^S#?W.M>-_B+KFK'[+JT=^+5[>$GRC&%&U]I[G/6OHS6DD
M6QG$$;2S;#M4="<5\P?LLZ%KLWQ:\>^(?%8;1[ZXD^S6FD2\"6)<XEQWSZT
M?3N^.;!BY%,U.;RM$N=LZV\C*0&/05*T13&T;>3TXKFO&5Z-/%BF&EN+B81B
M-.3C/)- AGA6VEL+B.T.R,1 L)<#$I/<5UQV")0Q!8]17,:K:I;:YI$\K20%
M05:%%R']&/I6_'/--=22E1':HH4*PY)H'8D%K'Y@RG.,YK.GLT%S=2P>;!*L
M1+G^%QM/:M6-F=L\YZ?2HM2*PV\KNS%4@?A?H:!'HG[$G_)I'@#_ +!\W_H^
M6K7[&'_)O^C?]?E]_P"E4M5?V(CG]D?X?G_J'S?^CY:M?L8?\F_Z-_U^7W_I
M5+0,]QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)\
M6ZRWAWPKK.JK&)FL;.:Y$9. Q1"V,^^*^";WX;?'CXU>+;WXK>![S3?#$'B&
MUCMGBCN8Y/-C@=T0LLB$J>N:^Y?BAS\-?%G_ &";K_T2U<+^RK&S_L]>%EC?
MRI#;SJKXSM/GRX.*ZX*$:+J.*D[I:^C\T8RYG445)I6Z?(^6O^&>_P!K/_H=
M+$?\"MO_ (W0/V>_VLCU\:V/_?5M_P#&Z];@3XKGXZ-\/V^*]P8H]*&JF^_L
M:URWSA?+V[>G/7->KZ!^TGX%UNZOK./5)HY=,2Y:^EN;9HT@$#;'9VZ#)^Z.
MK=A62K4[7]G'KWZ:/KY'T>)R'%T%%T:KJII2]Q2=D_AO>"WUMZ:GR:/V>_VL
M5Z>-++\[;_XW2-^SU^UDQR?&EC^=M_\ &Z^QO"?QS\+>,9[ZVLWO[>\M;4WW
MV2]L9()IK<?\M8D89=3[>HJGI_[07AG54UJ*"#5H=3TRQ?4&TR[TZ6&YGA7^
M.*-AEQG XYYH=:FMZ<?Q_P SS_[)S#F<>6=U:^FU]NA\C']GK]K(\_\ ":V6
M?]ZV_P#C=,/[//[61Z^,[$_\"MO_ (W7TO\ "C]J/2O&?PZOO$_B*SG\/"RF
M\J3]Q(T,I9V6-(7(_>N=H!51P3BNOTWX]^#K_P .ZWK,]_-I4&B!3J-OJ=N]
MO<6V[[FZ-AN^;MCK3=:FMZ<?Q_S-:^29EAZDZ<XSO%\KMJKZ:72UO=?>NY\<
M']G?]K)@0?&=CCTW6W_QND/[.7[6##!\:6)'H6MO_C=?0OAKX\W'CW]HK0]'
MT6[OK?PS/H<MS/I]_8&WD,P9MK_.H?!7:00<&O2M<^-7AGPYK?B32M0EN;:Z
MT#3EU6[+0'8UN>C1G^(Y.,>M+VU.UW3CU[]+^?D77R7'X>I&D^9R<5*RW2;L
MKJV]]/FCXO3]G#]JZ-<+XSL%7T#6V/\ T71_PSE^U?\ ]#E8?]]6W_QNOKV\
M^.OAW4;&V@TN]N4O-3T";7;2X%H9$@MU0D/(,\'(^[W(Q7FK?M7/X:L_AI;3
M6E[XI77[7[1>:K;:9+&TB\@&&%<[GRO*9RHP>]/VU.]O9Q_'S\_)FM#(,RQ"
M]Q2OKH]'HF^JM]EZ7NWLCPS_ (9Q_:O'(\9V.?\ >MO_ (W0?V<OVL#U\:6/
M_?5M_P#&Z]XTW]IFV\&_$WXC6?C+5+MM'L;RVCTZ&&Q+_98GCR[.47(7)&2Y
MKZ#N->LH- EUKST?3DMC=^>I^4Q!=VX'TQS4JO3<>?V<;?/_ #.;&93C<#*"
MJN5II.+Z.Z3LG97:ND_,^!!^SE^U@,_\5G8C/^U;?_&Z/^&<?VK_ /H<K'_O
MJV_^-U[C^SI\8?&/B/Q\+#QA?_:+'Q'I;:SHL30)'Y*+,ZM&"J@L NTY.3S6
M9\-?C_XJ'C_Q=H_B;4!<:9>W>I6N@71A1/(GMBW[DD*,Y7!&[)^7WH=>FE=T
MH[-]>FZWW/6J<,8^G4K4U5NZ:3T>Z=[\ONZ\MG?T=KGD/_#./[5__0Z6/_?5
MO_\ &Z/^&</VK_\ H<['_OJV_P#C=>S>%?C!XS@L?@AK^JZRUUH_B1IM-U9&
MMXE5[AG<0R9"@J<@# P.*TM5^,7C7[?\9=?T3.IZ1X76+3M,TT0*RM<C'GS$
M@;F"@DE<_P -.5>G&]Z<=+]^EO/S7WDRX:QL:CI^V7K?2_M/9VNX[\VO;EU/
M!C^S?^U>1_R.=@?^!6__ ,;IC?LU_M6.>?&5C_WW;_\ QNOJ?]G3Q1J/C*QN
M-6N/B3:>-[>:!&:RAL8[:2QF/+*0OS8[#<.W4UW'Q4\??\*_\,&ZMX/MVLWD
MJV6EV Y-S<OPBX'.!U)[ &FZT(J[I1_'_,\FMEF(I8SZDJCE.]NJU_[>C%JW
M6Z7?8^(!^S5^U:O3QE8_]]V__P ;I1^S;^U:!_R.5C_WW;?_ !NO>-!_:1\4
M'X/V>J7UCIM[XRU'Q%+X=LX8%>*U\Q7*[VRQ.T8)Z\\=*[/P)\4O%U]KGC3P
M;K6G:7>>,_#]O%=6[6,CPVM\DJDI]_)CYP#UZTO;TW_R[C^/9/OV9VUN'\=A
MU.4Y_ VG[RV4E%RU7PJ32O\ Y.WRD/V9_P!JH,S?\)C8Y;D_/;__ !ND;]F;
M]JIQ@^,;+'^_;_\ Q%?6WP ^)/B?Q_)XSM?%4&GVVH:'JQT\1Z:&\M0$5B-S
M$[L$]<#/I7KE4JL&D_9Q_'_,\G&8*M@J\J%6H[JVS36J3[=F?G<O[,_[5:]/
M&-D/^!V__P ;IP_9K_:L!_Y'&P^NZW_^-U^A]%'M8?\ /N/X_P"9R<D_YW^'
M^1^=K_LS?M5.I!\8V)S_ +=O_P#&ZP/A]^S7\58/CX^@^*/B'-HFOZAI;7RW
MMG;6]V/+4[0N&4!><]*_3 ]*\#U4?\9IZ&<=/"DW_HXUI!PJ<T>1+1[7_P R
M)<\&I<[>J.'/[&7C\]?CKJG_ (([6JH_8?\ &@N?M'_"\-3,IZ.=$MB1]/2O
MK^DQ7#RG9SL^2#^Q1XY\P.?CIJS,.YT6U-+/^Q9X[N8S')\==59"<X_L6U%?
M6V,T  4<HN9GR6/V,_'Z<#X[:IQZZ':TX_L;>/"C*WQUU4E@0W_$BM<$'C%?
M6=-V YXZTN4?.SA/@U\,(/@_\*= \$6M[-J%OI%L;87DZA7FR68N0.!DL>*G
M^#OPVB^$O@2T\-07<E]%;S32B:4 ,?,D:0CCT+8KM"@.>.M*%"]*HAV%HHHI
MB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>^)WB+3?LGVO4;#_ $&>& 6FJ,JP27EZ" Q\P%A:6XW ]VX!(XJ[*]O-_P#
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M[MD:9QSU8^IJ'1_@[XFT'P_<75BEBNOV'A6/PQHMNUR5BCP,RW#.$)!=PIP
M>$'<TE\-W_6C_5+Y,&M;+R_-?HW\T>I_#SQQ;_$;PK;Z]:6EQ9VES)*L27.W
M>RI(R;OE)&#M)'/2J_CCXEZ1X)T[5Y)9HKK4=.L&U%].24+*T0(4>N-S$ 9Z
MG\:@\"V%YX.L_#_A*+2L:;8:/&)M267Y%G7:OEA=HW%OG;<.F.1R*\X\8_ O
M6O''BGQ=<7:6%G9ZYJ>F1R7D$I%RVEVP#O#G9\K-+N[]&Z\"JDES63T[_.W_
M  ?0F+TNU\OQM]VGJ>TV&NVMWI,%]++%:HZJ9%DE7]TY'*,<XR#P?I4</B2T
MEU.]LV#0"V\O_2)6012EP3M0[LD@#D$#J.M?/^C_  $\4Q7-M#J5EITFBW[Z
MC-J&FV5\8HX9KBX#"0?NCO'DC9QM89//)-:6G_L[WVK:]:/KMGI<&D)XDN=:
MN(+1R6GC2 6]E']T8 0*7&><8R<FA:Z[?\.O^'7</ANGK;\=[?Y/M?L>WZSX
MJT?P]IT-_J.I6UI9S2)%%-)(-LCN0$53W))[5<BU*TF5VCNH9%0 L5D!"YZ9
MYXS7D/QT^$.I>.M*\,:-X?TK1'TC2_M$@MM04"&&3[.T=L538P*HS[MO'W16
M9>_ [4_!NG^$]+\&Z7I5YIEA92)?QZA.8OM5VD 2VFFPA\Y4.[Y#C&1CH*B]
MDW]W]?+\4/JE]Y[);G0]+N+NZ@_L^TGNV66YFC\M&F;A%9V'+'@*"?I5N75K
M&"1TDO;>-TQN5I5!7/3(SQ7RW:_LIZ['H5JES;Z1<WJ6.EZ685E*Q+%'.;F\
MFSY?,CR<+Z#.,$U!XG^'%[)\0M(T?5M'TR]F\1:K%K+Z6TXE,"6Z>;<1B<IG
MR7G$+*I&?E?MQ6G+K:_E_P -\M?*U@Z-_/\ #_/0^K#JED+=;C[7!Y#':LOF
MKM)SC .<=:)=5LH'9)+R"-USE6E4$8&3QGT&?I7SXW[//B*WCU2TBFTZ>WU7
M3[J% WRV^DW-U,S3R10[<-B,JJ'@Y3G&XUHC]GZ\T_P]\0;^&#3]1\8ZN)(=
M)GNVW);Q+;"WB)8KPY7<7;!R6QD@5&MF^MOQO:WZ^@U:Z7G^'?\ K8]JTCQ)
MI>O:9:ZCI]]#=6-T2()T;Y9<$CY<]>0>G6KGVVWW%?/BRJER-XX&<$_3(Q7F
M?B;X227/PU\)^'M BL=(N]"NM/EMI0F5M5A=/,*<<L4#CMDGFN'T[X&^*_#E
MEX?AA73];ALM1NQ/;W5T\9ELFDEE@6638QEQ+('=#@' '8YIV3=N_P"&FOX_
M@R5K%-[V7Z_Y?B?0)U.S79F[@'F-M3,@^8^@YY-5M2UV'3-0L;22*5S=%_WJ
M;=D(52Q9\D$ XQD \D5X#\._@+XETB[\'OK-CH\4FEW4]SJ#V\IE@NQ,[3MB
M(H-DB7 B*.#]U2#Z5TWQB^$_B+XA^)M4FLH],CLY?#<NC6EW<L3+#)<3+]H;
M;L.0(D7;SUSTSFDU:WS_ "T^_8K2[OMI^?Z;GKZZO8NP5;VW9BVS E7.[&<=
M>N.<>E(FLZ?*K,E];.J %BLRD#)P,\]S7R9XQ^"4OP>L+_Q:MKIIMK6^N+R.
M+S&=D"6@L]/C12GS.=V^0]RHR2!70V?[+$]YX9TG3!;:?HUD+73M-NX+5P7D
MMHIOM%Q*7"<R22 *O]U<D')Q323>^FGXK]'OY:DO17]?P?\ 5NY]*+JEFYC"
MW<#&1BJ 2K\Q'4#GDC!_*G)J%K( 4N86!4N") <J#@GZ ]:\/;X!WS>(-0MX
M(;"PT>?7;74X[N _O(;2$*XMHH]OR,\H<NV>=['DG R[WX">)['12M@^GRM;
M>(;BXM;"%_(']ES7)F>W,A1@"2$.W;MPF.]2M4K_ -;?YZ^C&^O]=_\ +\4>
MZZWXHT_0_#]YK$MW;FTMX))S(9E5&"*21N_ U'X2\2?\)-X2TK7)[5M+^W6L
M=R;>9P3$' (!/3N*^?\ Q9\ /%VIZ=KVB:;9Z0NDZDEJD;W=XTAMHVF,E\H4
MQX,LI))EX&, *,5Z;\4?"?B?5]0\-)H%IIU]HUBEP;C3[^X:*)IO*Q;,ZA6\
MQ$;)*<<X/:AZ)O\ K3?[]+>:[:ANTOZZ6_6_](]#?5[")2SWMNB@9RTJ@8SC
MU]>*Y_Q]X_M_ ]MIQ\A=0O+^_M["&S294D9I6QN .<X&6/LIKYZL_P!E'7?^
M$?M8KV#2)[U;#3M*>))2(EC%R;F^F/R<NSX"CL,XP378^%_A!XQF^('A/5_$
M<.E26FCWFHWUU<I.TMS=7$@*6TBY0;$2-MHCS\N.IJK+F2;Z_@O\U^/WB;T;
M7;]/T>_D>_T445(Q#TKXB\8_\GA_%#_L#:3_ "DK[=/2OB/Q@,_MA_$__L#:
M3_Z#)4O=%K9G19 8 G!(R*P'\=Z"EIK5S_:4)M]'8I?RJP*V[!=Q#$=\=A6X
MZ^<K*5^5AM93P"#7@=[X7&G:+\3[+2-,,%G!J]K=+:6L&3)%&(WEV@?>) .>
MN:9*L>K^#O'VA>/K.6YT/4%O4AD\J5"C1R1-C(#(P!7(Y&1R*Z!@8S\P(->8
M?"[4K7Q?\1O&'B?2;>;^P;^.S@AO)86A6[DC4B0J& )"Y"DX[5QGAWQ_?_V@
M+6YN]3G>'Q'J4,W[F1D$+1R?9UW 8VY QCIBC8%J?0+[B,!3D'GBE#;D!^HY
M]J^9M&\!27VG^%#=:WXD:74] O;O40=1E7=/%L,&1_"02< 8S7NGPNN[W5/A
MQX:NM0:66^DL(C.\P(<OC!W9[\4R4=+COZ4J\'%*@R<4X)@YH&"8)YZ4%1VH
MVX' I.1VH ;STI&#%2%X/:GXI#P#0!6=C;PJTPR_J#4P(< CI480MEI5)Q4L
M;J8\A>*!("5#+@<"I!@]:C9<XXIU "%<TA%/P?2FD'/2@8@7N!0%))YR*<I(
MXI^!V(HN!& >O0^N:49XQU]2:4@]A2XR.G- "KDL<\*W4"LOQ!X2T;Q58I9Z
MWI=MJUHDHE6"Y7*AP<JWU%:PZT$9H0,ABMTMH5BB011( JQKT4>E.*Y4@<9X
MSFE()/>G8P.!0!RNG?#NQT[Q&^MQZGJTER5*FWFNBT')SPE=/@TX9H(([4M@
MW&%2W;%8'C/2-?U?0YK;PWKD?AS4V*[;^2U$X4#J-A/>NA)(I"<8Q3 P[/3]
M3L?#B6^K:@-9U)(=LMY'"(A,W=MO:B)2-,P1M/E-D?@:TM08QV\K>BYQ5#S/
M,T]W48S$>/P- 'K_ .Q)_P FD?#_ /[!TO\ Z.EKPWPE\4/$?PT^!'@%]%>Z
MBM[JXUE56ULS<?:KXSNMK;OP=B%F+EO]C%>Y?L2_\FD?#_\ [!TO_HZ6G_L;
MP";]G_1-PR!>WQQ_V]RU+*3L:7[,.K>,M2\*:U#XSN[K4[FQU.2TM-2OK46T
MUW$H&7*  !=Y<*>Z@&O9:A@CV%CN9L]VJ:A:().["BBBJ)/(OBM\<X/",/C#
M3=/CFBU71-,ANVOIH#]F2:>39;QY(PQ8Y) / 7\M>Q^./AB/PT]_>:B[2VC3
M6]TJVDB/YD 'GL(R-VP$]>G( R2*AU+X%:9K>O:IJ&IZE=7T&H:S::S)92)'
MY6ZVC58HCQDH"H?![BLG1_V<;31=7TW4D\0WES=P)<I=/=VT$OVKSKC[0S8*
MX1P_\0&>G< TX[*_]:7_ #NGZ)CEY?U_5KKUL>A:GX[T?1Y= 2[GDB_MR406
M+>0Y5Y"A=58XPA(!P&QG&*PE^./@]H[%_P"T90EV5 )MI 8F*,X60;<H=JDX
M/08)QD5I^/OA[9?$.PTFTOKJZMH]/U&#44>U?8[/'G"ENH!R0<<XKF++X')H
MNLZ]?:1K\^F#4[H7B(EG [6S[45U1V4DQLL8!3I@GVPN_P#7;_@_<+M_7?\
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M3Z8:M=7\K_K_ , 3OT_K^E^)LWGQE\*V+F.:]F65+K[))%]FDWQOYQA&X8R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726608378464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Annovis Bio,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2540421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1055 Westlakes Drive, Suite&#160;300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Berwyn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-3913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANVS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,483,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,216,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001477845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WithumSmith+Brown, PC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">East Brunswick, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726606859264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,377,693<span></span>
</td>
<td class="nump">$ 31,987,091<span></span>
</td>
<td class="nump">$ 35,974,251<span></span>
</td>
<td class="nump">$ 42,668,838<span></span>
</td>
<td class="nump">$ 45,686,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,644,376<span></span>
</td>
<td class="nump">5,131,337<span></span>
</td>
<td class="nump">3,992,967<span></span>
</td>
<td class="nump">1,428,742<span></span>
</td>
<td class="nump">315,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,022,069<span></span>
</td>
<td class="nump">37,118,428<span></span>
</td>
<td class="nump">39,967,218<span></span>
</td>
<td class="nump">44,097,580<span></span>
</td>
<td class="nump">46,001,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,022,069<span></span>
</td>
<td class="nump">37,118,428<span></span>
</td>
<td class="nump">39,967,218<span></span>
</td>
<td class="nump">44,097,580<span></span>
</td>
<td class="nump">46,001,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,961,254<span></span>
</td>
<td class="nump">1,845,705<span></span>
</td>
<td class="nump">901,841<span></span>
</td>
<td class="nump">928,997<span></span>
</td>
<td class="nump">688,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,737,285<span></span>
</td>
<td class="nump">680,830<span></span>
</td>
<td class="nump">397,544<span></span>
</td>
<td class="nump">468,125<span></span>
</td>
<td class="nump">818,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,698,539<span></span>
</td>
<td class="nump">2,526,535<span></span>
</td>
<td class="nump">1,299,385<span></span>
</td>
<td class="nump">1,397,122<span></span>
</td>
<td class="nump">1,506,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,698,539<span></span>
</td>
<td class="nump">2,526,535<span></span>
</td>
<td class="nump">1,299,385<span></span>
</td>
<td class="nump">1,397,122<span></span>
</td>
<td class="nump">1,506,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">82,377,488<span></span>
</td>
<td class="nump">80,919,684<span></span>
</td>
<td class="nump">78,563,673<span></span>
</td>
<td class="nump">76,659,912<span></span>
</td>
<td class="nump">73,220,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(54,054,774)<span></span>
</td>
<td class="num">(46,328,607)<span></span>
</td>
<td class="num">(39,896,656)<span></span>
</td>
<td class="num">(33,960,270)<span></span>
</td>
<td class="num">(28,726,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">28,323,530<span></span>
</td>
<td class="nump">34,591,893<span></span>
</td>
<td class="nump">38,667,833<span></span>
</td>
<td class="nump">42,700,458<span></span>
</td>
<td class="nump">44,494,964<span></span>
</td>
<td class="nump">$ 7,540,954<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 36,022,069<span></span>
</td>
<td class="nump">$ 37,118,428<span></span>
</td>
<td class="nump">$ 39,967,218<span></span>
</td>
<td class="nump">$ 44,097,580<span></span>
</td>
<td class="nump">$ 46,001,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726608169488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,100,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,100,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726606063744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,123,538<span></span>
</td>
<td class="nump">$ 4,033,963<span></span>
</td>
<td class="nump">$ 2,149,641<span></span>
</td>
<td class="nump">$ 6,183,604<span></span>
</td>
<td class="nump">$ 10,307,142<span></span>
</td>
<td class="nump">$ 16,515,543<span></span>
</td>
<td class="nump">$ 8,479,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,361,299<span></span>
</td>
<td class="nump">1,938,447<span></span>
</td>
<td class="nump">3,104,071<span></span>
</td>
<td class="nump">5,042,518<span></span>
</td>
<td class="nump">7,403,817<span></span>
</td>
<td class="nump">8,995,736<span></span>
</td>
<td class="nump">6,058,190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,484,837<span></span>
</td>
<td class="nump">5,972,410<span></span>
</td>
<td class="nump">5,253,712<span></span>
</td>
<td class="nump">11,226,122<span></span>
</td>
<td class="nump">17,710,959<span></span>
</td>
<td class="nump">25,511,279<span></span>
</td>
<td class="nump">14,537,221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,484,837)<span></span>
</td>
<td class="num">(5,972,410)<span></span>
</td>
<td class="num">(5,253,712)<span></span>
</td>
<td class="num">(11,226,122)<span></span>
</td>
<td class="num">(17,710,959)<span></span>
</td>
<td class="num">(25,511,279)<span></span>
</td>
<td class="num">(14,537,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">52,886<span></span>
</td>
<td class="nump">36,024<span></span>
</td>
<td class="nump">19,649<span></span>
</td>
<td class="nump">55,673<span></span>
</td>
<td class="nump">108,559<span></span>
</td>
<td class="nump">182,712<span></span>
</td>
<td class="nump">13,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_IncomeFromGrants', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,754<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">52,886<span></span>
</td>
<td class="nump">36,024<span></span>
</td>
<td class="nump">19,649<span></span>
</td>
<td class="nump">55,673<span></span>
</td>
<td class="nump">108,559<span></span>
</td>
<td class="nump">182,712<span></span>
</td>
<td class="nump">50,089<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(6,431,951)<span></span>
</td>
<td class="num">(5,936,386)<span></span>
</td>
<td class="num">(5,234,063)<span></span>
</td>
<td class="num">(11,170,449)<span></span>
</td>
<td class="num">(17,602,400)<span></span>
</td>
<td class="num">(25,328,567)<span></span>
</td>
<td class="num">(14,487,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,431,951)<span></span>
</td>
<td class="num">$ (5,936,386)<span></span>
</td>
<td class="num">$ (5,234,063)<span></span>
</td>
<td class="num">$ (11,170,449)<span></span>
</td>
<td class="num">$ (17,602,400)<span></span>
</td>
<td class="num">$ (25,328,567)<span></span>
</td>
<td class="num">$ (14,487,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
<td class="num">$ (3.10)<span></span>
</td>
<td class="num">$ (1.90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
<td class="num">$ (3.10)<span></span>
</td>
<td class="num">$ (1.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,157,445<span></span>
</td>
<td class="nump">8,160,702<span></span>
</td>
<td class="nump">8,161,787<span></span>
</td>
<td class="nump">8,162,326<span></span>
</td>
<td class="nump">7,626,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,157,445<span></span>
</td>
<td class="nump">8,160,702<span></span>
</td>
<td class="nump">8,161,787<span></span>
</td>
<td class="nump">8,162,326<span></span>
</td>
<td class="nump">7,626,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726607439376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">$ 21,779,340<span></span>
</td>
<td class="num">$ (14,239,075)<span></span>
</td>
<td class="nump">$ 7,540,954<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">6,891,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">46,648,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,648,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">95,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">155,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodValueWarrantsExercised', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Cashless exercise of warrants, shares</a></td>
<td class="nump">53,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,697,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,697,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,487,132)<span></span>
</td>
<td class="num">(14,487,132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">73,220,361<span></span>
</td>
<td class="num">(28,726,207)<span></span>
</td>
<td class="nump">44,494,964<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">8,100,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,234,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,700,458<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">73,220,361<span></span>
</td>
<td class="num">(28,726,207)<span></span>
</td>
<td class="nump">44,494,964<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">8,100,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,170,449)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,667,833<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">73,220,361<span></span>
</td>
<td class="num">(28,726,207)<span></span>
</td>
<td class="nump">44,494,964<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">8,100,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,602,400)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,591,893<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">73,220,361<span></span>
</td>
<td class="num">(28,726,207)<span></span>
</td>
<td class="nump">44,494,964<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">8,100,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">63,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,152,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,152,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,328,567)<span></span>
</td>
<td class="num">(25,328,567)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 816<span></span>
</td>
<td class="nump">$ 82,377,488<span></span>
</td>
<td class="num">$ (54,054,774)<span></span>
</td>
<td class="nump">28,323,530<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,700,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,936,386)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,667,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,431,951)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,591,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726608384384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,234,063)<span></span>
</td>
<td class="num">$ (11,170,449)<span></span>
</td>
<td class="num">$ (17,602,400)<span></span>
</td>
<td class="num">$ (25,328,567)<span></span>
</td>
<td class="num">$ (14,487,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,434,944<span></span>
</td>
<td class="nump">5,338,705<span></span>
</td>
<td class="nump">7,694,716<span></span>
</td>
<td class="nump">9,152,520<span></span>
</td>
<td class="nump">4,697,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,113,278)<span></span>
</td>
<td class="num">(3,677,503)<span></span>
</td>
<td class="num">(4,815,873)<span></span>
</td>
<td class="num">(7,328,912)<span></span>
</td>
<td class="num">(270,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">240,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,157,631<span></span>
</td>
<td class="nump">3,273,180<span></span>
</td>
<td class="nump">346,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(350,315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137,610)<span></span>
</td>
<td class="nump">2,918,845<span></span>
</td>
<td class="nump">581,916<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,021,789)<span></span>
</td>
<td class="num">(9,716,376)<span></span>
</td>
<td class="num">(13,703,536)<span></span>
</td>
<td class="num">(17,312,934)<span></span>
</td>
<td class="num">(9,132,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,648,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">95,102<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">46,743,515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(3,017,176)<span></span>
</td>
<td class="num">(9,711,763)<span></span>
</td>
<td class="num">(13,698,923)<span></span>
</td>
<td class="num">(17,308,321)<span></span>
</td>
<td class="nump">37,611,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">8,074,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 42,668,838<span></span>
</td>
<td class="nump">$ 35,974,251<span></span>
</td>
<td class="nump">$ 31,987,091<span></span>
</td>
<td class="nump">$ 28,377,693<span></span>
</td>
<td class="nump">$ 45,686,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610892256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business, Going Concern and Management's Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business, Going Concern and Management's Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business, Going Concern and Management's Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1)&#160;Nature of Business, Going Concern and Management&#8217;s Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Annovis&#8221;) was incorporated on April&#160;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company&#8217;s lead product candidate, Buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#8217;s future operations are dependent on the success of the Company&#8217;s efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#8217;s primary source of capital has been the issuance of equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0<span style="white-space:pre-wrap;"> million.  The net proceeds of the offering were approximately </span>$46.6<span style="white-space:pre-wrap;"> million, after deducting underwriting discounts and issuance costs paid by the Company.  The Company&#8217;s common stock trades on the New York Stock Exchange under the ticker symbol &#8220;ANVS&#8221;.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the Company's inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2022, the Company had an accumulated deficit of $54.1 million. The Company's net loss was $25.3 million and $14.5 million for the years ended December 31, 2022 and 2021, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires management to assess the Company's ability to continue as a going concern for one year after the date the financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of December 31, 2022 is sufficient to fund operations through the third quarter of 2023, but not for more than one year after the date of this filing and therefore management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726693406400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2)&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Basic and Diluted Net Income per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options  and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#8217;s financial condition, results of operations, and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company&#8217;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g)&#160;Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors, and are realized in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h)&#160;Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i)&#160;Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur. For stock awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met. Stock option modification expense is calculated as the incremental fair value of the modified award over the fair value of the original award measured immediately before the award's terms were modified. For vested awards, the incremental fair value is recognized immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j)&#160;Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2022 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k)&#160;Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. We adopted this standard prospectively. As such, the adoption did not have an impact on our financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726693332720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3)&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;3&#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,001,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,001,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at  </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726609776640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NonOperatingIncomeGrantIncomeAbstract', window );"><strong>Grant Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_OtherNonoperatingIncomeGrantIncomeTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, as modified in September 2020, the Company received a Notice of Award for a $1.9&#160;million grant from the National Institute on Aging of the National Institutes of Health&#160;(the &#8220;NIH&#8221;) to cover costs of long-term chronic toxicology studies of Buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November&#160;<span style="white-space:pre-wrap;">2019.   The Company recognized grant income of </span>$0 and $36,754 for the&#160;years ended December 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 during the&#160;year ended December 31, 2021 and recorded a grant receivable of $0 as of December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of December 31, 2022, there were no remaining funds available under the grant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NonOperatingIncomeGrantIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NonOperatingIncomeGrantIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_OtherNonoperatingIncomeGrantIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the grant income classified as other non-operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_OtherNonoperatingIncomeGrantIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610957056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,736</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,528,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232,752</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,111</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,644,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 315,464</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726611113072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 556,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,768</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,180,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,672</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,737,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 818,440</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;">See Note&#160;7 for further detail on the accrued license payments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610952464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7)&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company has entered contracts with contract research organizations (CROs) and contract manufacturers (CMOs) related the Company's clinical trials.  The contracts require upfront payments, milestone payments, and pass through cost reimbursement, to be made.  While the contracts are cancellable with (written) notice, the Company is obligated for payments for services rendered through the termination date of the project with the CRO/CMO.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its office facilities under a&#160;month-to-month operating lease. Total rental expense was $66,802 and $51,760 for the&#160;years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the &#8220;Licensor&#8221;). Under the license agreement, the Company paid a minimum annual fee of $46,000 and was required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Licensor also granted the Company a buy-out option which was exercisable at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company had the right to terminate the agreement at any time by giving 90&#160;days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement were recognized in general and administrative expense in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> In July 2021, the Company gave notice to the Licensor of its termination of the license agreement and the license agreement was terminated effective October 14, 2021. The Company has paid to the Licensor the prorated annual fees through the termination date.  </span>No milestones had been achieved as of the termination date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreements were approximately&#160;$1,291,900&#160;at December&#160;31,&#160;2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#8217;s liquidity, financial condition and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, two securities class action complaints were filed against the Company and its executive officers following disclosure of interim results from the AD/PD Trials. Both complaints were voluntarily dismissed without prejudice by the plaintiffs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December&#160;31, 2022, the Company did not have any pending legal actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The extent to which the COVID-19 pandemic could have a material impact on the Company&#8217;s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726612144464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160; Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board of Directors (&#8220;Board&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Voting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preferred stock may be issued from time to time by the Board in one or more series.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. The warrants have a <span style="-sec-ix-hidden:Hidden_KVKI4UZ8Bk-1Y1WhTV4ecA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span>-year term and were exercisable as of January&#160;29, 2021. During the year ended December 31, 2021, 97,600<span style="white-space:pre-wrap;"> of the warrants were tendered to the Company by the holders pursuant to cashless exercises.  Warrants outstanding as of December 31, 2022 and 2021, were </span>2,400 and 2,400<span style="white-space:pre-wrap;">, respectively.  The Company accounts for the warrants as a component of stockholders&#8217; equity.</span><span style="white-space:pre-wrap;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610907904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective upon the closing of the Company&#8217;s IPO on January&#160;31, 2020, the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) became effective, succeeding the Company&#8217;s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of December 31, 2022, 392,874 shares were available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board. Stock options have a maximum term of 10 years after date of grant and are exercisable in cash or as otherwise determined by the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2022 and 2021 was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,778,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,680,882</p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,374,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,016,745</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,152,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,697,627</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock option activity for the years ended December 31, 2022, and 2021, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,111,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 2.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 538,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 33.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (159,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 2.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,489,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 13.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 348,294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 15.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 1.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 25.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,657,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 13.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 9,907,660</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,310,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 11.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 9,591,460</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was $803,357 and $11,163,998, respectively. As of December 31, 2022, there was $4,089,400 unrecognized compensation expense related to unvested options. That cost is expected to be recognized over a weighted-average period of 1.39 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the years ended December 31, 2022 and 2021, the Company issued 348,294 and 538,095 options, respectively. Under the grant agreements for the 2022 stock option grants, 10,000 of the options vested immediately, 9,947 of the options vested on March 29, 2022, 9,947 of the options vest on March 31, 2023, 43,333 of the options vest on August 29, 2023, and 255,067 of the options vest in substantially equal quarterly installments over two years<span style="white-space:pre-wrap;"> from the date of grant.  </span>20,000 of the options have performance-based vesting conditions. As of December 31, 2022, it was not considered probable that the performance conditions would be achieved, and no compensation expense was recognized during the period related to these options. Under the grant agreements for the 2021 stock option grants, 143,391 of the options vested immediately, 155,253 of the options vested on March 31, 2022, 155,251 of the options vest on March 31, 2023 and 84,200 of the options vest in substantially equal quarterly installments over two years<span style="white-space:pre-wrap;"> from the date of grant.  All of the options have a </span><span style="-sec-ix-hidden:Hidden_-usZI0ypmUm4aeI3-2x4jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span><span style="white-space:pre-wrap;">-year term.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average grant date fair value of options issued during the&#160;years ended December 31, 2022 and 2021 was $13.24 per share and $27.13<span style="white-space:pre-wrap;"> per share, respectively.  The fair value was estimated using the Black Sholes option pricing model.  The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment. The risk-free rate was based on the interest rate payable on U.S. Treasury securities at the time of grant for a period that is commensurate with the expected term of the option.  Given the lack of </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">a public market for the Company&#8217;s common stock prior to the IPO, the expected stock price volatility was based on a weighted approach that incorporates the historic daily volatility of the Company&#8217;s common stock since the IPO and the historic daily volatility of similar companies that have been publicly traded for a period commensurate with the expected term of the option.  The expected dividend yield is </span>0% because the Company has not historically paid and does not expect for the foreseeable future to pay a dividend on its common stock. The weighted average assumptions used in the valuation of options granted were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, previously issued stock options were modified for an employee who is no longer employed with the Company. As a result of this modification, $1,219,572 was recognized as stock option modification expense and included in general and administrative expenses on the accompanying statement of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726611122896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10) Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reported a net loss for the&#160;years ended December 31, 2022 and 2021, and the basic and diluted net loss per share attributable to common stockholders are the same for both&#160;years because all warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,328,567)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,487,132)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,162,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,626,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Nrt4V6gKP0yrinHj-NMeNg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_cE1AXSw2LUaR4c9ANXGfMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Potential common shares that are excluded from the computation of diluted weighted-average shares outstanding are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,657,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,489,748</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610957056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(11) Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal and state provision (benefit) for income taxes was&#160;$0&#160;for the&#160;years ended December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2022 and 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (52.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets are comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,919,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,512,249</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,767,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,759,129</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,725,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,002,431</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,445,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,618,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 648,077</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,476,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,921,886</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,476,267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,921,886)</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $27,536,031 which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2,764,240 will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2022, the Company also had U.S. state NOL carryforwards of $30,082,914 which may be available to offset future income tax liabilities and will expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2022 and 2021 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company experienced a net change in valuation allowance of $7,554,381 and $7,672,071 in the&#160;years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had federal research and development tax credit carryforwards of $1,618,294 available to reduce future tax liabilities which expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#8217;s tax&#160;years from </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2019 to the present remain open for review. All open&#160;years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726612079888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Restatement of Previously Issued Unaudited Condensed Financial Statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(12) Restatement of Previously Issued Unaudited Condensed Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During its preparation of its 2022 audited combined financial statements and notes thereto, the Company concluded that there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed financial statements as of and for each of the quarterly and year to date periods ended March 31, 2022, June 30, 2022 and September 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company noted the following items were improperly expensed during the three months ended March 31, 2022:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments, in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$800,840</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, were improperly recorded in research and development expenses during the three months ended March 31, 2022. These amounts should have been recorded as prepaid expenses and other current assets as of March 31, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Research and development expense amounts totaling </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$140,690</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> were not recorded during the three months ended March 31, 2022. This amount should have been recorded in accrued expenses and other current liabilities as of March 31, 2022.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">These errors in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets of </span><span style="font-weight:normal;">$800,840</span><span style="font-weight:normal;">, accrued expenses and other current liabilities of </span><span style="font-weight:normal;">$140,690</span><span style="font-weight:normal;"> and an overstatement of </span><span style="-sec-ix-hidden:Hidden_Fw2LNw0ysUal1BJuAIrjEg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating expenses</span></span><span style="font-weight:normal;"> and net loss of </span><span style="font-weight:normal;">$660,150</span><span style="font-weight:normal;"> as of and for the three months ended March 31, 2022. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company noted the following items were improperly expensed during the three and six months ended June 30, 2022:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments, in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2,883,977</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> were improperly recorded in research and development expenses during the three months ended June 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of June 30, 2022. Additionally, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$102,232</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> was expensed during the three months ended June 30, 2022 related to the prior quarter restatements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">These errors, including the errors from the three months ended March 31, 2022, in the accounting for research and development expenses resulted in a cumulative understatement of prepaid assets and other current assets of </span><span style="font-weight:normal;">$3,441,895</span><span style="font-weight:normal;">, as of June 30, 2022, and an overstatement operating expenses and net loss of </span><span style="font-weight:normal;">$2,781,745</span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$3,441,895</span><span style="font-weight:normal;"> for the three and six months ended June 30, 2022, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company noted the following items were improperly expensed during the three and nine months ended September 30, 2022:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments, in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1,320,321</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, were improperly recorded in research and development expenses during the three months ended September 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of September 30, 2022. Additionally, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$130,826</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> was expensed during the three months ended September 30, 2022 related to the prior quarter restatements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">These errors, including the errors from the six months ended June 30, 2022, in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets of </span><span style="font-weight:normal;">$4,631,390</span><span style="font-weight:normal;"> as of September 30, 2022, and an overstatement of operating expenses and net loss of </span><span style="font-weight:normal;">$1,189,495</span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$4,631,390</span><span style="font-weight:normal;"> for the three and nine months ended September 30, 2022, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of such errors, the Company concluded that the previously issued 2022 unaudited condensed financial statements were materially misstated and has restated herein our previously issued unaudited condensed financial statements for each interim period within the fiscal year ended December 31, 2022. The restatement corrections impact certain components within operating cash flows of the unaudited condensed statements of cash flows. Total operating cash flows, investing activities, financing activities, and cash and cash equivalents are unchanged as a result of the restatements and as a result are not restated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The following tables present the amounts previously reported, the restatement impact and the amount as restated. The 2022 quarterly restatements will be effective with the filing of our future 2023 unaudited interim condensed financial statement filings in Quarterly Reports on Form 10-Q.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The values as previously reported for the fiscal quarters ended September 30, 2022, June 30, 2022, and March 31, 2022 were derived from our Quarterly Reports on Form 10-Q filed on November 8, 2022, August 8, 2022 and May 4, 2022, respectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Annovis Bio, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Balance Sheets</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;March&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,668,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,668,838</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 627,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,428,742</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred clinical materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,296,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,097,580</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,296,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,097,580</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 928,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 928,997</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468,125</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,256,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,397,122</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,256,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,397,122</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock &#8211; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock &#8211; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares <span style="-sec-ix-hidden:Hidden_9SEDlZkijEKqtC-ySnJpRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_tZ3jki-L5k2vnk0YROVQzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at March 31, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,659,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,659,912</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,620,420)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,960,270)</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,040,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,700,458</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,296,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,097,580</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,809,791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (660,150)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,149,641</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,104,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,104,071</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,913,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (660,150)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,253,712</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,913,862)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,253,712)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,649</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,649</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,894,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,234,063)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,894,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,234,063)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KBQaGnyoDUm3mQc2xmzb9g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.72)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_AKXvNQ6KhkS17REUIUfQMQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.64)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,157,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,157,445</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;March&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement&#160;Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,894,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,234,063)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,434,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,434,944</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (312,438)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (800,840)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,113,278)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240,923</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (491,005)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (350,315)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,021,789)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,021,789)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,017,176)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,017,176)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,668,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,668,838</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,974,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,974,251</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 551,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,992,967</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deferred clinical materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,525,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,967,218</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,525,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,967,218</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 901,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 901,841</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 397,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 397,544</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299,385</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299,385</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Preferred stock &#8211; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Common stock &#8211; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares <span style="-sec-ix-hidden:Hidden_1KpyqUlIYEikh7iSvFo8QQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_QRqrEN-rqUqjxJGEYuDI_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at June 30, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 816</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,563,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,563,673</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,338,551)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,896,656)</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,225,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,667,833</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,525,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,967,218</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,815,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,781,745)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,033,963</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,938,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8211;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,938,447</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,754,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,781,745)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,972,410</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,754,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,781,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,972,410)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,024</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,024</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,718,131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,781,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,936,386)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,718,131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,781,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,936,386)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_gNBJeOes40Sa4G7lAiK58Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.07)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_yz2vRgL14Ee_24qI4nZ8pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.73)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,163,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,163,923</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,625,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,441,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,183,604</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,042,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,042,518</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,668,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,441,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,226,122</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,668,017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,226,122)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,673</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,673</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,612,344)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,170,449)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,612,344)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,170,449)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pn_EzwJF0kmaifLIJ3rdcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.79)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_eHH7Nb15lUyp1mobGSzCaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.37)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,160,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_i3zSlr-JE0itqi6e7cvv4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 8,160,702</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement&#160;Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,612,344)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,170,449)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,338,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,338,705</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (235,608)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,441,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,677,503)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (420,896)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (420,896)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,716,376)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,716,376)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,711,763)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,711,763)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,974,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,974,251</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,987,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,987,091</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 499,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,131,337</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,487,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,118,428</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,487,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,118,428</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,845,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,845,705</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 680,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 680,830</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526,535</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526,535</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock &#8211; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock &#8211; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares <span style="-sec-ix-hidden:Hidden_kuozT-fkoU2VpC3sMRmgDg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_IBAq19urw02_lqWC_B7pSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at September 30, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,919,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,919,684</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,959,997)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,328,607)</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,960,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,591,893</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,487,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,118,428</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,313,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,189,495)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,123,538</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,361,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,361,299</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,674,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,189,495)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,484,837</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,674,332)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,484,837)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,886</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,886</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,621,446)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,431,951)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,621,446)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,431,951)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_R0KpXRjzSkGPJsqmSAn4QQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.93)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9ngmT9i0wEWaZaFs0Tn7og;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.79)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,163,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,163,923</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,938,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,631,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,307,142</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,403,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8211;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,403,817</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,342,349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,631,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,710,959</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,342,349)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,710,959)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,559</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8211;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,559</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,233,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,602,400)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,233,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,602,400)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_lMJqv36yQEq7BdUNqY6Ieg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.72)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_boWkpKJFu0uuOAEChJvoRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.16)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_T1ooRgaQ1UGTXvhVXaOfsw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 8,161,787</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,161,787</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement&#160;Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,233,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,602,400)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,694,716</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,694,716</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (184,483)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,631,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,815,873)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,157,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,157,631</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (137,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (137,610)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,703,536)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,703,536)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,698,923)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,698,923)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,987,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,987,091</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI https://asc.fasb.org/topic&amp;trid=2126967<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL124452896-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726612079888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(13) Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 18, 2023, the Company granted options to purchase an aggregate of 81,705 shares of common stock at an exercise price of $13.17 per share to employees, members of the board of directors and consultants to the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726606823712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Basic and Diluted Net Income per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options  and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#8217;s financial condition, results of operations, and cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock', window );">Issuance Costs Associated with Equity Issuances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company&#8217;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g)&#160;Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors, and are realized in the ordinary course of business.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h)&#160;Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i)&#160;Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur. For stock awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met. Stock option modification expense is calculated as the incremental fair value of the modified award over the fair value of the original award measured immediately before the award's terms were modified. For vested awards, the incremental fair value is recognized immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j)&#160;Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2022 or 2021.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k)&#160;Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. We adopted this standard prospectively. As such, the adoption did not have an impact on our financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for issuance costs associated with equity issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610880720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,001,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,001,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at  </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610952464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,736</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,528,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232,752</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,111</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,644,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 315,464</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610957056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 556,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,768</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,180,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,672</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,737,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 818,440</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726608288304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,778,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,680,882</p></td></tr><tr><td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,374,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,016,745</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,152,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,697,627</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,111,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 2.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 538,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 33.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (159,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 2.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,489,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 13.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 348,294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 15.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 1.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 25.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,657,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 13.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 9,907,660</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,310,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 11.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$ 9,591,460</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions used to determine fair value of options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610966688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,328,567)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,487,132)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,162,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,626,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Nrt4V6gKP0yrinHj-NMeNg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_cE1AXSw2LUaR4c9ANXGfMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of shares excluded from the computation of diluted weighted-average shares outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,657,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,489,748</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726611087856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax provision (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (52.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,919,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,512,249</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,767,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,759,129</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,725,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,002,431</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,445,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,618,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 648,077</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,476,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,921,886</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,476,267)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,921,886)</p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726611049424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Restatement of Previously Issued Unaudited Condensed Financial Statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Annovis Bio, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Balance Sheets</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;March&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,668,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,668,838</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 627,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,428,742</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred clinical materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,296,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,097,580</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,296,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,097,580</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 928,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 928,997</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468,125</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,256,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,397,122</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,256,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,397,122</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock &#8211; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock &#8211; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares <span style="-sec-ix-hidden:Hidden_9SEDlZkijEKqtC-ySnJpRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_tZ3jki-L5k2vnk0YROVQzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at March 31, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,659,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,659,912</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,620,420)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,960,270)</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,040,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,700,458</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,296,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 800,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,097,580</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,809,791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (660,150)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,149,641</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,104,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,104,071</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,913,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (660,150)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,253,712</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,913,862)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,253,712)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,649</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,649</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,894,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,234,063)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,894,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,234,063)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KBQaGnyoDUm3mQc2xmzb9g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.72)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_AKXvNQ6KhkS17REUIUfQMQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.64)</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,157,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,157,445</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;March&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement&#160;Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,894,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,234,063)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,434,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,434,944</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (312,438)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (800,840)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,113,278)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240,923</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (491,005)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (350,315)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,021,789)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,021,789)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,017,176)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,017,176)</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td></tr><tr><td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,668,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,668,838</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,974,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,974,251</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 551,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,992,967</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Deferred clinical materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,525,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,967,218</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,525,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,967,218</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 901,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 901,841</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 397,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 397,544</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299,385</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299,385</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Preferred stock &#8211; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Common stock &#8211; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares <span style="-sec-ix-hidden:Hidden_1KpyqUlIYEikh7iSvFo8QQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_QRqrEN-rqUqjxJGEYuDI_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at June 30, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 816</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,563,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,563,673</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,338,551)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,896,656)</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,225,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,667,833</p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,525,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,967,218</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,815,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,781,745)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,033,963</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,938,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8211;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,938,447</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,754,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,781,745)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,972,410</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,754,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,781,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,972,410)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,024</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,024</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,718,131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,781,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,936,386)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,718,131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,781,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,936,386)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_gNBJeOes40Sa4G7lAiK58Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.07)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_yz2vRgL14Ee_24qI4nZ8pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.73)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,163,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,163,923</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,625,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,441,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,183,604</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,042,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,042,518</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,668,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,441,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,226,122</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,668,017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,226,122)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,673</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,673</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,612,344)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,170,449)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,612,344)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,170,449)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pn_EzwJF0kmaifLIJ3rdcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.79)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_eHH7Nb15lUyp1mobGSzCaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.37)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,160,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_i3zSlr-JE0itqi6e7cvv4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 8,160,702</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement&#160;Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,612,344)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,441,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,170,449)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,338,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,338,705</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (235,608)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,441,895)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,677,503)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (420,896)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (420,896)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,716,376)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,716,376)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,711,763)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,711,763)</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td></tr><tr><td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,974,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,974,251</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,987,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,987,091</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 499,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,131,337</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,487,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,118,428</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,487,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,118,428</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,845,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,845,705</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 680,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 680,830</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526,535</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526,535</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock &#8211; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock &#8211; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares <span style="-sec-ix-hidden:Hidden_kuozT-fkoU2VpC3sMRmgDg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_IBAq19urw02_lqWC_B7pSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at September 30, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,919,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,919,684</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,959,997)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,328,607)</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,960,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,591,893</p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,487,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,118,428</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,313,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,189,495)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,123,538</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,361,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,361,299</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,674,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,189,495)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,484,837</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,674,332)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,484,837)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,886</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,886</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,621,446)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,431,951)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,621,446)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,431,951)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_R0KpXRjzSkGPJsqmSAn4QQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.93)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9ngmT9i0wEWaZaFs0Tn7og;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.79)</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,163,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,163,923</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restatement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,938,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,631,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,307,142</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,403,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8211;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,403,817</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,342,349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,631,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,710,959</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,342,349)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,710,959)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,559</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8211;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,559</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,233,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,602,400)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,233,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,602,400)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_lMJqv36yQEq7BdUNqY6Ieg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.72)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_boWkpKJFu0uuOAEChJvoRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.16)</p></td></tr><tr><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_T1ooRgaQ1UGTXvhVXaOfsw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 8,161,787</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,161,787</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annovis Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restatement&#160;Impacts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,233,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,631,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,602,400)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,694,716</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,694,716</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (184,483)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,631,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,815,873)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,157,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,157,631</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (137,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (137,610)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,703,536)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,703,536)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,613</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,698,923)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,698,923)</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td></tr><tr><td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,987,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,987,091</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726605263952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business, Going Concern and Management's Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 26, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,648,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,328,607<span></span>
</td>
<td class="nump">$ 39,896,656<span></span>
</td>
<td class="nump">$ 33,960,270<span></span>
</td>
<td class="nump">$ 39,896,656<span></span>
</td>
<td class="nump">$ 46,328,607<span></span>
</td>
<td class="nump">54,054,774<span></span>
</td>
<td class="nump">28,726,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,431,951<span></span>
</td>
<td class="nump">$ 5,936,386<span></span>
</td>
<td class="nump">$ 5,234,063<span></span>
</td>
<td class="nump">$ 11,170,449<span></span>
</td>
<td class="nump">$ 17,602,400<span></span>
</td>
<td class="nump">$ 25,328,567<span></span>
</td>
<td class="nump">$ 14,487,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember', window );">Underwriters warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PercentageOfExercisePriceToShareOfferingPrice', window );">Percentage of exercise price to the share offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Secondary Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 46,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NatureOfBusinessAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NatureOfBusinessAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PercentageOfExercisePriceToShareOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise price to the share offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PercentageOfExercisePriceToShareOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_SecondaryPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_SecondaryPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610889024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash and cash equivalents, Federally insured limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726606866224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Carrying Value</a></td>
<td class="nump">$ 28,377,693<span></span>
</td>
<td class="nump">$ 31,987,091<span></span>
</td>
<td class="nump">$ 35,974,251<span></span>
</td>
<td class="nump">$ 42,668,838<span></span>
</td>
<td class="nump">$ 45,686,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Carrying Value</a></td>
<td class="nump">26,001,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Fair Value</a></td>
<td class="nump">$ 26,001,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726600858656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Grant Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_IncomeFromGrants', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember', window );">NIH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Grant Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GrantsReceivableNoticeOfAwardAmount', window );">Notice of Award, grant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_IncomeFromGrants', window );">Grant income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ProceedsFromGrants', window );">Proceeds from Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_UnreimbursedEligibleCostsIncurredDuringPeriod', window );">Unreimbursed, eligible costs incurred under the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GrantAwardRemainingAmountAvailable', window );">Remaining funds available</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GrantAwardRemainingAmountAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remining balance of funds available under a grant award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GrantAwardRemainingAmountAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GrantsReceivableNoticeOfAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of grant awarded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GrantsReceivableNoticeOfAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ProceedsFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ProceedsFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_UnreimbursedEligibleCostsIncurredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unreimbursed eligible costs incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_UnreimbursedEligibleCostsIncurredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726606881616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 67,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidResearchAndDevelopmentExpenseCurrent', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">7,528,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">37,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">11,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 7,644,376<span></span>
</td>
<td class="nump">$ 5,131,337<span></span>
</td>
<td class="nump">$ 3,992,967<span></span>
</td>
<td class="nump">$ 1,428,742<span></span>
</td>
<td class="nump">$ 315,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726605005760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related benefits</a></td>
<td class="nump">$ 556,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 712,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and clinical fees</a></td>
<td class="nump">3,180,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 3,737,285<span></span>
</td>
<td class="nump">$ 680,830<span></span>
</td>
<td class="nump">$ 397,544<span></span>
</td>
<td class="nump">$ 468,125<span></span>
</td>
<td class="nump">$ 818,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726610971328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rental expense</a></td>
<td class="nump">$ 66,802<span></span>
</td>
<td class="nump">$ 51,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726604996000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - License Agreement (Details) - Amended License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 14, 2021 </div>
<div>Milestone</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_LicenseAgreementMinimumAnnualCommitment', window );">Minimum annual fee | $</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CumulativeNumberOfMilestonesAchieved', window );">Number of milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination', window );">Period for advance notice of termination</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CumulativeNumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CumulativeNumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_LicenseAgreementMinimumAnnualCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of annual commitment under the terms of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_LicenseAgreementMinimumAnnualCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of advance notice required to terminate the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=anvs_LicenseAgreementTermsAmendedMay2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=anvs_LicenseAgreementTermsAmendedMay2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726605026752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Employment Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Litigation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of new claims filed | lawsuit</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementsAbstract', window );"><strong>Employment Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_MaximumAggregateSeverancePayments', window );">Maximum aggregate severance payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,291,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_MaximumAggregateSeverancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_MaximumAggregateSeverancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726611052624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity- Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Vote</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NumberOfVotesForEachShareOfCommonStock', window );">Number of vote for each share of common stock</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfVotesForEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vote for each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfVotesForEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726605055248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants (Details) - Underwriters warrants - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PercentageOfExercisePriceToShareOfferingPrice', window );">Percentage of exercise price to the share offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ConversionOfWarrantsNumberOfWarrantsConverted', window );">Number of warrants converted in a non-cash transaction</a></td>
<td class="nump">97,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ConversionOfWarrantsNumberOfWarrantsConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants converted in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ConversionOfWarrantsNumberOfWarrantsConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PercentageOfExercisePriceToShareOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise price to the share offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PercentageOfExercisePriceToShareOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=anvs_UnderwritersWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726600868864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">392,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member', window );">2019 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2018Member', window );">2018 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726606098784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,434,944<span></span>
</td>
<td class="nump">$ 5,338,705<span></span>
</td>
<td class="nump">$ 7,694,716<span></span>
</td>
<td class="nump">$ 9,152,520<span></span>
</td>
<td class="nump">$ 4,697,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,374,403<span></span>
</td>
<td class="nump">2,016,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,778,117<span></span>
</td>
<td class="nump">$ 2,680,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726606917680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of the year</a></td>
<td class="nump">1,489,748<span></span>
</td>
<td class="nump">1,111,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">348,294<span></span>
</td>
<td class="nump">538,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(70,101)<span></span>
</td>
<td class="num">(159,813)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(110,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of the year</a></td>
<td class="nump">1,657,342<span></span>
</td>
<td class="nump">1,489,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="nump">1,310,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of the year (in dollars per share)</a></td>
<td class="nump">$ 13.82<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">15.90<span></span>
</td>
<td class="nump">33.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.97<span></span>
</td>
<td class="nump">2.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">25.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of the year (in dollars per share)</a></td>
<td class="nump">13.95<span></span>
</td>
<td class="nump">$ 13.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year (in dollars per share)</a></td>
<td class="nump">$ 11.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of the year (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of year (in years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 9,907,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 9,591,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726603088032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional disclosures (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 803,357<span></span>
</td>
<td class="nump">$ 11,163,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 4,089,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period</a></td>
<td class="text">1 year 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">348,294<span></span>
</td>
<td class="nump">538,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 13.24<span></span>
</td>
<td class="nump">$ 27.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock option modification expense</a></td>
<td class="nump">$ 1,219,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2022Member', window );">Awards granted in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2022Member', window );">Awards granted in 2022 | Immediate Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2022Member', window );">Awards granted in 2022 | Vests one year from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="nump">9,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2022Member', window );">Awards granted in 2022 | Vests two years from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="nump">9,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2022Member', window );">Awards granted in 2022 | Vests three years from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="nump">43,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2022Member', window );">Awards granted in 2022 | Vests in equal Quarterly installments over two years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="nump">255,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2022Member', window );">Awards granted in 2022 | Performance-based vesting conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.24%<span></span>
</td>
<td class="nump">1.17%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">112.00%<span></span>
</td>
<td class="nump">113.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Awards granted in 2021 | Immediate Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Awards granted in 2021 | Vests one year from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Awards granted in 2021 | Vests two years from grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Awards granted in 2021 | Vests in equal Quarterly installments over two years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_PerformanceBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_PerformanceBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=anvs_AwardsGrantedIn2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726605243472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and diluted net loss per share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,431,951)<span></span>
</td>
<td class="num">$ (5,936,386)<span></span>
</td>
<td class="num">$ (5,234,063)<span></span>
</td>
<td class="num">$ (11,170,449)<span></span>
</td>
<td class="num">$ (17,602,400)<span></span>
</td>
<td class="num">$ (25,328,567)<span></span>
</td>
<td class="num">$ (14,487,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,157,445<span></span>
</td>
<td class="nump">8,160,702<span></span>
</td>
<td class="nump">8,161,787<span></span>
</td>
<td class="nump">8,162,326<span></span>
</td>
<td class="nump">7,626,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,157,445<span></span>
</td>
<td class="nump">8,160,702<span></span>
</td>
<td class="nump">8,161,787<span></span>
</td>
<td class="nump">8,162,326<span></span>
</td>
<td class="nump">7,626,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
<td class="num">$ (3.10)<span></span>
</td>
<td class="num">$ (1.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
<td class="num">$ (3.10)<span></span>
</td>
<td class="num">$ (1.90)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726609749152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potential shares excluded from calculation (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,657,342<span></span>
</td>
<td class="nump">1,489,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726606174816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income tax provision (benefit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract', window );"><strong>Federal and state provision (benefit) for income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax benefits at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local tax, net of federal benefit</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credit</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">15.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(29.80%)<span></span>
</td>
<td class="num">(52.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726605019376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 7,919,085<span></span>
</td>
<td class="nump">$ 6,512,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">3,767,330<span></span>
</td>
<td class="nump">1,759,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">1,725,622<span></span>
</td>
<td class="nump">2,002,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures', window );">Section 174</a></td>
<td class="nump">3,445,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit carryforwards</a></td>
<td class="nump">1,618,295<span></span>
</td>
<td class="nump">648,077<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">18,476,267<span></span>
</td>
<td class="nump">10,921,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(18,476,267)<span></span>
</td>
<td class="num">(10,921,886)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to amortization of research and experimental expenditures (Section 174).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726606105008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional disclosures (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in valuation allowance</a></td>
<td class="nump">$ 7,554,381<span></span>
</td>
<td class="nump">$ 7,672,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Recognized income tax interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">1,618,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">27,536,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. federal | Generated in 2017 and prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,764,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 30,082,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=anvs_GeneratedIn2017AndPriorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=anvs_GeneratedIn2017AndPriorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726604358240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 4,123,538<span></span>
</td>
<td class="nump">$ 4,033,963<span></span>
</td>
<td class="nump">$ 2,149,641<span></span>
</td>
<td class="nump">$ 6,183,604<span></span>
</td>
<td class="nump">$ 10,307,142<span></span>
</td>
<td class="nump">$ 16,515,543<span></span>
</td>
<td class="nump">$ 8,479,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Prepaid assets and other current assets</a></td>
<td class="nump">5,131,337<span></span>
</td>
<td class="nump">3,992,967<span></span>
</td>
<td class="nump">1,428,742<span></span>
</td>
<td class="nump">3,992,967<span></span>
</td>
<td class="nump">5,131,337<span></span>
</td>
<td class="nump">7,644,376<span></span>
</td>
<td class="nump">315,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">680,830<span></span>
</td>
<td class="nump">397,544<span></span>
</td>
<td class="nump">468,125<span></span>
</td>
<td class="nump">397,544<span></span>
</td>
<td class="nump">680,830<span></span>
</td>
<td class="nump">3,737,285<span></span>
</td>
<td class="nump">818,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">6,484,837<span></span>
</td>
<td class="nump">5,972,410<span></span>
</td>
<td class="nump">5,253,712<span></span>
</td>
<td class="nump">11,226,122<span></span>
</td>
<td class="nump">17,710,959<span></span>
</td>
<td class="nump">25,511,279<span></span>
</td>
<td class="nump">14,537,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,431,951)<span></span>
</td>
<td class="num">(5,936,386)<span></span>
</td>
<td class="num">(5,234,063)<span></span>
</td>
<td class="num">(11,170,449)<span></span>
</td>
<td class="num">(17,602,400)<span></span>
</td>
<td class="num">$ (25,328,567)<span></span>
</td>
<td class="num">$ (14,487,132)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember', window );">Timing of accruals for research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Prepaid assets and other current assets</a></td>
<td class="nump">4,631,390<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">1,189,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,781,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,441,895)<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member', window );">Error Corrections Due to Expenses Recorded in Q1 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidResearchAndDevelopmentCurrent', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Prepaid assets and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member', window );">Error Corrections Due to Expenses Recorded in Q2 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidResearchAndDevelopmentCurrent', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,883,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,883,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member', window );">Error Corrections Due to Expenses Recorded in Q3 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidResearchAndDevelopmentCurrent', window );">Prepaid research and development expenses</a></td>
<td class="nump">1,320,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,320,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Error correction adjustment | Error Corrections Due to Expenses Recorded in Q1 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Error correction adjustment | Error Corrections Due to Expenses Recorded in Q2 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Error correction adjustment | Error Corrections Due to Expenses Recorded in Q3 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 130,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726604358976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,377,693<span></span>
</td>
<td class="nump">$ 31,987,091<span></span>
</td>
<td class="nump">$ 35,974,251<span></span>
</td>
<td class="nump">$ 42,668,838<span></span>
</td>
<td class="nump">$ 45,686,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,644,376<span></span>
</td>
<td class="nump">5,131,337<span></span>
</td>
<td class="nump">3,992,967<span></span>
</td>
<td class="nump">1,428,742<span></span>
</td>
<td class="nump">315,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,022,069<span></span>
</td>
<td class="nump">37,118,428<span></span>
</td>
<td class="nump">39,967,218<span></span>
</td>
<td class="nump">44,097,580<span></span>
</td>
<td class="nump">46,001,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,022,069<span></span>
</td>
<td class="nump">37,118,428<span></span>
</td>
<td class="nump">39,967,218<span></span>
</td>
<td class="nump">44,097,580<span></span>
</td>
<td class="nump">46,001,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,961,254<span></span>
</td>
<td class="nump">1,845,705<span></span>
</td>
<td class="nump">901,841<span></span>
</td>
<td class="nump">928,997<span></span>
</td>
<td class="nump">688,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,737,285<span></span>
</td>
<td class="nump">680,830<span></span>
</td>
<td class="nump">397,544<span></span>
</td>
<td class="nump">468,125<span></span>
</td>
<td class="nump">818,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,698,539<span></span>
</td>
<td class="nump">2,526,535<span></span>
</td>
<td class="nump">1,299,385<span></span>
</td>
<td class="nump">1,397,122<span></span>
</td>
<td class="nump">1,506,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,698,539<span></span>
</td>
<td class="nump">2,526,535<span></span>
</td>
<td class="nump">1,299,385<span></span>
</td>
<td class="nump">1,397,122<span></span>
</td>
<td class="nump">1,506,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">82,377,488<span></span>
</td>
<td class="nump">80,919,684<span></span>
</td>
<td class="nump">78,563,673<span></span>
</td>
<td class="nump">76,659,912<span></span>
</td>
<td class="nump">73,220,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(54,054,774)<span></span>
</td>
<td class="num">(46,328,607)<span></span>
</td>
<td class="num">(39,896,656)<span></span>
</td>
<td class="num">(33,960,270)<span></span>
</td>
<td class="num">(28,726,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">28,323,530<span></span>
</td>
<td class="nump">34,591,893<span></span>
</td>
<td class="nump">38,667,833<span></span>
</td>
<td class="nump">42,700,458<span></span>
</td>
<td class="nump">44,494,964<span></span>
</td>
<td class="nump">$ 7,540,954<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 36,022,069<span></span>
</td>
<td class="nump">37,118,428<span></span>
</td>
<td class="nump">39,967,218<span></span>
</td>
<td class="nump">44,097,580<span></span>
</td>
<td class="nump">$ 46,001,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,987,091<span></span>
</td>
<td class="nump">35,974,251<span></span>
</td>
<td class="nump">42,668,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,947<span></span>
</td>
<td class="nump">551,072<span></span>
</td>
<td class="nump">627,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,487,038<span></span>
</td>
<td class="nump">36,525,323<span></span>
</td>
<td class="nump">43,296,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,487,038<span></span>
</td>
<td class="nump">36,525,323<span></span>
</td>
<td class="nump">43,296,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,845,705<span></span>
</td>
<td class="nump">901,841<span></span>
</td>
<td class="nump">928,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,830<span></span>
</td>
<td class="nump">397,544<span></span>
</td>
<td class="nump">327,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,526,535<span></span>
</td>
<td class="nump">1,299,385<span></span>
</td>
<td class="nump">1,256,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,526,535<span></span>
</td>
<td class="nump">1,299,385<span></span>
</td>
<td class="nump">1,256,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,919,684<span></span>
</td>
<td class="nump">78,563,673<span></span>
</td>
<td class="nump">76,659,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,959,997)<span></span>
</td>
<td class="num">(43,338,551)<span></span>
</td>
<td class="num">(34,620,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,960,503<span></span>
</td>
<td class="nump">35,225,938<span></span>
</td>
<td class="nump">42,040,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,487,038<span></span>
</td>
<td class="nump">36,525,323<span></span>
</td>
<td class="nump">43,296,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Impacts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="nump">800,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="nump">800,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="nump">800,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="nump">660,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="nump">660,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,631,390<span></span>
</td>
<td class="nump">$ 3,441,895<span></span>
</td>
<td class="nump">$ 800,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726600845104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,100,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,100,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726603482608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,123,538<span></span>
</td>
<td class="nump">$ 4,033,963<span></span>
</td>
<td class="nump">$ 2,149,641<span></span>
</td>
<td class="nump">$ 6,183,604<span></span>
</td>
<td class="nump">$ 10,307,142<span></span>
</td>
<td class="nump">$ 16,515,543<span></span>
</td>
<td class="nump">$ 8,479,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,361,299<span></span>
</td>
<td class="nump">1,938,447<span></span>
</td>
<td class="nump">3,104,071<span></span>
</td>
<td class="nump">5,042,518<span></span>
</td>
<td class="nump">7,403,817<span></span>
</td>
<td class="nump">8,995,736<span></span>
</td>
<td class="nump">6,058,190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,484,837<span></span>
</td>
<td class="nump">5,972,410<span></span>
</td>
<td class="nump">5,253,712<span></span>
</td>
<td class="nump">11,226,122<span></span>
</td>
<td class="nump">17,710,959<span></span>
</td>
<td class="nump">25,511,279<span></span>
</td>
<td class="nump">14,537,221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,484,837)<span></span>
</td>
<td class="num">(5,972,410)<span></span>
</td>
<td class="num">(5,253,712)<span></span>
</td>
<td class="num">(11,226,122)<span></span>
</td>
<td class="num">(17,710,959)<span></span>
</td>
<td class="num">(25,511,279)<span></span>
</td>
<td class="num">(14,537,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">52,886<span></span>
</td>
<td class="nump">36,024<span></span>
</td>
<td class="nump">19,649<span></span>
</td>
<td class="nump">55,673<span></span>
</td>
<td class="nump">108,559<span></span>
</td>
<td class="nump">182,712<span></span>
</td>
<td class="nump">13,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_IncomeFromGrants', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,754<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">52,886<span></span>
</td>
<td class="nump">36,024<span></span>
</td>
<td class="nump">19,649<span></span>
</td>
<td class="nump">55,673<span></span>
</td>
<td class="nump">108,559<span></span>
</td>
<td class="nump">182,712<span></span>
</td>
<td class="nump">50,089<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(6,431,951)<span></span>
</td>
<td class="num">(5,936,386)<span></span>
</td>
<td class="num">(5,234,063)<span></span>
</td>
<td class="num">(11,170,449)<span></span>
</td>
<td class="num">(17,602,400)<span></span>
</td>
<td class="num">(25,328,567)<span></span>
</td>
<td class="num">(14,487,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,431,951)<span></span>
</td>
<td class="num">$ (5,936,386)<span></span>
</td>
<td class="num">$ (5,234,063)<span></span>
</td>
<td class="num">$ (11,170,449)<span></span>
</td>
<td class="num">$ (17,602,400)<span></span>
</td>
<td class="num">$ (25,328,567)<span></span>
</td>
<td class="num">$ (14,487,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
<td class="num">$ (3.10)<span></span>
</td>
<td class="num">$ (1.90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
<td class="num">$ (3.10)<span></span>
</td>
<td class="num">$ (1.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,157,445<span></span>
</td>
<td class="nump">8,160,702<span></span>
</td>
<td class="nump">8,161,787<span></span>
</td>
<td class="nump">8,162,326<span></span>
</td>
<td class="nump">7,626,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,157,445<span></span>
</td>
<td class="nump">8,160,702<span></span>
</td>
<td class="nump">8,161,787<span></span>
</td>
<td class="nump">8,162,326<span></span>
</td>
<td class="nump">7,626,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,313,033<span></span>
</td>
<td class="nump">$ 6,815,708<span></span>
</td>
<td class="nump">$ 2,809,791<span></span>
</td>
<td class="nump">$ 9,625,499<span></span>
</td>
<td class="nump">$ 14,938,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,361,299<span></span>
</td>
<td class="nump">1,938,447<span></span>
</td>
<td class="nump">3,104,071<span></span>
</td>
<td class="nump">5,042,518<span></span>
</td>
<td class="nump">7,403,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,674,332<span></span>
</td>
<td class="nump">8,754,155<span></span>
</td>
<td class="nump">5,913,862<span></span>
</td>
<td class="nump">14,668,017<span></span>
</td>
<td class="nump">22,342,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(7,674,332)<span></span>
</td>
<td class="num">(8,754,155)<span></span>
</td>
<td class="num">(5,913,862)<span></span>
</td>
<td class="num">(14,668,017)<span></span>
</td>
<td class="num">(22,342,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">52,886<span></span>
</td>
<td class="nump">36,024<span></span>
</td>
<td class="nump">19,649<span></span>
</td>
<td class="nump">55,673<span></span>
</td>
<td class="nump">108,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">52,886<span></span>
</td>
<td class="nump">36,024<span></span>
</td>
<td class="nump">19,649<span></span>
</td>
<td class="nump">55,673<span></span>
</td>
<td class="nump">108,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(7,621,446)<span></span>
</td>
<td class="num">(8,718,131)<span></span>
</td>
<td class="num">(5,894,213)<span></span>
</td>
<td class="num">(14,612,344)<span></span>
</td>
<td class="num">(22,233,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,621,446)<span></span>
</td>
<td class="num">$ (8,718,131)<span></span>
</td>
<td class="num">$ (5,894,213)<span></span>
</td>
<td class="num">$ (14,612,344)<span></span>
</td>
<td class="num">$ (22,233,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (1.79)<span></span>
</td>
<td class="num">$ (2.72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (1.79)<span></span>
</td>
<td class="num">$ (2.72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,157,445<span></span>
</td>
<td class="nump">8,160,702<span></span>
</td>
<td class="nump">8,161,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,163,923<span></span>
</td>
<td class="nump">8,157,445<span></span>
</td>
<td class="nump">8,160,702<span></span>
</td>
<td class="nump">8,161,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Impacts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">$ (1,189,495)<span></span>
</td>
<td class="num">$ (2,781,745)<span></span>
</td>
<td class="num">$ (660,150)<span></span>
</td>
<td class="num">$ (3,441,895)<span></span>
</td>
<td class="num">$ (4,631,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(1,189,495)<span></span>
</td>
<td class="num">(2,781,745)<span></span>
</td>
<td class="num">(660,150)<span></span>
</td>
<td class="num">(3,441,895)<span></span>
</td>
<td class="num">(4,631,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">1,189,495<span></span>
</td>
<td class="nump">2,781,745<span></span>
</td>
<td class="nump">660,150<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="nump">1,189,495<span></span>
</td>
<td class="nump">2,781,745<span></span>
</td>
<td class="nump">660,150<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 1,189,495<span></span>
</td>
<td class="nump">$ 2,781,745<span></span>
</td>
<td class="nump">$ 660,150<span></span>
</td>
<td class="nump">$ 3,441,895<span></span>
</td>
<td class="nump">$ 4,631,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726600018272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,234,063)<span></span>
</td>
<td class="num">$ (11,170,449)<span></span>
</td>
<td class="num">$ (17,602,400)<span></span>
</td>
<td class="num">$ (25,328,567)<span></span>
</td>
<td class="num">$ (14,487,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,434,944<span></span>
</td>
<td class="nump">5,338,705<span></span>
</td>
<td class="nump">7,694,716<span></span>
</td>
<td class="nump">9,152,520<span></span>
</td>
<td class="nump">4,697,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,113,278)<span></span>
</td>
<td class="num">(3,677,503)<span></span>
</td>
<td class="num">(4,815,873)<span></span>
</td>
<td class="num">(7,328,912)<span></span>
</td>
<td class="num">(270,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">240,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,157,631<span></span>
</td>
<td class="nump">3,273,180<span></span>
</td>
<td class="nump">346,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(350,315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137,610)<span></span>
</td>
<td class="nump">2,918,845<span></span>
</td>
<td class="nump">581,916<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,021,789)<span></span>
</td>
<td class="num">(9,716,376)<span></span>
</td>
<td class="num">(13,703,536)<span></span>
</td>
<td class="num">(17,312,934)<span></span>
</td>
<td class="num">(9,132,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,648,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">95,102<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">46,743,515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(3,017,176)<span></span>
</td>
<td class="num">(9,711,763)<span></span>
</td>
<td class="num">(13,698,923)<span></span>
</td>
<td class="num">(17,308,321)<span></span>
</td>
<td class="nump">37,611,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">8,074,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">42,668,838<span></span>
</td>
<td class="nump">35,974,251<span></span>
</td>
<td class="nump">31,987,091<span></span>
</td>
<td class="nump">28,377,693<span></span>
</td>
<td class="nump">45,686,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,894,213)<span></span>
</td>
<td class="num">(14,612,344)<span></span>
</td>
<td class="num">(22,233,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,434,944<span></span>
</td>
<td class="nump">5,338,705<span></span>
</td>
<td class="nump">7,694,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(312,438)<span></span>
</td>
<td class="num">(235,608)<span></span>
</td>
<td class="num">(184,483)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">240,923<span></span>
</td>
<td class="nump">213,767<span></span>
</td>
<td class="nump">1,157,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(491,005)<span></span>
</td>
<td class="num">(420,896)<span></span>
</td>
<td class="num">(137,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,021,789)<span></span>
</td>
<td class="num">(9,716,376)<span></span>
</td>
<td class="num">(13,703,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(3,017,176)<span></span>
</td>
<td class="num">(9,711,763)<span></span>
</td>
<td class="num">(13,698,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">45,686,014<span></span>
</td>
<td class="nump">$ 45,686,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">42,668,838<span></span>
</td>
<td class="nump">35,974,251<span></span>
</td>
<td class="nump">31,987,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,686,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Impacts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">660,150<span></span>
</td>
<td class="nump">3,441,895<span></span>
</td>
<td class="nump">4,631,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(800,840)<span></span>
</td>
<td class="num">(3,441,895)<span></span>
</td>
<td class="num">$ (4,631,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 140,690<span></span>
</td>
<td class="num">$ (420,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139726611385248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 18, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,294<span></span>
</td>
<td class="nump">538,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">81,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice', window );">Exercise price of shares granted</a></td>
<td class="nump">$ 13.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of options granted during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>anvs-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:anvs="http://annovisbio.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="anvs-20221231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_PvoPPon-90icfGwFkudlGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TM4iBB8MpUGj7gk1hZK8HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HMHHIWqltEadtnNp5K9vRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dTPFMCnlUizoPLVgqDo4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M7i_UvTYrEaVMR0_3od1qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g1bPv-XlnEmFJB2EbHQo5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NnkAeElpr0ibdtyQmsK5Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qSbmtBj3ukCilwIfxwYMSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUHeKFPJvkygSacsBdj1pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0e58ugnkhkOqtDHQqnqd4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaZWK6ekPEC6t6LMwn5FUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_8tsiqJi9lEmJN9HBgLWOwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-26</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_FZnw0o15xUmaQw2wDnDl_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember_ChYbVG2dh0qNdtn6AHEW_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_R4senxF1EkumiKnOchMvOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_02HyU60TGUyED-4dfwaJfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_OUuVKvuXtkq-u1fVxFEu_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_VkaIA_opVUSZSU228t78pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_3phu_26-8EC8DSLEqSiFAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_RvTsofmI_0GsR8XGxxfQXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_1at2mAbtLEy8kiywIeDbHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_PerformanceBasedVestingConditionsMember_I8m5rTHYtEm0RpeBerchIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:PerformanceBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_nvrj-dGqOU6aKJERC6DdWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_qE-sUUUt40qGRKaPxGSmLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_mSBoJpEAKkmTzpJqFergRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_lxMQ0mAjHESuECDwuJ190w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_43OsGov8_0CKtp0gYKTwQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_T8bl_sZlz0iFUq0CaXz_5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_2llG4i7HYUGYKyNFCvAp9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JqPg780lPE6Z6dP0xYgvjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_TPQKDu5CTUOwF4Ecbc0PEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YB8rDynTHE2DxJUQucQRvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_zrhC9mvgWEyE7HMFE93j7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_vPBTijcqYUq2cqEFk9j3ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ32022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_ZSIgU1AfXUyGc1qV1Zr89Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_5aHRq5IyM0K4Mq8xtwIIPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-26</startDate>
            <endDate>2021-05-26</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_fb4PhuZvEUyAYxprN1iN7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">anvs:GeneratedIn2017AndPriorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ra5Wzdd2lUi3_iM1PWytxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Vi7H0gbpBkCBZr8biy-aFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_Yo6y8AqHFEmOOGOfLBgYxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_dnHdAMHdnkqQ9vuiISGRLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ12022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_AWaPPOKacE-NwSyODgUlNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uW5FryWwhEWgQoKhnkkxmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_WXJELeDryUOIsQTMpZhzWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_f6rfiOKViEG45RyBdeRPZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_zpReF9mePUKpfeIdK6dAxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ12022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l0Xel958IUW2OO3_3ATtqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_j-zkwi6Aj0y2twXZeHsjQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_rxJ3y47tSUmoX-kh_xFoXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_RbtDYEkBt0OdMp6ezICorA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_LvDPCB7paUK0MB8bwYZ-Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D51ABbLLJ0ar_OgKMrKt6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2-H7GqSKf02_tqC2kOqgJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NsdytOcdbEOeqNX5Qs-pDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OuG0ig-8I06-e5XU6-7N0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_6jD9f0YxekO4JmQcbKrXIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RelzNNUAf0uWCtCDxtOuNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nspaGMfz_EWneA97LJAfPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_fqcjJ89wu0-oiY1nhms5jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_MPv8wqMPt0GCQzly0NPo-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">anvs:AwardsGrantedIn2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_758s6N7iQkGfVS2-JwP_gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_30_2023_SP8NqcwiSE6CQzfBJ-nCsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_18_2023_To_1_18_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CNEPyGXQ7U2LW4h39gTpIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-18</startDate>
            <endDate>2023-01-18</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_26-oGseMPEeNfRhaZLLSPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ32022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_LXOH7EPaEECDbJNsMwmZFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_j4BX7lHcikG53t8xkKi-0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_3z17PfnHWEakqKGVOPTu-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_-fLIo0BDvUSb0fXlQjkFBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_9kGGHtw_vEKel92_hHoiuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_96WRLFOAHkurv9DzLPZC-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_DAlmQA-0OE6r9GQ5s8nIWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_JTrJWz3ebEirZiY64Y8mVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_X5uz9eIYMECujKqaMEdMmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_14_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_6KFn8E6JGkafxkOpuyUeRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">anvs:LicenseAgreementTermsAmendedMay2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_0xEMeWQcf0WgCqU3s1_d0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:UnderwritersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_w1NQBqyLWUGiwqQ90rxdHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">anvs:ErrorCorrectionsDueToExpensesRecordedInQ12022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_Milestone_di9IgBJq0ESfRR3NInDDpg">
        <measure>anvs:Milestone</measure>
    </unit>
    <unit id="Unit_Standard_Vote_S5Vg8LIuQ0WQwX_rru60RA">
        <measure>anvs:Vote</measure>
    </unit>
    <unit id="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_lawsuit_1hwym7Rltkul7iLlrQNJ9Q">
        <measure>anvs:lawsuit</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      id="Hidden_Xf7htH0lWUyGsLBri-KMXw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      id="Hidden_vtx97sYDjUWOZpnKxkT_Zg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      id="Hidden_b5CxiFHgF0qmCxB9v3qZrQ"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      id="Hidden_CKmZMxNY9EKNzVKvLMFfig"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Hidden_t3JpmuFC0kuECNoYyOooVw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      id="Hidden__67SmLkLaUCM7ruMNqJSrg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="2"
      id="Hidden_Ckrb12oy306ddpZ53Niy3w"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-3.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="2"
      id="Hidden_Z-k-vGB7x0igdz-3Y49S8A"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Hidden_6_KSFjJM1EG1R1--0NDhUw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8162326</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Hidden_J9co3IqiOkWlnUxwzu281Q"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">7626278</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Hidden_UFtYtOJrnUSr5vcQImd2vA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8162326</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Hidden_sqdL1CGCLUGcVu3lQoOFAw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">7626278</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="2"
      id="Hidden_Nrt4V6gKP0yrinHj-NMeNg"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-3.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="2"
      id="Hidden_cE1AXSw2LUaR4c9ANXGfMw"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.90</us-gaap:EarningsPerShareDiluted>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_r0ohK5OqsE2oeUsZThKMMA_2_1">0001477845</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_mrtisNQvx0C1zNtDbaS5ew_3_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_R70AsucFIkCeoefQ8EGKcg_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_vxm8Evbkn0qNOrHpP4PJzw_5_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Hidden_jrIh6zL5GUqxKHMNRWtSUA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Hidden_J9mXrKEvB0-Y0wdQqsv3gA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Hidden_VaKD4RT3_UaqR1WyWSHEKw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8100570</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Hidden_yN13rWRPTE6hgWOZKM6n6A"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg"
      id="Hidden_KVKI4UZ8Bk-1Y1WhTV4ecA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA"
      id="Hidden_-usZI0ypmUm4aeI3-2x4jw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Hidden_CbSvzWDZTEOpLcmifvaG0g"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Hidden_r0R8eMcNNUyTWF9TpK0MRg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="2"
      id="Hidden_gNBJeOes40Sa4G7lAiK58Q"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="2"
      id="Hidden_yz2vRgL14Ee_24qI4nZ8pg"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Hidden_lfDs6h-8fEqFxxCy5m72Yg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Hidden_TrJXSBRKJUCKwzud_WAemA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="2"
      id="Hidden_lMJqv36yQEq7BdUNqY6Ieg"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-2.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="2"
      id="Hidden_boWkpKJFu0uuOAEChJvoRg"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-2.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Hidden_DQvTMB6qb0iEL1KK36wy4g"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8161787</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Hidden_T1ooRgaQ1UGTXvhVXaOfsw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8161787</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Hidden_7ty8NaL6r0CeyGD1HaVNKQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8161787</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="2"
      id="Hidden_R0KpXRjzSkGPJsqmSAn4QQ"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="2"
      id="Hidden_9ngmT9i0wEWaZaFs0Tn7og"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Hidden_xAceUuxj_k6APHwI_SdT0w"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Hidden_4QktL8LOGkiNKn26kRJbBQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="2"
      id="Hidden_pn_EzwJF0kmaifLIJ3rdcw"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="2"
      id="Hidden_eHH7Nb15lUyp1mobGSzCaw"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Hidden_7bkd4o4uLU2Z4AnzXUusqA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8160702</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Hidden_Mp7_dZUxd0uqceObnl9uHA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8160702</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Hidden_i3zSlr-JE0itqi6e7cvv4A"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8160702</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="2"
      id="Hidden_KBQaGnyoDUm3mQc2xmzb9g"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="2"
      id="Hidden_AKXvNQ6KhkS17REUIUfQMQ"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Hidden_8zaKdW06ikS0JQjXfKGprw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8157445</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Hidden_DZ4J0sJ2wk27Iq8VEWpVhA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8157445</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_dnHdAMHdnkqQ9vuiISGRLg"
      decimals="0"
      id="Hidden_Fw2LNw0ysUal1BJuAIrjEg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">660150</us-gaap:OperatingExpenses>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="INF"
      id="Hidden_OH-39ladgkuRg5xVxhjYLQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Hidden_GpbuznL6YEmHJGSBM-Kb3Q"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Hidden_kuozT-fkoU2VpC3sMRmgDg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8100570</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="INF"
      id="Hidden_IBAq19urw02_lqWC_B7pSQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="INF"
      id="Hidden_qZ-A84FzdESZGsmj4aQNUg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Hidden_H9ncv06sKU6bMQBrdA79rg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Hidden_1KpyqUlIYEikh7iSvFo8QQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8100570</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="INF"
      id="Hidden_QRqrEN-rqUqjxJGEYuDI_g"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="INF"
      id="Hidden_qn4O9gSl_kCk8I6TK9rTRA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Hidden_8PJAW-kx3EmoTBTdRqBIqQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Hidden_9SEDlZkijEKqtC-ySnJpRg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8100570</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="INF"
      id="Hidden_tZ3jki-L5k2vnk0YROVQzg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:CommonStockSharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_pOPz8kdKpU6TpGUxiNx63w">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_P4ucR5fCjEySk7X-usoWUQ_0_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_92Y3KbIJg0CcSyGeEXYuaQ">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_ATP2Dlm39k668VIJri0UKA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_BXkWENABUk20fXePHQHoHw_4_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_DSEz1xGJSkyMyQkokeNeOA">001-39202</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_Mlk16xvnHkajby_fZ7KntQ">Annovis Bio,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_dwI3f9Wq1ESgysB_hf3k8g">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_gNzL-pMzTEiGCZ_moR0U-Q">26-2540421</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_PIMa9t_ZfUKc4TGUL6zwEg">1055 Westlakes Drive, Suite&#160;300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_GdXpn2u-PUig6EPi7urklw">Berwyn</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_gGBaazbZXEKT9QUF4xzvUQ">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_xu-IRZTw7U2YvcG7UbAK8A">19312</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_XVvqr5qKM0itJNJYlsOaUA">610</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_KCBkBUlylEakXpyvSU2Mvg">727-3913</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_HQ5dOSAqwEqU_iTBYWSoUA_2_0">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_axjOKcqmBECO6yJtKCAd2A_2_2">ANVS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_XUy8DgR2tUq2IXd4N-QxAg_2_4">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_DG_C8NdKiUuN9uVNEHLZCA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_1-88DwKJBUiHhNnno7tllA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_S2vB_GCOY0SxFGeL70X1Sw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_0AvjcITMn0yM4BeXSjGexw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_GFMDeCf9CU-R9-N1QnWG1Q">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_LLVwzxWFMUSB51AuBnVo5w">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_OJRliLtt0kedgHP-Ehx4Og">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_YGbP4D8dkkiIYCFTRZ23fg">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_PZMGt3eztEGNL2TJMxR1QA">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_MfxWmm0LuEGATtGyvBiAxw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Narr_YW-BX1P-00uwb5JwtY3wtg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">63483880</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_30_2023_SP8NqcwiSE6CQzfBJ-nCsg"
      decimals="INF"
      id="Narr_JgsYDSQfhkOBCufYfiodHg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8216678</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_N-Faw33akESwAH8DVq6y8g">WithumSmith+Brown, PC</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_H0n8gRTx10KGf3rB9CcW0Q">East Brunswick, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_zP4aI-KjdE2ttrf9Zj1dOQ">100</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_rbPA7t9Q-EKsvOcIKp8r1Q_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">28377693</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_CZT18GFPXUKyfTT1Vr-P3w_6_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">45686014</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_les5kNXLhkSBy8-NGoD-PA_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7644376</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_8WUxRsEXg0Gn4SS5JdRxUA_7_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">315464</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_CC1KjgoAdUSbkR3yOqVIQg_8_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36022069</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_7viYsc1Fw0KotpoqhVeLWQ_8_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">46001478</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_q9na98xDYEmT7k23AX2s0w_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36022069</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_mWkEMOqIlE6hrwfrQeWGZA_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">46001478</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_kGzJsh55r0W9j3q1GnyE5A_12_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3961254</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_iWTu1qGdU0mtrlp4JaIzjg_12_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">688074</us-gaap:AccountsPayableCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_V29fGD16bkyrTolkuxb2DA_13_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3737285</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc__NivYae4DECQhcrJ6R8LuQ_13_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">818440</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_li4rTvvcxkyayZaVkkQwlQ_14_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7698539</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_pXWXynWN2k-rvPqrb-L2vQ_14_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1506514</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_XZEqqm6DCkuAgp-1DATTug_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7698539</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_dDTtrSi9nEWu22erCPnIoQ_15_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1506514</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_I5m8uWjUNUuVw_GRX3RnjA"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Narr_dpTfywwYJEWR_Imbr2PBGA"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr__2qH8Bzmd0Cq0wpgEt29aA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Narr_ybhwGJaYYU2YEJyKS8Cmbg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_zIvcn8sdKU6zS1-WerLYJQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Narr_Wlh5DK0F90qF10tPvyBVpQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_MJKqjJhFsUSZrlu3vWb00w"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Narr_OqIeg8r1QEWQ86f2KVkywA"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_4MIu96yVwUewojBeKQN5Rw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Narr_QZDKLf1L1U-_8kvioL3ebA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Narr_20uICi3EP02RM78Pionb5g"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_ojgEHk46KEa_okqxBZ44LA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8100570</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_xQwW6Gi_aUyZq9g-nSlllA_19_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">816</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_kyd7SF9rKkmkWnbLve9lEw_19_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">810</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_lLpikxCcYkm32LqNog8TLg_20_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">82377488</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_eTwjqBQbrEy6HyTSMFINdg_20_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">73220361</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_FRYZEMf8_kKNovhFLEYZRw_21_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-54054774</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_w0TmMIZxq0mFm843rArC4Q_21_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-28726207</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_UfXHzcC5GkOygx5RW2GBSw_22_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">28323530</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_cHafilgpBEW-IXIvn0YboQ_22_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">44494964</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_z1vcPbVKfU-dlB7u_XrTGw_23_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36022069</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_kTREx4nwakWT0uiB73dVCw_23_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">46001478</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_XnNoxGMrcUqS5vG-wHmfzA_5_4"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">16515543</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_1WbSJwezc02cJvMb-K_p8g_5_7"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">8479031</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_RaF43VHWFEaVvyUUPPwbNg_6_4"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">8995736</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_zKBgjxB--U2N1UkqQQNRBQ_6_7"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">6058190</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_B8mYt3BOzU-uBlfBFc2qaA_7_4"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">25511279</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_D3sWkABtpEGY0hpPmYPMHw_7_7"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">14537221</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_UxNA8JXLZUeCfKNklmztUg_8_4"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-25511279</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_A2sOGFe6LE2v_NCsZYVIZg_8_7"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14537221</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_BLgyX717W0Gh5eVXzjMLVA_10_4"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">182712</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_I5jT2iib8EKoceR2vIHp8g_10_7"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">13335</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <anvs:IncomeFromGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_IHy02bUBRkCnvgTpJzLOHw_11_7"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36754</anvs:IncomeFromGrants>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_wzALTo9Y2UGL99QVpYsrQg_12_4"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">182712</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_KorbpRA6jkqT70iiGcLenw_12_7"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">50089</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_aIv3MOozTEKDY09tbPO9CQ_13_4"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-25328567</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_sKNFjU-YuE24rTR8IWlx-A_13_7"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14487132</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_2ex5VNwWHU6kAFx4ClYbSQ_15_4"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-25328567</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_zfTFTWihCEmRDpU-AyD-bA_15_7"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14487132</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="2"
      id="Tc_NoNx4yDJZEe--Y9e-scikA_16_4"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-3.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="2"
      id="Tc_Mbz9bEGV20KEuN81tFlb1w_16_7"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_4xFR2QCsIkK7WtpWb1Rn-g_17_4"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8162326</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_ob_4qLVO_U6MrVsBAm1PDA_17_7"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">7626278</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaZWK6ekPEC6t6LMwn5FUA"
      decimals="INF"
      id="Tc_6pJqXEPbw0KgUUar7eeLgQ_5_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">6891608</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaZWK6ekPEC6t6LMwn5FUA"
      decimals="0"
      id="Tc_pwK9zpVjtUmQtDQrpJSqhA_5_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">689</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qSbmtBj3ukCilwIfxwYMSA"
      decimals="0"
      id="Tc_sWktbgxisE6BG4xQE_FxvA_5_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">21779340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NnkAeElpr0ibdtyQmsK5Lg"
      decimals="0"
      id="Tc_wHZT5SP4LUqF1961aIgjrA_5_11"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14239075</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g"
      decimals="0"
      id="Tc_Ap1nBkQeWUeLay4RUZSeYw_5_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7540954</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA"
      decimals="INF"
      id="Tc_cQ_1NF31fEibN8TeLMWIBw_6_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA"
      decimals="0"
      id="Tc_f3xb-wovcE6rT3RJjV6ImA_6_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ"
      decimals="0"
      id="Tc_NmreNIgz0Eq18NhSMYnPRw_6_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">46648313</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_y6p8Zfrwtk6uUoYKYEv4hA_6_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">46648413</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA"
      decimals="INF"
      id="Tc_Je2ZPO0ZnkKtHC0VLp_Fzg_7_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">155038</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA"
      decimals="0"
      id="Tc_ycQpHKOYu0SBz4DP-Gy1YA_7_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">16</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ"
      decimals="0"
      id="Tc_8f5pTr7w_0-ZNlN3dZafqQ_7_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">95086</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_Fkco0yq2zkCpMOH3SD-ajA_7_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">95102</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <anvs:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA"
      decimals="INF"
      id="Tc_QyQIhUBtbkSz-BUa6DPKPw_8_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">53924</anvs:StockIssuedDuringPeriodSharesWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_T96qrV9atkiLoCsfTANzPA"
      decimals="0"
      id="Tc_IWl9H_KuX02ZeTPBVLwvqg_8_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ"
      decimals="0"
      id="Tc_X1kbYMgPaUO0wZsB4wNKog_8_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IKiDcW6RDUeSH5-a8f0QLQ"
      decimals="0"
      id="Tc__Zq2yrZEw0-D2NOVXsaakw_9_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4697627</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_xJkRNUBLVkOSRcp4pgRgtQ_9_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4697627</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l0Xel958IUW2OO3_3ATtqQ"
      decimals="0"
      id="Tc_D7IOjhe5cU-6SgflIegqTw_10_11"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14487132</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_iY7HKoFCgUici0gkI7FB8Q_10_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14487132</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0e58ugnkhkOqtDHQqnqd4w"
      decimals="INF"
      id="Tc_SB0yWJoIfEGxveOI7--iLg_11_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8100570</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0e58ugnkhkOqtDHQqnqd4w"
      decimals="0"
      id="Tc_BjizUWTEeESQOwh3vNevbQ_11_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">810</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g1bPv-XlnEmFJB2EbHQo5w"
      decimals="0"
      id="Tc_ma4s4fFOTUO7nJRLMAktvQ_11_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">73220361</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M7i_UvTYrEaVMR0_3od1qQ"
      decimals="0"
      id="Tc_WAEPwl6zmEak93H2eHaa4Q_11_11"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-28726207</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_F3XsYM7LDk6aw7BSgH9azA_11_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">44494964</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TM4iBB8MpUGj7gk1hZK8HA"
      decimals="INF"
      id="Tc_VVXeNmEyyEWH3xYJamIrEg_12_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">63353</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TM4iBB8MpUGj7gk1hZK8HA"
      decimals="0"
      id="Tc_5OMERvRYjE-fpbXACY_B8Q_12_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">6</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_758s6N7iQkGfVS2-JwP_gg"
      decimals="0"
      id="Tc_X6kWIZrwc0u6cfwNZ-hM2w_12_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4607</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_FBQnbM48gkqSj1MK-rG6CA_12_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_758s6N7iQkGfVS2-JwP_gg"
      decimals="0"
      id="Tc_XhY5IX2kSUm03aZFhR6h3w_13_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">9152520</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_gDn8uv8RNkKmsYboq3YHFQ_13_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">9152520</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uW5FryWwhEWgQoKhnkkxmA"
      decimals="0"
      id="Tc_pxnwsyrOIUej5H8x4GyUeA_14_11"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-25328567</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_X4pYUGNlfUC8tWStorkXNA_14_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-25328567</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUHeKFPJvkygSacsBdj1pQ"
      decimals="INF"
      id="Tc_30uIWfkPAkmmvwbh8Fjzgw_15_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUHeKFPJvkygSacsBdj1pQ"
      decimals="0"
      id="Tc_eFvPYcRpBE23oOBBd882Hg_15_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dTPFMCnlUizoPLVgqDo4w"
      decimals="0"
      id="Tc_K80B-NPpTk2erT_-ZprjzQ_15_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">82377488</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HMHHIWqltEadtnNp5K9vRg"
      decimals="0"
      id="Tc_YZ5xzxfT9ki3WagwqBU3AA_15_11"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-54054774</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_fCMJHllwxEqcDnTmOHBl7A_15_14"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">28323530</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_yYmpA7aXokKZJedsNJQLOg_4_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-25328567</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_hxtcUPqT6kqnlAGNY4ocpQ_4_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14487132</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_SbE16mYUPU-xh6bouMSIZg_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">9152520</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_2JvPyg6Yiku-ILqFe_pFTw_6_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4697627</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_qzGZZWOZ0kSR5lOpHHY3LA_8_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7328912</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_Cwh9OLUfw0isb-Ugl1B4VQ_8_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">270788</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_xTBaGSbUi0yxP1l292728w_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3273180</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_7ByMc3keQ0q5ytbT6S2_XA_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">346218</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_a6Lv3JInNE21elJExq-waw_10_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2918845</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_3B-qi6HwIkCb6S1VYFq_Sg_10_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">581916</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_Ya-u0rH2rEamKsLSvw3iEw_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-17312934</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_ngMElJQ_eEeeAPf-KrotBQ_11_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-9132159</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_A1qUyWciVEWbHpghxpS8Vg_13_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">46648413</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_JkKqg5-cukiE_tRqUm_xDg_14_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_H-YaydA5GUK29O8C2ZUuEQ_14_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">95102</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_Zvi4lsMV40KpxModkjdp_w_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_rPscFT8yeEeUkON5v9PR8Q_15_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">46743515</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_bCHJjucdl024s1Y4zh9n-g_16_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-17308321</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_qNQw09B2M0-tOd_C8D3Skw_16_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">37611356</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_Y0F0wj0FZEy-Z6sN0YShaw_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">45686014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g"
      decimals="0"
      id="Tc_q-FW_1403UOONCOq0607nw_17_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">8074658</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_GmED4OfqqEW_-5NbGGxpOg_18_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">28377693</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_en-MR1E44EecHogbkLsIAQ_18_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">45686014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_lwEiwIt8i0KgGtPOX-Fe6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(1)&#160;Nature of Business, Going Concern and Management&#x2019;s Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Annovis Bio,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;Annovis&#x201d;) was incorporated on April&#160;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#x2019;s disease (&#x201c;AD&#x201d;) and Parkinson&#x2019;s disease (&#x201c;PD&#x201d;). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company&#x2019;s lead product candidate, Buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#x2019;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#x2019;s future operations are dependent on the success of the Company&#x2019;s efforts to raise additional capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#x2019;s primary source of capital has been the issuance of equity securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0&lt;span style="white-space:pre-wrap;"&gt; million.  The net proceeds of the offering were approximately &lt;/span&gt;$46.6&lt;span style="white-space:pre-wrap;"&gt; million, after deducting underwriting discounts and issuance costs paid by the Company.  The Company&#x2019;s common stock trades on the New York Stock Exchange under the ticker symbol &#x201c;ANVS&#x201d;.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Since the Company's inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2022, the Company had an accumulated deficit of $54.1 million. The Company's net loss was $25.3 million and $14.5 million for the years ended December 31, 2022 and 2021, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires management to assess the Company's ability to continue as a going concern for one year after the date the financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of December 31, 2022 is sufficient to fund operations through the third quarter of 2023, but not for more than one year after the date of this filing and therefore management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Narr_pMAWKVFHn0WslcrRAGIbJQ"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_5aHRq5IyM0K4Mq8xtwIIPw"
      decimals="INF"
      id="Narr_VGjaksxqHUmn1FtjIyVIdA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_8tsiqJi9lEmJN9HBgLWOwQ"
      decimals="2"
      id="Narr_jx64HxjRjEa2xN_FJ38LgA"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">50.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_5aHRq5IyM0K4Mq8xtwIIPw"
      decimals="-5"
      id="Narr_c0EISKZ45UO4GjKVMtAB7Q"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">50000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_5aHRq5IyM0K4Mq8xtwIIPw"
      decimals="-5"
      id="Narr_Fb7cAj25FUe4P75oZkgZCw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">46600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="-5"
      id="Narr_g6HpD6zG00O3xn-p9ipb8g"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-54100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="-5"
      id="Narr_ZLAMm_npEkeiNlnKBx5ciA"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-25300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="-5"
      id="Narr_cJ6P0aiJX0GfChpI5AGhUg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14500000</us-gaap:NetIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_tN-VkBfhp0KLn3sAmT_T9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(2)&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Basic and Diluted Net Income per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options  and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&#160;Issuance Costs Associated with Equity Issuances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Issuance costs incurred in connection with the Company&#x2019;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&#160;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&#160;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors, and are realized in the ordinary course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(h)&#160;Grant Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(i)&#160;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur. For stock awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met. Stock option modification expense is calculated as the incremental fair value of the modified award over the fair value of the original award measured immediately before the award's terms were modified. For vested awards, the incremental fair value is recognized immediately.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(j)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2022 or 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(k)&#160;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. We adopted this standard prospectively. As such, the adoption did not have an impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccounting
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_YEzRwFmNmUashG5LiQxYXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_Alu8fOQ6pkGR_HODxixTvA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_fvmw005TvUaLjnMWwIb5oA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Basic and Diluted Net Income per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options  and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_ociDvZRgjUa-6bHUJZLICA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Narr_MUIEZW5uYEq9OcoFJvNwaQ"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">250000</us-gaap:CashFDICInsuredAmount>
    <anvs:IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_tXg-z1uKa0SooBRsY3iBEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&#160;Issuance Costs Associated with Equity Issuances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Issuance costs incurred in connection with the Company&#x2019;s equity issuances, which primarily consisted of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. &lt;/p&gt;</anvs:IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_FTN2nUDwnkaZhuoxnhsiiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&#160;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_5NMSQVouVESavzsNXJQu9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&#160;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on our contracts with our vendors, and are realized in the ordinary course of business.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <anvs:GrantIncomePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_HAW7kLnuw0KjPqriLgBqFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(h)&#160;Grant Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grants payments received in excess of grant income earned are recognized as deferred grant on the balance sheet and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.&lt;/p&gt;</anvs:GrantIncomePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_efXOChXmNESUIxRWNdnLVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(i)&#160;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur. For stock awards that vest based on performance conditions (e.g. achievement of certain milestones), expense is recognized when it is probable that the condition will be met. Stock option modification expense is calculated as the incremental fair value of the modified award over the fair value of the original award measured immediately before the award's terms were modified. For vested awards, the incremental fair value is recognized immediately.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_Nw87KG8Qv0Ot-CL8EwgcSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(j)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the provisions of ASC 740,&#160;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at December&#160;31, 2022 or 2021.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_BAdRWtRJNE6kBZXCQQA1zg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(k)&#160;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy.  The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. We adopted this standard prospectively. As such, the adoption did not have an impact on our financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_LLt4dh2HEU2dCLgsB256Vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(3)&#160;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;1&#x2014;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;2&#x2014;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;3&#x2014;Valuations based on unobservable inputs and models that are supported by little or no market activity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,001,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,001,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Fair Value Measurement at  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_XRka0RneXEmjoQnpk5-zbw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,001,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,001,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Fair Value Measurement at  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NsdytOcdbEOeqNX5Qs-pDQ"
      decimals="0"
      id="Tc_TlHiVcd1oUmpUoHKr_xb7A_4_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">26001934</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D51ABbLLJ0ar_OgKMrKt6w"
      decimals="0"
      id="Tc_UMJQWGVA_kOryHoF1OENiw_4_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">26001934</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OuG0ig-8I06-e5XU6-7N0w"
      decimals="0"
      id="Tc_b5zQwaakgkWXDRnegWil1g_4_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">60031</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2-H7GqSKf02_tqC2kOqgJQ"
      decimals="0"
      id="Tc_zjp0c3y6-0qd1ZrJ-ODprw_4_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">60031</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <anvs:OtherNonoperatingIncomeGrantIncomeTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_BEm30JPFnEa2YTfesh7C3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(4)&#160;Grant Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September&#160;2019, as modified in September 2020, the Company received a Notice of Award for a $1.9&#160;million grant from the National Institute on Aging of the National Institutes of Health&#160;(the &#x201c;NIH&#x201d;) to cover costs of long-term chronic toxicology studies of Buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November&#160;&lt;span style="white-space:pre-wrap;"&gt;2019.   The Company recognized grant income of &lt;/span&gt;$0 and $36,754 for the&#160;years ended December 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 during the&#160;year ended December 31, 2021 and recorded a grant receivable of $0 as of December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of December 31, 2022, there were no remaining funds available under the grant.&lt;/p&gt;</anvs:OtherNonoperatingIncomeGrantIncomeTextBlock>
    <anvs:GrantsReceivableNoticeOfAwardAmount
      contextRef="As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_JTrJWz3ebEirZiY64Y8mVw"
      decimals="-5"
      id="Narr_WY7BhcORdU2R5q2X4ODSPw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1900000</anvs:GrantsReceivableNoticeOfAwardAmount>
    <anvs:IncomeFromGrants
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_96WRLFOAHkurv9DzLPZC-Q"
      decimals="0"
      id="Narr_xE_98ID8QkO5ZfM6j4YrEw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</anvs:IncomeFromGrants>
    <anvs:IncomeFromGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_DAlmQA-0OE6r9GQ5s8nIWA"
      decimals="0"
      id="Narr_JLVUW4aHEE-ZFI1Tg61Hhw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36754</anvs:IncomeFromGrants>
    <anvs:ProceedsFromGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_DAlmQA-0OE6r9GQ5s8nIWA"
      decimals="0"
      id="Narr_0lrkbvb94EavyA_PyaQZ0A"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36754</anvs:ProceedsFromGrants>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_j-zkwi6Aj0y2twXZeHsjQg"
      decimals="0"
      id="Narr_HoV5TomEIEmrxAWdRWOGng"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:GrantsReceivableCurrent>
    <anvs:UnreimbursedEligibleCostsIncurredDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_DAlmQA-0OE6r9GQ5s8nIWA"
      decimals="0"
      id="Narr_FANmLHcLzk2QKVM0iQCFNA"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</anvs:UnreimbursedEligibleCostsIncurredDuringPeriod>
    <anvs:GrantAwardRemainingAmountAvailable
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_X5uz9eIYMECujKqaMEdMmA"
      decimals="0"
      id="Narr_h-N4-2rN3EidIdsupYxrJw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</anvs:GrantAwardRemainingAmountAvailable>
    <anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_QyPPIqcDiUiBbTT7gLOrJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(5)&#160;Prepaid Expenses and Other Current Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,736&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,528,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 232,752&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,865&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,644,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 315,464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_4PSpDhUuK0KEWP4h_qgnYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,736&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,528,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 232,752&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,865&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,644,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 315,464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_rs5K79yrskqTWqnD9gQs6A_3_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">67532</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_fqMvH-BzTECJbvQWpRn4nA_3_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">43736</us-gaap:OtherPrepaidExpenseCurrent>
    <anvs:PrepaidResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_s4-TX09ZfUCzD6defCpxPQ_4_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7528250</anvs:PrepaidResearchAndDevelopmentExpenseCurrent>
    <anvs:PrepaidResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_VmOujrgvj0qbTwfD2r5vMg_4_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">232752</anvs:PrepaidResearchAndDevelopmentExpenseCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_Zlse23832EqTeZq2Gxvk6A_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">37356</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_6ksTRVoTWE29mZRWzYwteg_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">29111</us-gaap:PrepaidInsurance>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_NMtC2MRQbkO_s2qg5jcu6g_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">11238</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_ylFWSUIVPkye41VOvyEL1g_6_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">9865</us-gaap:SecurityDeposit>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_E2ony6b4c0qQgRJPKIDprQ_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7644376</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_EORnfzhD-0ydq-JbWyJjHw_7_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">315464</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_7XviygOOB0Wtg82g2ZboNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(6)&#160;Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 556,827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 712,768&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional and clinical fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,180,458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,737,285&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 818,440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;See Note&#160;7 for further detail on the accrued license payments.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_yb8_L51LTUe7FC3_3sN_CQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 556,827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 712,768&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional and clinical fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,180,458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,737,285&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 818,440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_kR8rpUN4Z0mp82tDpc-9Ag_3_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">556827</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_kDOIfCOUT0KKyb9l0W4xZw_3_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">712768</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_a1_WySV2BEqjsBIxch5TcA_4_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3180458</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_XsK6b1Ezs0-xW3_295vTNA_4_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">105672</us-gaap:AccruedProfessionalFeesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_p22xoJYCqUe9rbgatoZ6TQ_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3737285</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_ZJIiCfrh5E6fMzAVcHMcng_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">818440</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_BZRQpHPgIE-l79JwhlrU_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(7)&#160;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Research &amp;amp; Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company has entered contracts with contract research organizations (CROs) and contract manufacturers (CMOs) related the Company's clinical trials.  The contracts require upfront payments, milestone payments, and pass through cost reimbursement, to be made.  While the contracts are cancellable with (written) notice, the Company is obligated for payments for services rendered through the termination date of the project with the CRO/CMO.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases its office facilities under a&#160;month-to-month operating lease. Total rental expense was $66,802 and $51,760 for the&#160;years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the &#x201c;Licensor&#x201d;). Under the license agreement, the Company paid a minimum annual fee of $46,000 and was required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Licensor also granted the Company a buy-out option which was exercisable at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company had the right to terminate the agreement at any time by giving 90&#160;days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement were recognized in general and administrative expense in the statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; In July 2021, the Company gave notice to the Licensor of its termination of the license agreement and the license agreement was terminated effective October 14, 2021. The Company has paid to the Licensor the prorated annual fees through the termination date.  &lt;/span&gt;No milestones had been achieved as of the termination date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Employment Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreements were approximately&#160;$1,291,900&#160;at December&#160;31,&#160;2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&#160;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#x2019;s liquidity, financial condition and cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2021, two securities class action complaints were filed against the Company and its executive officers following disclosure of interim results from the AD/PD Trials. Both complaints were voluntarily dismissed without prejudice by the plaintiffs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At December&#160;31, 2022, the Company did not have any pending legal actions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&#160;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The extent to which the COVID-19 pandemic could have a material impact on the Company&#x2019;s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Narr_-i5wvsSW6Ui6i0xjIfJCYw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">66802</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Narr_B3qUJx14bUujs2P_vgMZ-Q"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">51760</us-gaap:OperatingLeaseExpense>
    <anvs:LicenseAgreementMinimumAnnualCommitment
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_9kGGHtw_vEKel92_hHoiuw"
      decimals="0"
      id="Narr_GEEdLwmLdUSyY6t1O44hpw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">46000</anvs:LicenseAgreementMinimumAnnualCommitment>
    <anvs:LicenseAgreementPeriodOfAdvanceNoticeOfTermination
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_9kGGHtw_vEKel92_hHoiuw"
      id="Narr_3bmZSDNTjkOXkA6eS35K7g">P90D</anvs:LicenseAgreementPeriodOfAdvanceNoticeOfTermination>
    <anvs:CumulativeNumberOfMilestonesAchieved
      contextRef="As_Of_10_14_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_6KFn8E6JGkafxkOpuyUeRw"
      decimals="INF"
      id="Narr_6e-iC0dmtUeShg6LMcFEzw"
      unitRef="Unit_Standard_Milestone_di9IgBJq0ESfRR3NInDDpg">0</anvs:CumulativeNumberOfMilestonesAchieved>
    <anvs:MaximumAggregateSeverancePayments
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_-fLIo0BDvUSb0fXlQjkFBw"
      decimals="0"
      id="Narr_hg9kP97yyEy8jRwe4q6zyw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1291900</anvs:MaximumAggregateSeverancePayments>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="INF"
      id="Narr_utMgC_3zyUSenGimxGe5aQ"
      unitRef="Unit_Standard_lawsuit_1hwym7Rltkul7iLlrQNJ9Q">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_u0YRdOGK7kKfRgNtA9WL-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(8)&#160; Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a) Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board of Directors (&#x201c;Board&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liquidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Voting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Preferred stock may be issued from time to time by the Board in one or more series.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. The warrants have a &lt;span style="-sec-ix-hidden:Hidden_KVKI4UZ8Bk-1Y1WhTV4ecA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;-year term and were exercisable as of January&#160;29, 2021. During the year ended December 31, 2021, 97,600&lt;span style="white-space:pre-wrap;"&gt; of the warrants were tendered to the Company by the holders pursuant to cashless exercises.  Warrants outstanding as of December 31, 2022 and 2021, were &lt;/span&gt;2,400 and 2,400&lt;span style="white-space:pre-wrap;"&gt;, respectively.  The Company accounts for the warrants as a component of stockholders&#x2019; equity.&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <anvs:NumberOfVotesForEachShareOfCommonStock
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Narr_1zYx-q2PJ0u-xgDUeg-CZg"
      unitRef="Unit_Standard_Vote_S5Vg8LIuQ0WQwX_rru60RA">1</anvs:NumberOfVotesForEachShareOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg"
      decimals="INF"
      id="Narr_v4RPxY4sD0CTVBymcl0LPw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg"
      decimals="2"
      id="Narr_BuARBqTqaECYcrVPAU53og"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <anvs:PercentageOfExercisePriceToShareOfferingPrice
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg"
      decimals="2"
      id="Narr_mMqEi2uIeUm5VYEmjCn0Lw"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">1.25</anvs:PercentageOfExercisePriceToShareOfferingPrice>
    <anvs:ConversionOfWarrantsNumberOfWarrantsConverted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_0xEMeWQcf0WgCqU3s1_d0A"
      decimals="INF"
      id="Narr_iPj4-V_-wE-_sXudyqUYjA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">97600</anvs:ConversionOfWarrantsNumberOfWarrantsConverted>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_rxJ3y47tSUmoX-kh_xFoXA"
      decimals="INF"
      id="Narr_m2HX2Ls4TkCJlHd-bPZUIw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_RbtDYEkBt0OdMp6ezICorA"
      decimals="INF"
      id="Narr_XWCalEQYIUa9kmoSdizCWA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_NUw0TNx1y0aMqF4_FpQEwQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(9)&#160;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective upon the closing of the Company&#x2019;s IPO on January&#160;31, 2020, the Company&#x2019;s 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) became effective, succeeding the Company&#x2019;s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of December 31, 2022, 392,874 shares were available for future grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board. Stock options have a maximum term of 10 years after date of grant and are exercisable in cash or as otherwise determined by the Board. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2022 and 2021 was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,778,117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,680,882&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,374,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,016,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,152,520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,697,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock option activity for the years ended December 31, 2022, and 2021, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,111,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 2.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 538,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 33.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (159,813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 2.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,489,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 13.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 348,294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 15.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (70,101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 1.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 25.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,657,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 13.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 9,907,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,310,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 11.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 9,591,460&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was $803,357 and $11,163,998, respectively. As of December 31, 2022, there was $4,089,400 unrecognized compensation expense related to unvested options. That cost is expected to be recognized over a weighted-average period of 1.39 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;During the years ended December 31, 2022 and 2021, the Company issued 348,294 and 538,095 options, respectively. Under the grant agreements for the 2022 stock option grants, 10,000 of the options vested immediately, 9,947 of the options vested on March 29, 2022, 9,947 of the options vest on March 31, 2023, 43,333 of the options vest on August 29, 2023, and 255,067 of the options vest in substantially equal quarterly installments over two years&lt;span style="white-space:pre-wrap;"&gt; from the date of grant.  &lt;/span&gt;20,000 of the options have performance-based vesting conditions. As of December 31, 2022, it was not considered probable that the performance conditions would be achieved, and no compensation expense was recognized during the period related to these options. Under the grant agreements for the 2021 stock option grants, 143,391 of the options vested immediately, 155,253 of the options vested on March 31, 2022, 155,251 of the options vest on March 31, 2023 and 84,200 of the options vest in substantially equal quarterly installments over two years&lt;span style="white-space:pre-wrap;"&gt; from the date of grant.  All of the options have a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_-usZI0ypmUm4aeI3-2x4jw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;-year term.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average grant date fair value of options issued during the&#160;years ended December 31, 2022 and 2021 was $13.24 per share and $27.13&lt;span style="white-space:pre-wrap;"&gt; per share, respectively.  The fair value was estimated using the Black Sholes option pricing model.  The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment. The risk-free rate was based on the interest rate payable on U.S. Treasury securities at the time of grant for a period that is commensurate with the expected term of the option.  Given the lack of &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;a public market for the Company&#x2019;s common stock prior to the IPO, the expected stock price volatility was based on a weighted approach that incorporates the historic daily volatility of the Company&#x2019;s common stock since the IPO and the historic daily volatility of similar companies that have been publicly traded for a period commensurate with the expected term of the option.  The expected dividend yield is &lt;/span&gt;0% because the Company has not historically paid and does not expect for the foreseeable future to pay a dividend on its common stock. The weighted average assumptions used in the valuation of options granted were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2022, previously issued stock options were modified for an employee who is no longer employed with the Company. As a result of this modification, $1,219,572 was recognized as stock option modification expense and included in general and administrative expenses on the accompanying statement of operations.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_1_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_qE-sUUUt40qGRKaPxGSmLA"
      decimals="INF"
      id="Narr_hZnpdn26r0C3urctVzvF5A"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_31_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_lxMQ0mAjHESuECDwuJ190w"
      decimals="INF"
      id="Narr_Zfq6OPfHJUm1qrAmWPJXcg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_mSBoJpEAKkmTzpJqFergRg"
      decimals="INF"
      id="Narr_4WqteoiUxUy3mDFKYUD-eg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_nvrj-dGqOU6aKJERC6DdWg"
      decimals="INF"
      id="Narr_OuKrF4YuBkGEl5lZhAzbhQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">392874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_43OsGov8_0CKtp0gYKTwQQ"
      id="Narr_Y_XgzbnKyEe2swHkf7xfIg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_yjYjzdUCqUm0gtCla-Ow_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,778,117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,680,882&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,374,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,016,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,152,520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,697,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_TPQKDu5CTUOwF4Ecbc0PEQ"
      decimals="0"
      id="Tc_CPZzaXeq1EOPfQl3DvSXVQ_4_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5778117</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_zrhC9mvgWEyE7HMFE93j7g"
      decimals="0"
      id="Tc_g-L15D7P_kKI2KdGVGOBnA_4_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2680882</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JqPg780lPE6Z6dP0xYgvjA"
      decimals="0"
      id="Tc_J52MLKbm8U6fpDwG1Kp1qw_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3374403</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YB8rDynTHE2DxJUQucQRvw"
      decimals="0"
      id="Tc_PJ-ui7fLu0Ok2lcM6ixbug_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2016745</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_GioKQK1PD0meIRWw7db45g_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">9152520</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_T3EVJESBsEG_8X7RIpGMBA_6_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4697627</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_igMs_OI1AE-rquLF9_ENWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,111,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 2.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 538,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 33.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (159,813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 2.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,489,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 13.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 348,294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 15.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (70,101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 1.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 25.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,657,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 13.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 9,907,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,310,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 11.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$ 9,591,460&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g"
      decimals="INF"
      id="Tc_eHH_OihEfkyS4QcMi0xUEg_7_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">1111466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g"
      decimals="2"
      id="Tc__P9W2giTUUCH3ksm5TDR7w_7_5"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="INF"
      id="Tc_VOBDI1bSMk6aLjZ8ppv5mQ_8_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">538095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="2"
      id="Tc_jjOna_SrE0OJOkG9HoQMOA_8_5"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">33.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="INF"
      id="Tc_mldFL0bcVkus6OhsYDTFKA_9_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">159813</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="2"
      id="Tc__m7VIpvGLUGSz4vFAd-4eA_9_5"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">2.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Tc_AMb6-QxPdESjeVpmw3blHg_11_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">1489748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="2"
      id="Tc_XuPv2B-qsUS2Isfjps9WYA_11_5"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">13.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="INF"
      id="Tc_UmE7EE6lsUKnU9-PtsY2eA_12_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">348294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="2"
      id="Tc_uK9iiTBzm0KNmOMdVCOP5A_12_5"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">15.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="INF"
      id="Tc_ZE9kSK23P0y_T6NfyGO23g_13_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">70101</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="2"
      id="Tc_unUeImpgVESEb6j-6ECihg_13_5"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">1.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="INF"
      id="Tc_KXMUU6e-tkKiowLAW5rEwQ_14_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">110599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="2"
      id="Tc_B5_qOjd1h0aks9t09HPw1Q_14_5"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">25.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Tc_yTeN7UR9xE-Rh-wonBo9pw_15_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">1657342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="2"
      id="Tc_MO6NbVs_YEqIn2wrjDPSwA_15_5"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">13.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_JY7Z-r73MECDnN6G3VVrPw_15_7">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_rNQVCmILjkONcY3bgfaIag_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">9907660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="INF"
      id="Tc_4uSNCNICBU-39I_goobw3A_16_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">1310667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="2"
      id="Tc_hk-Pl0Pb-0ylPecu3OMruw_16_5"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">11.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tc_FcYnCvWCWEW0FM5wK9J9bA_16_7">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_Ee0qZ_sUX0m4mGObjUqAIA_16_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">9591460</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Narr_P1Xv8bnWXkuQL8eG3ziciQ"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">803357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Narr_WzozBTDYIkeCYw-JOVvvGA"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">11163998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Narr_nQKSpMqio0K03R-68ZI3CQ"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4089400</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Narr_myNHGNZsHkK2fS_mnbnTnA">P1Y4M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="INF"
      id="Narr_uATh9xu7QkS9Fj1l7pDr-w"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">348294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="INF"
      id="Narr_1RrkCxeVy0-v5JUwIsje-A"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">538095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_02HyU60TGUyED-4dfwaJfQ"
      decimals="INF"
      id="Narr_i3bZtdHsxUaL2L-V13A7zg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_R4senxF1EkumiKnOchMvOg"
      decimals="INF"
      id="Narr_UT11gOEOkkmUb4YmmVgDww"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">9947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_FZnw0o15xUmaQw2wDnDl_Q"
      decimals="INF"
      id="Narr_sdrUiHsSakW2RLsOPD8mJQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">9947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember_ChYbVG2dh0qNdtn6AHEW_A"
      decimals="INF"
      id="Narr_XAfgpkf-mEyf869E5pIGZQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">43333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_OUuVKvuXtkq-u1fVxFEu_A"
      decimals="INF"
      id="Narr_fukEOMXNLkCxTo-7ieGIuA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">255067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_T8bl_sZlz0iFUq0CaXz_5g"
      id="Narr_Mj15FLR8XUC_1QkkLlJLmQ">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_us-gaap_VestingAxis_anvs_PerformanceBasedVestingConditionsMember_I8m5rTHYtEm0RpeBerchIw"
      decimals="INF"
      id="Narr_5jxSYRjrmESOqLRh_WlxIw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2022Member_MPv8wqMPt0GCQzly0NPo-A"
      decimals="0"
      id="Narr_iScyHlKmU06kPHwD2dZeLg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_RvTsofmI_0GsR8XGxxfQXA"
      decimals="INF"
      id="Narr_ASlUn0kDTU-C2TT3YNiZDg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">143391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember_3phu_26-8EC8DSLEqSiFAQ"
      decimals="INF"
      id="Narr_vcJqj7YdEkyYUHvpLH7Eqg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">155253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember_VkaIA_opVUSZSU228t78pQ"
      decimals="INF"
      id="Narr_QP-8-stVOkqpPxLY3XKLOg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">155251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_1at2mAbtLEy8kiywIeDbHA"
      decimals="INF"
      id="Narr_BCkAx016sUWr3FZfMGcq5A"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">84200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_anvs_AwardsGrantedIn2021Member_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_2llG4i7HYUGYKyNFCvAp9A"
      id="Narr_GTvRXCJVjk-svI8YxwITkg">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="2"
      id="Narr_KsG_kYSO3kioyJP4lHfxfA"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">13.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="2"
      id="Narr_a3J1-fxLaE6zdmIQmk_NvA"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">27.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q"
      decimals="2"
      id="Narr_9HNDUZj2TUC2iY2ZjHk8Nw"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA"
      decimals="2"
      id="Narr_TLE3BZAt00qew1H5UTXVhg"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_JMxAhKxQlk6SBgHfy0WWiQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA"
      decimals="4"
      id="Tc_mwOZ5rtJNEOTE_p_c343tw_3_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.0224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q"
      decimals="4"
      id="Tc_E8TSze9mO02DGTQpp_2pBQ_3_5"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.0117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA"
      id="Tc_MafLX0QSkEyzKUJ5Bqrhzg_4_2">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q"
      id="Tc_nIVhpLNQK0mDUUVgRO6a2Q_4_5">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA"
      decimals="2"
      id="Tc_NJ5lDUyTjk2pWfJSfqLEkw_5_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q"
      decimals="2"
      id="Tc_vgSuRCY_FkqfHDo8YhnlYQ_5_5"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6qWeY-yivUe37_vlFW6ZeA"
      decimals="2"
      id="Tc_ODMkR_wTi0CJx46Xry3eyw_6_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gcXb99-lnUS1GCk9Rril2Q"
      decimals="2"
      id="Tc_UTPlf7v5MU-DamQrI72uLg_6_5"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Narr_jpHcfoz7S0ClDFWkTcrScQ"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1219572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_pCCq_Ds4uk-xrrwO6l1B_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(10) Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has reported a net loss for the&#160;years ended December 31, 2022 and 2021, and the basic and diluted net loss per share attributable to common stockholders are the same for both&#160;years because all warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,328,567)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,487,132)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,162,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,626,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Nrt4V6gKP0yrinHj-NMeNg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_cE1AXSw2LUaR4c9ANXGfMw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Potential common shares that are excluded from the computation of diluted weighted-average shares outstanding are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,657,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,489,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb__BcQgJJijUOiprh-7-3wZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,328,567)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,487,132)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,162,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,626,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Nrt4V6gKP0yrinHj-NMeNg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_cE1AXSw2LUaR4c9ANXGfMw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_ym1bLTjPm0uvRxgYWEqBQQ_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-25328567</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_CISIZv0npUud81xfgyj4sQ_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14487132</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Tc_L1vTe5La_U-XgqzpJRWaew_7_3"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8162326</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Tc_bJE23B6_b0yBzHQjTCPcAA_7_6"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">7626278</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="2"
      id="Tc_kOaLchG5HEC-y7o5nvJ06Q_8_3"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-3.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="2"
      id="Tc_SZN2WXtmHE-FfD0D26sN8g_8_6"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb__Yp-dRXMcEWRydVFbitcFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,657,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,489,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RelzNNUAf0uWCtCDxtOuNQ"
      decimals="INF"
      id="Tc_Efo6wKDrnkO-7_OXVX4OgQ_3_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">1657342</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_fqcjJ89wu0-oiY1nhms5jg"
      decimals="INF"
      id="Tc_ABqMfrH5806eR7r0nQOePA_3_4"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">1489748</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_6jD9f0YxekO4JmQcbKrXIA"
      decimals="INF"
      id="Tc_tMIEnSOIbkiCOzg_LJNQUw_4_2"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nspaGMfz_EWneA97LJAfPA"
      decimals="INF"
      id="Tc_KFwrEIdFKEeSQ91-1NBxkw_4_4"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_27fcWaHFQUebh74UpUBD5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(11) Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The federal and state provision (benefit) for income taxes was&#160;$0&#160;for the&#160;years ended December 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2022 and 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (52.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets are comprised of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,919,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,512,249&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,767,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,759,129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,725,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,002,431&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Section 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,445,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,618,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 648,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,476,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,921,886&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,476,267)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,921,886)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company had U.S. federal net operating loss (&#x201c;NOL&#x201d;) carryforwards of $27,536,031 which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2,764,240 will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2022, the Company also had U.S. state NOL carryforwards of $30,082,914 which may be available to offset future income tax liabilities and will expire beginning in 2028.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2022 and 2021 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company experienced a net change in valuation allowance of $7,554,381 and $7,672,071 in the&#160;years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company had federal research and development tax credit carryforwards of $1,618,294 available to reduce future tax liabilities which expire beginning in 2028.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#x2019;s tax&#160;years from &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;2019 to the present remain open for review. All open&#160;years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Narr_h_811DTrKE-80Al_FVl_Yw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Narr_F-JjEJ3P5kyatXudElbK8w"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_I2_9YPm-sUulcf_i7ZCTyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (52.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="3"
      id="Tc_g_2m8o6o6k6PEpi8xL9geg_4_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="3"
      id="Tc_ZrIUAMgHxUCVUU3nIIW7iw_4_4"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="3"
      id="Tc_ryNdSOGmUUCIk2TRtDdDzQ_5_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.057</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="3"
      id="Tc_tRGk1KNz4EyQG6MYOLtfAA_5_4"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.137</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="3"
      id="Tc_S7iU6IgExkOUVvSfI3lLjg_6_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="3"
      id="Tc_NDlfdFEzZkKa499xOQU_AQ_6_4"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="3"
      id="Tc_JtwcaH5NBkyTLVM8NQKmhA_7_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="3"
      id="Tc_dvBSNFnKak6KlEDPqzgDHg_7_4"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="3"
      id="Tc_-fR3FEb7oU2kSvOkyY5y_A_8_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="3"
      id="Tc_YV4vQzs00Umqw9Po0ydrsw_8_4"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.157</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="3"
      id="Tc_xoTu4WtkqU2X32ew2aD8Rw_9_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">-0.298</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="3"
      id="Tc_ZU8FbIIDukOuU22RHNHYcQ_9_4"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">-0.529</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="3"
      id="Tc_bMCbSZ-4iUup2voE4MZENQ_10_2"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="3"
      id="Tc_Xhj4JeqTDk6kP8O7j0jqjw_10_4"
      unitRef="Unit_Standard_pure_fPf89aWuVEeur4vXXHUX3g">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_eqKAcmtylkWBQZggDMsPkA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,919,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,512,249&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,767,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,759,129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,725,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,002,431&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Section 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,445,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,618,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 648,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,476,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,921,886&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,476,267)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,921,886)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_AxfpDq6r_Ei3MaDYP8fLJg_3_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7919085</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_RmPn1-Mup0m3aeD9rSJ9Eg_3_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">6512249</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_rxbZWRQUREaVqMwvR6nnGg_4_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3767330</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_6nbSMJoe70KcX47y11Y8mQ_4_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1759129</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_iGCkslC98kKu-P24wzN6-g_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1725622</anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment>
    <anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_ZeYsYyddsk63xe6egVhU6w_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2002431</anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment>
    <anvs:DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_EzIDo_EhBkiuQCGPl2dvwQ_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3445935</anvs:DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_aS4j6nJ-O0qtCl18HQT2RA_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1618295</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_s-bksqraYUeBdPyfqGtwMQ_7_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">648077</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_rPW8xEzOKUWbyJqGKUL2TQ_8_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">18476267</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_4KkuvO8XpEywIPcE9ApZxw_8_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">10921886</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_Fniel6PNQ0265WGw5wU3Qw_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">18476267</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_JCJ6LiFIX0mEcqC1gFz9xA_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">10921886</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Tc_5Ynoq_ziQEm3sD4IoeX7uQ_10_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_Gu3HHaUhykmD8X4v9WWCrQ_10_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Vi7H0gbpBkCBZr8biy-aFQ"
      decimals="0"
      id="Narr_0Th3As4rDEyg4zIX--QtbA"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">27536031</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_fb4PhuZvEUyAYxprN1iN7Q"
      decimals="0"
      id="Narr_akLmlD8umkW22zGg049Qjw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2764240</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ra5Wzdd2lUi3_iM1PWytxQ"
      decimals="0"
      id="Narr_lR96rOIGHUua3U4FwauDhQ"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">30082914</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Narr_Q7y7QOPTL06Qmz-r61Rynw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7554381</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w"
      decimals="0"
      id="Narr_XmQ-XjXpv0iaN9raLN1XZg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7672071</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_PvoPPon-90icfGwFkudlGQ"
      decimals="0"
      id="Narr_pKGHOUHwhUKxrW9CvUcemw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1618294</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA"
      decimals="0"
      id="Narr_lEvDb1NQvku2xY_mBV6HJA"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      decimals="0"
      id="Narr_aOZdcvKejkGfvytE2OhgrQ"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_qKJqleUqRkGjODxKE5RuIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(12) Restatement of Previously Issued Unaudited Condensed Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;During its preparation of its 2022 audited combined financial statements and notes thereto, the Company concluded that there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed financial statements as of and for each of the quarterly and year to date periods ended March 31, 2022, June 30, 2022 and September 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company noted the following items were improperly expensed during the three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments, in the amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$800,840&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, were improperly recorded in research and development expenses during the three months ended March 31, 2022. These amounts should have been recorded as prepaid expenses and other current assets as of March 31, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Research and development expense amounts totaling &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$140,690&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; were not recorded during the three months ended March 31, 2022. This amount should have been recorded in accrued expenses and other current liabilities as of March 31, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;These errors in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$800,840&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, accrued expenses and other current liabilities of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$140,690&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and an overstatement of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Fw2LNw0ysUal1BJuAIrjEg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;operating expenses&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and net loss of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$660,150&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; as of and for the three months ended March 31, 2022. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company noted the following items were improperly expensed during the three and six months ended June 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments, in the amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2,883,977&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; were improperly recorded in research and development expenses during the three months ended June 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of June 30, 2022. Additionally, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$102,232&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; was expensed during the three months ended June 30, 2022 related to the prior quarter restatements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;These errors, including the errors from the three months ended March 31, 2022, in the accounting for research and development expenses resulted in a cumulative understatement of prepaid assets and other current assets of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$3,441,895&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, as of June 30, 2022, and an overstatement operating expenses and net loss of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$2,781,745&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$3,441,895&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; for the three and six months ended June 30, 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company noted the following items were improperly expensed during the three and nine months ended September 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments, in the amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1,320,321&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, were improperly recorded in research and development expenses during the three months ended September 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of September 30, 2022. Additionally, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$130,826&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; was expensed during the three months ended September 30, 2022 related to the prior quarter restatements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;These errors, including the errors from the six months ended June 30, 2022, in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$4,631,390&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; as of September 30, 2022, and an overstatement of operating expenses and net loss of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1,189,495&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$4,631,390&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; for the three and nine months ended September 30, 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a result of such errors, the Company concluded that the previously issued 2022 unaudited condensed financial statements were materially misstated and has restated herein our previously issued unaudited condensed financial statements for each interim period within the fiscal year ended December 31, 2022. The restatement corrections impact certain components within operating cash flows of the unaudited condensed statements of cash flows. Total operating cash flows, investing activities, financing activities, and cash and cash equivalents are unchanged as a result of the restatements and as a result are not restated herein.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The following tables present the amounts previously reported, the restatement impact and the amount as restated. The 2022 quarterly restatements will be effective with the filing of our future 2023 unaudited interim condensed financial statement filings in Quarterly Reports on Form 10-Q.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The values as previously reported for the fiscal quarters ended September 30, 2022, June 30, 2022, and March 31, 2022 were derived from our Quarterly Reports on Form 10-Q filed on November 8, 2022, August 8, 2022 and May 4, 2022, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"&gt;Annovis Bio, Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"&gt;Balance Sheets&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;March&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,668,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,668,838&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 627,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,428,742&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred clinical materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,296,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,097,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,296,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,097,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities and Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 928,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 928,997&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 327,435&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 468,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,256,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,397,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,256,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,397,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commitments and contingencies (Note 7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock &#x2013; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Common stock &#x2013; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares &lt;span style="-sec-ix-hidden:Hidden_9SEDlZkijEKqtC-ySnJpRg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_tZ3jki-L5k2vnk0YROVQzg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt; at March 31, 2022 and December 31, 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Additional paid-in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,659,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,659,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,620,420)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,960,270)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,040,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,700,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities and stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,296,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,097,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,809,791&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (660,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,149,641&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,104,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,104,071&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,913,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (660,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,253,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,913,862)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,253,712)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,649&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,649&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,894,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,234,063)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,894,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,234,063)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KBQaGnyoDUm3mQc2xmzb9g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.72)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_AKXvNQ6KhkS17REUIUfQMQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.64)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,157,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,157,445&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Cash Flows&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;March&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&#160;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,894,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,234,063)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,434,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,434,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Changes in operating assets and liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (312,438)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (800,840)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,113,278)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (491,005)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (350,315)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in operating activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,021,789)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,021,789)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from financing activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from exercise of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in financing activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net (decrease) increase in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,017,176)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,017,176)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,668,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,668,838&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,974,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,974,251&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 551,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,992,967&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred clinical materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,525,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,967,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,525,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,967,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities and Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 901,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 901,841&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 397,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 397,544&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Commitments and contingencies (Note 7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Stockholders&#x2019; equity:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Preferred stock &#x2013; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Common stock &#x2013; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares &lt;span style="-sec-ix-hidden:Hidden_1KpyqUlIYEikh7iSvFo8QQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_QRqrEN-rqUqjxJGEYuDI_g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt; at June 30, 2022 and December 31, 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Additional paid-in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,563,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,563,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,338,551)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,896,656)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,225,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,667,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities and stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,525,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,967,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,815,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,781,745)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,033,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,938,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,938,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,754,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,781,745)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,972,410&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,754,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,781,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,972,410)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,718,131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,781,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,936,386)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,718,131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,781,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,936,386)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_gNBJeOes40Sa4G7lAiK58Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.07)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_yz2vRgL14Ee_24qI4nZ8pg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.73)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,163,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,163,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,625,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,441,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,183,604&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,042,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,042,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,668,017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,441,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,226,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,668,017)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,226,122)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,612,344)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,170,449)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,612,344)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,170,449)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_pn_EzwJF0kmaifLIJ3rdcw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.79)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_eHH7Nb15lUyp1mobGSzCaw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.37)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,160,702&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_i3zSlr-JE0itqi6e7cvv4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 8,160,702&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Cash Flows&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&#160;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,612,344)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,170,449)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,338,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,338,705&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Changes in operating assets and liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (235,608)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,441,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,677,503)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (420,896)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (420,896)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net cash used in operating activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,716,376)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,716,376)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from financing activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from issuance of common stock, net of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from exercise of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in financing activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net (decrease) increase in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,711,763)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,711,763)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,974,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,974,251&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;September&#160;30,&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,987,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,987,091&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 499,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,131,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,487,038&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,118,428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,487,038&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,118,428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities and Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,845,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,845,705&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 680,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 680,830&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,526,535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,526,535&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,526,535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,526,535&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commitments and contingencies (Note 7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock &#x2013; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Common stock &#x2013; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares &lt;span style="-sec-ix-hidden:Hidden_kuozT-fkoU2VpC3sMRmgDg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_IBAq19urw02_lqWC_B7pSQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt; at September 30, 2022 and December 31, 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Additional paid-in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,919,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,919,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,959,997)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,328,607)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,960,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,591,893&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities and stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,487,038&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,118,428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,313,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,189,495)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,123,538&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,361,299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,361,299&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,674,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,189,495)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,484,837&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,674,332)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,189,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,484,837)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,886&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,886&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,621,446)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,189,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,431,951)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,621,446)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,189,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,431,951)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_R0KpXRjzSkGPJsqmSAn4QQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.93)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9ngmT9i0wEWaZaFs0Tn7og;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.79)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,163,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,163,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,938,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,631,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,307,142&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,403,817&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,403,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,342,349&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,631,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,710,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,342,349)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,710,959)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,559&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,559&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,233,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,602,400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,233,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,602,400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lMJqv36yQEq7BdUNqY6Ieg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.72)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_boWkpKJFu0uuOAEChJvoRg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.16)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_T1ooRgaQ1UGTXvhVXaOfsw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 8,161,787&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,161,787&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Cash Flows&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&#160;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,233,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,602,400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,694,716&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,694,716&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Changes in operating assets and liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (184,483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,631,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,815,873)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,157,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,157,631&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (137,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (137,610)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in operating activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,703,536)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,703,536)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from financing activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from issuance of common stock, net of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from exercise of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in financing activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net (decrease) increase in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,698,923)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,698,923)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,987,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,987,091&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <anvs:PrepaidResearchAndDevelopmentCurrent
      contextRef="As_Of_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_w1NQBqyLWUGiwqQ90rxdHg"
      decimals="0"
      id="Narr_ftAm0Q2JK0W-a9DCdSVfWA"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-800840</anvs:PrepaidResearchAndDevelopmentCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_zpReF9mePUKpfeIdK6dAxA"
      decimals="0"
      id="Narr_XFVwFmtSD0-gjNkRIFNjjA"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">140690</us-gaap:ResearchAndDevelopmentExpense>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_w1NQBqyLWUGiwqQ90rxdHg"
      decimals="0"
      id="Narr_aOdp0PDZkkStVOsEcYossA"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">800840</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_w1NQBqyLWUGiwqQ90rxdHg"
      decimals="0"
      id="Narr_DhPx7rxtWUG0S0Nv-DrZtg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-140690</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member_zpReF9mePUKpfeIdK6dAxA"
      decimals="0"
      id="Narr_1bGE7np1YEivhFuZRFsfEg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">660150</us-gaap:NetIncomeLoss>
    <anvs:PrepaidResearchAndDevelopmentCurrent
      contextRef="As_Of_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_LXOH7EPaEECDbJNsMwmZFA"
      decimals="0"
      id="Narr_xcP-hz_9A0a4iXj57jX-2A"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2883977</anvs:PrepaidResearchAndDevelopmentCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member_ZSIgU1AfXUyGc1qV1Zr89Q"
      decimals="0"
      id="Narr_g5lxvamPik-wOXnY88AgTQ"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">102232</us-gaap:ResearchAndDevelopmentExpense>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_3z17PfnHWEakqKGVOPTu-g"
      decimals="0"
      id="Narr_97sIu_fXHkGUyaAgrVO9wg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_AWaPPOKacE-NwSyODgUlNA"
      decimals="0"
      id="Narr_8Nn2N9vSU02nPqRYwR4OFw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2781745</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_f6rfiOKViEG45RyBdeRPZA"
      decimals="0"
      id="Narr_8WBY_viyh0Ch-UzCmeCJaA"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-3441895</us-gaap:NetIncomeLoss>
    <anvs:PrepaidResearchAndDevelopmentCurrent
      contextRef="As_Of_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_26-oGseMPEeNfRhaZLLSPQ"
      decimals="0"
      id="Narr_V2WGUdPBlESTv8rW_dhxHg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1320321</anvs:PrepaidResearchAndDevelopmentCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member_vPBTijcqYUq2cqEFk9j3ag"
      decimals="0"
      id="Narr_2-mxADRjY0a2dkTLLVv76Q"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">130826</us-gaap:ResearchAndDevelopmentExpense>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_j4BX7lHcikG53t8xkKi-0w"
      decimals="0"
      id="Narr_U4RA-ruN_kWOKXytEGRoMg"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_Yo6y8AqHFEmOOGOfLBgYxA"
      decimals="0"
      id="Narr_jaeQlC-OOUmnf5YOiLpcxw"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1189495</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_WXJELeDryUOIsQTMpZhzWg"
      decimals="0"
      id="Narr_hMrX0ZYpVEqPQ-YowSuI7w"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_2qLIkySzv0StxjVBrGRekw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"&gt;Annovis Bio, Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"&gt;Balance Sheets&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;March&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,668,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,668,838&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 627,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,428,742&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred clinical materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,296,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,097,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,296,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,097,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities and Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 928,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 928,997&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 327,435&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 468,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,256,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,397,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,256,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,397,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commitments and contingencies (Note 7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock &#x2013; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Common stock &#x2013; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares &lt;span style="-sec-ix-hidden:Hidden_9SEDlZkijEKqtC-ySnJpRg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_tZ3jki-L5k2vnk0YROVQzg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt; at March 31, 2022 and December 31, 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Additional paid-in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,659,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,659,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,620,420)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,960,270)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,040,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,700,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities and stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,296,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 800,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,097,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,809,791&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (660,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,149,641&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,104,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,104,071&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,913,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (660,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,253,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,913,862)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,253,712)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,649&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,649&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,894,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,234,063)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,894,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,234,063)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KBQaGnyoDUm3mQc2xmzb9g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.72)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_AKXvNQ6KhkS17REUIUfQMQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.64)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,157,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,157,445&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Cash Flows&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;March&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&#160;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,894,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,234,063)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,434,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,434,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Changes in operating assets and liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (312,438)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (800,840)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,113,278)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (491,005)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (350,315)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in operating activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,021,789)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,021,789)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from financing activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from exercise of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in financing activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net (decrease) increase in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,017,176)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,017,176)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,668,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,668,838&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,974,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,974,251&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 551,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,992,967&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred clinical materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,525,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,967,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,525,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,967,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities and Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 901,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 901,841&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 397,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 397,544&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Commitments and contingencies (Note 7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Stockholders&#x2019; equity:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Preferred stock &#x2013; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Common stock &#x2013; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares &lt;span style="-sec-ix-hidden:Hidden_1KpyqUlIYEikh7iSvFo8QQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_QRqrEN-rqUqjxJGEYuDI_g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt; at June 30, 2022 and December 31, 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Additional paid-in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,563,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,563,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,338,551)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,896,656)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,225,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,667,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities and stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,525,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,967,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,815,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,781,745)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,033,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,938,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,938,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,754,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,781,745)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,972,410&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,754,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,781,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,972,410)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,718,131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,781,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,936,386)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,718,131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,781,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,936,386)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_gNBJeOes40Sa4G7lAiK58Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.07)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_yz2vRgL14Ee_24qI4nZ8pg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.73)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,163,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,163,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,625,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,441,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,183,604&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,042,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,042,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,668,017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,441,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,226,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,668,017)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,226,122)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,612,344)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,170,449)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,612,344)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,170,449)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_pn_EzwJF0kmaifLIJ3rdcw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.79)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_eHH7Nb15lUyp1mobGSzCaw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.37)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,160,702&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_i3zSlr-JE0itqi6e7cvv4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 8,160,702&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Cash Flows&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&#160;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,612,344)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,441,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,170,449)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,338,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,338,705&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Changes in operating assets and liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (235,608)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,441,895)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,677,503)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (420,896)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (420,896)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net cash used in operating activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,716,376)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,716,376)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from financing activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from issuance of common stock, net of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from exercise of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in financing activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net (decrease) increase in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,711,763)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,711,763)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,974,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,974,251&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;September&#160;30,&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,987,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,987,091&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 499,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,131,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,487,038&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,118,428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,487,038&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,118,428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities and Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,845,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,845,705&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 680,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 680,830&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,526,535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,526,535&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,526,535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,526,535&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commitments and contingencies (Note 7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock &#x2013; $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Common stock &#x2013; $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares &lt;span style="-sec-ix-hidden:Hidden_kuozT-fkoU2VpC3sMRmgDg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_IBAq19urw02_lqWC_B7pSQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt; at September 30, 2022 and December 31, 2021, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 816&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Additional paid-in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,919,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,919,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,959,997)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,328,607)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,960,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,591,893&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities and stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,487,038&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,118,428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,313,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,189,495)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,123,538&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,361,299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,361,299&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,674,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,189,495)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,484,837&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,674,332)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,189,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,484,837)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,886&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,886&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,621,446)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,189,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,431,951)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,621,446)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,189,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,431,951)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_R0KpXRjzSkGPJsqmSAn4QQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.93)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9ngmT9i0wEWaZaFs0Tn7og;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.79)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,163,923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,163,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,938,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,631,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,307,142&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,403,817&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,403,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,342,349&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,631,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,710,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,342,349)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,710,959)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,559&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Grant Income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,559&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,233,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,602,400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,233,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,602,400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lMJqv36yQEq7BdUNqY6Ieg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.72)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_boWkpKJFu0uuOAEChJvoRg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.16)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_T1ooRgaQ1UGTXvhVXaOfsw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 8,161,787&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,161,787&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annovis Bio, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of Cash Flows&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:39.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine&#160;Months&#160;Ended&#160;September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restatement&#160;Impacts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,233,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,631,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,602,400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,694,716&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,694,716&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Changes in operating assets and liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (184,483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,631,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,815,873)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,157,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,157,631&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (137,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (137,610)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in operating activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,703,536)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,703,536)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash flows from financing activities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from issuance of common stock, net of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds from exercise of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net cash used in financing activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net (decrease) increase in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,698,923)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,698,923)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,686,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents, end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,987,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,987,091&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_wixdQIKbZka2p4guTMXwHg_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">42668838</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_Niwz1b7HK0aWQISTGcvaZg_7_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">42668838</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_Jwhz9qeFBkKAufnE7W94fA_8_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">627902</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"
      decimals="0"
      id="Tc_NpWU6braFUS7lBIWTi1Snw_8_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">800840</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_lvXM0k8OVU2DKWxJKjV_hA_8_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1428742</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_AQhjnDrBRUeYTJWFq8j7og_10_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">43296740</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"
      decimals="0"
      id="Tc_GtOkbpwBOEajYEaWgHecJg_10_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">800840</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_4Z0bG-VNt0e-uRj6q1x9CQ_10_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">44097580</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_pHK9_fSE3UiC929dGw-5qQ_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">43296740</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"
      decimals="0"
      id="Tc_SZDcsuT7xUeFRydAMnpuAQ_11_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">800840</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_DdQH2hjTH0297VeNTyYa0g_11_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">44097580</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_O2s_9dnfI0aAx08GIfzprQ_14_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">928997</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_Zx3efvuktEm6hRoeRpFufQ_14_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">928997</us-gaap:AccountsPayableCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_2Qub7qZ6cEGCmsiKWUVnVg_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">327435</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"
      decimals="0"
      id="Tc_oDsitqs87EadiQLDiTrvdQ_15_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">140690</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_DHESKU93CUKF9hu-GAxlyA_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">468125</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_wuNW_80iX0GZ682UkMa6Ww_16_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1256432</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"
      decimals="0"
      id="Tc_zAqim6vWtkqpOyNs0g6hjg_16_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">140690</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_E6ZuJ2rQMke6sWoMlPPGwQ_16_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1397122</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc__YBCzy-mAUexNaFYuh9zmA_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1256432</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"
      decimals="0"
      id="Tc_alFRJyvw3EeP8H63NtyMmA_17_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">140690</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_1e6fXRCE70iZpR1YErlwpQ_17_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1397122</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="INF"
      id="Narr_I5tGCvO66UmWrLOaAluzvw"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_Ry2ZHHGzLUy_aSDssmVOng"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="INF"
      id="Narr_SGx8wr9nrkiRFeBwViY7zw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_m6UYssGd-kKXcuHJc_41uw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="INF"
      id="Narr_mPBnIAgf_EevaeFtZfaBMw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_ryXRZHegDUaceoDct1gibQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="INF"
      id="Narr_EdrO6uNXE0SQxFpchdA0BA"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_bZEXKiaaWk6eW1b8LdVZRg"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="INF"
      id="Narr_0RL3F7BOq0eXlIJX-tsq1A"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_QsXUrHmmzUWi7iGh-3b29g"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="INF"
      id="Narr_k6VCP_Dkh0SZRyDqVO6-mg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_L03kiGPbsUmWoa9nI9ioiw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8100570</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_VvCaFqDFaUeqGVXzPAjHuw_21_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">816</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_wXEO1ZpbDUW4Od4wiOhZQA_21_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">816</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_3MwrrKVaS020VurZMd9xuQ_22_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">76659912</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_39PMv2nqFkGc70g9uWDQJw_22_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">76659912</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_7TPoUQmS5Eu8kbwNQVhxzg_23_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-34620420</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"
      decimals="0"
      id="Tc_EoCQnqkvSkOPnlHvwdQnhA_23_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">660150</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_VzGG6tSx302ajH_iYaKwqQ_23_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-33960270</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_-1x8_hIHNEGNNlAfZ8dLLA_24_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">42040308</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"
      decimals="0"
      id="Tc_jPPu8ZbcFE-1XcrO1vIqWg_24_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">660150</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_y7Ch2EYGBESD8m10npHCeA_24_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">42700458</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_0Bt37UTw4kqqExzXm85Hfw_25_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">43296740</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_ZXtjjUzI-Eu3lIoUBuVZng"
      decimals="0"
      id="Tc_eSv2H4TPoEKnM70wl2muRA_25_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">800840</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_74jGUH32xUKi9cHimMe7Iw_25_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">44097580</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_HqW9D565E0mmJmg2hvgXLg_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2809791</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ"
      decimals="0"
      id="Tc_vy3tKays80uZpSC4gqPuYA_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-660150</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_Hs9qOteogUeAn9DdvAAF0A_5_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2149641</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_-unX50w-5EiYL_RGDmcnlQ_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3104071</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_wZ-VwS2GSEan2B4I_WCIzA_6_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3104071</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_yt3K7Df9OEKfw19Sz35Kgg_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5913862</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ"
      decimals="0"
      id="Tc_TfEIuPkG7EGs7FYVdbe4MA_7_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-660150</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_YKovfsIFPkyftM9AZawKnw_7_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5253712</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_wSIk8t1mMU-u6R--fT9psQ_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5913862</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ"
      decimals="0"
      id="Tc_VwyBrnY3MUSynjXIFZVfew_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">660150</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_NREftvFeBkidbTwp6TlzHQ_9_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5253712</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_ccu0clcPMEmPZh3P850T4A_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">19649</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_X-9sepZcEkyNwDba6HfCrA_11_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">19649</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_7a5jxtQjmkGq8TU3izXLaA_13_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">19649</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_0wYNc8lNFkmTOtH6JqN3fw_13_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">19649</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_Gujuq_Zx6kG9Ysdj9EkP6g_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5894213</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ"
      decimals="0"
      id="Tc_nEs7veYL0kGO4VRJhmDGeg_15_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">660150</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_F-H0ymWCPEOtSMAS0jt5iw_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5234063</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_NoVbWWQNnkyLHkYRY_TwQA_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5894213</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ"
      decimals="0"
      id="Tc_HZ_JyW4pVUaX5LMICWuDiw_17_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">660150</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_hUCkyeoUYUid8hZEjk_13w_17_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5234063</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="2"
      id="Tc_Y3VFxN0ln0qkAGUqLRD8Fg_18_3"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="2"
      id="Tc_XMgDHZNvdECOOz3xrHueTQ_18_9"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_BKlbS2zsk0GJMUFPSlWY7A_19_3"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8157445</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_4dpEzKdZd0KCkQxREXIrkg_19_9"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8157445</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_1BxBK8Fbj0yPwRiP-1uSxg_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5894213</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ"
      decimals="0"
      id="Tc_BquCXkGJh0K4tjo6NvySLQ_5_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">660150</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_uaMGU2asSUOFHGuefCuXcA_5_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5234063</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_sVqD_wWwaU2hbRJVhv7GiA_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3434944</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_8umeeX29w0e6_XcD-lXWcQ_7_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3434944</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_oPVHrPQjbkenL1dzQWz2gw_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">312438</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ"
      decimals="0"
      id="Tc_0zwyzFgZDEiR3vz49mMbsw_9_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">800840</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_tIYxhj8ncUCZSZ3znx6y2A_9_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1113278</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_BUW_BdbOxkSkBPJBTOwQAQ_10_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">240923</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_PkvMxr6bIUuTpmpbLyQ2Kg_10_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">240923</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_eEgYgcClc0GaWzM8PQV81A_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-491005</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_LQWzb1pbwUqjZ2Nbh-NnNQ"
      decimals="0"
      id="Tc_FolrhFAKrE-LhRuL2PCePg_11_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">140690</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_fKYlWcciq06EiaLcPGfF1w_11_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-350315</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_C9kyAo4Es0eHlu-C3i9UPA_12_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-3021789</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_KzdGM0aD-EigbBeOQAPFFQ_12_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-3021789</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_EBy4dVaSV0mydvKwhCNbLQ_14_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_VG9N9JclxUWPWxf6uv4Fyw_14_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_0c58XmoAs0qxlHdMD7SV-Q_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_xKjRz1e63UyEELZEN5MrTg_15_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw"
      decimals="0"
      id="Tc_7o8gn_8pOEy0XQQz0x4IAQ_16_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-3017176</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg"
      decimals="0"
      id="Tc_uX9ftuwtWk6jYJq0e_3RFw_16_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-3017176</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_LvDPCB7paUK0MB8bwYZ-Gg"
      decimals="0"
      id="Tc_HKuWf0oxFEmqHfCsLmKCFg_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">45686014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_MXCKPVKLHE6UZDi_jwTgGg_17_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">45686014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_DbD9BLeShUWJu6puTbQUog"
      decimals="0"
      id="Tc_h8M-SZ64O0qJtNRtP-K5yg_18_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">42668838</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2022_F7zHILfKDUONl0bQ4KAJFg"
      decimals="0"
      id="Tc_i2Xg5p92UUeh1CjAfob_2Q_18_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">42668838</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_9G8zaOFadEiH566Nudts-g_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">35974251</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_SWKbKlz-i0S-WB8DmgfskQ_7_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">35974251</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc__dy3Fs7GckO5qu-XW0xc4g_8_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">551072</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg"
      decimals="0"
      id="Tc_6H0d4FjWUUKvXpeTGxhi4g_8_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_N3zYrBj_f0eBLPksfg7IOw_8_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3992967</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_6heW0Fa8gkyIN5iRp0XFeg_10_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36525323</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg"
      decimals="0"
      id="Tc_x1Bndns7AkWbVp2wrYdaCA_10_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_lSZbTw41m0GMftrDhwCDEA_10_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">39967218</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_Brl02dCTfUeNHjRPqkK49g_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36525323</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg"
      decimals="0"
      id="Tc_S9fhPDj0sUCWukdRmnu9rA_11_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_kVt12jzr8kOuKlbcxZJ_jA_11_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">39967218</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_9DYautdyx061FS--Bgvc1w_14_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">901841</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_3y6kdXDn7kiJXpwqWIvMtQ_14_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">901841</us-gaap:AccountsPayableCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_1ZFgyO2q302dfaozfqLiHQ_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">397544</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_nc2z7vf5VEi054O3Atf6xA_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">397544</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_8vln-8YwUEWZ3SZ7HYR21A_16_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1299385</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_U9zkh6iTWEy5Xjs44l0J2A_16_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1299385</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_ahTAbOtiUkKHAHbqtp0TEg_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1299385</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_Dl_vjptKGEW60Etn91VfiQ_17_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1299385</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="INF"
      id="Narr_k6Npi8Ts-EOzFpW626gTGQ"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_uEOvHaAIx0GJRfds0rWgSw"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="INF"
      id="Narr_2h9mLw5zCE2gtAmY-HZBBw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_SSdMg2hMM0ezta7qoDI-AA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="INF"
      id="Narr_IcifYrB16kGmraMptJfH7w"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_2L4mun-LqE2DUxOarPakog"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="INF"
      id="Narr__S9uIk8jdkGcfltP3N_68A"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_ZJhfTMiHkk6uwZO5xKbJkQ"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="INF"
      id="Narr_YYeZpTRSkEydkhsAQBh_Jw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="INF"
      id="Narr_CEiY9jqmske6r0sz2pO_Qg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_9X6XMkZM6UW_fQOcYqTASw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8100570</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_J5Quxl_LjkKtGS8swl1llA_21_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">816</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_L4E7M4Fe_0C7zXJkM_LWnA_21_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">816</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_2IhcomDOqEeLhNjD2nuDQA_22_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">78563673</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_jjxXiTzWjEGchAE-J1Zu8Q_22_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">78563673</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_8wGPbkr9bkWJXbbM1hU5Ng_23_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-43338551</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg"
      decimals="0"
      id="Tc_aOR1zZZ-rEma5qcYQPlO4A_23_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_l9mq97u5W0OkfcUubgTdlg_23_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-39896656</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_tOjIIuSnsEqxNnKbl8pCKQ_24_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">35225938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg"
      decimals="0"
      id="Tc_IDIqUcdoKEmSbaRsuSTsVw_24_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_Q6YH68Fgckaw8h0T9L8XNA_24_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">38667833</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_myUYiNaKfkqlpIkFIavbWQ_25_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36525323</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_0JXeFaerTE2GiukjtQOOOg"
      decimals="0"
      id="Tc_hHo20TRw1k6eEzm-F-i5vA_25_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_YPRzZ96LNkGNeFMxFkjCIQ_25_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">39967218</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Tc_o5mJ3iBToU2wTRazx64xpQ_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">6815708</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw"
      decimals="0"
      id="Tc_7ocb7TZM60iocagMevlmng_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-2781745</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Tc__ngrXPv-UEaOr4VDbrOMqA_5_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4033963</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Tc_wi2B6tc3YEiO5H7wOhqUQA_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1938447</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Tc_uJDsGiru7kKYDauhVDruPw_6_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1938447</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Tc_IyJN1SBH0Em7MXZVMf28NQ_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">8754155</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw"
      decimals="0"
      id="Tc_1NJhnax4iEe_Ccc32wuU8Q_7_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-2781745</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Tc_U1JkjfhEQkinTaB_4Sk6yg_7_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5972410</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Tc_ynDMKdr82UG7v3sqzixQgw_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-8754155</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw"
      decimals="0"
      id="Tc_sOidMctHyEGjjL8YpbrXMw_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2781745</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Tc_OzcMZ4wh1UOsIXi7xlbjmg_9_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5972410</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Tc_NN3K6eY8L0Glzd74naHxEg_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36024</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Tc_hjW1eXxPLESFtc91Xj8ohw_11_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36024</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Tc_y5K9MoPCuk2aQGIsnkBIOA_13_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36024</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Tc_RfocnmTIIku41vJrf8Wkzw_13_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">36024</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Tc_2TmKkieHrEa8kzEP_N74pA_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-8718131</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw"
      decimals="0"
      id="Tc_cf4-4ZvnM06RNJRdZzUGdw_15_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2781745</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Tc_X-lR0lCLeU-bs6b-ko5hcw_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5936386</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Tc_Cy-NshiUkUmpRbHdBwQu7A_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-8718131</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jG2oRjbEREWGjYFV-C3glw"
      decimals="0"
      id="Tc_rg-FUR1IskqImHNKYDaQIg_17_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2781745</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Tc_VbBJRyXC2EqJr_Ud5KcJQA_17_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-5936386</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="2"
      id="Tc_quaI-tJmb0WO0x2AQDGgrg_18_3"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="2"
      id="Tc_WNof0lP6gkaR1dP_KKZYhw_18_9"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_wnLF-bSa3EyzeFcNIr-3kQ"
      decimals="0"
      id="Tc_wz7SNLH85kiPvHLCmaLgDQ_19_3"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_4A_3h53CMEaDukC8o4p_7g"
      decimals="0"
      id="Tc_OAGrz3-jc0CBihJpHJ3BOQ_19_9"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_8An-BmCzK0uJDe-StNScZg_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">9625499</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"
      decimals="0"
      id="Tc_T4d_QMpqnUSEpuhaSwTruA_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-3441895</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_0quCY_N2vEKh_FjF0E7LMQ_5_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">6183604</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_9U_dIXOfdUS0YfSb5dmiQw_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5042518</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_uxPMfCTHkUW-vz-SuZkFiA_6_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5042518</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_zFQfH8AIZkCiKET__meFYQ_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">14668017</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"
      decimals="0"
      id="Tc_ndVVcOPCMEu3ic3ZcSuiWA_7_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-3441895</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_-cJ6UYoXkkWjpWsmQO-8Cg_7_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">11226122</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_eatTnLa_ckahm_ZdXx9N_w_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14668017</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"
      decimals="0"
      id="Tc_n5nt_jMIoECuoHRIAM8koA_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_PYzRbQZskUm4yznqaEo_uw_9_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-11226122</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_iIyfyxJEVUWrYQxP1XbwyA_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">55673</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_MLi5Ch52lUSAgudHdfeiXQ_11_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">55673</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_TJEBeszT1UyL5DTUngEREQ_13_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">55673</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_VYeRPpi7NUS7-tSkWe_ryA_13_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">55673</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_wFahqPM6XECcnu0vwfsjtA_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14612344</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"
      decimals="0"
      id="Tc_gdgJR1MhAE-fMl7xkSYBWA_15_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_vvDe_Zd7OUuZHRCgbJuCUQ_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-11170449</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_bLgjFgYgCUay7rfdp9rI9g_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14612344</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"
      decimals="0"
      id="Tc_xuBx1XYkm0GSSqjKYVXJnQ_17_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_s2zy4OHDxEqu1s2DOHN_fw_17_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-11170449</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="2"
      id="Tc_LRc8CrGv5kKm4YJ15jD90Q_18_3"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="2"
      id="Tc_PPqcimxuAUCKkbh0JB7knA_18_9"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-1.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_ETwv68YNoUe_xZgYh0JkJw_19_3"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8160702</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_pdYrGzQ2k0mkYd4g_1F5Tg_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-14612344</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"
      decimals="0"
      id="Tc_1z5qBwousUakXrCnI6Jijw_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_4LQsozcEEUaOh3ISBzgiyA_5_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-11170449</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_ODXB0vTHi02JviLC7jP1oA_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5338705</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_syhIE0qb7EmFJ7w54G5ZzA_7_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5338705</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_9c6ha9Yme0C0J-J6BtBhYw_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">235608</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"
      decimals="0"
      id="Tc_GNDbT1CWhU2ks5TvDMzDAw_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3441895</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_67QE-lMRoUaVtv4-XLrTLw_9_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">3677503</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_1gfX96iMK06vVkEX9NNb-w_10_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">213767</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"
      decimals="0"
      id="Tc_54-INwseN0uiKAEfHXq-bA_10_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">213767</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_EFfl5sfbsUmF9JBQWN8-xg_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-420896</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_OlFmruVee06zwkV886625w"
      decimals="0"
      id="Tc_hMm9R8xBk0CgQtPoUgG7gA_11_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-420896</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_UMWoRzWxmEWfmZnucZMijA_12_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-9716376</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_y51qmdwOckGy2lpniC5Zvg_12_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-9716376</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_pIEOnAuU7Ey-dNeUilYugA_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_T-DuJ-0x_E2xF3RPSTFYcA_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_MyJlG7FIy0idi2wbfGz89w_16_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_7c2B4vLLqEmoNmcAEhrBTg_16_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_1Qg42g-h3020zjt7EQQtig"
      decimals="0"
      id="Tc_H1R1wQhOPEOtH3czlcXN0A_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-9711763</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_6_30_2022_lmolOXVnuU6xc2b8qOUQSA"
      decimals="0"
      id="Tc_dDYFstDysUu-KJgcx75Lgg_17_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-9711763</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_LvDPCB7paUK0MB8bwYZ-Gg"
      decimals="0"
      id="Tc_KJejLRaMvkyXRD-i7wJXpA_18_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">45686014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_jJMJh2L7CU62CXV9VskpNg_18_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">45686014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_tkxBffkeOkiy28UGlgEroQ"
      decimals="0"
      id="Tc_w2fRTWsGR0uf1U1ld8fhiA_19_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">35974251</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_57dtyqTuwkORJsX99R3KZg"
      decimals="0"
      id="Tc_Q_DuPNP9UkaUIPYfQINFFw_19_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">35974251</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_UX87sJaHh0-YwrNmAkivsQ_8_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">31987091</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_AZei8dMRmkKpXAFwVAI0LQ_8_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">31987091</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_tQ1VzicMaEeCkgLeVfd_mg_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">499947</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg"
      decimals="0"
      id="Tc_8hpDVfnIDUyLKdn7DIySlA_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_WkgtWVH5jEKerXty3RU7KA_9_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5131337</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_Kqpmb4uub02B5OQxqvGvxA_10_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">32487038</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg"
      decimals="0"
      id="Tc_uaApY1MKI0WnpgWtQE0s4A_10_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_IZ8gHkLBuEGdGxt3IP7guQ_10_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">37118428</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_qSZATTqUK0aV_hRhWm-DGQ_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">32487038</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg"
      decimals="0"
      id="Tc_Zy1xJT6KWkKxH-DVJiUJMA_11_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_C18Hsp0erkeOzJb9wLlCow_11_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">37118428</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_6yCK5mkDWEe4VMPGjxkR4Q_14_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1845705</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_TvzbbFel0k6puAYQ2u9voQ_14_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1845705</us-gaap:AccountsPayableCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_9jtgHhGgDkKJQnMzFkCG9w_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">680830</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_8_IZveOKbkKv_EC5slciGA_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">680830</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_Ujchfe4mlUOt18-WvAt1bA_16_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2526535</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_7LDE9sIGMUmGnRyGciQ1cg_16_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2526535</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_PP9gfoII2UuhR9SnN_YrRw_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2526535</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_N_9QqsIew0emI0nF-rHAtA_17_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2526535</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="INF"
      id="Narr_Cz0S_s49M06WsD9eMfe2yg"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_xLX0Jj-8L0mOyNtYKDIzkw"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="INF"
      id="Narr_CpM6Nd-e7ku5f5f52BgQzQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_aDMey5SG1EyXuGX1_dO8YA"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="INF"
      id="Narr_H0xIjTOa30SO6213TW7N0w"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_xE6Dlup-00iZ7oq44jTPUw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="INF"
      id="Narr_6bc6-tCLIUWmfOGwa71GzQ"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_mCjdq055H0-mveYfuhXCRw"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="INF"
      id="Narr_R2xgaCJt8UKpRMyjMDqMfg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_6V7WOAhEAk2PeqzA2lZ3Lw"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">35000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="INF"
      id="Narr_r3yoT0deLkGq-xe2gXrXvQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="INF"
      id="Narr_WWuLLOUFDUmYhWzae64IrQ"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8100570</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_XN7NTxiuk0quKpyGtT3GWg_21_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">816</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_4vh-dHIlbkKp5s0bL6ZdDg_21_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">816</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_VU0DbYuxvk2cOGZD2MvINA_22_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">80919684</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_dp6nBQjdPE-iTbWXXABU6g_22_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">80919684</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_-G8-jrJj0kuJVugvyW6CKA_23_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-50959997</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg"
      decimals="0"
      id="Tc_iKZYxd7TXEK_EzOSo3Z-pg_23_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_xmUlAtBFhEuPZxDFuHKNWg_23_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-46328607</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_HfebGYLoPkavpB5Jn21_kQ_24_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">29960503</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg"
      decimals="0"
      id="Tc_pFe7ApA3yUSQPHlvR4-B3w_24_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_iM-7r9cYg0ibE4qpQOZiew_24_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">34591893</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_SdkEhP0Sf0agjn-qVl2BbQ_25_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">32487038</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_kr-0GFbUJkmAGT8fCzObHg"
      decimals="0"
      id="Tc_CZ0UI5ObUUaskzAyABkkew_25_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_u9QQvLWg00K5PEpqPquKWA_25_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">37118428</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Tc_Z9sDJozay0qHnvt8pXgInQ_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">5313033</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw"
      decimals="0"
      id="Tc_GgptHgxVHESZZ1uHU8P7kw_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-1189495</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Tc_GOZ0PYl4AkWqErt9Lm9RpA_5_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4123538</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Tc_4TAByEZk2kWo2F9IIuuysw_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2361299</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Tc_3bg8skT3QEKtnm7fQgGR8w_6_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">2361299</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Tc_cP5c2Mn0wUqbIBcrn5p2tA_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7674332</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw"
      decimals="0"
      id="Tc_QQR6FXUs_kOnbViSvpdbbA_7_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-1189495</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Tc_UL2sZxBh50ucE-eKHEGKqw_7_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">6484837</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Tc_P7yCQxTfxkS64x4OzGtcnQ_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-7674332</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw"
      decimals="0"
      id="Tc_qfZ6fUg4BE2BgO8uVQhPtg_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1189495</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Tc_Fw5d2pNjt0uSLH3czem9sw_9_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-6484837</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Tc_HCfwBnp8402NjqBFyc73eg_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">52886</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Tc_vTAbYYAU9EK7rp7u3iz50Q_11_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">52886</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Tc_zeGJEQZHh0qFVA_u6287GA_13_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">52886</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Tc_TdxqbIlyXUeBdzcm-epBqw_13_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">52886</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Tc_4qX-2KbE8U2uPW-Tv84qeA_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-7621446</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw"
      decimals="0"
      id="Tc_TqqQdkvHe0umfJiyL0vVuw_15_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1189495</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Tc_pBW-wSw5W0K8K6Lny_VgQg_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-6431951</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Tc_WIQzVzuDyUCRTQRBCXz29Q_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-7621446</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_FSM8D3jFwEiW0VZS4RO_Fw"
      decimals="0"
      id="Tc_1WGX4U_fpkaBUChUvA5b3w_17_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1189495</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Tc_chVu4ms6MUCdBr_Nlr_Idw_17_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-6431951</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="2"
      id="Tc_9X8Pl4azs0CVHun4BKDC_g_18_3"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="2"
      id="Tc_EskCT7db4UOBOQS5PFOY0A_18_9"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ"
      decimals="0"
      id="Tc_GhHqjyE_DEy6WZTRzENcpQ_19_3"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A"
      decimals="0"
      id="Tc_a7xkdo8tbkKfBjHmUyP2xA_19_9"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8163923</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_pW6Ej8hda0etgc-OsmvC7A_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">14938532</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q"
      decimals="0"
      id="Tc_oS3yOZ5ZwUy8q5g6g32TmQ_5_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-4631390</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_v6j87_BvwkmHz0xNOv0hyA_5_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">10307142</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_HGt7zFWTqEGVt8ALqvKw8A_6_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7403817</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_kM42Eve7dkWFIkSd1TeV9A_6_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7403817</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_Goiq01EpBUSjNYetHUk0lA_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">22342349</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q"
      decimals="0"
      id="Tc_1FLLYbf0OEeHgSAa9gy2Lw_7_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-4631390</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_JRZDTEYhsUuszXlbWqlC_w_7_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">17710959</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_usVD0Mm2wEKSJ3wMZDhyrA_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-22342349</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q"
      decimals="0"
      id="Tc_SqeYRW02qUa4TxFz6UTqAA_9_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_G1jQHuvDckuP5f1BN5-tbw_9_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-17710959</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_ufzevBFickGBxh37oyqpMg_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">108559</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_oEnMXxZ-kUCN9Mb3U1nM3g_11_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">108559</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_6NatII2hQ0epfvqsbRW6Yg_13_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">108559</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_frS8L9PPaUOe8duLZVznBg_13_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">108559</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_iOxvppWWg0yylnmrOY04wQ_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-22233790</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q"
      decimals="0"
      id="Tc_3EXdcfi6102aorF027f98w_15_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_p1PLZ6vcb0eX1FwkNog64A_15_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-17602400</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_3P-GwDV97keri41xDbPBsw_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-22233790</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q"
      decimals="0"
      id="Tc_B6MMys1m7EG6Ujou9XHYZA_17_6"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_5-apegCtOEi2A1SwL5IM3w_17_9"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-17602400</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="2"
      id="Tc_wrEXMObYK0yZS9TjXghB9w_18_3"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-2.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="2"
      id="Tc_y3bUZBSx_ES86AQSn5iHCA_18_9"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">-2.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_cOrcpa8qxUKfCqM5BQF3ew_19_9"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">8161787</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc__p87WMhZqESBIuWtxOAukg_5_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-22233790</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q"
      decimals="0"
      id="Tc_raiHnq-L2Eu82yp7kvU4zA_5_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_qzljjub1EEmcyClGBmxCsA_5_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-17602400</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_ODHm6DM7a0CvIlsRx4s88g_7_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7694716</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_DhbjTxcw2USaDGjBsc09VA_7_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">7694716</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_YdAei--rr0Ct2vJ2xKvesQ_9_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">184483</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_RestatementAdjustmentMember_jw1rT_w83UW2sblaz0hr4Q"
      decimals="0"
      id="Tc_CZMyvMkq4kKLu_DXGbcWJg_9_5"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4631390</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_MEMz5PlWe0ONH3QBQgQiUg_9_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4815873</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_OCZshHGohEGu2yJXRXmGFA_10_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1157631</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_IgzsOCnJtkSXnqHf7q_8Vw_10_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">1157631</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_BIpyznnu8k23RC_nl-MmmA_11_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-137610</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_xe2gPu_DWESlwB70Gb-KBg_11_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-137610</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_x9MYshzDb0WjI0E8Mi4rug_12_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-13703536</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_Gy1KacYnfk2kiVjjAIa-eg_12_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-13703536</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_7kITeSIDp0OvG_cwR6BdRQ_15_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc__YK0gQUgKkK8YWQbWLwSow_15_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_SvRkJIEW70mX_d7SUePl2g_16_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_8fogJMM4fkui2uFtNa6Idg_16_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">4613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_rxYOSvv3yUu9724ESdP5CA"
      decimals="0"
      id="Tc_btwncQ63YEi_t5uh2-wERw_17_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-13698923</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_9_30_2022_icE4x0g3jkO13Sje7S1SnQ"
      decimals="0"
      id="Tc_diTt85NvKk-4gJA9WTY8zQ_17_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">-13698923</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_LvDPCB7paUK0MB8bwYZ-Gg"
      decimals="0"
      id="Tc_yV41rP5AtEiN3SCtDItlOg_18_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">45686014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g"
      decimals="0"
      id="Tc_9Gq_jBy510OzZdjvk8ef1Q_18_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">45686014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw"
      decimals="0"
      id="Tc_6gm-3rmslEa60-JrEKEiLw_19_3"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">31987091</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_PVDY3mE5HEqGJ-tWdWjehQ"
      decimals="0"
      id="Tc_51i01hA_kkSvuCKNnPr_PQ_19_8"
      unitRef="Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA">31987091</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g"
      id="Tb_S7X4h7ueHUePlQqiShKhGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(13) Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 18, 2023, the Company granted options to purchase an aggregate of 81,705 shares of common stock at an exercise price of $13.17 per share to employees, members of the board of directors and consultants to the Company.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_18_2023_To_1_18_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CNEPyGXQ7U2LW4h39gTpIw"
      decimals="INF"
      id="Narr_5Ldbsn53-06JFIolqkL8Qg"
      unitRef="Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA">81705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <anvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice
      contextRef="Duration_1_18_2023_To_1_18_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CNEPyGXQ7U2LW4h39gTpIw"
      decimals="2"
      id="Narr_pMHMxsRR9kaht2Kehne1yA"
      unitRef="Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ">13.17</anvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$A#7UX3PYX'<(#5[=/<?4$L#!!0    ( %B'?U9".W;F.@8  %DB   8
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M]A1XR$-FG=)]&^=% >4$6Y8#..JQ@%B).6[C"*'4!-L"3@!@$! <>5923-M
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M4M;^AY'(([;E -*+F,_LX,0@DC*.[7NP,80DA 28VS&:@-"@BCG&MO\ U&S
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M7% /N,>YRGU+/W%@Q[BSCE&N)6Q4S !C;[T;7NN]$MJ6!8CXP&QT+$ 8@B#
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MFUF4N&(XDR.)2N7#M##60DQ59TD##MY3U-:A6M;C'3L9?E#^P(HJ]0TPJ6^
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MTP"R .VO+#6]=L(&^J^DQ;]02P,$%     @ 6(=_5K(-\(Z\ @  . 8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULG57;;MLP#/T5PAN*%NCB2]*N
MER1 TFYK'QH4[2[/BLW80BW)DYBFW=>/DE,O!=)LV$LD4CQ'A[3(#%?&/K@*
MD>!)U=J-HHJH.8MCEU>HA.N9!C6?+(Q5@MBT9>P:BZ(((%7'69(<QTI('8V'
MP7=KQT.SI%IJO+7@EDH)^SS%VJQ&41J]..YD69%WQ.-A(TJ\1_K6W%JVXHZE
MD JUDT:#Q<4HFJ1GTX&/#P'?):[<QAY\)G-C'KQQ78RBQ O"&G/R#(*71[S
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MAG=[4</RAEF6SK7:$^VB$<UMFE*;;"3'I6O*@]5XRC'/ILLLTSO(R>TSMMF
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M[*VM]EZU^Z(U7F=JO!N&T$Z89:U+C@_D.KC$%P0D'*%@T$>64Q#=(QU(.JB
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M9X587@ZNPQ<W(Y*W K]+L2L[WQE9LM#Z,PW>I9>#@!022B2&$#@^MN*54(J
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M=T9B"?%%%(DLK7=A6\++-:47$L"JOI/E4VK49B7=JA=?Z+MHO%4:K(U\,M9
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M6J D"Q+ ^Z76IAG0 NVO0U?_ U!+ P04    " !8AW]6I:5/:)4#  "C"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RM5FUOVS80_BN$.A0-H%D2
M+=M*:AMHTA8;L 9&LS7H1UHZ6T0H4B6I./GW.U(O4]Z\ .T7B3S>/?<<[X[D
M\J#TC2D!++FKA#2KH+2V/HLBDY=0,3-1-4A<V2E=,8M3O8],K8$5WJ@2$8WC
M>50Q+H/UTLLV>KU4C15<PD83TU05T_?G(-1A%21!+_C*]Z5U@FB]K-D>KL#^
M4V\TSJ(!I> 52,.5)!IVJ^!#<G:>.GVO\(W#P8S&Q$6R5>K&3?XL5D'L"(&
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M2I,OU8?.D%+H80=O=RW2=<M85R M-LXC*SM'#AYI]*IKG/JSRS=BBL[WH?G
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M/L<PNVH\SKOPO@$O*461PZ"FB*LFG7#V@.DVZ= <J?_QY'Y]QNN3@:20K,-
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MDU=>Y4O;[/@UTW73MDW%'[=& ]1I 9X73=/&+W1 >O'X_+]02P,$%     @
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M;#R@%*(&:8221$.Y""ZC\ZO4Z7N%7P7LS-Z8.$]62CVZR9=B$82.$%206X?
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M-L*!AQP?EZRVI#C6,1FWV(Q51K]%X5441T543MMED4X_S]-XQK-<XO9>6K^
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MVD@8A?_*B%WMME(W^(8-V02IB>_:=*-&W?WLF"%8]86.AY!(^^-W;!R#P4Q
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M>LCQ I\V'D3=N+!!BJQC->S!/78[XSTRLY2B!66%5LA E>.[Q6J=AO@8\%O
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MF-Q\]0QF;-_1<;J++7/0SC=@-!L_\6!"@#^OM'8G)W3A_ \I_@)02P,$%
M  @ 6(=_5AIN7%PM P  .Q(  !D   !X;"]W;W)K<VAE971S+W-H965T,S N
M>&ULK9A=;YLP%(;_BL6FJ96Z\DV@2Y#6 -JF5:H:M;MVDY,$%7!JFZ25]N-G
M V6AH2B1?!-L..]C^[SD)/9X1^@36P-P]))G!9MH:\XW5[K.YFO(,;LD&RC$
MDR6A.>:B2U<ZVU# BTJ49[IE&)Z>X[30PG%U[Y:&8U+R+"W@EB)6YCFFK]>0
MD=U$,[6W&W?I:LWE#3T<;_ *9L#O-[=4]/26LDAS*%A*"D1A.=&^FU=)(..K
M@(<4=FROC>1*'@EYDIV?BXEFR E!!G,N"5A<MC"%+),@,8WGAJFU0TKA?ON-
MGE1K%VMYQ RF)/N3+OAZHOD:6L 2EQF_([L?T*S'E;PYR5CUB79UK.-H:%XR
M3O)&+&:0IT5]Q2]-'O8$YD<"JQ%8QPKL1F ?*W :@7.LP&T$[K$"KQ%X5>[K
M9%69CC#'X9B2':(R6M!DH[*K4HL$IX5\L6:<BJ>IT/$PP2E%#S@K =T 9B4%
M\=9PALXBX#C-V#GZBNYG$3K[?#[6N1A0RO1Y [^NX=8'\ CFE\@V+Y!E6%:/
M?#HLG\%&R(T/Y=&P_%=9#,KC8?D-IH.33XY?N]F5Z\*CUBBK-<JJ>/9I1O69
M4H.<?I"L5%=L@^<PT40I8D"WH(5?/IF>\:W/(I6P2"4L5@E+%,$ZUMJMM?80
M/9QBMD;P7*9;G$E/+] 44_J:%JO:\#Z/:Z);$>6/QS:T?'LT\@)[K&_W_3L,
MM,W 'QF!V0V,>@+=8.18[KO ^##0L3S/]VV_&YCT!+J>[QFFTP9V\N6T^7(&
M\W4'\Y)2D9Z^Q Q*3WWY5<(BE;!8)2Q1!.N8Z;9FNJKJFJO26I6P2"4L5@E+
M%,$ZUGJMM9[RNE83O?VZYAF&&=C.N[HV./2I_JF$Q2IAR6$^1#ILL[^ CEIC
M1L<54/07_88M9,CL\V(0<NKW324L4@F+5<(21;".K7YKJZ^JE/HJK54)BU3"
M8I6P1!&L8VW06AN<6$K_F]WG;W#X]["_C X.>ZIW*F&Q2EARF(^^,JKO[:/E
ML8K8 J[2@J$,ED)G7(X$@-9'%76'DTVUM7XD7&S4J^8:\ *H#!#/EX3PMX[<
MK;?G1>$_4$L#!!0    ( %B'?U;7?%AA6P,  )(/   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,Q+GAM;*V776_:,!2&_XJ535,G=<T'$#X&2(5L:R\ZH:)N
MUR8Y :M)S&P#W;^?[824M,&%-5Q [/A]C\\3V^0,=Y0]\A6 0$]IDO&1M1)B
M/;!M'JX@Q?R*KB&3=V+*4BQDDRUMOF: (RU*$]MS'-].,<FL\5#WS=AX2#<B
M(1G,&.*;-,7L[P02NAM9KK7ON"?+E5 =]GBXQDN8@WA8SYALV:5+1%+(.*$9
M8A"/K&MW$+B>$N@1OPCL^,$U4JDL*'U4C=MH9#EJ1I! *)0%EC];F$*2*"<Y
MCS^%J57&5,+#Z[W[=YV\3&:!.4QI\IM$8C6R>A:*(,:;1-S3W0T4"7647T@3
MKK_1+A_;:5LHW'!!TT(L9Y"2+/_%3P6( X'K'Q%XA<![*3@6H54(6J<*VH6@
MK<GDJ6@. 19X/&1TAY@:+=W4A8:IU3)]DJGG/A=,WB52)\8_&,X$NLU"F@*Z
M"$!@DO#/Z MZF ?HXN/GH2UD%#76#@O'2>[H'7%T/71',['BZ%L6050UL.7T
MRCEZ^SE./*-C .$5:KF7R',\KV9"T]/E;HT\,,OGL)9R1\G=OB&;5DF\I?U:
M)Q"OHYNKV_5J=0P,^!J',++D/N? MF"-/WUP?>=K'9DFS8*&S"K4VB6UMLF]
MH$:.4C.JSZ66FW6TF3HXM^.6W^VTA_;V$$=#(2LX.B6.CA''S]N;.@I&T;D4
MFC0+&C*KP/)+6/Z[=IS?)+4FS8*&S"K4NB6UKGF)44%"0#1&USO,HDNTU!AQ
M2C>9J,-HM#L78Y-F0??5?G;[COJ4.[I"J%<2ZKWK3.J]"NM4CY!I/L)_XZ Q
MSN(_5T&_S+%OS''&: @0<10SFB*=,:_+U>AR[L/OGX2EH9 5+*[S_-[DG/#P
M&81 MGB1U"X L\6Y5 HW__AZ"IH*6&5R\"[I&ID\9 Q(NM@P#O*\@(0LB22#
M0LH%5_MDPQA$:"-?"QD2*\A/E%IPQCAG@W/?VHA!4P&KX+QG<)X1W#VH$HUD
M2Q1+.ASAK7P-/[JJO#?/%7.X<X_/IMQR./9!L9("6^JBC\M%(O]6\IJ@["T+
MRVM=3KWHG[B#:5X>/MODU>H=9DN2<91 +"V=JZYDQ?(",&\(NM8ET8(*66#I
MRY4LFH&I ?)^3*G8-U2 L@P?_P-02P,$%     @ 6(=_5N_*XQ@Q P  "PX
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M<N#EIT<YD"PO6N4G)E7C79RNU=<:<!V@[B\9DV\#W7W7WW_A/U!+ P04
M" !8AW]67=/W)] "  #%"@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6RMEFMOFS 4AO^*Q::ID[9RO[0C2&T3M$V:%#7K]MF!0X)J,+.=I/WWLX&@
M7"A*);Z +^=];)\7;(<[RI[Y&D"@EX*4?**MA:AN=9TG:R@POZ85E+(GHZS
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M3D:JM 67.-=@2B&8OK_ 0FW'03?8+5SQ56[=0IB,UFR%UVAOUG--L[!AR;A
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MOWX5+Z(O+WB<3Q[G+]'S7YW:@R&Z(B<LFN#E(<"+FMB:&_#3Q7#"UM=RR?R
M7P2\OUBG/$[9Z=P1._OH_O[\Y.8@&DLD5*B)9A^O*3%#3PZ!TVWH@[UVV%5A
M6.,U!N,3<+W2:'4,?&M-/X;\+U!+ P04    " !8AW]6+Y(U.C$#  !9#
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M<VAE970T,2YX;6RU6&USXC80_BL:M].YFVFP);^GP$Q"[MI^N#:3]'J?A;V
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M?B!_(_DJ>P3_B4O)H^SEDI* BO0"]?V<<_GV)JV@_!7'[']02P,$%     @
M6(=_5CK#M=\/!   21,  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
MK5AKCYLX%/TK%KM:M5(G@'EGDTC-D,>NMJM1HVX_>X*3H +.VD[2_ONU@:$)
M<T-9E2\)-N><:]\'?DPNC'\1!THE^IIGA9@:!RF/8],4VP/-B1BQ(RW4FQWC
M.9&JR?>F.')*DI*49R:V+-_,25H8LTG9]\1G$W:265K0)X[$*<\)_S:G&;M,
M#=MXZ?B8[@]2=YBSR9'LZ8;*3\<GKEIFHY*D.2U$R@K$Z6YJO+?'ZTCC2\ _
M*;V(JV>D9_+,V!?=^".9&I8>$,WH5FH%HO[.])%FF192P_BWUC0:DYIX_?RB
MOBSGKN;R3 1]9-GG-)&'J1$:**$[<LKD1W99TWH^GM;;LDR4O^A280,%WIZ$
M9'E-5B/(TZ+Z)U]K/UP1E Y,P#4!MPGN'8)3$YR^!+<FN'V'Y-4$KR_!KPE^
MF^#?(00U(>@[A[ FA&5TJW"4L8R))+,)9Q?$-5JIZ8<R(4JV"F%:Z-3=2*[>
MIHHG9W^KZOB+"8&>*$>; ^$4/: Y$>D6D2)!29J=)$U0H6"9AAT53)2P-S&5
M),W$6T7XM(G1FU_?3DRIAJ2%S6UM?EZ9QW?,.^@#*^1!H$61T 3@+[KY_H_X
MRVY^]"/^JIMOXPX!4\6B"0A^"<@<=RINZ'&$'.L=PA;&P( >N^E_GHI.>MQ-
M_T"XHMMWZ8N?L[[\N;FONNDQW78.?MV?;G=$TFE*RRGUG'NE=<HI)Y)QJ"PJ
MJ@M3]7HU%D>RI5-#+4B"\C,U9K_]8OO6[U!*#"D6#RFV&%)L.:38:DBQ]4!B
M-VGF-FGF=JF77W#]:8:RK&)Z)5-O8LZS!]]U[,A3^7V^SB  Z$6.[X3^+3"&
M@-AQ+=^Y!2X H&W;@>6ZT2UR"2$#W\*N9=TB5P 2>PX./3^X1:XA3=<- ]O!
M#?+&VU[C;:^SJ&-:,+4,WRMK;\BR'E(L'E)L,:38<DBQU9!BZX'$;A+-;Q+-
M[RSKS^6NFR8/Y*Q6D3U%6Y;G:K-?;KX$4J<0(=4.+2WV[_3F/=U"Z5B9\*_*
M(+1])\*M8GWLB8LAG!>XKM<J?E#/"BS<*GT09P=AJYQ7( X[N/5U6K_&!3[V
M<1#"11\TL0@&BT6]8X:B$?2,1D]<#.&@:(!Z0#1 '! -$ =$XS6N,QIA$XVP
MUX+W_2S240&55'B]$%BCH+4$/<*HMK]!E.^VO V@[)'3\N$20.&1W?+@"D Y
MH];:O08-1K"/H\;'T?_V<4=F1[V\#*/:7@91K[P,H  O RC RP#JM9=!@VTO
MFU<'<;7YWY>7,D)]+DZ%K X.36]S[_.^O.YH]<_M<6P#_2M[O*ZN=;[+5Y=,
MZN2V3PN!,KI3II1?U>+%JXN;JB'9L;P&>&92LKQ\/%"24*X!ZOV.,?G2T ::
MV[/9?U!+ P04    " !8AW]6CH+_HL4"  !_"0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6S%5FUOTS 0_BM6D!!(L+PV+:.-M'8@D!A4JV"?O>3:
M6'/L8#OM^/><G2RT6UN&5(DOB>W<\_B>\UW.XXU4=[H$,.2^XD)/O-*8^MSW
M=5Y"1?69K$'@EZ54%34X52M?UPIHX4 5]Z,@2/V*,N%E8[<V5]E8-H8S 7-%
M=%-55/V: I>;B1=Z#PO7;%4:N^!GXYJN8 'F>SU7./-[EH)5(#23@BA83KR+
M\'PVLO;.X >#C=X:$ZOD5LH[._E<3+S .@0<<F,9*+[6, /.+1&Z\;/C]/HM
M+7![_,#^T6E'+;=4PTSR&U:8<N*-/%+ DC;<7,O-)^CT#"Q?+KEV3[+I; ./
MY(TVLNK Z$'%1/NF]UT<M@!A>@ 0=8#H,2 Y (@[0.R$MIXY69?4T&RLY(8H
M:XUL=N!BX]"HA@E[B@NC\"M#G,F^8J)\D5J3.2BR**D"\I;,I0%A&.5$VQ5-
MX#[G30$%62I9D9SRO.'4'<.K2S"4<?T:8:WQV#?HEV7W\\Z':>M#=,"',")7
M4IA2DP\"-]DE\%%0KRIZ4#6-CC)>0GY&XO -B8(HVN/0[/GP\(@[<1_DV/$E
M!_@61N9WY%MM([8W/D?AMI#/=4USF'A8J1K4&KSLY8LP#=[OTW8BLAVE2:\T
M<>SQL]-IG]SDE')/1+8C=]#+'1P]V NLDH+QQOZ*B(:\4<RPI_4BJ[HQ;;W(
M)0&J!!,K36J,D3X4HW;CU&UL?\7K+$P'PSC!=%YOR]]CEXS>#9-1;[>C+.V5
MI4>5W5"EJ#![L_4H\E^/[T1D.R*'O<CA";)U>$JY)R+;D3OJY8[^5[:.GF1A
ME 3!HU3]BU&KR=_J916HE6OQ&KUJA&D;0+_:WR(N7/-\M#[%VT5[&?A#TUY-
MKJA:,:$)AR52!F=#K"'5MOMV8F3M.N:M--A_W;#$&Q(H:X#?EQ(;9#>Q&_1W
MKNPW4$L#!!0    ( %B'?U:::X65K0,  .L,   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;*U7;7.;.!#^*QKNKN/,M :!\4MJ>Z9QVKE^Z$PFN=Y]
M5F QFH#$2;*=_OM* F-P &?:?+&1V'WT[*/5:ED>N'B2*8!"SWG&Y,I)E2JN
M75=&*>1$CGD!3+])N,B)TD.Q=64A@,36*<]<W_.F;DXH<]9+.W<GUDN^4QEE
M<">0W.4Y$3]N(..'E8.=X\0]W:;*3+CK94&V\ #J>W$G],BM46*: Y.4,R0@
M63F?\/4&!\;!6OQ+X2 ;S\B$\LCYDQE\C5>.9QA!!I$R$$3_[6$#66:0-(__
M*U"G7M,X-I^/Z%]L\#J81R)AP[/_:*S2E3-W4 P)V67JGA_^ABJ@T.!%/)/V
M%QTJ6\]!T4XJGE?.FD%.6?E/GBLA&@YXVN/@5P[^N<.DQR&H'*QR;LG,AG5+
M%%DO!3\@8:PUFGFPVEAO'0UE9AL?E-!OJ?93ZZ\LXCF@?\@S2/0!W4/$640S
M2JS(/$&T-%#D&16"[ZG=O]$C,$BHND*C6U"$9O)*.W]_N$6C/Z^6KM+$#+P;
M521N2A)^#PGLHV^<J52BSRR&N W@ZHCJL/QC6#?^(.(M1&,4X/?(]WR_@]#F
M]>YX@$Y0JQQ8O* '[PO$($B&"(N15$1!IY;Z4#;D!MDE9+G.I'L=<^:O94$B
M6#GZ4$L0>W#6[_[ 4^]CEPAO!-:29%)+,AE"KR7Y52%*]-"BFUJU7WM+=]^,
M;LBB13FL*8>#E!]^:^?"BX2'+%J$IS7AZ6#:#9[FBCS2$\5.08R(0BH%FY\[
MQ<4/E%1;U' 21@'%+P8[?<LT?2.PEH2S6L+9J]+TI7#2"'82RRC3I40)OVAN
MZMC4E-;.7S!J,9_7S.>OR%93<3(>Z0@T]?>(Z<9 I\%Q9ZM0NGB7X!BW.'GA
M[(QYIQD.9MW<%S7WQ2#W.] W- .F4$R3! 2PJ#O/AF%&>!QZ?W5=2)M%9WA>
MC^;8.UVGWN"2]SH#B8A2*WP,>]TG%;D))!(0=RM=(9YS">9G4O?8^9,>SHT6
M %_(%!X]?3#-4&RK@6[2;,'H)(N[A7M!MM,.ASV)@?T367^0["8E; OZ/*(]
MR79E82.9[D:)SI%.QL-X(W\QGO<DR277T!\O7KBVXSIU"'CPMEU_UGEN6]KS
M<ML94_"R8)QOP)!)R=%MM(TYB*WMIJ5.@1U39:M5S]8=^R?;IY[-WYA.WK:C
M)YCR,^ ;$5O*),H@T9#>>*9O-U%VUN5 \<(VIX]<Z5;7/J;Z:P2$,=#O$\[5
M<6 6J+]OUC\!4$L#!!0    ( %B'?U;DICM %0,  +,)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;*U6;6^;,!#^*Q:;JDY:"YCW-D%:$TVKM$U5
MTVZ?7;@DJ 8SVTG:_?K90!D)A%;3O@2_W'/W/([OSI,=XX]B#2#14TX+,376
M4I87IBF2->1$G+,2"K6S9#PG4DWYRA0E!Y)6H)R:V+)\,R=98<23:NV&QQ.V
MD30KX(8CL<ESPI^O@++=U+"-EX7;;+66>L&,)R59P0+D?7G#U<QLO:19#H7(
M6($X+*?&)_MB9EL:4%G\R& G.F.DI3PP]J@GU^G4L#0CH)!([8*HSQ9F0*GV
MI'C\:IP:;4P-[(Y?O'^NQ"LQ#T3 C-&?62K74R,T4 I+LJ'RENV^0"/(T_X2
M1D7UBW:UK6<9*-D(R?(&K!CD65%_R5-S$!V [1X!X : WPIP&H!3":V95;+F
M1))XPMD.<6VMO.E!=3856JG)"OTW+B17NYG"R?BZ2%@.Z(X\@4!G: Y+X!Q2
M)*N%TSE(DE'Q06W=+^;H]/V'B2E56 TVDR;$51T"'PDQA^0<.?9'A"V,!^"S
MM\/M?;BIQ+:*<:L85_Z<H_ZZ$H?DU'AW&*_SZD*4)(&IH1)' -^"$9^\LWWK
M<DC<?W*V)]5II3ICWN/OJ@RHA.=$9L4*428$2@CGSRK[=X2G@^)KCU[E4=>
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MNR"H<0(KSCW$?,G2?PNB_;!KX"A+['3!JW36^L^D"VNZ\!4Z"53$*[,NH9D
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MG;C01YL\FR!I 9060FD1E!:C:'U-=:DSHLV1:+>T>M?)BQ<;;]\=ESA\-*=
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M :7Y4%H I8506@2EQ2A:7WY=08*>]ZWCURVPBB\*,VHR.OR&H+X1DZ4&+3Y
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M35-N=@^/?BB;IESM7BYEIJ1L >K[Q[)L7MZTSZ,^/D/][G]02P,$%     @
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M:PX?.Y6MLL56V696V1*K;'.K;(N6K3\7 H\/C*43AX><LP,Z61S@B")GS5<
M0Q,6P-",18V"*8O8T)Q%.#1I4;.N&T8#F:9=IJDQT_^66QWGF[@O2M%FVJG3
M%[S7;*F4_0\CD4?4E .D%S&?J>+$$$D9=]5SL!E"$D("EZL:)1 :-)J[KII_
M )4;,!I*354)$"OG84 8'9"A,U.(\=19+D[[U/^:OCBSPV[?>7<KS[WNLQK[
MCE9]%:MLL56VF56VQ"K;_*^P.? X^N-$_8'7F2K$[*K\1]2#ISM$-Q6&YCM
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M@[/*%EMEFUEE2ZRRS:VR+6RQ]1\RT5F!W&P%CC'EN7[[&SYP " ^<  @/'
M'#YP " ^<)C3,E9$6VQ]$3M#D)L-09,9S\'E65@T<&48%@U<:P9%TW$#HNG
M =&LFH"VV ZB34^>\+41Y</^:6^5LRQV>7UXS-#QT^,3Y=[OGZ.F?'Y++F,"
M/I^3R\7A>7$=_>'Q=1_3\B'+*V<M[F53[D4@,UD>G@AW>%,7V_WSQ;X5=5UL
M]B\?1;H290.0W]\71?W]3=/ \;E\-W\"4$L#!!0    ( %B'?U8PE.U(.PD
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MO@4J)XCW*T+XKB,#=!5S] ]02P,$%     @ 6(=_5D;F WXR P  \!(   T
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MQ!', 7C D"1Q^^#>?A2O]ZEX\QO7Z!%02P,$%     @ 6(=_5I>*NQS
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MJ>@8T80$  !F(P  #P   'AL+W=O<FMB;V]K+GAM;,6:VV[;.!! ?X70R[9
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M:@%EU_J3X=7N-9'=*RX??@!02P,$%     @ 6(=_5GQ^Z1O4 0  QA\  !H
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MO:>U+IM#/NO^R4\^ 5!+ 0(4 Q0    ( %B'?U8'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " !8AW]60CMVYCH&  !9(@  &
M    @('F&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M6(=_5E=W$;!\!P  4CT  !@              ("!5B   'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( %B'?U:)1+!F_@4  "D=   8
M          " @0@H  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " !8AW]6L*R$BNH(   ?%@  &               @($\+@  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 6(=_5K;Y2Q!K#@  #B<
M !@              ("!7#<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( %B'?U;Y)9QXDP0  #$-   8              " @?U%  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !8AW]6L@WPCKP"
M   X!@  &0              @('&2@  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( %B'?U95P$$VJP(  .P&   9              "
M@;E-  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 6(=_
M5F_;E8:B @  1 8  !D              ("!FU   'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " !8AW]6T2TS5N<'  "+$@  &0
M        @(%T4P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( %B'?U;7!46M+@0  "0*   9              " @9);  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 6(=_5D;(-FHP"0  *1H
M !D              ("!]U\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " !8AW]6I:5/:)4#  "C"0  &0              @(%>:0
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( %B'?U;^$^K9
M_PD  *,;   9              " @2IM  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ 6(=_5M_PM>#N#P  FV   !D
M ("!8'<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !8
MAW]6]#?5@G8"  !\!0  &0              @(&%AP  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( %B'?U8^C0\8+P\  (0L   9
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M970R-"YX;6Q02P$"% ,4    " !8AW]6HS-BK_L"   M"   &0
M    @(%]I@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M %B'?U;Q'0__W ,  *X)   9              " @:^I  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ 6(=_5M%U;W%-#   !$\  !D
M             ("!PJT  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " !8AW]6F0EY,[(&  "C/P  &0              @(%&N@  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( %B'?U;WW9+T"P(
M $\$   9              " @2_!  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ 6(=_5AIN7%PM P  .Q(  !D              ("!
M<<,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !8AW]6
MUWQ885L#  "2#P  &0              @('5Q@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %B'?U;ORN,8,0,   L.   9
M      " @6?*  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ 6(=_5EW3]R?0 @  Q0H  !D              ("!S\T  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !8AW]6\,!&DDD"  ",!0
M&0              @('6T   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( %B'?U;Q(P1#O (  +4'   9              " @5;3  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 6(=_5LR 'B2_
M @  AP@  !D              ("!2=8  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " !8AW]6N?ZP^/T!   D!   &0
M@($_V0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( %B'
M?U8ODC4Z,0,  %D,   9              " @7/;  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ 6(=_5M\WF+3& P  <Q@  !D
M         ("!V]X  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " !8AW]6M026)9(#  #F$P  &0              @('8X@  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %B'?U:[WJ8EB00  .$3
M   9              " @:'F  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ 6(=_5NA4CZ@?!P  T3$  !D              ("!8>L
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !8AW]6.L.U
MWP\$  !)$P  &0              @(&W\@  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    ( %B'?U:.@O^BQ0(  '\)   9
M  " @?WV  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M6(=_5IIKA96M P  ZPP  !D              ("!^?D  'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " !8AW]6Y*8[0!4#  "S"0  &0
M            @('=_0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( %B'?U:M^0-X)00  /04   9              " @2D! 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 6(=_5@L,TC%Y"
M %,  !D              ("!A04! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " !8AW]6U'5+G/<*  !/70  &0              @($U
M#@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( %B'?U:?
MO$K2< ,  "@0   9              " @6,9 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ 6(=_5K-"I6I4"@  HT\  !D
M     ("!"AT! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
M" !8AW]6,)3M2#L)  !-0P  &0              @(&5)P$ >&PO=V]R:W-H
M965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( %B'?U8AHYA/RP(  #T+   9
M              " @0<Q 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L!
M A0#%     @ 6(=_5D;F WXR P  \!(   T              ( !"30! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !8AW]6EXJ[',     3 @  "P
M        @ %F-P$ 7W)E;',O+G)E;'-02P$"% ,4    " !8AW]6J>@8T80$
M  !F(P  #P              @ %/. $ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ 6(=_5GQ^Z1O4 0  QA\  !H              ( ! #T! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 6(=_5BIDTJ;* 0
MFQ\  !,              ( !##\! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     #T /0"B$   !T$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>110</ContextCount>
  <ElementCount>210</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Business, Going Concern and Management's Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlans</Role>
      <ShortName>Nature of Business, Going Concern and Management's Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Grant Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureGrantIncome</Role>
      <ShortName>Grant Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements</Role>
      <ShortName>Restatement of Previously Issued Unaudited Condensed Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables</Role>
      <ShortName>Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of Business, Going Concern and Management's Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails</Role>
      <ShortName>Nature of Business, Going Concern and Management's Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlans</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Grant Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureGrantIncomeDetails</Role>
      <ShortName>Grant Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureGrantIncome</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Commitments and Contingencies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Commitments and Contingencies - License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Employment Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stockholders' Equity- Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersEquityCommonStockDetails</Role>
      <ShortName>Stockholders' Equity- Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stock-Based Compensation - Summary of plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Share-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stock-Based Compensation - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails</Role>
      <ShortName>Stock-Based Compensation - Additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails</Role>
      <ShortName>Net Loss Per Share - Potential shares excluded from calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income tax provision (benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Income Taxes - Deferred taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Income Taxes - Additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails</Role>
      <ShortName>Income Taxes - Additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails</Role>
      <ShortName>Restatement of Previously Issued Unaudited Condensed Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails</Role>
      <ShortName>Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails</Role>
      <ShortName>Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails</Role>
      <ShortName>Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41205 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails</Role>
      <ShortName>Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="anvs-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 51 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations, us-gaap:OperatingExpenses, us-gaap:PreferredStockSharesOutstanding, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:WarrantsAndRightsOutstandingTerm, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding, us-gaap:WeightedAverageNumberOfSharesOutstandingBasic -  anvs-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  anvs-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="anvs-20221231x10k.htm">anvs-20221231x10k.htm</File>
    <File>anvs-20221231.xsd</File>
    <File>anvs-20221231_cal.xml</File>
    <File>anvs-20221231_def.xml</File>
    <File>anvs-20221231_lab.xml</File>
    <File>anvs-20221231_pre.xml</File>
    <File>anvs-20221231xex10d6.htm</File>
    <File>anvs-20221231xex23d1.htm</File>
    <File>anvs-20221231xex31d1.htm</File>
    <File>anvs-20221231xex31d2.htm</File>
    <File>anvs-20221231xex32d1.htm</File>
    <File>anvs-20221231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>anvs-20221231x10k003.jpg</File>
    <File>anvs-20221231x10k004.jpg</File>
    <File>anvs-20221231x10k005.jpg</File>
    <File>anvs-20221231x10k006.jpg</File>
    <File>anvs-20221231x10k007.jpg</File>
    <File>anvs-20221231x10k008.jpg</File>
    <File>anvs-20221231x10k009.jpg</File>
    <File>anvs-20221231x10k010.jpg</File>
    <File>anvs-20221231x10k011.jpg</File>
    <File>anvs-20221231x10k012.jpg</File>
    <File>anvs-20221231x10k013.jpg</File>
    <File>anvs-20221231x10k014.jpg</File>
    <File>anvs-20221231x10k015.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="665">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "anvs-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 665,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 110,
   "dts": {
    "calculationLink": {
     "local": [
      "anvs-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "anvs-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "anvs-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "anvs-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anvs-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "anvs-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 352,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 57,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 61
   },
   "keyCustom": 25,
   "keyStandard": 185,
   "memberCustom": 19,
   "memberStandard": 17,
   "nsprefix": "anvs",
   "nsuri": "http://annovisbio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://annovisbio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anvs:OtherNonoperatingIncomeGrantIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Grant Income",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://annovisbio.com/role/DisclosureGrantIncome",
     "shortName": "Grant Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anvs:OtherNonoperatingIncomeGrantIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://annovisbio.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://annovisbio.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://annovisbio.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements",
     "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://annovisbio.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://annovisbio.com/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://annovisbio.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://annovisbio.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables",
     "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Nature of Business, Going Concern and Management's Plans (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
     "shortName": "Nature of Business, Going Concern and Management's Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://annovisbio.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NsdytOcdbEOeqNX5Qs-pDQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "anvs:IncomeFromGrants",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Grant Income (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://annovisbio.com/role/DisclosureGrantIncomeDetails",
     "shortName": "Grant Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "anvs:OtherNonoperatingIncomeGrantIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_9_30_2019_us-gaap_TypeOfArrangementAxis_anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember_JTrJWz3ebEirZiY64Y8mVw",
      "decimals": "-5",
      "lang": null,
      "name": "anvs:GrantsReceivableNoticeOfAwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://annovisbio.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Commitments and Contingencies - Leases (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
     "shortName": "Commitments and Contingencies - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_9kGGHtw_vEKel92_hHoiuw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "anvs:LicenseAgreementMinimumAnnualCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Commitments and Contingencies - License Agreement (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails",
     "shortName": "Commitments and Contingencies - License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_anvs_LicenseAgreementTermsAmendedMay2012Member_9kGGHtw_vEKel92_hHoiuw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "anvs:LicenseAgreementMinimumAnnualCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_lawsuit_1hwym7Rltkul7iLlrQNJ9Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
     "shortName": "Commitments and Contingencies - Employment Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_RMsvD3cn30CEwVPUiK-E7w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_lawsuit_1hwym7Rltkul7iLlrQNJ9Q",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "anvs:NumberOfVotesForEachShareOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_S5Vg8LIuQ0WQwX_rru60RA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Stockholders' Equity- Common Stock (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://annovisbio.com/role/DisclosureStockholdersEquityCommonStockDetails",
     "shortName": "Stockholders' Equity- Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "anvs:NumberOfVotesForEachShareOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_S5Vg8LIuQ0WQwX_rru60RA",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_lqWwz40R6kKfq2FtcjX7Rg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Stockholders' Equity - Warrants (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails",
     "shortName": "Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_0xEMeWQcf0WgCqU3s1_d0A",
      "decimals": "INF",
      "lang": null,
      "name": "anvs:ConversionOfWarrantsNumberOfWarrantsConverted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_mSBoJpEAKkmTzpJqFergRg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Stock-Based Compensation - Summary of plans (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails",
     "shortName": "Stock-Based Compensation - Summary of plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_mSBoJpEAKkmTzpJqFergRg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://annovisbio.com/role/StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Share-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JqPg780lPE6Z6dP0xYgvjA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_odHDEA2ljUGM46B-y80T1g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Stock-Based Compensation - Stock option activity (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_C0LAPWLQpUGnSjTD4AVj5g",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
     "shortName": "Stock-Based Compensation - Additional disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Basic and diluted net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RelzNNUAf0uWCtCDxtOuNQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails",
     "shortName": "Net Loss Per Share - Potential shares excluded from calculation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RelzNNUAf0uWCtCDxtOuNQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of income tax provision (benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Income Taxes - Deferred taxes (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails",
     "shortName": "Income Taxes - Deferred taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - Income Taxes - Additional disclosures (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
     "shortName": "Income Taxes - Additional disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
     "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember_Yo6y8AqHFEmOOGOfLBgYxA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
     "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_0kU93GGiSUCYGy-OKIOoIw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaZWK6ekPEC6t6LMwn5FUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity",
     "shortName": "Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaZWK6ekPEC6t6LMwn5FUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_LZvG41ntFkq4AGcD6w14DA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_c0g_Vl1SNE-rg05bhPdUHQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails",
     "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_PxhInrsc6ku16TJRthwk8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41204 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
     "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_-FgaEWf5GUScmNraKCiLFQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41205 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
     "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_kO_zm3L1KES1vIHSumK2Vw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://annovisbio.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_18_2023_To_1_18_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CNEPyGXQ7U2LW4h39gTpIw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F90idjcVxEefw9AmSpR-WA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_3WViOpYUC0qiHvyPJd1upg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_blmnAn0-S0Gpb59CTK4vqA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://annovisbio.com/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of Business, Going Concern and Management's Plans",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlans",
     "shortName": "Nature of Business, Going Concern and Management's Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anvs-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_sFQnctfj7Ei99NXcI3z76g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accrued Liabilities and Interest, and Employee-Related Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_AwardsGrantedIn2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to awards granted in 2021.",
        "label": "Awards granted in 2021"
       }
      }
     },
     "localname": "AwardsGrantedIn2021Member",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_AwardsGrantedIn2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to awards granted in 2022.",
        "label": "Awards granted in 2022"
       }
      }
     },
     "localname": "AwardsGrantedIn2022Member",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ConversionOfWarrantsNumberOfWarrantsConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants converted in a noncash (or part noncash) transaction.",
        "label": "Conversion of Warrants, Number of Warrants Converted",
        "terseLabel": "Number of warrants converted in a non-cash transaction"
       }
      }
     },
     "localname": "ConversionOfWarrantsNumberOfWarrantsConverted",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "anvs_CumulativeNumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative number of milestones achieved.",
        "label": "Cumulative Number of Milestones Achieved",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "CumulativeNumberOfMilestonesAchieved",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to amortization of research and experimental expenditures (Section 174).",
        "label": "Deferred Tax Assets, Amortization of Research &amp; Experimental Expenditures",
        "terseLabel": "Section 174"
       }
      }
     },
     "localname": "DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Capitalized Research and Development",
        "terseLabel": "Capitalized R&amp;D"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Earnings Per Share, Basic and Diluted, Denominator [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedDenominatorAbstract",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Earnings Per Share, Basic and Diluted, Numerator [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedNumeratorAbstract",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anvs_EquityIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the 2018 Equity Incentive Plan.",
        "label": "2018 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2018Member",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_EquityIncentivePlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Company's 2019 Equity Incentive Plan.",
        "label": "2019 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2019Member",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ErrorCorrectionsDueToExpensesRecordedInQ12022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to error corrections due to expenses recorded in Q1 of 2022.",
        "label": "Error Corrections Due to Expenses Recorded in Q1 2022 [Member]",
        "terseLabel": "Error Corrections Due to Expenses Recorded in Q1 2022"
       }
      }
     },
     "localname": "ErrorCorrectionsDueToExpensesRecordedInQ12022Member",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ErrorCorrectionsDueToExpensesRecordedInQ22022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to error corrections due to expenses recorded in Q2 of 2022.",
        "label": "Error Corrections Due to Expenses Recorded in Q2 2022 [Member]",
        "terseLabel": "Error Corrections Due to Expenses Recorded in Q2 2022"
       }
      }
     },
     "localname": "ErrorCorrectionsDueToExpensesRecordedInQ22022Member",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ErrorCorrectionsDueToExpensesRecordedInQ32022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to error corrections due to expenses recorded in Q3 of 2022.",
        "label": "Error Corrections Due to Expenses Recorded in Q3 2022 [Member]",
        "terseLabel": "Error Corrections Due to Expenses Recorded in Q3 2022"
       }
      }
     },
     "localname": "ErrorCorrectionsDueToExpensesRecordedInQ32022Member",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_GeneratedIn2017AndPriorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to tax years 2017 and prior.",
        "label": "Generated in 2017 and prior"
       }
      }
     },
     "localname": "GeneratedIn2017AndPriorMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_GrantAwardRemainingAmountAvailable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remining balance of funds available under a grant award.",
        "label": "Grant Award, Remaining Amount Available",
        "terseLabel": "Remaining funds available"
       }
      }
     },
     "localname": "GrantAwardRemainingAmountAvailable",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_GrantIncomePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grant income.",
        "label": "Grant Income [Policy Text Block]",
        "terseLabel": "Grant Income"
       }
      }
     },
     "localname": "GrantIncomePolicyTextBlock",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anvs_GrantsReceivableNoticeOfAwardAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant awarded.",
        "label": "Grants Receivable, Notice of Award Amount",
        "terseLabel": "Notice of Award, grant amount"
       }
      }
     },
     "localname": "GrantsReceivableNoticeOfAwardAmount",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_IncomeFromGrants": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.",
        "label": "Income from Grants",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "IncomeFromGrants",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for issuance costs associated with equity issuances.",
        "label": "Issuance Costs Associated with Equity Issuances [Policy Text Block]",
        "terseLabel": "Issuance Costs Associated with Equity Issuances"
       }
      }
     },
     "localname": "IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anvs_LicenseAgreementMinimumAnnualCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of annual commitment under the terms of a license agreement.",
        "label": "License Agreement, Minimum Annual Commitment",
        "verboseLabel": "Minimum annual fee"
       }
      }
     },
     "localname": "LicenseAgreementMinimumAnnualCommitment",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of advance notice required to terminate the license agreement.",
        "label": "License Agreement, Period of Advance Notice of Termination",
        "terseLabel": "Period for advance notice of termination"
       }
      }
     },
     "localname": "LicenseAgreementPeriodOfAdvanceNoticeOfTermination",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anvs_LicenseAgreementTermsAmendedMay2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements, as amended May 2012, under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Amended License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementTermsAmendedMay2012Member",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_MaximumAggregateSeverancePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.",
        "label": "Maximum Aggregate Severance Payments",
        "terseLabel": "Maximum aggregate severance payments"
       }
      }
     },
     "localname": "MaximumAggregateSeverancePayments",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the National Institute on Aging of the National Institutes of Health.",
        "label": "NIH"
       }
      }
     },
     "localname": "NationalInstituteOnAgingOfNationalInstitutesOfHealthMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_NatureOfBusinessAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature of Business and Liquidity [Abstract]",
        "terseLabel": "Nature of Business and Liquidity"
       }
      }
     },
     "localname": "NatureOfBusinessAndLiquidityAbstract",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anvs_NonOperatingIncomeGrantIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Grant Income"
       }
      }
     },
     "localname": "NonOperatingIncomeGrantIncomeAbstract",
     "nsuri": "http://annovisbio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "anvs_NumberOfVotesForEachShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vote for each share of common stock.",
        "label": "Number of Votes for Each Share of Common Stock",
        "terseLabel": "Number of vote for each share of common stock"
       }
      }
     },
     "localname": "NumberOfVotesForEachShareOfCommonStock",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anvs_OtherNonoperatingIncomeGrantIncomeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the grant income classified as other non-operating income.",
        "label": "Other Nonoperating Income, Grant Income [Text Block]",
        "terseLabel": "Grant Income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeGrantIncomeTextBlock",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anvs_PercentageOfExercisePriceToShareOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of exercise price to the share offering price.",
        "label": "Percentage of Exercise Price to the Share Offering Price",
        "terseLabel": "Percentage of exercise price to the share offering price"
       }
      }
     },
     "localname": "PercentageOfExercisePriceToShareOfferingPrice",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anvs_PerformanceBasedVestingConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to performance-based vesting conditions.",
        "label": "Performance-based vesting conditions"
       }
      }
     },
     "localname": "PerformanceBasedVestingConditionsMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.",
        "label": "Prepaid Expense, Security Deposits, and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "verboseLabel": "Prepaid assets and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_PrepaidResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research and Development, Current",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentCurrent",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_PrepaidResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research and Development Expense, Current",
        "terseLabel": "Prepaid clinical trial expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_ProceedsFromGrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from grants.",
        "label": "Proceeds from Grants"
       }
      }
     },
     "localname": "ProceedsFromGrants",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_SecondaryPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary sale of stock.",
        "label": "Secondary Public Offering"
       }
      }
     },
     "localname": "SecondaryPublicOfferingMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exercise price of options granted during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Exercise Price",
        "terseLabel": "Exercise price of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted-Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period of equal quarterly installments over two years for award under share-based payment arrangement.",
        "label": "Vests in equal Quarterly installments over two years"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immediate vesting of awards under share-based payment arrangement.",
        "label": "Immediate Vesting"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One year vesting period of award under share-based payment arrangement.",
        "label": "Vests one year from grant date"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingPeriodOneYearMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodThreeYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three year vesting period of award under share-based payment arrangement.",
        "label": "Vests three years from grant date"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingPeriodThreeYearsMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodTwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two year vesting period of award under share-based payment arrangement.",
        "label": "Vests two years from grant date"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementVestingPeriodTwoYearsMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Cashless exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "anvs_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anvs_TimingOfAccrualsForResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to timing of accruals for research and development expenses.",
        "label": "Timing Of Accruals For Research And Development Expenses [Member]",
        "terseLabel": "Timing of accruals for research and development expenses"
       }
      }
     },
     "localname": "TimingOfAccrualsForResearchAndDevelopmentExpensesMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_UnderwritersWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Underwriters warrants.",
        "label": "Underwriters warrants"
       }
      }
     },
     "localname": "UnderwritersWarrantsMember",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anvs_UnreimbursedEligibleCostsIncurredDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unreimbursed eligible costs incurred during the period.",
        "label": "Unreimbursed Eligible Costs Incurred During the Period",
        "terseLabel": "Unreimbursed, eligible costs incurred under the grant"
       }
      }
     },
     "localname": "UnreimbursedEligibleCostsIncurredDuringPeriod",
     "nsuri": "http://annovisbio.com/20221231",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officers"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r126",
      "r127",
      "r142",
      "r286",
      "r287",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]",
        "verboseLabel": "Restatement Impacts"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r91",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r142",
      "r169",
      "r170",
      "r268",
      "r285",
      "r286",
      "r287",
      "r288",
      "r303",
      "r304",
      "r305",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r91",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r142",
      "r169",
      "r170",
      "r268",
      "r285",
      "r286",
      "r287",
      "r288",
      "r303",
      "r304",
      "r305",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "terseLabel": "Error correction adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r91",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r130",
      "r142",
      "r268",
      "r285",
      "r286",
      "r287",
      "r303",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r380",
      "r381",
      "r424",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "As Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r378",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r345"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional and clinical fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r345"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r364",
      "r365",
      "r366",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForErrorCorrectionDomain": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of error correction.",
        "label": "Error Correction, Type [Domain]"
       }
      }
     },
     "localname": "AdjustmentsForErrorCorrectionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r78",
      "r83",
      "r96",
      "r112",
      "r155",
      "r158",
      "r162",
      "r167",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r278",
      "r282",
      "r295",
      "r345",
      "r386",
      "r387",
      "r431"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r93",
      "r100",
      "r112",
      "r167",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r278",
      "r282",
      "r295",
      "r345",
      "r386",
      "r387",
      "r431"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r25",
      "r95",
      "r328"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash equivalents, Carrying Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents, Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r21",
      "r25",
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r21",
      "r76"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash and cash equivalents, Federally insured limit"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r50",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r50",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "verboseLabel": "Grant Income"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r80",
      "r86"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r38",
      "r173",
      "r174",
      "r327",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r364",
      "r365",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r345"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangements [Abstract]",
        "terseLabel": "Employment Agreements"
       }
      }
     },
     "localname": "DeferredCompensationArrangementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r71",
      "r419"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r69",
      "r71",
      "r419"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r71",
      "r419"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r213",
      "r244",
      "r245",
      "r248",
      "r253",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "U.S. federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r107",
      "r121",
      "r122",
      "r124",
      "r125",
      "r126",
      "r132",
      "r134",
      "r136",
      "r137",
      "r138",
      "r142",
      "r287",
      "r288",
      "r313",
      "r315",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per common share",
        "verboseLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r107",
      "r121",
      "r122",
      "r124",
      "r125",
      "r126",
      "r134",
      "r136",
      "r137",
      "r138",
      "r142",
      "r287",
      "r288",
      "r313",
      "r315",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per common share",
        "verboseLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Income per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r114",
      "r257",
      "r271"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax benefits at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r416",
      "r421"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r416",
      "r421"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r416",
      "r421"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r416",
      "r421"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r416",
      "r421"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r42",
      "r90",
      "r104",
      "r105",
      "r106",
      "r116",
      "r117",
      "r118",
      "r120",
      "r127",
      "r130",
      "r146",
      "r168",
      "r202",
      "r249",
      "r250",
      "r251",
      "r267",
      "r268",
      "r286",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r305",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of error correction.",
        "label": "Error Correction, Type [Axis]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Quarterly Financial Data"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r184",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r290",
      "r309",
      "r310",
      "r311",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r184",
      "r205",
      "r210",
      "r290",
      "r309",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r184",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r309",
      "r310",
      "r311",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r113",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Federal provision (benefit) for income taxes"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grants Receivable, Current",
        "terseLabel": "Grant receivable"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r15",
      "r77",
      "r81",
      "r88",
      "r155",
      "r157",
      "r161",
      "r163",
      "r314",
      "r332"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r171",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r258",
      "r259",
      "r265",
      "r269",
      "r272",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Recognized income tax interest and penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r129",
      "r130",
      "r154",
      "r256",
      "r270",
      "r273",
      "r316"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal and state provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r254",
      "r255",
      "r259",
      "r260",
      "r264",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Changes in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r112",
      "r167",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r279",
      "r282",
      "r283",
      "r295",
      "r331",
      "r386",
      "r431",
      "r432"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r79",
      "r85",
      "r345",
      "r362",
      "r379",
      "r426"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r94",
      "r112",
      "r167",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r279",
      "r282",
      "r283",
      "r295",
      "r345",
      "r386",
      "r431",
      "r432"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Litigation"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of new claims filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r21",
      "r22",
      "r24"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r16",
      "r24",
      "r82",
      "r87",
      "r92",
      "r101",
      "r102",
      "r106",
      "r112",
      "r119",
      "r121",
      "r122",
      "r124",
      "r125",
      "r129",
      "r130",
      "r135",
      "r155",
      "r157",
      "r161",
      "r163",
      "r167",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r288",
      "r295",
      "r332",
      "r386"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r155",
      "r157",
      "r161",
      "r163",
      "r332"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rental expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business, Going Concern and Management's Plans"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business, Going Concern and Management's Plans"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r359",
      "r382"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r345"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r329",
      "r333",
      "r382"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "verboseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Gross proceeds from issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r62"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r92",
      "r101",
      "r102",
      "r108",
      "r112",
      "r119",
      "r129",
      "r130",
      "r155",
      "r157",
      "r161",
      "r163",
      "r167",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r277",
      "r280",
      "r281",
      "r288",
      "r295",
      "r314",
      "r332",
      "r343",
      "r344",
      "r360",
      "r386"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialDataAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement of Previously Issued Unaudited Condensed Financial Statements"
       }
      }
     },
     "localname": "QuarterlyFinancialDataAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r31",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "verboseLabel": "Restatement of Previously Issued Unaudited Condensed Financial Statements"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r63",
      "r89",
      "r433"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r37",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r49",
      "r84",
      "r321",
      "r326",
      "r345"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r90",
      "r116",
      "r117",
      "r118",
      "r120",
      "r127",
      "r130",
      "r168",
      "r249",
      "r250",
      "r251",
      "r267",
      "r268",
      "r286",
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r153",
      "r156",
      "r159",
      "r160",
      "r164",
      "r165",
      "r166",
      "r203",
      "r204",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of shares excluded from the computation of diluted weighted-average shares outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income tax provision (benefit)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r129",
      "r130",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Restatement of Previously Issued Unaudited Condensed Financial Statements"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions used to determine fair value of options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r97",
      "r98",
      "r99",
      "r147",
      "r185",
      "r186",
      "r187",
      "r189",
      "r193",
      "r198",
      "r200",
      "r336",
      "r356",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Estimated fair value of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of the year",
        "periodStartLabel": "Outstanding at beginning of the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of the year (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Stock option modification expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r217",
      "r236",
      "r237",
      "r238",
      "r239",
      "r242",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Term of award (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at end of year (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at end of the year (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r28",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r363",
      "r415",
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "State provision (benefit) for income taxes"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r42",
      "r90",
      "r104",
      "r105",
      "r106",
      "r116",
      "r117",
      "r118",
      "r120",
      "r127",
      "r130",
      "r146",
      "r168",
      "r202",
      "r249",
      "r250",
      "r251",
      "r267",
      "r268",
      "r286",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r305",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Changes in Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r146",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r42",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r42",
      "r49",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "verboseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r42",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r42",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r35",
      "r345",
      "r362",
      "r379",
      "r426"
     ],
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r51",
      "r111",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r202",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r302",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r302",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r302",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r302",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r306",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r133",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding, diluted",
        "verboseLabel": "Weighted-average common shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r132",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding, basic",
        "verboseLabel": "Weighted-average common shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "https://asc.fasb.org/topic&trid=2126967",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r346": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r347": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r348": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r349": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r351": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r352": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r353": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r354": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r355": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001104659-23-040275-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-040275-xbrl.zip
M4$L#!!0    ( %B'?U;#SWV1TP\  *ZD   1    86YV<RTR,#(R,3(S,2YX
M<V3M7=USVS82?[^9^Q]P?FDZ4UE?21I[DG;DKYQG[$BUW8][ZD D)&%*$@I
MVG+_^EL !"F*)$A*5J+<\261B<4"N[_%8A< B?<_KWP//1(N* L^'/6/>T>(
M! YS:3#_<!2)#A8.I4<___3/?[S_5Z?SQ]G=#7*9$_DD")'#"0Z)BYYHN$ /
M;+G$ ;HEG%//0V><NG."4+]W/#CN';]&G4[,XPP+J,,"I)@-COM)R7G,CP6G
M:-@=]KN#WF"(WIV^?GLZ^!%-;A/"6^C?C%92KH1[*IP%\3$*,9^3\!/VB5AB
MAWPX6H3A\K3;Q4' 'JF84G;L,%^R&?0'P_X1PF'(Z30*R17C_@69X<@+02'!
MYPA[JFW0DT>D&C($:\6@V$"<0A^2QIZ>GHZ?AL>,SZ&A7K_[Q^W-O>J>(?9H
M\%>&>C7EGJ$?=F7Q%+1GR#F9E5*_[4)IT@DH<,.$=IWN35<7&M* S"4&I7Q/
MNIQYI!N3)0UXEF[_<0/]-I1@4G.,EPGY#(NI(HT+% 2I\FBU\CHT$"$.'+(N
M+;7T9Y/>85$0\N>L>@1QCN?LL1L79KH5A=RB'RA-U;():"Q!_^3DI*M*#:G@
M82=\7A*1UTQ2E.F$&_*-"IFN0'%7%LLZO4ZOWQGT34T</(KJ :!I21#Y@R+#
M&?2Z9!620-"I1SJ2C' <@A,1G8%T(K%J(\[!G93I-B[-*E=TI(45Z,&49,@%
M=8J90\$FWQ+]FI(L7U!Z23^2HFR%<,E+>@(E&5*R<A;%I+(D0QI@ZHAB6E64
M(:[ALQ+A"L7*&AA9<N+4<08I9>I%PFH/$J8MT6(1H6#3YBULW73@.6N>,6MR
M9);U,-+YT4+/^%9[1GH$4PE":C*1@R545JZ>F:?+)0UF+'X$#^6X/I5"/H!9
M(?GCU[OKLA&GE'%!A>,Q$7%R#Z[)Q=P=!>YY)$+FCU947# ?TR!&5!PA"I T
MJY)TSG3/)3,:4"4*^*)>#W50RA'^,$P1<$6:+9)\D6:,#.?WW4UVFRU%,-V/
M@Y_4;[ 3 5.F4J&<%>+:,8FMIH,])_*VJ)CVK+Q>_-1 M@N2H+=0A05GV).3
MS/V"$ -929D-&YCI%#9)5?@=UT:Z>@M "0#)#S&>C9=F=MI HH3(#LD@!TG*
M!K$92AFUX-0 YQR+Q97'GFS8I#1V:%Y70"/Y(,6HA:9L"IIPLL34O5PM(;PC
M B: <;@@_%Q%:^%("/ Z%R3$U,M-14VJVH!\W7O3ZV].23%S9+@CF*&0XH_B
M!I!N ;V*V_B^!;D,Y)'C\(@D2)7@64)EA^YM'KJ83PI=BU E0M<!/"0/>$7$
M'7%8X%"/JOZ/9TG1A$L&\.R,!-#/L 3&75A9L>[W\UAKCDBU!G]F&Y0^F&J"
M$*_0TC2*7DUUL]^WIM'(-" .)^#[W/B/*O@+R:L@'E1 ;)A*2-NQ;0$P7C@U
M_\/T>!F$-'R^AO21^TJ &+LZE/9(J'>B<CJS5KOV4TZ;FAM:8]>"52>1FV 9
M9RQ(2$$.6U:7):Q*\=Y84SST*L.M'5>ULHH%#N9$7 ?W(7/^6C#/)5Q<?H[
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MRZ<GLSAA".Z:LX,7633$3"55:^V[0_!1N)5@<UJ-?LJ^\=^YR^6)'G^>?/9
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M:>8GS!'"LD0DBJGO!N)ZEK4.ZO$:/_L,)Z]T]T:'K-1]LQ1L/A=M,DD:FMT
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M!:/T:IW]^X"I;;M*,A+10V'PFQ_GTN#D)%-#V)\#NQI@13] UP3*P <BKU&
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M&9\2O8XC/QT6[%IOXO_U_P-02P,$%     @ 6(=_5J+JO=O<4P  H8@% !4
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M9&_#_-N([JLD7NM%E>QBS1__%C[U^+:%+A5%$IK&V\2GG3ZJ*K_)UJ6,O 5
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M3WA5+1YCL>PJ;HKI=@EZ$4 *$OV-41ZA=.J-_2REGS*]UT0E-PAV6G%VN(X
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MW3GMTMXTO+>=@.U<HF9DPT^P8WLS@P?%DZD^]<[MC>LWS#.UK*/[SU[ZP@T
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MY4C4[QMU#3.&L7.:,X7,JU>:^"R%"X>C;O;H^)PY7!I-:Q,L3YB<,52:=<4
ME(IT;BNBX3.S0E'9Z)GMEH6R%_,SA72Q-%A"S=EGFBM*[Q/F4SA86$UU%ME>
MD#-'W?X?9Z0]^)92G#%N#S &!F"O[.(7"I!<@P+V*1$Z."]_.\-OU6#2<QXB
MW'[$_S\8''T&!R/ _X?]V6+]61SECOIEZ@]XQ1.?@ \D7I)"XE99>_3DN<],
MSWVG-*SV-+BE>7$,I\94:]H3CS&&5*L2S'U8M?\Y[.09[,Q^SL/K"%88<XBM
M+XQ1>SKM8J =OI)"]'WR\^RS@OS"0DY1OZL0YP[\O3Z*5>SO),$YPW\_0Z 8
M 4K1SW\0F/8K%=3.:R30G-J[& NZBW'NHT'/#V-U/.@HPSF/"'U-@6),T-XS
M.M=18>HO5=Y1FM6XT/Z>@H,SEO;<YSX*V/T,(UU^.E?,MVP!#&<LE8M2\\1W
M)%_%?*_*(LX;2L(-M=&181[H6I8*NX@C<7]BZX60$*ZX3G'TI1R)@!3*77Z0
MLA#>Q/RQE]9S98[>J0MB$M 59R%@O<Q".W%=OKE938YW'^K'Q0_%N/BA=EPL
M9'];#(6E]$01GX@TF:ZNF<WR(YW,,<R&G5>*Y<9;!R;3OJ^;^$PN"=)1%<'G
ML9+@N;\8V!=.CJR!81%5?U&M/<!-N*":V==J<7G-87[JH18U+U%-%GTWTK?M
M)\F9CQD#/H_-,:.'&&<\9@RQ!H8QHW[C[=S&#!=?JV%#SO5X,6#-IHR&U]QH
M+$J9_U<OW$[PA.6$WQRP?TQ3C_1,I<H,.XZ/JC,&M*[,\$LYB1!TGL<BX]E]
M^?R<B.PAA)6&V@%E@-\XSVP4']C/?<I>-=\$,_-3AG, X5&-/=(\^X@;=A@>
M5VD,.%R9->/!89R&;P7$],#?"1 +6UQR(6NJ>1VW00YW6I54A*HT0 PJ>CE[
MNR-0(T#.91FN4J?:PENGK>;B<^;B6D=-YN!WE@IHJ9XWH&*6X?*-H)[FK[ZN
M(VB@+0O4V!BIB[53LKQZ8FR)_9)(L^#]*UIMN,14/K1<Q<E:SG\V-,GR7;XL
MEI4VRY2O<.U:8->T5S[&L\%2J]ZH8?BN2QB^FVD8OFL=AN_F&H;'@D\?AN^<
MAZ$M&VC#\)V3F=A?:9IQH]?,^ZLMD,9EC3KJ[$OY,^*9ET[*OJZ6TW(YV<]%
MJ)WJ'[>9AYN9I_F5!OA=S=(4OW0V^_/[TVWTP^9.SE:^&KM>KVG ^"HC_ZUY
M^C&<)%(OM6DPS67V7O2P3WALJ=>[O'1!ENSR((I7Q31H&P7%>Y5\9W:3[\QZ
M!R&=74MW;:^<K@NLN8OHOU,OL0 QQY3. EFTYND.*!4R9X,C>JUZ7\V,\DN8
M!7K(]'XEB,P;0^S:"DBG)"XL!IXMEV(DX'CB D<>/\>@7VH!2$Y(G062Z W4
M'4JJ=,X&2PQJ]0T03NZ,P<2RL22:9+G)4A1PPLE0:X!R2NP\(,5@I!Z@<D3I
M?&#%I%AO8 &"YPPMM@V6@TMI-A3P<O7KU@O_LO62C";A_CI*,R\,H55ZMZ.)
MQ;E,1T9G 4M]C-L=LKIP.1LXZZ7TT*W0 [Y18$]^+?@3I@A 8BZ!.HF(DW/
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M<KRR;,9*N2<[I!&CF6T->U]!+.1080WXD2I#47_)AZ<OKFX@8K-<E2SLN!R
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M4;BX*]O4'N'$JY/8 UPY)TP*R@XON(ZN[C(MU73RSJ?-5?>ZUH@CLH6:NK=
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MO(?7P*>O!LM)BLT_.IJ<3 P%7:CE.? =+\.?@).$B!23PY=GO#-> WPYR7"
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MVO%*/EN_WL#(L;W_ G9(]\ZE)1V.-J0DR!72DY/[MI$WZ)NZ]2,EY7#4(2-
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M?'HQ>9K$K\@&_0G*-R'$,HV4&$)B#M_7HD[H]'TY"3*D&49-!(:(&A:>!I"
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M/KC81LZA[UX0Z:G1 SC=^YS2O3^3 JU2B69V\6WK9_/=!C\"#]]2)8M*$@<
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M?1 3'W#R>EJMSZ-H-N/HI5W+)=/8%".S GI0>),N>_!=WE3,.I*4T^P](X0
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M]IYB#RWYZ'?Z^YTJM6C=>^^IWZF9P]\B]* ?0><WVTLZV(DHUF=,'QJ(XX0
M>AJVX(8[JA3QZF#P*%6X/_SN#CX-3RSV<[-[ZKHP;?LVI?1;><<2=[NW%5KN
MML:/R]V-ND(/IQ&#C"/X]>!H<GP^:*MW7&OUM*(UZ)!.[1[H,8$P>I5;)1,?
MC4$3HCF(YCW08P(]^711Z1\@"<R@F:KG@1X3.-.9_JO4DP-IT/PA6%VA205O
MZ,O3F,>3/H8^)AJ#CEBX$8\Y:I52&4<*OI(8BC5TK*"<LI-FI[[>P+WU<0+Z
MRZ+4Q.9J4,AR-Q!N$*J<R*AR,F95LH0;M,']#40Q]!>,\7<GA7&Z[7KTY6&A
MR#>D5RHP1]Y"&N/HP%,/5:'#&G.K/-[2/!,H=4B_72Z!"Y'IR[ZEF_.619K*
M!'&3KP. (5-GYH/_ G:H@#&%DO:(*'RY^YPXM.7'\X\ 2Q<I($BQJ")2DS$S
M1$#P/B<4K2F"B@'*2%(J;)]H(B*Z(C^67HAR_<_$]OZ>V&$,0F]]ZT>Q[7ED
MSCY;@5"AI9&I:(\(UAH613XF*LF'))L'X=+VG12"3.#+P$^=.AAT$LPZ?(*T
M$531%2!##U@->1?'!%9UO<6B"<*1^'FVO_"WO:[^'" [WXE#LTC5YA%?#Q$5
M,KXMNMV\ -2],P((5] !];#>!_X*#7,@/::/"%2[OV/GMOL@_B\0/P(G6/CP
M3^#NQNGF.3;HK'M_NTA_\&J]"M-]Q%UM0*:6YR8(LZ]P.MH%@FX;\=%K>L19
M:UBIX07M->=EF;WJ"%V!J6B1L0+A2S *OO^66A;?Q0_M.NC/YP!_U=7+!:+5
M?_2,7A#6<#5MD)V%_*>P(\N\>JFHBJ)*#@UX@=EXTHNB.+*G"J8>*1>X]<!E
MCZC3?'6%,N\O&5O@D]'L="0T4SM+*P7 (#]B+] ;&X8Z]SHE6[&_Q#<!Z*P'
MG8VI!S4)+8"L# Q)8OY;>BK*WW/6:X,PX_/YF/C<1"OXWMWWP(5SZ) LM[X3
MD@S5O2W5PX!$U7O>"_I -S_R.MCW'K(9%Z=1E"S3$14MX[^#^#5P R]8K#GQ
M0#JH^:-_= UNWCW:'@F/8 >S#LE'&/WC)@0X[A) [(L?T02SB^Y15^]X.D=+
MSFKN/<+8:_6FZ.DQAR83U3H0-[O#.F*2<BO\Z"KLKM(=Z/OVJ)>,'G/T?@L\
M5(R'1.IJ>*FON:C (S15.?OH-?VBOV^/=#6!\0JNH M\M^O.LUOO1]?IMNMP
ML>_FH2U]$5'O07P71-$#"'-PH(/4< 6]!(E?^E4J)NKDX&!2CHF*RK-P@18J
MT2)%HB])G9;MNY:;UFKY*)F'D[VA9!%)9GYLU&L[Q&'0-V!Q=CGHR97<4BH7
M7U9LL@0A+HSUR(QL&<89)YY*-O>5E$BJ89G6\;")NN>MCXP$N*.[#Q;2&*-Q
M=5JL#BQ\B;4NT+]V8Q&N@!\LH=_2)M248@Q'5%L%45DU+$T[M@NE(_#4\2Z[
MMK?[*@(!B&(WI,HPAC,J>5"U+.TQ461Y:+OJW:_<*)!D4%>0D2,;K93]IIL4
M*HJ,F3F$JT5;<,Z^3[9*7'9%>TGF4B3#4I D6>H]I0E+>LV76KK?/7D(8E0>
MM+W4EEZ_.U[B O<&X7YI>T[BD:ID=U$.A791-G6G&R:1!;+:+:QVR]G6_[&7
MHF_?>1/28HIT0;:SX H\ 2=!E(0E1@3+MR0EWVQ>ED#L>1@5E11[YO'1Y.3
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MR;4Z]W1OT:5O'HAZU1M-%+:*9<@B9Q>&Z0!6]5,H.Q[D=U"908]EBQDQGY1
MH=6C_\2,N2634(P<1<#.$&!'8^&.K-1:O>V[IPDY7+N-H@2X5TF( $T7V.E[
M:_?@!_F)[B@@DGG$Y&D!@.:W^D[[C'YMDZ<.D3P/ (E$'M+QW5L?<1Y$\=1Q
MPH3ZV*-D*2/FE@HD1N8Z+PH).\";9"D?%&,BT4V\$WV^L(](OLS#:#9_",$*
M!DGDK5.C_JMO)VAJ@.^$^BZ&P+U!,/D.3*.#DER2WK*'U:<>=IJ 'W;8-L)*
M6V%MFF%MVF%M&F)M6S( C]J_)W:(=.VM-^V_LF.;XU3+SO1']W?&MJ\-78=A
M$%X&B.?D>#7*#QBRPR/WOY,HQKK9T;'84Z1-"S;.7/&55S.OT@.#HHT$3UV4
MBRB,=_B&/FVYAC[\L2-5S<E/30KCM*])DUO*B((P9-W7'@?5IC%&_Z)JH2J2
M(<\ 59D^SX0G&!O&E_K#M@/4GA4U+<940C#46Z:$(J&''^=(U()&.SA?K'<^
M9 G];'^+X4R@HRICJ-C9V-0YFHKVL!5:1@EZ[^!P$X0ES-C/5?-S%N$Z[_\!
MH<XX4:5C4[CZ''<I#F_/<(E#8\[))ICM87GJ(^=D6Q@1W16N85'&$:NI=DN.
M<RKAZ'WHI;"GW >O$O <Y/+@8*ZHW>ZM__<)SDIG3H-BC&&-<EV7:*0*FZ%3
MZ% -A0X_*-08F]Z?%FM)H2,U%#KZH%!C;#0<_@]@#7G'\7IL5:8Q'!S$JI -
M6^_TI%BXAQ"\V9 2T_(R";%*ZDR:2#[C^*->K25CUA@5K7Z4W1_",0<'CJM]
M;9Z]HE)S1!3-HVB>2ZHBSF;=)'^L"#@)N44+WH((QAC*6?P*PC30%]\&R12S
M5SQ2"I*B 4PWM3*7JSMHOT /EOVQ?/=Z^>8%:P >@4<B &[3,8C6NM#]HYT>
MR#1[9G8_4&X<QO(5#^\N2IYNKQ@EA\+(7K.[!W'J#'A'CT5<2+.7U. CH-4;
M<D,+D[TA+VP/7\!Y>@5 WC6R\GB7.M?(SU;6,BMMVI[Z2O80@7(@OI*G!_U?
MB>,K3[NO9 [# )VLVOA*FJ!]39H4]Y4<@^X;^DKVJ7]1M<CX2@Y6E4\.\&W$
M\NU0_PC> F057:I?)"^+J8IFJ*VHZD8"]GYBWMJ*BWC$4E,/7NFRLFG9EOTX
MG32$19W-$?3!UKO_17L/U?0)-?8"K)C(. *IUVN5.P(0C.PLLG"T(4204EKC
M>"*@0YKB140;64R?2SO")ZCX'QSP?F5[N M-TZ BT%_@"#6T?0RAO(;R0T35
M59HTE]@LVIA]\CQ4EB@5WJQWFM6.,R+C2Q&4R3 9(2Z9*@\X0YZ!3 5FZME0
M!3?2+$NEK7NP(2HM.BN0 %*O@8=$C-*7<CB31]'LQM&BBW5'*W"TCA3=KTBJ
MSB[BS&):9P.XU$K/3-J(2&[6'+3]&.,X^/YH]&"O\?809VY1F]AD@HAHM&8\
M$I=3*QV.%"U)!N"Q.&C>:,1C]..2\'@T'KI(RCBR5<V.U'S=FZQTQ9./?5C^
MX"<]83K1QSN @8\];8'OT+G R#%V;LB*KC4V=?=<D5X<#V@YK)@IS=:Z;:\X
MF$*4A[S5! ;664M-2N.HT9H,HD(J6KG0+KI\[?/5;.:!6RE9$1RT;CJ9#)P!
M0A)JOL?9O?JGK@M3&1YLB!9>E_8;C+% ]5L9]:G'1P8904<V@WC$5SQ\X%[;
MH8^F3A%:H2?+A*R^K\ <.I VD^!G'!]/&LH\LKE$%4;AR>;X*"$HHZK+D+5K
MU.['$=[<O.'1W/CHT4AB55<DV1L:)E^13)\'DKT;>:3S;F3:I#V]$]GW@O7!
M#F<A48=+9NL/("3Z$%K#TC(;9VWX2N"M9*5$-?3Z2V.2I#UTFL2OR-3]27T_
MBYUIA*00$G'X5P_JA$[-O 01T@Q%A([&0P*&>+U'QM-"@%D2HRF [Z+5F@0+
M=G*-E@H\&34L6OO;ZY2</PCD' 4OFLJI(;1/?]P0G#8P<HR-"T+R:8CCTS<'
MF+,%2NIQZIX_3S@=D=[YDP16EG$R0'!Z<*:<!D9O2VW^FLVS('@X5+KD-M6Q
MUFVJ[0=4U+:1>[IQ)>T=O#_!O,RW5+4QX37!,+@H0"V#>1F@?4V:W%)&%(0A
MZ[YI,*\>]2^J%JHB&?(,3I7:@WF9HVB&VHJJ;B2@H:<9_03S&J#2967[".95
M/TU4>(OXN/^8U=KG"/I@&_1+LY40[YQE&#6]<8Q2K^@JF>30&%F@KT>MCPZ9
M0"$Y]5;I(2_MR"[4?P,^0M##+S.[2^A#C%X,5X!-$DZNT=&DB;PC"^:DYEV6
M,9!!3,*178/>",U]>:4FI7$4Z'3FP<%!ZYWI'A[G"?R@*'G633C35FZ^O211
M,U2T7HSJGE)Y5)(" +O(W ,:JT2R&D>L9DJODJ>Q\&8M@RA1@E*I;A!RWT+;
MKP0>K$TS.E6+2SFRR#Q4X&2'E]%1HIG$(YNN;N=<N%NDP4@2!,36"^,"S(,0
MI.F>[7<07;\C=!$,T+?#-1FC$8(.RHD$\PB&J36ECC3::C2.HEW,?+K&4Y63
MM2'3\ TL6:>_ #Z84V^04U+O,?'$L%#D?>WUSY=V;ZJ>GO0?B::3Y1@7@6[>
M5.WN6#0+KY#?0;BP(^A0Z%&;=B]I(HZ$!A=ND^AR!;TDIOKQ4U)_4(:#A0:'
M[SY)\SN BU<DZW2%9G8+<)]@1Y/9O.+\SK(]4F7L)<':(Y31[GS<M,LZGNAU
M%,E2/JC7$*-\2_)@?Q^KW[WR@E^CNO&"'](W7DZZN_&"VVB11N[IC9>3CQLO
M%.>_LX/^]Q+XRJM:,DTP#,Y5OMV-%Q.TKTF36\J(@C!DW3>\\=*G_D750E4D
M0Y[!J5+WC1>#%,U06U'5C03\N/$R;*7+RO9QXX6RHZ=L-;D7<P1]L T_AMP]
MB/$"\B%$:VJTE+U8_XH6GK?^QJMRBJ!:I=%<.8Z%T@491T3U_*@]VE(!DUFN
M8PH"V05S&#/.1+<)BG#@,,1?>W8D4J/1*E4X,IOUQF!K"NQT+^Q.@A EW>HY
M> 0.^@P]4#@5?@[4F"W=U>X/77M!<F2W?_)C;+Q#O<1N,809M,W"VL3&$:X7
M7M3L*8JCI?D-I-,^O-1"@$2_ NF_.WAF#[]PK*1X <;13YN]:XG)R%[5J:+Q
M$((W&^)G8H@TN7>U[\[B5Q!.HPA4+A.T*\PXZK5DB CE&N/2UL:=I_3SP8(\
M6VPB 4OO=0MSK91O'VDE L'(IEZU()2>[I:A4"GKGK)(!(61C83B$X[6.VG&
MD4K;9*LE)EIOG1A#L<S#HOVF+:,@XRC7XZ:M+$PCNQOZ9.,S&Q)!^Q(!CY!)
M;XRA=3V *^#._.?01NMLA[6'(5.&<=Q3Q(N:S8K6L(SO@, !P"67% DL,R)0
M=/T.0@=&C!>/./GVAU/-H!C9+%\<W=8CYOXPJR4F([L3CZ' _X^?.UTA.YY-
M/4+H8,=S] .:H12_V$F9SEJJ2RG'2UP2"LMYM?T%>$03F>OY'% G=MTVHJA6
M_+[>T?@GA09 K+7G=#_(MT)41T?XX+42Q!2MOM^(D$^Q'<85LAY^D+4&^IZ?
MNQ@B6]6]]9?2]=JO'HYT< WN*7F)P#\35,CU"DLJ=W_MZ&!2OK^V+=!*2QS
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M\$=D'^ %,M>WD?;?'_]J5;/XJS.2S:57DL]GIF4/98,..T5D?>S2CW]:<M=
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MZ%N]4^PXW:M;JSKFO62O:E5ZLE12IYU$,*9+Y#P#%Q-)BF48\LA!9_Z'\ :
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M/,Z T^G,0VEPNL/)W!091F1@6E,\'I(=O"05_^!XX &4'4Y%FF[2++F&9[!
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M[J"ST.(7(Q.&OS0V.?[XR-F_+>,[<O8C9]\5[TIGR0D##C :%:N.<L]&E,_
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MIWG$Y",F+V-RUW-TX@!U7.@3W</VQ1%)CDBR0!+J&GDB58C&ZAT6\,8L"&#
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MAD60Z!#*"7)9.WB#S&(ER]8S50\M%17K#(!+F]&%L 0&"DA/&@D!<!F6V8M
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M<,"*U(==#RLFQ/%":U%/F+.+MF4:60;^@)S? 8T1P_$D;,Z:Y/@XU]:[]/
M11[1F" Y0^1(4T>:"F@JPTUD6P</!7AE-W<K#'@X.]J,AI])+A.HTJ%DI6>U
MZB,S/R+>DMZQ*"QDYV321IB$^_KV("W))*R;<?A%',(;C8SY!J;O/P>F&W[N
MA!YG"H?1,2MN:)E0C\62=S8$#$ZYHL8Z?BQ/B9TUNIS1)]N0<^WYCCQR[A^K
M[E4]>J:T9=,,0C3W#[FA_1TXSW0P/3FT(!-Z7)@F%E;X=O8F4E$PIX08/@T
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M>01V$XGYT6Z9WL;2$.+'6:\H6:3SKX6:_4:GI LO[#CI61?N?@C /?'[M\.
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MB->5RD%&<\VZTY>'R\'SC^9S+#]EKSB#7' S1;<G&ULO_ZM[C'8U!.K 30Q
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MX;D*S>]J495.K2J9+/9>$>B.<,Q&QZZ:Y8C:0Q7%9QJ/760;;NI8T;C4E*Z
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M&G)YVSW:Q)"W:L+6K<GGJ-$[QZIXSMU!%S;AH'B.:<"WDW?I UQ]T+9V4CR
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MH,T,FQ<?^+](Q<2_!.\GBL)81EE)VWTU?!LJ[9P4D5I.Y.6ED$ZK_<+R1F3
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M*#H."\\8[3>C)Y&8S#BG1ALH-<N:@,-SV59'%@KN!3O'[3&%^.=-0!#ZK^_
M,7UT[!ZHC\%F\)_V]P]0!!Z\XWN7IY298J T]M4,OCVF98"8GC9E6C6!ZC[[
MC#>*JRC9+"N6_KKW+B3NA&UOBX<3PY3,/O?:)6M@D8\#"<MF(^H?0""B$<5P
MCY$3IA?-$I<+^%;$R;L?+_A.O<VVS'G)XX!1WHB;D@>VO^MO,JNF5@BNSH )
MB)'4WF:+;,3 (,7ARBUU'3_^M<KL+#"(7R.JJC[%."B:]R(\ZF$Q=F6Q5;U4
MGDHLE_&Z(WK:_C4.2QPZNH$+!M.W$5().B\!HO0JAK"+=P6XV1\<_/7=P3RR
M6TXKCP9S "AK4J#4V2"U=X7,W" 4ZYVVH+=;XST%&0 P,-_1PU?-J"X6")^0
M'%YD$H?['H3_OLWA[[G1L1CM!YJ/+_)ZM)+(85'^SM1;%D9Z=7GAXDBL(ZZS
M><))&%DSIEK@2#T7&FJN7ZLLWK4@LZ=O_G%UO']B&&5Z4B8<O>B16-S (&54
M+2W,DIYI,76,/AHXC:A%4Y1ZC-*DJ)5WT4&,X'SR* 6$7S6\Q#Q'L-1#3X X
MQYT"A].02X,J*S&&K3P"+Q$<OR%9BCHDP+<#Z&-;J>6?RI ^):,](U6ACY'C
M2MJDL%X8LP*Q)V2TE#2H-5@2T74UG16994<0/G)1+UOV%I Z"AW T#"S?[@.
M W(1IW^D!YI<43'AMCM2&-!.RJ:L:P:&T^JOQW7U83UC 6"'Z]W/=K:T2(4>
M\>YG>8!BK6:%9?2T4'5.YK50 -$WD2FB\3B#VM8=A1<-(RF7JWD\1@W&1?5U
M\FSL<&0KR][C)!NVWE94$>I:_6*C#LAXBD53<(ZY%GJB+!Z%XYZ^R4DHS_)
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M+79MLK*]!*O9TB*K;@.Z#144\1X.=EA7V=BT^RTO#;?P"U['G2:10(K>%W6
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M?*XL<A&^JLF73GC&"ZRD859!&KP\\VI!WPC(7^LH!@E!-TR6E3[AJ7H*X?1
M/10HL[$&,PPO5:)U%EJ($MOIYHR_ND%[;9A[8VL"/GY &(,^P,GIK*G2G@MD
M4 U #2O_IF18"_>JA,EQA0L_2(V20F+<%D%BP ':,H![!4,:/0NYZRR922/&
MAM4_\O6T1!P !C7%4D22JLF <X+A659;.'!7.;ED.7.>N@]<7I),5T<>&X)3
M,1+'GN%0 K262R.1\A#$N\02+T*-QBZ<TYNNW7:D#J,A@^MY/_"$L%@<VAG1
M\1O!QAGLEFE[9C-Y#7^R-V+30\P'QN;_7-WF@.;KE7&3=WP] 7?=AAOD"J4*
MA.;%E"J]C.ZY*E8,%.S'I<H\/5K5A,&Y-1LVJ@.@C-0^\J(ZF]DO"OXZ1\:E
MG<W&93>!8>#F*ZMI"XK>(Z76(S4%]L" +D"T5&G%ZZ[#)LFFG;Y\[0 ?7:=D
MW1VT15F06A&84OO"T54<71?YC8!G;FA7T8'I7LV7)V=(0,L]=R<?C<Q4CR57
MW-2%E8LAK<_B+F8_J!1SOP[5&]VN,T 11M+[)92I663R3;77!X B$*H>R6]<
M_Y[VHQ2J0R4;_D(8CA[Q+*23(ZYSIM$S-DB5I+>E"^4NSS]DJHW@0#BV/YZD
M01MY__=B^B::KGW7'0AIABC; GB3X8+4D.O006E[L(L >Z2%+_>((73-TV,N
M4";HCY"G:8*$@'.PU+X#BV'0Q<ZW3/-#:!-K/F1-@H$Y>^T6J&S@6=HKHC>+
MB]"M=EX7H,<&;39J8JWZ%!S5!L-):LET+K.USH;!S*CZ"B<C;I2*:-5+KLA]
M:9PFJ;GNWR1^Y?D.O[+#KVP?OU+G0Q@1><U'EDY1$]E'AL3LZDZ[]NN" >VA
M^2(O$\XD(;*HW;=S(;U8:16-X#%4&<R8[*()B@L$G\E8&H\H43[".E^N:O2#
M8FDCC=3FVL@,YE[(D_1-Q4I^A@L+@^%5G:V$-^QTR"[#+Q:D"GJX?C65AO_,
MK<[._&)CV)[DX[S66D'@@B7:)KU.8)FY>6:8I\8XKOU*T!!67 R(P%ZC#P#
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M#F;:K.5Z(4OT^G17._?O:J-P%.Q,*+](GKT^#:X7H W.@'<WE+^M!G+02 '
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MTFAHVW("AM$;8WM?< !G&<"#R=N\J5;UB#%OPZVU<.0C]2H?UBNVPP[W#X\
M#+K.QF(+,Z![#XHX)TE2K7/.G?]3I30YA:B?A6:P^@<^HM(ICR\W JO+X#<C
M9:90R1[T5O'?U@TOZK&0X.2^ZZBK:O184'>!@^.1@MIM5;I>%5G,CX',/>2$
MC,QGS(UBB%Y  Q J=3=&MP:"^Y0.U"/I/[UJ4XU[,O W<*H%1!@\ G0QKC"%
M[P<=9FXT4AIWH+7['G+"=#;3).F0MM-P"*P6I4\4SR.B29#<3U4"B"J=;*/W
M2V',M*K&@V^2Y>#H8)?WW.4]OQ3+P4.Z5- UNX:D'ZFDKTW2)Q5@O^)FNRX
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M:*NM.8I[92DD>?QQ B3!*KA)@ ;(*M&__NZU,G/OW'BPJO2J[A$^S%C=38+
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MSD2%> 5_N6OW=;M8TV)-R9INP4WGH=Y:Q<EHS?*R=\+=+::TF)(+[+;;!#N
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M!.50>(!;XWT#M'^\ -H70/L[R,[ZP>(_GYDRIKD(I+=/+=^$C(Z349JF1WF
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MBZ.2$K3SG,25#F,G]1*3Y^]3"8D3[PEJ.@0PPW]22\IIEWI4C!,K/;/+ZV8
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M(B>P[.M6==29R:+]@>"-]=I(/Q\51 >*33K+SJR.4+(:(O;[^BW"!N&62:7
MC$8E]G2@O8.X'9-D'*1."<4FY*](JA=[7NSYD?:L*1=ICJ58M:YDE!:?EMJ[
M2S>U$LSJ.Z)ASQB$BH\C#%*:SJO\B0O1W&*'>>I/<ZHXU3C1'(%V^NVEKX,M
M(EM1Q5'E3SD N,0RT^$ 3BE6O\;TQ^\;*9V-K-O(6IZP)O&)F+1*\ZKTG6GC
M2&K#8=$*WP3:I<=SUY]KH9G)J+C8^9E336:7-9YP?O:4IQO*H/S:714/R9N0
M8.)OC2W"<MJ8'@MM4? :K?:XMM6F[B-^5RK-M0A]:[J;\XIIB<NY*B AC!S$
M>,(,R^0?U@I7BB:P<71@94E6H@QZ7E8CIN0P,&G/Z96E\^D&=^,T?Z2%OT:%
MP@6T%9\D<"D<&TM\!UU["?G8):=G@>.NN\WYT)^$Y$4@)(HK.6E=)Y$KL()+
M1 J@#P!*)PQ[5TD%MMV/>_-C8%EZ'H_RR@N$>=G+%SS*I$_Y8)6+ITU6<"0O
M0C' <D^BW@N'>9^%>_].[(<MX-X"0(=^$2KU(2#S?8'0_\D*@3.0[[&,N(HE
M#DF6PR%4]<<.#=C;*ICB[2H88=@7846%^$!,K3N,>8\4\,*6!S[E%E<Q'>=1
M4UC)X?9[_*\1Z*71(FW$6]]'(=.Q8 W/Z9 /SUK-'%">&#3:SV8H!1@F8VK"
M$Z4UM#FELJ)O J3)ZL^__;I/X^#AO=%?X@+9:H;,A:7$F$?(3R01H[B$67*M
M+_ZV/2B; [=F+"W'26O7JPHW>[H-$>1;HA/:>T!X3+T%,/=]I4?W)LVEU,VN
M*_M3=Q:^%$7WX!8O:^PZ<IP1ZT$?@@LS0,!SV3^B];VY9367IY#[T;#[VRW&
MBT "%OP*;^1RO&VY$];!I?V3T^II$6QHXKXJ%41O>&@XD:[2"2WY,+$2<DX$
MPR%%2C#4\#Q D;8>+09$0-J"F9I(26+4:ML"Z\LACN!L=L' @(K?$LQDI*$^
MVLE1K*TS(9F@9WP_Y&+%%'_4UND-90I+&A#JU*1XRHG+IE T.4B/X.5FB[Y?
M8BK4H2\>G9S,BS^OMC\!X!K01F@W*]X D' 9""X=4H6MPP"6^2");3)I]365
MHBZ'VU7I]^)JLUN=8?7Q;E[0&MID(V88Z5B?M XUKY$;/52J"Z+OHW.^=?QN
MIH#O:<L:5NW*K('"?R2BY"@;!FPXQT >P=A?M?583YPU^I,ZF$5J2STB!CYQ
M;A@K#HZF04RAS!,"GI?O)?CGCPOX9P'__%K@GQ_+]32#B,_ #QQ4USA0V%&N
MA8E,U4HACG<$G6F"6)R%H?S B(1:%(_L-"QU>SYA L,&L/U9/Q$BREUL<,+V
ME^!\#^I=[P@AG1D84\BDB\AP/O[J$9:!H-)$9WKZB3,D"_&'V( &.-A83C&\
MZ-S!;HB7?&"*%+0X4#C,>41PRF %>+&FVJ;C99 ^-=6-D2#(V"!BFM>D**I^
M*'&$(259?<5(]]4'KSX0PYI:8DV\,8>IPUVX^V]N<4)\^+M7^M'PUZ_?I(=E
M@=-EV GV^OK-Y]^%L/0 $B6R#O;G_BBT2[)B!B1JPG:+UUM7DI'H"=DV/!^3
M5(+9N)1OY%L8U.C.]2DFU: VE3_Q-=M1OM7J"F'V;N9T,/&T-2IYAT%S^+1X
M*XE?XH-(N&;#P0Y%&YYY+(F@*VX4SJ_?_.Z;-ZOO:1\O5PP&C#:YU5!6#%+C
M*VY\\C,\VB?,C.#E4^\C4^TGQG+DYPS!7/<,(0:H)J)!ANXA3LFFZH9<K'#,
M3\GTLVG*YY\6GS9!%_16QUK^WBU[7)_V?&(88?0LF/CURA<V*.L(HQ/1OX/!
M__FKUZYR-0/ ]+-SB2LKV22:8"3*=6;-5,&<36X&$IU./S]8I&]DY\=)8^WL
M;>/PB6<KP3\6LTLW6B[#O!9LEXRH&H9T%7X\V"V"#CD]@):="Y9]44=@7!-,
MV4)I8G37CH'XY>1V/DVNJ#R8Z!Y;V8U81MF%G*R5%<LX0(1T'+-T(8KBSC&Z
M/@$:-\:8*/LI5Y"%^ZT;CM4FKCNR<]*38!G"U1I#-9'(0+C_A=.Y[LXCZ)-!
MN#91, "_ CK(,C8<A)QE%_YVLP'_3;DE,<+)*K56S5'2<<,M4LGVU.M2O2^U
MPL\'CA4O*RK6%#SY7T0Q&^61T'EM :\"]"M)FZD+Z^2B,;XW[JV'W4/"OV?U
MF9]/8>8PUY<)]8 Y@+,M2?EEK,Q3<TOPF7"%NL%@DYX1^LQI;!U79"8M/=:+
M* 7I83T1^^B@#V:X)/08<(G.S4Y5S/%'2D<*3+5Q>00^1O1[5SE^4?V%D9X/
M\_>YWI'U^NC/TEBWW2WX.;5_=)W*65C_9Z=;Q64)6R^_9F.!W+.[:<IXC1>#
M<9S#)K[@1<$=%:Z?LX^D0U@\3#QR4)3+[*QD@ *?_BUYT/3]X8M@QTZ;742(
M"H2])T\4FJ,*Q:ZPS<K-900V06!5"X&VMO1O.@R$;6-K:<XR%)HZ/D;_IK3'
M*>=(9[)\*>JEZ :0/X[-S #VJ&TU6U=*C%)66CD$$W*$X<Z<[S:8?,.!!%62
M,=P\6?/%_^#<&"8[^GF68WVD[:;M,QFDH2-4YA"N ]JS[  ZWN );*VN68I=
M_L\"K_UMPB&L3Z7EVD>-)[%2#'D4;JU8R] 3%CT3.V!C[))E1KK1%WS88HA.
MA/SJ,+EK,:!M ,>WF,]B/LE\V&&5HSY)-TTI"DIUS2 5B-ZD>#J>Y;>JZ<E+
M6VE*+$>N;RTC.65(WE0W+<,0;1$A7+D#Z5,N!5 >6BHW[:A[=4HM3O?;BXDO
M)C[E(;]L0GQ].BLJZ=OJK@Z_]:>V[+81>_'EMW^*I/9)0_6TPC:A<3&D_+))
MM<D_GVX1LW^NFGY5NM2?/Y^\E-1?C2EDQ$>Q&.]BO-X_L[] 'L^S@B%C!@0X
M2&R<5 H-L%;)%#U>/HS=G ^ XBP&MQA<,KAH7*A@J'2QT] 2\V(-!V1Y4I$!
M?T%J?,GPZ8OS<3&LQ;"289';MK;$MDQ!(S1(@4Z::RFE\HN#QN,:3KE+JVIU
MWY^EQ#B<ZG+L8KX+2O+N6VW(NQOP7!L"FX=-I[+MJ0U&NGC.Q<#]Q'6.L=R&
M\%**JL+#D9D.1SFZ]GB4=IZPFCR8G[]O@+A/%D#< HA[&!"W^,K?G*\,OXZ.
M%KM;BJ32(UQ[_A%9P!%JUT$ES_3CW.5B5[]%NV*@.$YSQXU:K16&H_@=,J$/
M%@MZ7@O*:5F=&;D)>D(SAL/0QO_JQUFT^_[^#2X[J&!22C;$0):]:;VI=QA;
M+W# S.ZLW8 OO_T3LZDO__QYA!;6J29+,((T"HC0=+@6X390H '  /CJ&U#8
M?B?'QE=M ZXC?"HOZ+[Y[JL_I6$Z%<V^374,U\B]AFQ\N?J.N';7S245& 5;
M%/.N2] SQ4UKP*EHTR5.SBC*$J?\UDE*&8I[ C5$MFUH%%.+0KF.9S/7K(,<
M,U?\JC1R$M?QX&=RF:GD,4W-Y1&+IKFZ0KI/(EDW7P0HKF;T!J#TF7WAE\QS
M4Y?!8IIJ5RL)XKF74P&CY877A,V&2_4A[)$]*O N@0'#O^S+#77M(N^BT5H.
M>2OS)1V B^[3^-]X3F]0I*@X,\AKAG=XU'*N%G@CXG\WB:062FSJ&]XK)4'L
M]/6Z AI>U:*%AS[&UJG.%_&+-E ,2;FS3(?<$=:.K\)KYDHIG/?=5OVFJ]="
M2:*[D@Q/KSX;"5%@//"-ME8VY ?XGI,5W\ADQ4O=R>^*UL3WM],2#8G!.P&H
MYZAL_7Z!J]M7S<WI]B+(S%6.S,S@APZB'J4D;$P_41K^&'98G:B<PP+.:$LX
MGD:="/SE!NH? 9KG\GEYQB%SJO-CCW@UY'OR&DN8L3]=CMAIH(#"<#21I"+[
M+'#2R,.8F"B"6=OTR<1&5;1U+]+R#3372.@P/BMDDBDQ8X* M*N\/Y\[R+*)
MDV2R[;Z6H?^!&V0;_W(4S&QY0"R0W3R)Y)-$$W0PLV4F"E_DL6?RN)&%*?];
M/TU^F8$#! Z0\1<3[$AO184NOO5I*1'!_$U1URGV%V\]'%A]S2VDP$<1_P(6
M_6?;4KQEP^\>$3><U"%&%;3+[%!U'.O*U2;";]=[.62N:,E@V'?UE[ %/.OV
MRRCJ\R@R[F%0Y$"59*QIZL?!*Q<PY6\TYTK2$XX/QD5SUP4ZGH;!E++2M$#0
MC*H'9@ 0=5&:,=$F+96GQ8:3#4>16DHO F=/U@5D'"\,+YXU)?W,)NC1#,BA
MHZU3D3R0[A=:X%V]/>-O)+$1QBQ3;[*)NJFX;3#@T=M<DQW+*N,4_HA(Q^E%
MC:^VF/]B_LG\;1B<@<YA7=^<L1EL.HA1Q(Q%VV?B\%_D2H5![A'XD6P&H/C^
MI U60X1N7(B?UR4>?R(P,M%X9S'JQ:B?$)?,Q!+C_"4Q16A=B@!0_A[#"ZUV
M42Q^L<'%!G_BH!$)_W782#E!.1]YJKHC*"$M@F;N3N?\.%&WQ307T\Q-DQ:D
M&H+(\BE>.3SD9PL7(P)A@9ITON]&O@[ROEK-ZU#WO740I'@1XUK_K]T#1<_)
MJ@E$S/=]=8\Z:QQHU4/ %Q.MYNZ%TY:]LNR5'^?&9WUWL-NR<[(^W4%+LZ3)
MJO;:&/B=UFE5JR[2<,YMO,4V%]O\&4(,(SE0NDX"I6LV,<1Y;R(9VECPUK7(
M.J=^*W6].3)4)593?M7(IYOI9.74UI$T] %!@_<-6OOI JU=H+7O(+1VP:^]
M \Y\U-25.IMKZ_[(Y@F<?CZ.K9U=SAOJH*'HR1E/6=XG!O=U$H-UA;?W#2/W
M35?[!(-QV)!T(2JF3K:;9K*/<MVUI"4,!^:Y/V7U)AY_ONE?W=4"E&'>!6+]
M%RH7OQ]S[2BOV8.]M"D;B(H +'EY=8BAFN9,#TT00L(9%&[M#)+GU;>^/#Q'
M:33,)I5#(!8S!%>4" %P<"7QZ7M@!_<42A7P5/J1=FB<1HDY\V2B\TF!5RX
MO^,RV.F<=0YN<AUL^ 4:YT)(V*^@,@;F4WSMFS=%O,PMM'9. IW":X&B,^XO
M[&-2IPH2Y:,$T4QX-;?SL$IU9F?]JFO7L#WI9?WC7/5,<>$@C+/JY>K_MO?
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MDIA@A51.SUVR=,YWF5J9/'VZ;&OBE(94DN-5>!D55,\1NQZ*$1O\<)20!CM
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M:T.@>U7R&_L?9[Q5<P-M*.RO</Z%)<G\!>#>V!3PX1[/+FK(?4+ 2M<RF)+
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M?5ZJ*]5,WLP1!.^BHN$2%6:CYN;K3N%>^!]_P41?K^@F5=?3G_SU]-_?.#_
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MWCU8*M_*X$T%A( :D!@^%8C5FU[\%$*:Q)'# ?$Z[?_<O&TP'4*7;)):D@K
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M[Y._/#T6)#?.W+S1:$:V3+8WX?\Z$^W]:>CO@T^R5LH8(;.,_9H\N_FC\KV
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MLDNA536A:#9X1? \Y+\$X+;KN_:@N6=ZKDG=JH>VJK^:1!8IHW4]#)0B'>1
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MG?1$>6BB\G0W?<=O4.>WO/C$A;_CWXY6@0Q/>J,X!4Y1M\8IML1)G:+@0GU
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M";#YC2%U/"B1TG0+1WJT93@A=HUS#.3V;G@_,D?QOAY3AZ'*-A3?T&+3+_W
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M5ME'F;0=QGF.F"XER]!+T*J/FU,",_/(R,5?@X/M;:)C:^(9V3(IP@'*/<H
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M6.C"A783RSYS']KIU /G8MD7RSYKV9(7C\4)000/!E[FIGTVQ"0M2=&WW;9
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MJ+#,$E=.%#"*8R]NCC61*S2DRW(;CK2I14I18,8PVRZ>GM21YJ@4)@*C936
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MPI!2DM">VORW*,;"T9VQIA+DQ,Z*VQX<^(@ZVTA'10[X(9H'%C8(-$@42,,
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M,<!H)W$21PO_)LZS5[/PJPI<@TQ;CRQFL@3^/S!9HO08[3Z:CUG@?OE=LR;
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M0^[(;=Z[BM0HS#J34(AM7%%DV(E;<L4>.1EG8X< JAAU/3_TQA#/!#%9.2R
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MM).$J0#$+7 PO_HW7F? G+\!K#8D8([+!%'&S<U!Q:_?:K3 )FE9&438(P0
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M1(3D.+7/6:N"+;+ZCM1WI'A'"A[?XKUP:1#-9- >'.?</W-@W$$X944"ON>
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MAIFG5@UP/T$SDUP.BFI7L!8[I==B"!C4=\$.Y50W@:]-J[;(E70(4QIF-CV
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M4DT^M52_@P,1LB;FNO&?LUCD/'>_LB89UH$[D#)5]%7+^OJFU;*^XJ;%>4:
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MV ;*XUQOZOETKH(](/0^MM7G>1)96] 1,U6/YIHO-*W?HRWV]ZDO!;DG'R$
M!%T5G,31PK^)\^S5+/RJ@@)ZH*!7L$0M6N%B;P_XNY(&]%VS+JE/1$@PW]LT
MYS4%B5)>BG,J:5!K^>_?13#THEMA*][&TQS)()5+[:?>RD\R QG)*,BOC/*Q
MIC4]"WKI]_:37MK-/2.7"@:2-CT"*#7?&-%".*2I(A$#HH+*"AU1-:K&)?5
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M=>LV^]T#R'0[\/TN4OEN,T.?'97?$S7Q+B:S)UKR0UW@QUC.;9*,Y>[Z?XU
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M8HF_POZUGA)"E*5JF0:F!N*G!8$"(C.0)P;T9<<^XW&VCP^^<$N * ;@BQ2
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M)0O1 I\''T''8T/7P<%21._,M'"\SGB5<FP#PM>.( ]1I 2^#L?_1^B;.PN
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M@[UG-CI>&D)P"?QTV0'K2??VX3Z,[S\(($EXZHK@C3;1GX;)>)-)?._X+!:
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MW&3RC[76.(=]V,-"1.^)MP(@08_\GWM1B,*W+)])E_/I]J*9'$_K]#PQ,EE
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M2';=D\=KLKC=+&B&3T*SA$K%J>1KCEK$HM^>1:.@RA\%5=[!H?3"ZG7Z1F_
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M]@75%-@;>P6"_L/0!0U*[42ILM!".<H%1:*B(NB.8/IY$F0F2/*Z]#W/!U3
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M8_ X7@ 4OGZ&4K!E$QI?Z,\K88>V /[(/73!$^"V'',7 YH1R#A;!5#T8YT
M)$^J%H7!A""0AN*AJ@7#<& CEN.]6;5GZ(M/B8Y *1UK9X",(D"PMS.$.9C<
M^"Q_'3*9JCN"GY$OJ9M?_P'_!*0D:D#XPH*-V3_'&H>"@MZO/,'Q?UVE+$.4
M(3@#S4(F@J*3I\;+&&2%5;!O].]__]?A_I]:+F"BH1GFSZ N^N!@,\\P(%&A
MB2)C$X"F!29,P;M_"IHK[*R@Y#H-Q%]0<_US7UL-01%+/J33_XH]_0@!<@+-
MI;#%#F#FE[5@FCRU?WK?"CY"%2G!9X:%0M\_44@58!0^^^BI"#&VL?I)$@_T
ME?#RK J!>L+"?X38S(1"^G]ZS=PY0^YM6ZSG\<DT!DNJH!6^)U/AUP&"7R+,
M8ZB> Y>P']Q>D/J)XGB78)?+(MD:-&6KW6)X-+<=O6V_LB1GYJJ]K2X65=LH
MJC2U256&"H_&-1^OE 6^4U1<HHL7E=[6;#'I E94>/+TF6:VUDAMMO,.7NVI
M]7:U*.GC3ILG3Y^9[+!ZHR/6UISL+DL%=[/)=/H*3_'X\Y7LD*R)[5*BPG5S
M+#MOMG36SL.5U,G*Q(@FAIVNS K4K*[,.'IME=M@)?U\9<$FR]E1NI-CBV:G
M7^X)<TZLMOG$Z=O'*=-,+(:"RE5+%=P9/8[)7$+ADZ<KE>:*=JAU?P=6%3?D
MI):E,:X-5I[LTZTV"K/TNDQPW5FW*7*:4\BGX,J3?=K9;*+8:N487)BX\H0L
MNJUYC^'I_=N?23CO>Q.^P;EXK[$E=KA07Q<2?&'5AEVIX5+R"ASSW'A_04$#
MD>],-.!X@V\N9'M_&^+K0&C+$ZE_/$U@Z/[]"-"_<!FZ98F56\WXL5K8+Q+E
MV,: # $=A&/-)1S8ZJN5:0CBS-<ZNFB8*P-J'$\;!YH76/$ )(</]#7/JUL%
MZEZ4@WTB9?OF,X%AH&K Y1+1<U6T#; QY'9.9*#;/(B![]FF !V$(]7Y.RKS
MR'Z1D+$*-KI394V"6OACU]PK8&?PT]8TG1$&3I^5'3.Q&0Y+W)!2/F;?_FZD
M1!&'DTP&TW2N2Q1SBTS'5#6R_>EV\=[498"+MPPJ?3P@YWT8=P"2]I8P1AZ8
MPIE2(\^-YV2/RY'JB!S/2XMTP_UQ=22\>N?[ 230ZX$\PG;JAI.I%+_1"@-Z
M+']^'X _0T*OQE+9,6/C^%IVB5*2ZPW[,^7'KW-UG<\^^!=@55%P+/G$HH<Y
M $_6/.#BE:!*2#)(ANS]V>/%O2P$_\N6+"-[P;?C@>P#EC;@^CVW0D%O'PL?
MSWX_B4D(3Z  [@B\(O3,9>@'>1KCP'M1O! F> IT=>%MM:89KO4362B7+QIZ
MAG9Q)DN.)C>GY[%[6)'5#W9_@&ED8O7 GK(:6/@CT(25^I:95;=M;4%WLTII
MNL,' Q4("!G0P J\WC:!?WI7\2U41KRW_[W^2,#VUX25)?\,?CC<&=R([P-
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M'R\VYN.5.VEP:>GLV/ 1WFGD!Q39Q7>+40[+N\Y@,S@[-IS>M"<8G]+Z^'K
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MR2)\BJJCITQ570#; -]&3ML2FA*QW[".8ZIUP[H>=CH%IP*6R]ZQZ(##=(Y
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M"H;7!A"\!;X2(D2"L8%$1%/_MH$>O2SC>1I@+?";E@JW$W9?])L!0C'[XG:
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M47MXO#\WF"+Y*6?R.-U4GE\1]]82F/OS#$Q $\#@=U^ 'KWAZ=PTH>2,+%.
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M>J/C)FZ+SM$IN^CR2K^@Y;F-P(RM;IU>C?T;Y= X=?9.FH_C<T$W&7\%7PD
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M5I<Q+$%X]B, R1L@[2WZ!@O[UHVP :D+.\WN0H&W#_>?.8+OA4T?/H=_U!H
M/&0&GN)X$1<DI-]"??<!;"4 VZ.YUI\<_'\^[N]UR5)G^Z8VL#O.OC^E"B7H
MS4XO^ZL+7OR%^*)>,)L$4O32 !:0SS3\Y?IO>?$L7AL313=?.DV>6\EQRZB7
M[X!I>!?.GWL>C,.6\.X)V#/HN1U._*5_Z-&GD-K>=Y]_@!U7ED"1O&X)L%.<
MX3?T],Y\'HJ+<TP)WTD>CA&>3R\=<?*2_:ZN#Z*^0*9>5&\_=^U[P;J.&E*
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MC"VID<MJ:M&@AAHYR_'N:-CMU=-@ F?T<UJHYVF-&%N(T%V(R12ZLA8);VA
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MT';RQR\*0>(4<>X>C@< RB-MCSS\#3*/"ZJNONQ7$8VJ=SDL6^ZM2^5IEY]
M1TW#:Y0(C(JGB+=<]4/L(61E108$DF*BKAIPZL\WUT2["-<'56Y8@/[EQBZ$
MR[\=UAB!Y]]>+5Y%V&^]^@B!C[0B<A:75HM[0JQA\W#P#O\BO@B=OIQ2?R<-
MOBMU?6QT>[]=]UY&S#0G4R-KI5N</.B4>KD%-4V98WBM$:PGP>,838*<^$J
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M 3D9!4(VZEI&)=K0^M9&)0I9;GQ)TD<M1(J8YKD"CJVYLDJ+!756E5-%+_*
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M;,B6H'M)AR#-5$.U'<NK[GQ49/=6J4@([VWY$C#E513AUJL/LV4,2=:SLP[
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M06WUBN2&<S)#;H&3@TPRS4R:+6]HX*E8KCQ*8!61XLA:-[N>XLE"N@VX=48
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MM2SPNYC@170_'R#Y><A;UF\9J-VIBD8"_.T%^+W:S$A^[Y:UWT)^WRW@"[4
M/RPZ]MQ0AYR_V=(T2I3N/%&Z4)_1\*%=?I^U*S=9(WD<^<,VH8ZV3BN*)M<U
M=8-17%X?LY;9_)/N;(QQVG:-<3*"96T ^;N"[LIGNK#1>6HKU'."Q*J%)$G6
M7,D!3^2]QOUX,DZGB#B61*_3#30,ZG^Q]I^/H]5A1/).E?J2;4C#((:1%WHP
M .Z+O5 R)3F;1<==:?56R>[3= LO#_^HU>?O.)-VKSPJZ]N$BK03O325G8T5
M6VL"9T)_T)D\!O1X$D.#"& NJ%),7L]EPP9OAO&TZ4QD*R8>(911?AS:_/AR
M7<)OCCM^K_A8,);VSYT&LKX"MF6@=D!"L[)W<L\&EJX.M=$O_-AM&IRQ;KRT
MP7-V*B]J]>3"3?1[R%HDQKS7.#^91.-("KM>G!RI=&A5^N9(;$@T^O S:>K:
M#OQII\Q(J2_G!-GJL%A>=;6ITZS7ZY^.3RZHS&0!D8C<M,=QY65_+G?RZXGJ
M*3,);P(E"#1.T<E(G;^A.M\>F+[+W.&"NEG#MP,K/>451$Y7&IJMC%/%.FQU
M#-.(.$UC<9I,73R+N#]P/BLK,J"A%!-UU8"KBP$6@1<!GD7 R+4O9+GEE2M7
M2$A"N-X(#HRD_KHQ>PB7&PE])/17CFQ#N-X_D?H'PXR]CLT_?G5,!\1S$3[\
M!VK]L#J,WWYQX<E>0U)_\2[>-)%[2$Z@QMJF6$NJK3G2S\EC>-D-++0@XTDL
M&<<Q/$*<(IU_+5B-5/[F /1'M7V-I@W)L%.,UAMUY]C*&DA"AH':'L'+D;)_
M*$B/M/TJI2WO::[>'HXZJ__/WI?^)JXL?7]_I.=_0/.\5SI7PG.]+SGGCF3
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M,U\RE$?TX88^D7AOK'9E(S0APCLN? @@TR01WS_X]]UN(+PJM.N\6Q\#1(-
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M.FU7B*"_X]1',:,7YO"+]BV_S8DO4 >6''Z'@EC&4^3<K'TF?.I7[#D=OOA
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ML^3C@.V%4QQOA$F?14\!ETX( 0 FG>"/ R:=$.0#3 +J!M3MK,O;PW )&,W
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M!!K=%M+;:5)-Y)2LKE:5WD06YJH07CV&,TR:P:G+V?,/AQFQV[;N%#/VYCR
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MVQQ$NPLV-@=IGHIO-J?35"06"^:J>',Z1H-K9X_.OSG]M)@0X*SF\Y:L+8J
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M$4QGNKD&P(X04T\0WB C\Q5-V"+T1E8M(#DF_,8C!V$#7=U!+42_WS'TN^?
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MOHMSWIMS<WI6S6^MENJN55W_KEK=+PLOZX W,A+2$@ 86   YO4'>%D"? ;
MP<+^O5X3_.N%@(R   ^/@(J$A(B,CHJ.CH:*AH:!B?,& Q,;$PWM#?X;[+>X
M>'AXZ%@$A/BXA#BX>+A_F<# O;:!1T!!0$#!Q4##P/U_G5XZ -C(, JP*G P
M5 !8;!@X;)B7'@#%ZS@18/Z5 /^58&!?QXB(A(R"BO9: ?0&  L#!P<+#_=W
MU*^EWJ_E 'AL!)QW'&*(;Q6_(U'9XW+^C/V-3/VINA-/:?*,ALO0P0\%%9^
MD(B8]CT=/0,C-P\OWP=^@<]?Q"4DI:1EE%54U=0U-+6,C$U^F)J96S@Z.;NX
MNKE[^ <$!@6'A(;%Q2<D)B7_2DG-R<W++R@L*BZIJ:T#U8,;&INZNGMZ^_H'
M!H>FIF=FY^87%B$;FUO;.[M[^P>'T/.+RZOKF]N[^[]RP0#@8/Z=_H]R8;_*
M!0L/#P>/]%<N&%C7OQ6PX1'><2#BB"DB?;=_2\7Y$QGW4^SOZDX4:BZE,SQ#
MATE4?!KN#5KH7]'^)=G_,\'\_EN2_4>P_R$7!( .!_.J/#AL@"C@23DGC![P
M_]/_3_\=*JM\<YO4WXW_:?=>0O7'0DB8YDHK *]4SQ;*JUX][V39'+!2>.(V
MS+YA3(.=]35Z1]+8==U,\FU()/])96E-:W)Q>8Z7XC2/]O[Q*67#M&EB?>]U
M(HG.-<E/RK?[EC65R<_4MT-CW4]4$@\L34P$&<DP'XG@*8S\]7+7UZ)]R*!X
M92@TN_P]EKL#$;64UFW52=3"-8PEO4I9+*?-F?5\3%[5Q8'^1\ZMY4O%:Y;W
M,UJ(B?:>G'5^'.=][>X+EXI7/'L77G+S5C(Z*P>\.:/0AX38@-QG>#>Z,SS)
M/A&^M#[\3_/RU6962:HQNCJ#U5GF8[!;/Z]$ ^WO,RN+W>K'CWE=XI=E,(E8
MMMCHZCU9[6?2C5*+)#!9E:U9,TU=L)@C!=1[E.7 Y:O#!>/R;:9%:U[J$5^K
M#U)5^[)A3V.W1:24#P9HLJ97P2WOMDB ^$LC2@1U3;X_>5H"<!KWQ<C$KJXK
MR:(59X1P:SO+M&2MN=Y?771MW#XCP9=Z1FQ[*+=AWT[-4>#KZ5A@SB5-+=U)
M<Q5CIZ"G0!2L /Q"CC(6V'X))JXSJN=#;!@,BH4EZG*":Y= &D?1^LH3K"VV
MG_=@O^-'.MH6AA(-2_4;^7L:2%G HG8_LQEUV!<&$OQWVT)4C_T Y6-1&V&1
MZ>ZYZ<-5TCAO:1XF,N*3NK2&W3K+E$OE$NZ8 871-ZK&2,7KEY4?;\$;^@'M
M>'_JBAXM"Y9N@W2YQF3-%0N88$=*:M^9_8*M*(%C&*!T8'0'_E ((*>?IX)*
M/K[SD.M]C/T2N[)D$RDC"0..1HT@V F-,-@2M!-$_Y'J2<&@C*65H%(BEG?=
M9 ;U_GQ]/\.CCV5.H$=R:UV$H7>C=C9#+3_'9KUU4<;CNPMQ6^4S(&L!RY5'
MYOEU$^$U;[(M773K$4/5PQZ%Z8)X6#XK3KX'1V$7K&B/DYW%?XOJ]/M@5W3
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M8/<E-7 DFDJ6*IJ#2H@QXCP7[L--L:,*M=F@B/5CQ/N-Y(T9%8JFRWFUU1=
M\N>M+(+]9\8&*&W:RC+W.!/6^\WEA#!<I _]\)Q[F9S>1VM>[[9.3+OQ8[4K
MBM\N_5ZM4K"!%7&W BO&QW=NK=8 +4@$ES)D#C>[L#AH_=YH85\D((!C3S$G
M[)<J\;;U4>I.)+5F=J:D8XU:&$C?*]G5V#RL??Q=8SD:'D%>>,B#)_2')HBQ
MR>^;/D9R\HHM[9K17-O[YP7SC4@+07H^2:H70+G?I))Z]-.U#_\A@$QPOO)1
M]'8ISRVK6ZTI\&K$I9R3.;9*HF=@A9!^$(G23Q!;[^W6GT74\1[B!'4.V293
MT?;F*F=E]G%)32QX&-_N")=R!81;@:V-Z2QT<U[S=V#!;3Y,VN_MNT0F'38<
MXQ/J<GQ$@^+""F.9<*Q]BMMY<36MTS)J%ZUKJ]X8HCWMF+V%K<L>83HE#=&#
M@=()X.S/_G=0I5O7?HAZ*&MD&09+ZQP:,FONPAB24JM89;J01&I48L62SJ@M
MO'J7"8R_]7+ZWE*[S,'NO-KFGQ.2U;%=7OWW4@TFU*6>SOU48)4EI5E=X>9T
MO!IF;IP(TK2X)@_NMIV2BXE[-NJYI!9$!9)#8I,>6]M-_C^L/XFB/N]^6CO.
MY+@SF*]W<U4GO@XW]RG>N8,&,:2?"",_=A:9]YZWCJ?UFSA7<41*-_?>5XY,
MO;IJ0G;_]MDJC#99F_D"6\@JCGBA9;4'$.O98WLI*4FS35.8ZC$4'5)U!8TV
MABD6T!/C']G6SRR)5W7UM7V$Q68K,E4#V\9O![*G*+!WB9/[1_FZ,TG/GDX+
MOQ>MKJV9H6T*+EF38]-7UZI$C J>.@OBY76H+I_X!W[@D="'%'9RK*+Q>,M;
M]@69&_DQV6E)1$&MX2TO#%JB-B:!84)@PM+R!SXW 6O6J:Y=78]S-$NUZ=D*
MGE)_ZD7.G-:T!@.]E9:Z$=.(B!O^R?AUNI_Y4!++PB^J,V.UMI4H.*:JV@,L
MS^-O$9!@O@ [1)36.(AV_7\[$C;MG<!@!;31'F42S=8=I:R#FZKKJI/E=4^U
MM/E/"^(<3DMB^\F:ZS<6G.CP4)]G],A=I@VB/T&Y#@6*0=9L"@\TAMZ?T!)2
MLANB.0,UE@9BR'8T172'N'0C_W39HEN(L-N^75[@OF\>B6]N&3'ZH:UI+6$T
M-B64LJ/$X=\L_+$L ^D:>*8?S.8TW*PMN&CC-'BR4YUT\2W5!22%H^*'/%R]
MA,I\OBF28I4>PXZ0Y^R#!"W(@J)U":B'7":G']Q'B#C)V@7Q*\>51;6F:&I*
M[<6X\S0VMK< !?K.@@/JQF%O'<8_3?[V].:=!L:3#!@S-2XN,;N+<E4_6AKZ
MJ];GG-K^H1B+''W:NIM2_'A)X AT>W:R^9L7%P8GYLIW$[TGL?L,?3R@S^;^
M[Q?B:=R%7I"W@8;=9DQ5]6^ Y<Y,-_.'3"G0+(&<%T#CD^5H_PL _K@3V,(F
MX35;]#QEMW TGTHD*WH2#B20S4[39S7TZ4LZX<MJ)I&%WK@:D95 GJ>:K#+Q
M0>W^LC,VVPV!!G+B+)\.7@ 0Q(Y5=_2OF8:^N?#KOO(K/?ZZ3VM=XYAKV@JV
M/&6CZ/?=1V,Y&WVVY%PDHGIITB0>KA6HMHO)7Y-[FAS%W:Q:Z(RHY)M86I*)
M,E5K+-FG\!/Z&_J6F[*-0 Z.<5[&!\*31UI-AWJ3(H*=Y5[<\U=W3L.C%&J3
MW(0\I:6"#[8)>7/EW Z4ZK2YM#0 ?/4[9$I2E>KG":TOYRO:6OMZE#.5UJ<V
M)UYI@MRCG76H-COA3OX<?;J(\FC<826$>V3\MW(;N?E' O:UR<>I;;&VOU?I
M(!1LYNBVN&:8#GDT%7R8\@X>JH(O #\1W/9:;2#5]43Y[,I"0TU[*DJW+K!_
MR#VDX\[!P$3 CL,/IJA5\%C_3]R*SMC9>'\[QBVX!]_#)<.V>-#2T_F:1/?[
MR:Q58<,#U2KR+-AF\"<85@6]6$ELLY4:L5&.;8,NL$ZS;+MJVF> ^4KTQ-)M
M,S' 7L<[^=@W<(PWQ.ZWA^N1;A 3O\/:"J]_1NLY,S&[A8YBF+]VK,&DO])F
MQ#<"JLY<Q/Q>PFQ6<7\)#-DPCH\ZX8@1Q,FXAKZ-^!B$/*STO3 ._]4*=CO5
M\ 70,S3]W%1Y@??SX<OM01NQVX\_/9:DG"QUUXK2>T&,U<.NI*P+>M*JL;]@
MEE'W+R=$ZZR!1R4O ('HS>B@NA< @:G<S*9Y.7J,SHDT*MG92*V$ __&EG+4
M;;_'<:&MX1_09*?2:=/.ZLA9PE.!D]/,E65H8<"MQ;!:4U74.8EYJN96L%S8
M<49Y7? :-26)_)\$3'ESYTJ(JE,6OF1^%O+14/TWO>$R+6E;[);Z<^N34[P)
MYF8BH<9!HX9TWQ*4S69]?"^"L_EP;?6&EBKM\)-/FJ<9%?FQFUS#/^H#4_ 2
MMH:^$"JQJ]N]:RS#0O 9=R%F&:LN=@M6;(!B@DM"-U.WQ]E5@BS-K#/9C6-7
M0J/@[U)J,.T0/CF!S:S5M=[K0EW[1KFZ!)+2M9@RY+L>I(,5P=$*]9PZ.D05
MZ_6^[S4E1^91SF,S'6/]&"MR'R3<3*6KV]M:JN8,JNK]KLUL(DMJ]$DDT)Q)
M2722W!9B_7!YYQ@UT.?E@&?AW<3IJ9^7-65&\[6T-2!X#<Z+Z&^[[=]\$(JE
M;9&DBZ_S[^3)\CPCZ6P*M\C9[-J5<L9ME*SGJ[GCW=SI7DYS6@GY6I9=_8UK
M_&OZT+6N'$7]@9%C9QL/")KG4134]_"U9:H2(_ D*I<X;V)X)R\\HVSH,TU(
M1Y 0+R8R51,I\>\\-YONSS,\I4=2J8(9AB>VMD3I5>Y?%'N0D4XC8RD[MB)N
MRK^JR<]/K+(LK5)UEO).%B$L!2K&R4D0T!&^0D!V_1LQJT*<$5?V2\5GNCNU
MNM_C3'BFO+_)<]JR^$+BU*).3K)#UIGI$-(:W[<L]8@(9G6H:26._0:V]<W.
M$N7YCC+B4\*R2T@H>%QB",B&A#^E).2E)_[HPS#6\Q(1B)@>]V2VH"7]4EWF
M[R*&OM2T1<:T5G06FY.0^X=,I?!X;YBW49#']=FTOTWX%N2X^0+ @S2WKD26
M<97<57WUNGM+2;823490;[DJZ5\H0EX%Q8M(YEHY.)<CNVKRW=VD1*;%!8A1
M,/33E3NV<=W"M/>Z@ 400#5Z2V.L%:F?]/#A3PFCD9"$)>Q'75P$=L&YVI'P
MR$K\:/CI74HFZ#WU\BYQ#A(>LUJEWXJ#PJM/C9@8$[8PC>_S(:+S"AWC4)3X
M_L)N ?D,;&W/ZRC3&)PV%88@@ZU:[%C_U=;B=U%X*+B6I 8&C   7K<E.475
M-+<;JW4>@QW[SF2U?WJ<,%/=E&G<']G:S.\/B^_4;01C4[L_1(HK<:9IY;DE
MN@NGJS*=%]R<O@#6-;W\9$G<"S7SP&'2R7D1OE6/%E:D>ZVO-J\OZC*F]^.&
M0=^\_CY"3[='K&-'WD[EWA^2735A53?XM>JCT";R19Y@.MP,K ?J3"]AX2B3
M!DC-0BBTV85J26?K;I40:C)6A:-Y8OM.:IF.BK/%Z>2J(A?7J?SL:B^XJ.2S
M0_'LM:N<+L^/EO8\>ZV@<M--M D;YN5!ZI.PC80-@@8BTCT(2$AZO9G02YCK
MRR9_2TNHJB026:"-0EYO!?+QSH\(P<@:.A6;'I5I+X9Y9Y;Z9('\FH-M@]$W
M1N_T383@;N>G-ZJK>_J4RM%J)2/S)6,9,T=9K$[_W/H@(9Q=FE^8@Z_C$U+*
ML]#XY?(J/CR63ON@C'^HFCV&J"=-K6Z[D]R_WXCS7[#SR9L9/%.6KG?"=TU6
MBS% H58JTU^S)X*?-_]MIN9#.CTUU,?&B$ ;):_YZ\I005F;WU&"8P<43<$S
M:G=;HASY?BE-0174=-_.NAN(JRAUV_&?[VJCAN>K<Y9?,C?I]39&OI5%X0[=
MLH#$'D8#C7Z.X6;.%NII0O]T$M]$,GOQ>O$SLUMHZ5Z-'BHPKRJ&+LFU@$,G
MUA^[M$.BJP9/PM""X@1;B#GT.0[;$=LX0HB[9:$_?E,,VK1#:MVB?KB"S[]K
M6K?4%%JM.HRR01SC\M@^@SR>9#>B>V3;T?;OA;/"*HY-JN9YM /:K>75$\NT
MF*H+\L9O]E"H(<D2KXI#L7(@TUF5K%^_5PR[^ZQ^ZPW-[5J%:Y@1W:"<8_MS
M?!FI)[WAK3-B&%L6$EH^]VY7CB_]9_S(<NDN.VH>*S=W>Y H,>WLNY9H[>:J
MJ0)+U^JJ1BC-/(XY9^DGTX:,(6 !S6]CV)4VE67[R!< )2N0^N!149];ZY'F
MMC]?+G<0*]26;6D$U-06]-"#T]K8H)WFSWH:O?V4<0(E_9K=8N10M9+U\19K
MO9W<3=JY#SH?P@H:3@N.D#!IU,PV57K8"_'>]P]26#G+->L@C<.0V2N=E*V/
MK,.GQ6TV6_J((LXZY>%@T1KX5%%JEJRF_DU/J]&@5GN 1H*Q5P.1B)2=\OZ-
M.$!!G!7".P&K^+<A($'I)-<:\$]S6.^K^[#=%F.N$K:'PKOYK[F8[8HZ\Q'
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MOLP.[YS#LT#\ZZ7XY+?D? !V_*\1F<[.K]ZGCGF39!AHU%11>U3T@==;Q-*
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MNOP.\$"GW)PFG+8<S(%$1>>_%>O+G^YP<'$5BY*)JW>9Y>$-<6W+@.S8W?]
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M9).98<[([BB>DA*AIZ&?Y>\&;<C'^NNC_9 X'4#R)D*[#'(D=GX:3!G_<"/
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MPTLPI4$$3+'(C%9"HG8-D1*H@*E/?&N-XY!&*? Q)7HO<(9IN%2[XR/!9W
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M<--:F14]ETN3L7])"XW?;]W*UNUO..F2RV25_:NJ@#_2CR6SM^W_L8NX,52
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M>*3_V_+< R!Z@>*(&H6&\AJ 2H2"1H3R/ !@^&<G!LK_".#_%!34?S9B8KW
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MLWM%<W=2$H<B@_@PUAX6VU5-@$44'S+ K*UK;N]>.*\O\-HAV.SV?L,]A-H
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M,D+_X&&>'?])H2UQG^3;)JO,I*/7$_?\%0,ED-IIL"O"N<GCW;G?WQR<<EK
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M(,1L$_%*D[2QON)4O;WHFI@:7P*)RA_4X8M1<8$@,"CLPJ@Y\1JB-.L55R,
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M\H0/,%F?Q/0S"QPIWG(DVTYW9 .>\8-#=D;.)[R:P=6,UTIZ@.UF9OPO^<J
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M]YR&-85SP2-4F=PQ+^U^))WFOYUT]"W%,YZ[.?'/47-S<>B7R'US#?RLGF,
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M2VD*563"SJ1=OT$^8\,B4]#KB;9U4PFI8!-V]+!J-+N4(0%W_MP%\@+2!_[
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M6G)9R,BW2T; 5=\H.DIJ8YI+5UE//3M0(ZB][+R\P:6C)RZ01?J*[;-_R8=
MY'G2&7,>,NXI-TDY8]5" "G3FOQ&QL^ 808T7RO='/5_?L+U24[]K80K,%D7
MREC!7P7H"7LQI>1_P<TT=/<4]\-WO.^NMH"L(*&AAJ4D2J=> <_#.1:U:5O
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MV,_%6!?+9&7"WYD^G8?I49\;R1QG]'S*'C$-R[</EPHT?Y&Q+<OB1(V<7T2
M0%M*9D\*>9(ZVPZVD<927^-7(1;8,%.5DG)^2X$0AP60P*7;]E/*#LZLME^[
M,/96J1FDTT/(2'^]GT H-3W\^L-$0Z8^LS^A=N'KMB;>F*NZ;V?,Q$;[D*#
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M7WRI=$[<A.E&?:+NJJ:@?#,G(ZEE?@WS)&3#U&2 Y-*YNV.GY?,;LF(:73P
M/\-L@4.RB:^=JA_R&U_J*W <ZV/:7D*\_JVU^PHFGM /8S*/Y=:7J3 JO):]
M)P:LIS2*H^D-][+]:$R(SBI<Y+$/-]2C)<I:LXOW9[V]V7F@0AOJK^8CWX6/
M^ON'<&V4?"LS+!8SDLF4?"*G>N!^U19[;DSQU%0H34>=7IZ7U96H"L&V(ZWP
M5UJ6+J;SEJQF'/$9S0?S=^%#:C(MC.Z_LX_8H$P7IT\P":D^-+7K)OU*BKKN
M#CA?-N->[)290;U'7.]_T2C0_O,N*0AM\@:8MM-2:C^A(.GG4P<DDO'?T<X
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M5DBG:Q@%-P8G32+8_59\MZC$O7BNHVNM65+K[JG_0[93RE?\_O"%@PS3BCN
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M0>W,C7JFIZJ/)EHA_);Q@'_#-%BSS'<B2 3X9Z9BG7S^-P=7-GM8[,..ZW;
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MVHA7.U->GQ1"*#3*W2A\DI,JC[IR\//LI*:E5;K:"#S9<AU3Z;8KOE4!T0;
MV7'?-$?V^IIO]R/+DXM3]%W%):L3DX \IM2J\D)I*3^=P0@Y[KW)ELEYA(M
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MC\_-$X*EHP_XGSGH-0;=-!H-D90/6%A"' BY%]/#2>M/!,C7,M S+7< E3M
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M<PQJNIB,%B<(K2H9YVUZF7_F,.*^&KP,VPFF== ZN .0X(3]9)+2**J!J#?
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MA7UOTX6IM,QZ'Z4R)">]*J3!-TC'L=_4W') Z#$I3W3TVJ=XG3[IYJJE9YF
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MV-GX*8X46)U,)]J<(,QK$+BMFX,<(JG8+MCG!9,DW %L SSZ8*+8T%JD0U9
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M@>WEY<T3H-8C0LNX]:Z<9>L!R])6,Q?3CPWK-$+"PLG#B6;\2MTEG7?A:U)
MRJ 7U>B!:EF$7[WQ]GW*$X N31>KD*8N-;MDC=];S<"[\8B9/_98!N5J?,](
M#'34K4M(3+"RMJ9D16B<S,#Z9RNO$AS]!*@?[8H3C""0JVM.DZ]!$Q=G!XV_
M;:(687D>U]WNVTL>&/W(.%9G].<AL_CC@MPZG1;\4&4NMWY',Z[B+@;\S78N
MJ=?R7-M>;'5T2<DSQJA]^:*I"I+!]'/60UA1W8FCAK9ZO[.X4"5,V.VA:H>+
M_*.I\+>Q5V/B;@?3U6##D&XA(-GTVDOU=$Q#\S2LZ]SEN)"E:G<[/4AS:VU,
MZ[M#H:KC-Z+CDN\/CA2R*#U2C_>WL)E_9HF)4#9*_-#%F#"X:.*_L097P0['
MQ.61+H4']O,$MB=.9$T">!_5O0".SYM9XK+F+EQL=&6R&3\O[?#IY"5)E&-N
M)_E+#E22.<($]/7T=13=0!&??JHW<PYN7#P!+N=\;6V@#WQGG&PXU>^BM\>F
M>-:FB%BL[_EC_.WR1QT#7 ICP9CW^FG'B,&?UK<*C3HORIQ2?Q\=Q$SJ-X6I
M/1*E)N.EHGD.X@NP,C)E4K4&\<BJJ.BRS5 UF.T:X+P+Z?.\=HFHPM.I"2(U
MSATK3NAQ_EI<S<M^%E>0<NUT8*A*=<3AK#NFLN06KGET')"ROD\R3S+OY.@8
M0T>'P];$D/A7#6X>*:BHS9<KL*N[= *1_N6@+9DYCI&!M0^1L*5/X0/C$EH#
M? ?"K4)%+F9\F;[-KA)E*#?]WE2BX(EX/&38N'13X[F!0V\<BLF?0 28#Z'5
M[<  ]7BX*O>(%MERJ3VA2:F)N]R7-ZHJX7 _^(GP+"E^5W:5Z7;7O@FE?3S.
MW;>;>$2C1>3&NQOA' '9X[LS#%V8ZWSY*C0GWPS>];K-6U-N0],1+-)-4PV^
M,/)I%8-R(80O-JPVQEGH/.J\?)3//.OWYY,^!?G]X38]FF;=G!IX8J#5U@;.
M2S_M:GAJNJ_352!L63QBI^6'\.T\IMQP%VV7/2*.%^&^7D-R/&WBJNFT!"3E
M(MP./R/Z^@3H/-HQ"@:R=33.PNY%A=)]RPM/=WYS)!9F<$+R5&?E'RT[JYN>
M ,%N(# TA,JJCU_73V@BO^>A32/%T(S$Z%**0EFR4]K#S<W&3%Q/+X?F[M,]
M/=(-_AGD] 5I@M#Q\RHUU)?CI@_J?X'R[+LI7IP7OBSP^U^+POR1-DBZM&$L
M:^[85(KXXTNY;2&W8)\81$;\50U<^/=XV*U3N)\H'-R;9LB%0*V?IG+23(G^
ML(6!IP9@0?<"Y+KI<W?#%!QDEM7U[FJPZG%+O:4<K-!#T>\@TX+#7X1]*&0T
M=7,V2T"*=^S]P=KV>;/UBU$=#Z/=X4M;"7+[*L#9"^I(NX+%OH>B9\/V4Z6,
MM1L\L%!*C&T@N?62#R@ G9<P0D8H3-(/&W:4<5K)O=GU@YZ6#5U?W4!*2M10
M-T574:@%S[]8>TZUO8QF?*KU=#'#][537 Y9?6WB:HY>4V+4!LV%3ML<YI50
MT]?:7]ABUX)M=V\/$K0#)CL)[5SJO)::?L7AW#*N9-CZU<5EOV<O<3N-^H\#
MZR'1?S8<)TM-\,E9\VLX_K7JSIK?[OH$N(HD;GQ\$X:#\W:MI@39X$=5I%VY
MH5JZVE%!\O*4[M.[H$\[<92AD1'8<@K&OE3_M<(0)VF+I;:9DPM];42 !,Y!
M>EL5%@SJ/6_;DP]DN@\]PV%.GIQ^"U,L<>]IA7J#"<@TN5ISL!X*JMJU$':?
MX)_6B*,5?#N(E[7YE2IZ&(LLO@UVOI#F7?E=@2FC;6&Y/IY6MY<_@F.?W^[4
M2T/5L.!X;^*[V87:!\5YC02Z.508C99'Z[68QPFF[MA7CG#4D1:X/#9J/Q>Q
M0'_N;=6CL@2<AGKU.>&"OG2_Q7A-)21BT91JX/P$L#6$<!:2L/-IDZ+1]?W^
M\NB$ZN/VQQ*];M)0OM#/#"$;PRWX^@F  2+FM.O6)"]L_90V;2=O%^@*'S-I
M3EI:S.>MMS[<XALG$$Y%&K5T,:@\%'J\[G@MBZAXQ(O""1/K_(D:6]S86G5W
M*;^+^]Z#,S>)B,Y;!WU87([XHVG(+H8VCFM^.\;T59'-SH2@;S9_3X9DL,?=
MN4V1D1V0,WA8O3/47'OMD%W4%*_>=H3"NOE<HA9[]+@FB_MUP'(J-6N[XLMV
M;J;&XHRQRJ)Q.\X#"OKZAO8<]D*@UE@RQ1M36$/2^]3%X;K7N4JJAJB;3DN*
MO88LL_?<Y"#N3R$*<_>D.0)WBG9G9)O?^EZ!_, U,"O\D5\X/U ^&^U(,DG9
MW>DOO]_8EY"J -D?5!N!R"2LBONHG@!9\[%!S+7Z_<V)Y'H66&.G$I1<+XLL
M28 A^>UJF_$P+.^M]2BQO>!+*NZ>3IH9 3=*+2%NJ)&XNK=2!4&;M,V5Q3I&
M>DR TP_1F.R"O):BQ\E4\C085JD?S^-@*JO#AGN(T7G(>Y=264*U47-<;NP$
M%<KTU3%*8T(!G:]'%UHCZ]A/ (=,F@A-7:.436][#]'^*B<.EG;Q2NFL#];I
M\A'>D1+VA2* -RM A^*VW) NJDN:")^<Y&)02 \/Z*^1HPL_!K)./?:492*M
MZMS(6]L$>&H5*92(=Y:T\)]5K03I?#TF5)6F_;_GS?\I?GN(M*LX!'?/.NZ]
MVM1%I;AB1V9/)\64TX7VB>JU_B')O-NR+&')Z.?/ PE!:-/GPJ,#OU?#4L8+
M6,'Q N/+N:H(R0A=+!KI6O(/R&='^G_UI#_\"+Y<-)+A6QI +)*M6-9CT6P2
MY^*QOBP,90D%8AQ0\R&PBF,WE_VE>AMOS74?"S8=Y#EW:I,5DA [2A(KK^.3
M0"/T1CP%I5QH8BI\-.S U?Q.$#RM+S!JG:CJY *&T=-C^'KV@HI!I7F.XU[:
MSB7 <H:K,G7K>/*'5?1@),J2!="&*8[@VBJ01AB66[6"U#\DSJ#.1BN!@K%M
M,DJ^UM_E\CY.^KHY<^PU9,]",NAR%+W6294F/^&@RI>,A%KZ.TG[!?K>J=Y+
MA4LAX[T);VF6!7#PP>'VM&E_EC*6 !Z9=CA Q2UWVNSVENSVB$5*H5<BFN@3
MX3"\"B3+[R[B$PF#X@4[:GJDAW/U,',$]=2XNDXEM+G!N%:@TM[%.9*6DVLU
M](_QG_?NQ%9=JH:OM@(CC(@#<)#*2DZ]=AOC!)G]==/'L(MFKHM)J])5_3XG
M#+DS>9&,%8%%FW>A0?$1"YT$KZ'<,+RMP*]+*SGD" EJ:H1EPR\;A(&U;EB:
M S#%MN[M0V5DU(DH<XMYK'E'F(J@_HDJ_?&77]K-VK>F43>24",8_U;@MR6G
M>/?,4=F>'$9$8W(^5V6Q+F1324_^ZZ(C?=BG^JE!K%[1'%K&J,V79O5EAV_V
M:1ISFK:H EX[L'^:@M'^!=^T=_#+G:+M+V]GO\V[K+S>MUAFI;;_\J<!])R,
M4>A]03HZ.[ ]OU-WJLL:)Y+<(D3?+HV:>&;A7K$!SA<K*=M2_^RY:)SWV-V@
MZS$9!O8S(M%S8:Q:@X#I-<YX32=T:;-\X7B!;"-M U?F,"=Z3JZQ91C/*F.
MXR4_TUA.7AW?2>HG*Z<A ]3X4FLP/A(/T?H$Z,M]MH,,W=*[ VV&*QOHPO+@
MHU?16(62ECK;&G?ZX*N4SWH$_1_MT:FP0/&ADH[K1*#I*UL$)+H^EKU'^ F
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M9 %YE[=16RJA7*>"J-,3YC6#&'E-U8,P9658\W%_2DKZC'4KUHP0S+4BF7<
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MU4>$52CL>V<)<V2)4LGJP42,Y88L4R_47;6Y-82"K4KF\3O*X876]R-J7D1
M&\)QJ_N1>+9=LL3&&10PK7UG^+-(J50 )G"-M_G)ZW.I0749E5OSN>$;Z/K2
M>-\C!0(2*<'+N1[.(<B)/007.#^8UM==7]7[Z(AG]FQ7*&0T<H+(,LWLIVJ;
MJ/CD3S'8+UL8\Z.B6TZ##\@]6]9\R4BX">H?8H0?L"QFL'K:UT$O9[:.OY_X
M/#''[^8)<#M[Z=3S>AW?=HVP9N9>OM1&:WI]N<<#_T#7/=4.H]TD2NAFE^N]
M)(CH5FLXL#$PDGFJD^- J"9H:(E#)?BM55:@PC+:]U^+B5$.:A,W8+6P>T93
MD1] H:3RKUF7MVH72L*&D;]?L8_2#8AL8,"._>08-3@)=2Z7=7/A&=+FY0WJ
M3?H;6EW6$#6(\J>\'*KYJHNBN,.5$9=@'*-*B\!N[E)=X5$[KLW?3&Y?M2ZY
M(^=_5=8:M&^@+%5;(6/+Y5R;8MY*<UE?<['Y1[.\G_U.NBE?=U*2K)H+.)HN
MLQ&.2>QY'J,AC0RM:/L[S6Z9S:@Q(J/!67EMI@5S&66H=90_16U,^QLVE60V
M&6(Y=/Q2EEY2*7LSSJFOH77&"9F]LHZX"V^P_K/581S,V#( 2_S\=^+LF>6,
M1C\[(?0TT:WX)&1)HU5Z*4L ?<L%'7L)_3R@Y1K4(P*P;%%,;6M('#[!G"PG
M'5=&5S7LSL6GS3IIGS8U%3-WKS+K"V"8O*1J<T?.]LN)P@ZTN.2/J%[%2[A;
M;QX+LNO=N= +4<OP/*Q#3Q-A1_NV]6>!%@/@EQQU ]5$E&]8?E)G63;DSW#@
MI1$CZ+&_JF-JQIP6V0H-U3'O?<%(>0O\7I&Q4JDE%9FDJ,([,2KQP[2BM*TQ
M\?319U+/RW-N8*P1&4JY'83.'!4^.$ON.GH\'G_"0)P1?M+$P4?0H&)Y#$QQ
MG&$SZF5^6!8";(F,VJSKHCDGHK I-%.B69P^*FFT?CYPI!^JI>K=2S;**6.W
M]??B-MWV2:GP4DX,H]W&UTH()&_"NE,L30U*C8A-;/)@XU,RZRA>=GN#F5RZ
M0NIU?3N;_>Q\6,M+DXVHNG(EI[FBHN@7N_:^?LL,GNY[RKRA!0YE97\7]9_-
M+=[OM'-DS,[.7&TKA_Q3)[GPNL^#L$7&*^WUCG PB0=M*-WZG1F3T5V O8^"
MF<'LZ9?BW-@'KJ\M4O:8/;]LRM/)B-+ZS =NXN!*E:;%61=XKQF^-!6J$J>Q
M/;MC/\@Y?#E1GV ,^[05,B^H?*?^UV0-V%WR]3[;OQNQN,9T^6,(*1TUW7+3
M8*>1/B3O6OS9@D/!:%_>'HR1Y?,$N"P7&]:/.UF2JR[FV&X1#P.&9.Q)<$+O
MG/ /'';$))1;>'F'\]#1@5EW<YVQ5@Y6-,/..E11 V$2O^+6>:XK"+>SBV-7
M&!RM:SPH?.U*T"8;\[-'WHEH4G^[KBK&4C @4:CNP(.X89K9-,<$R]XM;L^9
MU&MS[D9J[#DR?BD(>OL0T/#A]HI*;(E)FEF+[&PH3/5R5$TN^T)80@H<?8 Z
M%,GI 2C@XUY-\0>=L,])FE$<S%_EP+45ZSR<W+F?ISBU=@^Y-83/:(WET'0U
ML:U;RY]@5FB9!7VED,A>A*A\HF9??0*8OA63?BB[IW#!3;73L#M6[G(/,7.)
MG>4M8=+%&0VP$)6>2CJS.KS\2P.?02;_(@']W#X5ZA[X^&^?I@C&:)C:,J1V
M:H0FXW!G0,[$Z,O)4+O/O(XTP&_Q"8#9 D5%?N9(@V0,(.2R0-$#UA5*X*NU
M4\F1<^#H'NR\>3PS.\N*4N-'NX,90@^*_GO4P42I:2YC1:OQ"V#M(W1-( ?=
MT%L+LY!&Q>>6+0IPX];7B3;?28R<WKP.NUCV]I ,.P=5S=TI)[O8") ]&Z*>
M/+^N7!D@9QX?T$C8)A1LNY,JB?1[#CWB)D!R3>G%2O7-A723L+^B?>]^W-]_
M"9>]S3\O,UO\/? ;_+,T#YN8KO >#:E5HOO'I'3=1HRI7:CXK=!L%<O"2ZT?
M>=M!PG)[R4$+F+W/=]>P$=CI3@@VZ/+&PTYXQ#V_1\'*VB&Y8ZX[A4+UC$2?
MT$AMU?;776[N= S/^)'%YIW'D/P@X-MV>'S\/<Y65ZBK789LV"4WP:$A:TM'
MYYS)O"-9 T6(F7.S\YS48)R(<V)^&D"F_&M+SE^=%FY$4,\=W(DY*T$#%?]I
M!\VF?WPXOK#"Y+J,V&O/T+.JBXF=CA3^]K!@+V+LC=;Y7QVY(<)#3OV>WY$?
MY-#,7,4J="\KQ!U\#BX37N8<B7K)B$N:@.-GV1F3__>!&O4=ZVV,P_#L"\O7
M0?D.;^4D3G(H2&6/:"N? %%UMEW8[7K>F^-8?0)X]W*-\2K5&;2>-K=1+X)U
M:H&GM]1,E)29_$=1M\Q1@#-NU'TA(#KRO&+_UO[96O=IMZYJ&.^]I'G&+B[Z
M_3/M\/L76BSP^$W+D"V;3F:5<OF*@5HD1"-83\_!YW%N3ON:2P,&33<U?D^[
MH[SY9P"<;YV'D]4I<"]L1.JG!W<*<W?0O/LSU;?Y5D=@>11C5Y'?\H S(@*%
M@,N4\CD- /P)M]!J?^D%-2]2!8J%_G[RYU0 J[587TY)A?7\TK<T?H.U915"
M1-VX,XRQ>BSQ*V$2[V=2S/L8].GZS^CI?^[D[L4?Q_#7D4G+'V=F93,W']1X
M;!%R[QXF:R4[;;!E9J4=;E"%G[TJ@7=U"U,SU2%..J .S(H41I2K-R$?.SXD
M2YLVUBSUUY5*,B;)4E_I[WB%BEC0^O01HIRK_,Y^W>MSW4OA+]D+7\E4"=4\
MV]<43J/$DCE4_=9Z,*A'0TMYGIGZ]LP*6?X$P#A_)+=3_@O9\7\9&W*E=4^/
M<Q6(5 @8W_9>=Z!Q&[_Q@JU.9UEVQN<'26@:D?L1P_^VS9\\KO03_BN 5B<P
M86AD(S0W^E/*F5AR=768YJ3 "]4S]7'_1;":F&3=8[G@95,4I[T@V>7ZBX5#
M0]EP#]]T<LL<',Y/B84CBBJ$7])BF9F:4/MWES,N,UB?]P30V6C1D ?P:H,T
MAS7;)R]R43ETYWZ6VD!)DN^459#G01R3 ]\*3>4S61?.Z20HR<,_3!<B\1 I
M!3/W4AZ_]H%O/\ "?U76<V)7.F;C)!+R?A5LWMIA;.ABX1QO5WU'PWKD4(%L
MZ[.[D[*^&G0K!#DL03Y-)ZWJ&JA)J[$9&CR3>0+PIH\D!+U;Q)':(S^=[FND
MQD2F>6U!LHS\)!$YZ:8%O4*EYDW3NR$C"_.8_#M_Z)5R!:LCAJ125EY=W;(^
M[W[D!-U]1(YOQ.K]-D29@4D8_#J:Y/QVK2L1[655].<-O6)T^L2/K6[&4-SL
MD]^H:H.Z5]0O)A_I_+20\YLPQ]4J][L(@?<)VXH$E>VAC+*'M6]00CQ>:'7^
M'3HO2$L?0=+C%*.[,]X;*7%DA T2,F+O_?4,\FN)::IU2!;%"G ,.K\.KH9*
MEP>0/^0T&$728%\./P$(D&"#"0\5JIJ92P>V.0HR^J!J&LMHO\9QGC-3.9)G
MJF$R;.H9MPK_]7/V_FU=,-/^"EY[WM<:FY-9@?2":-X:110UIYM&K1V^Y$K<
MMC0E4NU?)-RC,->]Y>[N%(?/Q^7E.&$APQ40F$+'^#8"Y0M5FD(,M+PR(HR>
M@FW2 &_JGT\ %JN?@0O)I8$'_MG.ZZ1 :MM W$>Q(^);XHXR:W)8;LAQE7U1
MS8PC)WWVW.WV#Q8>,=[8WTMRXFGB:8DA%Y5_/VMW&H)Z?_Z-S(,<E.FQT*U8
M,U4'POTF+4[.RQPP/YY$$Q\_&:/Y,_F8$7F/=XM_BI%U&]0%\+;?&6AUF[E$
M=JVSXT$XRQ>K]%>O4>.T->1:P]TU)X<^):3+CM(-XRJK"%YD$Z)L?&X*[V2_
M!UF:-\U+"%;=2\0VBJQ2P@=](+F_']Y?$XU*EX# F_']3JC6K0V-/Z'QV-:>
MY!W]D16_.QUF>]%>T/=_=FF%2K*&VD,US"7X.ORE_TY*"/0X/^XJ/R5X<3E\
M_+.\A&R%(6F[2M[RLT*=7Y*9;Q^Z[MM6I%A2\V4QCE52SH-_FB)YX04]CX+5
MB/O;'CN25Y(Q#0N6M=$&G6%CUH_+M*Q7DR/5K=4#Q@-2SZ2L!"\L"%&V.M_$
M^+$CZTRV7@G<H(=P":!.G+)4-W&URB8R)DNQ]P>E!%4D,8C%,,]PA@YST.!W
M\H "(8;8L^WL&U0*$ B0<9YCMSH8"W^3F[8>GSO5D:LPIE8*WVGU/,$(59U@
M>NFO7DRY=X(GJ\T'L*U9K]$@T$J*[3)POM:;67 6%[E9$"&B3BY(N20BB=I;
M/CAP4+@ZKI30AIQ!8%*_D%8:,WYL$L)%C=_F;OVJ#S,T>F.95HN0S<GCBN&F
M!CLKK@:#7!B-<O1=:D?GZX\8;Y\ 3+(]DE=H3X"E,ZUYYUH5_BC_HAL:JK[8
MBBHEK_A=?[,['C_Y&F0FW*IGOK&"^+![[:W8%>4YY21]V3VI@\MQSU2GY4-;
M5>KZ%G7<:^-L#((G0#()4=<3X,4N7+G)I B9W$<PSD%.=*.HZ/L!J!?)P%B_
M#J?\_L*#J>[:;EQR([]IU ;1)O5<7"4\3_0)T)29 1VQ_O)[5]#FLU=4H,>M
M7^-;3#">%E7J5*6!KI+_U='YRAFK1PFE(ZUG']-8.3,VMDJ57>)T TL6MV,@
M^1R!5>I;]O$4R[6]<G+;WNF5E1'?7!\YV*XHBV# F'H+W;M[.]NUWSP;CA6K
MYDV"ZO-2:%C[HNA$(@E?KP,5ULE-+^G3[H \;E'C1[PXEF.NUJO]A!IO.)D!
M6<91AP9XKPXR2EPX['*^LUTO$N:EJ:5F]&^V0:M/W2%NYS$^> :A:T7D<-XC
M;;&X_()JP0K;&?NAS\&B@P)NUTVPBN5Y7V7\#RX'NDT^U?:ET!HN<(''']I<
M-0.>,JZ*/1=I^0:=,[Y['%TVELZO\JC/5?5\953>;-.8ALV&I'ZN>0*4V_M!
MWM8DV'&=FZ=6(?@_])W)&K([J;UFQ',(D@B"::T& QNR)0YK\FO[(2XX7Y,"
MR9$^CH=[DX,ZWQEF6-KJB*_5B,Q):6.<]&^CF@H.=DD#UEV;IVLU^&/V:A@D
MO58T4ZK2'$K?OUSK6VQ\\>&5VVH<". S98OUD.(@.,S!IUQ>;;6GPT#IE^<.
MS&\,;<7?7@R!:@I=)Z:C)*XG!>ZD#VPY;:Y55<A39R"JYC=P$5EX%Q5*R@].
M6]'#GVO0>JU?T?G_K]K.\JT)!NK_\T;%($641F6$C Z1VBP: 8F-'MP@*0P8
M,7+24D-:VAL</1!AC YI!DQIB=&@4AL(C/[YZG<];YZ7SXOS)YS/^7ROZUSG
M1+D:?-3QAAD:GZX^77?:T=/>,O4D@-[D32O:M=QZL;56LG>O8QCV[61DP\_0
M2C.YG57A(Y]YE6@P<XO&=5=GFY!G[[M85)6"4>59P2LVT3+8VEX9>[ZGOZ5_
MHKD&7OG=(CR'=)K'*[E_2=98?Y 3[?AOJ)[R I_L5.S!!2"J51I/?9A%(M7%
MVD.A1LE/2-S(P]"J*RWX9E=<@FR3I5>EGA_;!NUXXCS&MHCLO+8M_"@@MT;,
M3UJ%6'^P)\##7[+.BS0RO.$T<LLY7\?TK(!3NT8LZ<ZB9L_HV8KMZ"^M<F<2
MP@ZX)$1F&CW5"?^%25O)NTFK0A:ZLC@'),>5<TK=:^QXDY>OP'D!4-V8'.V2
MJCD2D(ZA'_"??OI'?KW513_=@K?TX<EWQ295(>.WU>^J0<F %?MC6-UY9X9D
M4<BX-0M^1F(&V_QR%6Q4-[#8>,Z^1K03[^O->V6\:F81NG]09746OQT!P<,C
M*K8+I&;94%09AE[A8_9>11ZZ^$F3Z]:>^^KLL$;2V&^1@M:(W?]U80:^A.YB
MA"S".[<"N[.*S$E:>-=PCL<R;2_B^;IGR\)'Q62MZ4[$4;N,S#V39(86:EW*
M,O<.ZS3ZJ_Y!@H)1U)8;_JK UD0XT2[B<GDO293G0'X+#*;P%2Y7<:+DU_/(
MD!L_,QQA#80];E)C<SRZH'*N?O=[G*;>9KKQ$6I(LGOGTCR*I#E2)2>,)U"A
MX26=I;^,R#5 Y;&M](><)A\T@"^!;K6.:_0E?U'L9RU'A77.8RX [$%:[HX3
M*HRV?L42A,*NR%5\0BU-JS54 _@13KZW^IYN_(KRLD2Q,^[W/#N>%[P&(MYL
MBV#V1"#IKF),YZHRK307PJ[=.YFLI@FW3R=&MSX(>D*]LI*.<UUZN.E0%TOO
M@.IZ%',S>N M^#70)B?>D3YV+W#^A^_+!\M+ 31'@ZAY+2HL2L([&*+5Z& J
M1XS1'82JEOE:9 HY3A6NB,VH7P/0H3LO #6DMSZ2__Q,^47F_DSIJ?.F?0JW
MINPW_CJ.;,9='7U N@857E>$"EH I6PT*XL7_.+V)7F#Q+[M!]L6!%NENUKT
MW[<J!7[3I2A';G(6BH>VD]C#$8Y4;Y0YZ6E--24Z6@@SK:R_U3WN[B-,N!&J
M&^,R\1Y$X+F:*O)8V(-#=2?TE+<X"$Q)SUB<$]$Y8%1B97#S%#J"-RD3?!T$
M8_:%0Y_PT_T\CJ><=^3_>-3E?[P3:_12#=*E4_'1D2#-W"E?LX2(;4R,0=OG
M,YQ"HOVI)L,E08I(.M9Z-2>387V#?[)]5+P48)]0L@<Z5/>X1434,1^VQ"EE
M&H7N&G%MC%53&:X1LI,NN/K.'0(*;W):+^VOK/EZ ?BR>4R_!2D/4@]LTE*!
M2&?M#O?)<BZW9+*_=K *?9;\^EX4"9276352MO;XBF)_OP+G0,%>\@AHO?"(
M_X,A$4G/H:;6K<V*E13!^^NLENT[Q@;I3D;'H&U(48=L=QMV\:! 8;75:N;I
M!S=[3T2DMV)G*([A>%[FSC8>O#CS5_(]BD:G3OY-:PW'0E1TD!%WAY-"WX.D
MN;<]%X!\($]H?H;+GYJ0_E:)ORI^*XC^3F'!S7<JQCYQ,-FA5?&\K_^PK3H.
MSNIS")R5'4.6-*(E@FPI.]U*C"G=[&NE6"O3KWO) K#T.VIB3X ,GX<O/=YT
M#6?-_%[(;Z>NU6.4$M $7+V36]>:!<XZ5&4 PZQK6_"H^@&YI?38K9(!<7B@
M:]E&L=T*Y ?L!>69<PAO:_AB1IQ;D*GW20%9(FO:$ULMK<T9GAEKFR$"UF_6
M"'%E7H!M7@ 6YSG.A^Z2Y>I<A^[V<@5E^-T)6$U8J>[G?G;SP19C+5W\+0#B
MN?4%@&*W> 'HO@  ?BKI1^!+FUD5(BIP0G4R4ZK+\)SR5,77UP]_(-N/D!C7
M"(K&YB&UYFL^@P28IZ.*)JM+V=IKG'-);W/--HA5Y/!O-7W] E@)H^=AVZ,+
M4RJS&RN#>G2)D%\Y[RF@BI6K7L*:JOOU)3V+U?295E(=LE:U1USNA#1"T,AA
ML!CJ!UB<9G& G&PV*R2CDA#SAG&O1FL_Q-2W2!,OZZ\6L"M_Z,UY:*W/P3X>
MI$4Q)U&N_FCE/P53):-/[Q=O7  05/H(^?]4<1/8&T#[-AF5*,DTC8%9]MF[
M#Y-^YK.@'>99S9]2DL"\EC^K%4(O;]*_ V9"ES1V]78?0(61 C4,E3<9/$<+
M)IHEJ42+;[4)3U5T%H/YNY4</HWF*G5(,*6@W]C=N./K(^O.C5T(*A9!O89:
MAK2IJ2>.KZ7:/516E$M;%ZIB7QG'CFI\FSE1:DI#5SQMT):V')!VFV8QK,W/
M\L.,C/N(G1/OAEQMI7F-TJX>&KKQ;O-F:X]53CN.\B3W7($*_WOZ@T/8SU +
M.!ESZDX37FAJFR:V*WDW/CJ!W ZNW($E;ADQUQ*CW7XPIZ[018BJEL^B'1/#
MCO._EC0;E6X0LH*F=V)\KK8UXK\7V%?CCW(J/+8[6:.%@0P>BCUK*F@*VHP*
MZVV+/E>H;:A.U**<&O7Z,(P\SB667UI]&ZE/YB3>V'MH=S]ZT-48:[9;3[1H
M@8/J&JU'?IR2H)4W4#F-D4IC,)E4N2_?D:!?N"K>R;Z_T?0&[3=_1!L>U@VL
MH^3'_$6P6\5601UE+K0E^8IF08>'*8N4U'5AH7HXPUQPT\$3VBIRA8A81\4
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M>1,?9DENF?'T+ J^[M@]]UE6>;-\>=MZO>.O4_!'MW+1EHA6%&AQ.0JN9SH
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MBE/H:M,8EZR:L+:K5F]4/A(DP^'[P34VC7QJU(H:F6MPS#$K)%K[BIU?LA#
M:6_T'!@+SFQ#:?$\:-JTLR9KTWH30[^#9;%1/@#]1?.F?R-7(I9/V"-B>L)N
M<<A69_*6OJ>NJ:$?*8#Y@\62WJF#[4ON7FB>AMN^4VCV#O^<Q>Y"-W\5Z?2T
MW.-@ETK1,+"GR)[Q\_@6&V0)=@(^M$<18AI+\4N L"T.?\ MF/^05S!?<[@6
MF.*TH!2V4?;\U=?M$DUB%OEZ\"4\HAGR/)T3+QB^A>0(&&O69!(N5->\E"O)
M<HJ<O<^$YQ++VZ,ON"OB6N+;[T\^R;A4Z&2AW7>)L#Z[.[)=5?5SEQ/JH-$H
M 264M*+XEAJ5AG)(HS^&YHHJR#<WYYJ%-\/ZI6*W)=62"FAM1I_/+Z.8*>;Y
M1,L6 4S#\V]+LSV./D8Z-Q]MAO?+W">LWS0*USE#<<'YK_3A(LGJGW=/%Q4M
M"W0*$H9*"\M<AH9.CF7IGQWOTF?-8:+4:DAL+UZW!W/T<4!]"_J@#L^2'3].
M,>DAMD3$37!2+,WL$SI@=77]EEQ^A\2U5QWWV[5G'GEW&QW5R12U?M-D88[>
MVV@KG][6!VEYC<T149;!(L1P: MJWYAK8$34C\KZAPX?!WWFE]W]>=V3=%XW
M<]WE'[?\+"Y&K0G6RZ#(#C=<GCS45TA!%!*WM8^.WJQ>%4\3V]"-DNY*B$]"
MNLIJ;PM-1,]"G1&C]>U0?K0CE_BY9!N_<"R$/2!GV&AXG7*FX.OM#=."YK-O
M"I[>7^-GZ9GH(/ U]+QMJU-MN1 0L-%DDSVZ1$$3EOU(D.P!RZ]0<.QU@<:A
MV2G2TTC)Z?;( YEU'*-MM7E+@1UFIR6Y[]G<,&DVU3KZM)VL&S0D@";[$V=:
MKE*4*HB>4V8RUP>"/:>M*;H?ES7#FZH\&1!GV&6;9;DU(#X)EMFJT>UC?__8
MR,Z%K!CL":VP_+S.2=PP.^.35F0@;9JF,5YG).]URK,2*6UR,78S/'KKT[^.
M!0 /T2#,>39YA.B;Y:PTG69<XGO6]+*;P6-3UA)KO)OVMQC1BT7)SDG^3FR'
M2Z<LS$M6C_"WE2@^"=;R/?9)C)J3-CLZWBQUS#K!J[UK'."N+%QJSI/3Z) (
MG*#%V>??_'G3=K3UP=DG;=@A$\%C0FPJ G#]RHG06#>VSFG/)Q54FY"K8\T$
MY27>"?9%10'HJ^_:7=!2ZE;[\XTS2V;[M-T^TX%*[;KV)\%GBVRM>O+8X]0H
MOU9O&8\2\(KWBMZTV%R9>Y>Z4BSJ7?%1@J'^734U;\7S2/6&]LD/:?7UIM;R
MJ]*I+)-K\P];]K'$Z!R6BN22U;*,W19:7Z%Q$64NM8\TG,SYO"\S3!0 #C59
M(NW=&79;TI-L%J8084J2M<\].:P:O,="X@<^-+4VF#P1(AW<MO@V-7=](>S1
M0:USU*QK[;N?<I#3(0)8K;?G1J0K!M14'H\A$IDV#+\5PT_PS2Z(F"JJ?G?M
MWEEEB9MB+_+H;!Y>N.YN82LP;)QLG#Q[4ZZ<1K)^].2)H==SO;:3;S^GTX$+
M1/_IMP<)DYNPWI7"-??A>RK-AZX=WD@0Y?"ACCNC#/:5SQ&UIFHIZK[O3*?'
MSE3$%)14P]PE%.9A;5+REU8>Y3-KR[+W1P,;=( SM+^I1[^T'B_V/K%=)>LF
M?*SIXXVQ^.S124T/%Z[7DJ_',SE4]]]B&$O,R T=U'3?<'Z-:RRK%DZUY2N+
MN[*FWRJ:(&&UF6)M(<,R\[B944-CBQ>'^'(WR 3V=(6U\A;^"'+G]I/C+-(Z
MRW<T^@SU/E^)-7?S#&MDK#"5CFP^;4*031?Q;Q:,@X3JWEN@V1@S?-?U8Q1Z
M=]#M"[SB:=(,C-]EE[\*&2Q5T]^ZLG.?OZ:ZTBM.(FJ"56@TKN=N4[H7,T,0
MV8"X(1*9W&/TL;$\L@D?\/B7="Q98<CM1D=?^I1.*\NMQU#YN!^>7BSMXG/O
M*,=Q*4_5M,X:7>AUO^?IKA#:RM'[^+!!0HMXJ'VR?<U<X]V%Q$N]C8>)_KJ]
MQ3ZO"@7F?RQUN0Q#7)LKA@KFF2*^ZS@8) WJ_<KE8V@*X,*BHWR5>*V<4V<#
M'?H5LXZE^'KGMDJ92%:A^+<4\[^WLN@?U4P87Y5X]. FJ@5)D@L]1@>\P+9H
M($PXRS4->ZI]\D&6#C+'(/O+>VK&:I&[KG%#Q^.";\T%.KW73YX50G/)X]&1
ME6?A6/]HJ=*/Z6MJ-]04>!P89].A5VQK3B=='^'].2->T&$K0A1I@6\Q?8(2
MOKU+_)PN>?:4UCIYR^V7N3%"A=PE__W.A2*EP,59'',4S.P F485?@R+;)0Y
M>PI$U^0--W,+2%<CKOR,B>8 U\#P-9GF$K[$]LAM1CIPS^P<'3BH;=Y#N587
M226IY1? 2"F39J\[3,QGBTMIPL2/6[CY+!!><NK)-"L)BJ>+#*#7OQ29VR"Z
M&O'6;\#9@Q($'4#\.O=:Z9JM10:NN14[TD.1M$D!BU$R,[DI 1Z1?E)JIEGX
M-1VH.E!A_@&<BLB]I[ZK[0KG4Y<K$!$ZJM#-$TNHG:E!?Z+9#'R7WQ=&85;+
M+S(%S8AP^HE%%5FD9!2/-'(3?Z)(_&IP\*$=[(F.AL1,4V UC3%UT#*;LKQ^
MKGSE_GKOH(OFL!>(K()]D20^7W!(\9@O0'\I$1=//S1(!W"'AZ(_*2W  V62
M"!K6K@4[Q018N/A9222S&X3(X5I.X0,!!)6UKIW&*#QHF05*U7/Z.<6\.])8
M0(G04_-WPUW#,IIIB',,F>SWIL6&[#>2 :O2,Z?<QY4EE/UJF2U7:+X[F0_A
M]CVSB^;2)?J(,!0WR\P7S6':OM0BF<_(9^VYC]7 ,<0CI](J&OJ]<4O1\N?F
MPKJY0XD!XA&&!_K+<)B+6B<,DL*BC'+#U# 4)K7\EEY0Z+NY$*160K[)T"=I
M&D Q/:O-7 P.ED?R2\@ZP68R2 8W#)'%S2 J@PY !2>CYE+LN^?6S6=+3!()
M@<3TP !F.W *U#?'$ *(F8'!4'"NP'$,%?#JTT*5/C'+UXL[/J!]0/<$/H9]
MLDOT)6M1KEA9H2)I$H _66@;G/B\B'DP2B+F$&)*J$A +I)"0?[6T26];H[*
M*($E$CR)A8'!6G@N&H-P&!VXVQ/##,5[-( SQR/#2JM"Z!Y#1*=B>W+G9 ':
M9OLX]"XR1B:W&<6-F.+.7R6K!M^ ;II1C'Z3/U<"D354<J=D\Z"UGW;9A7PJ
M9V %JERFM;]_NCH*BF,:]*>^TE$ZA,".!H  'S!S+@U D$B03XC7VF4K#[4_
M+16^=1MRH*:$*HNC."C@,/9(P1Q\JZ.\#B9DA!/6MET#<MO#S3RF&='SD[I,
M:9E1;$]$!X;M6A:B5TKPB2ABE;@,&*X#>7"".;$329*FR4 )4X/Y;;?1"RL(
MG#3MSFR*_=?L7Z[[4TT?9J4*B0MA;TMYM;3:'A9]>O4,TR$6R>S <5192IN7
M!O$&%DD!7+?IP B2QKHZHQ25KL8;;-"[K<1,U(<Y!KTJX>VH'>"ZPJ&?_X$F
MLZ(A^B:JZ/4MW-9;ZT$+VU3/V4AA[\0RHU$(#H9!VJD1%W"I+@V.[[__6%0I
M>HN.LMJ/M !$WWZZ&/5([-&HR?8X\T 2"ISMN18;^?OD?4+$VSC534NC;E55
M5.G&MPK'[K^LR=9;\J4TZ0/V)&_!!=%X3X.Q77*]>!=O[%6/:0,^2R''_T\\
MS?P-505K@D79G2*^QCFU(0[Z<$);U.W8&QL:T_LO#PATB]:U</N+&VO=R+W(
M98.;\"0<)WZ9@80C!'T5+#K/EX$28QML';'.P6== H4G>";&7U%F-IYZJI4F
M4ABE!&:V_**9O3?#6Q%EJ'9(E#@C:(Y_8< -XQ\4LQFJJ?[ O8I.]SMGCL;>
MT'KX]8<H8.ZWV9OPP XYHS0";4]7)J+P2Z1;9>4_&ARG3,\R7VA(7KRT_'4Z
MSMKV@+6E%W>]V)F2*MEWBJ%^ ?4$1V([%LD<O#\%3G0#@R8( 9I]LY?$.6J'
M9FYH?6W(FZFN<[KW0<;#^O[]Z_?U)+PQ[-"[D"@[%CQL97O:#'ZA_]YZ,!1;
M!&_UQQOD&7ZM>FKJ<$"2XL"XPRSA6])_80,YRCC=]@E+E3$>IHCX)-MIX+J;
M[1;=%9G\&5+N5:VCIN/OGYF1\!%]0NC=VAB]?O+PJ[Z6G@25NOF@8_USGIVI
MPR'\(_BA:C(WQ11-M,;*2N'6XO.7!3!\N?B(]/"0T*<8B_ZWYTXIT@%?]H/Y
M$V5:T8N^2B-*6/4XM*-GE)VP#CL.UKS.O5S76DE+G)[8IY$1K>4L96A<K"@I
MXI#(\/G.6=58_$JH +6&<IPITH08E;,$YZ*8>F[<')T<_8I;$[N@\OBGS$"H
M3-$]&/F:#46W5A/29*:XW"8\GNM$>#GT0R_'*OQ+\L/#^W272PUOO%/3_DJ0
MNU_E?<%#[?[:29M-]/08&OK%4PMUBO* FJ:C3+F!;X\,MB\(5L-AHHMS<3<;
M(35]BMLUK8UA>2DO% 8<PS:5"XN563LD'^>[]11K[\=K36%:(2/]339&3U?4
MT,\"/1]5NAWW"8K3DPQK[M#PDB'7FM]O'CY<TH]F!?%JR<$1ETT[DP^VY].*
ME>X"9UNZ3$V.,(;51FF(<DS=/\%K0=2;MO7$)D?@>39A#X-O9%IWW[8/5)0R
MCQ;R_G3Q=M5IKX<2\:.%I.CHDVFQ8C]&=C8UX#_;IR9+<8*$!SA4>/"YWK=>
M@W?3\0KCFD92Y=H1C =%G.^SBCJ(/K!K_7_Y\E;OM4<-G)MB\X,BB14+;;?4
M=[F=M2A05U@]%N.YF9/*'RLA-%''_?RAX@&-XJ4:+E$*+VZG1<%N_?*@XX#Y
M^JFM_F*)JGKGZ=13_@G'''[9J<>_AMD__R3+G>1&-J-H?WH^WERDG3 N$> ^
M]..:/&HIU/QRK8QJ6XW8#M>TAK8)6==Y*)0[O$63S]MM"#Y:%_I6^3&K*7;A
MF^?$NZL_-$Q>K#!^&+VOUY)+\,7Y$R9?%U46=0]5YL2H[A_?,4L)@I]J^BX(
MO.EJK5EP?; 1>Q6'6J'F+F+8,G#I'[RE+!7R38HZ_;,N$N9%JFI=>IM:DMF%
MY&)0TWKQHV')Z.GL!J8OL39)@TTB5L5W NX=\ZU188G^PLV^V1WSC/59<'/W
MS><U_LU<R$"E%DZHX?,9O[?%2W+?3\V(1MZ)B&\6D%,^;>AU21FC9'<B%M_>
MI/04?E!^)GU;K2"@L?E(U=.FQ9^C(J8^2>N20J2[K$Z BI?)]<.D5V_$>':^
M0-E"3TJB">'6+NF\-TZ(?I%:Z'SP(.1(NH6'H^-3VYJ;MY05DO<]TCJK1"C%
M170/?5"C)+KLROM7#:6&S%9M%$P4?F2-G;PA>^+0U<-0B0_,G]S'0OO%&6N'
MI/N[MU<.R,2++\U<2M=R_"DCW? CS0]5-@YX=T0]ZGY8W4P']@<K#8^=#X=%
MMIX6CB1DDMCS+W0^<)*RN("WJ<*.W0DZ5[]OEA_6<-@R#S4R\^52D6B5.N^Y
M=B6^%$7SIQ[?67I@6V0D>1%1)[LO*655:^JLB0^FS Y^LS/4^DZT%FN4T<&^
M)R]6FU0UV#*>=3BVVQ1-8T;AS:.-:6X?,#?&%VU"5E)]+.:M'%SNN'VU,&YM
M6AF#R -'7HF&Q]O46:[L3)LI*BC QM:E^I/YGMY(R[1ZEJO:)@(P1FHL]C)8
M?R K!(C=ZK]S_$,'-=V=DIM &HG^G!<OR3NP/_KD\L;!AV>8 K<#4IYIA^01
M3;&PZ**5K&J?Q)4$7I4$[]F94O''GZH:/8CQ=$ :UH)9LZ8#O[)L ZS:?*\F
MU*KX&6X&WQMNIWPLI0-H][WOFLWPS2V,-"LKQ-['P]B")Q[;[%MJZ_)JD#E#
MT:YUR$SU,TN:[0IT?0R!-^<-#L(?UKZQ2 =V5O>^==XDR=5OJ[FQ&Y$NG]%9
MR-@;6WF4*/4NX//%O><1=, 9SE,"WL'\<6/S@US%6]<A@<B-(]Y:'H'70OMT
M9" ;JSET ),+:L^7H68%7_ZD4($A;X%PUO9AUG:>]+J-O#37[+GY%.\^7\@H
MM%7)>6K,Y:TES0J]$TGV(4%=$/S%#]QR$!@0A6"7ORFA9T9H!70@@\TD,+7O
M%@XL".&IMCW7H!4+,<R4ND7$SAQH25T4'7"%")2 -^!_W-AX"@*U18N/5HC9
M\YN=M<M&A!Q\ !U(,3M!HZ#!MG1%?=5\AH$.**;"J"0$3;$AJGZ RT;^H CI
MD#=(ODZV)'Y%=.: 80^5^N.+Z4** S/EX2)D!PL#R;TN;3/Z% DP<](!G5Z0
M8P5)OAG0B^A,1_[%<8Q:$NP*<OP"P_>;Q6Z/I<"*0XE"/N>=XOUSAEK2X"[6
MW<E^%B+_#;:KC9J K/:G$=KP372@,SD&1%@;"/PW'(;D"1U$))V^M)W9B4-O
MKK*GV_9X>(ZIMDO2;E: J#UQ[_MF=[)SP JB,SGJ+ZY:K0$EBS**#(6LUZ.X
M4(=>_3#3JFWU"T7D D&8:%X:812_!*IY'OD70Y3FH+7<D.T3.H!R1KDH+C2J
MKWZ: 6&%HC"$QMA)!]KEP)9&DU"BU#C#B9Q*>U^"[PLLDK;IO(_87&6N2/'^
M=8Q:IR.!)-WO1>"$X;0S8(2'\9R(N68]$/6Y((ASP81!CJ3,3F7$YB+[J&GM
M^@ZZVJGEC/L$Y].P<"3)+V685G<5O;J,YS>A U&A(.!]](,.X+^1OB]0;]"!
M]&W13V8VG<KP/6Y8[=:U4 R"NYW23(&"A&4@X6@<'? $.??.:8!@#3$ECZ;X
M-7H&/KW0YQB@1-J*6)49WS5 3[U#\1B9:35CB.R@$V)Y:30V7KR\3W^#UE]R
M2$6[PL54UR%ST 24\=GW9)0IFL*GCG5=H$E/BH+.6*.)JR'\9 7:<!5"V+H!
MBCU5^4/[5EJZ[/2W+R&'%TYZ2$5>&635]M+X"DG=\,\9G1QWJ7YA.]*C4#37
M$"//^[G5X;FN5^%[+Y:S)ZVP7A?% B\=>ASSJW?&QF2BG$#X<!/,\4L]U!'H
MBV(10NA0L%L)1:[/,QAQ6QR%/2Y)&@QX*$ECE;IXY\QAK^L^A%]::2@2ZPBB
M7F:#GV1NX_%RSJQB936G_?W;P<Z**P8.RG_[.=>^N!0*8@FZW0?=VI\9\W=,
M"MC]0?+XQEA0T#.%N9KH,VOL+'?\&=Y_[G07N\0LP\<0-@,3-9H^T*^0U5^\
M_=;R6A*VHK_PXAT3/\,?QF/O'<W9\A]*.20Q)LAE(UOIP &,\U!=8D ,K.(Q
M=DBD1W%M^FBR[%Q[LL,YK]<RHCO,O7TS&&9734)&AIN-V&I1<GV6J:JN9X:+
M^^QSJRXOR?RRZAVK0X'OQ%A+-&JI:<6GZ "GJ[!A"M9J]4 &9]++'ST>G\<-
M. L_EM6:\#]?>-G%=TA=]BI; @MS]B**9RNM ,IMA^D4C[//7/+,,?,-4GE_
M[[.A_@$9X&22+O,;JBL74[ -;B?NE/O155]V4_;5"Y-:+_MEZI&K;"5O7U_V
MWKP5OQS^/*D;AKN[-*R;.M1O54WKHP-/HCE#^]:*.B*[XH["CP\HR[/$/==C
MXN'";79;A?9X!\B<JZA!MM3Y6-9Y+UZ-Z1R#*HY3$X[?/O+YQ:%"F3M9_M_N
MG^EXQW6U89#"A>VVZ#>IJ^_UC3-TMI@?_>[T]*%4U,NRNN,=<M<%OJZH_BBE
MB5,L<3F?7"7*:GY4!+P?5#K5?;I/$<OIYSY[LE[*+=8Q[(CAI1^YQ%([MRE4
MA TZO/%X@!&LPEI-@=>8W=<_W^364;C:J>Q2ZOCD[?U6F1!YQ3FM#;]',!/H
M9Y%GVVYG4FY6FYIX"KM]D2[=O!!WU<R0/ZQZ6B2(=,_XS)47#'S"FHD/+GOY
MK?9N=PO:]@<;W:H>-:-6Y3JLF'O<F[>VOW.0A>-]>'BK77'0],*3E,]V3+W:
M&@GO9RZ4/NWI?@Y5<) -,]W?T6;\776R3IBC*=\5O<%13P>*S2CY$]<'$;-"
M_G3@9AKI\OZZ/T_J:9.Q)<W6M"-JL?<GI L5G/(6_3V:Y5_8CAWN?/?+VM9>
M0X/)8[[&3)]@DV:'9UL61L<(8+<642,_NMW?MW,4[O_4PAXYV6I_PLOTO,;=
MN(.&)^TZ_;&K!]M;3@=R?B^U/U#]4,34,]?D?LP#%8ZY9!5_[B^_M"#Z%O)J
M$UK7/S645WQZ/#_?TZG.?7XZ56&Y5O5Y6DK\DBQCE[8,[@*Y:;<JPOM!84[Y
M*<U(0G)&,"[&SYL_JKPJ6C;ER'5)'I,[)DQT0("YY(H!P =>_%.3BKCG)5A(
M5+IL&JQ<G?M=A>&MI1J=2P\ZQ#,_S3<HM>J<'FPXB3_1JNRR:23JH2 6WG)X
MH:,=\:ZX4!U: 88E\<2-:\<;!0.R:&%@5T=D[3738T1++%CKE<'NBN[;.Q7F
M2U,.>.-3%TX'&(8R$F=DHBVS)] TQJ(@MV7X!.5BR(]8%)NV1:"+PE\2!(@F
MV!^(V4.8G5TH3:X8VE8B<##%#^R6')6,%$^\%]@/YJIIC HVNQAGVI&U),@T
M<\Q8SG/,#@TD?X<(3U<^>^HNJ!V_I]V]49/XV:<!1!F?S?/@,SVQD:9CGI3]
M-GTAWA4([J!L2Z+JS-& OALTL'7L 9.KP0+XC,5,=2H= %M;] ?,#!V(8S8=
M@U.8;,!"ZPP3.8[='09]$2@*\=^3$"&F/Y4;)S#8T2<"C@&= >@&Z&BN"0[:
MMG+IU&E0ZS,T,=\CBZQ/G"@2%5D^IY)+.\M+;HJD9E'\<F/(, JC39^\OS/M
MZ Y+VA3\^24$]CR&R"U(!_@OHS\CQ=)3V1%3Y^$4<V,Z4)&+%,RFYM(8LO5E
M5E5GMA?S0)0UQ6,194\VP@O6SAMB&+0#O4$PQ/RGVHA&(  LGEV-8.QXN4 T
M 4.,!F'9M@;DZ0".5:Z>-H Z]&7F"MA-/O,5\71IZ>.YO+N,J*A0"0@I!44'
M]MW^ R"DATK$MT?^=6-1BIH?>K3$S!#LML#5C$1",?%Y5MR%]KUW1?+-%6!)
M$[]%!\I+6E3[FTOH0!C8YO"^O*'?X=R@$_$/0-UR$)KB*SI0B6J)[[\&8L+/
M3'EP0C7QE:9K,I0()+F>03J''J5B7@N'?@>E86>Y.&LE\J"+H" ?1+5^:#>*
M!T;IA(&B+^^)MD:XH:/B>^X;YMY.EH-13/O)F2 >NJ<4-9/S 33X\581G[=B
M+\6 C%8QHKZF28NG"R$H;& ^QH!:'8FO$/-6" K[G^\[B.\_J=W@H@AFGZ,#
M59ZM>OT6_:#%MF(VSYU&(21E.]1K+5H7E!<)8T?3]G\!4V: BZQ(N0S=/ ']
M\STGV278@IEV;A1!8\_*DZ)6TN25S."7Z,"7>[Z9SUWVI)3 NC[2@;+A5M[^
MIKT0W4?@?=EIWS!\/91OR#_?FZ/=,3&Z*&+:(H:H\#P#,1:#_;58Z((ARC\O
MTE=;!=T_QK](2DXC7"7F(>:O@WN.46)OO62H+W5.B*?S[-U0V,.8X$ZLAK;B
M^ZWZ$3AK,3M<S^H.7M4$SQGWO?H8JLB%56;7/-;/A;%3:&KEP8Z5K]",9+K<
M&V^'M"LY--PG)96DA144WE;"3X<GD9&&4J B,.\1(S+8/AEQ[CT5[GM' $,?
M@[M>( )O^OER0$QS=4%0SH3LEU]X#4D?+R5<73H+]&NX;5SP0$VXT*5+*D^N
MV<$HWY&WF8MZNF2H\3J*$-)+$(I^'ML[M@=="<?[;.&"4401S[T#B=MLT?#E
M8R=(DCO03:Z"]EJ2!QTHW6G=[/_R T(.^7T:D#VT'7X81NDH0TRY5^\!OH$E
M.?303?B&T1IB7FF/QP+D0;>IO@E0@5$.5NWQ;"%64.3#'5-CQ(;;^ /?CPU-
MA8R&/N\JR\Y@CGHOD>0"K3MP;IN,\5^Q.9'&B\+B3[U5.(IRPVPZ&CZYL\9_
M88%VS@^^UD&)L,VWA&[P@CO(#S9[8O[[XU6^*[K[_W;QW?OW\W76?S\W+KMO
M>X\LN':&'2KJ5L9Y81)V",GGHIZZ,J7O^*SHPEB7O/VC5X0&K_SF!'8!>3V)
MA!-+FK*,"YS^EL0TMR#IIIO+K6MJ;G3@XYC^K1R%OAZ/Y!<FSSIN^$<5OWU_
M1T57JVWP@.P\,7TWVD1>^'E^3VC*9:,\J[8[58YU Y+F^A_OP:456.\M<(A(
M/NCY\?(R<]B2_Z1\RK3EDY**\"+7QB-QQ7/U*5?[F4??U=*ZZS58\(J?%4\?
M33I\AHW]A'<K<1>#%<]X9_M+.#P@\6K_I$OR2-9''I,@I5VF*-%6R<_/6)7N
M8V2ID^J. -3JBB[DC,VRW<D?(C=-R;:A$T>KZ]SEVDU*-S+30C-\RB^NO&@4
M.TK6CCY9^S+9W,_>6N!*L'Z(/FS ,=P*/72WZL?/&TL"UI6<HBG?-FYG4?MG
M5N:>FY<>"Q#3>9_Y2,<FTII8%#*]0; ,/>90]7AI2<CCU&ST/'9.8073$6\C
M$8RN./M#%O PE^#)YPP2;(HSM?XT$ P_4+@;-ZJ7#QWQ])1P/IIPNH.[5:2M
M,/-D)6MG 7?-R7'=+<W_Z4BCQY^G)+E8\>U-D$,!X=B0E5X;&[,,U^'=NUFG
M"W>T9$H%7*??76=\L*GZZ)ON/FOOY^H/OX>1U2GG>T]):6HO3E-O.C]8E&HN
M^+;X:FOSX(/>M;?F2<_&'\7:>YQ8_B;+.-?9\QA^B"MBH/7!!UO70S]_&M@[
M^I8H/S\NL+1D;5_S\[JVGMT(JS[ZWJT#6J&>>?9,AAFE-0QO1&/[\_XXO_G/
M@1QN/!SCAN8J:8#C)5O]!:I/X]XC'&*CJAU0,F<C/_E..QTVOYI8=NS"K\TS
M<@V52UPX)6N/U @DV%?YV2D'AM)H=TY#P(9"M*PKO8YXU9R4;BYC4Z"D;U>&
M*:=5839YP$H)-EW:L0S$R,Q-3U(4.)*3P$R/*A)0C-QD/J$=L9M:(AW$&/K=
M!B1[E?X6; =08FH4^FYW"'K^.%BG9F&T8Y567=#-S(?2/_$?-%,+E*[9_<"4
MJS\3H=VI<Z*=!PN<*S,UA7(>LRG0#]T AT1>&WD/"*G7R[1TNBZ2$HC^\R3Y
M<(4KO&S]64)WQV!%@Z,1I8(&SN1WWX!%-R7*"E_H B<)[AEFH<5)^74S827@
M9I*-S4XD-5'[(F;S\ _$!CAT\5Y&K\1A0>#QZCL8Q7@$,;7/'H?^'M&AV![6
M8>ZPY/:+F?I"^_*$6I$D'3@*NJX&5B(=.4]2'#A+_RG^=@0XG#T#%03O*%BD
M9)1D8 BJ^!N(+F]#<'I"4_:^?"OUC#F,^.IO -[ 4,QLNNZC-O'L(YVEFVG;
M:G87=L^@[W@*0DA(9S1)9.],8QKA"#X(T15T_C>]@7.YO R% G_VZ4T]1+5Z
M=Z0QBW3]JD])U@PUD@)7:/W&B3B_GRT<I47.HD9[AS:EG_0DO3H%I8!#:(M%
M@2K8KWI:B3$C/:6;?$EVEYXVIB-^JK>!)5WU8,3>?P!!C ;+UBVDL#J,VQGZ
M6W^1@,MCT*4"/)>33GLG<JC %'Y-?85QQA[D$0<!$A@I8C3(.X4*5?<DO=:&
M_GFK[VZ-$FD7S1/RD@R1@UXS?U]2D$9C79P)1Q$_!/]%%(&>>CNI";(%G_T7
MVT\(R ;9X'+4:>\H\\TOVU+;+D=\T=3VPVRJ!H#H'(P]GM^_&8V[!.'1^>1(
M!UB9HT]E9$8QU L[OQQ7.9B?]A* 74Q__9WK GHUELF<FD\Q6,D->>Y-X.[3
M#I*)41.[9IBVDGX ,"H4R5;@' A?D]*G!2D:?=>X\N6[;DG?Z(+/.MNB#BO.
MO3$RXV=KKHO?E<++-\XIYS- 7LLDP*02S'S,2<6.<;NT(T-7RL9HD![:X:WC
MS0FGP6FAH5SWK['V;WU";O7JWD_3WZ:0RQ!'= 6=,Z,!V;]=6: /D%TDU0=&
M97#.[*1!MR&[OU"[^_IT>5S= ZMXWYZ12-A26DN>&[%7H/5=-H;HNJ60C5H@
M)!QNF,9\$X%/7<DKG!-WJC>R%5Y**,\5"L1L.<^$]N&9:<'::B"X&(90[B(K
M@O7 9>3B1$SY@LA-J/A;- K$S*_I %P246Q$"VY>0U#BVZA96"X*,0!L,8S%
M4&(WQ)D(PB0=<6&P6R\C::JV28X!N:W"GN&GV+N=+&K(:A'Y'OYLUE$R;/E9
MR7>E@'<\)H!OU@AZ'C'\M2X Z:9VZ2U+[5F>"Y;N6^--_VZSSK_;U["VTX82
M;7#(66AJY.BE',^!*JO'*+XMD;)KS8AY%D5;YC&X94+6"[Y -/%E)59/N?G@
MEC\:X96>.KB\J^[X[&(O]5%HO?WC6;DSB 8Z4!*_M;41;.;8:<@G?8W$UX_*
MO$GP[#A-*0Z"C.J H*DG\BD:IPDVZM@^ O(9='-ZNH1RL ;$"6H#+H%O<RIS
M1I<$!+DG1FS/E^MI*]1*&0I9,-=(#.:C_PK97';T%0^5#+[AE^BN_T6HSZ;1
MG*C!$=M?0=6O0O9^?JB!^0=5_FA2.X@$R]?\K0*<E9+W#IO7+")W9VS_/I9>
M6<%L0I=G(3>1%%+D.%AT)%_]CU&MEY,E>))0VQM<_Q=+S!>D3NG9)3$/@SM-
MY_8.E&;\O_8P?!G<Q"AE\MZOZAZ@_R'9Z!^A'W8T$.\&JPBM4>]_"DS6*N00
M8J&Y&4X4>[!W@+(L$_GG*DCLSB(6NG06Z$"'J.<_A:M.CU# H+%&QFC70PX*
M!8]Y*JNMMC&O"1ZF#F<'MGJ%"H$5!],&WQX%ASN3H;]D'M&^^5LFS0'ZOS9?
M_W^PXY_Y-7+%J!S1!6;HBQ OZ.8\!!S?9I^K_[N+SO_<W7_NJ/^GO?<,:W)9
M&X6#"@A21 'ID2(H"%@HHD!0!$2$T'L1$2%4$>DE*@+2!044A2B]A4COA!X!
M%>E2 Z%)3T @0,KWL-9^]U+7/M?[GGV^[SOE.C_F@B1W>V;F;O/,W*-<#=[9
M8*W>+T;"^RM9F:!?!]7;\.\S):2_2!&^)8>UG4+6)E-LBB!UD(48\U]9+7C!
MB7CX-A#F7^/P_F>7_/=+"O^+;<S_LA/TOO>0@/*>U=Q91=G:!ZO[^D8!_'BV
MK/-O$R[KUP/^_\=WBW\J)JZA16J/E=EU&K(P))!!>36 ^ATS^:\C[_\;=TA^
MMP>@I)4C<RTM%A4-D+XB)?1"C$_B7^G>/S3\VD\:/O1?UG#*_Y"^_O_2(<WX
MTL6XK8U"-0?FM;<7*BXHQJ]\JYI-U($SBI-_6I,OO]F).33[64S"G!S5KZ=V
M@9%GJ]QYJIY5;P!ETU7ZH2)AT8>R[)CUBJ(RU&6#UT&-8"W(A0U@WTI=@HSW
M_25_Y1);MN'K=E=A0G0APF*2B8F::V4FJE00[0EB-):)"K)#/4O^T'FGKK]P
M2#T$UB0ZVPJ-RW05)$G,V!#%.%%3J%!X>?#[20B3LS%/0PPN[L""S[IFCE4F
M(49GXO#GYF.9CZ;2OL?W>ZB 7;3VC!?DX.7]<)HUF=>2Y4=2V9TJ_*NK:<5>
MT$8+&(^%%/-7ND'N1YNP3:%'6?IP&LM3T]U1TXT)$-))\]1EK?2.W(*@]\C$
M([=$UO&9(M$J(QZ5WS4Z;"I>^D]$ 0(S-A#6PC_%Y08JX8L0N&K7#+XQ<]6'
M\>-B?1TIUX(>HX!8[HF[8Y(-!]JN.XKGEDH% @=A6_+NF(L&2P7XOKSK/]5&
MJZXC1?!VR!JC8#GU@8RI=";%(22KWSU82GNVS4F6 [K\0212@?M-E_)M ^&'
M1RB%N_V0<LA*"[A9^EGX5'AX,)<3G"/P^J[68DHV B:6S%R?Q.N]-O[19O90
M?!F(VT\$UR!*?H+BQ<5AUH:76BZNPAJX'6N6A_!I@7D\JY.B0>?NA:]S;")6
MS/!B.,X0 D'Y2N") 1DK:#NGO^"'P3K>PD1AW1++%Q_N'J]RI=6TUKOA=O^J
M*&ZU4DEBZP Q*CM0A\@T4A'B[N<PU3:PBNL[N_9-IN+#K&6C*=\Y#1_=\7Z6
M5(G>8##I8:^R2* ^,7P2*0%M.$84=;9P)NL87765V5"_NYXN&'7LD6T)'2O2
M;W[Y,6&HR1I"3KI-H(1..;."'+W/^$AE92P01+RW2AJ/Z'04&W*<I/]"TS0?
M;TVS)T+2)FBTD"].T<ZVISHHS6-0G$LCE%*EWEJH.U=<X $A+A!C.^NGPRT>
ML64)%>'6%SD47?WNB ?J#^PTH.8V@W/Z;-C1SI+'IW*BO.KIL,W6$H2G#?PE
M47H$CJ%P%[L4?AX&CE2>.^N"]TX7[@DSC1J^-<:TL8YHM:"9Z^@GJ2".45A-
M9;1+G560LVWZJ*\_UTP:8570[[VXR$/>FX**:;BZ*)U+Q-(]P"Q^D]:B@OHD
M!FW"*<S$C&FQY<=[4DU32DZC+2-ACQ[R/[#2P9V_:-'"\?399W87Q@Y1>TL)
M4GWW+4X/Q,U ">*+ (*$5GUM UXC(I!IJ^]PTE#K5U7VTIAW:U?92P[432>P
M:-Q<^FN%P@@'*85$!UIYX-"1#32$\&?P*>E:O#'*U16&ZH+Q%VX;;W-Z6 I]
MB@>]^5HK-7O0A_Y ?>W/E0?B;FY(LY""OY:?+M(I=_68TIRNKRT.&]5/$$N:
M7=&1NN5\I%H\_$E0^^6A')/$19M2RNM :1Y)9X.2JM1RD^,J'WDNPA4-M.*2
MTU\9J:P6-L[+T/2U$)R;*CGCQS5PV@K(F5 W#M(D?9)MPNT);&V8R?R[F'H)
M\>ZMQT2?W!&;L1%B2?,<+U=PSX.>B^=CE2C6.-"7@T=9LR>AAXZW6U Z:F0+
M[X]B</S:+L>A ?+EII.,JX/;WA0W[[ML_#.O]$([\]HLAB#VXV"SRMH8+[)Q
M3U%P3UV[G6 2[*2/NGZ5/<1!KXS0K=#XCB44XBA-UU'@)!>5UUXQXC 2C V2
M*/2X.H-A>AK3RLV.;+9]?JZ;O]W5*M 9/QL>)^/.-&YUJF#ILI/3Y:"Q[F(I
M>06CF*O<3"K=EQ;IK26>$.27"5-(>HVZNGY%K7SSX701XT_%&L(68Y?-KO+F
M'M8J3N@<"ST9G<35U-A*X"S'SV.L)?&K.;G$#</8N8.<B5Y'8,=&6X)DD9_<
M7W-/"NB,)H=[,!4D'8;*T"PF@P44>4416ZG2IA6#(LZ^JU.1#(F'OI9UL+Z*
MG=5[Y& =7K7)70EIAQ[12O=]H]M;;F%UE^AEBFURO7PFXK%M6>GSC)<>"1Z)
MMF]#K$VFL$^L#Q-B<UQDL"><_!_UE5E8*7-Q&QYZPFT7]8#S:M,+Z,E\/%<U
MYI-$9<B6?\^[KX%Z6<PW22VH;W"'+S/9W_M63ABL0I.+EBKYYD-M A^YC@<Z
MXO.Q8Z9F3A4UB9NI))Z@E3KYPTBG]9L]]I5'6;CYCE8KZ)]/$[?HCE&F[9NJ
M3)ENN^SB87E4R.Z<X :C#BM_79Y=X _&QC2)IP3I92*\\N'HN(!/]9YZ2;+_
MX[K7>K:5>RY#O2Z,U?>DI9/HU&D.I2F$=6TY5N!SPJ4HGW.MB1GZ<=":LB<C
M.[B*6*^$]B.R$:^%=U1B1\[7'IHI5OAR^N!(6?V=+HM*OV6IC-K'H@GCF1&5
MIQ/DSPC-#YB90:MDYWS\$\>36\&<R/J6YBPDP^& '3#9:4F9W5<*&@YG)BE,
M=:PJ#_OD#&MP# QZSG]17\CL6*JYMD(<XL@'@H'K!(>]0?BN:.T'S9LEVER#
MWF%A(;[A!O042#85U) OC),T !.H( AYTPB,O#8NL6 D#N]LF/[\(/G!DN\+
M(Q 5U-H,WUO,4!8=**:"!!FHH+7\=#+S=7_CSD3(K(T'7^^J-9S="3 Z']7_
M@!,?A'P_!41404;T2[IIB?D9T!V3L8CY9,_K1)39/$74![P]<)TB.?AX?[VA
MF[QI-E^O*J9GH1XC/6/SX-07JRX?BM1@3.G!?,LT$R)ZA'V.$%;%L+]P!<":
M#F$)RU008!&^ABKL#>:'[N,(IP4-9T]<&/(#@,J'R)M4T& NMCT%3P6]JO_S
M8V'%FFZ]2ZX>16U;R&]^/*5[VC60=>?(.!P+)SM%U+GC6. X#R 3"XK#%R8O
MZ,G[#]@"8;;07KQ ;]!P4: GC@]XNGMK%"#"7C*$3J/96'=B (.VC_W1K9PI
ME=:93XEU7Y(1Z YBPJ4R3E&=GA2&@JRA*>4^<.8&\;I2T>2B,7<?EZL!@HM0
MO )% R\[L]*;,-'KO/<,B<3!YA.?B#A>,-TU]HVFXZD78U"3EDDH-ESJ?_I"
M9WZ $PX,$)RR"_]^H&CH_"3_1=V>']EE_:L-0WX"C=WDG@^V%TFF"R^LE(*M
M],6/>^@L>*T&R5C Y K9]=3NZ?Y4^I5&ZZ^0.,\9O,[\!D^Y4_1K 5C#(OB,
MF#UE&?'1:.2G>D./I'I^+2-+H_[3,I#:3X'8(^G]7S>25PKVI)W!Y3ZA),&I
M-U;^?>I?R\AN2@;&83CY>[4Q[+DQC&DL CKU'W\4\4")8O#PNH-[:B098CP^
M7@9[T-377U.].#N88@#G>_3^F]DH;'U";3ZN=L'&3D\%?,4)7%*W.[3BB@-'
MUB1E.7A-(1V:NJ?,?J@>]_O$WU_+N5=[\\GYH13$EACY%0IR%QMJC@IQV\R5
M'4!85/4C5V]'9(P>R;SQ#)BT1]?7;TRG[!YZ3B,RR1CC]AXNX9(;V/,*WS+/
MU2U0YZD"/D7IQ'ZHPY8FKS 0KN!$4E;2LNQQ]ZJTY3H/<XN4AEF@% M>- F[
M.&/>HQ3([^'WX'R^0UNM R1M_#S.T(:%!,MS/#]Z77JE[J/7D0-IELV<+;8]
MSSFMJIO4#]T>PFZVD*!$L_1 FZ_(][5I 5=&-97[LITO/ZR5<LE>$=&!,,4^
M#3XD%AR>]2B)=^1FFM3B<>.YFZM2"WD61?F?X1+>@YA4T@%RO*(2WF?KKGM(
M2M98VJD^V<-2=H-2RL[NY6^B(ZXMNWZLO:$7]@6D\-G/(1H^F48%L9 $I^/"
ME"7PY/&MQU/=AVV4VE817LC%$\SWN8TDTRO&S[.Q26$3/>J.Y@A'_K!-#^X-
M9ANURUE*8R4D)I"*L4Y?M5P]*ROP;X^O,A1%-<*9%?5PTL<L?%_@(%%GZZX&
M9=W23@M-%TO.,;6DV1X#IY@9RM-25A_0W;]6N^S?UWGNF^.>T[?.!^%J=&-9
MPR*X:O>!SL$-?^4KN/!E D%T'H,]NHD*%Y# K[[(";S>ARR4_59W-4?;0_9%
MRT$+9-O[F &S:&A, I.;KF<'1R\1O14T^(,*"H4SUT'PTVV0;Y>'6N;+7"]8
M:8LD=.O&\GJZ?;76X#US]^$=38/$VX=1GNFY.YX?@T$D00)KR](:+Q'1[M^.
M*"!VMYN_--F-VY*M;;)S*59YKLHDOOSE6J;=68Q(VEO/1?__[*4+BQ;.+32H
MZ+L<9/@K.7L18U3<3]N 3W-J\>"MF2&DOG_6?5^B4]%B3V[)GU*0.3;JS'D4
M65&<[\1\MD".:+RX.[' (VO,N/J$N?9NY['AID;4G8%@05^?ZP1V?PY* 7-1
M[A;2W_:YG/!CU>,B<3'%16QXR^AE%P>ZFD->\4:)(1),3UBNLM/,0HX$GUA,
M8R!<UO0F:#DX9&N[\K=J'/ 30Z?,AHW-'.YOO^"?[/(095J(9O9-UB8$1[@6
M+,@+K>E4,]UY)2&U?-Z@!>2?!PYU^M,<6#NF\2',"-M1F9&FTXQ;4>'T%%]6
M DH+)=)07U5!#,4-A/D)T0)>J17>Q;C4G%=3$#_\VJ@D-N?:!*@.LKY)/P,+
MGUI9H(*2<R&BA?<&UC:H(' E>!O?KUUH ^2H*Q@R67;M]!UT:A"&55:J?310
MH5Z8HKQ"!8EF@\.&,!3K_7\+10?+0:R[7OO W(.;?' ,N9M,=AHP:*."+N]%
MS&61LC<"+S2(42"2?R"&;L]3;"31HD5!F^,WP#N'+0%C/4@%\3Q;JDF"S AZ
M >;4@N2L!N7>/YTR!I4%SSI<#^9THJ?8N*)%<T>GU-/ALUM#ZT[S.O5Y@,#'
M>5%[).RT'N29K(H&Z581X ,WX#%.>=/P>1S /8.$6I.7!8?R/#%7D*_ ^L%#
MT77BQD2U/,!MY)A3M"U3J:!GLJHNDXORU^W]/V$G!'[,$3@+7@"$KZ#W"9N+
MFV)WB TXOUPJ2&+ORUN20'\<"3U"T::PMQ/E\RJ!_^%820I'5^6S3?==A@DX
M=@MXF B25D'<3J3UGY]Z]#% =PYL'_^LNF,SX:6-MS.$;!PM WR\!>E,^&1V
M+GQ.T($*"D0334Y31 <!O_X<N4:F@MP)N6]:=S$0@FP]%81>H<CF9[V"_T4G
M9S(V'SXG_">FH2M>W@BRP58*4+4A2<2[LSM#?G ">(UA?\ACA&3=B<+")U7A
M,8ZY<Y"-+0B109$(GX'[?4,\-B\&KQ\K^1.SB@C'X[!-Q;*MJ\G^F2',E\#B
MTML&2DK=_@11@G4%X#RET7A!='MM=QB60V#"L'>S*RQ!S$4U0.+N>TCS?-_7
MK;65MKB6N0LM'9<CM?)O?L$.J3IQG%M,+W-=]*]'D.!8@ ]B%U10?K/[S=+:
M_FJA"H=WP]&MYM]JF3.:8T@A]TB05P7E/_G&7^N@_>0%BP8D_F/'(#N-]^^T
M_K,R-A\"_1.Z)FW8,AG7+L(J!3E/:G&NOP'9O9WOK<Q]Q_JR''K"=^@&/NO3
MB7LF7]_U!7=6^-3<7T]G@^T&=DG<4)^S.UN*^O1M,MK>V09*3)U>V R8+ERT
M^99R>BBXS4^&T]JK/9DKH#XJA&X\X=F*B<<%MKFDSG#+('J<-/-"P]E>K/8
M4FTEI.;&UNHGCLYS7DPTW+PO^018% X9R\?5N7I,=M3)/8==6(PJ<(K(^7@G
M\?CR=[OX3XCSO,6S/P2 "4P?E1-39Y)I,_P]0W?0RVR>P)G!WSL^S'IZY U6
MTI9)4&PV3"WQQD/=S >-M'QBH4#<Q6/N"VG>OAR$7"WUFHH1-^I+"3K_WM$-
M L21?BX?C[JQ=3RZP""2V,5F/8$N:W\LD&H']\I<3/*N'#%PVEHZ\^C3U\?5
M/M=+DJY]](EI/'#IBV]!"F*%(7/8J3O'PC&E/<.#?ZKD>1/?57UH!:_,;"8W
ML_+7\ST6'HUTC\YUQY#,W/$AZ@-N7O;2GH59]5^J[9WGZR[[I3YZ]3Z4O>&
MH.U1FU<?N.:J(&$3,@3$$Q+WU(;WMK<_<PHLB:Y76["4IR-'4Z)Z1VMFC,N
MGSTUYP4FW1E;]B75;JJU7X9\;'5W=5HMV;BBS&]279+KU-1S][-/:=U?Q>3
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M9#G7J13C*JT.>4MN[]><;G#?K'A>^I@686X%=Y+X*&27E8B@@NB3P20C,+[
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MBC6E )R$OG/E6&-\8$D!'-'@;KWK.Y>?&3/9 &)NVW]^#OR ]F#[5]/!-AN
M@/0DRI&XL,7IQ?"<V9GBD$+GYR-:R L- 2\DV8]O,BVOV\3@0/B2/G\AG.UD
M0[RE,*;"UR,,<^]>T5<3X=J3V:'K#QBY:=;[S3_P4@#L-6M55]"'&1W"G1EZ
M;%HU4:P+677I?KU;C.\:603QX8)\MX#_M5YUH7PXV!+[9?"HTU82D<10?4Y6
MR/4R&Q#@8^APK55/8#$6RAY#D'R(%B3M01I3.9<%[SWT/"48M5TC&2VF<Z3<
M;ZM+ZM%^+@6X6Q/#Y8RF0ZW3+NZU3$0@\EBJV#)7B.>)1<Y-->R5::!>0:FO
M,4\0%8D$\U:E%$'L3E.G=ZM@Z&OG!,O\=\==XK^QFM19L*-@S6CL91#30BJ=
MO,S3\L33F?D6SI9!?5"C2RQ/3G0Q/Q\+;@$"K+3]-4 D[NJS,]=),NY89'/Y
MQ,EXL52C7BNG%ZO\M\%X^%P-FBEP0D0(0SX(SYUA+TJ?7'A!\/HZ;..XR=&W
M.\[#6)4&RL\/O2K0D==V(R4.9Q]! 1C FZAU%B??^<9)3KAGK;[G8<& EF&3
MP^'[0I#>>A=<PNK1&5C,4T39Z02$PXP+Y"+,I:3;19']U7'U,XP/T2@@L/3M
M >#108V#V<BG) CQMA.849/#_PQV.SJYB'0.%UV1HZM1GBITH-J#3(KZ8EY!
M[H:6:;2U3J["7 P^)+8%>UJ?;32&Y>=^&EXK5):G667]<, B2$,_ZW2!K 7-
MDJ&_%-7'(SCPTRT-OX82PQDV:&,J^VGKV0&% .Y /%/,F RY\SZXS*$YE8_$
MM_^F7F 1HWFLO]9_4+663VHF0 /_-)V=N:&MYLQ,$.3B C*1S$8>4DSEUCRZ
M;,,4VZ2TIYB?Z:2?-R941=-EKG9&53#3C^A)\#8F<(DW^W@88#855.23-$24
MV#0^+Q'/H&W*:+9I/.EISXFGG4B&)O.A4:Y/ZR4"^RD D_QPK322(.CX8L8@
M^<0N/GLI[A-G-"A78>L4M!P=>HP@-A/S1 G/QRLS3?PH3RP2T15!I!2A+B/J
M1H(T7V14N8:*R"7,@(.VH(<,<CJSA"^.WV-X\Y4O\DS[@>I$0"(C')#(6<.G
M*?H) I[<O4,K3MY^IC2.6>.&LD%NP9<8>PS-QU1-T"-!PMIG]%-:W[#[7:;M
MT6,WOBBW>G%*FOLU/E.^P5*RIBY*4K,UCOHLNV2H-SBE_P9#1JQ\2,E0'TV_
MZ8%N9TMS("-<,LA$FQOX[YIY-QAE7XH#78JY%-%4S_ >1P$>GS:9P7A4'21J
M/3JCZ!!I_F4K1,LS#=2-?IQ:6H^:!@^SS)0GS_H=G=Z'F/I%&5SJG4_XK.H,
M7#_@Q^'6FTP\Z']VD&1 5"<TM4V(.BFX\A$26UTT&V?<-O?CE3_]\38E*)%8
MVB+"W4MR2)MP'&G)F%A,<+1+&?\X>FR'D>?$P^DZN<81A9S8K.&66[F6.L<>
MC? TZF2FT09I MBVE;[9MS)#M.L-2IK"=W!7$ZO' QX_TS=65ES9EZHCM&$A
M+;Z3;<B'FD?Z/&SWC,/D!\-,D_5HZ4K3D64DU%9.V<&E:Z'GZ3D").@VT'@8
M;KXY66AZL@7,1K@RW0$O&+0<E"FZU6\7=^W(\]<O=PM\'[X9S%A(+5F/J@<3
MP%,VX?$=!1..$Z*QY@,C!W:EXZ@U9HEFIGX>*],DPTI2**U%83&Q[+&N/O<'
MKV0)-'UJ.]4V-FCX+1P@>%_^4B]![J0 _)K'ES3YL4+P32U<%K7R5%0^NG9=
M.D>JXO9KLN!7(;PA#I^*A7S8\^Q*X)FK<YN]BCN0?>=N0QN,2W,&PKS/N3'8
M&Q6Q> X,AE'SR=_$FQ@(=VCK<?Q6*^64+G1=YOV9%[. ;>V.U7X<R7/&F-X?
M5E+19]I+ 2[CY"V[GA]>4:]!Q3 R#@TN@.,S4>+Q932[B[-6B"B$B()KB-G.
M) LH=(L"L,)X-YWY#ETJ["P%RFYZ&)T<;(8.#[8E3CZ!.%E%&+)]BVA1]>=T
MDJY$9,D^?Z8AM76P-1<E8CG+GP;JTA#"^Q%>4P,!80L\N2@B0-53RK(AEF1I
M]'8:.W7CPJ>SU;)P9(DF'7R]=9+CU+:P0<L$DPC+TVS:KHGKP5W+8Y7";+ZM
M'Q;/769WI)N;'$%?P>VC.I-34K$;'3,R0<53<)2P,B<>>2;F9206V.;9' A;
M:<,)3N+-L6UA0GJQQ//JM]B+$\\G^+PK/;0V'+O? \UD.*]R+/9F]T6  )Z1
M:8IYFDH/<4)PD72QN<%9N.*$F:(C%F6\[^E?8*QK N_B.TU3\9=QY&"B IQY
MK;%5J/LPW/4&@O-C>@WMBX0'G;R^M^F@:35\&A)#&A)T4UM]Y-/^+OO99![X
MI!7AP007%O_(7C^R3^JS0)A8"4EE0:I3W0JK3%@G,PL5$$YW7-OTY_,^I2F*
MV<IK6VMNU[QZ;UC\ -JH-GNKV.H"P7P:R@:O,,=I)F=:C<+V2@[@]W7N) G3
MB*, #XQ7S_!("_W90A.==$[NFQ*'@9/.$FFTX?^#]KS:M.<< [?)_ZP=/>(I
MCYJ&"@:>6 H4P;4^SQXY:BC;<R S7_FE:*R.E7,;/P3^]>O#<R*+SY=U=(M\
MP"W@IY8[CZR,DPS?&1 4+-0C)(;UCJULA,^_.PZ)<S-'B)#.(YW,3!>]F@R)
MU@M]MRLKSS&4M5>])(V!DQXF GNZQS%13?WF'9NDN[CLCI'%YV-.&&^.)OF-
M)1\M'DQK@TD*8SV$V2L9%].BY+L_'AX0>S%Q3K22SQM9/9[:00&N"2PPJ6^>
M QO3@K02+:<#V0GA.\TI/$XH*50=.M0[U.G0F: S*V?NZU86+P4Q2V3\KS2.
M>12=QJ+C?QP,>G':*F5-"8)G%+:R_^8[HEC?"&0DBRGAAH/ DDIQ>2VSS$.^
MA$D.!6&KJ^_+:DJ>(T<8GJTU70*TRG9FL6D@4^.G$R*N'%#'U;P/PN/)[\<[
MJL\!3ZL5 Z1DK#"U;,56EC E=R??A)<6(Y>Z(EO"Q*ZFD >^]?G3#V9C^WM4
M&V5:LK/\,N^+N$I^=(R83>?GX?)G'MA.>H4$ZU;T-69/=#@Y'.+VCK!5 ECG
M>X,T$A'"!,OS,!Y\=N[HV%VKQX_FKHZ]N7W8=R;'"LQ**&TJ-I5BT]6-B\Q*
M,XM,66WSW=10FC(HCZ'WC4Z^X^9;X67Z^L8!E^<G^!WVO(LZP*$CY:G3$!Y'
M3(IUN'/BXRC&X5''\'%<<GV80!J+#;B*X#?;S11!]).B2U\LK3TXR'E2]%(8
M?21>'.V+J:G!&E* L)$]'X_\L@?3E[JN?!I3IM/,S':CFPI9"\,G@XQO^4W#
MVM-ESWOL2HK>E8NQ99")".19NK^,J8Y_G7U]2=4SF=@E;W[T6-QUQ;76L\]\
MYH+47%D(R$9?^UR^T#*=\DCY$W-GG75?GE=N.)[?"7,F0WKD?2R9/%GL?+G?
MCSQ]J3>TW J;YZ\'P4L;$[V?H"I7IOI<A^^D&E6\TW2(D[LHJ-"6>P,3BL2J
M-?<-6185/3:%>9<O[:7DGVIXV^YSAUE'!P2$ WM*^K@3R44&IQ0K[G>X'3S@
M:'JN4T3GW$U5LVP?F48(W;(-%TZG5*PSI"XZ05Z_ A;VXOI])4W?(+<O@T67
M:;2Y_W>:?N)9'0D@\_YV)EUOK.-6&L,I!F N$G11E;HMR0B_R6VB#?R[YI/:
M8GQXDG"EV9*;]_695_?NS4?I[O4(LN6GYA<;&8_07>_=6K#OET_R?F'U^+$/
MNZ]RN_)\R!IL4*'[X"+Y2/_6\G)[9*S%[B/(A<,N=XY7'LLLQ3*&E1$NF>UI
M%YJ\,/J24N=(UVZ[GZ&@5TNLB5)MG6FP[K1]9FED,^O+&B:UW[=WK4YN-K3*
M&W;XT&*YUUY(?TE1[88*;WNQW.:;^>/;2)TOFCP$NZ;8,6.'['.E76OKQXNM
MYI8TX^Y!PNH/1Q@E?I#WNU;V>N<CAY$ =::/GC*1FB=[/#M252>-JQ^N3H6+
MEKF+PM1*A#H0WN%OW_H'X'BZPO+$DJ-"0M,='*2;-\:[46"8BXAQ_GJGGPG6
MZ/%=P0[BZ<F5PD=R'.<?9:8A4RB H^N(W%3,RFJ1DX@0KN5%RZEG0A$6F66;
MW"?N^^Q]8?0K]+^$\6CWEY6^:5"SKV6D7_Z):'=Z5,<*;+EP!&>?G4>X0+;:
M"3;N7\V%>3F*-JJQ/[Q>[3!1X,]'B)M*C9E@>H]S",G@4[UL7_%(/WWH8]D&
ML")55X/%)R,<-+);LDQ'C?1?*-KP[R4"N]V-8-YM0P.C 7L<] GD7>S%$/1
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M/S$SBETGZJM8W'Z7M="^)&!\&9;0XW\^GW1H</):W^/!P,-5SX3V57167U.
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MP"_R6/"ELKPSKPKZ[_-^]\8$.]HXN050QPD@&JMESAJ>QIV[?GB>).7Z-W?
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M>>]9FP>0F]T/YS;FYHSI1B[U?3JQ\?7Y)YWA[O:JQLU%F_6?#'!0@'_2[',
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M.7P]FT("[=(N07Y8X')F+([(1WSW)I"ZFMA9(/X=")GM6+YAQKV:,+)]H);
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M6F+@XTDE[07PBPT@?S9H ^VFP,59_ =&=N"A%65N*FQ-"1^_[HZ&^ZF$ZM^
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MF'\03*48?M8R$ZQ0J5?MC!69JND<ERD9U?I2S;<\3^1[Z3MY%V^$4#X5_D2
M<HXAY7KS)-'?D(''\$)$TYAGX9:XRP\+==D;C5J2?O)=RHKAJ9ZJ/"[P%:I@
M[?,6J*O^RU.>%.1M,[3=JDT,8W^))FFB=+SR-QC5W>JXS4LB-:.,709DUSI6
M8,SYB9U<%MCO+,L"2(D9)?<29\3)PGG9T%3;XNC/D1ND;*6?3[EFI\$<D,?)
MK&Y@UB/:ESB +%3P.T9HYF@HE3OT4HW*5Q*D=9K[$ %R+G)HB#?M02<W#NA6
M^=5!!AM/S'(8[,O>9[#$Z+QG2=W.RDW:R0[0D4\UHWT;JRO]8NUG5]?PCBJ(
M'1T)@\9WBF!NG[^RCX&+U11MYPDA"I(6#1/?EDPY1,BZ."3$L$M&$&Q-Y<Q"
MG4%-YSA@U^=,#>.!L.D[=WKP#:/40M37R9*!A?UB'YA0&6=_K$4SUD03-A#:
MO)?'=?[RW<4K4F"GI8?H#DO:*(XG,Z2@W3WH0JA]D!S1>N@.MV?TZ6Q:Z'<0
M9?#-LWO861 IEDN]6%^EL"S6 Z-=-<CX(D:/+<7]+;*I,?V)5\HZ[;X!62HZ
M#9]+GT#LQ$F"U9":L3XO\+U*)[_9MFN#M0(+BL;R-I7K/;Z$/3$F7X<Z;70O
M+#\.S 7QV&?#2"&@_<H>7=:,^E3FUMO@^8./U[,-'A-_)[QY4^PAL_RX=?KA
M\9[4V8U>Y!EL/TI)H&P;B;X_WGLZEE=!,PI65FKW<7AH["?V-0)06..FMI@
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M45R=LAIYL_GX^+2NK^WJ)))]RN$E41#JB+T1/#NT6KHTLOF.2^=XI>V3=K7
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MS%\Q\<2:$*05#$A ^BL$_@@)&-$D=^&]0XCY3! !( '+^6O*E[>M8$M//4G
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M7:\I\M)S#KMVD^:_P6<?_U\.:M+(_P!02P,$%     @ 6(=_5H_;C0]23@
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M*&Z=\G8[/E=5';'F=XO7[T:B?,^*A+W_)!4/YRAQ7$ 2[1FB0>6;8(XR2Q>
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MH%/K9<O6,C;HL^^P(3T_IT?NP'T#6^YKR\Y)EG?QUE&L1H/>AE!L04$DP'X
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M?S2L!*]*]DSEL+W&4%;N0S%!I33V:3D6SNH6_4E;X*K# -94*SS=#5$1WC+
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MBJ?W$!<Q7XD.1ZG&IC)XD2M@/!&$PY" I=MJMMER@ TEQ%/JM\,9!Z-CZ*S
MN."/IGW'R-+J_.^GO[WUH^OQ1.7\/F:+R?J$H;_RDHOQ?V&/RA%F?K>_Q4^>
MC'ZH-@EH8C[_SE!36PUMV2R\W_6VE2_93_A!82&MKO !X)-Q2JQ4JL'%GZ@T
MHH@SS(-N6(94=+A?=!$UO^40TWM:F?X(*7LUB9J])Q9FA:TN=%&ICDYQ+ZZ2
M\M'X:,]4?%%%+I$_>YE2OKWN"65H_S8 ,LYLB#U:IJW.LG[4./0E:;K?*LIM
MJ]Y3H4<^XRJ#7->UIUPW/Q%1RU=/E6FC.A#N2'>6"0-X3>Q/8>M2M(1X!'<X
M_WU:G@>^#Y@!UPEU\GYTS'XH<T1'?"7AZC;I/O,HKI($U.G=FD[,*C -^'Y(
M<XJ8V/S!-K QM"1,?WY8/N:H6MX5LU<+YTOK*7:UQ+@0.GN;C$C ,Z*Q'X0P
M<FPVTA282N@B@_X$";", ^L15V!'9% J@0Y T72;L,$G)* 91J@]@F[=^PT3
MCU7P5*LRE\A]PL1/^)?2\1%\GL,0 L]8V=H&8C:.2( =%AJ/E@@9%"X9/Z.@
M%^QI6GNERN8O$YLF;YYHE,*B_//G7/L\?J!\V?'C\(_\CN2*GQ5-1^L3GO(_
M.8UP]R:(+P1Q*V0B(CB=A-@?)$. *%[BL&*5D8PN.W>@Q^NPW01R@+E:DN.+
M#.[^Z62%]S\J C$3*F K*2XP#">$P"[E;P>U#YP\^CKKKSS"I3+;:GPS)AO6
MR^NV_(+0^PJV8B:(UB$:H=F)VB,D@ EV+J^9V 0^"M_/-5I2_7AJG<=L6FA?
MM/S$;0EVS%69?G(03@*N<>:9V_".[B2WOM"1?R)UGLA.:-ZQA/[)K>,79>B+
MFP.[XH(MX9GX*&]LW'+<\9G#A1,B&9!O*N$LE>X\O,9VYK>I;D%P^#]JQCN4
MOGVB,0<FOG;;484B2_8(D.R>ZO3>0SGGS$C<_CJH ;SX80&]@081<"!"35G-
MUI(G5L1]UG0\_71#YTSRUTYJ3$U9-0(N!5O[0GX*(%BSE=I=?+0K'G'PWC_V
M*@$)E>GFVNHC2L(ZV]-QB-&)EX0"-Q*@#B+LP5H:CI QHV8*TW[N]8SKVD^A
MK.11UO;^//Y\&8*;#83%MQAJ<AYOG%"\),_PV\8\PC/.79/%% GJL1*+6."M
M_43-G^>_K+PKD"$M'XL_6LY;[_7N]3<F >\<D ,X&FO8>F[)[N^KQOG#WV#4
M?07KAH1;7+YB,BA(#KTTO1T;H@)A.@\+7?$U!Q^EP)#0C\>3"[X$ETM628J)
M^&R825A -TZ,!'1?J"(!904PC"76HVF6D%BV&+YT\5O](J$0NB0Z,MV$"X&M
MN)(C7*9?]#NZ#!\Y@5T^5IC.+T1#FQ7"M'L%9B!8DTC".O[,/Z7V#0IJUK<O
M3:4_+WZFTJEV>RDET#\^E^UB*?:%(?I'&+_0EV/]60&YSML3-:G;*-U+VF\O
M)$WQ_7+\W@_\<GLW0A2QU,O!ANP:C)0]"Q]$LL_-W*?VX^0#RWF5?_"0P%_N
M AOH"9^<FBGP#CSC:_'(7;(C.(^0-&SGQ:1%<UY8M1?T-/@8=-T,+G-J?;HW
M"3&\(\/3=[99X1;/Q].V_&F+]J"' 6[O:K#MGHX>YVH&X6)PQHOO FX,/)/$
M)*&+/4:X0/#74UGG+DD&VD87%%T!M1,$V_A^3#LT& EO^+H;=PWM/&",4WA]
MK+4R _\Z]>SX<4OA\&QJIUU=9D*.8A^/JKQT8&:%9 "G8+H@_@""6S=<ZR1'
M!SOQA(/BXE\:E8C+ 9>:_&'[0^#=+SK[G7"$[V=P@QCKTG# ;D^J?L*ND=MF
MW <&L<P/-!H+!'_8+H.#!HM('&'IFL"R)S$3?*2]5R!.+QK7%7<4<:2-!MV&
M_:,3LY[&@3PK-D/#8[)P';A%#N8P@7]V8__>./ ?>>U_5#>@?F]$/900?&%M
M\Y)_&W&/^ S8U#+8- D2UZ)7WW#.8/%3H\EL+YW;8KWN1?OE.64_:GZ KXOR
MT?W,&AN.3U[-*T_[M%5:TUGNS\W/]N4*?YN_-=AO'S\IZV#RD*.*ZG1$,B W
M+>\ZMQMUT OBV&@2>.=XI00O/\"A\RJ8STZR,W--E7<K-#:<A\SF.0^DY(G$
M:1B\<-HO A/L<=?H=O"=5MXSE:$OHNT2WIYJ_DY;*7!J2.I@LIBKV6;XLO![
M;8G*U+1KS5.];-9OGG<_A"@]O3'X2$TI5SMOXVM VKC\#X[ZRQ<CA),>Z@HG
M= M/2")X&C2JE3%'@FX5'_%#\A!:C1[T;L^=D,>=O0$U7:I;70,N;N#IDLS4
M7M^&-M#/GGKK)PHA5UDWKK$-:7( AG^=*!:A52XD(,HEAP1,FH /[L+1,0&?
M<8YQV*H4BQU"8?J)B"6V _%D2?"8LQ-_#_P>3UZ4^ ,2T"K8=0D%*R.O*7[C
M/18\T4E$$;TQ;_#=VX$I6+MT9A?PX0:(&"2A7Z$FU_GZ#_"$]H[!(F1,87X&
M1 YU[A7._XR.7M WQ,OD+@:LR0_X!N)  >K20IY=S^3- !&3!B*T($*3PVPA
M_5H 63I3=Y" ./ ;V.XD;*<]H!/* FN60RP/( 5Q&$'RC;PF_BL,TO@AVN.P
MV H2X'.2<A"Y#XL21*.=B+N'2FA>!.Y3$_3CR'L2T-BY=BP (W>TEK=.LP,B
MWL"D'PZ:-9J%K,/VN,D;<VE(XV93YWFL^(NLY?V%V/0LAI]-ES[Y*Z =P>N<
M9+64F5*70K9$X_]D:<0[X> 0%*(+]16VJT@"VA *^S%-Z)/A>]7S8,O;Q'O@
MPI:F%<)[V$H\&4\G1A$X*7\5Z)/ 'O">3@EL:Q-*2/IK6)O,S_P/4-8W_DPB
MP/W\?E2G>KU?U;[6"D]V)W-L3&S- ^W\4NA-[/TZI["R2L9&Q[5[WYKV-<8D
MO[8E#*P*2534Y4NNO)T9N&QPQ<MZS+$9J2>^H:0=95#E>U!KR;_&QES5GU_:
MLY9QWD+WH.^>I[U(?,<L_LQK[/T^KS)7>5?N+4F^F$4=D]*=%9VA+^+LKLQ?
M,Y@R9(]CGW04^]8O8N*6&1&5]WN5&D+,9_U.\5!P6EAH&>_-1"P<!3-<Y]=T
M 47:<"@K5SM95IM+.S@+2?+J+\7,O(_.YW^?] !@RE.U3<5H* T>2G27N'N+
M.=5&KD^IZ>@OR3+=7D;0XV,UM-9"3?PNN'.YL\;?E=72O^L,P65FDU$M;AL-
M&R!/=Y.FH%,4T2^/L"=^6XP27$'6:VHCQ&..@#29X]7THZX"L0QZX@ W?A^"
M6[FGWF!E=>0R@LO,R47,>N90JDE#&O7R=(\0XNX!AOMD&6$$Y#7_&"(!#9?>
MXV"'9*QJ$*.:>1 B<P$\ES<GV*(N#OF] RL2D!]'&,(7WCXVJSW8>OA776?+
M__6 VEA#X_F<"$/Z>R.XHF.C_ S*S-I@CY*<L(]#]C?",I_$4O!TV79I+,??
M&[IVA@\O4EV)-LEM="AQC9]M;HQ6,9/RXBBVW7M?M5P3!*C.=0_<33#QE@DE
M =/59GK2%1>L%(?G9VZ>K:%EK%5.D$;J_V3*?B6$[===/KLT)CEA:$7E S39
M[VL6Q/L/?^Q8K.U7WR@I-K\XBNE[Z2'MOKR?^ZJG?AFR*]M_[4C-@(X;W"*A
M=T??&<Z?4XM(6WU9%'/CJH,NHT[-#*OPAU'.Z&51#?/NRTJ#ONPMZ:@P7]<%
M79QAP]['A1^LQZXJE]T+/UXU=@+LQ]_S_4KUQD!%#>"I.SK#5L=/)?QZ$'X)
M=*M4M6?%9^]EHX7CZ[KY@WHVG_ (O!) !@FE]#"^GA.VC2O5TR8DDEF-FO:J
MZQP'A1%.?(+H&_=CZ'^+<7]M)\Z!!M'J+I<5+7'6D/8);"T:CF[\#5G)Y$5Q
MF 1LB_^OH37Z1]#![*7_A*R)6*>[<$_F#>$6>??SOV U$G?^T?D8C)$$=,')
MNGHB&WP"E%PAVA3A=5]4X'K"45_6$1<RAG>N4]]0.%3"9BT[G%J6>B;VG7N$
M'+942KBG9,!5_7< =XP,N'V5KU='D-P?@K]B>%9.[IO-+$R9(O;; AV;R!(_
MQ [6F=<&/MH&8Y!-RV7=3Q>.><:.81MBQV=\<&U-T'?B,(??J"+K<<K^0J1R
MN17$Y6?&_;*RVC*],A5L.0D0Y(+](@%&_X6"KAT8:@:^" RR'C+6*'$MEF<*
MC3P";1=!CY%@!9OS9,K;93-"K&,X*L2="5\LV(R+&PB\$AA=\/N"5.4L?58Q
M&RDM]MAY554MIRC?6?MZQ39$GD6;%BY65O#>."$Z<43#5H4K^W.*6CV1-W6I
MD\"X1IX=LE/(=1+PVA'K10)N'). []TD %MWR"?11>SLA:WS"6*I85V'B"H%
MF9-3Z40:F?W_TGRK'#405"E#MW$GST7YPGB?>4U<G\_*X>6'>L\XS/28$'1A
MZ95?M.22O3G2%V-?'+]68 <YV51FUU]61G"914&JPUJ%;<U]NHLX#*W7?M^T
M/Y9N5-=]KKL86Z(1?T[XX[G(RXSV#RC/0FX.\&S8P#+]A48//$]ABUH'"F?F
M9]PTQZ35XBXA:<?LY*]$'\<.2UL).PFO"4<>7A%_GS*H)^+'DH-"M$WG_((7
MJDW?O1);[^:5-]?R[?:0U4UA ^U5K1D*'TK*YV\S?E$)>=PYW TU0V^!IP6X
M1]DUW^I'@V&7KNH\%?+I[&]^=9/^\>*R7YE59M'GA)Y70N=BTV^_FEY)6+NM
M,*D$T72T@&ZG'TQ[XC;COL%&7!"[A>6:5X/_JXV;$C$%WJA<.!H3LL3G'8T\
M(Q(L_@;#W*Q+D*."2W_CF-![_M_),_']$HKIQ^<FV^&/D&H2 !7$M02I%S+>
M;Q;<S<%E81L+2( ]"<@=@2V87$2<O"$!<X(]V66)CTZ>F>%$"<JIQ).L?W1?
M;*C9\1>V[T&6BZ%KM[TV1W>%B"FZ)"# N-* PO!^1,JTH4=7POL+RHEWQ!X]
MUJ%F4Y@1VKHWI .Z4(52B9!L$M* >S%LTI1I[L_=&BH6,*_8NZO+_FY+!-WJ
M\=T4+-MME%Z&5YCP=B/H:.=\I[*VAJ;6BE[SM'NOI9EE)QPP%^[3^V:">BW.
M/3-(S?1HB2NK<*8WO_W1LQ)3Y-ZF3HG:REZ)K7? %\S:ZM]_C][6W\EL%%K"
M6\X*<%;&M3$4Y'_QGLR4-97M[&42.I;GYIUI?V9L0,U^4S'FPR^FFX/GP/U9
M.*4)/)%,E> >D4 !QJWL& \^VG'^WV<]WL=T1#H3^3;2')K?PUSS:  2D"1_
M5!:SM;T[HT+4S4TF ;9D/3DD/]&AA$NF)S_VI6!D/+X *8J/RR/R$*]#PC\F
MG/%O^0@)_4US@-:@SG$_;#HWH*]+?D'"%3.ENP3MH^*D?H/-[0GH/A:V._W?
MXF95+;4C*AWG""<#YP/M:/B@_C)FX[@#'#VQTQ<HA%TF:JO[$!&Y)&"P+R"/
M$6_2!"TX^&BZ?QR8>Y'#$!H80'%DAF=7OF1?@0W[V?_P>%OA%9W:_1<3,PN.
MOQU%MY* P/%_#SH#4K:(,! !9TF&3KGN,Y@T^PYH<EWP[(E9[D0JWIQ,A*/
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MA]OD _?2-D$'T6.&.-R]&=P.>:-5^3MX8W*JCV:(6$]4UO_7"\I^0#@"VTD
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MIP]!9C9YS%K3JJ5KOG?JRW63@(]#X WN+O3Y^Z/;4Z\J_/C3'7,O9!(](1$
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M*%64+3SNT,K9:D39V7%QJP'=>%5Z=L.HYX+?\<D-A[?E=9$:ET0"5^FB=_N
M0)Q&@/H24PR(>T?\D,'[9N!3Y7.IS]DAZ4*UR/#8J26^"K_=XZ&?-<Q6?JW4
MCZH, _JO7?PT+SD(JX@M7&JR6$1E=*D(?!T/,!^_=_/H4_0S3=E7S^[U:H1_
MU.-:#EJZNS]QY=8 5>$@5'@#KXR>Q:BA\[M2$ P!!HL9I&A(J_E.?YB+^%$,
MSQ'-D7_#4YHYN_.2\32>5=ZD:/+TT<1E\#19)X@"+XE^K85*"=EKU,M=GZ,=
M]MHQ!U%;: EP/2T5^.[O_NLGJN$VJ<3H:CCYPJ,8(#!"(V 6!3I>1)X$NP7H
MX-(6X&SH?AUD9QIE/MSIC+5$</ZNSL*%UIA?O=$_;$1V*L]%?JM6[/2)1K@A
MZ-$*%F,[MDBM*+=#!%-;SNS6B]E/30WFCF-G;QR0VJ?O%?E_ $6%8%'FM]*J
M*I\_-SN@/V$\UT$,>]@G*#1[!_X*<NV-1*+^6(!.CH7JF.EXZ2H!R$X4*&J'
MIP:_EV#Y0E7F)!F.0!I*AD$95/@VYSA',IN2V]0;PPS&JKK+Q-FX.5>G0_9Y
M;6L_W'^QYYO]\,/-9\](#E=9@E\#:N2\:CP;#L _6?6_%:**>,AX4UB$=B$X
M3M=<F.P]4J@=QHC5'Y;C)@!,T,#F88,1U^?%'[B$XK[7U7@D"EXD]?["S_]Z
M(G5912QHN)D,?17>'+.D%X7>>SR8AZ)HG=C8G[G2%&U0GA<?KVT(7>7<?*84
MC?VPZ#8)LT3!X[ T.>CYEOJ2.7I>:=1<5E'KOO(U678F;C/97!X='>K>V%6_
M9?A[T*3/DGP-$K<VIDQ59HU.F%[ X2-<Y"8DKS=S-1:ZN7V:04Q,/ 0M\#<!
M0<7FLQK^+A3M6E+?.>)I.)2TJ<XB_?EDLJ4+;<%7^=^Z3R/A/^:GH L9D573
M&5$#<\0S6Q,=X%^,2\*R+P6R+8:$?LHK.7>UZOJ'VW=B*_:BLZ13J'!9 UA'
M7#)6:PGGLVP0Y8)56&)'6:"[U&$,T EK _KXB>W*V'V+A[' :<!"7S3V-::2
MY$R ],L"Z8T@X]EXV6+!$6F7RU"RZ\<J2:?+2_!)9^L*E&O%0B!3J_D,B,YB
M"1XFQ^VL9/'A#5W>)\5QHR2! X5P['#8I36AR*@VZ-?0JH52NVFKP8"K2W3B
M]]70H^3F_'0]LT^QPK;1O7SJETE'WR2R+0LA= $<:^O:Q2>>D:N-9"CV-@3+
M\[0=/;6/LU..4Y_&/LA\I]/Z^FM.,]*0C&0PF#N,JBHHP!%!CH6 VIDH!0N1
MB,X:V(5M_)660G1:5^=BABYBJ'F:/_OR077E8[9PZO:'':O5[A_EBJ&3<&,D
M^,WS]T<&H;R7QO#<^7'*6GY+!E3K8@3@Z8CX;*^C@@HDM5162AA\R=5']-R$
M+,G9W1\L3]Y2%18,35';)1A'RB;?<?,RY&R2]A__AB!%V(-8-N<O-'-]7YZG
M=29K>6$;%B[QO$G&O,XY=,AEI3FD<EJI9NYV0H[%A"C;]'YL8>?)ML^"Y'EG
M$+N7A3[L'E?-ZV;:&2A:K_5$3TG;32CUWIY8?E;"W$B+2^PSO1,B0%DL24:F
M,R*A<5C)A:;[]T+;VIO%%<1S)]];*-B1,TD\D!BX%1_3;I_9DX?66C)XA1=$
M9[2;VT7YNQ1O\3*,J+057'VY6U[G\-/$+*5LJ%?W E;7P @J&C0.I0H(1)$M
MEW;%*8MG65M! Q21H['YB_8MS%"GU_<.RL1'2!5VJZ.^\^-3:0]N,AT[H:L6
MF$@#=(8.7?@?9%BAYM\\=V-V3C&M45&W=,HV2M6_UZKHN7_G>/BKI$UPOV(F
MTY!7)%BVMZ#91OC> OU;F>",NP9KEGE1*%!;D#0J/PK+Z<QOY33'82%3U")7
MQWRI+OH[XQB_\ZIQ8O3RQ?$U[WPDNPE*  ^.6B0 K087?2^TO"BM"17?>=YD
MEA/I[5#U\ 1^WN_G0#";#G?P8@9ZWQ\:#JJ8CSJ$3<ETO"@->RUW$[*0GN&_
M6.ZS*"YT8E#<XO)X\#;RXR_?G2M3_4^USS_347)7!671%F29W'I)U4OU:$=[
M@[NLB[KMTL[#&VNO3\?76/N_[44H$( JQNR"+3:\6,VX:Z.=' ]_1[WU2XG2
MG><O-P=NCY?Z<[71MM/?,W^OH_B8+#&U>*E_LLWL*^Y=E,&"&^NL[Q2FTSRT
MT#-O8K+J;/:S@:]8=E-8?PS^ATW\K<H[]"Z7$GD\2$XDLC"J:"I==(TC<FS-
M.E22T[+C5U?^^VFAR[IEVS:>E#-4STK7G> =B,GQU@Q.+SING-T:=-BM])*S
MD7NFLX^YIS[9Q4KI<"OU+)5L?B'R)V,&P<V [WWC$2PGBK_=FJYF2$7 ?'VL
M_&Z4CP !>/Q>G>M]6[+2#W]=*L7NV8\KJ<=.0 <2_EH63.X+T4/.A>6IY3N8
M6]*XV-MPK5Z.H62A7\DH[!%*\+0P-E*E8/G?%%_7" PW5CYJL2KL5:-^ML:R
MBTB;<?-H:9JY:A_+^/T>V?>3P2UO"XY)FWHC@7T"\!)<,1\&MH>&1"U &2K[
M\]/2B@LEA&BOQ/^*3Q,"F))T+RWO=M:M"7XIA=D&T@X?F[H%ZY5LBF=^$C]$
M[,@SXXIM% /G?5P]W(>:JA$W5>CP8V!V]D5(6Q^=^M AXJ)O J:UOC]2\BB.
MU<GS]I*2_EV'ZH3PCAZK\.Q8[1X2?2!0#0D[AGY%VRXK!MB4H+O:8><:S64)
MP'::E5[[_=L:,>D+?2S,[>&%=4EZ\G0\V?$_7^! BSRA,:B,=ACS<G-]H)[%
M4,GAAY)IMT0NB\:RLD9[=^F/*\O!T SHA2!%K"8Z9HE(TU^8E@<NEI(TRBP4
M;S&H=%G5A4_&Z!F&]5&RD%[E#$^5]U[ARU,Y(-EK%L.5-_,[+ENA[L8LP!AG
M JX/!SQ)I\-H[,+YG.*N->J9N08D1>>G_)*B37N]3*\IH\H#CB( CP)EVJ?2
MJQCRVR59'8+.C1ZM8PT\%Y7D:YSY"R*&[-_*M#]A;L@[..>2]7-Q@&3( M]M
MS1W6$5/6#"_XN;>L-,^EX\S7^=AO]ZG&Q^2UU?ZDBOAYH5(_WAJ,8X!Q)8HW
MYPS:UL^PR<L5MG2EJ\U?*\T\E;LA;?9']<'74['"<TH^'RN\IJ[WF57@RO%"
M3BZ??1]_;U'A3%MBZ(JI,B"?[1(LO.%8+)?[>0:7IZA<(912WB("<9]2;5$&
M?* ,B,?Z[(LYX][506(C>\HWZ@-_IN5MR&S4OZB*]KQJF994<^%'=\X;>P_5
MA>3BBJ!.E8MI;3<8([UV3!X.8BD"%ZAS2,7[G3U9W!MW]I?[2*]IJE@FQEN[
M(\>/1] A2PPVWU*LKR(%7^?XWF_GZLQ>C%@;/C)SE>0?$5O^E/N!7RIDG\ZB
M/D0,&KV6*8/6.JY'%R\YSX><O9FC0%;%A00)SEAV+9Z&5HFE)!=55^A3-ZBQ
MS2"2<]Y_?\I)[MH!O !AI8X_*+0SA>+YZU&A=3ZV"WK.#RK[>):K'[1_L>#V
M2OSYX$UO6;YG.\BFFH8#@$"6"<!DU.));".%_^(#6248C=K-0_-*A3F.5S=5
M-L<-PW^)=L_) 7?RT>&*Y*_?.J_")Q./D]%M\  ^M/,B@ZC!8.,C%+?YEU&O
M\=%&@^(9 ;J\Z7D.JM0E>9]/N1Z1Q:V?+PLE4+D@#X[[46M=(.8'&T&DR+M1
M+ AD6-^2Z,31IUOZ/7ZLL[/Q%>&=:4],:VLL=;6YZ2[:D[Z\*:J*>Z^LQI ?
MCE@40,\2[62>WTRUV) ?-YIM>RB[8F=ZD!5+/7IGH0A_%'R]>_VN1\!-S(4-
M<U@\K 0];(4"1:1U<OE$PZN*"Q8B]B3$LJ74Z+2XR!\<7Y0RJDW7*095K.T\
MA#G,LVZ,I5\<NF3%-MXF/Y4?#N>UD\QW2JPS&;ZU8#N@(:-X$[BKXK0/CYVO
MG&M IAR/?&EH&+6O0:LM]O$.WT7=N77K44T]@CW!XF[/L&)UA(\W4^PAR9%6
M%)Y+,@;KMA@(-1DQM[K0MCL^X/#X\FI?P;/+=4D'!WYZC9]M2"94=&YW74;2
M'3\9Q .;+U9W/Y58;<84J%%$ZRF?4U^9:CU0=OHE %5Q&3_OFGZG@:%.V7,?
MOGV*L0K0(2H1,$<<ZR0X',_GK"(SE(G$IQ19<Y3N\(_M9-=^C=2Y=N=9YV?U
M2OI7M+%5<\Z@:D@'C-$WS )IE[T I86UNMLL?:)J198VPY\=7U#)=7&7GF&7
MHC*&7F'L:_CR0_'2>9*-.7%<O%T]*BY";IXLP!!EWR:L; 2>JIJ54;MVLVFT
MQ1#NSI[&S>WWD:1N8%_U>G<IC_VQSH!708 MR]SEL5450:0MXE69??T'^T\N
M2V:J'[L7*G[,>;+9=0O8LRYET((=P6QQ4Z^[$#0[[G#?T(..H1G9^M&9^ G'
M%\;RIGE>53WB J%:+F^%5/7JC!)-L4R8(-^H+M"YIR%Q;=-I&21.-WZ<R;)[
M)W.]2_$NBD65;N_CWIO["=YNX],UOS8I\%85V WPP3 XSHE9!<WKHB.6$#2.
M08)#XI5P9L>S^Q;OJXS<7,67DAJ[WW=VRIG Q J\#)D"-K<(0+E/*%9M$1Z1
M*EN/+V5142H?+'&[$JU1/_E\/>%ZM)FE;2OI=$7/]0X_O:!I,$L6FAMYL*0_
M'JRL8)/C^Q4UY7++?ZOKRV!)DK'F>$(76:6;;+K=^)1--,7<I-QF,P=2LO,Y
MKL@+Q#+GVSQWL,C3E^[RO&"7C-'D6 2>,J+(:!%=++G'S0U0O0D:R/AJWP$-
M#P*C:L*P5VU],M'LG2]RR[(*9J?0J<RY.GSO&[<^;%O/[_"Z/WAYE27=XFOV
MA1;6/:Z3;?NL33!K%1/'1CI_\Z"X5^ M<<B#09OAYY@"N(2A2+*9J_A*,NM;
MO@AF#LH5Y%WG]1?")*RW"@" "F <J?RW^.F>O23FAF(TH(ORY=NO+JRMK9-J
MC'U\(-^>=@W-T?^#:>ZZDKZWR0\G:\HXX_'LD;Q1+[98SI 1^2N#F9'NG#%/
M#(V_?!/8^3D[L],'/-[*8"\]I)O5*).MF];^FFHA$W@QTEPOYW6_5/C90H$(
M-]C7!G@XJM0?HY/MQ#855)I],V1O"M_GC7"":+.4W.'A)OMQ:F\J ER^IS[H
M-SJB<G[C1=/H\-P<U-)\ECW90GR]G#OL=;=C)\LUCP\+/)D)JGW6E6A_1X:0
MV:;1HU^YXCLC/CXI"H)25UI4BPJF#87U"XIN!<=_Q"V_93"@]PUE8G$8V#SW
MU.3MVT&QXLO1KT^@;IIDG-:9J*G*.8<ES&XA'M7A.4>%O!+VLL35Y>F5]">U
M[W3[GAF_)141B<FDI]#@5!3B%$BT(G^KI3 ? \*M4K[D/JX%KU7"3B:R=Y[!
M^AT(P%ZYSK$H['21'8<4QK BL,@H/)H%0#B_QOMK$8# 2)5Q*NQQ'![#DO&X
MA@"D,\/F2>/*+0A /S5B+UB5[O_C[OH&9*VH6JOOF:U7FW+IER3V>" G->/Y
MO_.S)]QBY[1[K&/3(R18&=3A1@"4^0A ,P7H7\.^9/_7&%I3"\2'@P1@_G'B
MMBD!.&B5Q"P8_6M@DJ!_&AU8QG2Z \(=7U7Y/[]'4F,O]Z2';2,7APL+HK@6
M680/R5@V >'/D7\4T;YF 73%?>1:^%/;R$/USU/3)2?5QS5L6UZ"&TDLX:N:
M8MGQ(2(Z3\D^TAZFYOI_=IR*F2T=G0TI'>TK=JU)=3"9N] EW&YK0):?"_@1
M@-A&FV)'E2MU>N)JX@O#B\.K^N#OFC=>6UK)2M1=^O+-D-WN6E]B?(='\3*,
MR^F&GGQ*B9J?EWN>1O&/UNOG'!<:(P=)VUR_W5KS$P]?;?D)'-LA=]^=L%54
M?[ ;GJJXV9@W2W?KAT<'HW1.@@Y_J1@O[]".*>K1\--%BS')Y_S!+'>["@.8
MWF,^#E#Q(Z>7I%"!N[DV/A>13N?*TWI]DVRT]UE$WNH]84YL)$N^WLTZJR\5
MXL'O=_/MDQ'Y,ZM/N:M],VQOU;V\*ON5W8L:IS79_4F2ORW8YYIGTF:XN9T>
MUA*W0 L]>'Q, #+TXC KL!B+SR]% IL0:T/+^%/0LK7%(GBR?['K%;N!%7OK
M_<DH!JX]U1K2)<BDC:=BNF^S(Z./MIXK^-HZ]45(V: JKT3&5Z+H.QRT'=)Z
M74;QIOJ&=2HJL,C5Y7 C8%J@_T/&+$)Q<[Y=NX0 G,=W@Z@#K):=X:R;UM1U
MB9"ZYCCCE)[FNM#9/:.DY/5OB=2-RY6D&(^V2XF)&;Z?7RK7X%FT7C9F@;!\
MP]N\(BKR71E"V% %5XS!6?_]3QF>N%0Q%7)?.CW4;16^:F0CRIG9>3Q(4"].
M13WFUJ\9BW[Y84$5AW<2,RX<W<"!=:X&X&?W 0GZ9JZL HH<;CUAULIT5E"Y
M-!R6<7G?K8P^U-$O\=?LFLY^M;'K CWM+ZPXYA+V,A(:<[C'MMY,75<^]OQ[
MG=OS_91QP;E.'9,WGZGI.X63:LI%BE@^7GPFM7MH2!6R!?JJU>KBUL)[$9F#
MIV\(TT%NU.)[G96VHOS3U)0J?D:Y7RR6Z*'CZ7WPNNLBO=<< UII(2.L?J>L
M?!%!2P!LYLT=XGV]R5QJM7C>>%06GM/'^"9H/9Z8T;N8:!VC ?CN;:\B;57(
MT%H/*C[F%2XQP,R;4)05!1.340[V];7OJOFCRX7#T\Z1&LP*U15;7\-EJ/#X
MGC%=5(>C-?5UP5Q5:<Z?S7(HMZ<HV";X5._;#<:D^:\IRFVQ&%(E^N8?^Z+=
ME\%H75@5EFM<O7ULS+3^_?D;-*;]/I-FWK7[<^)KSGEC%ST['J,MCG711@L;
MG]/N( ,W9_)*;<O2TC[=^K5D)KG#IO'*QT_P\8_/CC*)H;/=USE.;@B3]52!
M)_<6=TL#_6#@D#*(4=UX8ONO,^X/-NGB&C;:[:CNKY31[V*,B]Z64%(KREEH
MXU+Q%QU YYZ@TC\M?KKU_8'?6L-^UHBK:8^$X+V*.]6OW*X\>=:73).8\.+C
M>+F1*B\_/*@71A>@MP"C\U7!M$+Z%N<9;B,=QPPW%:X5M:(/+K_-^?:=>\'5
MC(XL\@CC-_1S3OC2EU0./L/XSO@"$\-K .<""63]OWA M*:G\8$2X+UXO)QK
M)%#XMWJ@OYJ/U@N3YO^KHNPZG#Z6??M J$&XZZ!8UI!$@X586%=28Q/]0>V_
MFKB\#J!EQ3RM3CITE:)Y43?AY]SC\34^N_7)MD]Y,\G&UN%4*-?@TDWSZCJ)
ME'PG9_B,@;N8>4(G2M1QQZ;JLADCX*;@P(QL:7G*F-NW(-JDD79OH'3ON06W
MOJG\D.S&#H^\JU[@_O9C>A&!F)/SC*N.JJ!&\I?^5:QM 9<;QNR0WZ>WN&P<
MX8Z2B>P?N+-[Y8MEKGGHG=M>J%WLG@$H&Q0[.K42;,AP7PSV,VD*BMXWXX\0
MN/WY94U)1!,1U0-JT ,4]2)Y__IKG!L%6;JRU@9BZ"B^^9%]\T34];&IL*9)
MFN(:!E%J:UHBW#)2L)V\<M?IHV7N5Z4IT5]NZ*=FL'5+*):: &P9$0"&*$D<
M'5$I!X-P3OO@:B3HX  )6W''^3-AYU^K?/C<;$< 0CM2\"$=!.!;'+[J!;B5
M*5H!R@:N4FZZP7/]07@S)F4> 1OFF#P;.Y2Y(\CW.5?7)W$?MN)HP*Y9\NZR
M.+1PTQB2$O 0C?!!?I*M2;P;9F2QI[!;=RM-/M#S$P'(]8-CY641A^+Y>'+8
M4?%F@:UOHX:<Z3N)C%0"()->;1O2-O)\4[?/#[RODO:Y^0G1G$ZB.95_F@-"
M3@P1@('J##0S 1@K)=)F]_F#/13TEPVN_!4>UD( X@]G6=<(  V>?R[ $+ER
M]M6LY6'Y3%5MQ(>/'_GD/;M.4&B(F2=E.?]KAMD2T;CZA^+]93ZTR'+=,N;:
M6D4=1UMGO+AD^]'Z78[PPDYSE7H"D-2G*\J^_6(/1^X"1K(0 )1Q8)P5 <B,
MR<>39N!%&OO+B%$UTQ%W2 !.98HGM?!!DEW8F*+_V,;$E?I((%RLPD)W6=&=
M6\+OL*<L4F[3)"E?T_ @ (%YFH:E?L?/ZB6 )P"C?#C6?407=%IW;P'>KM=/
M!P[)&@WJ9[E'E]0@M3L77%[CV"D36[4VC]QOR#ACMB&NS $!:#?^SGWKO/N[
M*NL[2[Z1[MY/,7F1: L\+\23 -P2@Z%Y8>A(XOY3B-0),*'5LM?P&?U$:6N$
MRPK%N_U>-K!9[@SF<^1:  @.11>WF@O6K%I,PQP?M/BMK*9]/^"'3*?+Q$S\
M%(6RS\\164:S!=9YX.[F^H;YIL7GHL<8S!@!./D.B^'XIPO?L:V_&N^7!GYA
M7(/AN7H(&&FP_%%,Y:N6>=C;QH^]S6.S6$M')TF%IX44'V8F4+*PV1I:  E4
MYI/PFZB3EU4&YYW&#1Y=29UR\F9V'(][]D.@YO;[GE^:I&]7PMQ?0<BO]ANI
M\MPM7&;@UA@M.?P^C5YH;IA>O:6F.#,-$:"7^'6JN23MRRGWG@"P!@CQE*Y^
M=WY&+2[P8#6P-+K\(2WJ0,((;]N+C>GO=8]9RB#;LKX\NIL3\S2K8I2_XA4J
MU5MZNK3J>V\IJ"=4 AY]OL'B8]43,RP?HJ'<02Y\6Y"-R]PQU:/%780F4B9>
MK"3+3#KGJH;XVR><E\M5>7-M"\TW!1?,?R:>GO>[QZ)(BU&WN8E^-#Q6"B%#
M;GT[FW_M%6,B4650[5"6:7[+UD[IJ]G'+$-^Y;>W$FL_?GQ>MNEP^_NKGXA=
MJ?MGAN3O3*#;1-=*KP&=G"(ZX_YV_U+<R 16,8Q_,0.;_T4 N&)_==R;,S4K
M(Z'65O%\$>A >L2*C$=O+6?"5A[78SN$L))N/+"!#J_3R%/P41P#-@$+_H$B
M )4;,%'B':8^$JV%9Z^)1:S_KJVH<@.]\4D-Q3!&<\0"*_%U6TE9Q#_"Y>N=
M0A?Q]K/O3+UBWB;WSLXYA]K%Z*AX>K@?P>.P_JC$3G/)F*HM.OV@324+_XVE
M"#JR*C9-( @@@0:^_#;R0V!9/]<V4+_\_::O<.=]_?GRXQA69!A6,HZ'>*S;
MB*:!%P-\]_"AW/ ?D I\V1(L'1QWR@LY:PG#ZP2!?@7.:P1<)@!TRUVPPVNS
M08^;OZ%=Q,[67AXJ8::+(\IVQ9-U!&2NS70A*!MGO"$0$HH;"7=WIZ#8.'6*
M#T-=^JW,3KUGT]B?S9$H6'B0R.BA)(OEE-GFA2[2-R*Y/9U&.CB=,F<\&R@<
MMBX$QATZ(^^TM6/A$ITF+2-91KT?/UKHRC=:59Y4@]6RVFH_:@B/1F<["IP=
MG8(T!Z&*L-8V%!..G @^S3$@Y!>L.@%04R0R\&Q+$(IM/^Z,JOB$^"A!@0"8
M2D'[05W8N&R',J7%T8[.AL6<^J;ZVF1/?M(Y9\9K-QD"DC#.6"=45RL!B*P/
M2EG,.#^WX7U^0\I2F;HE^.UWZ>3OI"]$\"9GS1?D<J._;]A=BS(J2-29.CL9
MFX_8OU[;>'&59JMW)^M$CO54BHCY]BAG?)B+^KX!7C .[0R.@AXJ.8$28"A9
MF-,0'H*&??B%\^#Y<-:O$70'UF:&-2< 6=.&V$0"$ &O0#QF J'CEC)>5NVH
M=W#US17[N!7Z,>OP[TREW_L84+NK_]RP:QBNHIWG:,#,E;"J?68768Q+SS@8
M6R9"F0)Z\&_WXSE>R05%B,D- G#3%;QW (NYH20744,C*#28^QA\7Y7M3]51
M.XJ.XL;>3FEMG>/XH:9N:>"YVAAK<R#?Q3NC0L)Y&KSIOI\*;!? P>,JDA8.
M[%,1=<,2W-H51%D/XRZ4]'CK]^LRR)*50MU^C_XA/5>^'ZKH)K=A]9?12D=9
MS'P5+G5'92CV+2G?P\T)7OOO-\H-26@3>*.ZJ?*,S*PY4>2\0H-9(Y>FB@75
M8IY '+K!7M6'#Z62-IEXBF]9O'\(;DSB)PK2EYDT#D4$8$H><7# A,.RP!RF
MB-KV!_@$:4A!=*VI-KS.IQK<&R(T#]X;__+76U-PQ"&8R;?_K@6/[<.F*C/R
M8LZ/>1RD)+U?;G+@O;JBL\4T>9]G-YA>@U/=^YA9GY'^#C(#1N:H<,,&^*8)
M )DM 5A^!VM]BW8A *I1;EB&%**F@K01@.+W\%]Q<P2@&XFH$#F!QIV"F"#$
M0%G>9< :*([X6+4!_;=>D@;0!BUX5J14W8V+;,>4:P[OHD(#,9XU>U)$7NVU
MOGHJP4\3$>/8(PNOPLA-;+0]=#(JRA<LB6/'?04OC[?.6V3@LJ%2D&%P-<\/
MF6E?Z/<D@9:ZGYU4H,WB7T[XUSVP&4<L 9 /B'7'8\ I*Z\BA>%/409?8$\R
M3@5K$,<7B,ZEH6$];<V-$;)JH6KS'TUP6';;N<K(^0V\^1GNA!^L(I*_]S!B
M!.PY )_T-N=O*KIA/H%O=;!",9KC^*!'! #Q*FZ'&WIZ&H;'TQXP:9=K0/YJ
ME?U7I9=@:80;T^GU&"B^R05VJ OIESL$[4R*Z&'4-[=CRU2^._=^) #?6>$9
MHDM2X*Z,8I4@..K*)DOAR?B6CFX^O4R7W(\G0;V_82=!?P&.(27RJ3=E];7P
M-Y#C'F1VB],X,ZFLWB4U]Z[=\_7S_[((,Q% -W!V'2O\G]E5\KF#I7M5!^)Q
MH_ZLL#M_X$_J^@=]70V208?X.1=/6D_,]E$&.U,GG)'O+S1Z#(N0K<S<MGKK
MH:*?&W6.XRT%\"*7]5?0#51L:8YO\NI3>,+<_-TP@Z2GRCDV!=Q1>2'C FP<
MM*3;73]F5MPM"U!=,5X, M4?BHFBVI,HJKM;A?\AJB>L7H90_2&JA0" R%Y;
M N31,402%;*;:^MU<8 HD-_?1E'$V'1;%7D\>*MY=X'1@NR27<.'O'T(GT+B
M)*4^H*-AC!\ 'VRY$WDJ$RH;HTKT^-(N'!),C%(C"C#4A@(F!ELDN4-& %2(
MT>L;,5Q%;F+3S,(F75668<#AV9 _R6GOK.-5B](K08(!E^Y_)@ /$.8N-V0B
MV+=403E<;MC7I;"M!-AE* GV/G$KXI=@&!I+ K ^!F^LW-J7Q1@=6[S&Y.*9
MUV]N+?1'BC<L*43$CD'1'RR1;>1!1\5GSJ&("+#&Z:=3 H!T/,.'26JP0.9!
MYUA/3EJ93@55N D 7!;^TGD/^L8G5X43_30PU9L J-^]%8>")RY)GOB^P$>?
MI8/PRCBPL=]X!^*4QPT\&T?TXE+WJG&L24H?*FGZJ2_>>+&3:<9\113;NT2,
M6\N(K1T#W-6,D3HW3!((">\F(MSIZZ&;>XOLV(A!V+@I_E8S!P%X%07K>3H$
MVZ:@PL>E-R^@C;P?(=_H'?MEG)3V"O/7- 40PPC%N92?Z-&<FA0!&(HO+((2
MO-IXA*N))P ]4J^(IC_#QK5ZSI]$SB_9?W]NI&&T_PB:!4/J$RGI%;P@ ?B"
MP _J8@_A U"TD%Q/V&)<Q,M0,_"2VR@+,S[WYM;P=\0<^X\M8KAA!4&-3,"5
M3-@S(JD@PSK\;5/AI3<_S[+>_]O6?F)=C&_%I3\YL05@-X *HO.2LU<_<Y+W
MG)KIK+#X$:K([QJ=\_ U&B)!#$([C-F.LB]B#DWE72NF-H+?3K=(M]M [A0^
M>JDSV>"ZZYZZM9[)R&V$ULES.H$8!/H'NCL^MW9\6L/7[LK+=#F?P[ ETCYZ
MASR!TNDHOVWZP;;$SNY>V=%5-]?EAL:ZVOVV&183DUNLM]Y,1>8(<W+VSREN
M$OMS_C9']@7)$#-:^J;B1\WY"+-\T3^RID54M)'2'@;W=.0&OXIZ&09]_J0!
MR/3$8:).C5:Z<!W8PD-#,F4B<ZQ%)/'>@<U >S/^]^\#IC$VGTOA(5\R/3T'
M8.,BI['-G_XC6FYR2F)BP!F_^OLJXDXFL0@!%B,-?_O(P&#,E<\U;<XS!6"4
M3&(! <@S@E3]#MSN,!$4=%((KU.ZAWNS0@PF1I#J\973#,PJ]/[1Q1K<SXS,
M?D'PKN2J5B+HA'T_?]#ZT0;]O@U^"6_L]V?S0!:2T]<8'V'H%#\$ (A8-XRO
M+0TX@JH'S8'VW;D0N!?$T+3^#I[N_&_8%S:6D*1RAG-^WXU+0*N?![W!TUYA
MR=C6DY@_;!$M_6,,D_\)$YN/0:2'*K%@6LX_%JG@3U/.1'K/"1N]!'C_0Y+?
MJ&G@<%9W=VQSSZ"JOK[29>R@G[:AU7>5([IPX?EA\?T9#6?R1'T^=7HGLY7X
M5T7!(PDO:-?FE\"A]VX*JI=,<QP9FXG-ZM@F<81 NCEH]83IG]$\E$E4Y7);
M[!/4B[(('=I.]=>TKTDJ':@4ZQ(S7!;1$4BX,>BV."LRZ&;*(/V3M>GQR2VE
MYT9*O+E(%9N>K?0JRL(E'.@?4J)TKZS[7.NDP&IUF3:'5=]^S$3/PI,Q&ZPQ
M\J-W38UXZ72XV,J#O !YDL??F+M^U&F=IO"ON ;=?\D8.J_[M:*QON'53VJ)
MW>JTB.4(4YWJ:(EC,O'@;_VZ528E1Z)6MW^*Y^M@(Y0+:2^&!&:59V0S_2SY
M$_X-9PE 5\[\KL)^81$W GV8ANO$&Z=_"W*I,=<UW=*!1F10LZPCQB3'TNY&
MX1[C',@.7Q./^%LO.,[#8$5T 1P)V[^G;$  'HEFX+A&3WZE$8!+6]"SE8QN
MR#<848:NY/AFX%LAX#.Y_QD/Q?\3/-Q[ ]J_$T!DK=:.4*%VZ"[R",=YI S&
M^IT%%1R HF#[-^9@#2!\E/FR\R!>T!=J.JILX>7NG#]C0$=.LASQ'A2O92B:
M1 #><%L39;+^/ [MAH0?>$9X_ B\L\=]W3#M;LGVB*W]'IC_S$>B?2"6,>'=
MZ"G$9*+U<PULD7(<L7[!AP $<6.%_ZV+-'S/#]@Z%PQ-CN@^5*D*(T;8J#TM
M>  ?4<S>D#S;G.^&M(&01FZGXJD&N)>9Q--S,#X'HJ_<^B39.MCB0S;]0\#F
MJX:(>_#$.%'__EO%X[OZ=Y_7.E/11N1ET>5GFX/"USSNP4TZ9CU!8D05&Y=$
MBZ,CXK8;$7XE40JX$ )P' E9RPTBWK00EVHE!9V&)Z(I1D/T[]!J::3!>I1?
M^<\O#S]#7'C>9]$>1(_2?UF=3CTVFMIS.-UU8?;Z+6_IHE?9WI1D/+/7-RQW
M\!_\0>WSU3$JV/FRPHL;!0+2LJ)Y=#?AYQX1E]6BX03F6R%J4WO4*TS6@C7+
MVDJ-A9?IYSYPLFF_T.\N9A[9)> PY?]@1]M4/83AUPZI"L=U\>"QCP$T?@5L
M(Y7";I7.=/](9@GH-R3,!P1SO#X?P9_H_E!-,X5LC1Q3Q4+2%G"Y<4Q"^=KQ
M6?/[,^<I_96.7YKK^S%%/_H:$]J5KDNH0"Y]61AWE/ZIO9\N"]K)<EO1T-,
M3";]B42?N)X(HH]V&'T]P?NK$7>2Z).1Q<:&%%8IB(,I)LSA/-:$6Q*V5@DZ
MV4"@BZK^^^T"AC&/Q);&6_'.G=B9Y<>L1)ULG3/^X^CP9">ZY!C/9D(1ZQH+
M]&-1\ ]!_9+8?1AF97R34X0 /,P_P$Z>EKGC<42F&KY>J/*/MX/'?K U(E&=
M%VQJX)7K+R4 3U9KP0Q[ 85\)OBAQ+#H1'R1I+OU\-\MA//@$H*AH2>]FAQ.
M'D]XLT^(D WY#Y"=!;'=PQZ_QN.(?L*J^7W^=(<*=^:&%RDU(J(WJS?1P_L=
MP'O#,)3QTR;B% 9@\WD$8*EHE(CD,(Q7!-4.4_%I=,F\;=4JA RGBTD]W6\.
MQ36"5Y;D8&='1)XY>!6J/-[^&!8'-@W 09?T1JY"]NB]^JZ(!!Z=C4O%8SB1
M,1+]K7$4.\GG$!/)#RCY#,[>$ "G^KZ_UM431@U;2?05Q7]+AIY=%BV#-X5]
M:V+*CFN-;/AKQ>7_LM3$*?)KJ.9%R3U.LR;CAS 9@W]\>O2[]#4./4&,*!AX
M_=J(H8G4E]?F]UUYBEO2[L_L=._PB\Z@J>H8%*N<R!V>E) -EXTZM9KA8%.,
M3G^B[M;_=O>:]T*(8J?SA' FDR+*X)4<_-SFR3W-9,/)S?C)%N^^9YT67M5U
M?B;9W-=61U&O(,Z>R251X#>0$V\&2CAK=+;!T/"=X>2Y7\8'OY,TT5EF)*:T
M1GI/9%\+<!U-"9.]1'LMQ'BV3'46I;S(GY;5,A3GDV93BA#KKW!@3M>^Q#9S
M]^X-B(^RBL>"-@J3U5(HG$F;,;F&#RH#[Y7C66#V&:=GOW/276B3WSGI8S\B
M A7'8;9A(1I>#S4JNW8@5"MNR[P9N@,%KD3%->1VPGUZC\ARJ__&<K-_:>ST
MR7]B/^LX&Z!:K_[T\&Z&4]#H,_#SC,Z;5%4!G"@-;ZPFZMI,'P&X()K^8"5C
MKBH00_2'[AOC^#JA?=9E_"5<<B-X2=S3<%1H5(X\=7])+\QX,D2B(QPDJ9:*
MC^Z1>O?,\UVQDA7_3-^7)/?GBURZQ_9=QI"Q>62W-1<13:MSB1+R=RJ@[;*O
M,_[55 J>2#;;Q\<(@.M#Q ?<C].X;4O[?7@32&!\#D&]'86504YB[FSA0S]2
M@A8MJ;#2[*&(=?%"V'(&5M]?*/0Y1X!DYH,-^7WE+U.W^;02N<-Y:^%DUW\\
M0_<:A;![?SK>OSF33P*E,;U75)*Z]\L,WP\^."+RR\ X9#9&F>A1HUVX8W!K
MZ2!4(%#G_M^>Q&T?$  P!'0R00!H:S0 X[^U+ -W$&4MEAE%=B_.$"495G(T
MO;YT[DK']J-9&_*WF6>V[_&"#?4BMJQ7'$4C<DZ4L_&<D$4%''4J&(=F@;6)
M8(D,.>N"%A%Q2)NL(_LGAO$F)WQ^_).\1@2 OAB9AG^C#\)C:;<"0,BN-AC3
MT[P*9&<:6XBC;/K3+Q,%&C[?N,.[+ $P[69!4<QUC3DIO14YCM)[(G_S$"-<
M.FQM<QF/ 2V:KI?2_OW5_<\54K5NE7?P/[[%K9HZ9))&"F<RPKJL1=TH?8E'
M#!)W-\/46?M'Z-1LTEU (-GNN@EPWD#E6[JH6, M&Q0YVFOG<G4-MY'K[I,D
M+C\N29FGZKW[$\&Q]"^1$R!Q%Z=TQB$YBYMV5!615*.+UZQG+#[G#!7>RY:@
MU $^VE\O\L&358YX31PI5C%H-.9?Z+!SE7&[V"K#U5N@UD8A%+W3WU>C/$!)
MB4 %^+[8NI?L<F5U<'OW2CG&TC-.7N]=S<$Q=>_"52#39=[70ZK/>$1%IB_+
MR7#CK"R\>ES'Y]B_,W*]AT77E)V!V\_&;U)^*4>"[2KC74H?MR 6AZE/.S_&
M$^9FU3UX<BO\7H;D^0:$9@"D E(K3R[2)P!"<AY=B[B0O$_NSN*C.Q@K*RT?
M'W>?2XZN9J0AD,NJ4^0.\B])R#ZNK)">O,'JNRWUL8G?FEU4BC#C"_5ZU]J&
MOA@;2RG=%,=[5"@W(K]"8ZO=@S]X_ 7+O1"H]&W,1W[*\^Z&\F=-YPB%+R2L
MS"3?3DU,C'V6$PSD!@8HH#MZX-/3*#R&!>9D]CMU SV9^!UZ_A]Z3NDRDZJ/
MGZ_$)2R[>I]F68#NC,+*?6'XP,H]S&'&HH6QR54=AP\25S<'HXXEF8CMJC\1
MHTLB5AC#3F0Y:]-WB8ZJ@V>MTE#Q\V$7\.<\KN&R?6>GY%,53-/SH+J@OXQ"
M'U=H3SPM4K#YQZ5&]V9/KHH^-<&/5/Q.0B#VRK6.<S.PV([?7ZRHTKB<!*L2
M(_;Z2Q*S;?3W9JJ@% )08SG8CU'?W.$NCOLZM9\/WN]P7NL]XSY&$H#$\%$"
ML#4V3@!NYP8<0)DCB-+8[. (%B%IF'L_E/SP[Q$G[EZ500@OG6EM^+5!L6"*
M+E"M[A;X7\-"%)!A>!V%5XAM&EL"\/E\_>:_DB?%?UD4]\_%9/T=;31$[C1D
M/]O:S)<]$_[CR/PN])\,+!^XY@R+K00?U=3(J+D]LS(*N\3V,)^,?\OZ21 ?
M.A%SH?6LXT<$X_OGZ-TC_RCJ+&_&?9%H#8&T]@ %$8Z#3NV6XQLM:=_2>6H3
M]?UD+=@#KU-4BI-F")!2TVU3DS.VDXT84DDMNW$Y<TF&NX:\^W(E-H7US;!Y
MH])*$T;_>ZN)!;_K0(8$R7=Y)AX_"#IBV?'PRS&#?:"7?WY;B>;E:M"ZD4S]
M^VY'P*L[FEW@G/)8RS>RT3RD:YB[OZV?1!+1T1,KIOL$'J4*VHEI"^&R&R;V
MKXIAV3,W!IVDIC;8O%&; FE5L9?(3W^JOXC[4+MQ +JOR@%FQ/-K+"M%8?Q,
MM27Y;414!Z0O15T.@H #7DG/7GO .%GVTZ\QJ3]YW_]23Y&W"N^P;)\NQJCR
M2TU-<[.(JRM_M&A?Y4/7FRAS61*#/\5]_V]Q'_=GK@;\1ZZF3@.X_T<JP/./
M5$#!;A6I2Q[(MA;$#Z.J&:L4^4_%"@'XNUJ!W$7P&U01VX'K#19X7\^5P!Q
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M3\.R21E%:H[#<$J6L'D$O@DT!3K<(9ZA( )P=DBRG'^LBR0&A)0=*)X :!"
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MVU90HOR_XE<Y@5RD\6AO\0K2[[6$/ @K'NR1)/JGX4L*8/M3VE_1$1\N/LL
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MVM-9,#-A51Z:5 4Q"@;5(@L5UD<XO'X*,!$>2_&]3E6Z=ND^D!>F/:X%V62
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MWI&=7-+AJG-F3J^F_W-!1':CMEM<8%?I7]]U_G\WFK.)_P)02P,$%     @
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MA&[;)WF=O+8':$=491>(70JKX8J [RC"/A4E3!ZY[EQ=ZF?V5<??VQ\Y][B
M,X2'ZN$A:S]TM)VL"N6;]4&U*%P )15ON6[AU.#'],7->VF[6K5GM9-LMF^E
MK/"*=+6*9S'W:Z8!Z+!O#E,0 ^J&)=( _T((2E'-_OQJC9\'9K;I6Y6,7[S?
M:DZ=@;==4[K]WMA7>U,>6_Z+13U2,WT(V&<X\T6R[OE+*:I/%"@F!@NSBGXN
MM+VCRF_@O>VQ4A34+JW(8VZ$D(J;9T1-1<,^'=#;R.IWY5ENK1^M#]*EF]-M
MT7V\+%>_S(T\KZ7(NG\8OQ9/ !QR8L%L5]D1AE%J0AO9"A-C5F.RE?3<_D)F
M<JBN(_$JB:@G.M_L\K #];=ZO<2'VD'0P?G+Z*ZE1#Y(]7$'^R37.(SNJ2 2
MEQ:1]ZIZ<CESR?"R2'2R78J +0UZ-D(!,TYR/"<)?0H= Y,%^2W-PJ/WYK#7
M41[QK6[ET\X[" 86YX#</K=\*^%6<4\W@3=C YYB0]\^< _M4]VQ\\5+X=X&
MZ0:B/'K@C.58Q=*!)2<U42?S -4#\X0/WC[ZFJV0[SKL S9KI2OVH2$:'>\9
M6J^([WVP'Q-$[RP.G),Y\2&NA[6./Y3B^@%)%W_ML6WV6Y=M83M:,9G\.O5(
MGI/ID[WHG_*/3[4[$J>/E]*C,3K.,T4QYMU' ;C"!ABL%%*X8%CO!KI?ZY?4
M1SOW=ECZ0;9<O!E?31@M28B<0PCHMFAN#/"?MLIKN,*Z1&:TZR)?0MTN]58I
M8LY/<]3=YX&4]5?E*GPBMY[MWLH)]-E;><9G'$DW8DYBCXIQ-:VZBWS3NYUL
MO!<F#P9 ,<V[X8]1JK\_0)"WZ^5B:612\KWH*R5&4UF,*!0'W@&O2([M6??A
M.S:HR&Z^\P3 #I/( P$]L JV(0#50?%W)R>5=_H]?3RX6SUY\L/SXVO]A)ZT
MFFNB/V)NHBO X?/,[2C5J1 ?#U;7&5RMTNI'A)5W>^N8FR1SH,7:IZ2T%]/A
M,?=93WRS#TB.TUB70#6@GASF($TD7^P.UNQI(0H<%J11#'$@ /?&<J_/@O6?
MLJ8C&%-KO+Z\>?CNFDV?QM[Q]C#&/L@L%H&O0M$NW>;JB\$R9O)<^.P]SQM[
MQ]GG3:79/"TWNS';ILCY<Z]#6):S<T- M]8KHZ!*^&D0<ZUA)(Q)9M8PTL^:
M!+4;83,B]6AMPDWJR9Z45&O6R*>;"=2W.+^0<W(L/NW/Y)N-QW-90=(9F#2?
M5T 2,'T!%;&%&YEU.^4O*[+HR]CV[D3LF/#><7A<\JWL]Y"R%Z#V([==#S8[
M\\A/%_EJG@YM6X(N-9[R;C,Q2C54RFK[6"W'+/907&?:W*1%=/,NKO_%_L76
MNJF=MJ58CRC+A1@)K,A'5Q!]!B+]S=*6I,#\ ^BX4&.C_?Y#L8Q[Y^R@#P1F
M:U]?>@D$MVGZ\X6"G&'4D+ N*&G+5)V;8)?E0CPKO-H[<<=)"CJ^9/#6)E/
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M$$)35(K_W-"%6.N&G7.V%J@.#(9];J8*/QAH07,,4!T]>[8WD##<I$/[O?B
MA60'*HLKPS-BE5!9?>%8[>6V&_HH"GC&FH5N6YS!995:!U.QBHY0QJSNYW'/
M+1<HU:[RQ2:CYQ(R<!D$@'HAQH>!WG9X'SIRY&"T%CS2X+O;,G1]?&IX@84
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MGIC7FR.'HI=H8U5%C!J?T/9+-C,-,*7_,/=<V;>^1=6W&P>Z(%OY<@,!9]R
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MC-TD  =GD1YNH(T5.(7CR*["=\>,''B(XU/_2^16!B'8)\Y>%"!N$IH)UR0
M#E;^;E!*M/65/(C]@U6ZA (='#8K/J#)"[=U0,2WB,9FW<4/CD?$?'!<-#?F
ME&SOWK_2$&(CS2Z>">WB',NK3_>X1L5N+"UZ=X759/C.^>S#7S/#H6O5\$GA
M5)W6R5J_J45X8ZT?YM:CGJ-KX2]]3](<1'V]2=6H2-N(\D3%FW0%Y*&5.].5
M"B/]RWL*U5'SSEOU!J.J+1)";(_Y!D2<GV+S?^\D9Q5A;TS6<2]L[QA/+G&?
M,'OLT,-^)5_E=X5,*O@K)IUC>LY-]T0.U#?<:J3.:X#LTD5I1P1I90;/)2N)
M__C ?H-_@;FXV\B=(43+ZOK+COY+B7J'SF1I:E9B#:5TB:M7#NY1@*_NXP.)
M>!V:>/:T,<.? *@N$GFM_?>ZT_\EPSHC\VZ@]L@B[!X(:VKUARUG=P05R9].
MGHY=V?\CV,*'M)LP2S^(0KY%XPW:,KGH]X^E]8/Q%OQ07??W%[]$'B3^46WR
M]\O9GV? ',#0)3+#)Y0SL"D6HH9J6OY#HB!V\N<LE9;ADUTJW"EQ#Y:YS=3_
M<BB$/]J=#+JG,QW,)LVP+ZOZY]M5I-<OZ9*)\#!8+OHT!FD4NT)9QLG],GTZ
M^WUX9H+,2:U,!UMGA5Z5Q"]<NV.WZ%AXUQ6>&Z+B2.3"S%$[U]1RU:,GW-,'
M44\2=[;DCB:P;^*V"^^^BZKN6I%04'7-;JEMQTA.3;MA=524?QG@WG!8?7C6
MG#B-^-'--T^QK_*3[43^M^KGR@_K[QEH)MR";!?;G@2B7RY$,>M'N1<UF.;8
MO$DW_KB7/G3NW%Y(&",;CVQ@;HJZT./3 .,1=59]Z[6HQ;Z6!K2Q>SL11?D2
M8QL*WGE6"98'PX:581CT D)K:_=DS8, P+BQ8F=%=Y]C['X#4:3Q>);_=]'_
M]B(]KF.5/H_$X]FS&AL0FY7G2V;[SGM0DJ@Y#Z/0$1FVIH^4-<=W?\M@1NQ0
M')/T*[U"^R3)KZB1GDU5J6.*Y =*A<FNY1H\\IZUR7T"7S_8V76=CQ33_C7:
ME'@!*P=F_%RJR5;N\[BYX*>\O#Z78'XICSY?RM>NU[,NZ1=/J$(U@)3C)?M7
M2I31'Z<?6&^ZE=UTEW3COV]QYPGH^H_?C_-H=_OYZ=9D,SQ1#=H1G!4I0T>/
M% 2#L]'D#RJ$[YL[93PGS1=/?!,"3CLY\1^?5"&1JW%^7%G^<V;>0B2#8JZ,
MZ9*I$[9):[3@6<=:T5?UOCOWN;0[XV]HC2]E<K^-'"OOJFO/$#6+N,)[Z4*[
M9U-U"%*7TU>U%Y!5X5LN!_5^\J\7V\SE6+&Y]#"T2_C9N7YK:>V!?;H+@]X2
MFV$2-Q.-/1^:1^)9G-LOHNX';+-?:/LZR\%I<8_J>?PH&PWWN^!O.U1))!43
M(W8/I2-XPQU".(^*06NUL./O>3OW8,-.Q#CW0?=('':"8,<A13&L<"PR%H]F
M > N8?A [3.$I#9!A3U*Q)^RY#PA"C*;";9 FEAE103@U/#=%^JT_W?<+M^U
M6"]G07L,T_GGJ,ZD+\+PM\ &[O-9WG+C#U=:IN]\/1GNNY!V8SL5-BR'+<6N
M/4L[ @48QS<(Y!9@A!;V!^%B:OWRV'V/KT4ICR('>5?NHR%O0/,LN]5$P*TR
MNU?4Y2B?^2:^';ES*[S\T[L\M^'"VH%BK;=.="-AOT10#!IFT+]MF=7<H"9D
M8[(I5.5$]]W[ U;';3,"L-\IA5DT/[T2B:=395^!,H'B8_\K+&%M(L65,)SL
M\.$.1#'W^?9G0)AUX^"8!3R$"!2":-1ZB":I(D  VBD 19&$6R^3.4XI*?.+
M1^=%AXR%;FV64.C^^3S@B4NVU-A!(J-S@ P^T'I30"M*DTQ:]+:C\&LZNI<*
M%W77E9:=(Q8UAAAX>,Q!4F$VYB.6,[]7+Q4,2J""<\V;'!UC=/".R;&,*IT!
M1V0%@$9!T,VQ0]I'UH%OK78$,5<I6IIB[X4+EM&5#5QF:2 71#[K^$A.\S5U
M^7(:?<L;F4&+JTL,0D>7YX+0EQZ,:KWI"'I**\![[ND[6_Z0'3)$^636>Y=F
MLX*RBA+91TNG^]O9ICT=D&F>&@]!/_$X@(7_7N/&35C8%+NXIZ=4U)I2W4\/
M5[^ ^F+R^F%F+=MS[\2?R#XF0O^$:[XA].5\2]FQ%5O,&_5/5O7#&QDO_9#[
M>H-?^LKP3\HK)")4+S[_;-H6'VHU1YKKHZXN$R/D]""FSH2<^AFKQ8-WN#7^
MC^?]35CL@N>#&>G?G[^KZD3B5%)TI];V_VOGVJ.AT+KX:!2I**]!\DIY3.A!
M+A-#C$=B7&&DBT1B&'E=0T8>7>J.&2./&4EY-R(S)888).]7B"OC468BDM=$
M# 97ON[ZNM]W5_>/[Z]OK?O'7GN=?=8Z^X^SSS[GM]?O[*1M(@NYZZV;[^2,
M(&[^%C)7[5D/[_F4\U5OP>NI0OCR$KR5\%5O8?'B(NCX,%3U#[V%W/]8Y_]S
MP3PIITR=5=WKMCQ(+,P:*V8BNIMG$UR)P6VJD^"QVO&-+&Y)U.[@06UE:#WZ
M.$Z0H[-(56?OJ&3=$Z]KVGL!GC])\EAS+:N@E9KJ!FEX)H+,/FEOUP$F6CQ6
MPF$!GP? 31@C5@MY+N(7YX^(ZE=J>4_GM<"I=R^W!X:3,&!Y0,H1Q@_K"MOF
MTZ7#H0BV;\UUGXA2RA37,BC)%.TJ?ZS6&U"&STD D-N.C,M<;&G'US(B>69M
M$4D8#3:-"KW58]@GS)JY\M@\FZX>G)H,*!95%91^HN^JH\A3<ND+$]L<MOL-
MKE^VN0LX45"->LM=K=N\^@A?ZJI;M-JY#< 6KW:K2OXGRU>F+?0KTQ:)+?R3
M(;0L8GY6:&T=^J\J^O*_AS+?>C$0S__'[;=N^>\S[PK#I#0*FATVL9("^1OZ
MF@G$-ETD*EV J>4B/$F@<L[, -&N>4-M@0<:4[1202)B92F]28D&K;N5&P-;
MI@T.C(F-.HMS;E(F';4)OC.)K+>VM/:*X'NA[EVI$@,[A8>- )<OVA(; \R;
MVK#O*=RP_-H]H]8AC5Z:<2$>Y<5]T( .=#"MJYG60$/Y/QN: OJOUM1A 2L"
MV+D.>-.Z\IS54\V5*6J@J^)7,O.9[Y&9AZV$Q -DPS^L:V8@,]8QN9N9O(?K
M^>6@36]"\\[DC*6!"+SL/U/_\Y1R10:4/2:W 8@B<S8#2D64:&TV8#8JTUOR
MG?^FH36--;\ZDNI0)ZR>]:"**.[/;M\F,L\_!APX^?@SY:R]ZGU!7&$?QZUF
M--CU:*E_Z;N;.6R+J^T+6/"8"\$%=%T!/B?[?&4\6GUJ@2#E+:/QI$<N'M;P
M:)5\VUAX9L@XP,?NDHYDLP+=S6GM 3V<;5JK+]]+5XI@H=1GYEFQ=YAMX>+=
M12@MB";J^,G*GCZ+7XX=+&I.ONIG@M"I%2L2Z*JWP7NB%-,6/.PF.H7L@Y"8
M'U%0NZR5@S#,\BHD9-REAI/%EGU1K=2G<:B\NVA!M+1'*RPN5'WD2L_!Q/'
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M]G_5BX^AUSX6%F86R)Y>3/O\]@3X6%B/G=Q_\*(1Q,:+7UPEE UZ*2FWK/F
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MUXQSL7KN7'77WC7OVVE<^WRP58DJ(8WU1+"N+#U8Y3,W\]>(,__0$Y^[%>5
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M=GNL! XV2-"!K^&J&HVMZ1BX4TB/#YI,=0WP=S&9RZM/H7:PKWF,G0.UW3C
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M\^,OV,5[6:*;$SC,YS*&/N'(1W M!4NV<"U\>Z<9YQFE%6IYY_VI<R2<Z.(
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M"0K^8YJ)J>\MS_=G+S"+UH6.U306@!U5=@1T&X)ST?KL2)!^,7GB"_YZ TF
MZLD15>(V=1*G+7(_!BV>+IF4YFA[W0 (YN??*9.8$GZD7C @;BA[ZH(WE"DC
M&-A[$?:?=!1]]+\ 4$L#!!0    ( %B'?U821S_832$  !LI   8    86YV
M<RTR,#(R,3(S,7@Q,&LP,3(N:G!GY7D).)3_V^]CRYZL6=+\RI[P0XADDI!4
MDK)K$A*21)8:1@E%3 B5&$OVF&3+DLF>I>R$T%#V;2QCUF?.PV^I<\[[_[_G
M_5_G?=_K7.<QW^N:>;[K?=^?^W/?]Q?C"^,;L.N4D8D1P,0, $S0'\ 8 0P
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MJG(FC'B4W2"07^,5W\TD7AY/'>8"!?-*_3FFN0.V\ECI>:C""OEG37>:&,8
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M[95[J&B\)V#7&P%!J<K3NVY& C?UM>MV5+@&\OOLN>2V/AJ9&+D:DX$9OL$
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M"?, 4#Z LQ"'YZFH\52T,O>9;!Z],DM\UQK#*KK_YLVF>V+'C(_B3BI^"S+
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M7Z=!!&KJ>]%,=@T,AK;#P>D)-L>.AS2J^_]V)4324.@<$T*%=,[5. *L,F,
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M874;;'M/CJ!$+(.M>? 23_CT !\5@F2^^_#MM![LR;('L'T,X,<S<#8?W?B
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MX'$B&(/W_+;G];^7(QXAI;CD#=N;9-DLQ%ST:Z(%,5$&9XX*800G4Q/17QE
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M4D)[/:Z3]<LL3=;"N&!M;-DFA]Z+VG3>+;LDKA2]%O.&EE866HVIH$VU@\?
MLGAQ87TT6LBEQ+%PWA#F/$DES$Y8YF_RI #_^ 6>?('8P8&7U+F+2Q!_O];:
MSX03B5J'?]YN_/UZF%1$/7(0-K(G3?8\Y)#;#3$-)1TSC47"?5K(,]"3UB5W
M8KMN 9 -YFU^8F@L NU,59Y[CJTX$*$3TG'T.3=:8M;@[=4F/FK.*IE V%L?
MFR.?2K2A,JPRPUTBE6#_<7^OHP-&ZH$9I0 \RPD(S-:!KQ\YLMK:F* %^QI'
M'0+MIP"Y"W!=\D@U-<6.I !*\RT7?)[X['1@G?=K]\<W4VEM1F3::/C<6U46
MPP)?V.I[?7Y[8<24*O'DILRU>M^8EL,Z5&=@WUWTJ8<G@:I]J;DEZP$U(=,H
M4R:3J4!D@Z;![&PIP-(($?(-L^^Q[BOHY[U.3>M%=F%[7=3D@\,4@<G:@BS+
M%\'05"DW)U&&=\160.GPB?(2<?<&?=JOO(WZF:4A..J'#&*2Z+[79?1^I2K9
M]&>=45*2JU"_I@G_VX_"Q[\G;YEPA0(:7U5"H469[<@HHIO5C,)WQ#K?W[(G
ME$1WD"R51TXO9_\C?5JQ'_SY[D_Z- <))T/3,#.B> 4,C-N%X['?VY:\<PLY
M-ZI;*OV?O!(''IU-N_^,26/(R$HH&(."G'#FGG3(JBC(K#LKGS6G,T6K<\V7
M+[->[*/:V\8%@N$"P71<C',SI2BUO,<7R_9B:([*5 8O*,"1GJ#?M*]6:S7*
M^Y^;F@."E"UO(LHC2F_@G:CDBE'@7RXO,&.\=UEC6=.P%KN?ZB1\:F7\R[%C
M,O1A6BGJK:@>WC+FH5'Y?CVIU4&6*.9>;^E$;L[L;#Y@ON@V\#TW372X(^&*
MYIW=*74JZ;K^1@(,;?-2+/<#P:N62-2D ('1:O]^NZR*(S7U&3@@E%* '&9<
M^CZ(UZJ5+-!LG'[5)@]0%-MBQAW]SU [+P3R2NA\<><;UXV]WVG7QCAZ!\=#
MVI?X%Z) E8L)5898FI,FK!ONK[D=XF/(!*Z#I=%D9%; =?S![%#8C"PV-:SI
M1G&O\R=\X?SZI-V%IYNB0>\_\X)EC(\^B]&)>F<_K?D-<\36EP=*M1%$!?AC
MI:"<CV;.M0>3_H<IJ0IL>;UT#V/SA+18G>C2\"ZXK;9L[B:]N0&Z#O/8U/3L
M<*F6WH^W]K=XXXZ>:;<=ADJ7W\7%<BQ[A>7YP#J"!)L133_6Y::55LD&5U==
MS'XH9&(9S>*;Q,O<:BU@0YW0@Y\?CB\7,VS4*W)T&A#F"NDOTY\._1X-F.,H
M0$QI8X^Y-"FD_$_BQN +[K*?GA\0(+>9_GF#BY4:0PYM7R[#0M8^?GWW\::Q
M6_]^7O\^O/"7"D'0L4T>!9O#4 %E@OZ-I[>^$6V)M4:X9U1:+'7['<#56J!\
M1-\ A,AP'E:8N@V1/R_&S439!KIS[EB4]G*&& N_9HEU=0 PD:W='K'NIF9A
M]%FAZ=^J<&II0>,Q#$/OD X:S*^>U*:\Z.U6G-1F4OQPXKRF6Q/-4;3!><BF
M]*+^)9Z/=&MZ.T:$M</O- L]I"YB\;8M>8Y\W_<C:8^X_.]V,"K$VFIBQW#,
M'S:L0TDYU@K6O?,7./&/\8ST&]848(,9U_#_ 5K :3J?I$ZV1$2SOU@R^(!G
M&WX:ZTS7F2+Z_L3>>M!C6"!,B>0?"IM:A<7L:J&Q!X2F9MA-H3NP*6A?PA^W
MM-*ST=#!!'E("R(S\'#OS/_>L44QZF.+/ L/?S>ND)P N#@^J[')/Q_V\_P:
M!=!"C4VTB*U]7CTX\LSBJPI9'1ZTR3:V=XQ,8K?OI.=\XD4_NZA_[.QG^4 M
M(YQ85%FUP+0:TB!\IL_"WDS:_,4+W[-/7MO> 414A\SWGE5=-"HN.E=4LOY\
M]+T]#Z?Q-JEXN[D$G;JAE;IAC9 9L/6>Q:-*?>I@(P.UOZ-GJK4L9L#6%)M5
M6J;G4C"QRGVPQ1H] JUB+3A[7[@XJK'<(XLDD3=,%ETS+XIZLAN,Z7=PAOAZ
M2+84VA%$5>:T&+G ,KS&@V8+P6$V*D_TF)/>E_Q^NI?1>YLWUDLYPYI<OP1%
M3:]^F>ZI,)[Z$"[4Z2DR92*)"*GJ?_2DY+Q=R.STV:K\! 7E6G^/04:F:K<Q
M_U*"BUBM1=1\<+GHJ7;1AZP)(2_@'UO%A+I?BJ8<^]63QM\;G_&&W_&G)&)I
M1IHP>W_W+CWXX>\3[8/8"M;ZMYL97Q3EF*^:7$'Q_C@C3.<G_'4!O&*))%Y$
M00Z)J>1#+I2AM8FT1-M\88G-A1VY,J1;TQP\I&/.KL"<QVEG9U:2%UJ=L-]
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MORQ,1ZY:ZIZ(D^>[<5FH$EB5_)_:^F_EKP)]TE^Q<-W,UB&O(9%U)WIG;)D
M\B@'\=4.R'BP"@@CUU]QZZ'L_QJ5D2!TYO2F3T$Z^P^%D>R8=6MPI].ND8,2
MS6'?$O_UIMU7ZMGG2_<.M$&>7Q4*1/X+LY(?*?Y[]A6!-(0XY8>-7P9'2GXL
M_(?@$21<.;_%B;^*'$K[DVIK1Z,12-NI<]@H,&C)@,1^I1)M+#/$Q8I:^/K0
M&(OJV=%ZA,?-N272(I0;OKMOG:MLJK'X8/Q^>J*TS=^D6TTT_9BXZO/GMS_<
M6/!5;0_$M/;'3?%^"Q&%1DK@"][",89U0R/P*HGJJHHL@8H+5VM8CQ5=$S14
MGG3T/X%Z:5F$>(Q3V@K5XG55ZTLE5:<LV%CE=V3[>-1 '&L"!\325*VC'6[=
MNW6Q>X5A9@=#I]2G8(>C)2IC3FXVA. F E'WZK_=*[]-MR?D[!<J;ZS:$;1\
MRO+[\&N_9..CT;Z0ZSMGTD7<D3"O/9[U_0@H)_ZS?C/W8W\](ABL6QJ,9Q@W
M<+!8/=)%E^DCP9]!CHAW#ELQ*%"E%420.?X\#'GI^[)1 KL##V4RY1JKJ*U.
MS4LP/J>OY3RE3.NML-WU8[E,;5=EMT]91MJP\L.S\HAQSJ=,D->N[TU3UIY:
MK+QE++@1EXR82 B60.+*].92OW=&-@A[!=G[>=&VJ#TA^PAAS&W;'R$%H N7
MZBE 6;0M_&I^U+NL43TML2I==W^G" K0,HC3(]&=1VY5Z!%E9#F1W^XMDPE*
M7P9@07N/H5V-"XC(ZF+BUI;3+0K 9-@.V>4%$=C8YS?-A' K@\=V6%A8'F7V
MCO0W? Q\YL1>#GD/20W4#,#0(!>R04<S@.Z:CRI+A4M^>VUBK15;_IFQ2M!9
M0J)NE8#21SX P:_I =TB4(!XR!@H*ONM$PED"C!OL8)^HM542'H-(>[5@OIZ
MBZRTI*5">D'F1!C@!#LP<TAZJS6UOI:<GD OC8E)J7"31S./WK*V?'X0,Y[J
M6BG6=^V&;)T_,>J-B*F5ZUHO-A%OCWP*W;WA^WLH* 4XE4OFA<T8DTYFJH/#
M]5. 3NF?*V68C5.>1)#'R304H+=S=1CZ/+CK7YNB=?'!V-@6)*.ORD"#2%X\
MO6'@^&*INU.*2VIHZ&3Y1>&;(5P_!FY_[[CGUIE<:F#@[X[IK1W(IX?K2*R
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M97LWYM(2N0EK[=A3)FW99HK45#=9?O\ M?#]/QV[_Q<+E#+V/P!02P,$%
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M.8OY @,@_0,HG<]N;4=>RE[]C.NXY/)!Z[6Z$_/6%R7P-^ A\/!\U]EO>3$
MY\A0%Z@F+;25<GWHEEJ3+F'NB(_W()]\.>TQCSX?(0&CG-3U3';+C;2/74_S
M2&79P'5<=F6)N?'J;?O$9K]T?F^K+7?VH]!'6[R$+&'9[R/2;DP"!*:SM!P1
MQG8Y9_E$"0/I!QX8($X&?VI#UPD6)]@=.+X=@D*8]#]Z"2:>74G K]?^MGY6
M'ID9^ X## P>CW;<XG05N[&E7FHU-M>GS\"V=5H=;%-L T_%@WY^PP#>P%L
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M$4",FY#E:_O<\&PP^>Z7F&\+AO)+14)/&^.B:$<?O,QYZ?JR6<43 _"U>V$
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M08Z)[GN/,F4C=+\0?[_R$=^8::;' %%,#!,"Y$-:,V<W/!<$MU0F*>36K%Z
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M+VQZ1!VG+Y<<_#!R@%6V[T5EP+_9 QQ_IZD_+GIV6TCB"(X(]CA 3^$^=BQ
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M1W7.QC3 ]E+@5/9UO*Q#8H\;%MA)W*RQJ\4[O]F[YD>+0@'^Y!KO,P6)G=_
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MI_S)V]1M;_Y"'BCH+2D*#_[*"!A=:Y5+6,LLG!.TTJLO3/FBU>@;2E'S4,1
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MUZIX^0BR.=-6J#7A&9CU'<<3TF<4UHM1W\=BN]P$6L1>A^- >=\TOX=VYQZ
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M#&OPG3BU&7Q5)\RD;.6%@C^CUME7? WI!?^U9U5X+(-/E"I@X??2_"S$-DD
MB',CR0J'YTN6D-NVF,-)3%4I ?!>WJP,>"W  XK<.DCG_MCOXOQLVJG/1T?5
MU1MB%@K%]O)*6L :S<3@CG5,4<5O^>S[8RCDQ7W_W34)EEQ6'Z.G7M!M\Y<@
M<QM) "G+]S7[?IL3">RYNY*\8U;@7]\ZS 6S_WZ^0+#/N+:U*J0[=I*$30QD
M.NI+G".'6F67?Z(? :)\B /N%ROOJU=NHR/;/SN[1*YLTJ_UVPDK+[ZK62[&
MR>^C13ZTD]3MCS%X@M3=)%$?"P%BAUS@FY@_#0)U?'?\MW3H1'2^LT;^_RW-
M<_U7FG?O@I<&8G\=OJQ7SEY!-M12_N:(HWBPY!^DVH3G4GC;:C+0TI!FIC\E
MO#,\[4+[\.Z].. MGVO4C)1[9\6< :(RUW0?M;AUT[_8S_LL^M6D@K&MDNF(
MNZ?VG&((TX>JHD*G<N"?\^<B46@4'C7J/UL)/Z%P $[_:EV8/YNW=FM*_,KJ
M9>$6!;17-(-\@-Q5X*[H=RJ>]X\V:FYK:(9!1$G Q-V@L,#PE*,A#_;]UG99
M4<3G)<KS"&[>2Q&11%/DYR6 H@2W[;%#_2"2K3QT]]KFCFB06/>7+XQ65VIA
MEQ<MT/5JK[)]MPYVV@TSNZ;5OQF\D<%Z5Y]Y<HMQ4/UQU]U"<5%BC\3GG*_B
ML4G4.OH?" ! J_$2_*.9?8R4$Y6(/LR2S%+Z0%?OJ7GZ6J,-O@FMDF1>34Y<
MZ%F,R44($@"E^XEB!( >'SMKZ).((?@'ZK%!S?&W<V>8T_-K84:5>'N'I3@P
MV')%KKE*)YZ9T;+G&XJ5OLY3H;_QHFTX69]%O>>6_,#M!&O'0*%9+RV#;0;?
M=]G*I.+L@%*D[(ZQ^8D=',O0!:<#([\YS%-A28]24;\\;$LM%@K6R.>_VX@\
M\A0+GYJ\%H%B$@.]Q.Y'KW.38ZH1+("'^]&3XB/'AI?8"P*@JF<P]I!L-C5A
M,%=M9\A[/JU6K[QN=-*)[?.22-0"C5NH% Z"8!.(4&^(16HD/TNB$O=SB>8J
M/?OB.JNMX/Z$9;PZ(9=4"LH>_'1_K;(@\_6H70P8C<O0JSJ)$Q_(([N#^:1!
M;6-EML#:_F07F;P$D,@B%EE5QNU@$7A_?]6JP$']S7[T86).*'S-HX( N,>B
MYB'Z/BX^P$!7K1YF.;[;BK+WV5\_@6#)(T>7;XT]0!DUCZZ/!"O^-- QK=79
MY,*LGF5KR';09^0277I]QXDL;I^;;7CAH+^<E]=ZUU93;ZFN2$_?.&$;'\Q-
MA+-XX(L[B;&I4)S5 @MD/?H#4-;!Y'7E1=^&:ULUWG5===GY79E<4JR?7^AN
M+G&$^?;RW.7<\)81CG4Y[@@WJV8DWVKU@P"P(_88*WL#NX2+ ,TV@TT7J>_K
M7TC]6FQC<H$L<;KP+.A]ZE>:2KY=_I@JT9^2G&6MU3W8%[>LW<U& XQO-:!.
MS&4A -:A'R"RCT.,%%JSL UQH=>8)7'+'I<^D%5(NJLC;J:(8>P!65;20R2J
MH2?6XPJWEO>BS:Z=2RI$U2A-_:OYPLR6V6=_3-T[]):K]&6^K'R@.[\N=!IN
M-HYG]!_4;DI"([MI<4E[5G^JEM/\OOP^@WK9K,Z*%WA-M@LD_+-(#)O^!Z\<
M>&N1+G8=\T&ACNTNXJHN;RF?:S0K%'\"R9 )?@EU%4_]F5#?4#74SSM2WE_9
MX*MX&[.H'^,*MYV[]PNQ[>&/T#S8W6$?YJ%KTHZ+@+-*US A C?:F2^!6/LN
MMPAQ4Y.B= ],9NGJF#!^E)/95)@[S3O"G:EWGKS-OSDX (?A7W5IY1[%9T 2
MM$+E@CV!!WM+=Q?P9I"$5UU%LVT%/H?XUG9,1E7(QTH]5"G=\J9<@GGY!KQK
M%9<3L4@=_J"W&#,'Z0F5&O5VN2-DKH<?2E/=/T+=7!N\@>I_B-9U%]6@MG(J
MGH38 6]NUCB,3%MN-=_8H-45RD/5:]_]O-+A.W^1R47ILV$E\E].LG_M)$+L
M^VU*LO<^DW\0V[A @PP3DM:A"X?TSQ\BGI>5,^E(:W-5OTM:G8:%2+:TP%Z9
M=X%^YGZ4A$;KT6ZV*!B^6>:L!(_,S=7WY+WVY;N)EJZ+79!E-2&V*MU/6T+&
M>.^Q^!<CK(0O2-O;JC1)?TZ!?TK6F'71=#!/W?BMS[7H3;\,WV\+?;("R<>I
M;J0'%%RO^!9VD.N,[>XO5F! #P7E]STD.[Q?I/_!<B.4*2%2:QS$NGOF4PMN
MK!:X_K&EZ2Z$+)1MBXT<2]ZM._32VL1GR.>8 LACN=+]4GE65#HK B&U*85=
MNO:_[O@XR$U*J"FD-Q)W/0=P4^$AA E<(:?-_62CZ K*29^0(UQ>:2#7XMS"
M!><*B58/#E22O?1X*T;^X0FK!*]D,0:*>%A\JD0CNY?^I'B;X1"Q)ZM8? J:
M#0D+?+"O:(BXE$Z,$2<B #X86%US^K');/9$"$L8 0"%W#S:?E=%W6W%A5N
M8"[TF<')_D\GNXU.>)^_]$QJ:_I08Y/"LMN_E8&B>=U4L)8#M7M6L/XN>8X]
MU/64+L?Q/!:G%?SVJNPF ? )VN5% +@: R\-V?<;X8[0\UO!,@1 AT NGK_Q
M3C9U"PSZ4GM-I*3Z WS)(W3L6@Q:W#7%"/OW!PD\@\R.7A*PKIV%TN^"'DD
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M']U+7/X'N4H4(G/#*N2%MKP(Y)VI!2OA0DC#W#%S@ER/]8^F0S83CD,>#=*
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M( +;ZOT/;C ]V1I,-]9@^M"L^ 3ELPH.Y40FZ\F+G[SL4,DKE\*SC+W2Y9)
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M=*E.<$GPIC*H*'4!QS&.ND41$.T4<!7#2.1@9!G\!SVB(,<D$51#WD?@P+)
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MHN2S11+LV -R)UE<.[[7L[WNIIC49"B?/:M7TN4[[N&_4$L! A0#%     @
M6(=_5L//?9'3#P  KJ0  !$              ( !     &%N=G,M,C R,C$R
M,S$N>'-D4$L! A0#%     @ 6(=_5GG#\ZNB"0  L7D  !4
M ( ! A   &%N=G,M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( %B'?U9U
M8:R;BB8  +=E @ 5              "  =<9  !A;G9S+3(P,C(Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " !8AW]6HNJ]V]Q3  "AB 4 %0
M@ &40   86YV<RTR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ 6(=_5LSQ
MF7&=/P  IZ$$ !4              ( !HY0  &%N=G,M,C R,C$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( %B'?U9\NLLQDL(# )M=(@ 5              "
M 7/4  !A;G9S+3(P,C(Q,C,Q>#$P:RYH=&U02P$"% ,4    " !8AW]6*3F/
MCF-G  "2;P  &               @ $XEP0 86YV<RTR,#(R,3(S,7@Q,&LP
M,#,N:G!G4$L! A0#%     @ 6(=_5MM4.NK5&P$ ;"(! !@
M ( !T?X$ &%N=G,M,C R,C$R,S%X,3!K,# T+FIP9U!+ 0(4 Q0    ( %B'
M?U9,T/,!47,  (F*   8              "  =P:!@!A;G9S+3(P,C(Q,C,Q
M>#$P:S P-2YJ<&=02P$"% ,4    " !8AW]6T:+RY%A,  "F6@  &
M        @ %CC@8 86YV<RTR,#(R,3(S,7@Q,&LP,#8N:G!G4$L! A0#%
M  @ 6(=_5K95BHWI;P  VGX  !@              ( !\=H& &%N=G,M,C R
M,C$R,S%X,3!K,# W+FIP9U!+ 0(4 Q0    ( %B'?U:/VXT/4DX   U:   8
M              "  1!+!P!A;G9S+3(P,C(Q,C,Q>#$P:S P."YJ<&=02P$"
M% ,4    " !8AW]6&>0-ZYA7  #T80  &               @ &8F0< 86YV
M<RTR,#(R,3(S,7@Q,&LP,#DN:G!G4$L! A0#%     @ 6(=_5B&LLY]/2P
MEE@  !@              ( !9O$' &%N=G,M,C R,C$R,S%X,3!K,#$P+FIP
M9U!+ 0(4 Q0    ( %B'?U8"JN?IDB(  !HF   8              "  >L\
M" !A;G9S+3(P,C(Q,C,Q>#$P:S Q,2YJ<&=02P$"% ,4    " !8AW]6$D<_
MV$TA   ;*0  &               @ &S7P@ 86YV<RTR,#(R,3(S,7@Q,&LP
M,3(N:G!G4$L! A0#%     @ 6(=_5L*R-:1=*@  TRX  !@
M ( !-H$( &%N=G,M,C R,C$R,S%X,3!K,#$S+FIP9U!+ 0(4 Q0    ( %B'
M?U;2+0_R\S,  ',\   8              "  <FK" !A;G9S+3(P,C(Q,C,Q
M>#$P:S Q-"YJ<&=02P$"% ,4    " !8AW]6+AE\HN#*  #DSP  &
M        @ 'RWP@ 86YV<RTR,#(R,3(S,7@Q,&LP,34N:G!G4$L! A0#%
M  @ 6(=_5G#HKT.8'   2\D  !@              ( !"*L) &%N=G,M,C R
M,C$R,S%X97@Q,&0V+FAT;5!+ 0(4 Q0    ( %B'?U:2,6=U2@0  "X.   8
M              "  =;'"0!A;G9S+3(P,C(Q,C,Q>&5X,C-D,2YH=&U02P$"
M% ,4    " !8AW]6>"<;7=,(  #S+P  &               @ %6S D 86YV
M<RTR,#(R,3(S,7AE>#,Q9#$N:'1M4$L! A0#%     @ 6(=_5N9[/B.G"
MC"X  !@              ( !7]4) &%N=G,M,C R,C$R,S%X97@S,60R+FAT
M;5!+ 0(4 Q0    ( %B'?U;3!Q<&8@4  "T8   8              "  3S>
M"0!A;G9S+3(P,C(Q,C,Q>&5X,S)D,2YH=&U02P$"% ,4    " !8AW]6NZ_2
MX5$%  "W%P  &               @ '4XPD 86YV<RTR,#(R,3(S,7AE>#,R
<9#(N:'1M4$L%!@     9 !D P 8  %OI"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
